Details of Disease

General Information of Disease (ID: DIS0J828)

• Disease Name: Hepatocellular carcinoma
• Synonyms: hepatoblastoma; liver cancer; liver and intrahepatic bile duct carcinoma; hepatoblastoma caused by somatic mutation; adult primary hepatocellular carcinoma; adult hepatoma; hepatocellular carcinoma, childhood type, somatic; liver cell carcinoma; carcinoma of the liver cells; primary carcinoma of liver cells; liver cell cancer (hepatocellular carcinoma); hepatocellular cancer, somatic; primary carcinoma of the liver cells; cancer, hepatocellular; carcinoma, hepatocellular, malignant; carcinoma of liver cells; hepatocellular carcinoma, somatic; hepatocellular adenocarcinoma; hepatocellular carcinoma; hepatoblastoma, somatic; hepatocellular cancer; carcinoma of liver; liver carcinoma; HCC; hepatoma
• Disease Class: 2C12: Liver cancer
• Definition: A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.
• Disease Hierarchy:
  DIS3IHTY: Adenocarcinoma
  DIS8WA0W: Carcinoma of liver and intrahepatic biliary tract
  DISH9F1N: Carcinoma
  DIS0J828: Hepatocellular carcinoma
• ICD Code:
  ICD-11: ICD-11: 2C12.02
  ICD-10: ICD-10: C22.0
  ICD-9: ICD-9: 155
  Expand ICD-9: 155
• Disease Identifiers:
  MONDO ID: MONDO_0007256
  MESH ID: D006528
  UMLS CUI: C2239176
  OMIM ID: 114550
  MedGen ID: 389187
  HPO ID: HP:0001402
  Orphanet ID: 88673
  SNOMED CT ID: 109841003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 14 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
90Y-loaded glass microspheres	DMA8696	Approved	Radiopharmaceutical therapy agent	[1]
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[2]
Capmatinib	DMYCXKL	Approved	Small molecular drug	[3]
Doxorubicin	DMVP5YE	Approved	Small molecular drug	[4]
Durvalumab	DM4PVDY	Approved	Monoclonal antibody	[2]
ImmuCyst	DMUSUVY	Approved	NA	[5]
Lenvatinib	DMB1IU4	Approved	Small molecular drug	[6]
Pembrolizumab	DMFQEA6	Approved	Monoclonal antibody	[2]
Ramucirumab	DMWUFQ4	Approved	Monoclonal antibody	[2]
Siponimod	DM2R86O	Approved	Small molecular drug	[7]
Sorafenib	DMS8IFC	Approved	Small molecular drug	[8]
Tepotinib	DMUQ0E8	Approved	Small molecular drug	[2]
Tislelizumab	DMGVUO5	Approved	Monoclonal antibody	[9]
Tremelimumab	DMOQ9H1	Approved	Monoclonal antibody	[10]

This Disease is Treated as An Indication in 73 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABC294640	DMCKPG4	Phase 3	Small molecular drug	[2]
Aglatimagene besadenovec	DMACVU8	Phase 3	Gene therapy	[11]
Bavituximab	DMCGW5R	Phase 3	Monoclonal antibody	[12]
BGB-A317	DM7NJYC	Phase 3	NA	[2]
BMS-582664	DMDAN8H	Phase 3	Small molecular drug	[13]
CreaVax-HCC	DMZO5FI	Phase 3	NA	[14]
CS-1003	DM5XGM9	Phase 3	Monoclonal antibody	[15]
JX-594	DM5WCV4	Phase 3	NA	[2]
Napabucasin	DMDZ6Q3	Phase 3	NA	[2]
NX-1207	DMERJ19	Phase 3	Small molecular drug	[16]
PEG arginine deiminase	DMZSAUD	Phase 3	NA	[17]
Pegargiminase	DMQKFWX	Phase 3	Recombinant protein	[18]
Peretinoin	DMESAZK	Phase 3	Small molecular drug	[19]
PI-88	DMGZPX6	Phase 3	Small molecular drug	[20]
PV-10	DM95UYC	Phase 3	Small molecular drug	[6]
Tirapazamine	DMBFE4K	Phase 3	Small molecular drug	[2]
Tivantinib	DMNVP8Q	Phase 3	Small molecular drug	[6]
TRC105	DM1874J	Phase 3	Monoclonal antibody	[12]
AMT-2003	DM1GHKR	Phase 2/3	NA	[21]
DW-167	DMYYRXN	Phase 2/3	NA	[22]
LY2157299	DMP8HW1	Phase 2/3	Small molecular drug	[2]
AK104	DMXJ8Z4	Phase 2	Antibody	[23]
BBI503	DMDSNIR	Phase 2	NA	[24]
CF102	DMP56WJ	Phase 2	Small molecular drug	[2]
EFT508	DMX6RZG	Phase 2	NA	[2]
ENMD-2076	DMJZVPB	Phase 2	Small molecular drug	[6]
GC33	DMXTD74	Phase 2	NA	[25]
GPC-3298306	DMOHAS2	Phase 2	Vaccine	[26]
IFN-alpha	DM4H8EZ	Phase 2	NA	[12]
OBI-3424	DM5D6Y7	Phase 2	Small molecular drug	[27]
PHY-906	DMO4MHA	Phase 2	NA	[28]
Resminostat	DMNE1FR	Phase 2	Small molecular drug	[29]
RG7686	DM6CNFW	Phase 2	Antibody	[30]
SF1126	DML10K3	Phase 2	Small molecular drug	[2]
Voyager-V1	DMNUDO0	Phase 2	Oncolytic virus therapy	[31]
VT-122	DMUY20Y	Phase 2	NA	[2]
YIV-906	DMQT7QC	Phase 2	NA	[32]
Alpha-fetoprotein cancer vaccine	DM3F1Y2	Phase 1/2	NA	[33]
Anti-C-met CAR-T cells	DMV5H0S	Phase 1/2	CAR T Cell Therapy	[34]
Anti-DR5 cells	DMYKZB3	Phase 1/2	CAR T Cell Therapy	[34]
Anti-EGFR V III CAR-T cells	DM8EAGV	Phase 1/2	CAR T Cell Therapy	[34]
Anti-MUC1 CAR T Cells	DM0C1IX	Phase 1/2	CAR T Cell Therapy	[35]
BMS-986183	DMFBUTF	Phase 1/2	NA	[2]
CAR-T Cells targeting EpCAM	DMREQCF	Phase 1/2	CAR T Cell Therapy	[36]
CAR-T cells targeting Glypican-3 (GPC3)	DMDSKR2	Phase 1/2	CAR T Cell Therapy	[37]
CAR-T cells targeting GPC3	DM6H1MQ	Phase 1/2	CAR T Cell Therapy	[38]
CBL0102	DMKCJ75	Phase 1/2	NA	[39]
DCR-MYC	DMWE205	Phase 1/2	siRNA drug	[40]
ET140203	DMGF304	Phase 1/2	Cell therapy	[41]
FGF401	DMWEJ0C	Phase 1/2	NA	[2]
GPC3-CART cells	DMGN679	Phase 1/2	CAR T Cell Therapy	[42]
MB07133	DMJBIBK	Phase 1/2	Small molecular drug	[43]
MGD013	DMCVMUL	Phase 1/2	Antibody	[44]
MTL-CEPBA	DMIS75V	Phase 1/2	Small activating RNA	[45]
OPB-31121	DM6VGO3	Phase 1/2	NA	[46]
Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs	DMDO6J1	Phase 1/2	CAR T Cell Therapy	[47]
TAI-GPC3-CART cells	DMCFSZ5	Phase 1/2	CAR T Cell Therapy	[48]
AFP TCR	DMHBUMZ	Phase 1	NA	[2]
Anti-GPC3 CAR T	DMUMWFK	Phase 1	CAR T Cell Therapy	[49]
Autologous ET1402L1-CART cells	DMJW4TP	Phase 1	CAR T Cell Therapy	[50]
BIIB 022	DMZ1V0E	Phase 1	NA	[51]
BLU-554	DM27J3D	Phase 1	NA	[2]
C-Met/PD-L1 CAR-T Cell	DMHBNKP	Phase 1	CAR T Cell Therapy	[52]
CAR-GPC3 T Cells	DMQH2DK	Phase 1	CAR T Cell Therapy	[53]
CC-122	DM0SRAN	Phase 1	Small molecular drug	[2]
CYTO-402	DMMGMBC	Phase 1	NA	[54]
ET140202	DM87XVD	Phase 1	CAR-T cell therapy	[55]
GLYCAR T cells	DM1PK0T	Phase 1	CAR T Cell Therapy	[56]
GPC3 targeting CAR-T cells	DMVWHS1	Phase 1	CAR T Cell Therapy	[57]
H3B-6527	DMAYTRK	Phase 1	NA	[2]
OPB-111077	DM7YFW5	Phase 1	Small interfering RNA	[58]
RG6115	DM6TLPD	Phase 1	NA	[59]
CAR-GPC3 T cell	DMBDT3V	Clinical trial	CAR T Cell Therapy	[60]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
UNC0379	DMD1E4J	Preclinical	Small molecular drug	[61]

This Disease is Treated as An Indication in 8 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anti-miR-191 modified oligonucleotide	DMO41UZ	Investigative	Antisense drug	[62]
CLDC	DMFHDZ9	Investigative	NA	[63]
COP1-LNP	DMDT4YV	Investigative	NA	[63]
H-102	DM5RUX5	Investigative	NA	[63]
IMM-160	DMI5W63	Investigative	NA	[63]
PAN-22	DMXY77V	Investigative	NA	[63]
TBI-302	DM1CXYJ	Investigative	NA	[63]
VLI-03B	DMIKB5G	Investigative	NA	[63]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1356 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCB11	TTUXCAF	Limited	Biomarker	[65]
ABL2	TT1A6HL	Limited	Altered Expression	[66]
ADRA2A	TTWG9A4	Limited	Biomarker	[67]
AKT2	TTH24WI	Limited	Biomarker	[68]
ANXA2R	TTM7D9O	Limited	Altered Expression	[69]
ATR	TT8ZYBQ	Limited	Biomarker	[70]
BAZ2A	TT2MV0R	Limited	Biomarker	[71]
BTLA	TTER58P	Limited	Altered Expression	[72]
CA12	TTSYM0R	Limited	Altered Expression	[73]
CASP3	TTPF2QI	Limited	Altered Expression	[74]
CASP9	TTB6T7O	Limited	Biomarker	[75]
CCL17	TTMPHAE	Limited	Biomarker	[76]
CCL22	TTBTWI1	Limited	Biomarker	[77]
CD160	TTOFEAS	Limited	Altered Expression	[78]
CD19	TTW640A	Limited	Biomarker	[79]
CD83	TTT9MRQ	Limited	Altered Expression	[80]
CDC25C	TTESBNC	Limited	Biomarker	[81]
CDH1	TTLAWO6	Limited	Altered Expression	[82]
CDK8	TTBJR4L	Limited	Biomarker	[83]
CLEC4C	TT7YT06	Limited	Biomarker	[84]
CMKLR1	TT4UGZL	Limited	Altered Expression	[85]
COL18A1	TT63DI9	Limited	Biomarker	[86]
CREBBP	TTFRCTK	Limited	Genetic Variation	[87]
CXCL11	TTWG0RE	Limited	Biomarker	[88]
CXXC5	TTVS4C3	Limited	Biomarker	[89]
DCN	TTB3XAN	Limited	Biomarker	[90]
DNMT1	TT6S2FE	Limited	Biomarker	[91]
DNMT3A	TTJUALD	Limited	Posttranslational Modification	[92]
ENAH	TTY36UA	Limited	Altered Expression	[93]
ENG	TTB30LE	Limited	Biomarker	[94]
FDFT1	TTFQEO5	Limited	Biomarker	[95]
FDXR	TT3W4IX	Limited	Biomarker	[96]
FFAR2	TT0FYAN	Limited	Biomarker	[97]
FFAR3	TTXDOHN	Limited	Biomarker	[97]
FGF4	TTCEKVZ	Limited	Biomarker	[98]
FHIT	TTMS54D	Limited	Genetic Variation	[99]
FOLR2	TTT54CI	Limited	Biomarker	[100]
FOSL1	TTY8LZG	Limited	Altered Expression	[101]
FOXP1	TT0MUCI	Limited	Altered Expression	[102]
FPR2	TTOJ1NF	Limited	Biomarker	[103]
GATA4	TT1VDN2	Limited	Biomarker	[104]
GHR	TTHJWYD	Limited	Biomarker	[81]
GPR183	TTME5YJ	Limited	Biomarker	[105]
GUSB	TTHS7CM	Limited	Biomarker	[106]
HMGCR	TTPADOQ	Limited	Biomarker	[107]
IDE	TT2EDHU	Limited	Altered Expression	[108]
IGF2R	TTPNE41	Limited	Altered Expression	[109]
IL11RA	TTZPLJS	Limited	Altered Expression	[110]
IL1RN	TT6GSR3	Limited	Biomarker	[111]
IL21R	TTZO9B0	Limited	Genetic Variation	[112]
IMPDH2	TTTB4UP	Limited	Altered Expression	[113]
INSR	TTCBFJO	Limited	Altered Expression	[114]
IRAK4	TTILUKB	Limited	Biomarker	[115]
ITGB6	TTKQSXZ	Limited	Altered Expression	[116]
KCNJ11	TT329V4	Limited	Altered Expression	[117]
KHK	TTPAFR9	Limited	Altered Expression	[118]
KIR2DL2	TTU0P73	Limited	Genetic Variation	[119]
LONP1	TTM1VPZ	Limited	Biomarker	[120]
LPAR3	TTE2YJR	Limited	Biomarker	[121]
LTBR	TTFO0PM	Limited	Genetic Variation	[122]
LYZ	TTAOZBW	Limited	Biomarker	[123]
MAP3K2	TTIX0ZU	Limited	Biomarker	[124]
MBTPS1	TTNSM2I	Limited	Biomarker	[125]
MGAT1	TTYJRN5	Limited	Biomarker	[126]
MKNK1	TTEZAUX	Limited	Biomarker	[127]
MYB	TT8V13P	Limited	Biomarker	[128]
NAAA	TTMN4HY	Limited	Biomarker	[129]
NEDD4	TT1QU6G	Limited	Biomarker	[130]
NEK7	TTJ5SWP	Limited	Biomarker	[131]
NLRX1	TTKT026	Limited	Altered Expression	[132]
NOD1	TTYSRXM	Limited	Biomarker	[133]
NR1H3	TTECBXN	Limited	Biomarker	[134]
NRAS	TTW2R9X	Limited	Biomarker	[135]
OLR1	TTKSND3	Limited	Biomarker	[136]
PCSK7	TTD30LY	Limited	Altered Expression	[137]
PGD	TTZ3IFB	Limited	Biomarker	[138]
PGRMC1	TTY3LAZ	Limited	Altered Expression	[139]
PHB	TT6U071	Limited	Biomarker	[140]
PKD2L1	TTAHD89	Limited	Biomarker	[141]
PKLR	TT31N4S	Limited	Biomarker	[142]
PLAU	TTGY7WI	Limited	Biomarker	[143]
PPARA	TTJ584C	Limited	Biomarker	[144]
PPARGC1B	TTKSQ3W	Limited	Altered Expression	[145]
RALBP1	TTVSRUA	Limited	Biomarker	[146]
RNF7	TTODWGT	Limited	Biomarker	[147]
ROR1	TTDEJAU	Limited	Biomarker	[148]
RRM1	TTWP0NS	Limited	Biomarker	[149]
S100A12	TTQ4ESF	Limited	Biomarker	[150]
S1PR2	TTVSMOH	Limited	Biomarker	[151]
SELL	TT2IYXF	Limited	Altered Expression	[152]
SENP1	TTW9HY5	Limited	Biomarker	[153]
SLCO3A1	TT5CE6L	Limited	Altered Expression	[154]
SMPD2	TTE5VI6	Limited	Biomarker	[155]
SMYD2	TT7YJFO	Limited	Altered Expression	[156]
SPOCK1	TTF23RE	Limited	Biomarker	[157]
SVIL	TTBLQS5	Limited	Altered Expression	[158]
SYVN1	TT8XKYM	Limited	Biomarker	[159]
TBXA2R	TT2O84V	Limited	Biomarker	[160]
TCIRG1	TTVRN05	Limited	Biomarker	[161]
TDGF1	TTN7HMG	Limited	Altered Expression	[162]
TDO2	TTXNCBV	Limited	Biomarker	[163]
TEK	TT9VGXW	Limited	Biomarker	[164]
TFRC	TT8MG4S	Limited	Altered Expression	[165]
TLR1	TTW14D0	Limited	Biomarker	[166]
TMPRSS6	TTL9KE7	Limited	Altered Expression	[167]
TNFRSF18	TTG6LA7	Limited	Biomarker	[168]
TNNI3	TTNLDK6	Limited	Biomarker	[169]
TP53BP1	TTX4UE9	Limited	Biomarker	[170]
TTK	TTP7EGM	Limited	Biomarker	[171]
TUBB2A	TTJ2PTI	Limited	Biomarker	[172]
TXNIP	TTTLDZK	Limited	Altered Expression	[173]
TXNRD3	TTDYFVB	Limited	Biomarker	[174]
UBA3	TTXZEUS	Limited	Biomarker	[147]
UBE2E2	TTXJEOF	Limited	Biomarker	[175]
UBE3A	TTUZX6V	Limited	Biomarker	[176]
USP2	TTUEQ1W	Limited	Biomarker	[95]
USP30	TTQ9EDI	Limited	Biomarker	[177]
VSIR	TT51SK8	Limited	Altered Expression	[178]
ENPP1	TTZTIWS	Disputed	Altered Expression	[179]
FBXO11	TT6G10V	Disputed	Altered Expression	[180]
FES	TTLBY21	Disputed	Biomarker	[181]
MC4R	TTD0CIQ	Disputed	Biomarker	[182]
NPC1L1	TTPD1CN	Disputed	Altered Expression	[183]
P2RY4	TT24DGP	Disputed	Biomarker	[184]
SLC8A1	TTCF82X	Disputed	Biomarker	[185]
SORD	TTLSRBZ	Disputed	Biomarker	[186]
ADAMTS5	TTXSU2Y	moderate	Altered Expression	[187]
ADCY5	TTN64VU	moderate	Posttranslational Modification	[188]
AGXT	TTF5NVW	moderate	Biomarker	[189]
AKR1B1	TTFBNVI	moderate	Biomarker	[96]
ANGPTL3	TT59GO7	moderate	Altered Expression	[190]
APLNR	TTJ8E43	moderate	Altered Expression	[191]
AVPR2	TTK8R02	moderate	Biomarker	[192]
BLVRA	TTJBPN3	moderate	Altered Expression	[193]
CAD	TT2YT1K	moderate	Genetic Variation	[194]
CASP7	TTM7Y45	moderate	Biomarker	[195]
CD248	TTYJWT7	moderate	Biomarker	[196]
CD27	TTDO1MV	moderate	Biomarker	[197]
CDH11	TTRGWZC	moderate	Biomarker	[198]
CDH3	TTARMD9	moderate	Biomarker	[199]
CGA	TTFC29G	moderate	Biomarker	[200]
CHMP4B	TT09EZF	moderate	Biomarker	[201]
CNP	TT71P0H	moderate	Biomarker	[202]
COL6A3	TT5WCAH	moderate	Altered Expression	[203]
CRAT	TTC8M31	moderate	Altered Expression	[204]
CTPS1	TTN12BZ	moderate	Biomarker	[205]
CUL3	TTPCU0Q	moderate	Biomarker	[206]
CXCL13	TT0NIZ1	moderate	Biomarker	[207]
CXCL2	TTZF0K2	moderate	Biomarker	[208]
CYBB	TT5T8MR	moderate	Altered Expression	[209]
DDX5	TTZKPVC	moderate	Altered Expression	[210]
DGKA	TTGL8F0	moderate	Altered Expression	[211]
EIF4EBP2	TTNBTCW	moderate	Biomarker	[212]
EPHB4	TTI4ZX2	moderate	Biomarker	[213]
FTO	TTFW3BT	moderate	Biomarker	[214]
G6PD	TTKN8W0	moderate	Biomarker	[215]
GABRQ	TTXDUR9	moderate	Biomarker	[216]
GAL	TTXZAJ5	moderate	Altered Expression	[217]
GRK3	TT5A4DX	moderate	Altered Expression	[218]
GZMB	TTKEPHX	moderate	Altered Expression	[219]
HAX1	TT21BYA	moderate	Biomarker	[220]
HCRT	TTU5HJP	moderate	Biomarker	[221]
HDAC11	TT8K17W	moderate	Biomarker	[222]
HMGCS2	TTS0EZJ	moderate	Biomarker	[223]
HNRNPA2B1	TT8UPW6	moderate	Biomarker	[224]
ICOS	TTE5VP6	moderate	Genetic Variation	[225]
IL19	TT87RWS	moderate	Biomarker	[226]
IL1RAP	TTWS50K	moderate	Biomarker	[81]
IL25	TTVMO5W	moderate	Biomarker	[227]
IL31	TT1RJXK	moderate	Biomarker	[207]
INPP5D	TTTP2Z1	moderate	Biomarker	[192]
ITGB3	TTJA1ZO	moderate	Altered Expression	[228]
JAG2	TTOJY1B	moderate	Biomarker	[229]
LIFR	TTID542	moderate	Biomarker	[81]
LILRB2	TTHC6XU	moderate	Altered Expression	[230]
LPAR1	TTQ6S1K	moderate	Biomarker	[231]
MAN2A1	TT34DCN	moderate	Biomarker	[232]
MAP4K3	TTI0AHJ	moderate	Biomarker	[233]
MCM6	TTQGKSD	moderate	Biomarker	[234]
MMP15	TTNSTO3	moderate	Biomarker	[235]
MYCBP	TTVW4XU	moderate	Biomarker	[236]
MYLK	TT18ETS	moderate	Altered Expression	[237]
NES	TTHZ752	moderate	Altered Expression	[238]
NKX3-1	TT1E0JK	moderate	Biomarker	[239]
NLRC5	TTWZC78	moderate	Biomarker	[240]
NPEPPS	TT371QC	moderate	Genetic Variation	[241]
NR1D1	TTAD1O8	moderate	Altered Expression	[242]
NRP2	TTRXUVC	moderate	Biomarker	[243]
NSD1	TTTSJ3H	moderate	Altered Expression	[244]
NUCB1	TT6A5ZL	moderate	Biomarker	[245]
OAT	TTTSCQ2	moderate	Biomarker	[246]
OPRK1	TTQW87Y	moderate	Altered Expression	[247]
ORAI1	TTE76YK	moderate	Altered Expression	[248]
P2RY11	TTYXPCO	moderate	Altered Expression	[249]
PGC	TT7K6AD	moderate	Biomarker	[250]
PIGU	TT2LHI6	moderate	Altered Expression	[251]
PLCG1	TT6T4JI	moderate	Altered Expression	[252]
PRAME	TTPH7T0	moderate	Altered Expression	[253]
PRDX4	TTPBL9I	moderate	Altered Expression	[254]
PRKCZ	TTBSN0L	moderate	Posttranslational Modification	[188]
PRKD1	TTSLUMT	moderate	Altered Expression	[255]
PTGER2	TT1ZAVI	moderate	Biomarker	[256]
PTK7	TTXH2ZN	moderate	Biomarker	[257]
RICTOR	TT143WL	moderate	Altered Expression	[258]
RPGR	TTHBDA9	moderate	Biomarker	[259]
RTN4R	TTVRZUO	moderate	Biomarker	[260]
SCN10A	TT90XZ8	moderate	Biomarker	[261]
SERPINH1	TTPSWQG	moderate	Biomarker	[262]
SIGMAR1	TT5TPI6	moderate	Biomarker	[263]
SLC12A3	TTP362L	moderate	Biomarker	[264]
SLC18A2	TTNZRI3	moderate	Biomarker	[265]
SLC34A2	TTQPZTM	moderate	Biomarker	[266]
SLC7A1	TT4S150	moderate	Altered Expression	[204]
SSTR1	TTIND6G	moderate	Altered Expression	[267]
SSTR5	TT2BC4G	moderate	Biomarker	[267]
ST3GAL5	TTVF2BJ	moderate	Altered Expression	[268]
STK33	TTP34DQ	moderate	Biomarker	[188]
STRAP	TT165DP	moderate	Altered Expression	[269]
TIGIT	TTWNL74	moderate	Biomarker	[270]
TMSB4X	TTMVAIU	moderate	Altered Expression	[271]
TNFRSF4	TTL31H0	moderate	Altered Expression	[272]
TOP1	TTGTQHC	moderate	Biomarker	[273]
TREM2	TTQRMSJ	moderate	Altered Expression	[274]
TRIM59	TT613U4	moderate	Biomarker	[275]
TRIP10	TTKHTGE	moderate	Genetic Variation	[276]
TRPC6	TTRBT3W	moderate	Biomarker	[185]
TRPV6	TTBK14N	moderate	Altered Expression	[204]
TYK2	TTBYWP2	moderate	Biomarker	[277]
UTS2R	TTW5UDX	moderate	Biomarker	[278]
VKORC1	TTEUC8H	moderate	Altered Expression	[279]
WDR5	TT7OFWB	moderate	Altered Expression	[280]
ABCA1	TTJW1GN	Strong	Biomarker	[281]
ABCA4	TTLB52K	Strong	Biomarker	[282]
ABCB4	TTJUXV6	Strong	Biomarker	[283]
ABCC1	TTOI92F	Strong	Biomarker	[284]
ABCC2	TTFLHJV	Strong	Biomarker	[285]
ABCC4	TTUEAFL	Strong	Biomarker	[286]
ABCG2	TTIMJ02	Strong	Biomarker	[287]
ACAA2	TTM3F49	Strong	Altered Expression	[288]
ACAT1	TTK3C21	Strong	Biomarker	[289]
ACHE	TT1RS9F	Strong	Biomarker	[290]
ACKR3	TTRQJTC	Strong	Biomarker	[291]
ACLY	TT0Z6Y2	Strong	Genetic Variation	[292]
ACO2	TTMTF2P	Strong	Biomarker	[293]
ACR	TTAHE2N	Strong	Biomarker	[294]
ACTG1	TTGAZF9	Strong	Altered Expression	[295]
ACVRL1	TTGYPTC	Strong	Biomarker	[296]
ADAM10	TTVXEGU	Strong	Altered Expression	[297]
ADAM8	TTQWYMD	Strong	Altered Expression	[298]
ADAM9	TTTYQNS	Strong	Biomarker	[299]
ADAMTS1	TTS2TEI	Strong	Altered Expression	[300]
ADAMTS13	TTUREBK	Strong	Biomarker	[301]
ADH1A	TT5AHZ0	Strong	Biomarker	[302]
ADIPOQ	TTXKA7D	Strong	Biomarker	[303]
ADM	TTV14YH	Strong	Biomarker	[304]
ADM2	TTM642F	Strong	Biomarker	[305]
ADORA2B	TTNE7KG	Strong	Altered Expression	[306]
ADORA3	TTJFY5U	Strong	Biomarker	[307]
ADRA1A	TTNGILX	Strong	Biomarker	[308]
ADRA1B	TTBRKXS	Strong	Biomarker	[160]
ADRA2B	TTWM4TY	Strong	Biomarker	[308]
ADRB2	TTG8ZWP	Strong	Biomarker	[309]
AGER	TTMO9HF	Strong	Biomarker	[310]
AGR2	TT9K86S	Strong	Biomarker	[311]
AGRP	TT4DE1O	Strong	Biomarker	[312]
AGTR1	TT8DBY3	Strong	Altered Expression	[313]
AHCY	TTE2KUJ	Strong	Biomarker	[314]
AHR	TT037IE	Strong	Altered Expression	[315]
AHSG	TTKF4WV	Strong	Biomarker	[316]
AIF1	TT12MEP	Strong	Biomarker	[317]
AIMP2	TTXWHGF	Strong	Biomarker	[318]
AKR1C3	TT5ZWB6	Strong	Altered Expression	[319]
AKT3	TTO6SGY	Strong	Altered Expression	[320]
ALAD	TTJHKYD	Strong	Altered Expression	[321]
ALCAM	TT2AFT6	Strong	Biomarker	[322]
ALK	TTPMQSO	Strong	Biomarker	[323]
ALOX12	TT12ABZ	Strong	Biomarker	[324]
ALPI	TTHYMUV	Strong	Biomarker	[325]
AMD1	TTBFROQ	Strong	Biomarker	[326]
ANGPTL4	TTWALY5	Strong	Altered Expression	[327]
ANPEP	TTPHMWB	Strong	Altered Expression	[328]
ANXA10	TT0NL6U	Strong	Biomarker	[329]
ANXA5	TT2Z83I	Strong	Biomarker	[330]
APCS	TTB7VAT	Strong	Biomarker	[138]
APLN	TT87D3J	Strong	Biomarker	[331]
APOA1	TT5S8DR	Strong	Biomarker	[332]
APOA2	TTGQA9W	Strong	Biomarker	[333]
APOA4	TTNC3WS	Strong	Altered Expression	[334]
APOB	TTN1IE2	Strong	Biomarker	[335]
APOBEC3G	TTP96KH	Strong	Biomarker	[336]
APOC3	TTXOZQ1	Strong	Biomarker	[337]
AQP3	TTLDNMQ	Strong	Biomarker	[338]
AQP9	TTQEI32	Strong	Biomarker	[339]
AR	TTKPW01	Strong	Altered Expression	[340]
ARAF	TT5TURO	Strong	Altered Expression	[341]
AREG	TT76B3W	Strong	Altered Expression	[342]
ARG1	TT7ZQEV	Strong	Altered Expression	[343]
ARL2	TTIDSFT	Strong	Biomarker	[344]
ARRB1	TTMVD4A	Strong	Biomarker	[345]
ASAP3	TTB4ZEN	Strong	Biomarker	[346]
ASGR1	TTYM94H	Strong	Biomarker	[347]
ASPH	TT2KHP7	Strong	Biomarker	[348]
ATAD2	TT9A0HI	Strong	Altered Expression	[349]
ATF3	TTCE793	Strong	Biomarker	[350]
ATF4	TTQCKWT	Strong	Biomarker	[351]
ATG7	TTLVB9Z	Strong	Altered Expression	[352]
ATIC	TT9NVXQ	Strong	Biomarker	[353]
ATM	TTKBM7V	Strong	Biomarker	[70]
ATP1A1	TTWK8D0	Strong	Biomarker	[354]
ATP7B	TTOPO51	Strong	Biomarker	[355]
ATRAID	TTFLIKM	Strong	Altered Expression	[356]
AURKA	TTPS3C0	Strong	Altered Expression	[357]
AURKB	TT9RTBL	Strong	Biomarker	[358]
AVP	TTJ8EWH	Strong	Altered Expression	[359]
AXL	TTZPY6J	Strong	Biomarker	[360]
AZGP1	TTUPYLV	Strong	Biomarker	[361]
BAGE	TTS5GLJ	Strong	Altered Expression	[362]
BAK1	TTFM7V0	Strong	Posttranslational Modification	[363]
BBC3	TT7JUKC	Strong	Altered Expression	[364]
BCAT1	TTES57P	Strong	Altered Expression	[365]
BCL2A1	TTGT9C7	Strong	Altered Expression	[366]
BCL2L1	TTRE6AX	Strong	Altered Expression	[367]
BCL2L2	TTQ79W8	Strong	Altered Expression	[368]
BDKRB2	TTGY8IW	Strong	Altered Expression	[369]
BECN1	TT5M7LN	Strong	Biomarker	[370]
BIRC2	TTQ5LRD	Strong	Biomarker	[371]
BIRC3	TTAIWZN	Strong	Biomarker	[372]
BIRC5	TTTPU1G	Strong	Altered Expression	[373]
BMI1	TTIPNSR	Strong	Biomarker	[374]
BMP1	TT0L58T	Strong	Biomarker	[375]
BMP10	TTTG6H1	Strong	Biomarker	[376]
BMP2	TTP3IGX	Strong	Altered Expression	[377]
BMP4	TTD3BSX	Strong	Biomarker	[378]
BMP7	TTKOBRA	Strong	Biomarker	[379]
BMX	TTN2I9E	Strong	Biomarker	[380]
BRAF	TT0EOB8	Strong	Altered Expression	[381]
BRD1	TTT09OB	Strong	Biomarker	[382]
BRD4	TTSRAOU	Strong	Altered Expression	[383]
BRD7	TT07ZS1	Strong	Altered Expression	[384]
BRS3	TTKYEPM	Strong	Biomarker	[308]
BST2	TT90BJT	Strong	Altered Expression	[385]
BTG1	TTL7N2W	Strong	Biomarker	[386]
BUB1	TT78309	Strong	Biomarker	[387]
C1QBP	TTWTD7F	Strong	Biomarker	[388]
C3	TTJGY7A	Strong	Biomarker	[389]
C5	TTKANGO	Strong	Biomarker	[390]
C5AR1	TTHXFA1	Strong	Altered Expression	[390]
CA2	TTANPDJ	Strong	Biomarker	[391]
CA3	TTXUK5D	Strong	Biomarker	[392]
CA9	TT2LVK8	Strong	Altered Expression	[393]
CACNA1G	TT729IR	Strong	Biomarker	[394]
CACNA1S	TT94HRF	Strong	Biomarker	[395]
CACNA2D1	TTFK1JQ	Strong	Altered Expression	[396]
CALCR	TTLWS2O	Strong	Biomarker	[397]
CALR	TTUZ7OA	Strong	Biomarker	[397]
CAMKK2	TTV298Y	Strong	Biomarker	[398]
CARM1	TTIZQFJ	Strong	Biomarker	[399]
CASP1	TTCQIBE	Strong	Altered Expression	[400]
CASP10	TTX5HEK	Strong	Genetic Variation	[401]
CASP2	TT12VNG	Strong	Altered Expression	[402]
CASR	TTBUYHA	Strong	Biomarker	[403]
CAV1	TTXUBN2	Strong	Biomarker	[404]
CBR1	TTVG0SN	Strong	Altered Expression	[405]
CBS	TTVZJ7G	Strong	Biomarker	[406]
CBX7	TTBN3HC	Strong	Altered Expression	[407]
CCK	TT90CMU	Strong	Genetic Variation	[408]
CCKBR	TTVFO0U	Strong	Biomarker	[409]
CCL21	TTLZK1U	Strong	Altered Expression	[410]
CCL3	TT8I4WB	Strong	Biomarker	[411]
CCL5	TT9DWLC	Strong	Biomarker	[412]
CCN1	TTPK79J	Strong	Altered Expression	[413]
CCN2	TTIL516	Strong	Altered Expression	[414]
CCNA2	TTAMQ62	Strong	Genetic Variation	[415]
CCNB1	TT9P6OW	Strong	Biomarker	[416]
CCND3	TT1JXNR	Strong	Biomarker	[417]
CCR1	TTC24WT	Strong	Biomarker	[418]
CCR6	TTFDB30	Strong	Biomarker	[410]
CCR7	TT2GIDQ	Strong	Biomarker	[410]
CD14	TT6I7DC	Strong	Altered Expression	[419]
CD163	TTTZ9DE	Strong	Biomarker	[420]
CD200	TT0BE68	Strong	Biomarker	[421]
CD22	TTM6QSK	Strong	Altered Expression	[422]
CD24	TTCTYNP	Strong	Altered Expression	[423]
CD276	TT6CQUM	Strong	Biomarker	[424]
CD36	TTPJMCU	Strong	Altered Expression	[332]
CD3G	TTV3XPL	Strong	Genetic Variation	[425]
CD40	TT1ERKL	Strong	Altered Expression	[84]
CD44	TTWFBT7	Strong	Altered Expression	[426]
CD47	TT28S46	Strong	Biomarker	[427]
CD59	TTBGTEJ	Strong	Biomarker	[428]
CD69	TTPQE9F	Strong	Biomarker	[429]
CD74	TTCMYP9	Strong	Altered Expression	[430]
CD86	TT53XHB	Strong	Altered Expression	[431]
CD9	TTZEIBV	Strong	Altered Expression	[432]
CD96	TT83C4X	Strong	Altered Expression	[433]
CDA	TTQ12RK	Strong	Altered Expression	[434]
CDC123	TT3PRUG	Strong	Biomarker	[435]
CDC25A	TTLZS4Q	Strong	Biomarker	[436]
CDC25B	TTR0SWN	Strong	Altered Expression	[437]
CDC37	TT5SOEU	Strong	Altered Expression	[438]
CDH2	TT1WS0T	Strong	Altered Expression	[439]
CDK1	TTH6V3D	Strong	Altered Expression	[440]
CDK12	TTJ21A9	Strong	Biomarker	[441]
CDK13	TTRIM0E	Strong	Biomarker	[442]
CDK4	TT0PG8F	Strong	Biomarker	[443]
CDK5	TTL4Q97	Strong	Biomarker	[444]
CDK6	TTO0FDJ	Strong	Biomarker	[445]
CDK7	TTQYF7G	Strong	Biomarker	[446]
CDK9	TT1LVF2	Strong	Biomarker	[262]
CDKL2	TTMO45N	Strong	Altered Expression	[447]
CDKN1B	TTLGFVW	Strong	Biomarker	[448]
CDKN1C	TTBSUAR	Strong	Biomarker	[449]
CDKN2C	TTBRUGA	Strong	Biomarker	[81]
CEACAM1	TTA9CK4	Strong	Altered Expression	[450]
CEACAM3	TTPX7I5	Strong	Biomarker	[451]
CEBPA	TT5LWG1	Strong	Altered Expression	[452]
CEBPB	TTUI35N	Strong	Biomarker	[453]
CEL	TTTRNQW	Strong	Biomarker	[454]
CENPE	TTZD5QR	Strong	Biomarker	[455]
CES1	TTMF541	Strong	Biomarker	[456]
CFI	TT6ATLX	Strong	Biomarker	[457]
CFLAR	TTJZQYH	Strong	Biomarker	[458]
CFP	TTLA0VS	Strong	Biomarker	[81]
CHKA	TT10AWB	Strong	Biomarker	[459]
CHPF	TTAZB7S	Strong	Biomarker	[460]
CHRM3	TTQ13Z5	Strong	Biomarker	[461]
CHUK	TT1F8OQ	Strong	Posttranslational Modification	[462]
CLCN3	TT8XNZ7	Strong	Altered Expression	[463]
CLDN4	TTMTS9H	Strong	Altered Expression	[464]
CLDN6	TTKSV48	Strong	Biomarker	[465]
CLIC1	TT8KZG6	Strong	Biomarker	[466]
CLN3	TTORF9W	Strong	Biomarker	[467]
CMA1	TT8VUE0	Strong	Altered Expression	[468]
CNR2	TTMSFAW	Strong	Biomarker	[469]
CNTF	TTGEM5Q	Strong	Altered Expression	[470]
COMT	TTKWFB8	Strong	Biomarker	[471]
COPS5	TTSTNJR	Strong	Altered Expression	[472]
CPB2	TTP18AY	Strong	Biomarker	[473]
CPS1	TT42M75	Strong	Biomarker	[474]
CR1	TTEA8OW	Strong	Genetic Variation	[475]
CRBN	TTDKGTC	Strong	Biomarker	[476]
CREB1	TTH4AN3	Strong	Biomarker	[477]
CRHBP	TT3PKZE	Strong	Altered Expression	[478]
CRHR2	TTIY658	Strong	Genetic Variation	[479]
CRK	TTFEUYR	Strong	Biomarker	[318]
CRY1	TT5MLZR	Strong	Genetic Variation	[480]
CRY2	TTAO58M	Strong	Altered Expression	[242]
CRYZ	TTP6UO8	Strong	Altered Expression	[481]
CSE1L	TTTRULD	Strong	Biomarker	[482]
CSF1	TT0IQER	Strong	Altered Expression	[483]
CSF1R	TT7MRDV	Strong	Genetic Variation	[484]
CSK	TTX6F0Q	Strong	Biomarker	[485]
CSNK1E	TTA8PLI	Strong	Altered Expression	[486]
CSNK2A2	TT7GR5W	Strong	Altered Expression	[487]
CSPG4	TT7MYXI	Strong	Biomarker	[81]
CTAG1A	TTE5ITK	Strong	Altered Expression	[488]
CTCFL	TTY0RZT	Strong	Biomarker	[489]
CTH	TTLQUZS	Strong	Altered Expression	[490]
CTLA4	TTI2S1D	Strong	Biomarker	[491]
CTSB	TTF2LRI	Strong	Altered Expression	[492]
CTSD	TTPT2QI	Strong	Biomarker	[493]
CTSH	TT3G406	Strong	Altered Expression	[494]
CTSL	TT36ETB	Strong	Altered Expression	[495]
CTSS	TTUMQVO	Strong	Biomarker	[496]
CUL7	TTI8R0P	Strong	Biomarker	[497]
CX3CR1	TT2T98G	Strong	Altered Expression	[498]
CXCL1	TTLK1RW	Strong	Biomarker	[499]
CXCL9	TTWE5PB	Strong	Biomarker	[76]
CXCR1	TTMWT8Z	Strong	Altered Expression	[500]
CXCR2	TT30C9G	Strong	Biomarker	[499]
CXCR6	TT2BVUA	Strong	Biomarker	[501]
CYP11A1	TTSYVO6	Strong	Biomarker	[502]
CYP17A1	TTRA5BZ	Strong	Biomarker	[503]
CYP1A2	TTS1DTU	Strong	Altered Expression	[504]
CYP1B1	TTI84H7	Strong	Genetic Variation	[505]
CYP21A2	TTP4GLG	Strong	Genetic Variation	[506]
CYP24A1	TT82UI1	Strong	Altered Expression	[507]
CYP2A6	TTAQ6ZW	Strong	Biomarker	[508]
CYP2C19	TTZ58XG	Strong	Altered Expression	[509]
CYP2C9	TTR40YJ	Strong	Altered Expression	[510]
CYP2D6	TTVG215	Strong	Biomarker	[511]
CYP2J2	TTNE1C7	Strong	Biomarker	[512]
CYP3A4	TTWP7HQ	Strong	Altered Expression	[343]
CYP3A5	TTHS0OK	Strong	Biomarker	[513]
CYP51A1	TT67TDP	Strong	Biomarker	[514]
CYTH2	TTOM97J	Strong	Biomarker	[515]
DAPK3	TTERVQN	Strong	Biomarker	[516]
DCLK1	TTOHTCY	Strong	Biomarker	[517]
DDC	TTN451K	Strong	Biomarker	[518]
DDR1	TTI1FPZ	Strong	Biomarker	[519]
DDR2	TTU98HG	Strong	Biomarker	[520]
DDX58	TTVB0O3	Strong	Altered Expression	[521]
DEK	TT1NMGV	Strong	Altered Expression	[522]
DEPDC1	TT8S9CM	Strong	Biomarker	[523]
DFFB	TT2SRE0	Strong	Genetic Variation	[524]
DHCR24	TTTK0NH	Strong	Biomarker	[525]
DIABLO	TTN74LE	Strong	Biomarker	[526]
DIO1	TTU3X26	Strong	Altered Expression	[527]
DKK2	TTST5KX	Strong	Altered Expression	[528]
DKK3	TTY2ZV6	Strong	Biomarker	[529]
DLK1	TTF4AVB	Strong	Altered Expression	[530]
DLL1	TT9CFQD	Strong	Altered Expression	[531]
DLL3	TT1C9K6	Strong	Posttranslational Modification	[532]
DLL4	TTV23LH	Strong	Biomarker	[533]
DNAJB1	TTPXAWS	Strong	Altered Expression	[534]
DNASE1	TTYWGOJ	Strong	Genetic Variation	[535]
DNM2	TTVRA5G	Strong	Biomarker	[536]
DPYD	TTZPS91	Strong	Biomarker	[537]
DTL	TT8396I	Strong	Altered Expression	[538]
DUSP1	TTG8HIM	Strong	Altered Expression	[539]
DUSP9	TT1GV6C	Strong	Altered Expression	[540]
DUT	TTH6MBO	Strong	Altered Expression	[541]
E2F2	TT5FYX0	Strong	Altered Expression	[542]
E2F3	TTWIJYH	Strong	Altered Expression	[543]
EDNRA	TTKRD0G	Strong	Biomarker	[308]
EDNRB	TT3ZTGU	Strong	Altered Expression	[544]
EEF2K	TT1QFLA	Strong	Biomarker	[545]
EGFL7	TT7WD0H	Strong	Biomarker	[546]
EGLN1	TT9ISBX	Strong	Biomarker	[547]
EGR1	TTE8LGD	Strong	Altered Expression	[548]
EHMT2	TTS6RZT	Strong	Biomarker	[82]
EIF2AK2	TTXEZJ4	Strong	Altered Expression	[351]
EIF2AK3	TT79U1M	Strong	Biomarker	[549]
EIF4E	TTZGCP6	Strong	Biomarker	[550]
EIF4EBP1	TTKGEBL	Strong	Altered Expression	[212]
EIF5A	TTIVCNR	Strong	Biomarker	[551]
EIF5A2	TTH53G9	Strong	Altered Expression	[552]
ELANE	TTPLTSQ	Strong	Biomarker	[553]
ELAVL1	TTPC9D0	Strong	Biomarker	[554]
ELK3	TT5OJMV	Strong	Altered Expression	[555]
EML4	TT92GY4	Strong	Genetic Variation	[556]
ENOX2	TTUJZRL	Strong	Biomarker	[557]
ENPP2	TTSCIM2	Strong	Altered Expression	[558]
EP300	TTGH73N	Strong	Altered Expression	[383]
EPHA1	TTLFZVU	Strong	Altered Expression	[559]
EPHA2	TTRJB2G	Strong	Biomarker	[560]
EPHA3	TTHS2LR	Strong	Biomarker	[561]
EPHA4	TTG84D3	Strong	Biomarker	[562]
EPHA5	TTV9KOD	Strong	Biomarker	[563]
EPHA8	TTHZ2LW	Strong	Altered Expression	[564]
EPHB1	TT8MDAC	Strong	Altered Expression	[555]
EPHB2	TTKPV6O	Strong	Biomarker	[565]
EPHB6	TTZEMUY	Strong	Genetic Variation	[566]
EPO	TTQG4NR	Strong	Altered Expression	[567]
EPOR	TTAUX24	Strong	Altered Expression	[568]
ERBB4	TTWALCO	Strong	Biomarker	[569]
EREG	TTYSB89	Strong	Altered Expression	[570]
ERN1	TTKIAT3	Strong	Biomarker	[571]
ESRRB	TTKF0XS	Strong	Biomarker	[572]
ESRRG	TT9ZRHB	Strong	Altered Expression	[573]
ETS1	TTTGPSD	Strong	Altered Expression	[574]
ETS2	TT9AH0M	Strong	Altered Expression	[575]
EZH2	TT9MZCQ	Strong	Biomarker	[576]
EZR	TTE47YC	Strong	Altered Expression	[577]
F12	TTRJSMV	Strong	Biomarker	[578]
F2	TT6L509	Strong	Biomarker	[579]
F2R	TTL935N	Strong	Biomarker	[580]
F2RL1	TTQR74A	Strong	Altered Expression	[581]
F2RL3	TTD0652	Strong	Biomarker	[582]
F3	TT38MDJ	Strong	Biomarker	[583]
F5	TT1O264	Strong	Genetic Variation	[584]
F9	TTFEZ5Q	Strong	Biomarker	[585]
FABP1	TTIV96N	Strong	Altered Expression	[586]
FABP4	TTHWMFZ	Strong	Altered Expression	[587]
FABP5	TTNT2S6	Strong	Altered Expression	[588]
FADS2	TTT2VDU	Strong	Altered Expression	[589]
FAM83D	TTFIW7J	Strong	Altered Expression	[590]
FAP	TTGPQ0F	Strong	Biomarker	[591]
FAS	TT7LTUJ	Strong	Biomarker	[592]
FASLG	TTO7014	Strong	Genetic Variation	[593]
FASN	TT7AOUD	Strong	Biomarker	[107]
FAT1	TTGUJYV	Strong	Biomarker	[594]
FBXW7	TT29KY7	Strong	Altered Expression	[595]
FCAR	TTGUJAO	Strong	Biomarker	[596]
FCGR3A	TTIFOC0	Strong	Altered Expression	[597]
FCGRT	TTKLPHO	Strong	Altered Expression	[598]
FER	TTRA9G0	Strong	Biomarker	[232]
FGF1	TTMY81X	Strong	Altered Expression	[599]
FGF18	TT6ICRA	Strong	Biomarker	[600]
FGF19	TTGCH11	Strong	Biomarker	[98]
FGF2	TTGKIED	Strong	Genetic Variation	[601]
FGF21	TTQ916P	Strong	Genetic Variation	[602]
FGF8	TTIUF3J	Strong	Altered Expression	[603]
FGFR4	TT1KX2S	Strong	Biomarker	[604]
FGG	TTR31L7	Strong	Altered Expression	[605]
FGL2	TTYBS89	Strong	Biomarker	[606]
FGR	TTPOGS1	Strong	Biomarker	[607]
FHL1	TTI7ENL	Strong	Altered Expression	[608]
FKBP4	TTHY0FT	Strong	Biomarker	[609]
FKBP5	TT0J5KQ	Strong	Biomarker	[610]
FLT1	TT1VAUK	Strong	Biomarker	[611]
FLT4	TTDCBX5	Strong	Biomarker	[612]
FN1	TTPJ921	Strong	Genetic Variation	[613]
FOLH1	TT9G4N0	Strong	Biomarker	[614]
FOLR1	TTVC37M	Strong	Biomarker	[615]
FOXC1	TTNT3YA	Strong	Biomarker	[452]
FOXC2	TTLBAP1	Strong	Biomarker	[616]
FOXJ2	TTV1FDA	Strong	Altered Expression	[617]
FOXM1	TTD3KOX	Strong	Biomarker	[618]
FOXO1	TTLRVIA	Strong	Biomarker	[619]
FOXP3	TT1X3QF	Strong	Altered Expression	[77]
FOXQ1	TTEJZOL	Strong	Altered Expression	[620]
FSCN1	TTTRS9B	Strong	Biomarker	[621]
FSHR	TTZFDBT	Strong	Biomarker	[622]
FST	TTDNM9W	Strong	Altered Expression	[623]
FTH1	TT975ZT	Strong	Altered Expression	[624]
FURIN	TTH9WF6	Strong	Biomarker	[625]
FUS	TTKGYZ9	Strong	Altered Expression	[626]
FZD7	TTUQMO5	Strong	Biomarker	[627]
G6PC	TTBQMJ8	Strong	Biomarker	[628]
GABRA3	TT37EDJ	Strong	Biomarker	[629]
GADD45B	TTMDW9L	Strong	Altered Expression	[630]
GAPDH	TTUGSWA	Strong	Biomarker	[631]
GAS6	TT69QD2	Strong	Biomarker	[632]
GBA	TT1B5PU	Strong	Biomarker	[633]
GCG	TT6Y4PN	Strong	Biomarker	[634]
GCK	TTDLNGZ	Strong	Biomarker	[635]
GCLM	TTNFESW	Strong	Biomarker	[636]
GDF15	TT4MXVG	Strong	Altered Expression	[637]
GEM	TTAZF9M	Strong	Altered Expression	[638]
GGCX	TT76OLR	Strong	Biomarker	[639]
GGT1	TTZVT7O	Strong	Biomarker	[640]
GH1	TTT3YKH	Strong	Altered Expression	[641]
GJB1	TTSJIRP	Strong	Altered Expression	[642]
GJB2	TTRGZX3	Strong	Biomarker	[643]
GLB1	TTNGJPH	Strong	Altered Expression	[644]
GLI1	TTJOMH6	Strong	Biomarker	[645]
GLI2	TT045OH	Strong	Altered Expression	[646]
GLO1	TTV9A7R	Strong	Altered Expression	[647]
GMNN	TT390KA	Strong	Biomarker	[81]
GMPS	TTCFP0V	Strong	Biomarker	[648]
GNAI3	TT8QF3W	Strong	Altered Expression	[649]
GNAO1	TTAXD8Z	Strong	Biomarker	[650]
GNRHR	TT8R70G	Strong	Altered Expression	[651]
GP1BA	TTVB0Q9	Strong	Biomarker	[652]
GPBAR1	TTSDVTR	Strong	Biomarker	[653]
GPD1	TTKTEAH	Strong	Genetic Variation	[654]
GPER1	TTDSB34	Strong	Biomarker	[655]
GPI	TT19JIZ	Strong	Biomarker	[631]
GPNMB	TT7315J	Strong	Altered Expression	[656]
GPR137	TTATO6X	Strong	Biomarker	[657]
GPR182	TTT23CG	Strong	Altered Expression	[658]
GPR39	TTTPCNU	Strong	Biomarker	[659]
GPRC5D	TTHRAPJ	Strong	Altered Expression	[660]
GPX1	TTYAHBP	Strong	Genetic Variation	[661]
GRB2	TTEYRJ9	Strong	Altered Expression	[662]
GRHL2	TTUGH4C	Strong	Biomarker	[663]
GRIK1	TT0MYE2	Strong	Genetic Variation	[664]
GRK2	TTAZ3MN	Strong	Altered Expression	[665]
GRN	TT0LWE3	Strong	Biomarker	[666]
GSK3A	TTQWAU1	Strong	Biomarker	[667]
GSK3B	TTRSMW9	Strong	Biomarker	[619]
GSTA3	TT29VDX	Strong	Biomarker	[668]
HBEGF	TT15SL0	Strong	Biomarker	[669]
HCAR1	TTVK4ZO	Strong	Biomarker	[670]
HDAC1	TT6R7JZ	Strong	Altered Expression	[671]
HDAC10	TTYHPU6	Strong	Biomarker	[222]
HDAC2	TTSHTOI	Strong	Altered Expression	[672]
HDAC3	TT4YWTO	Strong	Altered Expression	[673]
HDAC4	TTTQGH8	Strong	Biomarker	[222]
HDAC5	TTUELN5	Strong	Altered Expression	[674]
HDAC6	TT5ZKDI	Strong	Altered Expression	[427]
HDAC8	TTT6LFV	Strong	Biomarker	[675]
HDGF	TTKGV26	Strong	Biomarker	[676]
HEXIM1	TTFOKAH	Strong	Biomarker	[677]
HGF	TT4V2JM	Strong	Altered Expression	[678]
HGFAC	TTD96RW	Strong	Biomarker	[138]
HIPK2	TTOB49C	Strong	Biomarker	[679]
HK2	TTK02H8	Strong	Biomarker	[393]
HLA-A	TTHONFT	Strong	Biomarker	[680]
HLA-DQA1	TTU2I3J	Strong	Genetic Variation	[681]
HLA-DQB2	TTL7VOU	Strong	Genetic Variation	[506]
HMBS	TTT0HW3	Strong	Biomarker	[682]
HMGA1	TTBA219	Strong	Altered Expression	[683]
HMGA2	TTSTVM0	Strong	Biomarker	[437]
HMGB2	TTA78JQ	Strong	Biomarker	[684]
HOXA11	TTEX4ZA	Strong	Altered Expression	[685]
HOXA13	TTN26OM	Strong	Biomarker	[686]
HOXB13	TTZ6I58	Strong	Altered Expression	[687]
HP	TTLC8E1	Strong	Biomarker	[688]
HPGDS	TTCYE56	Strong	Altered Expression	[689]
HPN	TT25MVL	Strong	Biomarker	[690]
HRAS	TT28ZON	Strong	Biomarker	[135]
HRC	TTR4FKD	Strong	Biomarker	[691]
HRH1	TTTIBOJ	Strong	Altered Expression	[692]
HRH3	TT9JNIC	Strong	Altered Expression	[693]
HSD11B1	TTN7BL9	Strong	Altered Expression	[694]
HSD11B2	TT9H85R	Strong	Altered Expression	[695]
HSD17B1	TTIWB6L	Strong	Genetic Variation	[696]
HSD17B13	TTDJYZR	Strong	Genetic Variation	[697]
HSD17B2	TT0PT1R	Strong	Genetic Variation	[696]
HSD17B4	TTL1WGS	Strong	Biomarker	[698]
HSF1	TTN6STZ	Strong	Biomarker	[699]
HSP90AA1	TT78R5H	Strong	Biomarker	[700]
HSP90AB1	TTH5YN2	Strong	Biomarker	[701]
HSP90B1	TTFPKXQ	Strong	Altered Expression	[702]
HSPA8	TTMQL3K	Strong	Biomarker	[703]
HSPA9	TTMTPG3	Strong	Biomarker	[704]
HSPB1	TT9AZWY	Strong	Biomarker	[705]
HSPB3	TTLH8WG	Strong	Biomarker	[705]
HSPB8	TTY0OJN	Strong	Altered Expression	[706]
HSPG2	TT5UM29	Strong	Biomarker	[707]
HTATIP2	TTC6IX5	Strong	Altered Expression	[708]
HTR1D	TT6MSOK	Strong	Altered Expression	[709]
HTRA1	TT8POQR	Strong	Biomarker	[710]
IAPP	TTHN8EM	Strong	Biomarker	[325]
ICOSLG	TTB9Z8R	Strong	Biomarker	[424]
ID1	TTBXVDE	Strong	Altered Expression	[711]
ID2	TTW8A5N	Strong	Biomarker	[675]
IDO1	TTZJYKH	Strong	Biomarker	[712]
IDUA	TT0IUKX	Strong	Biomarker	[171]
IFNAR1	TTSYFMA	Strong	Genetic Variation	[613]
IFNB1	TT4TZ8J	Strong	Genetic Variation	[713]
IFNL1	TTM624L	Strong	Biomarker	[713]
IFNL3	TTRF4Q2	Strong	Biomarker	[714]
IGF1R	TTQFBMY	Strong	Biomarker	[715]
IGFBP1	TTCJTWF	Strong	Biomarker	[716]
IGFBP2	TTU4QSN	Strong	Biomarker	[717]
IGFBP5	TTDWEA8	Strong	Altered Expression	[718]
IGFBP7	TTUQ01B	Strong	Posttranslational Modification	[719]
IKBKB	TTJ3E9X	Strong	Biomarker	[720]
IL10RB	TTJTRMK	Strong	Genetic Variation	[721]
IL11	TTGUYTR	Strong	Altered Expression	[722]
IL12A	TTRTK6Y	Strong	Genetic Variation	[723]
IL13RA2	TTMPZ7V	Strong	Biomarker	[724]
IL15	TTJFA35	Strong	Biomarker	[725]
IL16	TTW4R0B	Strong	Genetic Variation	[726]
IL17D	TTC5LTG	Strong	Biomarker	[727]
IL2	TTF89GD	Strong	Biomarker	[728]
IL20	TTNZMY2	Strong	Biomarker	[729]
IL21	TT9QEJ6	Strong	Altered Expression	[730]
IL22	TTLDX4N	Strong	Altered Expression	[730]
IL23A	TTC1GLB	Strong	Biomarker	[731]
IL23R	TT6H4QR	Strong	Genetic Variation	[732]
IL24	TT1EPXZ	Strong	Biomarker	[733]
IL32	TTD4G7L	Strong	Biomarker	[734]
IL33	TT5MD4P	Strong	Genetic Variation	[735]
IL37	TTQTX98	Strong	Biomarker	[731]
IL4R	TTDWHC3	Strong	Biomarker	[736]
IL9	TT0JTFD	Strong	Altered Expression	[737]
IMP3	TTEJA2R	Strong	Biomarker	[738]
INHBA	TTVB30D	Strong	Altered Expression	[739]
IRAK1	TTXAJWN	Strong	Altered Expression	[115]
IRAK3	TTBPJOK	Strong	Biomarker	[740]
IRF1	TT4TU3L	Strong	Altered Expression	[741]
IRF3	TTYR7OH	Strong	Altered Expression	[742]
IRS1	TTAJSQ0	Strong	Biomarker	[743]
IRS2	TTF95B8	Strong	Altered Expression	[744]
ISG15	TTVOH3T	Strong	Biomarker	[745]
ITCH	TT5SEWD	Strong	Biomarker	[679]
ITGA2	TTSJ542	Strong	Biomarker	[746]
ITGA5	TTHIZP9	Strong	Altered Expression	[747]
ITGA6	TT165T3	Strong	Biomarker	[748]
ITGAV	TTT1R2L	Strong	Altered Expression	[747]
ITGB1	TTBVIQC	Strong	Biomarker	[749]
ITPR1	TT5HWAT	Strong	Altered Expression	[750]
JAK1	TT6DM01	Strong	Biomarker	[751]
JAK2	TTRMX3V	Strong	Biomarker	[752]
KAT2B	TTVK7SB	Strong	Genetic Variation	[753]
KAT6A	TT6O1J0	Strong	Altered Expression	[754]
KCNA2	TTVFB0O	Strong	Altered Expression	[755]
KCNA5	TTW0CMT	Strong	Altered Expression	[756]
KCNH1	TT9XKUC	Strong	Altered Expression	[757]
KCNJ3	TTGM19J	Strong	Altered Expression	[758]
KCNK9	TTL4FMB	Strong	Altered Expression	[759]
KCNN4	TT7M9I6	Strong	Altered Expression	[565]
KDM1A	TTNR0UQ	Strong	Biomarker	[760]
KDM3A	TTKXS4A	Strong	Biomarker	[761]
KDM5A	TTIG67W	Strong	Altered Expression	[762]
KDM5B	TTCLI75	Strong	Biomarker	[763]
KDM5C	TT94UCF	Strong	Biomarker	[764]
KDM6B	TTDIJUQ	Strong	Biomarker	[765]
KEAP1	TT3Z6Y9	Strong	Altered Expression	[766]
KHDRBS1	TTAT6C7	Strong	Altered Expression	[767]
KIF20B	TTQECT2	Strong	Biomarker	[768]
KIR2DS2	TTV3CFI	Strong	Altered Expression	[638]
KISS1	TTU2O6T	Strong	Altered Expression	[769]
KISS1R	TT3KBZY	Strong	Biomarker	[660]
KITLG	TTDJ51N	Strong	Altered Expression	[770]
KLF4	TTTI53X	Strong	Biomarker	[771]
KLK2	TTJLNAW	Strong	Altered Expression	[756]
KLK3	TTS78AZ	Strong	Genetic Variation	[241]
KLRK1	TTLRN4A	Strong	Altered Expression	[423]
KMT2A	TT1GNDM	Strong	Biomarker	[772]
KMT5A	TTGC95K	Strong	Biomarker	[773]
KNG1	TTDJ4MY	Strong	Biomarker	[774]
LAG3	TTNVXAW	Strong	Altered Expression	[775]
LAIR1	TTSI7A8	Strong	Altered Expression	[776]
LAMP2	TTULDG7	Strong	Altered Expression	[777]
LANCL1	TTZW8NS	Strong	Biomarker	[778]
LAPTM4B	TTEJQT0	Strong	Biomarker	[779]
LASP1	TTZJA87	Strong	Genetic Variation	[780]
LATS2	TTML7FG	Strong	Biomarker	[781]
LBP	TTVQJLY	Strong	Biomarker	[782]
LCK	TT860QF	Strong	Biomarker	[783]
LDHA	TTW76JE	Strong	Altered Expression	[784]
LDLR	TTH0DUS	Strong	Biomarker	[785]
LEP	TTBJEZ5	Strong	Biomarker	[786]
LEPR	TT0HD6V	Strong	Altered Expression	[787]
LIF	TTGZ5WN	Strong	Biomarker	[76]
LILRB1	TTC0QRJ	Strong	Altered Expression	[788]
LIN28A	TTO50LN	Strong	Biomarker	[789]
LIPE	TTLUQ8E	Strong	Biomarker	[790]
LNPEP	TTY2KP7	Strong	Biomarker	[791]
LOX	TTQHNAM	Strong	Biomarker	[792]
LOXL2	TTFSUHX	Strong	Altered Expression	[793]
LPA	TTU9LGY	Strong	Biomarker	[337]
LPAR2	TTB7Y8I	Strong	Biomarker	[308]
LPAR6	TTZDAGB	Strong	Biomarker	[184]
LRP5	TT7VMG4	Strong	Biomarker	[794]
LRP6	TTSXOWE	Strong	Biomarker	[794]
LTA	TTP73TM	Strong	Biomarker	[795]
LTB	TTHQ6US	Strong	Altered Expression	[796]
LY9	TTZCL1U	Strong	Altered Expression	[797]
LYVE1	TTG8DNU	Strong	Biomarker	[81]
MAD1L1	TTNE9U7	Strong	Altered Expression	[798]
MAGEA1	TT63M7Q	Strong	Biomarker	[81]
MAGEA2	TTOZT28	Strong	Altered Expression	[799]
MAGEA3	TTWSKHD	Strong	Altered Expression	[800]
MAGEA4	TT9EQUY	Strong	Biomarker	[801]
MAGEA6	TTJIWMO	Strong	Biomarker	[802]
MAGEC2	TTKGUEB	Strong	Biomarker	[803]
MANF	TT56RYE	Strong	Altered Expression	[804]
MAOB	TTGP7BY	Strong	Genetic Variation	[805]
MAP2K1	TTIDAPM	Strong	Biomarker	[806]
MAP2K7	TT6QY3J	Strong	Biomarker	[807]
MAP3K1	TTW8TJI	Strong	Biomarker	[808]
MAP3K11	TTETX6Q	Strong	Altered Expression	[809]
MAP3K14	TT4LIAC	Strong	Altered Expression	[810]
MAP3K5	TTOQCD8	Strong	Altered Expression	[811]
MAP3K7	TTJQT60	Strong	Altered Expression	[812]
MAP3K8	TTGECUM	Strong	Biomarker	[813]
MAP4K4	TT6NI13	Strong	Altered Expression	[814]
MAPK1	TT4TQBX	Strong	Biomarker	[565]
MAPK10	TT056SO	Strong	Biomarker	[815]
MAPK11	TT73U6C	Strong	Altered Expression	[816]
MAPK12	TTYT93M	Strong	Altered Expression	[817]
MAPK14	TTQBR95	Strong	Biomarker	[318]
MAPK7	TTU6FSC	Strong	Biomarker	[818]
MAPK8	TT0K6EO	Strong	Biomarker	[807]
MAPK9	TT3IVG2	Strong	Biomarker	[819]
MAPKAPK2	TTMUG9D	Strong	Altered Expression	[755]
MAPT	TTS87KH	Strong	Altered Expression	[820]
MARCKS	TTHRM39	Strong	Biomarker	[821]
MARK2	TTAJ45Y	Strong	Biomarker	[580]
MAS1	TTOISYB	Strong	Biomarker	[822]
MAT2A	TTSMPXQ	Strong	Altered Expression	[823]
MAZ	TT059DA	Strong	Biomarker	[824]
MCAM	TTHRE05	Strong	Biomarker	[825]
MCL1	TTL53M6	Strong	Biomarker	[826]
MCM7	TT1RM3F	Strong	Biomarker	[827]
MDK	TTV8UE7	Strong	Biomarker	[828]
MDM2	TT9TE0O	Strong	Biomarker	[829]
MDM4	TT9OUDQ	Strong	Altered Expression	[367]
MECP2	TTTAU9R	Strong	Biomarker	[830]
MELK	TTBZOTY	Strong	Biomarker	[831]
MERTK	TTO7LKR	Strong	Genetic Variation	[832]
MGLL	TTZ963I	Strong	Biomarker	[833]
MGMT	TTJ8DV7	Strong	Posttranslational Modification	[834]
MIA	TT5HNVS	Strong	Genetic Variation	[835]
MMP1	TTMX39J	Strong	Genetic Variation	[836]
MMP10	TTXLEG7	Strong	Altered Expression	[837]
MMP11	TTZW4MV	Strong	Biomarker	[838]
MMP14	TTJ4QE7	Strong	Altered Expression	[839]
MMP16	TTNP4CU	Strong	Altered Expression	[840]
MMP3	TTUZ2L5	Strong	Altered Expression	[841]
MPL	TTIHYA4	Strong	Biomarker	[842]
MRC2	TTYVR8M	Strong	Biomarker	[843]
MSI1	TTSM4BA	Strong	Altered Expression	[844]
MSI2	TTTXQF6	Strong	Altered Expression	[845]
MSLN	TT4RXME	Strong	Altered Expression	[846]
MSMB	TTYH1ZK	Strong	Biomarker	[394]
MSRB1	TT1QUZV	Strong	Biomarker	[847]
MST1R	TTBQ3OC	Strong	Biomarker	[848]
MTDH	TTH6SA5	Strong	Biomarker	[849]
MTF1	TTTQDEO	Strong	Altered Expression	[850]
MTNR1A	TT0WAIE	Strong	Biomarker	[851]
MTR	TTUTO39	Strong	Altered Expression	[852]
MTTP	TTUS1RD	Strong	Biomarker	[853]
MUC1	TTBHFYQ	Strong	Biomarker	[854]
MUTYH	TTNB0ZK	Strong	Genetic Variation	[855]
MVD	TTE5J6X	Strong	Altered Expression	[856]
MVK	TT5DFHW	Strong	Biomarker	[95]
MYC	TTNQ5ZP	Strong	Biomarker	[857]
MYCN	TT9JBY5	Strong	Biomarker	[858]
MYD88	TTB6Q2O	Strong	Biomarker	[859]
NAMPT	TTD1WIG	Strong	Biomarker	[860]
NCAM1	TTVXPHT	Strong	Biomarker	[84]
NCK1	TTMA3VF	Strong	Biomarker	[861]
NCOA3	TT124R0	Strong	Biomarker	[862]
NCR1	TTQNRJM	Strong	Altered Expression	[863]
NDUFA13	TTRU1NG	Strong	Altered Expression	[864]
NEDD8	TTNDC4K	Strong	Biomarker	[865]
NEDD9	TT1UREA	Strong	Biomarker	[866]
NEK2	TT3VZ24	Strong	Altered Expression	[867]
NEK6	TT8I2M7	Strong	Altered Expression	[868]
NFKB1	TTUIZKC	Strong	Altered Expression	[869]
NFKBIA	TTSHAEB	Strong	Genetic Variation	[870]
NOD2	TTYPUHA	Strong	Altered Expression	[871]
NODAL	TTK2O1Q	Strong	Altered Expression	[872]
NOX4	TTQRBSJ	Strong	Biomarker	[209]
NPM1	TTHBS98	Strong	Biomarker	[873]
NR0B2	TT25A9Q	Strong	Altered Expression	[874]
NR1H2	TTXA6PH	Strong	Genetic Variation	[875]
NR1H4	TTS4UGC	Strong	Altered Expression	[876]
NR1I2	TT7LCTF	Strong	Biomarker	[580]
NR1I3	TTRANFM	Strong	Biomarker	[403]
NR3C2	TT26PHO	Strong	Biomarker	[877]
NR4A1	TTMXE2Q	Strong	Biomarker	[878]
NR4A2	TT9HKN3	Strong	Biomarker	[879]
NR4A3	TTJQB49	Strong	Altered Expression	[880]
NR5A2	TTAU3SY	Strong	Altered Expression	[881]
NRP1	TTIPJCB	Strong	Biomarker	[882]
NT5E	TTK0O6Y	Strong	Altered Expression	[883]
NTN1	TT0AH4L	Strong	Biomarker	[884]
NTRK3	TTXABCW	Strong	Biomarker	[885]
NTSR1	TTTUMEP	Strong	Biomarker	[886]
NUAK1	TT65FL0	Strong	Biomarker	[887]
NUAK2	TTHVOTQ	Strong	Biomarker	[888]
NUF2	TTIXBFP	Strong	Biomarker	[889]
ODC1	TTUMGNO	Strong	Biomarker	[890]
OGFR	TT6IEYX	Strong	Biomarker	[891]
OPA1	TTTU49Q	Strong	Biomarker	[892]
OPRD1	TT27RFC	Strong	Biomarker	[893]
OPRM1	TTKWM86	Strong	Altered Expression	[894]
OSM	TTIVXSE	Strong	Biomarker	[895]
OSMR	TTAH0KM	Strong	Genetic Variation	[896]
OTC	TT5KIO9	Strong	Altered Expression	[897]
OXGR1	TTAS1QK	Strong	Posttranslational Modification	[898]
P2RX1	TTJW7B3	Strong	Altered Expression	[899]
P2RX3	TT2THBD	Strong	Biomarker	[899]
P2RX4	TT1NLOA	Strong	Altered Expression	[900]
P2RX7	TT473XN	Strong	Altered Expression	[900]
P2RY1	TTA93TL	Strong	Altered Expression	[899]
P2RY2	TTOZHQC	Strong	Altered Expression	[901]
PABPC1	TTHC8EF	Strong	Biomarker	[902]
PADI4	TTQHAXM	Strong	Altered Expression	[903]
PAK1	TTFN95D	Strong	Biomarker	[904]
PAK2	TT279WO	Strong	Biomarker	[905]
PAK4	TT7Y3BZ	Strong	Biomarker	[906]
PAM	TTF4ZPC	Strong	Genetic Variation	[907]
PARP1	TTVDSZ0	Strong	Altered Expression	[908]
PAWR	TT3I4WV	Strong	Biomarker	[582]
PAX5	TTA4REJ	Strong	Biomarker	[909]
PBK	TTMY6BZ	Strong	Biomarker	[910]
PBRM1	TTH8ZRL	Strong	Genetic Variation	[911]
PCSK9	TTNIZ2B	Strong	Biomarker	[912]
PCYT1B	TTUAIKM	Strong	Biomarker	[913]
PDCD1LG2	TTW14O3	Strong	Altered Expression	[914]
PDE1B	TT3ZS42	Strong	Biomarker	[915]
PDE3B	TTN34SQ	Strong	Altered Expression	[916]
PDE4A	TTZ97H5	Strong	Biomarker	[917]
PDE5A	TTJ0IQB	Strong	Altered Expression	[918]
PDGFA	TTSM78N	Strong	Altered Expression	[919]
PDGFB	TTQA6SX	Strong	Biomarker	[920]
PDGFC	TTOABM9	Strong	Biomarker	[921]
PDGFD	TTSN0GA	Strong	Biomarker	[922]
PDGFRA	TT8FYO9	Strong	Altered Expression	[923]
PDGFRB	TTI7421	Strong	Biomarker	[924]
PDK1	TTCZOF2	Strong	Biomarker	[925]
PDPK1	TTYMGWX	Strong	Biomarker	[925]
PDX1	TT8SGZK	Strong	Biomarker	[926]
PDXP	TT9UYG4	Strong	Biomarker	[927]
PEBP1	TT1BGU8	Strong	Biomarker	[928]
PECAM1	TT4EZB2	Strong	Altered Expression	[929]
PEMT	TT735V2	Strong	Altered Expression	[930]
PFKFB3	TTTHMQJ	Strong	Altered Expression	[931]
PGF	TT48I1Y	Strong	Biomarker	[932]
PHF8	TT81PFE	Strong	Altered Expression	[933]
PHGDH	TT8DRCK	Strong	Altered Expression	[934]
PI4KA	TTCUS9F	Strong	Altered Expression	[935]
PIM1	TTTN5QW	Strong	Biomarker	[120]
PIM2	TT69J2Z	Strong	Biomarker	[936]
PIM3	TTCGOIN	Strong	Biomarker	[937]
PIN1	TTJNTSI	Strong	Biomarker	[938]
PKM	TT4LOT8	Strong	Altered Expression	[628]
PKMYT1	TTB4PAZ	Strong	Biomarker	[939]
PLA2G2A	TTO8QRU	Strong	Altered Expression	[940]
PLA2G4A	TTT1JVS	Strong	Biomarker	[941]
PLAC1	TTM18HX	Strong	Biomarker	[942]
PLAUR	TTNOSTX	Strong	Posttranslational Modification	[943]
PLCB1	TTLPGU7	Strong	Biomarker	[944]
PLG	TTP86E2	Strong	Altered Expression	[945]
PLK1	TTH4IP0	Strong	Biomarker	[946]
PLK2	TT976FS	Strong	Posttranslational Modification	[947]
PLOD1	TTEKJP3	Strong	Altered Expression	[948]
PLOD2	TT8MEUD	Strong	Altered Expression	[948]
PLP2	TTK5OG6	Strong	Biomarker	[949]
PML	TTLH9NY	Strong	Biomarker	[950]
PMS1	TTX1ISF	Strong	Biomarker	[951]
PNP	TTMCF1Y	Strong	Biomarker	[952]
POR	TTOQ9GZ	Strong	Altered Expression	[953]
POSTN	TT8ALTZ	Strong	Biomarker	[954]
PPARD	TT2JWF6	Strong	Altered Expression	[955]
PPAT	TTZFTY4	Strong	Altered Expression	[956]
PPIA	TTL2ADK	Strong	Altered Expression	[957]
PPIB	TT6ZFQ4	Strong	Altered Expression	[958]
PPIF	TTRFQTB	Strong	Altered Expression	[959]
PPM1A	TTLA7IX	Strong	Altered Expression	[343]
PPM1D	TTENJAB	Strong	Altered Expression	[960]
PPOX	TTNFMS9	Strong	Biomarker	[682]
PPP1CA	TTFLH0E	Strong	Altered Expression	[961]
PPP2CA	TTHTKNY	Strong	Altered Expression	[962]
PPP5C	TTTW7FJ	Strong	Biomarker	[963]
PPT1	TTSQC14	Strong	Biomarker	[964]
PRDX5	TTLPJWH	Strong	Altered Expression	[965]
PRKACA	TT5U49F	Strong	Altered Expression	[534]
PRKAR1A	TTNAHEX	Strong	Biomarker	[403]
PRKCA	TTFJ8Q1	Strong	Altered Expression	[966]
PRKCB	TTYPXQF	Strong	Altered Expression	[967]
PRKCE	TT57MT2	Strong	Altered Expression	[968]
PRLR	TTBPXMA	Strong	Biomarker	[969]
PRMT1	TTVOJAI	Strong	Altered Expression	[970]
PRMT5	TTR1D7X	Strong	Biomarker	[971]
PROM1	TTXMZ81	Strong	Biomarker	[972]
PRSS8	TTT4N0Q	Strong	Altered Expression	[973]
PSEN1	TTZ3S8C	Strong	Altered Expression	[974]
PSEN2	TTWN3F4	Strong	Biomarker	[975]
PSMB8	TTEAD9J	Strong	Genetic Variation	[976]
PSMD10	TT2H4LN	Strong	Posttranslational Modification	[91]
PTBP1	TTWMX0U	Strong	Altered Expression	[977]
PTGDR	TTNVEIR	Strong	Biomarker	[978]
PTGER4	TT79WV3	Strong	Biomarker	[979]
PTGES	TTYLQ8V	Strong	Altered Expression	[980]
PTH1R	TTFPD47	Strong	Altered Expression	[981]
PTK2	TTON5IT	Strong	Biomarker	[982]
PTK2B	TTTEFBV	Strong	Biomarker	[68]
PTN	TTA9EJK	Strong	Biomarker	[983]
PTP4A1	TTA8GFO	Strong	Biomarker	[984]
PTP4A3	TT7YM8D	Strong	Biomarker	[985]
PTPN1	TTELIN2	Strong	Altered Expression	[809]
PTPN14	TTNIR6C	Strong	Altered Expression	[986]
PTPN2	TTY8PUS	Strong	Altered Expression	[987]
PTPN6	TT369M5	Strong	Altered Expression	[874]
PTPRC	TTUS45N	Strong	Biomarker	[988]
RABL3	TTYGK57	Strong	Altered Expression	[989]
RAC1	TT2M9CG	Strong	Biomarker	[990]
RACK1	TTJ10AL	Strong	Biomarker	[991]
RAF1	TTAN5W2	Strong	Biomarker	[992]
RARA	TTW38KT	Strong	Biomarker	[993]
RARB	TTISP28	Strong	Altered Expression	[994]
RARG	TT1Q3IE	Strong	Biomarker	[995]
RASA1	TTPNZ1F	Strong	Biomarker	[996]
RBP5	TTV2DON	Strong	Altered Expression	[997]
RCE1	TT2AP5B	Strong	Altered Expression	[998]
RECK	TTRZBW7	Strong	Genetic Variation	[999]
REL	TT1ZCTH	Strong	Altered Expression	[818]
RENBP	TTZCG0Q	Strong	Altered Expression	[1000]
RET	TT4DXQT	Strong	Biomarker	[1001]
RGS4	TTGTKX9	Strong	Biomarker	[1002]
RGS6	TTJ96M8	Strong	Biomarker	[1003]
RHO	TTH0KSX	Strong	Altered Expression	[1004]
RHOB	TT6LPFO	Strong	Biomarker	[1005]
RIPK1	TTVJHX8	Strong	Biomarker	[146]
RIPK4	TTB4S01	Strong	Altered Expression	[1006]
RNASEL	TT7V0K4	Strong	Altered Expression	[1007]
RNF43	TTD91BL	Strong	Biomarker	[1008]
RNF6	TT4S09X	Strong	Biomarker	[1009]
ROBO1	TTND1YP	Strong	Altered Expression	[1010]
ROBO4	TT3S9TY	Strong	Biomarker	[1011]
ROCK1	TTZN7RP	Strong	Biomarker	[1012]
ROCK2	TTGWKQJ	Strong	Biomarker	[1013]
ROR2	TTUDPCI	Strong	Biomarker	[1014]
RORA	TT1TYN7	Strong	Altered Expression	[1015]
ROS1	TTSZ6Y3	Strong	Biomarker	[1016]
RPS6KA1	TTIXKA4	Strong	Biomarker	[807]
RPS6KA2	TT0ZW9O	Strong	Biomarker	[807]
RPS6KA3	TTUM2ZR	Strong	Biomarker	[807]
RPS6KB1	TTG0U4H	Strong	Biomarker	[1017]
RRM2	TT1S4LJ	Strong	Biomarker	[391]
RSF1	TTMP86V	Strong	Biomarker	[1018]
RUNX2	TTD6SZ8	Strong	Biomarker	[1019]
RUNX3	TTKCVO7	Strong	Biomarker	[1020]
RXRA	TT6PEUO	Strong	Biomarker	[1021]
S100A3	TTCDFR1	Strong	Altered Expression	[1022]
S100A4	TTPR5SX	Strong	Altered Expression	[1023]
S100A6	TT716MY	Strong	Biomarker	[1024]
S100A9	TT0TMQG	Strong	Biomarker	[1025]
S1PR1	TT9JZCK	Strong	Biomarker	[1026]
SAA1	TTY0DN9	Strong	Biomarker	[1027]
SATB1	TTLFRIC	Strong	Altered Expression	[1028]
SCAP	TTL6U2P	Strong	Biomarker	[1029]
SCARB1	TTRE324	Strong	Altered Expression	[1030]
SCD	TT6RIOV	Strong	Biomarker	[1031]
SCT	TTOBVIN	Strong	Altered Expression	[1032]
SDC1	TTYDSVG	Strong	Biomarker	[1033]
SDC2	TT5H2F0	Strong	Altered Expression	[1034]
SDHD	TTVH9W8	Strong	Genetic Variation	[1035]
SEMA3A	TTVKD3S	Strong	Altered Expression	[1036]
SENP8	TTMBUHI	Strong	Altered Expression	[1037]
SEPTIN6	TTAGE7U	Strong	Altered Expression	[1038]
SERPINA1	TTA7UJC	Strong	Biomarker	[1039]
SERPINA6	TTJL8VG	Strong	Biomarker	[1040]
SERPINB5	TT1KW50	Strong	Genetic Variation	[1041]
SERPINC1	TT4QPUL	Strong	Biomarker	[1042]
SERPINF1	TTR59S1	Strong	Biomarker	[1043]
SERPING1	TTVQ6R9	Strong	Biomarker	[1044]
SETD2	TTPC3H4	Strong	Altered Expression	[1045]
SETD7	TTJ0FSU	Strong	Altered Expression	[1046]
SF3B1	TTL2WUI	Strong	Genetic Variation	[1047]
SFRP4	TTX8I1Y	Strong	Biomarker	[1048]
SGK1	TTTV8EJ	Strong	Biomarker	[1049]
SGO1	TTBPKGD	Strong	Biomarker	[1050]
SHCBP1	TTZ9WGL	Strong	Biomarker	[416]
SHH	TTIENCJ	Strong	Altered Expression	[1051]
SIK1	TT1H6LC	Strong	Biomarker	[1052]
SIRT2	TTLKF5M	Strong	Altered Expression	[1053]
SIRT5	TTH0IOD	Strong	Biomarker	[1054]
SIRT6	TTUXYWF	Strong	Biomarker	[1055]
SKP2	TT5B2EO	Strong	Biomarker	[1056]
SLC10A1	TTWZRY5	Strong	Genetic Variation	[1057]
SLC11A2	TT2IS7P	Strong	Genetic Variation	[1058]
SLC13A5	TTFIMH7	Strong	Biomarker	[1059]
SLC15A1	TT5LF3C	Strong	Altered Expression	[1060]
SLC15A2	TT27Q3A	Strong	Genetic Variation	[1061]
SLC16A1	TTN1J82	Strong	Altered Expression	[468]
SLC16A3	TTG6VD5	Strong	Biomarker	[1062]
SLC17A5	TTFSUIA	Strong	Altered Expression	[1063]
SLC1A1	TTG2A6F	Strong	Altered Expression	[1064]
SLC1A3	TT8WRDA	Strong	Altered Expression	[1064]
SLC22A1	TTM5Q4V	Strong	Biomarker	[1065]
SLC22A16	TTITAVR	Strong	Posttranslational Modification	[1066]
SLC22A3	TTG2UMS	Strong	Biomarker	[1067]
SLC25A1	TTTD730	Strong	Biomarker	[1068]
SLC2A1	TT79TKF	Strong	Biomarker	[1069]
SLC2A4	TTP6MT5	Strong	Biomarker	[1070]
SLC2A9	TTIF3GB	Strong	Altered Expression	[1071]
SLC33A1	TTL69WB	Strong	Altered Expression	[1072]
SLC38A1	TT1YE9Z	Strong	Altered Expression	[1073]
SLC38A4	TTJE54U	Strong	Biomarker	[1074]
SLC39A6	TTZN1CF	Strong	Altered Expression	[1075]
SLC3A2	TT5CZSM	Strong	Altered Expression	[1076]
SLC52A2	TT6TKEN	Strong	Biomarker	[580]
SLC5A1	TT2UE56	Strong	Altered Expression	[1077]
SLC5A2	TTF8JAT	Strong	Biomarker	[1078]
SLC5A5	TTW7HI9	Strong	Biomarker	[1079]
SLC6A2	TTAWNKZ	Strong	Biomarker	[1080]
SLC6A5	TTI0138	Strong	Biomarker	[1080]
SLC6A8	TTYUHB5	Strong	Biomarker	[397]
SLC7A11	TTBZMIO	Strong	Altered Expression	[1081]
SLC7A5	TTPH2JB	Strong	Altered Expression	[1082]
SLC9A1	TTGSEFH	Strong	Altered Expression	[1083]
SLCO1B1	TTFGXEB	Strong	Altered Expression	[1084]
SLCO1B3	TTU86P0	Strong	Biomarker	[1085]
SLIT2	TTDWK85	Strong	Biomarker	[1086]
SMAD1	TT9GR53	Strong	Altered Expression	[1087]
SMAD3	TTHQZV7	Strong	Biomarker	[1088]
SMAD6	TTON5JB	Strong	Biomarker	[1089]
SMAD7	TT0J32Z	Strong	Biomarker	[1090]
SMARCA4	TTVQEZS	Strong	Biomarker	[1091]
SMN1	TT8QL6X	Strong	Altered Expression	[1092]
SMYD3	TTKLJYX	Strong	Altered Expression	[1093]
SNCG	TT5TQNZ	Strong	Altered Expression	[1094]
SOAT2	TTAK0IN	Strong	Altered Expression	[1095]
SOCS3	TTI0ME6	Strong	Biomarker	[1096]
SOD2	TT9O4C5	Strong	Altered Expression	[1097]
SP1	TTZEP6S	Strong	Biomarker	[1098]
SPARC	TTBQFM7	Strong	Genetic Variation	[1099]
SPDEF	TT2ZUPY	Strong	Biomarker	[1100]
SPHK1	TTOHFIY	Strong	Biomarker	[1101]
SPHK2	TTCN0M9	Strong	Altered Expression	[1102]
SPRY1	TT0PSN6	Strong	Altered Expression	[1103]
SQLE	TTE14XG	Strong	Biomarker	[1104]
SQSTM1	TTOT2RY	Strong	Altered Expression	[767]
SREBF2	TTRQ4AP	Strong	Altered Expression	[1105]
SRGN	TTCHB06	Strong	Altered Expression	[1106]
SRPK1	TTU3WV6	Strong	Altered Expression	[1107]
SRPK2	TTCZEJ9	Strong	Biomarker	[1108]
SSRP1	TTETDKQ	Strong	Altered Expression	[1109]
SST	TTWF7UG	Strong	Altered Expression	[1110]
SSTR2	TTZ6T9E	Strong	Biomarker	[267]
SSTR3	TTJX3UE	Strong	Biomarker	[267]
SSTR4	TTAE1BR	Strong	Biomarker	[308]
ST14	TTPRO7W	Strong	Biomarker	[1111]
STAB1	TTJFEOC	Strong	Altered Expression	[1112]
STAB2	TTM3DAY	Strong	Biomarker	[81]
STAT6	TTWOE1T	Strong	Biomarker	[1113]
STC1	TTDLUER	Strong	Altered Expression	[1114]
STC2	TT4EFTR	Strong	Altered Expression	[1115]
STK4	TTCPLVN	Strong	Biomarker	[1116]
STMN1	TT7W5OT	Strong	Biomarker	[1117]
STOML2	TTOI329	Strong	Biomarker	[1118]
STS	TTHM0R1	Strong	Biomarker	[1119]
STYK1	TTRMCYJ	Strong	Biomarker	[1120]
SULF2	TTLQTHB	Strong	Biomarker	[1034]
SUV39H1	TTUWQTK	Strong	Altered Expression	[1121]
SYK	TT2HUPM	Strong	Biomarker	[1122]
TAGLN	TTDRZ9H	Strong	Biomarker	[1123]
TAGLN2	TTP6BIJ	Strong	Altered Expression	[1124]
TAP1	TT7JZI8	Strong	Biomarker	[1125]
TBK1	TTMP03S	Strong	Altered Expression	[1126]
TBL1X	TTAL6S1	Strong	Altered Expression	[1127]
TBL1XR1	TTYXT16	Strong	Altered Expression	[1128]
TBX21	TTNF9PH	Strong	Biomarker	[1129]
TCF3	TTULOD8	Strong	Biomarker	[1130]
TCF7L2	TT80QAL	Strong	Biomarker	[1131]
TCL1A	TTUKRDV	Strong	Biomarker	[1132]
TEC	TT1ZV49	Strong	Genetic Variation	[564]
TERF1	TT1Y6J2	Strong	Altered Expression	[1133]
TERF2	TT5XSLT	Strong	Altered Expression	[1134]
TF	TT8WXAV	Strong	Biomarker	[1135]
TFAP2A	TTDY4BS	Strong	Biomarker	[1136]
TFF1	TTNOJIZ	Strong	Biomarker	[975]
TFPI	TT068JH	Strong	Biomarker	[1137]
TGFA	TTTLQFR	Strong	Posttranslational Modification	[1138]
TGFB2	TTI0KH6	Strong	Biomarker	[374]
TGFB3	TTWOMY8	Strong	Altered Expression	[1139]
TGFBR1	TTP4520	Strong	Altered Expression	[1140]
TGFBR2	TTZE3P7	Strong	Altered Expression	[1141]
TGM2	TT2F4OL	Strong	Altered Expression	[1142]
TH	TTUHP71	Strong	Biomarker	[1143]
THBS1	TTKI0H1	Strong	Biomarker	[1144]
THPO	TTCG5PE	Strong	Biomarker	[1145]
THRA	TTTSEPU	Strong	Altered Expression	[1146]
THRB	TTGER3L	Strong	Altered Expression	[1146]
TIE1	TTT4236	Strong	Altered Expression	[1147]
TKT	TT04R7I	Strong	Biomarker	[1148]
TKTL1	TTNQ1J3	Strong	Biomarker	[1149]
TLN1	TTQSMFG	Strong	Biomarker	[1150]
TLR4	TTISGCA	Strong	Altered Expression	[1151]
TLR5	TTCXP8J	Strong	Genetic Variation	[1152]
TM6SF2	TTE1OHM	Strong	Genetic Variation	[1153]
TMBIM6	TT7QSMG	Strong	Altered Expression	[1154]
TNFAIP3	TT5W0IO	Strong	Biomarker	[1155]
TNFRSF12A	TTKPS7V	Strong	Biomarker	[1156]
TNFRSF14	TTWGTC1	Strong	Biomarker	[72]
TNFRSF25	TTDV6BQ	Strong	Altered Expression	[1157]
TNFRSF9	TTPW9LJ	Strong	Biomarker	[1158]
TNFSF11	TT9E8HR	Strong	Biomarker	[1159]
TNFSF13	TTOI1RM	Strong	Biomarker	[1160]
TNFSF14	TTKVENM	Strong	Biomarker	[1161]
TNFSF15	TTEST6I	Strong	Altered Expression	[1162]
TNK2	TTIET93	Strong	Biomarker	[1163]
TNKS	TTVUSO7	Strong	Biomarker	[1164]
TPH1	TTZSJHV	Strong	Altered Expression	[709]
TPP1	TTOVYPT	Strong	Altered Expression	[1165]
TPX2	TT0PHL4	Strong	Biomarker	[1166]
TRAF6	TTCDR6M	Strong	Altered Expression	[1167]
TRIM24	TT9Q7AE	Strong	Biomarker	[1168]
TRIM27	TTTO3QN	Strong	Biomarker	[1169]
TRIM28	TTQ2BKV	Strong	Altered Expression	[1170]
TRPC1	TTA76X0	Strong	Biomarker	[1171]
TRPM7	TTFPVZO	Strong	Biomarker	[1172]
TRPV1	TTMI6F5	Strong	Biomarker	[1173]
TRPV2	TTBECWA	Strong	Altered Expression	[1174]
TSPO	TTPTXIN	Strong	Biomarker	[461]
TST	TT51OTS	Strong	Altered Expression	[1175]
TTR	TTPOYU7	Strong	Biomarker	[1176]
TXN	TTZJ5U9	Strong	Biomarker	[1177]
TXNDC12	TTL0E3Y	Strong	Biomarker	[1178]
TXNRD1	TTR7UJ3	Strong	Altered Expression	[766]
TYMP	TTO0IB8	Strong	Biomarker	[611]
TYMS	TTP1UKZ	Strong	Genetic Variation	[1179]
TYRO3	TTIEMFN	Strong	Biomarker	[1180]
UBC	TTBP3XA	Strong	Biomarker	[1181]
UBE2T	TT0A1R8	Strong	Altered Expression	[1182]
UCHL1	TTX9IFP	Strong	Biomarker	[1183]
UCHL5	TTSX29Z	Strong	Biomarker	[1184]
UCP1	TTI12YJ	Strong	Biomarker	[1185]
UCP2	TTSC2YM	Strong	Altered Expression	[1186]
UGCG	TTPHEX3	Strong	Biomarker	[1187]
UGT1A1	TT34ZAF	Strong	Genetic Variation	[1188]
UMPS	TTAFJUD	Strong	Biomarker	[149]
USP14	TTVSYP9	Strong	Biomarker	[1189]
USP5	TTGYTMA	Strong	Biomarker	[1190]
USP7	TTXU3EQ	Strong	Altered Expression	[1191]
UTRN	TTNO1VA	Strong	Altered Expression	[1192]
UTS2	TTERU0T	Strong	Biomarker	[1193]
VANGL1	TT18WJB	Strong	Altered Expression	[1194]
VCAM1	TTHCEF6	Strong	Altered Expression	[1195]
VCP	TTHNLSB	Strong	Biomarker	[1196]
VDAC1	TTAMKGB	Strong	Biomarker	[1197]
VDAC3	TTT48SQ	Strong	Biomarker	[1198]
VDR	TTK59TV	Strong	Genetic Variation	[1199]
VEGFB	TTPJQHE	Strong	Altered Expression	[1200]
VEGFC	TT0QUFV	Strong	Biomarker	[1201]
VEGFD	TTOM5H4	Strong	Altered Expression	[1202]
VHL	TTEMWSD	Strong	Biomarker	[1203]
VIP	TTGTWLF	Strong	Biomarker	[1204]
VIPR1	TTCL30I	Strong	Biomarker	[1205]
VIPR2	TT4O5P0	Strong	Biomarker	[1205]
VTCN1	TTCK85E	Strong	Altered Expression	[1206]
VWF	TT3SZBT	Strong	Biomarker	[1207]
WAS	TTE8T73	Strong	Altered Expression	[1208]
WEE1	TTJFOAL	Strong	Biomarker	[1209]
WNK1	TTJ9UMX	Strong	Biomarker	[804]
WNT5A	TTKG7F8	Strong	Altered Expression	[1210]
WWP1	TTBWMKT	Strong	Biomarker	[1211]
XDH	TT7RJY8	Strong	Biomarker	[1212]
XIAP	TTK3WBU	Strong	Altered Expression	[481]
XPA	TTGT87E	Strong	Genetic Variation	[1213]
XPO1	TTCJUR4	Strong	Altered Expression	[1214]
XRCC5	TTCB9KW	Strong	Biomarker	[1215]
YAP1	TT8UN2D	Strong	Biomarker	[1216]
YES1	TT0SQ8J	Strong	Biomarker	[1217]
ZEB2	TTT2WK4	Strong	Biomarker	[574]
ZFAND5	TTLFY3S	Strong	Biomarker	[1218]
ZIK1	TTQZULJ	Strong	Biomarker	[1219]
ZNF217	TTY3BRA	Strong	Altered Expression	[1220]
ZWINT	TTWY768	Strong	Biomarker	[1221]
AADAT	TTT3IXG	Definitive	Biomarker	[81]
ADAMTS4	TTYG6BU	Definitive	Genetic Variation	[1222]
AICDA	TTKRTP6	Definitive	Biomarker	[1223]
ALOX5	TTSJ6Q4	Definitive	Altered Expression	[1224]
AMACR	TTLN1AP	Definitive	Biomarker	[1225]
ASRGL1	TT4WT91	Definitive	Genetic Variation	[1226]
BMP6	TT07RIB	Definitive	Altered Expression	[1227]
CASP8	TT6SZNG	Definitive	Biomarker	[370]
CD46	TTMS7DF	Definitive	Altered Expression	[1228]
CDCA8	TT04YCM	Definitive	Biomarker	[81]
CDKL1	TTBTI6P	Definitive	Biomarker	[1229]
CETP	TTFQAYR	Definitive	Biomarker	[81]
CXCR5	TTIW59R	Definitive	Biomarker	[1230]
DBH	TTYIP79	Definitive	Biomarker	[81]
DCK	TTJOCE4	Definitive	Biomarker	[1231]
DEPTOR	TTLYP6D	Definitive	Biomarker	[1232]
DGAT2	TTRHEQ4	Definitive	Biomarker	[1233]
DYRK3	TTV4EX0	Definitive	Biomarker	[862]
EBP	TT4VQZX	Definitive	Altered Expression	[1234]
FUT4	TTNV1KZ	Definitive	Altered Expression	[1235]
GABRD	TTGXH6N	Definitive	Biomarker	[81]
GSTO1	TTWO3SH	Definitive	Biomarker	[1236]
HLA-G	TTLKFB3	Definitive	Genetic Variation	[1237]
IFNA5	TTLHGSF	Definitive	Biomarker	[1238]
IFNAR2	TTMQB37	Definitive	Biomarker	[1239]
ITPR3	TTH1769	Definitive	Altered Expression	[1240]
KCNN2	TT2T5M0	Definitive	Biomarker	[81]
KIF11	TTBGTCW	Definitive	Biomarker	[81]
KIF26B	TTQWICZ	Definitive	Altered Expression	[1241]
KLB	TTARBVH	Definitive	Biomarker	[1242]
LCAT	TTGZ91P	Definitive	Biomarker	[81]
LMO2	TTFX379	Definitive	Altered Expression	[1243]
LY6D	TTINE9B	Definitive	Biomarker	[1244]
MAP3K21	TTSW9YL	Definitive	Biomarker	[1245]
MFGE8	TT1GLAJ	Definitive	Biomarker	[1246]
MOGAT2	TTN17BP	Definitive	Biomarker	[81]
MTAP	TTDBX7N	Definitive	Biomarker	[1247]
MUC16	TTC1PS3	Definitive	Biomarker	[1248]
NCL	TTK1V5Q	Definitive	Biomarker	[1249]
PDK2	TTJGCKM	Definitive	Altered Expression	[1250]
PLA2G1B	TT9V5JH	Definitive	Altered Expression	[1251]
PLXDC1	TTPSK7A	Definitive	Biomarker	[81]
PRKCI	TTWJTHX	Definitive	Altered Expression	[1252]
PTGER1	TTG1QMU	Definitive	Altered Expression	[1253]
PTPN13	TT405FP	Definitive	Biomarker	[1254]
RBP4	TT0C8BY	Definitive	Biomarker	[1255]
REG3A	TTL4H8N	Definitive	Biomarker	[1048]
RSPO3	TT7HJTF	Definitive	Biomarker	[81]
S100A8	TT4AF6N	Definitive	Biomarker	[1256]
SOX5	TTXHSZK	Definitive	Biomarker	[1257]
SRD5A2	TTT02K8	Definitive	Biomarker	[1258]
TACC3	TTQ4UFD	Definitive	Biomarker	[81]
TEP1	TTQGAVX	Definitive	Genetic Variation	[1259]
TK1	TTP3QRF	Definitive	Biomarker	[81]
TSLP	TTHMW3T	Definitive	Biomarker	[81]
YY1AP1	TTYED1Q	Definitive	Biomarker	[1260]

This Disease Is Related to 43 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC25A10	DTJYKDQ	Limited	Altered Expression	[1261]
SLC25A11	DT0YAUQ	Limited	Biomarker	[1261]
SLC25A16	DTNU9EW	Limited	Biomarker	[1262]
SLC25A3	DTCRIWV	Limited	Biomarker	[1263]
SLC27A5	DT0TQS3	Limited	Altered Expression	[766]
SLC9C1	DT9J8DO	Limited	Biomarker	[1264]
SLC6A19	DTOTAUP	Disputed	Biomarker	[1265]
SLC31A1	DTP8L4F	moderate	Biomarker	[1266]
ABCA2	DTJ4NEG	Strong	Altered Expression	[1267]
ABCB5	DTKVEXO	Strong	Altered Expression	[1268]
ABCB6	DTF9Y2V	Strong	Biomarker	[1269]
ABCD1	DTKM9DZ	Strong	Biomarker	[1270]
ABCD2	DT4MBHD	Strong	Altered Expression	[1271]
KCNK2	DTENHUP	Strong	Biomarker	[759]
SLC12A2	DTHKL3Q	Strong	Biomarker	[1272]
SLC22A17	DTXI9E6	Strong	Altered Expression	[1273]
SLC22A5	DT3HUVD	Strong	Altered Expression	[1274]
SLC22A7	DT0OC1Q	Strong	Altered Expression	[1275]
SLC25A12	DT85HYR	Strong	Biomarker	[477]
SLC25A13	DTDSYAQ	Strong	Genetic Variation	[1276]
SLC25A20	DTQOUM4	Strong	Genetic Variation	[1277]
SLC25A21	DT2UQYR	Strong	Biomarker	[1278]
SLC25A37	DTLBGTZ	Strong	Biomarker	[1279]
SLC25A5	DTL1TRY	Strong	Biomarker	[1280]
SLC26A3	DTN1FMD	Strong	Biomarker	[1281]
SLC26A5	DTPGHJ7	Strong	Genetic Variation	[1282]
SLC28A1	DT0EQPW	Strong	Altered Expression	[1283]
SLC29A2	DTW78DQ	Strong	Altered Expression	[1284]
SLC2A2	DTUJPOL	Strong	Altered Expression	[1285]
SLC30A1	DT1BO38	Strong	Biomarker	[1286]
SLC35A4	DT2OPRB	Strong	Biomarker	[1287]
SLC35C1	DT3LZWR	Strong	Altered Expression	[1288]
SLC39A14	DTZ6IJW	Strong	Genetic Variation	[1289]
SLC39A4	DTEZCUM	Strong	Biomarker	[1290]
SLC4A1	DTB0Q3P	Strong	Biomarker	[1291]
SLC4A2	DTF7GAL	Strong	Altered Expression	[1292]
SLC52A1	DT7NOKR	Strong	Biomarker	[1293]
SLC5A8	DTE3TAW	Strong	Biomarker	[1294]
SLC7A2	DTWY9RT	Strong	Genetic Variation	[1074]
SLC7A8	DTJF3DX	Strong	Biomarker	[1074]
ANXA11	DTGQ2CF	Definitive	Biomarker	[1295]
SLC26A6	DTVGOLN	Definitive	Biomarker	[81]
SLC35A1	DTVZIRG	Definitive	Genetic Variation	[1296]

This Disease Is Related to 94 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
AKR1C2	DEOY5ZM	Limited	Biomarker	[293]
APRT	DE2MV1R	Limited	Altered Expression	[1297]
BCO1	DE6BOK3	Limited	Biomarker	[1298]
CYP2C18	DEZMWRE	Limited	Altered Expression	[509]
CYP2C8	DES5XRU	Limited	Biomarker	[1299]
CYP4F12	DED26GV	Limited	Biomarker	[1300]
GLDC	DEIN8FB	Limited	Altered Expression	[1301]
GSTZ1	DEQPEMB	Limited	Biomarker	[1302]
HSD3B2	DEN0GVQ	Limited	Biomarker	[138]
MT1A	DE5ME8A	Limited	Biomarker	[1303]
PGM1	DEA3VM1	Limited	Altered Expression	[1304]
SMOX	DEOH5V3	Limited	Biomarker	[1305]
FXN	DEXVHDB	Disputed	Biomarker	[1306]
GMDS	DE8K7F3	Disputed	Biomarker	[1307]
P4HA2	DE5EGK0	moderate	Biomarker	[1308]
PSAT1	DEBS17P	moderate	Genetic Variation	[241]
SULT1A3	DEP7E8X	moderate	Biomarker	[1309]
SULT2B1	DEZBN53	moderate	Altered Expression	[1310]
ACP5	DESITDW	Strong	Altered Expression	[1311]
ACSS2	DEE76VW	Strong	Biomarker	[1312]
ADH4	DEOCWU3	Strong	Biomarker	[510]
ADH5	DEIOH6A	Strong	Altered Expression	[1313]
ADH6	DE017IC	Strong	Biomarker	[1314]
AKR1A1	DED2FW3	Strong	Biomarker	[1315]
AKR1B10	DEP6GT1	Strong	Biomarker	[1316]
AKR1C1	DE7P2FB	Strong	Genetic Variation	[1317]
ALAS2	DE437BY	Strong	Genetic Variation	[1318]
ALDH1A2	DEKN1H4	Strong	Biomarker	[1319]
ALDH1B1	DEXI4UQ	Strong	Biomarker	[1320]
ASNS	DEXISVQ	Strong	Genetic Variation	[1321]
B4GALT7	DEKRS6L	Strong	Biomarker	[1322]
BLMH	DECH1VP	Strong	Posttranslational Modification	[1323]
CHDH	DEAHED0	Strong	Posttranslational Modification	[198]
CRMP1	DE0EUXB	Strong	Altered Expression	[1192]
CYP27B1	DE3FYEM	Strong	Altered Expression	[959]
CYP2R1	DEBIHM3	Strong	Genetic Variation	[1324]
CYP3A7	DERD86B	Strong	Altered Expression	[1325]
CYP4A11	DE2XQGW	Strong	Biomarker	[1326]
CYP4B1	DEMF740	Strong	Biomarker	[1327]
CYP4F2	DE3GT9C	Strong	Biomarker	[1300]
CYP4F3	DEFCMPI	Strong	Biomarker	[1328]
CYP7A1	DEDZRQ1	Strong	Biomarker	[1329]
DCXR	DE3FEV8	Strong	Biomarker	[1330]
DDAH1	DEY0TQC	Strong	Altered Expression	[1331]
DHCR7	DEL7GFA	Strong	Genetic Variation	[1324]
DIO3	DET89OV	Strong	Genetic Variation	[1332]
FADS1	DE05S8C	Strong	Biomarker	[333]
FUT10	DEP8X02	Strong	Altered Expression	[1333]
FUT11	DERG61P	Strong	Altered Expression	[1333]
GCLC	DESYL1F	Strong	Altered Expression	[1334]
GGT5	DEH6CAO	Strong	Biomarker	[1335]
GLS	DE3E0VT	Strong	Biomarker	[631]
GSTO2	DEHMPZR	Strong	Biomarker	[1336]
HIF1AN	DEY1CBW	Strong	Biomarker	[676]
HINT1	DEWJATF	Strong	Altered Expression	[1337]
HK1	DEDMAGE	Strong	Altered Expression	[628]
HPGD	DEHKSC6	Strong	Biomarker	[1338]
HPRT1	DEVXTP5	Strong	Biomarker	[1339]
MAT1A	DEQ6NC9	Strong	Biomarker	[289]
MAT2B	DEKF1OH	Strong	Biomarker	[1340]
ME1	DE97WM8	Strong	Biomarker	[1341]
MSRA	DEU2ZBY	Strong	Altered Expression	[1342]
MT2A	DEFKGT7	Strong	Biomarker	[81]
MTRR	DE6NIY9	Strong	Genetic Variation	[1343]
NAT1	DE7OAB3	Strong	Genetic Variation	[1344]
NAT10	DEZV4AP	Strong	Biomarker	[1345]
NNMT	DECVGJ3	Strong	Biomarker	[1346]
NT5C2	DE1DOKJ	Strong	Biomarker	[916]
PAPSS1	DEDG68B	Strong	Biomarker	[1347]
PARK7	DEPOVCH	Strong	Altered Expression	[1348]
PCK1	DEPLH5Z	Strong	Genetic Variation	[1349]
PER1	DE9HF0I	Strong	Biomarker	[1350]
PFAS	DE5LFD8	Strong	Biomarker	[1351]
PRKCSH	DE073GW	Strong	Altered Expression	[1352]
PTGR1	DE4Q2OE	Strong	Altered Expression	[1353]
SAT1	DEMWO83	Strong	Biomarker	[1354]
SCLY	DEH4TD6	Strong	Altered Expression	[1355]
SULT1A1	DEYWLRK	Strong	Genetic Variation	[1356]
SULT1E1	DESTKG6	Strong	Altered Expression	[1357]
SULT2A1	DE0P6LK	Strong	Altered Expression	[1358]
TGM3	DEOEB3Q	Strong	Biomarker	[1359]
THOP1	DE95LJC	Strong	Biomarker	[1360]
UAP1	DETYWG5	Strong	Altered Expression	[1361]
UCK1	DE478BP	Strong	Altered Expression	[1362]
UCK2	DETN1O0	Strong	Biomarker	[1363]
UGP2	DE4U39Y	Strong	Biomarker	[1364]
UGT1A10	DEL5N6Y	Strong	Biomarker	[1365]
UGT1A9	DE85D2P	Strong	Altered Expression	[1366]
UGT2B28	DEB7I4M	Strong	Genetic Variation	[1367]
UGT2B4	DENUPDX	Strong	Altered Expression	[1368]
UGT2B7	DEB3CV1	Strong	Altered Expression	[1369]
CPA4	DEXKD7J	Definitive	Altered Expression	[1370]
CYP27A1	DEBS639	Definitive	Biomarker	[1371]
CYP39A1	DEEG96X	Definitive	Biomarker	[81]

This Disease Is Related to 2604 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACAN	OTUOCW8K	Limited	Biomarker	[477]
ACCS	OTHIHI9D	Limited	Biomarker	[1312]
ACER3	OTIVQBG5	Limited	Altered Expression	[1372]
ACTR3	OT05LJSH	Limited	Biomarker	[1373]
ADD1	OTTF68DC	Limited	Biomarker	[138]
ADGRE2	OTUYJVYG	Limited	Altered Expression	[308]
ADGRE5	OTTSB84Q	Limited	Altered Expression	[308]
ADGRL4	OTN1GAG7	Limited	Biomarker	[1374]
AGBL2	OTCX9987	Limited	Altered Expression	[1375]
AGGF1	OTA7U2T8	Limited	Biomarker	[1376]
AGPS	OTFBFPV4	Limited	Altered Expression	[1377]
AKAP1	OTIIB2JB	Limited	Biomarker	[1378]
ALG1	OTVXPA9E	Limited	Biomarker	[851]
ANGPTL1	OTXIN6V5	Limited	Biomarker	[1379]
ANGPTL8	OTQFINCD	Limited	Biomarker	[1380]
APOBEC3A	OTYO6F5P	Limited	Biomarker	[1373]
APOBEC3F	OT750IJM	Limited	Altered Expression	[1381]
ARHGAP18	OTYMJP6H	Limited	Altered Expression	[1382]
ARHGAP9	OTJNHX96	Limited	Biomarker	[617]
ARHGEF39	OT9UKTQ5	Limited	Altered Expression	[1383]
ARHGEF9	OTB1FLIW	Limited	Biomarker	[1384]
ARID4B	OTYLPILE	Limited	Biomarker	[1385]
ASCL1	OTI4X44G	Limited	Biomarker	[1386]
ATP5PD	OTAJDLE2	Limited	Biomarker	[293]
B3GALNT2	OTOF6O2B	Limited	Biomarker	[1387]
BIRC6	OTCQJAB0	Limited	Biomarker	[1388]
BRI3	OT1RWIH7	Limited	Altered Expression	[1389]
C11orf96	OTEQU0V7	Limited	Biomarker	[311]
C20orf204	OT0GVQPP	Limited	Biomarker	[1390]
CADM1	OTRWG9QS	Limited	Altered Expression	[1391]
CALML3	OTM8DNQU	Limited	Biomarker	[1392]
CAND1	OTGB6NU0	Limited	Biomarker	[1393]
CAPZA1	OTAXA66U	Limited	Altered Expression	[1394]
CCDC6	OTXRQDYG	Limited	Biomarker	[585]
CCN6	OTRFHQ2Z	Limited	Biomarker	[1395]
CCNY	OTK1KG5W	Limited	Altered Expression	[1396]
CCR10	OT7ZWSSD	Limited	Altered Expression	[1397]
CD300C	OT4BSR7D	Limited	Altered Expression	[631]
CDC37L1	OTGKTFAC	Limited	Biomarker	[1398]
CDH13	OTD2CYM5	Limited	Biomarker	[81]
CDK14	OT385ZH1	Limited	Biomarker	[1399]
CDYL	OTCUK5KZ	Limited	Biomarker	[676]
CEACAM8	OTLL9WWO	Limited	Altered Expression	[152]
CEBPD	OTNBIPMY	Limited	Altered Expression	[1400]
CEMIP	OTK80FYN	Limited	Biomarker	[1401]
CENPK	OTKPUF8K	Limited	Altered Expression	[1216]
CEP55	OTGSG2PA	Limited	Genetic Variation	[1402]
CFHR3	OTYL8SDO	Limited	Altered Expression	[1403]
CHGB	OT7SAQT2	Limited	Biomarker	[1404]
CHL1	OT6E6E8P	Limited	Altered Expression	[1405]
CHP1	OTHTXN1A	Limited	Biomarker	[1406]
CKMT1A	OTCINHH5	Limited	Biomarker	[1407]
CLCA4	OTCRR1M9	Limited	Biomarker	[1408]
CLDN17	OTQCEYBY	Limited	Altered Expression	[1409]
CNPY2	OTGY8ESX	Limited	Altered Expression	[1410]
CPEB1	OTLCXC6H	Limited	Biomarker	[1411]
CPNE3	OTCR3WG2	Limited	Altered Expression	[1412]
CSMD1	OTIVDSC4	Limited	Biomarker	[1413]
CTRL	OTB6NA5O	Limited	Altered Expression	[1414]
CXCL16	OTD49T9R	Limited	Biomarker	[501]
DAB2	OTRMQTMZ	Limited	Biomarker	[1415]
DCTN3	OTQOSUES	Limited	Biomarker	[1406]
DDX1	OT3U8FD0	Limited	Biomarker	[1416]
DDX39A	OT0Z6E1K	Limited	Biomarker	[1417]
DEAF1	OTCLX3ZW	Limited	Biomarker	[1418]
DGKG	OTBL32T3	Limited	Altered Expression	[1419]
DIAPH3	OTPOT23F	Limited	Altered Expression	[1420]
DLAT	OT9LBJVN	Limited	Biomarker	[1421]
DLGAP5	OTWCN39U	Limited	Altered Expression	[1422]
DNAH8	OTGES2OU	Limited	Biomarker	[1423]
DNAJB11	OTDDK2SY	Limited	Biomarker	[1424]
DPY30	OTLHCJ6C	Limited	Altered Expression	[1425]
DSCC1	OTPUVLZT	Limited	Altered Expression	[1426]
DSG2	OTJPB2TO	Limited	Altered Expression	[1427]
DSN1	OTHROI0H	Limited	Altered Expression	[1428]
DUSP6	OT4H6RKW	Limited	Altered Expression	[1429]
DVL2	OTMNYNCM	Limited	Biomarker	[1430]
DYNC1H1	OTD1KRKO	Limited	Biomarker	[1406]
ECHDC2	OTL0DWCO	Limited	Biomarker	[1431]
ELF3	OTUTLEQO	Limited	Biomarker	[1432]
EPS8	OTZ6ES6V	Limited	Biomarker	[1433]
ERO1A	OTVKOQWM	Limited	Biomarker	[1026]
ESM1	OT331Y8V	Limited	Biomarker	[1434]
ETFA	OTXX61VZ	Limited	Biomarker	[293]
EXO1	OTI87RS5	Limited	Genetic Variation	[1435]
EYA1	OTHU807A	Limited	Biomarker	[1436]
FATE1	OTPYXV64	Limited	Biomarker	[1437]
FBXL5	OT93D50X	Limited	Biomarker	[1438]
FCGBP	OT63T6XQ	Limited	Biomarker	[1439]
FCN3	OTPRENLS	Limited	Biomarker	[1440]
FLII	OT7G9JG6	Limited	Biomarker	[1441]
GAB2	OTBFN705	Limited	Altered Expression	[1442]
GARS1	OT5B6R9Y	Limited	Biomarker	[379]
GAS8	OT8KT2AK	Limited	Altered Expression	[1443]
GATA6	OTO2BC0F	Limited	Altered Expression	[1444]
GATAD1	OT0UZ3EP	Limited	Biomarker	[1445]
GGA2	OT43HO27	Limited	Altered Expression	[1446]
GNA14	OTYZ1ZI0	Limited	Biomarker	[1447]
GNPAT	OTF6LWPO	Limited	Biomarker	[177]
GUCD1	OTGUB3CM	Limited	Altered Expression	[1448]
HHEX	OTLIUVYX	Limited	Altered Expression	[1067]
HIPK3	OT4WYQM2	Limited	Biomarker	[1377]
HLA-DQB1	OTVVI3UI	Limited	Genetic Variation	[1449]
HOXC6	OTBCRAZV	Limited	Biomarker	[1450]
HPCAL1	OTOBBFRD	Limited	Altered Expression	[1451]
HRNR	OT560QR5	Limited	Altered Expression	[1452]
HSF4	OT1UX9SK	Limited	Biomarker	[1453]
HSPA14	OTZCA5LK	Limited	Biomarker	[1454]
IGBP1	OTTHH4YE	Limited	Biomarker	[1455]
IGF2BP3	OTB97VIK	Limited	Biomarker	[1456]
IL34	OTZ15VVK	Limited	Biomarker	[1457]
INSRR	OT3F75WA	Limited	Genetic Variation	[1458]
IPO7	OTDFMQ00	Limited	Biomarker	[1459]
IPO8	OTBHGNKT	Limited	Biomarker	[1459]
IRGM	OTKD3O5Z	Limited	Altered Expression	[1375]
IRX5	OT05J514	Limited	Biomarker	[1460]
ITGA9	OTHN1IKA	Limited	Biomarker	[485]
ITGB5	OT21MF51	Limited	Biomarker	[1461]
ITIH3	OT4SLMLY	Limited	Biomarker	[138]
KANK3	OTEZFS98	Limited	Biomarker	[1462]
KAT2A	OTN0W2SW	Limited	Biomarker	[1463]
KLF11	OTKVQDJD	Limited	Altered Expression	[1464]
KLF14	OT8BXLBS	Limited	Biomarker	[1465]
KLHDC2	OTBHH882	Limited	Altered Expression	[1466]
KLRB1	OTQ2959Y	Limited	Biomarker	[84]
LETM1	OT8N4MRU	Limited	Therapeutic	[1467]
LHB	OT5GBOVJ	Limited	Genetic Variation	[1468]
LIN52	OT14OQ1C	Limited	Biomarker	[1469]
LIN7A	OTFL3PUX	Limited	Biomarker	[1470]
LMO3	OTR7AJHN	Limited	Altered Expression	[1471]
LNPK	OTOBNX6G	Limited	Biomarker	[1472]
LOXL4	OT6XY2JL	Limited	Altered Expression	[1473]
LRRC59	OT6BQJ5E	Limited	Biomarker	[1474]
MACROD1	OTWFEVRW	Limited	Biomarker	[1475]
MAFF	OT9B7MX0	Limited	Altered Expression	[1476]
MAFG	OTBQFUZH	Limited	Altered Expression	[1477]
MAGEH1	OTVE05K7	Limited	Altered Expression	[1478]
MAVS	OTTQ0J64	Limited	Biomarker	[146]
MBTPS2	OT67CC7W	Limited	Biomarker	[125]
MCM5	OTAHLB62	Limited	Biomarker	[1479]
MFF	OTEVIXOM	Limited	Altered Expression	[1480]
MFN1	OTCBXQZF	Limited	Biomarker	[1481]
MLXIPL	OTR9MLLW	Limited	Altered Expression	[1285]
MORC2	OT52A8BJ	Limited	Altered Expression	[1482]
MPC1	OT6DYFUO	Limited	Biomarker	[1483]
MPC2	OT0GHXGG	Limited	Altered Expression	[1483]
MPV17L	OT8A75Q7	Limited	Biomarker	[1484]
MTFP1	OT3L6F7U	Limited	Biomarker	[1485]
MTG1	OTC9U1LI	Limited	Biomarker	[837]
MTX1	OTLSDNZO	Limited	Genetic Variation	[1486]
MUC13	OTWKS9MF	Limited	Altered Expression	[1487]
MYL6B	OTWTRGT7	Limited	Altered Expression	[1488]
MYO18B	OTGYY4NK	Limited	Altered Expression	[1489]
NABP1	OTFTNFHW	Limited	Altered Expression	[1490]
NANS	OTMQ2FUH	Limited	Genetic Variation	[1491]
NASP	OTNE4THC	Limited	Biomarker	[1492]
NCS1	OT6JHAWM	Limited	Biomarker	[1493]
NDC80	OTS7D306	Limited	Biomarker	[1494]
NEDD4L	OT1B19RU	Limited	Altered Expression	[1495]
NEIL2	OTV6JEON	Limited	Genetic Variation	[1496]
NIBAN2	OTVDQSPI	Limited	Altered Expression	[1497]
NKAP	OT7K7I8Q	Limited	Posttranslational Modification	[1498]
NKAPL	OTIU393R	Limited	Posttranslational Modification	[1498]
NKD2	OTCYT3I6	Limited	Biomarker	[1499]
NPC2	OTE9UEJC	Limited	Altered Expression	[183]
NRF1	OTOXWNV8	Limited	Biomarker	[1500]
NUSAP1	OT85HIJ5	Limited	Biomarker	[1501]
OIP5	OTI5C2DE	Limited	Altered Expression	[1502]
OTUB1	OT8WWM9O	Limited	Altered Expression	[1503]
PAFAH1B1	OT9T2TCJ	Limited	Altered Expression	[1504]
PARP12	OTCQTYIO	Limited	Biomarker	[1505]
PCDH19	OTSOW3MV	Limited	Altered Expression	[1506]
PDIA3	OTHPQ0Q3	Limited	Biomarker	[1507]
PDK4	OTCMHMBZ	Limited	Biomarker	[327]
PGAM5	OT6Q5M0C	Limited	Biomarker	[1508]
PGRMC2	OTH6G1CV	Limited	Altered Expression	[139]
PHB2	OTCAX3AW	Limited	Biomarker	[1406]
PKP1	OT9HSQ8F	Limited	Biomarker	[293]
PLA2G15	OT6VJTPA	Limited	Biomarker	[1312]
PNKD	OT6G9UXN	Limited	Altered Expression	[1509]
PNMA1	OTEUG8RL	Limited	Altered Expression	[1510]
PNPT1	OTBR2Q0F	Limited	Biomarker	[293]
POU3F3	OT6BBXPD	Limited	Altered Expression	[1511]
PPIL3	OT0GPU73	Limited	Biomarker	[1512]
PPP1R1A	OTGTAGCV	Limited	Biomarker	[1513]
PRAF2	OT1QN4LV	Limited	Biomarker	[1514]
PRDM8	OTRA3265	Limited	Altered Expression	[1515]
PRDX6	OTS8KC8A	Limited	Biomarker	[293]
PRMT9	OT6OBK3K	Limited	Biomarker	[1516]
PSMB2	OTX0UG5W	Limited	Biomarker	[1517]
PSORS1C1	OT9HK436	Limited	Genetic Variation	[1518]
PSPC1	OTYS6WQ8	Limited	Biomarker	[1519]
PTBP3	OTVVYKIF	Limited	Biomarker	[1520]
PTPN18	OT0S09B3	Limited	Biomarker	[1521]
PTPRN	OTAP7NOL	Limited	Biomarker	[1521]
PTPRU	OTHDO0QG	Limited	Biomarker	[1263]
PYCR1	OTQHB52T	Limited	Altered Expression	[1522]
PYGL	OTS1YFGR	Limited	Biomarker	[1523]
RAB11A	OTC4FW0J	Limited	Biomarker	[1524]
RAB3A	OT2GIUO5	Limited	Biomarker	[1525]
RABAC1	OTGB32NG	Limited	Biomarker	[1514]
RAD54B	OTMWB2P2	Limited	Altered Expression	[1526]
RALY	OT78NNWY	Limited	Altered Expression	[1527]
RAMP3	OTX6XLLM	Limited	Altered Expression	[1528]
RAP1B	OTHEIIMM	Limited	Altered Expression	[1529]
RASA3	OT9C54MN	Limited	Biomarker	[1530]
RASSF7	OT0V4EIZ	Limited	Altered Expression	[1531]
RBBP5	OT12W2MK	Limited	Altered Expression	[1532]
RBX1	OTYA1UIO	Limited	Biomarker	[147]
RECQL4	OT59LSW7	Limited	Biomarker	[1533]
RGMB	OT2DROYU	Limited	Biomarker	[1534]
RGN	OTD04KB1	Limited	Biomarker	[1535]
RGS17	OT5RVUDS	Limited	Altered Expression	[1536]
RGS22	OTCTFGW6	Limited	Biomarker	[1537]
RPA1	OT76POLP	Limited	Biomarker	[1538]
RPL17	OTTYMPS6	Limited	Biomarker	[1539]
RRAD	OTW2O4GD	Limited	Altered Expression	[295]
RTL1	OTOT33IM	Limited	Biomarker	[1540]
RYR2	OT0PF19E	Limited	Genetic Variation	[1541]
SART3	OTC1AM7S	Limited	Biomarker	[746]
SCD5	OTSSUQ3Z	Limited	Genetic Variation	[836]
SCIN	OT6U09OL	Limited	Biomarker	[1542]
SDCBP	OTS3NCC5	Limited	Altered Expression	[928]
SEMA4C	OTF5JHQ0	Limited	Biomarker	[1543]
SEMG1	OT6Z4BPQ	Limited	Biomarker	[1404]
SENP7	OTQJ05ZS	Limited	Biomarker	[1544]
SEPTIN9	OT1VMRFQ	Limited	Posttranslational Modification	[1545]
SH2B1	OTJZO2CI	Limited	Biomarker	[1546]
SHC3	OT305NPA	Limited	Biomarker	[1547]
SHMT1	OTIINA3J	Limited	Altered Expression	[1548]
SIN3A	OTM8OZWV	Limited	Altered Expression	[1549]
SIVA1	OTDT0XZK	Limited	Biomarker	[1550]
SIX3	OTP5E3VU	Limited	Biomarker	[1551]
SLC22A10	OTUVJI3H	Limited	Biomarker	[1474]
SLIT3	OTU8MKEU	Limited	Altered Expression	[1552]
SMAD2	OTC6VB4K	Limited	Posttranslational Modification	[1553]
SMARCA5	OT5GR4Z2	Limited	Altered Expression	[1554]
SMC1A	OT9ZMRK9	Limited	Biomarker	[1555]
SMC3	OTWGFRHD	Limited	Biomarker	[1556]
SOCS2	OTBPNKJQ	Limited	Biomarker	[1557]
SOX6	OTT0W0LE	Limited	Altered Expression	[1558]
SP6	OTRAB1PN	Limited	Biomarker	[1465]
SPATA2	OTOA45GL	Limited	Biomarker	[1539]
SPP2	OTX254AR	Limited	Biomarker	[1413]
SPRTN	OT01D5CE	Limited	Genetic Variation	[1559]
SPTLC2	OTBTMH1Z	Limited	Biomarker	[1560]
SPTY2D1	OT1RY99Z	Limited	Biomarker	[1560]
SRCIN1	OTQZNQQ5	Limited	Biomarker	[1561]
SRF	OTW18FQN	Limited	Biomarker	[1172]
SSBP2	OTYG1G80	Limited	Altered Expression	[1490]
SSR3	OTJQP0IZ	Limited	Biomarker	[1562]
STK17B	OT4NYNO8	Limited	Biomarker	[1563]
SUV39H2	OTU0F4LL	Limited	Altered Expression	[1564]
SYNE1	OTSBSLUH	Limited	Altered Expression	[837]
TACC2	OTW4M7HI	Limited	Biomarker	[1565]
TAF1	OTDYS5G4	Limited	Biomarker	[1566]
TAS2R38	OTX5MM36	Limited	Biomarker	[585]
TCEA1	OTBFO594	Limited	Altered Expression	[1567]
TCF21	OT393IMA	Limited	Altered Expression	[1568]
TFIP11	OT7NVSWU	Limited	Biomarker	[886]
TGFBRAP1	OT80QNR5	Limited	Altered Expression	[1451]
THBS4	OTA1T9KK	Limited	Altered Expression	[1569]
TINAG	OTY7BSD7	Limited	Altered Expression	[1570]
TMEM100	OTRJ6OHY	Limited	Biomarker	[1571]
TMEM165	OTMVJ0GA	Limited	Altered Expression	[1572]
TMEM176A	OTOZDWXX	Limited	Posttranslational Modification	[1573]
TMEM70	OTLTKYXG	Limited	Biomarker	[175]
TMOD4	OTXLGJ4R	Limited	Altered Expression	[1574]
TMSB10	OTLVZ13T	Limited	Altered Expression	[1575]
TNIP1	OTRAOTEW	Limited	Altered Expression	[1576]
TRIM29	OT2DNESG	Limited	Biomarker	[1577]
TRIM50	OTXA2IXF	Limited	Biomarker	[1578]
TRIM66	OT0VJCP6	Limited	Altered Expression	[1579]
TRIM7	OT1A26OW	Limited	Altered Expression	[1429]
TRIP13	OTFM3TI9	Limited	Altered Expression	[1580]
A1BG	OTFVUGNQ	Disputed	Altered Expression	[1581]
ALDOA	OTWRFTIB	Disputed	Biomarker	[1582]
ALKBH3	OTS1CD9Z	Disputed	Biomarker	[1583]
ATG13	OTYMHNEJ	Disputed	Biomarker	[1584]
CARD14	OTADQHOV	Disputed	Biomarker	[561]
CITED2	OT812TV7	Disputed	Altered Expression	[1585]
DUSP4	OT6WAO12	Disputed	Altered Expression	[1586]
EIF3D	OTDOMP80	Disputed	Biomarker	[206]
EIF4A3	OTYYFE7K	Disputed	Altered Expression	[1587]
ENOPH1	OTKXMWNN	Disputed	Altered Expression	[1588]
FXYD3	OT9PPRHE	Disputed	Biomarker	[1589]
FZD5	OTXFFY56	Disputed	Biomarker	[1590]
GPX4	OTRAFFX2	Disputed	Altered Expression	[1591]
GTSF1	OTV7PQJF	Disputed	Altered Expression	[1592]
KCTD10	OT5HFZXU	Disputed	Biomarker	[206]
MCM3AP	OT895FEC	Disputed	Biomarker	[1593]
NTM	OTHF0UQU	Disputed	Biomarker	[1594]
PARP10	OTILI1DU	Disputed	Altered Expression	[1595]
PARP14	OTFXJAKK	Disputed	Biomarker	[1596]
POU5F1B	OT0FKQ51	Disputed	Biomarker	[1597]
RBM3	OTAJ7R31	Disputed	Altered Expression	[1598]
RUSC1	OTYB8ZMT	Disputed	Altered Expression	[1599]
SARDH	OTQ49Q27	Disputed	Biomarker	[186]
TNPO1	OT7W2CM8	Disputed	Altered Expression	[1600]
TRIM14	OTLQKUG0	Disputed	Altered Expression	[1601]
ABI1	OT5H4M62	moderate	Biomarker	[1602]
ACIN1	OTK81F92	moderate	Altered Expression	[1603]
ACOT12	OTN4RQK8	moderate	Biomarker	[1604]
ACOT7	OT7C68YV	moderate	Biomarker	[1605]
ADAM21	OTGBAVYU	moderate	Biomarker	[1606]
ADAMTS14	OTFJ1PDB	moderate	Biomarker	[1607]
ADGRB1	OTJSEXRC	moderate	Genetic Variation	[1608]
ADRM1	OTOU4EY6	moderate	Biomarker	[262]
AFM	OTPOR8IO	moderate	Biomarker	[1609]
AIFM1	OTKPWB7Q	moderate	Biomarker	[1610]
ARHGEF2	OTBQTFRT	moderate	Genetic Variation	[262]
ASH2L	OT3HG324	moderate	Altered Expression	[1611]
ASL	OTI2NGQR	moderate	Biomarker	[1612]
ASPG	OT5E2EKR	moderate	Biomarker	[81]
ATP2A3	OTFYDEES	moderate	Altered Expression	[1613]
ATP4B	OTIP2EYJ	moderate	Biomarker	[1614]
AZU1	OTHXU264	moderate	Biomarker	[1615]
B3GALT5	OTWXPEMU	moderate	Biomarker	[1616]
BAG6	OT4Z0S2U	moderate	Biomarker	[1617]
BAMBI	OTCEJ8W5	moderate	Altered Expression	[1618]
BARX1	OT2VP73H	moderate	Altered Expression	[1619]
BCL2L12	OTS6IFZY	moderate	Altered Expression	[1620]
BCLAF1	OT7T8H6A	moderate	Biomarker	[1621]
BRINP1	OTEUVSCP	moderate	Altered Expression	[1622]
BTG3	OT9ANHVT	moderate	Altered Expression	[1623]
BUD31	OTN3HZYF	moderate	Biomarker	[231]
C1QTNF6	OT57EPQC	moderate	Altered Expression	[1624]
C4BPA	OTHNH6Y8	moderate	Biomarker	[561]
C8orf33	OTFCF3V5	moderate	Biomarker	[1625]
CADM2	OT45PVKC	moderate	Altered Expression	[1626]
CAPRIN1	OTEJAMS3	moderate	Biomarker	[1627]
CBX2	OTOQ5WS4	moderate	Biomarker	[1628]
CBX6	OTO1I9W0	moderate	Biomarker	[1629]
CCAR1	OTUXLQZZ	moderate	Biomarker	[1630]
CCAR2	OTLUDG5T	moderate	Altered Expression	[1622]
CCDC178	OTS6N7I6	moderate	Biomarker	[1631]
CCL1	OT23NON8	moderate	Biomarker	[1632]
CCL18	OT7JYSK9	moderate	Biomarker	[1633]
CCL24	OT9LGHV0	moderate	Biomarker	[1634]
CD1C	OT4XINUJ	moderate	Biomarker	[230]
CDH15	OTJ1TO02	moderate	Posttranslational Modification	[198]
CDH8	OTS3SRZ6	moderate	Biomarker	[198]
CDK20	OTOLNN68	moderate	Biomarker	[1229]
CELF1	OT6JQ5RS	moderate	Altered Expression	[1635]
CHAD	OT7PF813	moderate	Biomarker	[1636]
CHCHD2	OTL5PA3Y	moderate	Biomarker	[1637]
CHODL	OTVCNOUQ	moderate	Biomarker	[1638]
CHPT1	OT4FJ0K3	moderate	Biomarker	[1639]
CKLF	OTHLPHA0	moderate	Altered Expression	[1640]
CLEC11A	OT9KBH7C	moderate	Altered Expression	[1641]
CMTM3	OTS75IGC	moderate	Biomarker	[1642]
CMTM4	OTA3Z072	moderate	Biomarker	[1643]
CMTM6	OT70T27A	moderate	Altered Expression	[1644]
CNN2	OTH3CSXA	moderate	Biomarker	[1645]
CRX	OTH435SV	moderate	Biomarker	[259]
CSN2	OT22C0PD	moderate	Biomarker	[1646]
CTTNBP2	OT4CL1EW	moderate	Biomarker	[1647]
CYBA	OT16N9ZO	moderate	Altered Expression	[193]
CYGB	OTX153DQ	moderate	Biomarker	[1648]
DARS2	OTVPFTBG	moderate	Biomarker	[1649]
DCC	OT2C1SHW	moderate	Biomarker	[1650]
DHDDS	OTVLYBUS	moderate	Biomarker	[1639]
DIRAS3	OT3XHLQA	moderate	Biomarker	[81]
DLG5	OTU9Z17K	moderate	Biomarker	[1651]
DTHD1	OTW00SHB	moderate	Genetic Variation	[1652]
DUOX1	OTQ2AEW0	moderate	Biomarker	[1653]
DUSP16	OTK7S078	moderate	Altered Expression	[1654]
EBF1	OTZ61YYH	moderate	Biomarker	[1655]
ECRG4	OTHZYUXX	moderate	Altered Expression	[1656]
EEF1E1	OTRA6XOB	moderate	Altered Expression	[1657]
EFNA3	OTJGOUMZ	moderate	Biomarker	[1658]
EGR2	OTAVQ78J	moderate	Biomarker	[81]
EIF4E3	OTTWVS2R	moderate	Altered Expression	[1659]
EIF5	OT79PQUN	moderate	Altered Expression	[1660]
ELMO1	OTY2ORXK	moderate	Altered Expression	[1661]
ENTPD2	OTZ2PKPM	moderate	Altered Expression	[1662]
EPB41L3	OTS6CHG2	moderate	Altered Expression	[1663]
EPS15L1	OTTFPZY2	moderate	Altered Expression	[1664]
ERBIN	OTNWTUA8	moderate	Biomarker	[1665]
ESS2	OTZ08VCZ	moderate	Biomarker	[1666]
ETV4	OT8C98UZ	moderate	Biomarker	[910]
FAH	OTGZA1YR	moderate	Genetic Variation	[1667]
FAM168A	OTDXQCS5	moderate	Biomarker	[1668]
FANCD2	OTVEB5LF	moderate	Biomarker	[81]
FAT4	OT7QONNV	moderate	Biomarker	[1669]
FBRS	OTUVH446	moderate	Biomarker	[1670]
FGF9	OT2SKDGM	moderate	Biomarker	[1671]
FHL5	OT6C00Z1	moderate	Biomarker	[1605]
FLOT1	OT0JPPJZ	moderate	Altered Expression	[1672]
FMR1	OTWEV0T5	moderate	Biomarker	[1673]
FMR1NB	OT5IC2M2	moderate	Biomarker	[1674]
FNDC5	OT5CSK9X	moderate	Altered Expression	[1675]
FOXG1	OTAW57J4	moderate	Altered Expression	[1676]
FOXP4	OTHCGIEZ	moderate	Biomarker	[1677]
FZD2	OT952ML1	moderate	Biomarker	[1678]
GADD45GIP1	OT4IZ4TP	moderate	Biomarker	[841]
GALNT4	OT6WKC13	moderate	Altered Expression	[1679]
GATA5	OTO81B63	moderate	Altered Expression	[1680]
GIT1	OTHO92S5	moderate	Altered Expression	[204]
GOLGB1	OT2S0GK8	moderate	Genetic Variation	[1681]
GP2	OTB6TMGY	moderate	Biomarker	[1086]
GPR155	OT2ZCDS7	moderate	Altered Expression	[1682]
GPT2	OTS5VF7N	moderate	Biomarker	[1683]
GSKIP	OTEYSV5M	moderate	Posttranslational Modification	[1684]
GTPBP4	OT6ZHAWC	moderate	Biomarker	[1685]
GTSE1	OTPP742Z	moderate	Biomarker	[81]
HAT1	OT307KEN	moderate	Biomarker	[1686]
HCFC1R1	OTGDPS5C	moderate	Biomarker	[1687]
HDGFL3	OTNN7WYH	moderate	Biomarker	[1688]
HEBP1	OTR9MPDX	moderate	Biomarker	[1615]
HEG1	OT3CUXA7	moderate	Biomarker	[1689]
HELLS	OTVVV668	moderate	Biomarker	[1690]
HERC4	OTU4DSDE	moderate	Biomarker	[1691]
HEY1	OTJQL0I3	moderate	Altered Expression	[1692]
HEY2	OTU4J3ZI	moderate	Altered Expression	[1693]
HILPDA	OTEID3ZM	moderate	Biomarker	[1694]
HNRNPD	OT5UO1FA	moderate	Biomarker	[1695]
HNRNPL	OT0DJX74	moderate	Altered Expression	[1696]
HOMER1	OTWFD3SI	moderate	Biomarker	[1697]
HOXD9	OTZ4GVR1	moderate	Biomarker	[81]
HUWE1	OTFH6BJS	moderate	Biomarker	[1698]
ICMT	OT8CNKBO	moderate	Biomarker	[1699]
ID4	OTPMJ39I	moderate	Altered Expression	[1700]
IDH2	OTTQA4PB	moderate	Altered Expression	[1701]
IFIT3	OTPGHZB9	moderate	Biomarker	[1702]
IL1RAPL1	OTW3T4B2	moderate	Biomarker	[1703]
IL4I1	OTK54C63	moderate	Biomarker	[1704]
IL6ST	OT1N9C70	moderate	Genetic Variation	[1705]
ING3	OTDIJXFP	moderate	Altered Expression	[1706]
INTU	OTXB13E6	moderate	Biomarker	[1707]
KDM4B	OT5P1UPY	moderate	Altered Expression	[1708]
KHSRP	OTDHZARB	moderate	Altered Expression	[1709]
KIF3B	OT0HJREB	moderate	Biomarker	[1710]
KIF4B	OTCLIB57	moderate	Biomarker	[1711]
LAMTOR5	OTER0U8L	moderate	Altered Expression	[1712]
LDB2	OT6Y8IEK	moderate	Altered Expression	[1713]
LRP10	OT8490HT	moderate	Altered Expression	[1714]
LTBP1	OTR7Q75L	moderate	Biomarker	[188]
MAP1S	OT5WUD4C	moderate	Biomarker	[1715]
MAP6	OTPUI00F	moderate	Genetic Variation	[1716]
MARVELD1	OT5CPOJE	moderate	Biomarker	[1717]
MCF2	OTB9N93T	moderate	Altered Expression	[1718]
MCM3	OTOOHQPM	moderate	Altered Expression	[1719]
MCM8	OTC93H3S	moderate	Altered Expression	[234]
MCRS1	OT8K2X8P	moderate	Biomarker	[1720]
MEOX2	OTKZCJCB	moderate	Biomarker	[1721]
METTL14	OT6TPQMH	moderate	Biomarker	[1722]
MINDY4	OTBZ2SZB	moderate	Altered Expression	[1723]
MMUT	OTBBBV70	moderate	Biomarker	[1719]
MRPL58	OTPTWLZY	moderate	Biomarker	[1724]
MTA2	OTCCYIQJ	moderate	Biomarker	[1725]
MTHFD1L	OTV01EFP	moderate	Biomarker	[1726]
MYOF	OTRFC3IJ	moderate	Biomarker	[1727]
NAP1L1	OTI7WBZV	moderate	Altered Expression	[1728]
NCAN	OT8OO6ZE	moderate	Genetic Variation	[1729]
NCKAP1	OTEZQXXJ	moderate	Biomarker	[1730]
NELFB	OTCFH88S	moderate	Biomarker	[1731]
NHS	OTKE8QAT	moderate	Genetic Variation	[1732]
NLRC4	OTAIA3NA	moderate	Altered Expression	[1733]
NMI	OTYVG3NM	moderate	Altered Expression	[369]
NONO	OTN36Q6U	moderate	Biomarker	[1734]
NRDC	OTWBBCXO	moderate	Altered Expression	[1735]
NSD2	OTQ6SW4R	moderate	Biomarker	[1736]
OCA2	OTDWIGBF	moderate	Biomarker	[1737]
OCIAD2	OTSWB4SZ	moderate	Biomarker	[1738]
OPRPN	OT6K1ZD6	moderate	Altered Expression	[984]
ORM2	OTRJGZP8	moderate	Biomarker	[389]
OSR1	OTB19LEQ	moderate	Biomarker	[1739]
OVOL2	OTFM1GKF	moderate	Biomarker	[1173]
PA2G4	OT7IG7HT	moderate	Biomarker	[1229]
PADI1	OT13WAQX	moderate	Biomarker	[1740]
PAXIP1	OTRHTKG3	moderate	Biomarker	[1741]
PBLD	OTI3A8RS	moderate	Biomarker	[1742]
PBXIP1	OTEAAUBY	moderate	Biomarker	[1687]
PCDH18	OTTLQWRN	moderate	Altered Expression	[1743]
PDHA1	OTGEU8IK	moderate	Altered Expression	[1744]
PDIA2	OTC2WMXS	moderate	Biomarker	[1740]
PDZK1IP1	OTWA6M5K	moderate	Biomarker	[1745]
PEA15	OTKCKTSX	moderate	Biomarker	[1737]
PFN1	OTHTGA1H	moderate	Biomarker	[1746]
PHF6	OT8DXI40	moderate	Altered Expression	[1250]
PINK1	OT50NR57	moderate	Altered Expression	[1692]
PITX1	OTA0UN4C	moderate	Biomarker	[81]
PIWIL2	OT1PXQIF	moderate	Altered Expression	[1747]
PLAG1	OTT9AJQY	moderate	Genetic Variation	[241]
PLRG1	OTIVZ5LL	moderate	Altered Expression	[984]
PMAIP1	OTXEE550	moderate	Biomarker	[1748]
PMEPA1	OTY8Z9UF	moderate	Altered Expression	[1749]
POLDIP3	OTTB5SV7	moderate	Altered Expression	[1750]
PPAN	OT0UFQBZ	moderate	Altered Expression	[249]
PPIL1	OTS5S837	moderate	Altered Expression	[1751]
PPP1CB	OTYFTYFR	moderate	Genetic Variation	[1752]
PPP1R11	OTSHYPPW	moderate	Biomarker	[1668]
PPP1R12A	OT4AVU95	moderate	Biomarker	[1752]
PPP2R2C	OTXK0SDM	moderate	Altered Expression	[1753]
PRDM1	OTQLSVBS	moderate	Altered Expression	[1754]
PRM3	OT6574BF	moderate	Biomarker	[1656]
PRMT6	OT5V3XIN	moderate	Biomarker	[1755]
PRSS3	OTN3S5YB	moderate	Biomarker	[1756]
PSG9	OT0UWPND	moderate	Biomarker	[1757]
PSMD4	OTH1VZTM	moderate	Biomarker	[1758]
PTPN9	OTNAR1I2	moderate	Altered Expression	[1759]
QSOX1	OT4ZPK4P	moderate	Biomarker	[419]
RAB24	OTOFNAJK	moderate	Altered Expression	[1708]
RAB34	OTHKTSA0	moderate	Altered Expression	[1760]
RAD52	OT0OTDHI	moderate	Altered Expression	[1761]
RALA	OT734R7X	moderate	Biomarker	[1762]
RAP2B	OTD2NDQP	moderate	Biomarker	[1763]
RASAL2	OTGMMX6W	moderate	Biomarker	[1764]
RASSF6	OT25GVWY	moderate	Altered Expression	[1765]
RBM4	OT5SFQA3	moderate	Biomarker	[1766]
RBM8A	OT5SR6G0	moderate	Biomarker	[1767]
RELN	OTLKMW1O	moderate	Altered Expression	[1768]
REST	OTLL92LQ	moderate	Biomarker	[1769]
RFC4	OTWALD2R	moderate	Biomarker	[1770]
RFX5	OT73KJ5P	moderate	Biomarker	[1771]
RHEB	OTFLTSEC	moderate	Biomarker	[1660]
RING1	OTCWTAX0	moderate	Biomarker	[1772]
RIT1	OTVNOGOH	moderate	Biomarker	[1773]
RLIM	OTEBRNHJ	moderate	Altered Expression	[1774]
RNASE4	OTA5SZLC	moderate	Biomarker	[1775]
RNF2	OTFPLOIN	moderate	Biomarker	[1776]
RNF41	OTN1DQOY	moderate	Biomarker	[1777]
RNF5	OTDQGI37	moderate	Biomarker	[1617]
RPA3	OT8JAQGL	moderate	Altered Expression	[1778]
RPIA	OT805SMH	moderate	Biomarker	[1779]
RRS1	OTTNCZN6	moderate	Biomarker	[1780]
RTKN	OTSS8XR6	moderate	Biomarker	[1781]
RTN3	OTGZ51QF	moderate	Biomarker	[1782]
SAFB	OTGRV2LW	moderate	Biomarker	[1782]
SCAI	OTAK3TMO	moderate	Biomarker	[1783]
SCARA3	OT46I38Y	moderate	Altered Expression	[1687]
SCPEP1	OT43LYEZ	moderate	Biomarker	[1784]
SDHA	OTOJ8QFF	moderate	Altered Expression	[186]
SDHB	OTRE1M1T	moderate	Biomarker	[186]
SDS	OT5WTJ2M	moderate	Biomarker	[461]
SEC62	OTCWEL5F	moderate	Biomarker	[1785]
SERBP1	OTZVSU0X	moderate	Biomarker	[1786]
SF3B3	OTAC9LZT	moderate	Genetic Variation	[1681]
SH3GLB1	OTAZ5OP8	moderate	Altered Expression	[1787]
SH3PXD2A	OTYRQJIH	moderate	Biomarker	[1788]
SHC1	OT1J5IRN	moderate	Altered Expression	[1789]
SIM2	OT0QWHK4	moderate	Biomarker	[1790]
SIRT4	OT5S0J23	moderate	Biomarker	[1791]
SIX2	OTYOVGSC	moderate	Biomarker	[1792]
SLBP	OTVYYQRT	moderate	Biomarker	[1615]
SMAD5	OTQNSVCQ	moderate	Biomarker	[1793]
SMARCE1	OTAX4ITH	moderate	Altered Expression	[1794]
SMC5	OT91M6N4	moderate	Altered Expression	[1795]
SMURF1	OT5UIZR8	moderate	Biomarker	[1796]
SOCS5	OTN1ABYR	moderate	Altered Expression	[1797]
SPAG11A	OTNQ9UB0	moderate	Biomarker	[256]
SPDYA	OTYKC1AJ	moderate	Altered Expression	[1798]
SPINT1	OT1CLR5L	moderate	Altered Expression	[1799]
SRI	OT4R3EAC	moderate	Biomarker	[1800]
SRP9	OT4CQTCM	moderate	Biomarker	[1801]
STAM2	OT9OBWPH	moderate	Biomarker	[1615]
STEAP4	OTFTLAEZ	moderate	Biomarker	[1802]
STK10	OTC33Y2F	moderate	Biomarker	[1803]
STPG4	OT5K4UFL	moderate	Biomarker	[1804]
SYT7	OTBWAOWY	moderate	Altered Expression	[1805]
SYTL2	OTUIOWKL	moderate	Altered Expression	[1806]
TBX2	OTTOT7A9	moderate	Posttranslational Modification	[1807]
TCF7L1	OTTUTF0O	moderate	Altered Expression	[1808]
TENM3	OTWY13GR	moderate	Genetic Variation	[207]
TENT2	OTB7J28X	moderate	Altered Expression	[204]
TEX10	OTNTU9CB	moderate	Biomarker	[1809]
TIPRL	OTS2FZ8O	moderate	Biomarker	[1810]
TMED3	OTNOPHHC	moderate	Biomarker	[1811]
TNFAIP8	OT1G9297	moderate	Biomarker	[1812]
TRIB1	OTPEO17G	moderate	Biomarker	[1813]
TRIM71	OTH8UB6H	moderate	Biomarker	[1814]
TRIP6	OTIPA4ZR	moderate	Biomarker	[1815]
TSPY3	OTQK3AKI	moderate	Altered Expression	[1816]
TTC23	OT0F3HCQ	moderate	Biomarker	[1807]
TTL	OTSS1CK4	moderate	Biomarker	[1817]
TTLL1	OTCE097J	moderate	Biomarker	[1817]
A2M	OTFTX90K	Strong	Biomarker	[1818]
AADAC	OT8VACT2	Strong	Biomarker	[1819]
AATF	OT1QOKLD	Strong	Biomarker	[1820]
ABCF2	OTXIBZ3N	Strong	Biomarker	[1821]
ACAA1	OTVKRET0	Strong	Altered Expression	[1822]
ACACA	OT5CQPZY	Strong	Altered Expression	[366]
ACADSB	OTDO6HBG	Strong	Biomarker	[1823]
ACAT2	OTZ092ZJ	Strong	Biomarker	[1095]
ACE	OTDF1964	Strong	Altered Expression	[1824]
ACKR4	OTZPWT2N	Strong	Biomarker	[1825]
ACMSD	OTPSXPSF	Strong	Altered Expression	[1826]
ACO1	OT2VUR7L	Strong	Altered Expression	[1827]
ACOT8	OTHY684G	Strong	Biomarker	[1828]
ACOX1	OTM0A0DY	Strong	Altered Expression	[1829]
ACOX2	OT3VH359	Strong	Altered Expression	[1830]
ACP1	OTJ9CKLU	Strong	Biomarker	[1831]
ACRBP	OT0MK3L1	Strong	Biomarker	[1832]
ACSBG1	OTM040MW	Strong	Biomarker	[1833]
ACSL1	OTB06ESI	Strong	Altered Expression	[1834]
ACSL3	OT3MWER1	Strong	Biomarker	[1835]
ACSL4	OTI71MUJ	Strong	Altered Expression	[1836]
ACSM3	OT0AE1IV	Strong	Altered Expression	[1837]
ACSS1	OT6C1WQD	Strong	Altered Expression	[1838]
ACTBL2	OTD6B81U	Strong	Biomarker	[1605]
ACTG2	OTRDWUO0	Strong	Altered Expression	[1839]
ACTL6A	OT0EC5BQ	Strong	Biomarker	[1840]
ACTN4	OTCNZAJ5	Strong	Biomarker	[1841]
ACTR1A	OT1QAU16	Strong	Biomarker	[1842]
ACTR1B	OTGBCKLO	Strong	Altered Expression	[1843]
ACY3	OTZWAB73	Strong	Biomarker	[1844]
ADAM28	OT3GBVHL	Strong	Altered Expression	[1845]
ADAR	OTQNOHR8	Strong	Biomarker	[746]
ADARB1	OTGKSZEV	Strong	Biomarker	[1846]
ADD3	OTDRSHAZ	Strong	Biomarker	[1847]
ADGRE1	OTQQ9Q7G	Strong	Genetic Variation	[1848]
ADGRF1	OTRAOBYH	Strong	Biomarker	[1849]
ADI1	OT8IOD03	Strong	Altered Expression	[1850]
ADIPOR1	OT65ZFZN	Strong	Biomarker	[1851]
AFAP1L2	OTJBI0VN	Strong	Altered Expression	[1852]
AGA	OTNWT1WB	Strong	Biomarker	[1853]
AGAP4	OT3NU4DH	Strong	Biomarker	[1854]
AGO1	OTD3R434	Strong	Biomarker	[1855]
AGR3	OTONJPDP	Strong	Altered Expression	[1856]
AHI1	OT8K2YWY	Strong	Biomarker	[1857]
AHNAK	OT6KH1WG	Strong	Biomarker	[1140]
AHSA1	OTC7AFHT	Strong	Biomarker	[318]
AIM2	OT86QUI8	Strong	Biomarker	[1858]
AIP	OTDJ3OSV	Strong	Biomarker	[1859]
AJAP1	OTAAW121	Strong	Biomarker	[1860]
AKAP12	OTCVRDDX	Strong	Altered Expression	[1861]
AKAP3	OT42QOFG	Strong	Biomarker	[1862]
AKIP1	OT7XPG27	Strong	Biomarker	[1863]
AKIRIN2	OTQ6WSKW	Strong	Altered Expression	[1864]
AKR1E2	OT7GBQEB	Strong	Biomarker	[1831]
AKR7A3	OTW3GO4Y	Strong	Biomarker	[1865]
AKT1S1	OT4JHN4Y	Strong	Altered Expression	[1866]
AKTIP	OT78TJID	Strong	Altered Expression	[1867]
ALDH18A1	OT6W40XU	Strong	Altered Expression	[1522]
ALDH1L1	OT15HOJX	Strong	Altered Expression	[1868]
ALDOC	OTEC13I5	Strong	Biomarker	[1869]
ALPP	OTZU4G9W	Strong	Biomarker	[325]
AMELY	OTVG0EXE	Strong	Altered Expression	[1048]
AMER1	OT8EFJPM	Strong	Genetic Variation	[1870]
AMFR	OTQRX7LC	Strong	Altered Expression	[1871]
AMPD1	OTU17BCI	Strong	Altered Expression	[1872]
AMPD2	OTBS30JU	Strong	Altered Expression	[1872]
AMY1A	OT6G4B8O	Strong	Altered Expression	[1873]
ANAPC1	OT2YY35L	Strong	Biomarker	[1874]
ANGPTL2	OTB6JG41	Strong	Biomarker	[1875]
ANKHD1	OTVYQ7ZL	Strong	Biomarker	[1876]
ANLN	OTXJY54C	Strong	Altered Expression	[1877]
ANOS1	OTZJT4KN	Strong	Posttranslational Modification	[1878]
ANP32A	OTRHPFO2	Strong	Altered Expression	[1879]
ANP32B	OT3SQMLU	Strong	Biomarker	[1160]
ANXA3	OTDD8OI7	Strong	Biomarker	[1880]
ANXA4	OTUCRYXL	Strong	Altered Expression	[1881]
ANXA6	OT9KIQ0Y	Strong	Altered Expression	[1882]
ANXA7	OTLMD0TK	Strong	Biomarker	[1883]
AP1G1	OTEO6Y9H	Strong	Biomarker	[1884]
AP2A1	OTEFZB21	Strong	Biomarker	[1136]
AP2B1	OTL6LZJ4	Strong	Altered Expression	[1885]
AP2M1	OTQCOSFN	Strong	Altered Expression	[1886]
APAF1	OTJWIVY0	Strong	Biomarker	[1887]
API5	OTYX9YCZ	Strong	Biomarker	[1888]
APOA5	OTEVKLVA	Strong	Biomarker	[1889]
APOBEC1	OTY8QX2R	Strong	Altered Expression	[1890]
APOBEC2	OT4CCS0Q	Strong	Altered Expression	[1891]
APOC2	OTLINYIQ	Strong	Altered Expression	[1892]
APOD	OTT77XW8	Strong	Genetic Variation	[1893]
APOF	OT12S5QS	Strong	Biomarker	[81]
APOO	OTAHHRGZ	Strong	Altered Expression	[1894]
AQP5	OT77GBY8	Strong	Altered Expression	[1895]
ARF6	OTVV7KJO	Strong	Biomarker	[346]
ARFIP2	OTK9JXIJ	Strong	Biomarker	[1896]
ARFRP1	OTP1OV78	Strong	Biomarker	[1842]
ARHGAP1	OT0H2ZBZ	Strong	Biomarker	[1897]
ARHGAP11A	OTVQCFVP	Strong	Altered Expression	[1898]
ARHGAP4	OTXV053R	Strong	Altered Expression	[1899]
ARHGAP5	OTOQELUN	Strong	Altered Expression	[1900]
ARHGDIA	OTEXWJDO	Strong	Biomarker	[1901]
ARHGDIB	OT9PD6CS	Strong	Altered Expression	[1901]
ARHGEF10L	OTUAMHIZ	Strong	Altered Expression	[1902]
ARHGEF28	OT3F32IU	Strong	Biomarker	[1903]
ARID1A	OTRWDV3P	Strong	Biomarker	[1669]
ARID1B	OTILK3Q7	Strong	Genetic Variation	[1904]
ARL4C	OTQ3QNNU	Strong	Biomarker	[1905]
ARMC10	OT7YU4HK	Strong	Altered Expression	[1906]
ARMH1	OTTJC0D6	Strong	Biomarker	[778]
ARNT	OTMSIEZY	Strong	Altered Expression	[1907]
ARNT2	OTAQD3YV	Strong	Altered Expression	[1908]
ARPP19	OTZS3IT6	Strong	Biomarker	[1909]
ARR3	OTRZ00CH	Strong	Biomarker	[403]
ART1	OT7FBG5W	Strong	Altered Expression	[1910]
ARTN	OTWIWGL6	Strong	Biomarker	[1911]
ASAP1	OT4DLRYY	Strong	Altered Expression	[1912]
ASB3	OTI3TK38	Strong	Biomarker	[370]
ASCL2	OT3D62WB	Strong	Altered Expression	[1913]
ASF1A	OT4S44GP	Strong	Biomarker	[1914]
ASPM	OTKXQMNA	Strong	Biomarker	[81]
ATAD1	OTJ02XFL	Strong	Genetic Variation	[1915]
ATAD5	OTI8ABKF	Strong	Biomarker	[1916]
ATF1	OT251CI0	Strong	Biomarker	[1917]
ATF2	OTNIZPEA	Strong	Altered Expression	[1918]
ATF7	OTM8T3OD	Strong	Altered Expression	[1919]
ATG12	OTJRO09Y	Strong	Altered Expression	[1920]
ATG16L1	OTEOYC5D	Strong	Genetic Variation	[1921]
ATG3	OT28VBVK	Strong	Biomarker	[1922]
ATG4B	OTQ4RNRM	Strong	Posttranslational Modification	[1923]
ATG5	OT4T5SMS	Strong	Genetic Variation	[1924]
ATN1	OTNZFLKY	Strong	Altered Expression	[1925]
ATOH1	OTBZYG2R	Strong	Altered Expression	[1926]
ATOH8	OT7SY3BN	Strong	Posttranslational Modification	[1927]
ATP6AP2	OT0IABVV	Strong	Biomarker	[1928]
ATP6V0C	OTKPL09B	Strong	Altered Expression	[1929]
ATRNL1	OTY5JUX2	Strong	Genetic Variation	[1226]
ATRX	OT77RSQW	Strong	Biomarker	[1209]
ATXN7	OTL3YF1H	Strong	Biomarker	[1930]
AXIN2	OTRMGQNU	Strong	Altered Expression	[1931]
AZIN1	OTX5W77I	Strong	Biomarker	[1932]
AZIN2	OT8OB7CG	Strong	Biomarker	[1933]
B3GALT6	OTF4HBAT	Strong	Biomarker	[1641]
B3GNT2	OTE69HV8	Strong	Biomarker	[1934]
B4GALNT1	OTCY80HS	Strong	Altered Expression	[1935]
B4GALT1	OTBCXEK7	Strong	Altered Expression	[1936]
BABAM2	OTOY7FNT	Strong	Altered Expression	[1937]
BAD	OT63ERYM	Strong	Altered Expression	[1938]
BAG1	OTRQNIA4	Strong	Biomarker	[1782]
BAIAP2L1	OTZ71SK9	Strong	Altered Expression	[1939]
BARD1	OTTC0Z9Y	Strong	Biomarker	[1940]
BASP1	OTF4VS5G	Strong	Biomarker	[1941]
BATF2	OT4XBZC9	Strong	Biomarker	[1942]
BCAM	OTHZOPSD	Strong	Biomarker	[1943]
BCAP31	OTKSACR4	Strong	Altered Expression	[1944]
BCAR1	OTKT2C2N	Strong	Biomarker	[482]
BCKDHB	OT8OSVYU	Strong	Biomarker	[1945]
BCL10	OT47MCLI	Strong	Biomarker	[1946]
BCL2L10	OTYXQJ3I	Strong	Biomarker	[1947]
BCL2L11	OTNQQWFJ	Strong	Biomarker	[1948]
BCL2L13	OT2VRFTM	Strong	Altered Expression	[1949]
BCL3	OT1M5B95	Strong	Altered Expression	[1950]
BCL6B	OT1T5KM6	Strong	Altered Expression	[1951]
BCL9	OTRBIPR4	Strong	Altered Expression	[1952]
BCL9L	OTTWI90E	Strong	Biomarker	[1953]
BCO2	OTP1L0BZ	Strong	Altered Expression	[1600]
BCOR	OTG013AX	Strong	Genetic Variation	[1954]
BCORL1	OTPTFQN5	Strong	Altered Expression	[1955]
BEX1	OTBQIF0H	Strong	Altered Expression	[1956]
BEX2	OT4G5SIC	Strong	Altered Expression	[1957]
BHLHE22	OTZUQY5L	Strong	Biomarker	[1958]
BHMT	OTYB6PXZ	Strong	Biomarker	[1959]
BID	OTOSHSHU	Strong	Biomarker	[1960]
BLCAP	OTGJVU0C	Strong	Biomarker	[1961]
BLVRB	OTHCFN2C	Strong	Biomarker	[193]
BMPER	OTBYON4H	Strong	Biomarker	[81]
BMPR1A	OTQOA4ZH	Strong	Biomarker	[1962]
BMS1	OTEGQ8ZO	Strong	Biomarker	[1963]
BNC1	OTGJ5WUF	Strong	Altered Expression	[1964]
BNC2	OTU22H9Z	Strong	Altered Expression	[1964]
BNIP3	OT4SO7J4	Strong	Biomarker	[1965]
BNIPL	OTDHOA74	Strong	Altered Expression	[1966]
BOLA2	OTVZP6YB	Strong	Biomarker	[1967]
BPIFA1	OTQFD2J5	Strong	Biomarker	[1968]
BPTF	OTD1RZAD	Strong	Altered Expression	[1969]
BRF1	OTQC6DMG	Strong	Altered Expression	[1970]
BRI3BP	OTWCFPRM	Strong	Biomarker	[1971]
BRMS1	OTV5A6LL	Strong	Altered Expression	[1972]
BRMS1L	OTJIW47U	Strong	Biomarker	[1973]
BTBD3	OTZ607YT	Strong	Altered Expression	[1974]
BTBD7	OTNUV6MQ	Strong	Biomarker	[1975]
BTC	OTW4B2O0	Strong	Biomarker	[1976]
BTG2	OTZF6K1H	Strong	Altered Expression	[1977]
BTRC	OT2EZDGR	Strong	Biomarker	[1978]
BUB3	OTU91HAU	Strong	Genetic Variation	[1979]
BVES	OT4GT1WC	Strong	Altered Expression	[1980]
BZW2	OTBT0A1B	Strong	Altered Expression	[1981]
C1GALT1	OT2ZSZ6P	Strong	Biomarker	[1982]
C1GALT1C1	OTRTZUF5	Strong	Altered Expression	[1983]
C1orf43	OTT9CVZR	Strong	Biomarker	[1984]
C1QL1	OTNQ0G3E	Strong	Biomarker	[1985]
C2	OTHMF4YM	Strong	Genetic Variation	[506]
C6	OTCKR304	Strong	Genetic Variation	[1986]
C9	OT7I5FDX	Strong	Biomarker	[81]
CAB39	OT2CL9ST	Strong	Biomarker	[1987]
CABIN1	OT4G5CIK	Strong	Biomarker	[1988]
CABYR	OTKYMT99	Strong	Altered Expression	[1989]
CACYBP	OTJMZD2T	Strong	Altered Expression	[1777]
CALD1	OTNJKJ6Q	Strong	Altered Expression	[1990]
CAMTA1	OTAN1S5B	Strong	Biomarker	[1991]
CANX	OTYP1F6J	Strong	Biomarker	[1992]
CAP1	OTYM8A2N	Strong	Biomarker	[1993]
CAPN3	OTCHG3YK	Strong	Biomarker	[1994]
CAPNS1	OT95EBBD	Strong	Biomarker	[1995]
CARD10	OT2RPM4I	Strong	Altered Expression	[1996]
CARD8	OTXXZYWU	Strong	Genetic Variation	[1997]
CASP14	OTKY93H9	Strong	Genetic Variation	[1998]
CAST	OTBXZZGF	Strong	Biomarker	[1999]
CASZ1	OTWJ2OR8	Strong	Biomarker	[1423]
CAVIN2	OTFHHDRU	Strong	Altered Expression	[2000]
CBLL2	OTB4AD3V	Strong	Biomarker	[2001]
CBX1	OT2L4XZX	Strong	Altered Expression	[2002]
CBX8	OT4U5V1T	Strong	Biomarker	[378]
CCDC50	OTSE1YM5	Strong	Altered Expression	[2003]
CCDC8	OTO295IH	Strong	Genetic Variation	[2004]
CCDC88A	OT3SSYYC	Strong	Biomarker	[2005]
CCL14	OT8QETQU	Strong	Altered Expression	[2006]
CCL15	OTOGZ85M	Strong	Biomarker	[418]
CCL16	OTOOQI1F	Strong	Biomarker	[2007]
CCL19	OTQ2UJMH	Strong	Altered Expression	[2008]
CCL26	OT2B7HR9	Strong	Biomarker	[2009]
CCL27	OTUZYC61	Strong	Genetic Variation	[1226]
CCL28	OTY6XNQ7	Strong	Altered Expression	[2010]
CCL4	OT6B8P25	Strong	Altered Expression	[2011]
CCL4L2	OTDBSXOU	Strong	Biomarker	[2012]
CCN3	OTOW5YL4	Strong	Altered Expression	[1092]
CCN4	OT69BER9	Strong	Biomarker	[2013]
CCNA1	OTX4HD45	Strong	Altered Expression	[2014]
CCNB2	OTIEXTDK	Strong	Altered Expression	[2015]
CCNC	OTMVK4K4	Strong	Altered Expression	[817]
CCND2	OTDULQF9	Strong	Biomarker	[2016]
CCNDBP1	OTBWG1M0	Strong	Altered Expression	[2017]
CCNG1	OT17IA9L	Strong	Altered Expression	[2018]
CCNH	OTKDU3SR	Strong	Biomarker	[1695]
CCNJ	OTCR4WVV	Strong	Biomarker	[2019]
CCNL2	OT0NIKYM	Strong	Posttranslational Modification	[2020]
CCT3	OTL6EOS1	Strong	Altered Expression	[2021]
CCT4	OT5D452X	Strong	Biomarker	[835]
CCT6A	OTCYWL5F	Strong	Altered Expression	[2022]
CCT8	OTA7GQN9	Strong	Biomarker	[2023]
CD109	OTDADBM4	Strong	Altered Expression	[2024]
CD151	OTF3UZS7	Strong	Biomarker	[2025]
CD1D	OT3ROU4J	Strong	Altered Expression	[2026]
CD200R1	OT65Q9M6	Strong	Biomarker	[421]
CD226	OT4UG0KB	Strong	Biomarker	[433]
CD244	OTSMR85N	Strong	Genetic Variation	[2027]
CD5L	OTPY4WQR	Strong	Biomarker	[1413]
CD81	OTQFXNAZ	Strong	Biomarker	[2028]
CD82	OTH8MC64	Strong	Biomarker	[2029]
CD8A	OTDWQJXK	Strong	Altered Expression	[178]
CD8B	OTMZ1T7J	Strong	Biomarker	[1695]
CDC16	OTB914M7	Strong	Biomarker	[2030]
CDC26	OTHYYBGH	Strong	Genetic Variation	[2031]
CDC34	OTNBK390	Strong	Biomarker	[2032]
CDC40	OTOYUNHN	Strong	Altered Expression	[2033]
CDC42	OT5QBC5M	Strong	Biomarker	[2034]
CDC5L	OTTPFUU5	Strong	Biomarker	[2035]
CDC6	OTX93FE7	Strong	Biomarker	[2036]
CDCA3	OTUI8QK3	Strong	Biomarker	[2037]
CDCA5	OTZLCQ5U	Strong	Biomarker	[1447]
CDCA7L	OT1FFWKC	Strong	Biomarker	[2038]
CDH17	OT9EV2XK	Strong	Biomarker	[2039]
CDH4	OT8LH3HN	Strong	Altered Expression	[2040]
CDHR2	OTTHEUPO	Strong	Biomarker	[2041]
CDHR5	OTTBWQMN	Strong	Altered Expression	[2042]
CDK10	OTKP7TTR	Strong	Biomarker	[2043]
CDK11A	OTN5TSGQ	Strong	Biomarker	[2044]
CDK15	OT8S67QS	Strong	Altered Expression	[810]
CDK16	OTUBXIIT	Strong	Altered Expression	[810]
CDKN2B	OTAG24N1	Strong	Biomarker	[2045]
CDO1	OTLG1P77	Strong	Posttranslational Modification	[2046]
CDSN	OTQW4HV6	Strong	Altered Expression	[2047]
CDX1	OTOHTMJE	Strong	Altered Expression	[2048]
CDX2	OTCG4TSY	Strong	Altered Expression	[2049]
CEACAM7	OTKFDTZY	Strong	Biomarker	[451]
CELSR1	OT7PS8O1	Strong	Altered Expression	[1162]
CELSR3	OT8P6QNJ	Strong	Altered Expression	[2050]
CENPA	OT0NEJ4X	Strong	Biomarker	[1697]
CENPF	OT7AG0SW	Strong	Altered Expression	[2051]
CENPH	OTPOO9LK	Strong	Biomarker	[2052]
CENPM	OTYK9KOX	Strong	Altered Expression	[2053]
CEP131	OT6PF80T	Strong	Biomarker	[81]
CETN1	OTGQ8JOZ	Strong	Altered Expression	[2054]
CFAP20	OTIG8TR5	Strong	Altered Expression	[2055]
CFAP52	OTSSXF56	Strong	Altered Expression	[2056]
CFHR1	OT72R16T	Strong	Altered Expression	[2057]
CFL1	OTT6D5MH	Strong	Altered Expression	[1761]
CHAF1B	OTOMK4KH	Strong	Biomarker	[2058]
CHD1L	OT7CZK7C	Strong	Biomarker	[2059]
CHD4	OTBDEHDP	Strong	Altered Expression	[2060]
CHD5	OTS5EVHH	Strong	Genetic Variation	[2061]
CHI3L1	OT2Z7VJH	Strong	Biomarker	[1457]
CHMP2B	OTZA7RJB	Strong	Genetic Variation	[1058]
CHRNA3	OTCZQY1U	Strong	Biomarker	[2062]
CHST11	OTNJJ5Q1	Strong	Altered Expression	[2063]
CHSY1	OTB1XSSF	Strong	Altered Expression	[2064]
CIAO2A	OTYPPL5X	Strong	Biomarker	[2065]
CIAPIN1	OTWS90F9	Strong	Biomarker	[2066]
CIB1	OT4BVCRU	Strong	Biomarker	[2067]
CIB2	OT9ZJX1I	Strong	Biomarker	[2068]
CIC	OTFXCHNZ	Strong	Biomarker	[2069]
CILK1	OTWOYEYP	Strong	Altered Expression	[810]
CIP2A	OTVS2GXA	Strong	Altered Expression	[2070]
CIRBP	OTXWTPBL	Strong	Altered Expression	[2071]
CISD2	OTVS7S2H	Strong	Altered Expression	[1576]
CISD3	OT0MM1MW	Strong	Genetic Variation	[2072]
CISH	OT8T5NYL	Strong	Biomarker	[2073]
CIZ1	OT3UKHPI	Strong	Biomarker	[2074]
CKAP4	OTDUC9ME	Strong	Biomarker	[2075]
CKS1B	OTNUPLUJ	Strong	Altered Expression	[1654]
CKS2	OTPTMHIV	Strong	Altered Expression	[2076]
CLDN1	OT27KV99	Strong	Altered Expression	[2077]
CLDN10	OT2CVAKY	Strong	Altered Expression	[2078]
CLDN11	OTNN6UTL	Strong	Altered Expression	[2079]
CLDN14	OTS7GKOI	Strong	Biomarker	[2080]
CLDN3	OT71MN9S	Strong	Altered Expression	[2081]
CLDN7	OTNE0XHQ	Strong	Altered Expression	[2077]
CLDN9	OTCKI2IZ	Strong	Biomarker	[277]
CLEC10A	OTD8HQT6	Strong	Biomarker	[833]
CLEC1B	OTO38TRG	Strong	Altered Expression	[2082]
CLEC3B	OTFD29NF	Strong	Genetic Variation	[2083]
CLIC4	OT6KTPKD	Strong	Biomarker	[2084]
CLIP1	OTTGAEJE	Strong	Biomarker	[1177]
CLIP2	OTSCIQIY	Strong	Biomarker	[1177]
CLOCK	OTNEOJY7	Strong	Genetic Variation	[2085]
CLPTM1L	OTDJWQXI	Strong	Genetic Variation	[2086]
CLTC	OTBFASMA	Strong	Biomarker	[1291]
CLVS1	OTQH008A	Strong	Biomarker	[2087]
CMTM5	OTMS7NDP	Strong	Altered Expression	[2088]
CMTR2	OT82FBWS	Strong	Genetic Variation	[896]
CNBP	OTTGM9NK	Strong	Altered Expression	[1105]
CNDP2	OTJR9436	Strong	Biomarker	[2089]
CNN1	OTVPG39Z	Strong	Biomarker	[1123]
CNOT4	OTM8I5RH	Strong	Genetic Variation	[2090]
CNOT9	OT1NIIQD	Strong	Genetic Variation	[87]
COG8	OTDEA7YO	Strong	Altered Expression	[2091]
COL11A2	OT3BQUBH	Strong	Biomarker	[461]
COL15A1	OTTFKK18	Strong	Biomarker	[81]
COL25A1	OT7M23Z9	Strong	Altered Expression	[1873]
COL3A1	OTT1EMLM	Strong	Genetic Variation	[2092]
COL4A3	OT6SB8X5	Strong	Biomarker	[2093]
COL8A2	OTASWJ69	Strong	Biomarker	[2094]
COMMD1	OT7WUD5R	Strong	Altered Expression	[2095]
COMMD7	OTWWJ97D	Strong	Altered Expression	[2095]
COMMD8	OTRMN4EU	Strong	Altered Expression	[2096]
COMP	OTS2FPMI	Strong	Biomarker	[103]
COP1	OT6J2K12	Strong	Biomarker	[2097]
COPA	OTZ1DTXU	Strong	Biomarker	[1846]
COPS3	OTZWPJ24	Strong	Biomarker	[2098]
COPS6	OTG9AAG0	Strong	Altered Expression	[2099]
CORO1A	OTVAZOHC	Strong	Biomarker	[449]
CORO1C	OTXDF9T3	Strong	Biomarker	[2100]
CORO7	OTG7MEAJ	Strong	Altered Expression	[2101]
CORT	OTX3GUHB	Strong	Altered Expression	[2102]
COX1	OTG3O9BN	Strong	Genetic Variation	[2103]
COX3	OTNNGBYJ	Strong	Altered Expression	[2104]
COX5A	OTP0961M	Strong	Genetic Variation	[2105]
COX8A	OTU0NR39	Strong	Genetic Variation	[2105]
CP	OTM8JE4Y	Strong	Biomarker	[2106]
CPD	OT2CS64Y	Strong	Biomarker	[2107]
CPEB3	OTP1GQCH	Strong	Biomarker	[2108]
CPEB4	OTW1SCZW	Strong	Altered Expression	[2109]
CPOX	OTIAY121	Strong	Genetic Variation	[2105]
CPSF7	OT4WE5J7	Strong	Biomarker	[2110]
CPT2	OTIN6G20	Strong	Altered Expression	[288]
CRABP1	OTISDG5X	Strong	Posttranslational Modification	[2111]
CRAMP1	OT0X95YA	Strong	Biomarker	[2112]
CREB3	OT9617UO	Strong	Altered Expression	[2113]
CREB3L3	OTDMU3GP	Strong	Biomarker	[1690]
CREB5	OTJDUJPI	Strong	Altered Expression	[2114]
CRISP2	OT8HLTV5	Strong	Biomarker	[2115]
CRISPLD2	OTVSFHTL	Strong	Biomarker	[2116]
CRKL	OTOYSD1R	Strong	Biomarker	[2117]
CRLS1	OT7XNL0K	Strong	Biomarker	[2118]
CROCC	OTVNOZSM	Strong	Biomarker	[2119]
CRTAP	OT53H5U6	Strong	Genetic Variation	[2120]
CRYL1	OT0SJSJM	Strong	Biomarker	[2121]
CSN3	OTR61MI8	Strong	Altered Expression	[2122]
CSRP1	OTUS7RM2	Strong	Biomarker	[2123]
CSTA	OT1K68KE	Strong	Biomarker	[493]
CSTB	OT3U0JF8	Strong	Biomarker	[1296]
CT83	OTQEGHAB	Strong	Altered Expression	[2124]
CTAG1B	OTIQGW6U	Strong	Altered Expression	[488]
CTAG2	OT8HISP4	Strong	Biomarker	[2125]
CTBP1	OTVYH2DH	Strong	Biomarker	[2126]
CTBP2	OTGZGT87	Strong	Altered Expression	[2127]
CTBS	OT135K92	Strong	Biomarker	[913]
CTCF	OT8ZB70U	Strong	Biomarker	[2128]
CTHRC1	OTV88X2G	Strong	Altered Expression	[2129]
CTNNA3	OT9Z0P1E	Strong	Biomarker	[2130]
CTNNBIP1	OTX9SBJG	Strong	Biomarker	[2131]
CTNND1	OTUMPSHR	Strong	Biomarker	[2132]
CTNND2	OTYKE30Y	Strong	Biomarker	[2133]
CTTN	OTJRG4ES	Strong	Altered Expression	[2134]
CUL1	OTXPE1UZ	Strong	Altered Expression	[2135]
CUL2	OTPF83PG	Strong	Altered Expression	[2136]
CUL4A	OTTBV70J	Strong	Altered Expression	[2137]
CUL4B	OT2QX4DO	Strong	Biomarker	[2138]
CUL5	OTMTZD47	Strong	Altered Expression	[2139]
CUX1	OTU1LCNJ	Strong	Biomarker	[746]
CXADR	OT9ZP02A	Strong	Biomarker	[403]
CXCL14	OTM189TA	Strong	Altered Expression	[2140]
CXCL17	OTRCEVIZ	Strong	Altered Expression	[2141]
CXCL5	OTZOUPCA	Strong	Biomarker	[76]
CXCL6	OTFTCQ4O	Strong	Altered Expression	[2142]
CYLD	OT37FKH0	Strong	Altered Expression	[2143]
CYP2A7	OTRJ3P2Z	Strong	Biomarker	[1299]
CYP2W1	OTXSB1AE	Strong	Biomarker	[2144]
CYP4A22	OTHO7KC4	Strong	Biomarker	[1326]
CYTB	OTAHB98A	Strong	Altered Expression	[2145]
CYTH3	OTBXAT3Z	Strong	Biomarker	[2146]
CYTIP	OTRJ3ZC5	Strong	Genetic Variation	[2120]
DACH1	OTMKNAGG	Strong	Altered Expression	[2147]
DACT1	OT19Z704	Strong	Altered Expression	[2148]
DACT2	OTNLCC0K	Strong	Posttranslational Modification	[2149]
DAP	OT5YLL7E	Strong	Genetic Variation	[2150]
DAPK2	OTWODUQG	Strong	Altered Expression	[1192]
DBP	OTE0W7LN	Strong	Genetic Variation	[2151]
DBX2	OT2OBSP0	Strong	Altered Expression	[2152]
DCAF13	OTQQ0QXT	Strong	Altered Expression	[2153]
DCD	OTV5PBGJ	Strong	Altered Expression	[2154]
DCTN4	OTM7C943	Strong	Altered Expression	[767]
DCTN6	OTI8PIN9	Strong	Altered Expression	[2155]
DDB1	OTTR2L3Z	Strong	Biomarker	[2156]
DDIAS	OTTGG2PM	Strong	Biomarker	[2157]
DDIT3	OTI8YKKE	Strong	Altered Expression	[2158]
DDX19B	OT2084EJ	Strong	Altered Expression	[210]
DDX20	OT6G8YF3	Strong	Biomarker	[2159]
DDX53	OTHK3EGZ	Strong	Biomarker	[2160]
DDX56	OTGURA53	Strong	Biomarker	[2161]
DDX6	OTKWXVDY	Strong	Biomarker	[2162]
DECR1	OTCDIR6X	Strong	Altered Expression	[2163]
DENND4A	OT8FFZ29	Strong	Altered Expression	[2164]
DENR	OTXP9HOY	Strong	Altered Expression	[1192]
DEPDC1B	OTMVFOT1	Strong	Altered Expression	[2165]
DEPDC5	OTE70JLY	Strong	Genetic Variation	[2166]
DERL2	OTI3TUUZ	Strong	Altered Expression	[2167]
DESI2	OTHUOKOC	Strong	Biomarker	[2168]
DEUP1	OTXLM86J	Strong	Altered Expression	[2169]
DGKK	OTHIMF7L	Strong	Altered Expression	[2170]
DHDH	OTKA2AL6	Strong	Altered Expression	[319]
DHX15	OT4F98TK	Strong	Altered Expression	[2171]
DHX33	OTREUESJ	Strong	Biomarker	[2172]
DIXDC1	OT87DXEG	Strong	Altered Expression	[2173]
DKC1	OTX7DJR6	Strong	Altered Expression	[2174]
DKK4	OTWCCVF6	Strong	Biomarker	[2175]
DLC1	OTP8LMCR	Strong	Biomarker	[2176]
DLEC1	OTMKKBUW	Strong	Posttranslational Modification	[2177]
DLX2	OTKC2DQ0	Strong	Altered Expression	[2178]
DLX4	OTLWVCN4	Strong	Biomarker	[2179]
DMBT1	OTVNU9D9	Strong	Biomarker	[2180]
DMRT1	OT5PU9U1	Strong	Genetic Variation	[1058]
DMRT3	OTNV7F7Q	Strong	Biomarker	[1831]
DNAH17	OT4G6E70	Strong	Altered Expression	[2181]
DNAJB4	OTUD01BK	Strong	Altered Expression	[2182]
DNAJC10	OTD2EG0R	Strong	Biomarker	[2183]
DNAJC3	OT7ROIJF	Strong	Biomarker	[2184]
DNAJC6	OT1P6ZIE	Strong	Biomarker	[81]
DNALI1	OTTB3L8N	Strong	Biomarker	[2185]
DNASE2	OT6RC1BL	Strong	Genetic Variation	[292]
DND1	OTHLC8TA	Strong	Biomarker	[2186]
DNER	OT2GH2E5	Strong	Biomarker	[2187]
DNM1L	OTXK1Q1G	Strong	Altered Expression	[420]
DNM3	OTDMUGCR	Strong	Altered Expression	[2188]
DNMBP	OTMHH14H	Strong	Altered Expression	[2189]
DOCK8	OTNQLL21	Strong	Altered Expression	[2190]
DOK1	OTGVRLW6	Strong	Posttranslational Modification	[2191]
DPAGT1	OTYEJAGZ	Strong	Biomarker	[2192]
DPT	OTINRFC7	Strong	Biomarker	[2193]
DPYS	OTLTUIVL	Strong	Biomarker	[537]
DPYSL3	OTINJV20	Strong	Altered Expression	[2194]
DRAM1	OTIJTXEN	Strong	Biomarker	[2195]
DRG2	OTFYAWE5	Strong	Biomarker	[2196]
DSE	OTQ108VJ	Strong	Altered Expression	[2197]
DUOX2	OTU14HCN	Strong	Biomarker	[1653]
DUSP21	OTZAGY5R	Strong	Altered Expression	[2198]
DUSP28	OTDYDBN7	Strong	Biomarker	[2199]
DVL3	OTPRROHJ	Strong	Altered Expression	[1931]
DYM	OTQ670WI	Strong	Biomarker	[1556]
DYNLL1	OTR69LHT	Strong	Posttranslational Modification	[2177]
DYNLL2	OTLIT58K	Strong	Biomarker	[2176]
DYNLRB1	OTWVKOFB	Strong	Altered Expression	[2200]
DYNLRB2	OT1G3HAF	Strong	Altered Expression	[2200]
E2F4	OTB3JFH4	Strong	Biomarker	[1549]
E2F5	OT1XWING	Strong	Altered Expression	[2201]
E2F6	OT2PN28R	Strong	Biomarker	[2202]
E2F7	OTWW358N	Strong	Altered Expression	[2203]
E2F8	OTQKZGFP	Strong	Altered Expression	[2202]
EAF2	OTSOET5L	Strong	Biomarker	[2204]
EBAG9	OTTQLQCP	Strong	Altered Expression	[2205]
EBNA1BP2	OTBRVMZH	Strong	Biomarker	[778]
ECM1	OT1K65VW	Strong	Biomarker	[81]
ECT2	OTQDUCT6	Strong	Altered Expression	[2206]
EDIL3	OTDVVNS0	Strong	Biomarker	[2207]
EEF1A1	OT00THXS	Strong	Altered Expression	[2208]
EEF1A2	OT9Z23K5	Strong	Biomarker	[2209]
EEF1B2	OTW64NPU	Strong	Altered Expression	[1657]
EEF1D	OTM5ZD8Y	Strong	Altered Expression	[1657]
EEF2	OTZ7SZ39	Strong	Biomarker	[2210]
EFCAB11	OTXDJ9R8	Strong	Genetic Variation	[2211]
EFEMP1	OTZVUOOB	Strong	Biomarker	[2212]
EFNA1	OTU2NUA2	Strong	Biomarker	[2213]
EFNA5	OTOH4DRR	Strong	Biomarker	[2214]
EFNB1	OT7JJW8P	Strong	Altered Expression	[2215]
EFNB2	OT0DCUOM	Strong	Altered Expression	[2216]
EGR3	OTGPJIRA	Strong	Altered Expression	[2217]
EHHADH	OTBAAHL5	Strong	Biomarker	[2218]
EIF1	OTB4GZ0V	Strong	Altered Expression	[2219]
EIF3A	OTFABY9G	Strong	Biomarker	[2220]
EIF3B	OTF67VPH	Strong	Biomarker	[2221]
EIF3C	OTR8RF9X	Strong	Altered Expression	[2222]
EIF3H	OT61RBF5	Strong	Biomarker	[778]
EIF3I	OTE07WND	Strong	Biomarker	[2223]
EIF3J	OTJ4TAWK	Strong	Biomarker	[2221]
EIF3K	OTGTKVGO	Strong	Altered Expression	[2224]
EIF4A1	OTMTBX6N	Strong	Genetic Variation	[2225]
EIF4B	OTE8TXA8	Strong	Altered Expression	[2221]
EIF4G1	OT2CF1E6	Strong	Altered Expression	[2221]
EIF5B	OTZTT22W	Strong	Biomarker	[1912]
EIF6	OTEXMUED	Strong	Altered Expression	[2221]
ELAVL2	OT6EJ8MQ	Strong	Biomarker	[2226]
ELF1	OTV5LKIA	Strong	Biomarker	[2227]
ELK1	OTH9MXD6	Strong	Biomarker	[2228]
ELOVL2	OTDAF6U3	Strong	Altered Expression	[2229]
ELOVL4	OT2M9W26	Strong	Biomarker	[2230]
ELOVL6	OTB26UJJ	Strong	Altered Expression	[2231]
EMB	OT67E3Q1	Strong	Biomarker	[2232]
ENC1	OTJEUB6U	Strong	Biomarker	[2233]
ENDOG	OT5IM7B3	Strong	Altered Expression	[2234]
ENO1	OTB1KWJS	Strong	Biomarker	[2235]
ENOX1	OT4WOLA8	Strong	Altered Expression	[2236]
EOMES	OTB9VQFA	Strong	Biomarker	[2237]
EP400	OTVQ75NX	Strong	Biomarker	[2238]
EPB41	OTGCFPV8	Strong	Altered Expression	[2239]
EPS15	OT7NPP8U	Strong	Biomarker	[2240]
EPS8L3	OT7XYA2T	Strong	Biomarker	[1433]
ERCC1	OTNPYQHI	Strong	Genetic Variation	[2241]
ERCC2	OT1C8HQ4	Strong	Biomarker	[829]
ERCC3	OTVAW3P1	Strong	Biomarker	[2242]
ERCC5	OTQAKFJM	Strong	Genetic Variation	[1213]
ERCC6	OT2QZKSF	Strong	Biomarker	[2243]
ERH	OTJDWX99	Strong	Biomarker	[2244]
ERP29	OTNKANMH	Strong	Biomarker	[2245]
ERRFI1	OT7VZ2IZ	Strong	Altered Expression	[2246]
ETHE1	OTP9A2BQ	Strong	Biomarker	[2247]
ETNPPL	OTSXO9P6	Strong	Biomarker	[2248]
EVA1A	OTCY3Q2M	Strong	Altered Expression	[2249]
EVI5	OTOPAP55	Strong	Altered Expression	[2250]
EXOC7	OT4YA137	Strong	Biomarker	[2251]
EXT1	OTRPALJK	Strong	Altered Expression	[2252]
EYA4	OTINGR3Z	Strong	Biomarker	[2253]
FA2H	OT8HA13U	Strong	Biomarker	[341]
FADD	OTV7GFHH	Strong	Biomarker	[2254]
FAIM2	OT6QINVO	Strong	Altered Expression	[2255]
FAM3B	OTC2S91N	Strong	Altered Expression	[2256]
FAM3C	OTBR6U9G	Strong	Biomarker	[2257]
FAM43B	OTLND7C6	Strong	Posttranslational Modification	[2258]
FAM83H	OTN0SF11	Strong	Altered Expression	[2259]
FAM9C	OTKMB3SZ	Strong	Biomarker	[2260]
FANCC	OTTIDM3P	Strong	Biomarker	[2261]
FANCG	OT7MC8TZ	Strong	Biomarker	[2262]
FARP2	OTNRQIMK	Strong	Genetic Variation	[2263]
FBL	OTRODIE5	Strong	Biomarker	[2264]
FBLIM1	OTFHXMON	Strong	Biomarker	[2265]
FBLN1	OT5MHHOP	Strong	Biomarker	[2266]
FBLN5	OTLVNZ8U	Strong	Biomarker	[2267]
FBN2	OT3KYJQL	Strong	Biomarker	[2268]
FBP1	OTQBANEP	Strong	Biomarker	[2269]
FBXO17	OTDSRA7P	Strong	Altered Expression	[2270]
FBXO22	OTEJ5MO0	Strong	Biomarker	[2271]
FBXO31	OTF96IC2	Strong	Altered Expression	[2272]
FBXO5	OTTR957W	Strong	Biomarker	[2273]
FBXO8	OTZNGJGW	Strong	Biomarker	[1670]
FBXW10	OTLBLG11	Strong	Altered Expression	[770]
FBXW11	OT2A6RLR	Strong	Biomarker	[2274]
FBXW4	OTEGSZOX	Strong	Biomarker	[1819]
FCGR3B	OTSLSPZG	Strong	Altered Expression	[597]
FCN2	OTTHJBKZ	Strong	Biomarker	[1440]
FCRL1	OTXOYT29	Strong	Biomarker	[2275]
FDX1	OT7I3DN0	Strong	Biomarker	[2276]
FEN1	OT6QGG7O	Strong	Biomarker	[2277]
FERMT1	OT626PBA	Strong	Altered Expression	[2278]
FERMT2	OTZNPWWX	Strong	Altered Expression	[2279]
FERMT3	OTFQOT3C	Strong	Biomarker	[2280]
FETUB	OT7V07NI	Strong	Biomarker	[2281]
FGF13	OTHNNVSG	Strong	Biomarker	[2282]
FGF16	OT6BHWZP	Strong	Biomarker	[1671]
FGF17	OTAQSFZ2	Strong	Altered Expression	[2283]
FGF20	OTJIQ8YZ	Strong	Biomarker	[1671]
FGF3	OT9PK2SI	Strong	Biomarker	[2284]
FGF5	OTQXGHBY	Strong	Biomarker	[2285]
FGFRL1	OT8HZ3ZL	Strong	Altered Expression	[2286]
FHL2	OT0OAYWT	Strong	Altered Expression	[1505]
FKBP11	OTY2GC67	Strong	Biomarker	[2287]
FLNB	OTPCOYL6	Strong	Biomarker	[1846]
FLNC	OT3F8J6Y	Strong	Biomarker	[2288]
FLOT2	OTZ0QR5L	Strong	Altered Expression	[2289]
FLT3LG	OTU0YGC4	Strong	Biomarker	[2290]
FLVCR1	OT9XCFOC	Strong	Biomarker	[2291]
FMNL2	OT9OVWCV	Strong	Altered Expression	[2292]
FNDC3B	OTBILGDR	Strong	Biomarker	[2293]
FOXA1	OTEBY0TD	Strong	Altered Expression	[2294]
FOXA2	OTJOCVOY	Strong	Biomarker	[618]
FOXA3	OTRGT2OT	Strong	Biomarker	[2295]
FOXD3	OTXYV6GO	Strong	Altered Expression	[2296]
FOXE1	OT5IR5IT	Strong	Biomarker	[2297]
FOXF2	OTV20NGX	Strong	Biomarker	[2298]
FOXJ1	OT7LLBZ7	Strong	Biomarker	[2299]
FOXK1	OTLZGS7J	Strong	Altered Expression	[2300]
FOXK2	OTFXDZ3R	Strong	Altered Expression	[2301]
FOXN1	OTE80D6I	Strong	Genetic Variation	[2302]
FOXN3	OTOJYJZP	Strong	Biomarker	[2303]
FOXO3	OTHXQG4P	Strong	Altered Expression	[2304]
FOXO4	OT90X9LN	Strong	Biomarker	[2305]
FRAT1	OT1PS84E	Strong	Altered Expression	[2306]
FRK	OTEKV1SC	Strong	Biomarker	[2307]
FRMD5	OTC73XJK	Strong	Biomarker	[2308]
FRZB	OTTO3DPY	Strong	Posttranslational Modification	[2309]
FSD1	OT8P6PT3	Strong	Altered Expression	[2310]
FSD1L	OTBQ48RF	Strong	Altered Expression	[2310]
FSTL1	OT6KEZUD	Strong	Biomarker	[2311]
FSTL5	OT18C29S	Strong	Biomarker	[2312]
FTCD	OTX9HZT5	Strong	Altered Expression	[2313]
FTL	OTYQA8A6	Strong	Biomarker	[2125]
FUBP1	OT77SC9N	Strong	Biomarker	[2314]
FUBP3	OTX6DZS5	Strong	Altered Expression	[2315]
FUNDC1	OTA6IVKQ	Strong	Biomarker	[2316]
FUNDC2	OTY3TQM5	Strong	Biomarker	[2317]
FUT1	OTODG57A	Strong	Biomarker	[1616]
FUT2	OTLXM6WI	Strong	Altered Expression	[2318]
FUT5	OTOPGL9M	Strong	Altered Expression	[1333]
FUT7	OTJF6BSN	Strong	Biomarker	[2319]
FUT8	OTJJCVG1	Strong	Biomarker	[2320]
FUT9	OTLIJBQY	Strong	Altered Expression	[1333]
FXYD5	OT81DIOD	Strong	Biomarker	[2321]
FZD1	OTZATHVS	Strong	Biomarker	[1430]
FZD3	OTIWDN78	Strong	Altered Expression	[2322]
FZD4	OTGLZIE0	Strong	Altered Expression	[2323]
GAB1	OTQKE6V4	Strong	Biomarker	[2324]
GABARAPL1	OT4U7SBG	Strong	Altered Expression	[2325]
GABPA	OT9YB2SA	Strong	Altered Expression	[766]
GABRB3	OT80C3D4	Strong	Altered Expression	[2326]
GADD45A	OTDRV63V	Strong	Biomarker	[2327]
GADL1	OTJM4A0R	Strong	Biomarker	[1933]
GAGE1	OT53E50E	Strong	Genetic Variation	[2328]
GAGE4	OTPB5C0O	Strong	Genetic Variation	[2328]
GAGE5	OTFI6OVS	Strong	Genetic Variation	[2328]
GALNT1	OTO3RO36	Strong	Biomarker	[2329]
GALNT10	OTZ6FDOL	Strong	Altered Expression	[2330]
GALNT14	OT9BSDDQ	Strong	Genetic Variation	[2331]
GALNT2	OTZZ5386	Strong	Biomarker	[460]
GAS2	OT50JKXQ	Strong	Altered Expression	[2332]
GATA2	OTBP2QQ2	Strong	Altered Expression	[2333]
GC	OTWS63BY	Strong	Biomarker	[2334]
GCA	OTAJ7ZHG	Strong	Biomarker	[2335]
GCNT3	OTQ9ALTR	Strong	Altered Expression	[2336]
GDE1	OTU6FSBF	Strong	Altered Expression	[2337]
GDF11	OTOSNMND	Strong	Biomarker	[2338]
GEMIN2	OT4L6TLL	Strong	Altered Expression	[2339]
GEMIN4	OTX7402E	Strong	Genetic Variation	[2340]
GFER	OTVK43OK	Strong	Biomarker	[2341]
GFPT1	OTQBDO45	Strong	Biomarker	[2342]
GFRA1	OT3WBVYB	Strong	Genetic Variation	[2343]
GGA3	OTXZ2W65	Strong	Biomarker	[2344]
GGPS1	OTVEHG28	Strong	Biomarker	[2345]
GGTLC1	OTWJKUHQ	Strong	Altered Expression	[2346]
GIMAP5	OTMND7IR	Strong	Biomarker	[2347]
GIMAP6	OTDKV8V8	Strong	Biomarker	[2347]
GKN1	OT7ZYFQ9	Strong	Biomarker	[2348]
GLDN	OTA8TQU9	Strong	Biomarker	[2349]
GLI3	OTKDOE94	Strong	Biomarker	[2350]
GLIPR2	OTFTH6ZY	Strong	Altered Expression	[2351]
GLIS2	OTOUUV1X	Strong	Biomarker	[725]
GLOD4	OTBJKFXA	Strong	Altered Expression	[2352]
GLRX3	OTUPAU1N	Strong	Biomarker	[2353]
GLRX5	OTE3L48D	Strong	Altered Expression	[2353]
GLS2	OT08MSHL	Strong	Altered Expression	[2354]
GLYAT	OT3WWYXD	Strong	Altered Expression	[2355]
GLYATL1	OTS8JSRY	Strong	Altered Expression	[2356]
GNA12	OT3IRZH3	Strong	Biomarker	[282]
GNA13	OTVDL515	Strong	Biomarker	[2357]
GNAI2	OTTLGRGH	Strong	Biomarker	[2358]
GNAS	OTMH8BKJ	Strong	Genetic Variation	[87]
GNL3	OTILGYO4	Strong	Biomarker	[2359]
GNLY	OTZJKA8C	Strong	Altered Expression	[2360]
GOLM1	OTOZSV6O	Strong	Biomarker	[1101]
GOLPH3	OTDLGYM3	Strong	Biomarker	[1101]
GON4L	OTWQVLO9	Strong	Altered Expression	[589]
GOPC	OTRBGH71	Strong	Biomarker	[2361]
GORAB	OTP65YD7	Strong	Altered Expression	[2362]
GORASP1	OTQS91S7	Strong	Biomarker	[804]
GOSR1	OTX8TMVU	Strong	Biomarker	[2185]
GOT2	OT6XBWN0	Strong	Altered Expression	[2363]
GPAA1	OTWVRR35	Strong	Altered Expression	[2364]
GPC1	OTQKRSSV	Strong	Altered Expression	[2365]
GPC5	OT8NR7GC	Strong	Biomarker	[2366]
GPR162	OTK4LT3K	Strong	Biomarker	[2367]
GPR37	OTIMDDI3	Strong	Biomarker	[2368]
GPR42	OTEB0ROY	Strong	Biomarker	[308]
GPRC5A	OTPOCWR7	Strong	Posttranslational Modification	[2369]
GPRC5C	OT45AJT3	Strong	Altered Expression	[660]
GPSM2	OT6RPMRM	Strong	Biomarker	[2370]
GPX2	OTXI2NTI	Strong	Biomarker	[2371]
GPX3	OT6PK94R	Strong	Posttranslational Modification	[2372]
GRAMD1A	OTV6U1ZN	Strong	Biomarker	[2373]
GRAP2	OTS5NIZ3	Strong	Biomarker	[318]
GRB7	OTF8Y9XY	Strong	Altered Expression	[2374]
GRP	OT8JDFNI	Strong	Altered Expression	[2375]
GSC	OT4DH7PR	Strong	Altered Expression	[2376]
GSDME	OT1ZWY32	Strong	Biomarker	[2377]
GSX2	OTLA7BAI	Strong	Biomarker	[2378]
GTF2B	OTAH5NSO	Strong	Altered Expression	[2379]
GTF2H1	OTCRXC6B	Strong	Altered Expression	[767]
GTF3A	OTVROUVQ	Strong	Biomarker	[2380]
GTPBP1	OTA9KV6C	Strong	Biomarker	[2381]
GYPA	OTABU4YV	Strong	Biomarker	[2382]
GYPC	OTOEDR7O	Strong	Biomarker	[2383]
GYS2	OTCKIUYR	Strong	Biomarker	[2384]
H1-0	OTRLJK4Z	Strong	Biomarker	[2385]
H2AX	OT18UX57	Strong	Altered Expression	[2386]
H2AZ1	OT3KJJNQ	Strong	Biomarker	[2387]
H3-3B	OT9XHQ3C	Strong	Biomarker	[2388]
H4C1	OTB71W46	Strong	Biomarker	[2389]
HACD1	OTEC7EP7	Strong	Biomarker	[791]
HAO2	OTDWSQ0L	Strong	Biomarker	[81]
HAPLN1	OTXWR9TJ	Strong	Biomarker	[2390]
HAS1	OTJIAG1W	Strong	Biomarker	[2391]
HAS3	OTPM8IL8	Strong	Biomarker	[2391]
HAUS3	OTFNDWNE	Strong	Altered Expression	[2392]
HAVCR2	OTOL603T	Strong	Biomarker	[2393]
HBE1	OTJPKMX4	Strong	Biomarker	[2394]
HCP5	OTV0YRI8	Strong	Genetic Variation	[2395]
HDGFL2	OTWX2GHS	Strong	Biomarker	[2396]
HDLBP	OTKDEEYX	Strong	Biomarker	[1615]
HECA	OTWG3P6C	Strong	Altered Expression	[2397]
HELZ	OTMKFJZY	Strong	Biomarker	[2398]
HEPACAM	OT1MJ51D	Strong	Biomarker	[2399]
HERC5	OTZ5PR39	Strong	Biomarker	[2400]
HES5	OTW7JEHV	Strong	Altered Expression	[2401]
HES6	OTWO5SCF	Strong	Altered Expression	[2402]
HGS	OTCYYCAC	Strong	Biomarker	[2403]
HHIP	OT77RQYS	Strong	Altered Expression	[2404]
HIF3A	OTPWAAMC	Strong	Altered Expression	[2405]
HINT2	OTW9GS0U	Strong	Altered Expression	[2406]
HIP1	OT7AKCFQ	Strong	Altered Expression	[2407]
HJURP	OTWMV16B	Strong	Altered Expression	[2408]
HLA-DOA	OTZE5Q7R	Strong	Genetic Variation	[2409]
HLA-DPA1	OT7OG7Y2	Strong	Genetic Variation	[2410]
HLA-DQA2	OT1DH0N9	Strong	Genetic Variation	[506]
HLA-DRA	OT7KZMP2	Strong	Altered Expression	[430]
HLA-DRB4	OTNXIHQU	Strong	Genetic Variation	[2411]
HLA-E	OTX1CTFB	Strong	Biomarker	[2410]
HLA-F	OT76CM19	Strong	Altered Expression	[2412]
HLF	OTTRK9XN	Strong	Biomarker	[2413]
HLTF	OTRX2OSF	Strong	Genetic Variation	[2414]
HLX	OT7DTH46	Strong	Biomarker	[2415]
HMGB3	OTCJ2EZY	Strong	Altered Expression	[2416]
HMGN4	OTD7GPRL	Strong	Biomarker	[2417]
HMMR	OT4M0JTZ	Strong	Altered Expression	[2418]
HNF1B	OTSYIC3T	Strong	Biomarker	[2419]
HNRNPC	OT47AK4C	Strong	Biomarker	[2420]
HNRNPDL	OTB3BFCV	Strong	Biomarker	[2420]
HNRNPH1	OTFRWOLM	Strong	Altered Expression	[2421]
HNRNPH3	OTODTW0I	Strong	Altered Expression	[1696]
HNRNPK	OTNPRM8U	Strong	Biomarker	[2422]
HOOK1	OTTTKV7V	Strong	Altered Expression	[2423]
HOOK2	OTPO4NQV	Strong	Altered Expression	[756]
HOXA1	OTMSOJ7D	Strong	Biomarker	[2424]
HOXA10	OTB6GQ09	Strong	Biomarker	[2425]
HOXA9	OTKNK5H0	Strong	Posttranslational Modification	[394]
HOXB7	OTC7WYU8	Strong	Biomarker	[2426]
HOXB9	OTMVHQOU	Strong	Altered Expression	[2427]
HOXC8	OTJUYU8J	Strong	Altered Expression	[2428]
HOXD10	OT0NOWU2	Strong	Posttranslational Modification	[2429]
HOXD13	OTWSC8TF	Strong	Biomarker	[2430]
HOXD3	OTBUZ35T	Strong	Biomarker	[2431]
HOXD8	OTJ5H7AT	Strong	Biomarker	[2432]
HPDL	OTW7D1SV	Strong	Posttranslational Modification	[740]
HPS5	OTLO2374	Strong	Biomarker	[2433]
HPX	OT14T7Q1	Strong	Biomarker	[2434]
HRG	OTPLUFOG	Strong	Biomarker	[2435]
HSF2	OTXNJIJ9	Strong	Biomarker	[2436]
HSPA12A	OTFOCDD6	Strong	Biomarker	[2437]
HSPA1A	OTKGIE76	Strong	Altered Expression	[2438]
HSPA1L	OTC2V1K6	Strong	Altered Expression	[2439]
HSPA2	OTSDET7B	Strong	Altered Expression	[2440]
HSPA4	OT5HR0AR	Strong	Biomarker	[2441]
HSPA6	OTH4S7WB	Strong	Biomarker	[2437]
HSPB2	OTS01646	Strong	Biomarker	[705]
HSPB6	OTFPLGZI	Strong	Altered Expression	[2442]
HSPH1	OTVRR73T	Strong	Altered Expression	[2443]
HTN3	OTEUXA81	Strong	Genetic Variation	[2444]
HTRA2	OTC7616F	Strong	Biomarker	[2445]
HUS1	OTY1XON9	Strong	Altered Expression	[2446]
IBSP	OT29944Y	Strong	Posttranslational Modification	[2447]
IER3	OTZJI5FZ	Strong	Biomarker	[2448]
IFI16	OT4SPU0U	Strong	Biomarker	[2449]
IFI27	OTI2XGIT	Strong	Altered Expression	[2155]
IFITM3	OT2QP8D3	Strong	Genetic Variation	[2450]
IFNL2	OT4BMJF7	Strong	Biomarker	[713]
IGF2BP1	OT9G360P	Strong	Biomarker	[645]
IGF2BP2	OT4ZSEEE	Strong	Altered Expression	[2451]
IGSF11	OTQEG2X1	Strong	Biomarker	[2452]
IHH	OT1DWGXC	Strong	Biomarker	[2453]
IKBKE	OT5VYOSM	Strong	Biomarker	[2454]
IL17B	OTS86H50	Strong	Biomarker	[729]
IL17RB	OT0KDNSF	Strong	Biomarker	[2455]
IL26	OT2WYCW4	Strong	Biomarker	[2456]
IL27	OTIS3OF8	Strong	Biomarker	[2457]
IL6R	OTCQL07Z	Strong	Altered Expression	[787]
IL9R	OTILCLXA	Strong	Altered Expression	[2458]
ILF2	OTWWVM9X	Strong	Biomarker	[2459]
ILF3	OTKMZ5K5	Strong	Biomarker	[2459]
IMMP2L	OT9WGAFD	Strong	Genetic Variation	[2460]
ING2	OT6H0EWF	Strong	Biomarker	[2461]
ING4	OT0VVG4V	Strong	Altered Expression	[2462]
ING5	OTRNNSFM	Strong	Altered Expression	[2463]
INHA	OT7HWCO3	Strong	Biomarker	[2464]
INPP4B	OTLROA7G	Strong	Altered Expression	[2465]
INPP5K	OTQFLQKA	Strong	Altered Expression	[2466]
INPPL1	OTCDAVBQ	Strong	Biomarker	[2467]
INTS2	OT2N5TCK	Strong	Biomarker	[2468]
INTS3	OT7NX4CD	Strong	Biomarker	[2469]
INTS6	OT6GDV46	Strong	Altered Expression	[2470]
INTS8	OT3SRRLM	Strong	Altered Expression	[2471]
IQGAP1	OTZRWTGA	Strong	Altered Expression	[2472]
IQGAP2	OTX2UA7P	Strong	Altered Expression	[2473]
IQGAP3	OT4RZV2M	Strong	Altered Expression	[2474]
IQSEC1	OTK1PBFD	Strong	Biomarker	[2475]
IREB2	OT747D24	Strong	Altered Expression	[1827]
IRF5	OT8SIIAP	Strong	Biomarker	[2476]
IRF7	OTC1A2PQ	Strong	Biomarker	[742]
IRS4	OTTOL40K	Strong	Biomarker	[2477]
IRX3	OTLJ48FG	Strong	Altered Expression	[2478]
ISX	OTULQRWA	Strong	Biomarker	[2479]
ISYNA1	OT49ONSE	Strong	Biomarker	[146]
ITGA2B	OT4Y17PY	Strong	Genetic Variation	[2480]
ITGA3	OTBCH21D	Strong	Altered Expression	[2481]
ITGA7	OTTBTAYW	Strong	Biomarker	[982]
ITGB4	OT28UK84	Strong	Biomarker	[2482]
ITIH4	OT460OO1	Strong	Biomarker	[2483]
IVL	OT4VPNGY	Strong	Genetic Variation	[2484]
JAZF1	OTXTYSYD	Strong	Genetic Variation	[2485]
JDP2	OTW35WKX	Strong	Biomarker	[2486]
JMJD6	OTILR7E4	Strong	Biomarker	[2487]
JPT1	OT6CRZEU	Strong	Biomarker	[2488]
JPT2	OTJGPA4T	Strong	Biomarker	[2112]
JTB	OT314JB6	Strong	Biomarker	[2489]
KAT5	OTL7257A	Strong	Biomarker	[2490]
KAT7	OTUN98IC	Strong	Altered Expression	[2491]
KCND2	OTIFUVV7	Strong	Biomarker	[1617]
KCNH4	OTHJ8WTU	Strong	Biomarker	[2228]
KCNH8	OT3I5FLB	Strong	Biomarker	[2228]
KCNK15	OT8ELIFL	Strong	Biomarker	[759]
KCNK17	OTG2NEZM	Strong	Biomarker	[759]
KCNRG	OTXHYFOD	Strong	Altered Expression	[2492]
KCTD11	OT64DFBU	Strong	Biomarker	[2493]
KDELR1	OT8YBS5G	Strong	Altered Expression	[2494]
KDM3B	OTZU5J5S	Strong	Biomarker	[2495]
KDM8	OTCN5ST8	Strong	Biomarker	[81]
KIF14	OTXHT4JM	Strong	Biomarker	[81]
KIF15	OTJRJEXL	Strong	Biomarker	[349]
KIF18A	OTSMBJ24	Strong	Altered Expression	[1877]
KIF20A	OTXOQHE0	Strong	Altered Expression	[2496]
KIF22	OTY6X6BL	Strong	Biomarker	[2497]
KIF23	OTY850JC	Strong	Biomarker	[1628]
KIF2A	OT2WQ6QD	Strong	Altered Expression	[756]
KIF4A	OT3UWL7D	Strong	Biomarker	[1166]
KIFC1	OTNQDS00	Strong	Biomarker	[2498]
KIR2DL5B	OTSV0JL9	Strong	Altered Expression	[638]
KIR2DS3	OT3PSLDL	Strong	Biomarker	[2499]
KIR2DS4	OT00N6UJ	Strong	Genetic Variation	[2500]
KIR3DL1	OTPOSXFX	Strong	Altered Expression	[638]
KIR3DS1	OTJWIO4T	Strong	Genetic Variation	[2499]
KL	OTD4VWU6	Strong	Altered Expression	[2501]
KLF10	OT4F4UGS	Strong	Altered Expression	[2502]
KLF17	OT5NWVP7	Strong	Biomarker	[2503]
KLF2	OTIP1UFX	Strong	Biomarker	[2504]
KLF5	OT1ABI9N	Strong	Altered Expression	[545]
KLF6	OTQY9S7F	Strong	Biomarker	[2505]
KLF8	OTUC5CDB	Strong	Biomarker	[2506]
KLF9	OTBFEJRQ	Strong	Biomarker	[2503]
KLHL1	OTAX6SAD	Strong	Biomarker	[285]
KLHL2	OT1NG8V7	Strong	Biomarker	[2507]
KLHL21	OT28Y2LQ	Strong	Biomarker	[598]
KLHL35	OT1DL3FY	Strong	Biomarker	[2508]
KLK10	OTD573EL	Strong	Posttranslational Modification	[898]
KLRD1	OTMYLOV4	Strong	Biomarker	[2509]
KMT2B	OTMMAZQX	Strong	Biomarker	[2510]
KMT2C	OTC59BCO	Strong	Genetic Variation	[1904]
KMT2D	OTTVHCLY	Strong	Biomarker	[2511]
KPNA2	OTU7FOE6	Strong	Biomarker	[2512]
KPNA3	OTLI3TM2	Strong	Biomarker	[2513]
KRT10	OTSVRD3Q	Strong	Biomarker	[2514]
KRT18	OTVLQFIP	Strong	Biomarker	[2515]
KRT23	OTQW6UAG	Strong	Biomarker	[144]
KRT4	OT24PHPM	Strong	Biomarker	[2516]
KRT7	OTLT3JFN	Strong	Biomarker	[2517]
KTN1	OTQAV541	Strong	Biomarker	[2518]
LAMA2	OTFROQWE	Strong	Altered Expression	[2519]
LAMA4	OTHI7TA0	Strong	Altered Expression	[2520]
LAMA5	OTIIXE4M	Strong	Biomarker	[2521]
LAMB1	OT6J9LJR	Strong	Altered Expression	[2522]
LAMC1	OTIG527N	Strong	Altered Expression	[2523]
LAMTOR1	OTIBJBW9	Strong	Altered Expression	[356]
LARP6	OTUQ9QS9	Strong	Biomarker	[2524]
LATS1	OTOOCG4R	Strong	Altered Expression	[2525]
LBR	OT1HG3HG	Strong	Biomarker	[2526]
LCP1	OTK61F2A	Strong	Posttranslational Modification	[2527]
LDHB	OT9B1CT3	Strong	Altered Expression	[2528]
LEF1	OTWS5I5H	Strong	Altered Expression	[2529]
LETMD1	OTZTZ4RD	Strong	Biomarker	[1971]
LGALS14	OTOR23GX	Strong	Altered Expression	[2530]
LGALS3BP	OT9AGQKH	Strong	Biomarker	[2531]
LGALS4	OTKQCG0H	Strong	Biomarker	[2532]
LGALS9	OT7MF91K	Strong	Genetic Variation	[2533]
LHPP	OT9AGAIJ	Strong	Biomarker	[2534]
LIG4	OT40DNXU	Strong	Genetic Variation	[2535]
LIN28B	OTVWP0FN	Strong	Biomarker	[977]
LIN9	OTLHW00C	Strong	Altered Expression	[1469]
LLGL1	OTAIQSXZ	Strong	Biomarker	[2536]
LMCD1	OT3AWE8O	Strong	Genetic Variation	[2537]
LMLN	OTQF0JPY	Strong	Biomarker	[394]
LMNB1	OT100T3P	Strong	Biomarker	[2538]
LMNB2	OTXRDUOS	Strong	Biomarker	[2539]
LMTK2	OT93MVIC	Strong	Altered Expression	[2540]
LNX1	OTZWFMAZ	Strong	Biomarker	[2541]
LPCAT1	OTCV7AGV	Strong	Biomarker	[2542]
LPCAT3	OTWI96P4	Strong	Biomarker	[2542]
LPXN	OTUNV3CK	Strong	Biomarker	[2543]
LRG1	OTLD0KWA	Strong	Altered Expression	[622]
LRIG2	OTDUBLIH	Strong	Biomarker	[2544]
LRPAP1	OT6DVD2Q	Strong	Biomarker	[2545]
LRPPRC	OTXSK5LP	Strong	Altered Expression	[2546]
LRRC1	OTSVD30Q	Strong	Biomarker	[81]
LRRC28	OTFTT6VN	Strong	Biomarker	[333]
LRRC8A	OT23OE7H	Strong	Altered Expression	[330]
LRRFIP1	OTN7XAUD	Strong	Biomarker	[2547]
LRSAM1	OTOKWR6C	Strong	Biomarker	[2548]
LSP1	OTSPSIFO	Strong	Biomarker	[2549]
LTBP2	OTS88GSD	Strong	Biomarker	[2550]
LTBP3	OTME98V7	Strong	Biomarker	[2551]
LUZP1	OTQV3VZM	Strong	Altered Expression	[2113]
LXN	OTZQ2M6Y	Strong	Altered Expression	[2552]
LY6E	OTMG16BZ	Strong	Altered Expression	[2553]
LYPD5	OTGP7UKA	Strong	Biomarker	[2554]
LZTS1	OTXXL864	Strong	Biomarker	[2555]
MACC1	OTV3DLX0	Strong	Biomarker	[2556]
MACROH2A1	OTV2DQDD	Strong	Biomarker	[2557]
MAD2L1	OTXNGZCG	Strong	Biomarker	[1959]
MAD2L1BP	OT2O2IUJ	Strong	Biomarker	[1874]
MAF1	OTKB0N8Q	Strong	Biomarker	[1970]
MAFB	OTH2N3T8	Strong	Biomarker	[2558]
MAFK	OTZJUE4P	Strong	Altered Expression	[356]
MAGED4B	OTO37U7W	Strong	Altered Expression	[2559]
MAGEE1	OTOQQO2X	Strong	Biomarker	[670]
MAGI1	OTMV4ASV	Strong	Biomarker	[2560]
MAGI2	OTXDDKZS	Strong	Biomarker	[2561]
MAGT1	OTQSAV5C	Strong	Biomarker	[325]
MAK16	OTD546E5	Strong	Altered Expression	[977]
MAL	OTBM30SW	Strong	Biomarker	[2562]
MAL2	OTVPEI80	Strong	Biomarker	[2563]
MAN1A2	OTITCN3Q	Strong	Altered Expression	[2564]
MAN1B1	OTI780UB	Strong	Biomarker	[2565]
MAP1LC3A	OTPMGIU4	Strong	Altered Expression	[2566]
MAP1LC3B	OTUYHB84	Strong	Biomarker	[2567]
MAP2K3	OTI2OREX	Strong	Altered Expression	[2568]
MAP3K13	OTS93BTX	Strong	Biomarker	[2569]
MAP7	OTVSSJ33	Strong	Altered Expression	[2570]
MAPRE1	OTCVQD60	Strong	Biomarker	[2571]
MAPRE2	OTAE3MX4	Strong	Biomarker	[2572]
MARCHF1	OTI2EYO6	Strong	Biomarker	[2573]
MARCHF5	OTBK6BBM	Strong	Altered Expression	[2574]
MARCHF8	OTH7PNN2	Strong	Genetic Variation	[2575]
MARCKSL1	OT13J2FM	Strong	Biomarker	[1416]
MASTL	OTQ7YKK5	Strong	Biomarker	[2576]
MATN2	OTVDR68G	Strong	Biomarker	[2577]
MATR3	OTESJ5S7	Strong	Biomarker	[262]
MAU2	OTALDF8Q	Strong	Biomarker	[2578]
MBD2	OTUQPP0R	Strong	Biomarker	[2579]
MBD4	OTWR9YXE	Strong	Altered Expression	[2580]
MBD5	OTFHT4MO	Strong	Altered Expression	[2581]
MBNL3	OT2T2YOK	Strong	Biomarker	[2582]
MBOAT7	OTHRCBLK	Strong	Biomarker	[1729]
MCAT	OTH07FIW	Strong	Altered Expression	[468]
MCC	OTQVI1EM	Strong	Biomarker	[2583]
MCM10	OTV0O3JN	Strong	Altered Expression	[234]
MCM2	OTGGORIQ	Strong	Altered Expression	[2584]
MCM4	OT19PNNG	Strong	Biomarker	[1479]
MCM9	OTALGFW8	Strong	Biomarker	[2585]
MCPH1	OTYT3TT5	Strong	Biomarker	[2586]
MCTS1	OT7SAOJP	Strong	Altered Expression	[468]
MCUR1	OTSL49SR	Strong	Biomarker	[2587]
MECOM	OTP983W8	Strong	Altered Expression	[2588]
MED1	OTOO24C4	Strong	Altered Expression	[383]
MED15	OT0D0JVD	Strong	Biomarker	[2589]
MED19	OTT9RT5N	Strong	Biomarker	[2590]
MED23	OTKZQT0R	Strong	Altered Expression	[2591]
MEF2A	OTV2SF6E	Strong	Biomarker	[2592]
MEF2C	OTZGF1Y5	Strong	Biomarker	[2593]
MEF2D	OT7CEIG0	Strong	Altered Expression	[2594]
MEFV	OTRJ6S6K	Strong	Biomarker	[2595]
MEGF8	OT5G38CH	Strong	Altered Expression	[2596]
MEIS2	OTG4ADLM	Strong	Genetic Variation	[2597]
MEN1	OTN6U6V0	Strong	Biomarker	[772]
MEST	OT8Q4U8Y	Strong	Posttranslational Modification	[2598]
METTL1	OTRQC5ER	Strong	Altered Expression	[2599]
MFAP1	OTZN4FT3	Strong	Altered Expression	[1297]
MFSD2A	OTVG1VG0	Strong	Altered Expression	[2600]
MGAT3	OTXI5X4T	Strong	Biomarker	[2601]
MGAT5	OTU4DD4G	Strong	Altered Expression	[1619]
MGAT5B	OT5HP73K	Strong	Biomarker	[2336]
MIA2	OTOGTUTU	Strong	Biomarker	[2602]
MIA3	OTBVIZQD	Strong	Biomarker	[2603]
MIF4GD	OTEUG1GR	Strong	Biomarker	[2604]
MIP	OTEBLU3E	Strong	Biomarker	[2605]
MITF	OT6XJCZH	Strong	Altered Expression	[1718]
MLC1	OTCNZLSP	Strong	Biomarker	[2606]
MLXIP	OT30UNI7	Strong	Genetic Variation	[2575]
MMP26	OT9O89KU	Strong	Biomarker	[599]
MMP28	OTHQZXM1	Strong	Biomarker	[2607]
MMRN1	OT7ZNYHT	Strong	Biomarker	[2608]
MNAT1	OTXLOYCB	Strong	Biomarker	[2609]
MNT	OTPC4ANL	Strong	Biomarker	[2610]
MNX1	OTXP9FH1	Strong	Altered Expression	[2611]
MOB2	OTMBE0NS	Strong	Altered Expression	[2612]
MOK	OTQK7M9V	Strong	Altered Expression	[2613]
MOS	OTNMQPFJ	Strong	Posttranslational Modification	[2614]
MPEG1	OT7DAO0F	Strong	Biomarker	[171]
MPG	OTAHW80B	Strong	Biomarker	[2615]
MPP2	OTPH8CZY	Strong	Biomarker	[2616]
MPRIP	OT5FV5NS	Strong	Biomarker	[499]
MPST	OTCDPH5D	Strong	Biomarker	[2093]
MPZL1	OTJSUUHR	Strong	Biomarker	[2617]
MR1	OTZU3XX7	Strong	Genetic Variation	[2618]
MRE11	OTGU8TZM	Strong	Biomarker	[2619]
MRPL24	OTEIQZ5G	Strong	Biomarker	[1801]
MRPL28	OT4LUTZU	Strong	Altered Expression	[2620]
MRPS11	OTEERNWQ	Strong	Altered Expression	[2621]
MRPS18B	OT1K9PFX	Strong	Altered Expression	[2622]
MRPS23	OTDVWT5V	Strong	Biomarker	[2623]
MRPS5	OTZZR208	Strong	Biomarker	[2624]
MRTFA	OTCVXASM	Strong	Biomarker	[1727]
MSC	OTBRPZL5	Strong	Biomarker	[2625]
MSH3	OTD3YPVL	Strong	Altered Expression	[2626]
MSH6	OT46FP09	Strong	Biomarker	[951]
MSN	OTZJ4J6G	Strong	Biomarker	[2627]
MST1	OTOC4UNG	Strong	Biomarker	[2628]
MT1B	OTUA4FFH	Strong	Biomarker	[851]
MT1E	OTXJKU4Y	Strong	Genetic Variation	[1166]
MT1F	OTZVUYG1	Strong	Biomarker	[851]
MT1G	OTAV1OCR	Strong	Biomarker	[2629]
MT1H	OT0MVBM6	Strong	Altered Expression	[2630]
MTA3	OTIA6C79	Strong	Biomarker	[2631]
MTBP	OTWLCW9C	Strong	Altered Expression	[2632]
MTHFD1	OTMKHVWC	Strong	Altered Expression	[2633]
MTHFD2	OT1LQSGX	Strong	Altered Expression	[2634]
MTSS1	OT5DTDO2	Strong	Biomarker	[2635]
MTSS2	OTKMNSBF	Strong	Biomarker	[2636]
MTUS1	OTBPALMU	Strong	Genetic Variation	[2637]
MUC4	OTLT11V1	Strong	Biomarker	[2638]
MUL1	OT2JC9YR	Strong	Biomarker	[2001]
MUS81	OTVZ4E60	Strong	Biomarker	[2639]
MVP	OTJGHJRB	Strong	Biomarker	[2640]
MXI1	OTUQ9E0D	Strong	Biomarker	[2641]
MXRA8	OT43JEP1	Strong	Biomarker	[2642]
MYADM	OTZTZI7P	Strong	Altered Expression	[2643]
MYBL2	OTZ3JX8Q	Strong	Altered Expression	[2644]
MYBPH	OTQJBPUR	Strong	Altered Expression	[2052]
MYCL	OT1MFQ5U	Strong	Genetic Variation	[2645]
MYCT1	OTZ8A9L3	Strong	Biomarker	[2646]
MYDGF	OT9HRPL6	Strong	Biomarker	[227]
MYH6	OT3YNCH1	Strong	Biomarker	[1866]
MYL12B	OTXMLQOT	Strong	Altered Expression	[2647]
MYLIP	OTL0PFGV	Strong	Genetic Variation	[2575]
MYO1E	OTM9YSIZ	Strong	Biomarker	[2619]
MYO6	OTJQYRC7	Strong	Biomarker	[1866]
MYRIP	OTH2TFYH	Strong	Biomarker	[2619]
MZB1	OT071TET	Strong	Posttranslational Modification	[2648]
MZF1	OTMVZCPW	Strong	Altered Expression	[2649]
N4BP2L2	OTV2F04G	Strong	Altered Expression	[2650]
NAA10	OTYB9R6I	Strong	Biomarker	[2651]
NAA11	OTEEQGR7	Strong	Biomarker	[2652]
NAA40	OTFLRVQO	Strong	Biomarker	[2653]
NABP2	OTQU8081	Strong	Biomarker	[2654]
NAE1	OTMC6F3Y	Strong	Genetic Variation	[865]
NAF1	OTMJKJAK	Strong	Altered Expression	[1576]
NANOG	OTUEY1FM	Strong	Altered Expression	[991]
NANOS2	OTFM2IDJ	Strong	Altered Expression	[2655]
NBN	OT73B5MD	Strong	Biomarker	[2656]
NBPF3	OTRM16MN	Strong	Altered Expression	[1292]
NCAPH	OTXOS97C	Strong	Biomarker	[2657]
NCKIPSD	OT24UORN	Strong	Biomarker	[1857]
NCOA1	OTLIUJQD	Strong	Altered Expression	[2658]
NCOA2	OTMQFPBB	Strong	Biomarker	[607]
NCOA5	OTOGWTWB	Strong	Biomarker	[2659]
NCOR1	OT04XNOU	Strong	Biomarker	[2660]
NCOR2	OTY917X0	Strong	Biomarker	[2661]
NCR2	OT2H13BX	Strong	Altered Expression	[863]
NCR3	OT20M764	Strong	Biomarker	[2662]
NCR3LG1	OT15YWU7	Strong	Altered Expression	[2662]
NCSTN	OT5QBTA4	Strong	Biomarker	[2663]
ND1	OTCLGIXV	Strong	Altered Expression	[2664]
ND5	OT45LW1K	Strong	Biomarker	[2665]
NDP	OTGDJ4US	Strong	Biomarker	[2666]
NDRG1	OTVO66BO	Strong	Biomarker	[2667]
NDRG2	OT5L6KD7	Strong	Altered Expression	[2668]
NDRG3	OTJTJCHD	Strong	Biomarker	[2669]
NDUFA4L2	OTK0PG7R	Strong	Altered Expression	[2670]
NDUFB2	OT4717TF	Strong	Biomarker	[2671]
NECTIN1	OTTE5ZR6	Strong	Biomarker	[1928]
NEFH	OTMSCW5I	Strong	Biomarker	[2672]
NEIL1	OTHBU5DJ	Strong	Genetic Variation	[2673]
NELFE	OTL4E94L	Strong	Biomarker	[2674]
NET1	OTZHNMJV	Strong	Biomarker	[1080]
NEU1	OTH9BY8Y	Strong	Altered Expression	[2675]
NFAT5	OTKIE59S	Strong	Altered Expression	[2676]
NFATC1	OT4TMERS	Strong	Altered Expression	[2677]
NFATC2	OTK5T6HZ	Strong	Altered Expression	[2678]
NFE2L3	OT1MGXT0	Strong	Altered Expression	[2679]
NGB	OTW0SIUY	Strong	Biomarker	[2680]
NHEJ1	OTYOO05J	Strong	Biomarker	[2681]
NID2	OTHC33FF	Strong	Biomarker	[2682]
NKD1	OTY3MO97	Strong	Altered Expression	[2683]
NKRF	OTUVY0P6	Strong	Altered Expression	[2684]
NLK	OT2LETFS	Strong	Altered Expression	[2685]
NLN	OTFRITPU	Strong	Altered Expression	[894]
NLRC3	OTWLLFFN	Strong	Altered Expression	[2686]
NLRP12	OTGR132Z	Strong	Biomarker	[2687]
NLRP2	OTJA81JU	Strong	Biomarker	[2656]
NME2	OTCYGLHV	Strong	Biomarker	[2688]
NNAT	OTNRLO7G	Strong	Biomarker	[2689]
NOB1	OTW0YNSL	Strong	Altered Expression	[2690]
NOL3	OT1K0L0D	Strong	Genetic Variation	[2691]
NOLC1	OTKDZU0D	Strong	Altered Expression	[2692]
NOP53	OTA2YKO6	Strong	Altered Expression	[2693]
NOTUM	OT03MYQ2	Strong	Altered Expression	[2694]
NOVA1	OT6A9KHY	Strong	Biomarker	[2695]
NOX1	OTZPJQCC	Strong	Altered Expression	[1548]
NPAS1	OTZKO6ZN	Strong	Biomarker	[2696]
NPAS2	OTMRT2TS	Strong	Biomarker	[2697]
NPRL2	OTOB10MO	Strong	Altered Expression	[2698]
NR2C2	OTDZWVOJ	Strong	Biomarker	[2699]
NR2F1	OTGWZWYL	Strong	Biomarker	[2700]
NR2F2	OTJFS67N	Strong	Biomarker	[1842]
NRBP2	OTJSTU62	Strong	Biomarker	[2701]
NRIP1	OTIZOJQV	Strong	Biomarker	[2702]
NRSN2	OT4OS3M2	Strong	Biomarker	[2703]
NT5C3A	OT67KZJA	Strong	Biomarker	[2609]
NTS	OTPGDNQS	Strong	Altered Expression	[886]
NUCKS1	OTL4VJC5	Strong	Biomarker	[2704]
NUDT1	OTZSES3W	Strong	Biomarker	[2705]
NUDT21	OTZHKWAR	Strong	Biomarker	[2706]
NUDT6	OTCS3NYZ	Strong	Biomarker	[2707]
NUP37	OTPZH72U	Strong	Biomarker	[1695]
NUP62	OTMN63DH	Strong	Altered Expression	[767]
NUP88	OT647WOR	Strong	Altered Expression	[2708]
NUP98	OTNT12G2	Strong	Biomarker	[1846]
NUPR1	OT4FU8C0	Strong	Biomarker	[2709]
NUS1	OT4DQ82L	Strong	Altered Expression	[2710]
NUTM1	OTONYC08	Strong	Altered Expression	[2711]
NXF3	OTI0RW72	Strong	Altered Expression	[2712]
NXT1	OT0VO6AY	Strong	Altered Expression	[2620]
OBP2A	OTBIJ5TI	Strong	Biomarker	[2497]
OCLN	OTSUTVWL	Strong	Biomarker	[2077]
OCM	OTQRML29	Strong	Genetic Variation	[2713]
OGA	OT7ZBWT1	Strong	Altered Expression	[2714]
OGT	OT1Z1ZXE	Strong	Biomarker	[550]
OIT3	OT20DO1Z	Strong	Biomarker	[81]
OLFM1	OTOYPEWW	Strong	Altered Expression	[1873]
OLFM2	OT7TSF7I	Strong	Biomarker	[2715]
ONECUT1	OTK1QUQT	Strong	Altered Expression	[2716]
OPCML	OT93PQ6Y	Strong	Biomarker	[2717]
OPN1LW	OTFNUZ7O	Strong	Altered Expression	[2718]
OPN1MW	OTPJ7LX4	Strong	Genetic Variation	[2719]
OPN3	OTON6BFU	Strong	Biomarker	[2720]
OPN4	OT1LZ7TS	Strong	Altered Expression	[894]
OPN5	OTCYGHDA	Strong	Biomarker	[2721]
OPTN	OT2UXWH9	Strong	Genetic Variation	[2722]
ORM1	OTZKSBRE	Strong	Biomarker	[2723]
OSCP1	OTZ4IFGJ	Strong	Biomarker	[880]
OSGIN1	OT9KIVZW	Strong	Biomarker	[2724]
OTUD7A	OT3GCY98	Strong	Biomarker	[2725]
OTUD7B	OTMVM8R7	Strong	Biomarker	[2726]
OTX1	OTRGSGH9	Strong	Altered Expression	[2727]
OXA1L	OTS0BFRD	Strong	Biomarker	[2728]
OXCT1	OT536PE7	Strong	Altered Expression	[2729]
P2RX2	OT0LF34A	Strong	Altered Expression	[899]
P2RX5	OTLBR20R	Strong	Altered Expression	[881]
P2RX6	OT1FNTXA	Strong	Altered Expression	[899]
P4HB	OTTYNYPF	Strong	Biomarker	[1740]
PABPC4	OTICKKBQ	Strong	Biomarker	[2730]
PAF1	OTDDGUBQ	Strong	Biomarker	[2731]
PAG1	OTFOJUIQ	Strong	Altered Expression	[2718]
PAK5	OT32WQGL	Strong	Biomarker	[2732]
PAK6	OTAHPZTT	Strong	Altered Expression	[905]
PANX1	OTXPEDOK	Strong	Altered Expression	[2733]
PAQR3	OTTKJ9Y4	Strong	Biomarker	[2734]
PARP9	OT7K4494	Strong	Biomarker	[2735]
PARPBP	OTPZDGW7	Strong	Altered Expression	[2736]
PAX8	OTRPD9MI	Strong	Biomarker	[2737]
PBOV1	OT67PERT	Strong	Altered Expression	[2738]
PBX3	OT8WMVM4	Strong	Biomarker	[124]
PC	OT6O0V51	Strong	Altered Expression	[2739]
PCBP1	OTHN0TD7	Strong	Biomarker	[2740]
PCBP2	OTXCN9CG	Strong	Altered Expression	[2741]
PCBP4	OTDLL4NB	Strong	Altered Expression	[2718]
PCDH17	OTRK0M05	Strong	Biomarker	[2742]
PCDH20	OTFSNRXK	Strong	Biomarker	[2743]
PCDH9	OTX3BFV4	Strong	Genetic Variation	[896]
PCK2	OTJ8LX4N	Strong	Altered Expression	[2739]
PCLAF	OTMVIOUU	Strong	Biomarker	[2744]
PCNT	OTW4Z65J	Strong	Genetic Variation	[2745]
PDCD4	OTZ6NXUX	Strong	Altered Expression	[2746]
PDCD5	OT6T2DDL	Strong	Biomarker	[2747]
PDCD6IP	OTS8T6A7	Strong	Genetic Variation	[2748]
PDE6D	OTIFVXWD	Strong	Biomarker	[2749]
PDIK1L	OTISF4KG	Strong	Biomarker	[2750]
PDLIM1	OT4EGCPG	Strong	Biomarker	[2751]
PDLIM3	OTVXQC81	Strong	Genetic Variation	[1226]
PDLIM4	OT23LZYY	Strong	Biomarker	[2752]
PDLIM5	OTLQVV22	Strong	Biomarker	[2753]
PDP1	OT82RTMT	Strong	Biomarker	[631]
PDPN	OTBUV19I	Strong	Biomarker	[2754]
PDSS2	OTEOQBMX	Strong	Genetic Variation	[2755]
PDZD7	OTX3VAOB	Strong	Altered Expression	[2756]
PDZRN4	OTHPD5LB	Strong	Biomarker	[2541]
PEG10	OTWD2278	Strong	Altered Expression	[2757]
PENK	OT8P3HMP	Strong	Biomarker	[2758]
PER2	OTU2B1DJ	Strong	Genetic Variation	[2085]
PER3	OTVKYVJA	Strong	Altered Expression	[486]
PES1	OTMZK7XE	Strong	Biomarker	[2759]
PEX5	OTK4LMG7	Strong	Biomarker	[2760]
PFDN4	OT5NRHER	Strong	Biomarker	[2761]
PFKFB4	OTQYEXL2	Strong	Biomarker	[2762]
PFKL	OTVHGAT7	Strong	Biomarker	[2763]
PFKM	OT1QY9JM	Strong	Biomarker	[2764]
PGAM1	OTZ5DB06	Strong	Biomarker	[2765]
PGBD3	OTV3I2W1	Strong	Biomarker	[1617]
PGLYRP2	OTF8319A	Strong	Biomarker	[92]
PGP	OT6QQ7OR	Strong	Altered Expression	[2766]
PHEX	OTG7N3J7	Strong	Genetic Variation	[2767]
PHF5A	OTS94JFM	Strong	Biomarker	[2768]
PHLPP1	OTIFXW8D	Strong	Altered Expression	[2769]
PHLPP2	OTXB1OUI	Strong	Biomarker	[2628]
PI15	OTPJL6ML	Strong	Genetic Variation	[2770]
PI4K2A	OTL9L6MX	Strong	Biomarker	[2771]
PIAS1	OTZVAHZI	Strong	Altered Expression	[2772]
PIGK	OTAFSYLD	Strong	Genetic Variation	[2773]
PIGR	OT6GLSUL	Strong	Biomarker	[2774]
PIGS	OTCC4CEN	Strong	Biomarker	[2775]
PIK3C2A	OTFBU4GD	Strong	Biomarker	[2776]
PIK3C2B	OTY2PROB	Strong	Biomarker	[2777]
PIK3R1	OT5BZ1J9	Strong	Biomarker	[709]
PIK3R2	OTZSUQK5	Strong	Biomarker	[2778]
PIK3R3	OTXGJ8N1	Strong	Biomarker	[2779]
PITX2	OTWMXAOY	Strong	Biomarker	[2780]
PIWIL4	OTDA9MY0	Strong	Genetic Variation	[2781]
PKD2	OTIXBU8H	Strong	Biomarker	[2782]
PLA1A	OT2IXYNX	Strong	Altered Expression	[2783]
PLA2G10	OTRZ2L5A	Strong	Altered Expression	[333]
PLA2G4D	OTKBAB0F	Strong	Altered Expression	[2784]
PLA2G6	OT5FL0WU	Strong	Biomarker	[2785]
PLAAT4	OTI66SAJ	Strong	Biomarker	[1553]
PLB1	OTZ6TTYV	Strong	Altered Expression	[1251]
PLCB2	OTPAHDGO	Strong	Biomarker	[944]
PLCE1	OTJISZOX	Strong	Genetic Variation	[2786]
PLEC	OTU4XDEG	Strong	Altered Expression	[2787]
PLEKHM2	OT4ZYV73	Strong	Altered Expression	[2466]
PLIN2	OTRXJ9UN	Strong	Biomarker	[2788]
PLIN5	OTV8G50L	Strong	Altered Expression	[2789]
PLOD3	OTT00T7Q	Strong	Altered Expression	[1944]
PLXNA1	OTN0BING	Strong	Biomarker	[2790]
PLXNA3	OTMZIBVG	Strong	Genetic Variation	[2791]
PMPCA	OT5X1G9Q	Strong	Biomarker	[2792]
PMPCB	OTRMBHNM	Strong	Biomarker	[2793]
PMS2	OTNLWTMI	Strong	Biomarker	[2794]
PNLIPRP3	OT7H4PSU	Strong	Altered Expression	[2190]
PNN	OT0HXICH	Strong	Biomarker	[2795]
PNO1	OT010GIS	Strong	Altered Expression	[977]
PNPLA2	OTR3ERMR	Strong	Altered Expression	[2796]
PNRC1	OTQMLEE1	Strong	Altered Expression	[2650]
POFUT1	OTOBJZIT	Strong	Biomarker	[2797]
POLD1	OTWO4UCJ	Strong	Altered Expression	[2798]
POLDIP2	OT8SZSJ6	Strong	Biomarker	[318]
POLG	OTDUCT04	Strong	SusceptibilityMutation	[2799]
POLL	OTZ24QGM	Strong	Altered Expression	[2800]
POLR2C	OTZ0ULJ9	Strong	Altered Expression	[2801]
POLR2E	OTH5IL2A	Strong	Biomarker	[997]
POLR2K	OT3PXV3H	Strong	Biomarker	[333]
POT1	OTNBXJCQ	Strong	Altered Expression	[1133]
POTEF	OTV3WXYE	Strong	Altered Expression	[2802]
POTEM	OT7L2HGH	Strong	Altered Expression	[2803]
POU2F1	OTK7ELJ0	Strong	Biomarker	[1065]
POU3F1	OTYARA94	Strong	Posttranslational Modification	[1066]
POU4F1	OTMHYGWQ	Strong	Biomarker	[2804]
POU5F1	OTDHHN7O	Strong	Altered Expression	[1580]
PPARGC1A	OTHCDQ22	Strong	Altered Expression	[145]
PPDPF	OT4LO2GJ	Strong	Altered Expression	[2805]
PPIG	OTZ8BTTM	Strong	Altered Expression	[2806]
PPIP5K1	OT06HYH8	Strong	Biomarker	[146]
PPM1F	OTU0MVR7	Strong	Altered Expression	[2807]
PPM1K	OTNZ4N4E	Strong	Altered Expression	[2808]
PPP1R13B	OTC88VQO	Strong	Posttranslational Modification	[2809]
PPP1R13L	OTNCPLWE	Strong	Altered Expression	[2810]
PPP1R3C	OTEU05TX	Strong	Altered Expression	[2811]
PPP1R8	OTH5KB2P	Strong	Biomarker	[2651]
PPP1R9A	OTJL2TOC	Strong	ModifyingMutation	[2812]
PPP1R9B	OTDCTHTT	Strong	Altered Expression	[2813]
PPP2R1A	OTYA3GB4	Strong	Genetic Variation	[2814]
PPP2R1B	OTFIHQGD	Strong	Biomarker	[2815]
PPP2R2D	OTCZPP0N	Strong	Altered Expression	[2816]
PPP2R3A	OTSK5GFC	Strong	Altered Expression	[2817]
PPP6C	OTR1STMJ	Strong	Altered Expression	[2818]
PRAP1	OT48QD82	Strong	Altered Expression	[2819]
PRB2	OTAD4JZ0	Strong	Altered Expression	[2820]
PRC1	OTHD0XS0	Strong	Altered Expression	[2821]
PRDM5	OTU1GB68	Strong	Posttranslational Modification	[2822]
PRDX1	OTZ3BEC4	Strong	Altered Expression	[1184]
PRDX2	OTLWCY9T	Strong	Altered Expression	[2823]
PRDX3	OTLB2WEU	Strong	Altered Expression	[965]
PREX2	OTYT1J6J	Strong	Biomarker	[2824]
PRICKLE1	OT9HHEM9	Strong	Biomarker	[2825]
PRIMA1	OT9ITT3P	Strong	Altered Expression	[2826]
PRKAA1	OT7TNF0L	Strong	Biomarker	[2827]
PRKAA2	OTU1KZPV	Strong	Biomarker	[2827]
PRKAB1	OT1OG4QZ	Strong	Biomarker	[2827]
PRKACG	OTKOQYF8	Strong	Altered Expression	[810]
PRKAG2	OTHTAM54	Strong	Altered Expression	[1238]
PRKN	OTJBN41W	Strong	Biomarker	[2001]
PROCR	OTRHED17	Strong	Genetic Variation	[2828]
PROK1	OT8S7RUG	Strong	Altered Expression	[2829]
PROM2	OTT8IVS7	Strong	Altered Expression	[1365]
PROX1	OT68R6IO	Strong	Altered Expression	[2830]
PRPF19	OTQ1STV3	Strong	Biomarker	[2035]
PRPF31	OTSJ0Z1Y	Strong	Biomarker	[2831]
PRPF38B	OTQLH551	Strong	Biomarker	[1080]
PRPF4	OTK0XRQN	Strong	Biomarker	[2832]
PRPS1	OTN3A6CN	Strong	Genetic Variation	[2833]
PRR11	OT2JJ08Z	Strong	Altered Expression	[2834]
PRRX1	OTTZK5G8	Strong	Altered Expression	[2835]
PRRX2	OT8UR4AU	Strong	Genetic Variation	[2836]
PRSS22	OTANEFGM	Strong	Biomarker	[2837]
PRSS55	OTXXWI5Y	Strong	Biomarker	[2115]
PSAP	OTUOEKY7	Strong	Biomarker	[2838]
PSG2	OT2EIXAI	Strong	Biomarker	[451]
PSG4	OTCFNW3L	Strong	Biomarker	[1757]
PSG5	OTHTU98X	Strong	Altered Expression	[2839]
PSMA6	OTJ6RPX5	Strong	Biomarker	[2840]
PSMC3	OTSKT0JI	Strong	Biomarker	[2841]
PSMC3IP	OT9UB5UO	Strong	Biomarker	[2841]
PSMD14	OTJWHMZ5	Strong	Altered Expression	[2842]
PSMD7	OT7PZZ4K	Strong	Biomarker	[778]
PSMD8	OTY6X27P	Strong	Biomarker	[2690]
PSMD9	OT6Y5CC3	Strong	Altered Expression	[2155]
PSME3	OTSTC4YY	Strong	Altered Expression	[2843]
PSMG2	OTEMF20S	Strong	Biomarker	[2844]
PSTPIP1	OT4PGEAB	Strong	Altered Expression	[2845]
PTMA	OT2W4T1M	Strong	Altered Expression	[2846]
PTOV1	OT94WT5X	Strong	Altered Expression	[2847]
PTPN12	OT5WA666	Strong	Biomarker	[1521]
PTPN3	OTSLZBVY	Strong	Altered Expression	[2848]
PTPN4	OT6SXU5Y	Strong	Biomarker	[473]
PTPRD	OTZPJ3GX	Strong	Altered Expression	[2849]
PTPRH	OTDUHQGF	Strong	Altered Expression	[2850]
PTPRN2	OTL6SH28	Strong	Biomarker	[2851]
PTPRO	OTFLKWOY	Strong	Biomarker	[2852]
PTPRT	OTV5TXNN	Strong	Genetic Variation	[2853]
PTS	OTTYWQXR	Strong	Genetic Variation	[2854]
PTTG1	OTIMYS4W	Strong	Biomarker	[2855]
PTX3	OTPXHRKU	Strong	Altered Expression	[2856]
PUF60	OTG90DYF	Strong	Genetic Variation	[2263]
PUS1	OTS2DQ0N	Strong	Biomarker	[1801]
PVR	OT3N91T7	Strong	Altered Expression	[2857]
PYCARD	OT67RON3	Strong	Biomarker	[1119]
PYCR2	OTS2HLGD	Strong	Biomarker	[302]
PYGO2	OTZHB2OI	Strong	Biomarker	[2858]
QRSL1	OTJDU2UG	Strong	Altered Expression	[2333]
QTRT1	OTC33MCV	Strong	Altered Expression	[2859]
RAB10	OT8ZN26V	Strong	Biomarker	[2860]
RAB11FIP4	OTIGHER7	Strong	Biomarker	[2861]
RAB17	OT7NBUGQ	Strong	Biomarker	[2862]
RAB18	OTNMAQLS	Strong	Altered Expression	[2863]
RAB1A	OTKPHRD0	Strong	Biomarker	[2864]
RAB23	OTBAKFBR	Strong	Altered Expression	[2865]
RAB25	OTW0W6NP	Strong	Altered Expression	[2866]
RAB27A	OT9SQRWY	Strong	Biomarker	[2867]
RAB27B	OTPF9D0K	Strong	Biomarker	[2868]
RAB31	OTMLXQZ0	Strong	Biomarker	[2869]
RAB35	OTRH1E2T	Strong	Biomarker	[2870]
RAB3GAP1	OT4DQ8F2	Strong	Biomarker	[2068]
RAB40AL	OTZWO8A5	Strong	Altered Expression	[1956]
RAB40B	OTCA9ZF5	Strong	Biomarker	[2871]
RAB5A	OTFR2KM4	Strong	Biomarker	[2872]
RAB5IF	OTNNWX7E	Strong	Altered Expression	[2873]
RAB8A	OTPB54Y3	Strong	Genetic Variation	[2874]
RABEPK	OTCZSREH	Strong	Biomarker	[778]
RABGEF1	OTWC3Z3R	Strong	Biomarker	[2875]
RAC2	OTAOHFNH	Strong	Biomarker	[2876]
RACGAP1	OTQE8IEH	Strong	Biomarker	[2877]
RAD23B	OT0PGOG3	Strong	Altered Expression	[2878]
RAD51AP1	OTXM7UTD	Strong	Biomarker	[2879]
RAD51D	OTKOU5XN	Strong	Genetic Variation	[2880]
RAE1	OT54OKC3	Strong	Biomarker	[2881]
RANBP3	OTI8ESC3	Strong	Altered Expression	[2882]
RAP1A	OT5RH6TI	Strong	Biomarker	[2875]
RAPH1	OTMQXW7S	Strong	Biomarker	[1833]
RARRES1	OTETUPP5	Strong	Posttranslational Modification	[2369]
RARRES2	OT1BJE8K	Strong	Biomarker	[2883]
RASAL1	OTAHUNN7	Strong	Altered Expression	[2884]
RASGRF1	OTNWJ7EN	Strong	Biomarker	[2885]
RASGRP3	OTEMEV3P	Strong	Biomarker	[2886]
RASSF10	OTGB7EBG	Strong	Altered Expression	[2887]
RASSF5	OT6Q41I2	Strong	Altered Expression	[811]
RBBP4	OTG3BT3M	Strong	Genetic Variation	[2879]
RBBP7	OTLB56HX	Strong	Biomarker	[262]
RBFOX3	OTL0F3D6	Strong	Biomarker	[2888]
RBL2	OTBQSOE6	Strong	Genetic Variation	[2889]
RBM14	OTO9GMBD	Strong	Biomarker	[1519]
RBM19	OT3Q6UIM	Strong	Altered Expression	[2581]
RBM23	OTDNGLHY	Strong	Biomarker	[2890]
RBM38	OTPO8EXU	Strong	Altered Expression	[2891]
RBM39	OTCMPTF9	Strong	Biomarker	[2892]
RBM45	OTWTHD77	Strong	Genetic Variation	[681]
RBMS3	OTFSC9MR	Strong	Altered Expression	[977]
RBMY1A1	OTM2F25H	Strong	Biomarker	[2893]
RBP1	OTRP1MFC	Strong	Biomarker	[2894]
RBP2	OTR8QG5V	Strong	Biomarker	[762]
RCAN1	OT1MVXC7	Strong	Biomarker	[1607]
RCHY1	OTAE7504	Strong	Altered Expression	[2362]
RCN2	OTIU8JWD	Strong	Biomarker	[2895]
RDH10	OTL9FSGF	Strong	Altered Expression	[2896]
RDH11	OTIND43N	Strong	Altered Expression	[2897]
RDH16	OTCJ915F	Strong	Altered Expression	[2898]
RDM1	OTBSJEAG	Strong	Biomarker	[2899]
RDX	OTNSYUN6	Strong	Altered Expression	[2900]
RECQL	OTPCH3JH	Strong	Biomarker	[2242]
REEP5	OTZU4TJI	Strong	Biomarker	[978]
REG1A	OTMHUH1D	Strong	Altered Expression	[2901]
RELB	OTU3QYEF	Strong	Biomarker	[2448]
RERG	OTF6MMLV	Strong	Altered Expression	[2902]
RETREG1	OTYOSLZX	Strong	Altered Expression	[2903]
RFC3	OT1MS7AO	Strong	Altered Expression	[2904]
RFX1	OTZUDMPR	Strong	Altered Expression	[2905]
RGCC	OTYJMLWM	Strong	Biomarker	[2906]
RGS5	OTUY0Q2I	Strong	Altered Expression	[2907]
RHBDD1	OTL5J132	Strong	Biomarker	[2908]
RHBDF1	OTCQ7UDS	Strong	Altered Expression	[2909]
RHOC	OTOLE1FT	Strong	Biomarker	[2910]
RIN1	OTPBROUD	Strong	Altered Expression	[2911]
RIN2	OTCY73U9	Strong	Biomarker	[821]
RIOX2	OT2YFPI2	Strong	Biomarker	[2912]
RITA1	OTUH8IPS	Strong	Biomarker	[2913]
RMDN1	OTE1NB6U	Strong	Altered Expression	[1715]
RMDN2	OTK5WSFI	Strong	Altered Expression	[1715]
RMDN3	OTKO7AUM	Strong	Altered Expression	[1715]
RNASE3	OTVE2XD1	Strong	Altered Expression	[2914]
RND1	OTOC223Z	Strong	Altered Expression	[2915]
RND3	OTXMXPIH	Strong	Biomarker	[81]
RNF181	OT7YB7WD	Strong	Altered Expression	[2916]
RNF187	OTXTN1HP	Strong	Altered Expression	[2917]
RNF19A	OTKWCV80	Strong	Biomarker	[318]
RNF38	OTRLV4WZ	Strong	Altered Expression	[1140]
RNGTT	OT59E0KX	Strong	Genetic Variation	[2918]
ROBO3	OTPVG40S	Strong	Altered Expression	[521]
RPE	OT0XT3JU	Strong	Biomarker	[2919]
RPGRIP1L	OT6Z069I	Strong	Biomarker	[1867]
RPL10	OTBHOZGC	Strong	Biomarker	[2790]
RPL10A	OTDLCJ53	Strong	Biomarker	[2920]
RPL14	OTZZW7TK	Strong	Biomarker	[333]
RPL23A	OTPYLCCX	Strong	Biomarker	[2921]
RPL24	OTCY9DEB	Strong	Biomarker	[2922]
RPL30	OTLQVY1Z	Strong	Biomarker	[2923]
RPL35A	OTDDJUWF	Strong	Genetic Variation	[2225]
RPL36	OT9R9LWG	Strong	Altered Expression	[2924]
RPL36A	OT1LYV85	Strong	Altered Expression	[2246]
RPL37A	OTAMQLY7	Strong	Altered Expression	[2925]
RPL39L	OTAV1MJQ	Strong	Altered Expression	[2926]
RPL4	OTTYJB0X	Strong	Biomarker	[2927]
RPL41	OTFW5IFO	Strong	Biomarker	[333]
RPL7A	OT6E6UKF	Strong	Altered Expression	[2928]
RPL8	OTHMZ1R9	Strong	Biomarker	[333]
RPLP0	OT3XKD6Y	Strong	Altered Expression	[2929]
RPN2	OTJ1SKOA	Strong	Altered Expression	[2930]
RPRD1B	OTB41D5K	Strong	Altered Expression	[2931]
RPS10	OTE3VSAH	Strong	Altered Expression	[2932]
RPS15A	OT0BUA12	Strong	Biomarker	[2933]
RPS17	OTWHZ2JQ	Strong	Biomarker	[333]
RPS19	OTBKGP48	Strong	Biomarker	[2934]
RPS24	OTSNKIL5	Strong	Biomarker	[333]
RPS27	OTFXKY7P	Strong	Biomarker	[171]
RPS27A	OTIIGGZ2	Strong	Biomarker	[1181]
RPS3	OT0K3TMH	Strong	Altered Expression	[2935]
RPS3A	OTUEP7CL	Strong	Biomarker	[2936]
RPS5	OTPSWQRS	Strong	Biomarker	[2937]
RPS6	OTT4D1LN	Strong	Biomarker	[2938]
RRAS2	OT83NCEB	Strong	Genetic Variation	[2939]
RRBP1	OT4ZTPTM	Strong	Biomarker	[2940]
RSL1D1	OT3CL4R3	Strong	Altered Expression	[2941]
RSPO2	OT3HHXU0	Strong	Altered Expression	[2942]
RSU1	OTO5GHT1	Strong	Biomarker	[2943]
RTKN2	OTV2AXQM	Strong	Biomarker	[2944]
RTP3	OTZUDJ6Q	Strong	Altered Expression	[2945]
RTRAF	OTJ6NVMW	Strong	Altered Expression	[2946]
RUVBL1	OTWV19L7	Strong	Biomarker	[2947]
RUVBL2	OTGWJ4T4	Strong	Altered Expression	[2948]
RYBP	OTZZ4P2Z	Strong	Altered Expression	[2949]
S100A11	OTI57KDN	Strong	Biomarker	[2222]
S100A14	OTVFJJ91	Strong	Biomarker	[2950]
SAA2	OTYAVJWG	Strong	Biomarker	[1027]
SAGE1	OT4H6FFA	Strong	Biomarker	[1830]
SALL3	OTJ2LZKQ	Strong	Altered Expression	[2951]
SAMD9L	OTKEJUCI	Strong	Altered Expression	[2952]
SAMHD1	OTBCIBC7	Strong	Biomarker	[2953]
SAMM50	OTRYFYIU	Strong	Genetic Variation	[2954]
SAMSN1	OT7N88T1	Strong	Biomarker	[2955]
SARNP	OTE0OVK5	Strong	Biomarker	[2892]
SARS1	OTFKXQ1O	Strong	Biomarker	[2956]
SARS2	OTU4T99W	Strong	Biomarker	[2956]
SART1	OTHMOGO1	Strong	Biomarker	[578]
SASH1	OTQA8BD4	Strong	Posttranslational Modification	[2957]
SAT2	OT28QL7H	Strong	Posttranslational Modification	[2958]
SATB2	OT2W80XC	Strong	Altered Expression	[2959]
SAV1	OTSAEV92	Strong	Genetic Variation	[2960]
SCAF11	OTX59D0X	Strong	Altered Expression	[2339]
SCAMP3	OTUNPYCE	Strong	Altered Expression	[2961]
SCARA5	OTOVA96E	Strong	Altered Expression	[472]
SCO2	OTJQQDRS	Strong	Biomarker	[611]
SCRIB	OTW4N3FV	Strong	Biomarker	[2663]
SCTR	OTC80IMR	Strong	Altered Expression	[1032]
SCYL1	OTQ0IN7P	Strong	Altered Expression	[2962]
SDC3	OT1P0LJM	Strong	Altered Expression	[983]
SDHC	OTC8G2MX	Strong	Altered Expression	[186]
SDK1	OTX26906	Strong	Biomarker	[2851]
SEC14L2	OTJST64D	Strong	Biomarker	[1125]
SEC23IP	OTTZ0FXP	Strong	Biomarker	[2963]
SELENBP1	OT3NZNTR	Strong	Biomarker	[2596]
SELENOI	OTX2A47A	Strong	Biomarker	[2964]
SELENOK	OTKM7N7P	Strong	Altered Expression	[2965]
SELENOM	OTJ7PORS	Strong	Altered Expression	[2966]
SELENOP	OT02B8IR	Strong	Biomarker	[2967]
SELENOS	OTUEWIU9	Strong	Biomarker	[2968]
SEMA3B	OTCZCPMS	Strong	Biomarker	[2969]
SEMA3C	OTEGUY7F	Strong	Altered Expression	[2970]
SEMA4A	OT8901H3	Strong	Altered Expression	[2971]
SEMA6A	OTDQ7QAW	Strong	Altered Expression	[2972]
SENP2	OTPQJXIR	Strong	Biomarker	[2973]
SENP5	OTN9Q07Y	Strong	Biomarker	[2974]
SENP6	OT05LLF4	Strong	Posttranslational Modification	[2975]
SEPTIN11	OTX2O0ZX	Strong	Biomarker	[2652]
SEPTIN2	OT3G33TM	Strong	Altered Expression	[2976]
SEPTIN4	OTD16B30	Strong	Genetic Variation	[2833]
SEPTIN7	OTJI08YX	Strong	Biomarker	[2977]
SERINC1	OTF3UASX	Strong	Altered Expression	[2978]
SERINC2	OTZ039U0	Strong	Altered Expression	[2978]
SERPINA3	OT9BP2S0	Strong	Biomarker	[2979]
SERPINA4	OTBK0GG7	Strong	Therapeutic	[2980]
SERPINA5	OTTZXPGD	Strong	Biomarker	[2981]
SERPINB1	OT5RDUFO	Strong	Biomarker	[2982]
SERPINB2	OT72QLZB	Strong	Biomarker	[2983]
SERPINB6	OT7G55IK	Strong	Biomarker	[791]
SERPINI1	OTUJHIJW	Strong	Biomarker	[2984]
SERTAD2	OTYIG6TP	Strong	Altered Expression	[2985]
SESN2	OT889IXY	Strong	Biomarker	[2133]
SET	OTGYYQJO	Strong	Altered Expression	[2986]
SETDB1	OTWVUA1B	Strong	Altered Expression	[2987]
SEZ6L2	OTUIKN2I	Strong	Biomarker	[2988]
SF3B2	OTNW2U4Y	Strong	Genetic Variation	[87]
SF3B4	OTGB9OR9	Strong	Biomarker	[2989]
SFN	OTLJCZ1U	Strong	Biomarker	[2125]
SFPQ	OTLCIAPJ	Strong	Biomarker	[1734]
SFRP1	OT0U9G41	Strong	Biomarker	[81]
SFRP2	OT8GZ0CA	Strong	Biomarker	[2990]
SFRP5	OTLCVVSH	Strong	Biomarker	[2991]
SGK2	OTCTVSHF	Strong	Biomarker	[2992]
SGK3	OTQ6QO99	Strong	Genetic Variation	[2993]
SGSM3	OTIB1P8A	Strong	Biomarker	[2994]
SH2D4A	OTH562MY	Strong	Biomarker	[2995]
SH2D5	OTJDS1NN	Strong	Biomarker	[2996]
SH3BGRL3	OTKMW34I	Strong	Biomarker	[2997]
SH3BP1	OTGED7Z2	Strong	Biomarker	[2997]
SH3BP4	OTVIRKW7	Strong	Biomarker	[2998]
SHBG	OTPWU5IW	Strong	Altered Expression	[2999]
SHMT2	OT5NCAZN	Strong	Altered Expression	[3000]
SHOX2	OTLCZZJW	Strong	Altered Expression	[3001]
SIAH2	OTKED2XN	Strong	Biomarker	[3002]
SIDT1	OTJM5S74	Strong	Altered Expression	[3003]
SIN3B	OTFB59FK	Strong	Altered Expression	[747]
SIX1	OT70YYWM	Strong	Altered Expression	[3004]
SKA1	OTDYJ12A	Strong	Biomarker	[3005]
SKA3	OTLHEVJD	Strong	Altered Expression	[3006]
SLAIN1	OTMT25MN	Strong	Biomarker	[3007]
SLAMF1	OTBTT3ZQ	Strong	Altered Expression	[432]
SLC16A4	OT1YXBKC	Strong	Biomarker	[1062]
SLC22A18	OT9C3KR4	Strong	Posttranslational Modification	[3008]
SLC25A47	OT5NGRWC	Strong	Biomarker	[81]
SLC25A51	OT0ZR03H	Strong	Biomarker	[3009]
SLC46A3	OTEMDLPS	Strong	Biomarker	[3010]
SLPI	OTUNFUU8	Strong	Genetic Variation	[1226]
SLU7	OTZUUICN	Strong	Biomarker	[3011]
SMARCA1	OT0Y6PTU	Strong	Biomarker	[3012]
SMC4	OTEJE6AG	Strong	Biomarker	[3013]
SMG1	OTTS3SXE	Strong	Biomarker	[3014]
SMN2	OT54RLO1	Strong	Altered Expression	[1092]
SMOC2	OTK1EQ49	Strong	Biomarker	[3015]
SMPD3	OTHQBETH	Strong	Genetic Variation	[3016]
SMR3B	OTL5HNM8	Strong	Biomarker	[985]
SMYD5	OTE5VET6	Strong	Biomarker	[3017]
SNAI2	OT7Y8EJ2	Strong	Altered Expression	[3018]
SNAP23	OTY2MYBX	Strong	Biomarker	[2870]
SNAPIN	OT2FBS5N	Strong	Biomarker	[2469]
SND1	OTT734JN	Strong	Biomarker	[3019]
SNRPA	OT02TSQT	Strong	Biomarker	[333]
SNW1	OTKWG3PS	Strong	Biomarker	[2466]
SNX5	OT6ZOWMU	Strong	Altered Expression	[3020]
SOAT1	OTB4Y5RJ	Strong	Altered Expression	[3021]
SOCS6	OT2O5ZBK	Strong	Biomarker	[3022]
SORBS1	OTWH8762	Strong	Biomarker	[791]
SORBS3	OTVEUODC	Strong	Biomarker	[2995]
SOS1	OTTCWXC3	Strong	Altered Expression	[3023]
SOX1	OTVI1RAR	Strong	Biomarker	[3024]
SOX10	OTF25ULQ	Strong	Altered Expression	[1173]
SOX11	OT4LG7LA	Strong	Biomarker	[3025]
SOX12	OT93P8C9	Strong	Altered Expression	[3026]
SOX17	OT9H4WWE	Strong	Altered Expression	[3027]
SOX18	OTPUMHWA	Strong	Biomarker	[3028]
SOX30	OTGT38E3	Strong	Biomarker	[3029]
SOX4	OTSS40SS	Strong	Biomarker	[3030]
SOX7	OTOZOFAG	Strong	Biomarker	[3031]
SOX8	OTEJXYZM	Strong	Altered Expression	[3032]
SP3	OTYDQZ1T	Strong	Altered Expression	[3033]
SPAAR	OTWXG2R8	Strong	Biomarker	[2118]
SPAG5	OTCLJ56M	Strong	Altered Expression	[3034]
SPAG9	OT45AHMB	Strong	Altered Expression	[3035]
SPANXC	OT1033B9	Strong	Biomarker	[1862]
SPARCL1	OT74DWMV	Strong	Altered Expression	[3036]
SPC24	OT1HVYV4	Strong	Altered Expression	[3037]
SPG7	OT8OY9ST	Strong	Biomarker	[403]
SPHKAP	OT5RHUYJ	Strong	Altered Expression	[2466]
SPIN1	OT69VAOX	Strong	Biomarker	[3038]
SPINK13	OTEU2OSU	Strong	Biomarker	[3039]
SPINK7	OTK3VOI3	Strong	Biomarker	[3040]
SPINT2	OTQV7BKQ	Strong	Biomarker	[3041]
SPON2	OTE7JLNM	Strong	Altered Expression	[3042]
SPOP	OTP0107S	Strong	Biomarker	[1544]
SPPL3	OT2HLJF6	Strong	Genetic Variation	[2460]
SPRED1	OTKX7P8G	Strong	Altered Expression	[3043]
SPRED2	OTUX685J	Strong	Biomarker	[3044]
SPRY2	OTH0CRCZ	Strong	Biomarker	[3045]
SPRY4	OT2VK9N0	Strong	Altered Expression	[3046]
SPRYD4	OT85SX7C	Strong	Altered Expression	[3047]
SPTB	OT1Q9ABM	Strong	Altered Expression	[1958]
SPTBN2	OTDMJ75N	Strong	Biomarker	[1958]
SPZ1	OTQH8HJ5	Strong	Altered Expression	[3048]
SRA1	OTYOGMTG	Strong	Altered Expression	[2658]
SRM	OT4N5MDP	Strong	Biomarker	[3049]
SRPRB	OTUUFHQS	Strong	Biomarker	[3050]
SRPX2	OT6A63TX	Strong	Altered Expression	[3051]
SRRM2	OTSIMMC9	Strong	Altered Expression	[977]
SRRT	OTMYPSWV	Strong	Altered Expression	[3052]
SRSF1	OTF61HOV	Strong	Biomarker	[3053]
SRSF2	OTVDHO6U	Strong	Altered Expression	[3054]
SRSF3	OTOFT707	Strong	Biomarker	[2003]
SRSF5	OTC5WP98	Strong	Altered Expression	[1289]
SRY	OT516T6D	Strong	Biomarker	[3055]
SSX1	OTZ7NRCY	Strong	Biomarker	[81]
SSX2	OT2Z6RLL	Strong	Altered Expression	[3056]
SSX5	OTNOHH4H	Strong	Altered Expression	[3056]
ST18	OTPRIMTA	Strong	Biomarker	[3057]
ST3GAL3	OTOORKUE	Strong	Biomarker	[3058]
ST3GAL4	OTNENJZQ	Strong	Biomarker	[3059]
ST3GAL6	OTB17Q43	Strong	Biomarker	[3060]
ST6GAL1	OT7US3NO	Strong	Biomarker	[3061]
ST7	OTZG8RC6	Strong	Genetic Variation	[3062]
ST7L	OT0I8XNI	Strong	Altered Expression	[3063]
STARD13	OTB4U1HY	Strong	Biomarker	[2176]
STAT2	OTO9G2RZ	Strong	Altered Expression	[3064]
STAT4	OTAK3VFR	Strong	Genetic Variation	[1153]
STAT5A	OTBSJGN3	Strong	Altered Expression	[3065]
STAT5B	OTZVPEBT	Strong	Biomarker	[3065]
STATH	OTQHBHM9	Strong	Genetic Variation	[3066]
STEAP3	OTS9GZK5	Strong	Altered Expression	[3067]
STIM1	OT8CLQ1W	Strong	Biomarker	[3068]
STING1	OTDAP4G0	Strong	Biomarker	[3069]
STIP1	OT7TXLOX	Strong	Biomarker	[3070]
STK11	OT1YZSP3	Strong	Biomarker	[2141]
STK26	OTW4QE0D	Strong	Biomarker	[3071]
STK3	OTLNSCQD	Strong	Biomarker	[3072]
STX17	OT8TUN64	Strong	Biomarker	[3073]
SUB1	OTK71JYU	Strong	Altered Expression	[2620]
SUCO	OT3I9VO9	Strong	Biomarker	[3074]
SUGP1	OT7W0EB8	Strong	Genetic Variation	[1364]
SULF1	OTJCNCO0	Strong	Biomarker	[846]
SUMO1	OTJFD4P5	Strong	Biomarker	[934]
SUMO2	OT1Y5IKN	Strong	Biomarker	[3075]
SUMO3	OTTUJQJ1	Strong	Biomarker	[3075]
SUMO4	OT9B447E	Strong	Altered Expression	[3076]
SUPT20H	OTTMC0LH	Strong	Biomarker	[1287]
SUZ12	OT655XF8	Strong	Altered Expression	[3077]
SVBP	OT2VI301	Strong	Biomarker	[3078]
SYBU	OT3FQV7N	Strong	Altered Expression	[1715]
SYCE1L	OTXU44F3	Strong	Biomarker	[285]
SYF2	OTY2ZW1H	Strong	Altered Expression	[3079]
SYNE2	OTBUXGQ0	Strong	Genetic Variation	[3080]
SYNJ2BP	OT2Q677P	Strong	Altered Expression	[3081]
SYNM	OTOI8TRJ	Strong	Altered Expression	[3082]
SYP	OTFJKMO4	Strong	Biomarker	[3083]
SYPL1	OTBX291E	Strong	Biomarker	[3083]
SYT1	OTVTPOI6	Strong	Biomarker	[804]
TAB3	OT1ECMDL	Strong	Biomarker	[3084]
TAF9	OTCTH3C6	Strong	Biomarker	[3085]
TAL1	OTX4K6QZ	Strong	Genetic Variation	[1319]
TALDO1	OTDKV2S2	Strong	Altered Expression	[1779]
TAOK2	OTNUMOZ1	Strong	Biomarker	[2988]
TAP2	OTWSYFI7	Strong	Genetic Variation	[3086]
TARBP1	OT14Z6RJ	Strong	Altered Expression	[3087]
TAS2R13	OTSTOX5G	Strong	Biomarker	[3088]
TASP1	OTOX7946	Strong	Altered Expression	[2240]
TAT	OT2CJ91O	Strong	Biomarker	[3089]
TATDN1	OTQ3S9AL	Strong	Altered Expression	[3090]
TBP	OT6C0S52	Strong	Biomarker	[1339]
TBPL1	OT4I143E	Strong	Biomarker	[1134]
TBX3	OTM64N7K	Strong	Altered Expression	[3091]
TBX5	OT70PISV	Strong	Biomarker	[2274]
TCF12	OTZVONNU	Strong	Biomarker	[3092]
TCF19	OT7NKLF9	Strong	Biomarker	[3093]
TCF7	OT1ID822	Strong	Biomarker	[3094]
TCFL5	OTJL4348	Strong	Genetic Variation	[3095]
TCIM	OTARUXQF	Strong	Biomarker	[3096]
TCL1B	OT4CSO39	Strong	Biomarker	[1132]
TCN1	OTW6A49Y	Strong	Altered Expression	[3097]
TCOF1	OT4BOYTM	Strong	Biomarker	[3098]
TCP1	OT1MGUX9	Strong	Biomarker	[2021]
TCP10L	OTWEW67K	Strong	Biomarker	[3099]
TDRD5	OTYSOQS0	Strong	Biomarker	[2125]
TENM1	OTSKSU4V	Strong	Genetic Variation	[3100]
TENT5C	OTOWVQ4O	Strong	Altered Expression	[3101]
TERF2IP	OT3M5P3G	Strong	Biomarker	[2875]
TET1	OTZDHT1D	Strong	Altered Expression	[3102]
TET3	OT76U3YF	Strong	Altered Expression	[3103]
TEX101	OTNO747E	Strong	Biomarker	[3104]
TEX11	OTJDBGSS	Strong	Biomarker	[1290]
TEX35	OT80OVC0	Strong	Biomarker	[3105]
TFAM	OTXXV5V7	Strong	Altered Expression	[3106]
TFAP2B	OTR1T8E9	Strong	Altered Expression	[1885]
TFAP2C	OTUDIW05	Strong	Biomarker	[2112]
TFAP4	OT1KQIUX	Strong	Biomarker	[3107]
TFCP2	OTA246TE	Strong	Biomarker	[3108]
TFDP1	OT6RZ7VT	Strong	Biomarker	[2263]
TFDP2	OTKQFX5H	Strong	Altered Expression	[817]
TFDP3	OTI4K6MN	Strong	Altered Expression	[3109]
TFF3	OTJJDRTU	Strong	Biomarker	[3110]
TFPI2	OTZCRWOR	Strong	Altered Expression	[1476]
TFR2	OTMYCCEO	Strong	Altered Expression	[165]
TGFB1I1	OTIK337D	Strong	Biomarker	[3111]
TGFBI	OTR443C5	Strong	Altered Expression	[3112]
THAP11	OTEMWLZ0	Strong	Biomarker	[3113]
THBS2	OTXET551	Strong	Biomarker	[3114]
THEM4	OTSIZU8Y	Strong	Therapeutic	[1467]
THOC5	OTHY50SK	Strong	Altered Expression	[2881]
THRAP3	OTG25JOG	Strong	Biomarker	[474]
THRSP	OTKYE01L	Strong	Biomarker	[3115]
THY1	OTVONVTB	Strong	Altered Expression	[932]
TIA1	OTGPN3P8	Strong	Altered Expression	[1480]
TIAM2	OTPYIPT6	Strong	Altered Expression	[3116]
TICAM2	OTK7GIJ5	Strong	Altered Expression	[2155]
TIGAR	OTR7NMRJ	Strong	Biomarker	[3117]
TIMM8A	OTDX9687	Strong	Biomarker	[3118]
TIMP1	OTOXC51H	Strong	Altered Expression	[689]
TIMP2	OT8S1RRP	Strong	Biomarker	[3119]
TIMP3	OTDGQAD1	Strong	Biomarker	[3120]
TIMP4	OT8A68SW	Strong	Genetic Variation	[3121]
TINAGL1	OTZZO56M	Strong	Biomarker	[1088]
TINF2	OT861N2N	Strong	Altered Expression	[3122]
TJP1	OTBDCUPK	Strong	Biomarker	[3123]
TKTL2	OTULV5TA	Strong	Altered Expression	[1149]
TLK1	OTICTXI8	Strong	Altered Expression	[810]
TLK2	OTZ09CG8	Strong	Biomarker	[3124]
TLN2	OT10QQBC	Strong	Altered Expression	[3125]
TLNRD1	OTNOLROI	Strong	Biomarker	[3126]
TM4SF1	OTY0ECQN	Strong	Altered Expression	[3127]
TM4SF4	OTRI8EHN	Strong	Altered Expression	[3128]
TM4SF5	OTPAV531	Strong	Biomarker	[1017]
TMED10	OTUXSHH7	Strong	Biomarker	[2881]
TMED5	OT70W1J8	Strong	Biomarker	[2185]
TMED6	OTLYX1ZZ	Strong	Altered Expression	[2091]
TMED7	OTONO8E6	Strong	Altered Expression	[2155]
TMEM74	OT3IZBM0	Strong	Biomarker	[3129]
TMEM9	OTXC0JXR	Strong	Biomarker	[3130]
TMEM98	OTKDUEED	Strong	Biomarker	[3131]
TMPRSS13	OTMAOAP3	Strong	Biomarker	[394]
TMPRSS4	OTCCGY2K	Strong	Biomarker	[3132]
TMUB1	OTR4RO3N	Strong	Biomarker	[3133]
TNFAIP8L1	OTVVKOTV	Strong	Biomarker	[3134]
TNFAIP8L2	OTII0RM0	Strong	Altered Expression	[3135]
TNFRSF10C	OTVHOL9B	Strong	Biomarker	[3136]
TNFRSF6B	OTKAN9G7	Strong	Altered Expression	[1139]
TNFSF9	OTV9L89D	Strong	Biomarker	[3137]
TNIP2	OTDQWTUB	Strong	Biomarker	[3138]
TNS3	OTPG2D8Z	Strong	Altered Expression	[3139]
TOB2	OTEEHL60	Strong	Biomarker	[1819]
TOMM34	OTH6MITE	Strong	Biomarker	[3140]
TONSL	OTBWODM9	Strong	Altered Expression	[3141]
TOR1AIP1	OTTG8MAK	Strong	Biomarker	[3142]
TP53AIP1	OT1XVNDP	Strong	Altered Expression	[3143]
TP53I11	OTFPDYZU	Strong	Biomarker	[2615]
TP53INP1	OT2363Z9	Strong	Biomarker	[3144]
TPD52	OTPKSK43	Strong	Altered Expression	[3145]
TPM3	OT5RU5G6	Strong	Biomarker	[3146]
TPPP2	OTI3WA6X	Strong	Altered Expression	[356]
TRA2A	OT5NHOO3	Strong	Altered Expression	[2438]
TRADD	OTBOSJHO	Strong	Biomarker	[3147]
TRAF2	OT1MEZZN	Strong	Altered Expression	[1753]
TRAF3	OT5TQBGV	Strong	Biomarker	[3142]
TRAF4	OTJLRVMC	Strong	Biomarker	[3148]
TRAF5	OTSBTLO0	Strong	Altered Expression	[74]
TRAF7	OTW8Q5TF	Strong	Biomarker	[771]
TRAM1	OT3I0H8E	Strong	Biomarker	[3149]
TRAT1	OTMPUNPD	Strong	Biomarker	[3150]
TRDMT1	OTAYQ8ZF	Strong	Altered Expression	[2580]
TREH	OTJE0NOY	Strong	Biomarker	[2516]
TRIB3	OTG5OS7X	Strong	Altered Expression	[3088]
TRIM11	OTMD6IM2	Strong	Biomarker	[3151]
TRIM13	OTQIUACB	Strong	Biomarker	[403]
TRIM16	OTLRXYOZ	Strong	Biomarker	[3150]
TRIM21	OTA4UJCF	Strong	Altered Expression	[3152]
TRIM23	OTVIGJ4T	Strong	Biomarker	[2651]
TRIM25	OT35SG1R	Strong	Altered Expression	[2554]
TRIM26	OTS0DJIP	Strong	Biomarker	[3153]
TRIM3	OT704FQ0	Strong	Altered Expression	[3154]
TRIM31	OT7VW6RP	Strong	Biomarker	[3155]
TRIM35	OTT9V87M	Strong	Biomarker	[3156]
TRIM44	OT0B1T2B	Strong	Altered Expression	[3157]
TRIM52	OTKTKCT1	Strong	Altered Expression	[3158]
TRIM55	OTY5YQFX	Strong	Biomarker	[3159]
TRIM63	OTUSWA74	Strong	Biomarker	[3160]
TRIM65	OTSQTK3A	Strong	Biomarker	[3161]
TRIO	OT71X1AK	Strong	Altered Expression	[3162]
TRO	OTRZQMU8	Strong	Altered Expression	[3163]
TROAP	OTC8CE0R	Strong	Altered Expression	[3164]
TRRAP	OT68OI2Y	Strong	Biomarker	[2490]
TSC1	OTFF4YZ7	Strong	Genetic Variation	[3165]
TSGA10	OTIF1O1T	Strong	Altered Expression	[3166]
TSHB	OTFDI39D	Strong	Biomarker	[3167]
TSHZ1	OTYQ9ECW	Strong	Genetic Variation	[3168]
TSN	OTOFAQ2Z	Strong	Altered Expression	[2897]
TSPAN1	OTZQPIYK	Strong	Biomarker	[1080]
TSPAN15	OTNQXXIG	Strong	Altered Expression	[3169]
TSPAN31	OT8WQ83R	Strong	Genetic Variation	[1491]
TSPAN8	OT1F68WQ	Strong	Biomarker	[3170]
TSPY1	OTPY57X4	Strong	Altered Expression	[1816]
TSPYL2	OTGGW2EF	Strong	Biomarker	[3171]
TSPYL5	OT7QEI2X	Strong	Biomarker	[1831]
TTC36	OT90ZLHE	Strong	Biomarker	[81]
TTF1	OT4K90WD	Strong	Posttranslational Modification	[3172]
AASS	OTYCN07T	Definitive	Biomarker	[3173]
ABCF1	OT6Q079J	Definitive	Altered Expression	[3174]
ACADS	OTGFANYQ	Definitive	Biomarker	[3175]
ADGRG7	OT4IPNZC	Definitive	Biomarker	[81]
AGFG1	OTI8ZKC4	Definitive	Biomarker	[3176]
ALDH3A1	OTAYZZE6	Definitive	Altered Expression	[3177]
ALPK2	OTWZZDQ9	Definitive	Biomarker	[3178]
ANGPTL6	OTOQ5W67	Definitive	Biomarker	[81]
APOBEC3H	OTXIH4X4	Definitive	Biomarker	[3179]
APOC4	OTE8ZUXY	Definitive	Biomarker	[337]
ARHGAP44	OTHJUCO1	Definitive	Biomarker	[3180]
ASF1B	OTKXX12I	Definitive	Biomarker	[81]
ATF5	OT03QCLM	Definitive	Altered Expression	[3181]
ATG10	OTVRPC5X	Definitive	Genetic Variation	[3182]
AWAT1	OT8OTY3E	Definitive	Altered Expression	[1233]
BDH2	OTDD7G8S	Definitive	Altered Expression	[3183]
BHLHE40	OTITX14U	Definitive	Altered Expression	[2696]
C14orf180	OT6KDFIP	Definitive	Biomarker	[81]
CBX3	OTOP9RLD	Definitive	Altered Expression	[3184]
CBX4	OT4XVRRF	Definitive	Biomarker	[3185]
CCBE1	OTO4UIDB	Definitive	Biomarker	[81]
CCNF	OTJFVU43	Definitive	Biomarker	[81]
CDC45	OT6NNLOD	Definitive	Biomarker	[81]
CDCA2	OTX8UF9J	Definitive	Biomarker	[81]
CDK2AP2	OTR99SJ8	Definitive	Genetic Variation	[834]
CDK5RAP3	OTC0Q2QS	Definitive	Biomarker	[3186]
CDT1	OTVY53VG	Definitive	Biomarker	[81]
CEBPE	OTKZA25M	Definitive	Biomarker	[2123]
CENPU	OTQ4TZRS	Definitive	Biomarker	[81]
CENPW	OTZL05QN	Definitive	Biomarker	[81]
CKAP2L	OT4T73GG	Definitive	Biomarker	[81]
CLEC4G	OTUGTR0H	Definitive	Biomarker	[81]
CLEC4M	OT2WUIIP	Definitive	Biomarker	[81]
CLSPN	OTZZXNDK	Definitive	Biomarker	[1628]
CLTRN	OTXGFJ3F	Definitive	Biomarker	[81]
CNDP1	OTOYSQG7	Definitive	Biomarker	[81]
CNTNAP4	OTKXR9AW	Definitive	Biomarker	[81]
COLEC10	OTMBADGZ	Definitive	Biomarker	[81]
COX7B2	OTYWMO7S	Definitive	Biomarker	[81]
CPA6	OT43RD23	Definitive	Biomarker	[3187]
CRIP1	OT0EICG3	Definitive	Biomarker	[2123]
CSRNP1	OTDK1FPH	Definitive	Biomarker	[81]
CST1	OTE4I83Q	Definitive	Biomarker	[3188]
CST6	OTZVHJTF	Definitive	Altered Expression	[1296]
CST7	OTQWZUVQ	Definitive	Altered Expression	[1296]
DCAF1	OT3ZDVOE	Definitive	Biomarker	[3176]
DCAF4L2	OTDEHW14	Definitive	Biomarker	[81]
DCDC2	OTSUFH1H	Definitive	Biomarker	[2433]
DDX17	OTXRMMBP	Definitive	Biomarker	[3189]
DIPK2B	OT6MK0VT	Definitive	Biomarker	[81]
DIS3L2	OTWABM04	Definitive	Biomarker	[3190]
DNASE1L3	OTEUIMC2	Definitive	Biomarker	[81]
ECHS1	OTS0593S	Definitive	Biomarker	[3191]
EHD3	OTOKC2G5	Definitive	Biomarker	[81]
ERN2	OTUS6GKR	Definitive	Genetic Variation	[3192]
ETFDH	OTOSKSFH	Definitive	Altered Expression	[3193]
FAM111B	OT9IQ9NV	Definitive	Biomarker	[81]
FAM180A	OTKQ7XUG	Definitive	Biomarker	[81]
FAM72B	OT6AOG64	Definitive	Biomarker	[81]
FAM83A	OTBI16V7	Definitive	Biomarker	[3194]
FANCI	OTW8E3SC	Definitive	Biomarker	[81]
FBXL18	OTW4455M	Definitive	Biomarker	[81]
FGL1	OTT0QHQ1	Definitive	Altered Expression	[3195]
FRMD6	OTY6X9V5	Definitive	Biomarker	[3196]
FTSJ1	OTNE7W96	Definitive	Altered Expression	[3197]
FUT6	OTBZUQ7F	Definitive	Biomarker	[1235]
GABPB1	OTEXDEJN	Definitive	Biomarker	[3198]
GAL3ST1	OTSFFZRD	Definitive	Genetic Variation	[1296]
GBA3	OT86XWU2	Definitive	Biomarker	[81]
GINS1	OTVQZMMQ	Definitive	Biomarker	[81]
GLRA2	OTDQ0KW7	Definitive	Biomarker	[3199]
GPM6A	OT8G13EG	Definitive	Biomarker	[81]
GPR158	OTYOC1RQ	Definitive	Biomarker	[81]
HEPN1	OT5V1WAR	Definitive	Biomarker	[3200]
HES1	OT8P19W2	Definitive	Biomarker	[3201]
HIC1	OTI9TWY4	Definitive	Biomarker	[3202]
HLA-C	OTV38BUJ	Definitive	Biomarker	[3203]
HNRNPU	OTLQN1E2	Definitive	Biomarker	[3190]
IGFALS	OTTWCZYM	Definitive	Biomarker	[81]
INMT	OT5NWOZH	Definitive	Biomarker	[81]
INS-IGF2	OTZR74BO	Definitive	Biomarker	[81]
ISCU	OTSW6DQP	Definitive	Genetic Variation	[3204]
ISM1	OTZTK2TV	Definitive	Altered Expression	[3205]
KBTBD11	OTBOY3WH	Definitive	Biomarker	[81]
KCNE2	OTUO214Y	Definitive	Biomarker	[3206]
KIF18B	OTOBUDOE	Definitive	Biomarker	[81]
KIF2C	OTJ8G3NP	Definitive	Biomarker	[81]
LAMTOR2	OTHEDISB	Definitive	Genetic Variation	[834]
LAT	OTZC1XZ1	Definitive	Altered Expression	[3207]
LHX3	OTQ5BAJ9	Definitive	Biomarker	[3208]
LILRB5	OT19NR0C	Definitive	Biomarker	[81]
LIX1L	OTAK119S	Definitive	Biomarker	[3090]
LPIN1	OTQ75KF2	Definitive	Biomarker	[3209]
LRAT	OTB7CJKY	Definitive	Biomarker	[81]
LZTFL1	OTIEIOEW	Definitive	Biomarker	[3210]
MACIR	OTPSW8Y8	Definitive	Biomarker	[3211]
MAP2K6	OTK13JKC	Definitive	Altered Expression	[3212]
MARK4	OT6Z2TGV	Definitive	Altered Expression	[3213]
METTL3	OTSXP1M3	Definitive	Biomarker	[3214]
METTL8	OT7E09Y4	Definitive	Biomarker	[3215]
MRO	OT5U38CP	Definitive	Biomarker	[81]
MSH5	OTDARQT3	Definitive	Biomarker	[81]
MSL2	OTVPQYBG	Definitive	Altered Expression	[3216]
MXD1	OTS5CTHX	Definitive	Biomarker	[2819]
MYBBP1A	OTIVEMIU	Definitive	Altered Expression	[3217]
NCAPG2	OTZYENKO	Definitive	Altered Expression	[3218]
NDFIP1	OTIORSWF	Definitive	Biomarker	[3219]
NEIL3	OTBCI2NS	Definitive	Biomarker	[81]
NFASC	OTBDUXZT	Definitive	Biomarker	[3220]
NOC2L	OTNT7R33	Definitive	Biomarker	[3221]
NOP58	OTP536HD	Definitive	Biomarker	[3194]
NPTX1	OTKVHCV0	Definitive	Biomarker	[3222]
NR2F6	OTNVO2B6	Definitive	Biomarker	[3223]
NUP155	OTIIAH4E	Definitive	Altered Expression	[3197]
NUP43	OTDF5K8Y	Definitive	Biomarker	[1229]
OAS2	OT64CCTM	Definitive	Altered Expression	[3224]
OLFML2A	OT416MJA	Definitive	Biomarker	[81]
OLFML2B	OTDNJFR4	Definitive	Biomarker	[81]
ORC1	OTHWU8IJ	Definitive	Biomarker	[81]
OSBPL11	OTU2IC5O	Definitive	Altered Expression	[3225]
PAMR1	OT83ZH5U	Definitive	Biomarker	[81]
PHF2	OTJCIQR2	Definitive	Altered Expression	[3226]
PHLDA1	OTFTWMIQ	Definitive	Biomarker	[81]
PITPNM3	OTHLZY8D	Definitive	Biomarker	[81]
PLAC8	OT3SYRUJ	Definitive	Biomarker	[81]
PLCG2	OTGVC9MY	Definitive	Biomarker	[3227]
PLPP5	OTHT51D6	Definitive	Biomarker	[3228]
PLVAP	OTAQGWYA	Definitive	Biomarker	[81]
PSMC6	OTG8997V	Definitive	Biomarker	[1229]
PSMD1	OTW258OV	Definitive	Altered Expression	[3229]
PSMD2	OT6HZHN7	Definitive	Altered Expression	[3229]
PXN	OTVMMUOF	Definitive	Biomarker	[3230]
PYROXD2	OTJIX22S	Definitive	Altered Expression	[1712]
RAB14	OTF1J0TB	Definitive	Biomarker	[3231]
RAD54L	OTEGMAKG	Definitive	Biomarker	[81]
RBM5	OTCBWHHV	Definitive	Altered Expression	[3232]
REXO1	OTZT6RAW	Definitive	Biomarker	[2649]
RHOD	OTALMEIN	Definitive	Altered Expression	[3233]
RNF157	OTOEA0T5	Definitive	Biomarker	[81]
RPAIN	OTBMXAYK	Definitive	Biomarker	[3176]
RPP14	OT4OYFSK	Definitive	Genetic Variation	[834]
SESN3	OTJRY1Y5	Definitive	Genetic Variation	[3234]
SETD3	OTO5RAU2	Definitive	Biomarker	[517]
SF3B6	OTPRKS6S	Definitive	Genetic Variation	[834]
SHPRH	OTKCBWWS	Definitive	Biomarker	[3235]
SIAH1	OT29A838	Definitive	Biomarker	[3002]
SORBS2	OTJSX44Y	Definitive	Biomarker	[3236]
SPART	OTIVOS2I	Definitive	Altered Expression	[3237]
SPC25	OTCAS0OH	Definitive	Biomarker	[81]
SRPX	OT5B9LXS	Definitive	Biomarker	[81]
STAM	OT6X5RR1	Definitive	Biomarker	[3238]
TBCA	OTCCWMGK	Definitive	Biomarker	[1231]
TEAD1	OTK6971C	Definitive	Altered Expression	[3239]
TEDC2	OT87I374	Definitive	Biomarker	[81]
TICRR	OT2HKWOC	Definitive	Biomarker	[81]
TIMD4	OTGGC20G	Definitive	Biomarker	[81]
TLX3	OTBUHHK3	Definitive	Biomarker	[3240]
TMOD3	OTQPNSTH	Definitive	Biomarker	[3241]
TOX	OTE8BL5Z	Definitive	Altered Expression	[3242]
TRAIP	OTMPT9Y2	Definitive	Biomarker	[81]
TRARG1	OTQ1R3JD	Definitive	Biomarker	[3243]
TRIAP1	OTEAUJXN	Definitive	Altered Expression	[368]
TRIM33	OT0KS4J7	Definitive	Altered Expression	[3244]
TRMT6	OT4DEXG6	Definitive	Altered Expression	[3245]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031741)
• [4] ClinicalTrials.gov (NCT02112656) Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (OPTIMA). U.S. National Institutes of Health.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] ClinicalTrials.gov (NCT01665144) Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND). U.S. National Institutes of Health.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
• [9] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [10] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761289.
• [11] ClinicalTrials.gov (NCT03313596) Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC. U.S. National Institutes of Health.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8097).
• [14] Clinical pipeline report, company report or official report of CreaGene Inc.
• [15] ClinicalTrials.gov (NCT04194775) A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC). U.S.National Institutes of Health.
• [16] ClinicalTrials.gov (NCT02003742) Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH. U.S. National Institutes of Health.
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014082)
• [18] Clinical pipeline report, company report or official report of Polaris Pharmaceuticals.
• [19] ClinicalTrials.gov (NCT01640808) Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC. U.S. National Institutes of Health.
• [20] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [21] ClinicalTrials.gov (NCT00405561) Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003. U.S. National Institutes of Health.
• [22] ClinicalTrials.gov (NCT02208804) Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization. U.S. National Institutes of Health.
• [23] ClinicalTrials.gov (NCT04728321) A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma. U.S. National Institutes of Health.
• [24] ClinicalTrials.gov (NCT02232633) A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer. U.S. National Institutes of Health.
• [25] ClinicalTrials.gov (NCT01507168) A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma. U.S. National Institutes of Health.
• [26] Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015 Aug;14(4):361-6.
• [27] ClinicalTrials.gov (NCT03592264) This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer. U.S. National Institutes of Health.
• [28] First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2014 Feb;73(2):373-80.
• [29] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7502).
• [30] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8406).
• [31] ClinicalTrials.gov (NCT04291105) Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients. U.S. National Institutes of Health.
• [32] ClinicalTrials.gov (NCT04000737) YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC). U.S. National Institutes of Health.
• [33] A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006 May 1;12(9):2817-25.
• [34] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [35] ClinicalTrials.gov (NCT02587689) Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
• [36] ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
• [37] ClinicalTrials.gov (NCT02723942) CAR-T Cell Immunotherapy for HCC Targeting GPC3
• [38] ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
• [39] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025385)
• [40] ClinicalTrials.gov (NCT02314052) Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma. U.S. National Institutes of Health.
• [41] ClinicalTrials.gov (NCT04502082) An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-1). U.S.National Institutes of Health.
• [42] ClinicalTrials.gov (NCT03130712) A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
• [43] ClinicalTrials.gov (NCT00073736) Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma. U.S. National Institutes of Health.
• [44] ClinicalTrials.gov (NCT04212221) MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients. U.S. National Institutes of Health.
• [45] Clinical pipeline report, company report or official report of MiNA Therapeutics.
• [46] ClinicalTrials.gov (NCT01406574) Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma. U.S. National Institutes of Health.
• [47] ClinicalTrials.gov (NCT03084380) Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
• [48] ClinicalTrials.gov (NCT02715362) A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
• [49] ClinicalTrials.gov (NCT02395250) Anti-GPC3 CAR T for Treating Patients With Advanced HCC
• [50] ClinicalTrials.gov (NCT03349255) Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
• [51] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027382)
• [52] ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
• [53] ClinicalTrials.gov (NCT03146234) CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma
• [54] Clinical pipeline report, company report or official report of Cytocom
• [55] ClinicalTrials.gov (NCT03998033) An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140202 T Cells and Determine the Recommended Phase II Dose ("RP2D") in Adults With Advanced Hepatocellular Carcinoma ("HCC"). U.S.National Institutes of Health.
• [56] ClinicalTrials.gov (NCT02905188) Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
• [57] ClinicalTrials.gov (NCT03198546) GPC3-T2-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
• [58] ClinicalTrials.gov (NCT02250170) Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor. U.S. National Institutes of Health.
• [59] Clinical pipeline report, company report or official report of Roche.
• [60] ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
• [61] Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
• [62] hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res. 2010 Oct 15;70(20):8077-87.
• [63] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [64] ClinicalTrials.gov (NCT01130519) A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer. U.S. National Institutes of Health.
• [65] Tissue Biomarkers in Hepatocellular Tumors: Which, When, and How.Front Med (Lausanne). 2017 Feb 23;4:10. doi: 10.3389/fmed.2017.00010. eCollection 2017.
• [66] Anti-tumor properties of anthocyanins from Lonicera caerulea 'Beilei' fruit on human hepatocellular carcinoma: In vitro and in vivo study.Biomed Pharmacother. 2018 Aug;104:520-529. doi: 10.1016/j.biopha.2018.05.057. Epub 2018 May 25.
• [67] Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).Exp Mol Pathol. 2018 Aug;105(1):144-149. doi: 10.1016/j.yexmp.2018.07.005. Epub 2018 Jul 17.
• [68] The therapeutic effects of nicotinamide in hepatocellular carcinoma through blocking IGF-1 and effecting the balance between Nrf2 and PKB.Biomed Pharmacother. 2019 Apr;112:108653. doi: 10.1016/j.biopha.2019.108653. Epub 2019 Feb 20.
• [69] MicroRNA-139-3p Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by Repressing ANXA2R.Oncol Res. 2018 Oct 17;26(9):1391-1399. doi: 10.3727/096504018X15178798885361. Epub 2018 Feb 8.
• [70] The effect of inhibitors of phosphatidylinositol 3-kinase-related kinases on dibenzo[def,p]chrysene genotoxicity measured by H2AX levels and neutral comet assay in HepG2 human hepatocellular cancer cells.Toxicol In Vitro. 2020 Mar;63:104749. doi: 10.1016/j.tiv.2019.104749. Epub 2019 Dec 12.
• [71] The transcription factor 7 like 2binding protein TIP5 activates catenin/transcription factor signaling in hepatocellular carcinoma.Mol Med Rep. 2018 Jun;17(6):7645-7651. doi: 10.3892/mmr.2018.8806. Epub 2018 Mar 28.
• [72] Distinct Changes of BTLA and HVEM Expressions in Circulating CD4(+) and CD8(+) T Cells in Hepatocellular Carcinoma Patients.J Immunol Res. 2018 Jul 18;2018:4561571. doi: 10.1155/2018/4561571. eCollection 2018.
• [73] pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma.Oncoimmunology. 2018 Mar 26;7(7):e1445452. doi: 10.1080/2162402X.2018.1445452. eCollection 2018.
• [74] LINC00467 promotes cell proliferation and metastasis by binding with IGF2BP3 to enhance the mRNA stability of TRAF5 in hepatocellular carcinoma.J Gene Med. 2020 Mar;22(3):e3134. doi: 10.1002/jgm.3134. Epub 2020 Jan 20.
• [75] Combination Suicide Gene Delivery with an Adeno-Associated Virus Vector Encoding Inducible Caspase-9 and a Chemical Inducer of Dimerization Is Effective in a Xenotransplantation Model of Hepatocellular Carcinoma.Bioconjug Chem. 2019 Jun 19;30(6):1754-1762. doi: 10.1021/acs.bioconjchem.9b00291. Epub 2019 Jun 7.
• [76] Longitudinal studies can identify distinct inflammatory cytokines associated with the inhibition or progression of liver cancer.Liver Int. 2020 Feb;40(2):468-472. doi: 10.1111/liv.14323. Epub 2019 Dec 26.
• [77] p65/miR-23a/CCL22 axis regulated regulatory T cells recruitment in hepatitis B virus positive hepatocellular carcinoma.Cancer Med. 2020 Jan;9(2):711-723. doi: 10.1002/cam4.2611. Epub 2019 Nov 25.
• [78] Reduced CD160 Expression Contributes to Impaired NK-cell Function and Poor Clinical Outcomes in Patients with HCC.Cancer Res. 2018 Dec 1;78(23):6581-6593. doi: 10.1158/0008-5472.CAN-18-1049. Epub 2018 Sep 19.
• [79] Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.Blood. 2019 May 16;133(20):2212-2221. doi: 10.1182/blood-2018-12-893396. Epub 2019 Feb 26.
• [80] Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study.Clin Exp Med. 2018 Nov;18(4):535-546. doi: 10.1007/s10238-018-0521-6. Epub 2018 Jul 30.
• [81] Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells initro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017 Jun;152(8):2022-2036.
• [82] LncRNA TRERNA1 facilitates hepatocellular carcinoma metastasis by dimethylating H3K9 in the CDH1 promoter region via the recruitment of the EHMT2/SNAI1 complex.Cell Prolif. 2019 Jul;52(4):e12621. doi: 10.1111/cpr.12621. Epub 2019 Apr 22.
• [83] miR-152-3p Modulates hepatic carcinogenesis by targeting cyclin-dependent kinase 8.Pathol Res Pract. 2019 Jun;215(6):152406. doi: 10.1016/j.prp.2019.03.034. Epub 2019 Apr 1.
• [84] Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions.World J Gastroenterol. 2018 Mar 21;24(11):1228-1238. doi: 10.3748/wjg.v24.i11.1228.
• [85] Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.Anticancer Res. 2018 May;38(5):2649-2657. doi: 10.21873/anticanres.12507.
• [86] Circulating pro- and anti-angiogenic factors in multi-stage liver disease and hepatocellular carcinoma progression.Sci Rep. 2019 Jun 24;9(1):9137. doi: 10.1038/s41598-019-45537-w.
• [87] Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
• [88] CXCL11 promotes self-renewal and tumorigenicity of 21(+) liver tumor-initiating cells through CXCR3/ERK1/2 signaling.Cancer Lett. 2019 May 1;449:163-171. doi: 10.1016/j.canlet.2019.02.016. Epub 2019 Feb 13.
• [89] CXXC5 suppresses hepatocellular carcinoma by promoting TGF--induced cell cycle arrest and apoptosis. J Mol Cell Biol. 2018 Feb 1;10(1):48-59.
• [90] Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma.Int J Mol Sci. 2018 Oct 8;19(10):3070. doi: 10.3390/ijms19103070.
• [91] The long non-coding RNA Linc-GALH promotes hepatocellular carcinoma metastasis via epigenetically regulating Gankyrin.Cell Death Dis. 2019 Jan 28;10(2):86. doi: 10.1038/s41419-019-1348-0.
• [92] Tumor-Derived Peptidoglycan Recognition Protein 2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma.Hepatology. 2020 May;71(5):1626-1642. doi: 10.1002/hep.30924. Epub 2020 Jan 24.
• [93] Mammalian-enabled (MENA) protein enhances oncogenic potential and cancer stem cell-like phenotype in hepatocellular carcinoma cells. FEBS Open Bio. 2017 Jun 22;7(8):1144-1153.
• [94] Elevated Expressions of Survivin and Endoglin in Patients with Hepatic Carcinoma.Cancer Biother Radiopharm. 2019 Feb;34(1):7-12. doi: 10.1089/cbr.2018.2539.
• [95] Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.Gastroenterology. 2011 Mar;140(3):1071-83. doi: 10.1053/j.gastro.2010.12.006. Epub 2010 Dec 11.
• [96] In Vivo Pharmacokinetics Assessment of Indocyanine Green-Loaded Nanoparticles in Tumor Tissue with a Dynamic Diffuse Fluorescence Tomography System.Mol Imaging Biol. 2019 Dec;21(6):1044-1053. doi: 10.1007/s11307-019-01340-7.
• [97] A short-chain fatty acid, propionate, enhances the cytotoxic effect of cisplatin by modulating GPR41 signaling pathways in HepG2 cells.Oncotarget. 2018 Jul 31;9(59):31342-31354. doi: 10.18632/oncotarget.25809. eCollection 2018 Jul 31.
• [98] Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.Liver Int. 2019 Sep;39(9):1682-1691. doi: 10.1111/liv.14055. Epub 2019 Jul 11.
• [99] Evaluation of Relationship between Occurrence of Liver Cancer and Methylation of Fragile Histidine Triad (FHIT) and P16 Genes.Med Sci Monit. 2019 Feb 18;25:1301-1306. doi: 10.12659/MSM.912315.
• [100] Prognostic significance of CD68, CD163 and Folate receptor- positive macrophages in hepatocellular carcinoma.Exp Ther Med. 2018 May;15(5):4465-4476. doi: 10.3892/etm.2018.5959. Epub 2018 Mar 14.
• [101] FOS-like antigen 1 is a prognostic biomarker in hepatocellular carcinoma.Saudi J Gastroenterol. 2019 Nov-Dec;25(6):369-376. doi: 10.4103/sjg.SJG_595_18.
• [102] Circular RNA circ-FOXP1 induced by SOX9 promotes hepatocellular carcinoma progression via sponging miR-875-3p and miR-421.Biomed Pharmacother. 2020 Jan;121:109517. doi: 10.1016/j.biopha.2019.109517. Epub 2019 Nov 4.
• [103] Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP.J Exp Clin Cancer Res. 2019 Apr 18;38(1):170. doi: 10.1186/s13046-019-1163-6.
• [104] The zinc finger protein GATA4 induces mesenchymal-to-epithelial transition and cellular senescence through the nuclear factor-B pathway in hepatocellular carcinoma.J Gastroenterol Hepatol. 2019 Dec;34(12):2196-2205. doi: 10.1111/jgh.14684. Epub 2019 May 13.
• [105] Downregulation of Epstein-Barr virus-induced gene 3 is associated with poor prognosis of hepatocellular carcinoma after curative resection.Oncol Lett. 2018 May;15(5):7751-7759. doi: 10.3892/ol.2018.8272. Epub 2018 Mar 15.
• [106] Highly Specific near-Infrared Fluorescent Probe for the Real-Time Detection of -Glucuronidase in Various Living Cells and Animals.Anal Chem. 2018 Mar 6;90(5):3276-3283. doi: 10.1021/acs.analchem.7b04813. Epub 2018 Feb 14.
• [107] Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.Gut. 2020 Jan;69(1):177-186. doi: 10.1136/gutjnl-2018-317581. Epub 2019 Apr 6.
• [108] Glucose inhibits the insulin-induced activation of the insulin-degrading enzyme in HepG2 cells.Diabetologia. 2009 Aug;52(8):1656-64. doi: 10.1007/s00125-009-1350-7. Epub 2009 Apr 25.
• [109] Expression and prognostic significance of insulinlike growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization.Oncol Rep. 2019 Apr;41(4):2299-2310. doi: 10.3892/or.2019.6995. Epub 2019 Feb 1.
• [110] miR?3b inhibits proliferation of SMMC?721 cells by directly targeting IL?1.Mol Med Rep. 2018 Aug;18(2):1591-1599. doi: 10.3892/mmr.2018.9151. Epub 2018 Jun 11.
• [111] Association Between Polymorphisms of Interleukin 1 Family Genes and Hepatocellular Carcinoma.Med Sci Monit. 2018 May 26;24:3488-3495. doi: 10.12659/MSM.907524.
• [112] Interleukin-21 receptor gene polymorphism is associated with hepatitis B virus-related hepatocellular carcinoma in Chinese patients.J Clin Lab Anal. 2019 Jun;33(5):e22860. doi: 10.1002/jcla.22860. Epub 2019 Feb 13.
• [113] Over-expression of IMPDH2 is associated with tumor progression and poor prognosis in hepatocellular carcinoma.Am J Cancer Res. 2018 Aug 1;8(8):1604-1614. eCollection 2018.
• [114] Insulin receptor isoform A favors tumor progression in human hepatocellular carcinoma by increasing stem/progenitor cell features.Cancer Lett. 2019 May 28;450:155-168. doi: 10.1016/j.canlet.2019.02.037. Epub 2019 Mar 6.
• [115] IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma.Cancer Res. 2018 May 1;78(9):2332-2342. doi: 10.1158/0008-5472.CAN-17-2445. Epub 2018 Feb 26.
• [116] Transforming growth factor-1 and lysophosphatidic acid activate integrin 6 gene promoter in Hep-3B cells.Oncol Lett. 2018 Jul;16(1):439-446. doi: 10.3892/ol.2018.8672. Epub 2018 May 8.
• [117] NFB mediated elevation of KCNJ11 promotes tumor progression of hepatocellular carcinoma through interaction of lactate dehydrogenase A.Biochem Biophys Res Commun. 2018 Jan 1;495(1):246-253. doi: 10.1016/j.bbrc.2017.11.011. Epub 2017 Nov 3.
• [118] The protein kinase activity of fructokinase A specifies the antioxidant responses of tumor cells by phosphorylating p62.Sci Adv. 2019 Apr 24;5(4):eaav4570. doi: 10.1126/sciadv.aav4570. eCollection 2019 Apr.
• [119] KIR2DL2 combined with HLA-C1 confers risk of hepatitis C virus-related hepatocellular carcinoma in younger patients.Oncotarget. 2018 Apr 13;9(28):19650-19661. doi: 10.18632/oncotarget.24752. eCollection 2018 Apr 13.
• [120] Midazolam inhibits proliferation and accelerates apoptosis of hepatocellular carcinoma cells by elevating microRNA-124-3p and suppressing PIM-1.IUBMB Life. 2020 Mar;72(3):452-464. doi: 10.1002/iub.2171. Epub 2019 Oct 25.
• [121] Bioinformatics analysis to identify the key genes affecting the progression and prognosis of hepatocellular carcinoma.Biosci Rep. 2019 Feb 22;39(2):BSR20181845. doi: 10.1042/BSR20181845. Print 2019 Feb 28.
• [122] Association of LTBR polymorphisms with chronic hepatitis B virus infection and hepatitis B virus-related hepatocellular carcinoma.Int Immunopharmacol. 2017 Aug;49:126-131. doi: 10.1016/j.intimp.2017.05.031. Epub 2017 May 30.
• [123] Synergistic cytotoxicity and mechanism of caffeine and lysozyme on hepatoma cell line HepG2.Spectrochim Acta A Mol Biomol Spectrosc. 2018 Mar 15;193:169-174. doi: 10.1016/j.saa.2017.12.020. Epub 2017 Dec 6.
• [124] miR-302a inhibits human HepG2 and SMMC-7721 cells proliferation and promotes apoptosis by targeting MAP3K2 and PBX3.Sci Rep. 2019 Feb 14;9(1):2032. doi: 10.1038/s41598-018-38435-0.
• [125] Dietary alpha-linolenic acid reduces COX-2 expression and induces apoptosis of hepatoma cells.J Lipid Res. 2004 Feb;45(2):308-16. doi: 10.1194/jlr.M300396-JLR200. Epub 2003 Oct 16.
• [126] MGAT1 is a novel transcriptional target of Wnt/-catenin signaling pathway.BMC Cancer. 2018 Jan 8;18(1):60. doi: 10.1186/s12885-017-3960-7.
• [127] MAP Kinase-Interacting Kinase 1 Promotes Proliferation and Invasion of Hepatocellular Carcinoma and Is an Unfavorable Prognostic Biomarker.Med Sci Monit. 2018 Mar 26;24:1759-1767. doi: 10.12659/msm.909012.
• [128] LINC01287 regulates tumorigenesis and invasion via miR-298/MYB in hepatocellular carcinoma.J Cell Mol Med. 2018 Nov;22(11):5477-5485. doi: 10.1111/jcmm.13818. Epub 2018 Aug 22.
• [129] Combination of albumin-bilirubin grade and platelets to predict a compensated patient with hepatocellular carcinomawho does not require endoscopic screening for esophageal varices.Gastrointest Endosc. 2018 Aug;88(2):230-239.e2. doi: 10.1016/j.gie.2017.12.023. Epub 2018 Jan 6.
• [130] NEDD4 promotes cell growth and motility in hepatocellular carcinoma.Cell Cycle. 2018;17(6):728-738. doi: 10.1080/15384101.2018.1440879. Epub 2018 Apr 10.
• [131] Downregulation of NIMA-related kinase-7 inhibits cell proliferation by inducing cell cycle arrest in human retinoblastoma cells.Exp Ther Med. 2018 Feb;15(2):1360-1366. doi: 10.3892/etm.2017.5558. Epub 2017 Nov 23.
• [132] NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells.J Hematol Oncol. 2018 Feb 26;11(1):28. doi: 10.1186/s13045-018-0573-9.
• [133] Evodiamine Induces Apoptosis in SMMC-7721 and HepG2 Cells by Suppressing NOD1 Signal Pathway.Int J Mol Sci. 2018 Oct 31;19(11):3419. doi: 10.3390/ijms19113419.
• [134] Snail mediates crosstalk between TGF and LXR in hepatocellular carcinoma.Cell Death Differ. 2018 May;25(5):885-903. doi: 10.1038/s41418-017-0021-3. Epub 2017 Dec 11.
• [135] Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.Neoplasia. 2019 Mar;21(3):257-268. doi: 10.1016/j.neo.2018.11.011. Epub 2019 Jan 25.
• [136] Endoplasmic reticulum stress induced LOX-1(+) CD15(+) polymorphonuclear myeloid-derived suppressor cells in hepatocellular carcinoma.Immunology. 2018 May;154(1):144-155. doi: 10.1111/imm.12876. Epub 2017 Dec 21.
• [137] Dysregulated serum metabolites in staging of hepatocellular carcinoma.Clin Biochem. 2018 Nov;61:7-11. doi: 10.1016/j.clinbiochem.2018.09.002. Epub 2018 Sep 6.
• [138] Discrimination of tumorigenic triazole conazoles from phenobarbital by transcriptional analyses of mouse liver gene expression.Toxicol Sci. 2009 Jul;110(1):68-83. doi: 10.1093/toxsci/kfp076. Epub 2009 Apr 10.
• [139] Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma.World J Gastroenterol. 2018 Mar 14;24(10):1152-1166. doi: 10.3748/wjg.v24.i10.1152.
• [140] The mitochondrial chaperone Prohibitin 1 negatively regulates interleukin-8 in human liver cancers.J Biol Chem. 2019 Feb 8;294(6):1984-1996. doi: 10.1074/jbc.RA118.004863. Epub 2018 Dec 6.
• [141] Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma.Mater Sci Eng C Mater Biol Appl. 2018 Oct 1;91:395-403. doi: 10.1016/j.msec.2018.05.011. Epub 2018 May 4.
• [142] Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma. Hepatology. 2015 Oct;62(4):1145-59.
• [143] Lectin BS-I inhibits cell migration and invasion via AKT/GSK-3/-catenin pathway in hepatocellular carcinoma.J Cell Mol Med. 2018 Jan;22(1):315-329. doi: 10.1111/jcmm.13320. Epub 2017 Sep 18.
• [144] Keratin 23 Is a Peroxisome Proliferator-Activated Receptor Alpha-Dependent, MYC-Amplified Oncogene That Promotes Hepatocyte Proliferation.Hepatology. 2019 Jul;70(1):154-167. doi: 10.1002/hep.30530. Epub 2019 Mar 20.
• [145] Tumor-Derived -Fetoprotein Suppresses Fatty Acid Metabolism and Oxidative Phosphorylation in Dendritic Cells.Cancer Immunol Res. 2019 Jun;7(6):1001-1012. doi: 10.1158/2326-6066.CIR-18-0513. Epub 2019 Apr 15.
• [146] Up-regulation of RIP1 and IPS-1 in chronic HBV infected patients.Genet Mol Biol. 2019 Apr-Jun;42(2):337-343. doi: 10.1590/1678-4685-GMB-2018-0071. Epub 2019 Aug 19.
• [147] Overactivated neddylation pathway in human hepatocellular carcinoma.Cancer Med. 2018 Jul;7(7):3363-3372. doi: 10.1002/cam4.1578. Epub 2018 May 30.
• [148] ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells.Cells. 2019 Mar 2;8(3):210. doi: 10.3390/cells8030210.
• [149] Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue.J Chemother. 2007 Dec;19(6):709-15. doi: 10.1179/joc.2007.19.6.709.
• [150] High expression of S100A12 on intratumoral stroma cells indicates poor prognosis following surgical resection of hepatocellular carcinoma.Oncol Lett. 2018 Oct;16(4):5398-5404. doi: 10.3892/ol.2018.9270. Epub 2018 Aug 6.
• [151] Sphingosine 1-phosphate (S1P) reduces hepatocyte growth factor-induced migration of hepatocellular carcinoma cells via S1P receptor 2.PLoS One. 2018 Dec 13;13(12):e0209050. doi: 10.1371/journal.pone.0209050. eCollection 2018.
• [152] Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma.Cell Death Dis. 2018 Apr 1;9(4):422. doi: 10.1038/s41419-018-0458-4.
• [153] SENP1 promotes hypoxia-induced cancer stemness by HIF-1 deSUMOylation and SENP1/HIF-1 positive feedback loop. Gut. 2017 Dec;66(12):2149-2159.
• [154] Solute Carrier Organic Anion Transporter Family Member 3A1 Is a Bile Acid Efflux Transporter in Cholestasis.Gastroenterology. 2018 Nov;155(5):1578-1592.e16. doi: 10.1053/j.gastro.2018.07.031. Epub 2018 Jul 29.
• [155] Exosomal neutral sphingomyelinase 1 suppresses hepatocellular carcinoma via decreasing the ratio of sphingomyelin/ceramide.FEBS J. 2018 Oct;285(20):3835-3848. doi: 10.1111/febs.14635. Epub 2018 Aug 25.
• [156] Positive Expression of SMYD2 is Associated with Poor Prognosis in Patients with Primary Hepatocellular Carcinoma.J Cancer. 2018 Jan 1;9(2):321-330. doi: 10.7150/jca.22218. eCollection 2018.
• [157] MiR-139-5p, miR-940 and miR-193a-5p inhibit the growth of hepatocellular carcinoma by targeting SPOCK1.J Cell Mol Med. 2019 Apr;23(4):2475-2488. doi: 10.1111/jcmm.14121. Epub 2019 Feb 1.
• [158] Supervillin promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma in hypoxia via activation of the RhoA/ROCK-ERK/p38 pathway.J Exp Clin Cancer Res. 2018 Jun 28;37(1):128. doi: 10.1186/s13046-018-0787-2.
• [159] HRD1-mediated PTEN degradation promotes cell proliferation and hepatocellular carcinoma progression.Cell Signal. 2018 Oct;50:90-99. doi: 10.1016/j.cellsig.2018.06.011. Epub 2018 Jun 27.
• [160] Utility of miR?33a?p as a diagnostic indicator for hepatocellular carcinoma: An investigation combined with GEO, TCGA, metaanalysis and bioinformatics.Mol Med Rep. 2018 Jan;17(1):1469-1484. doi: 10.3892/mmr.2017.8040. Epub 2017 Nov 14.
• [161] T-cell immune regulator 1 enhances metastasis in hepatocellular carcinoma.Exp Mol Med. 2018 Jan 5;50(1):e420. doi: 10.1038/emm.2017.166.
• [162] CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.J Pathol. 2018 Jul;245(3):297-310. doi: 10.1002/path.5083. Epub 2018 May 9.
• [163] Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers.Cancer Immunol Res. 2020 Jan;8(1):19-31. doi: 10.1158/2326-6066.CIR-19-0040. Epub 2019 Dec 5.
• [164] TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.PLoS One. 2017 Sep 13;12(9):e0183880. doi: 10.1371/journal.pone.0183880. eCollection 2017.
• [165] Transferrin receptor 1 overexpression is associated with tumour de-differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma.Histopathology. 2019 Jul;75(1):63-73. doi: 10.1111/his.13847. Epub 2019 May 16.
• [166] Anti-tumor activity and mechanism of oligoclonal hepatocellular carcinoma tumor-infiltrating lymphocytes in vivo and in vitro.Cancer Biol Ther. 2019;20(9):1187-1194. doi: 10.1080/15384047.2019.1599663. Epub 2019 Apr 24.
• [167] Functional diversity of TMPRSS6 isoforms and variants expressed in hepatocellular carcinoma cell lines.Sci Rep. 2018 Aug 22;8(1):12562. doi: 10.1038/s41598-018-30618-z.
• [168] GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.Int J Cancer. 2019 Aug 15;145(4):1111-1124. doi: 10.1002/ijc.32181. Epub 2019 Feb 27.
• [169] Ultrasensitive Plasmonic Biosensors for Real-Time Parallel Detection of Alpha-L-Fucosidase and Cardiac-Troponin-I in Whole Human Blood.Anal Chem. 2018 Jul 3;90(13):7795-7799. doi: 10.1021/acs.analchem.8b01816. Epub 2018 Jun 19.
• [170] A Direct Interaction Between P53-Binding Protein 1 and Minichromosome Maintenance Complex in Hepg2 Cells.Cell Physiol Biochem. 2018;47(6):2350-2359. doi: 10.1159/000491607. Epub 2018 Jul 10.
• [171] Insights into Resistance Mechanisms of Inhibitors to Mps1 C604Y Mutation via a Comprehensive Molecular Modeling Study.Molecules. 2018 Jun 20;23(6):1488. doi: 10.3390/molecules23061488.
• [172] Identification of chromatin-accessible domains in non-alcoholic steatohepatitis-derived hepatocellular carcinoma.Mol Carcinog. 2018 Aug;57(8):978-987. doi: 10.1002/mc.22818. Epub 2018 Apr 16.
• [173] Thioredoxin interacting protein promotes invasion in hepatocellular carcinoma.Oncotarget. 2018 Dec 7;9(96):36849-36866. doi: 10.18632/oncotarget.26402. eCollection 2018 Dec 7.
• [174] TGF- and Hepatocellular Carcinoma: When A Friend Becomes An Enemy.Curr Protein Pept Sci. 2018;19(12):1172-1179. doi: 10.2174/1389203718666171117112619.
• [175] Identification of epigenetically downregulated Tmem70 and Ube2e2 in rat liver after 28-day treatment with hepatocarcinogenic thioacetamide showing gene product downregulation in hepatocellular preneoplastic and neoplastic lesions produced by tumor promotion.Toxicol Lett. 2017 Jan 15;266:13-22. doi: 10.1016/j.toxlet.2016.11.022. Epub 2016 Nov 30.
• [176] SIRT6 Is a Target of Regulation by UBE3A That Contributes to Liver Tumorigenesis in an ANXA2-Dependent Manner.Cancer Res. 2018 Feb 1;78(3):645-658. doi: 10.1158/0008-5472.CAN-17-1692. Epub 2017 Dec 7.
• [177] Amplification of Glyceronephosphate O-Acyltransferase and Recruitment of USP30 Stabilize DRP1 to Promote Hepatocarcinogenesis.Cancer Res. 2018 Oct 15;78(20):5808-5819. doi: 10.1158/0008-5472.CAN-18-0340. Epub 2018 Aug 24.
• [178] VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.BMC Cancer. 2018 May 2;18(1):511. doi: 10.1186/s12885-018-4435-1.
• [179] The hepatic ectonucleotide pyrophosphatase/phosphodiesterase 1 gene mRNA abundance is reduced by insulin and induced by dexamethasone.Braz J Med Biol Res. 2018 Mar 1;51(4):e6980. doi: 10.1590/1414-431X20176980.
• [180] The tumor suppressive miR-26a regulation of FBXO11 inhibits proliferation, migration and invasion of hepatocellular carcinoma cells.Biomed Pharmacother. 2018 May;101:648-655. doi: 10.1016/j.biopha.2018.02.118. Epub 2018 Mar 22.
• [181] Epigenomic profiling of DNA methylation for hepatocellular carcinoma diagnosis and prognosis prediction.J Gastroenterol Hepatol. 2019 Oct;34(10):1869-1877. doi: 10.1111/jgh.14694. Epub 2019 Jun 20.
• [182] Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors.Am J Pathol. 2018 May;188(5):1213-1224. doi: 10.1016/j.ajpath.2018.01.012. Epub 2018 Feb 16.
• [183] The prognostic value of Niemann-Pick C1-like protein 1 and Niemann-Pick disease type C2 in hepatocellular carcinoma.J Cancer. 2018 Jan 1;9(3):556-563. doi: 10.7150/jca.19996. eCollection 2018.
• [184] Anticancer Effects of Emodin on HepG2 Cell: Evidence from Bioinformatic Analysis.Biomed Res Int. 2019 May 19;2019:3065818. doi: 10.1155/2019/3065818. eCollection 2019.
• [185] The NCX1/TRPC6 Complex Mediates TGF-Driven Migration and Invasion of Human Hepatocellular Carcinoma Cells.Cancer Res. 2018 May 15;78(10):2564-2576. doi: 10.1158/0008-5472.CAN-17-2061. Epub 2018 Mar 2.
• [186] SDHC-related deficiency of SDH complex activity promotes growth and metastasis of hepatocellular carcinoma via ROS/NFB signaling.Cancer Lett. 2019 Oct 1;461:44-55. doi: 10.1016/j.canlet.2019.07.001. Epub 2019 Jul 3.
• [187] Efficiency of dual siRNA-mediated gene therapy for intervertebral disc degeneration (IVDD).Spine J. 2019 May;19(5):896-904. doi: 10.1016/j.spinee.2018.10.016. Epub 2018 Nov 12.
• [188] Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice.Oncogene. 2017 Aug;36(31):4415-4426. doi: 10.1038/onc.2017.73. Epub 2017 Mar 27.
• [189] Loss of alanine-glyoxylate and serine-pyruvate aminotransferase expression accelerated the progression of hepatocellular carcinoma and predicted poor prognosis.J Transl Med. 2019 Nov 26;17(1):390. doi: 10.1186/s12967-019-02138-5.
• [190] Angiopoietin-like protein 3 and 4 expression 4 and their serum levels in hepatocellular carcinoma.Cytokine. 2017 Aug;96:75-86. doi: 10.1016/j.cyto.2017.03.006. Epub 2017 Mar 31.
• [191] Prognostic Role of Apelin Receptor Expression in Hepatocellular Carcinoma Treated With Curative Surgical Resection.Anticancer Res. 2019 Jun;39(6):3025-3031. doi: 10.21873/anticanres.13435.
• [192] Therapeutic effects of Euphorbia Pekinensis and Glycyrrhiza glabra on Hepatocellular Carcinoma Ascites Partially Via Regulating the Frk-Arhgdib-Inpp5d-Avpr2-Aqp4 Signal Axis.Sci Rep. 2017 Feb 6;7:41925. doi: 10.1038/srep41925.
• [193] Predictive role BLVRA mRNA expression in hepatocellular cancer.Ann Hepatol. 2016 Nov-Dec 2016;15(6):881-887. doi: 10.5604/16652681.1222104.
• [194] Positive association between miR-499A>G and hepatocellular carcinoma risk in a Chinese population.Asian Pac J Cancer Prev. 2013;14(3):1769-72. doi: 10.7314/apjcp.2013.14.3.1769.
• [195] Resveratrol inhibits proliferation and migration through SIRT1 mediated posttranslational modification of PI3K/AKT signaling in hepatocellular carcinoma cells.Mol Med Rep. 2017 Dec;16(6):8037-8044. doi: 10.3892/mmr.2017.7612. Epub 2017 Sep 26.
• [196] Hepatic stellate cells limit hepatocellular carcinoma progression through the orphan receptor endosialin.EMBO Mol Med. 2017 Jun;9(6):741-749. doi: 10.15252/emmm.201607222.
• [197] Liver-infiltrating CD11b(-)CD27(-) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression.Cell Mol Immunol. 2017 Oct;14(10):819-829. doi: 10.1038/cmi.2016.28. Epub 2016 Jun 20.
• [198] Meta-analysis of possible role of cadherin gene methylation in evolution and prognosis of hepatocellular carcinoma with a PRISMA guideline.Medicine (Baltimore). 2017 Apr;96(16):e6650. doi: 10.1097/MD.0000000000006650.
• [199] KLF4-Mediated CDH3 Upregulation Suppresses Human Hepatoma Cell Growth and Migration via GSK-3 Signaling.Int J Biol Sci. 2019 Mar 10;15(5):953-961. doi: 10.7150/ijbs.30857. eCollection 2019.
• [200] Clinicopathological features of neoplasms with neuroendocrine differentiation occurring in the liver.J Clin Pathol. 2017 Jul;70(7):563-570. doi: 10.1136/jclinpath-2016-203941. Epub 2016 Nov 23.
• [201] Vps4A mediates the localization and exosome release of -catenin to inhibit epithelial-mesenchymal transition in hepatocellular carcinoma.Cancer Lett. 2019 Aug 10;457:47-59. doi: 10.1016/j.canlet.2019.04.035. Epub 2019 May 3.
• [202] Fabrication of -chitosan nanoparticles and its anticancer potential against human hepatoma cells.Int J Biol Macromol. 2017 Jan;94(Pt A):194-201. doi: 10.1016/j.ijbiomac.2016.10.016. Epub 2016 Oct 7.
• [203] COL6A3-derived endotrophin links reciprocal interactions among hepatic cells in the pathology of chronic liver disease.J Pathol. 2019 Jan;247(1):99-109. doi: 10.1002/path.5172. Epub 2018 Nov 27.
• [204] Hepatitis B virus X protein-induced upregulation of CAT-1 stimulates proliferation and inhibits apoptosis in hepatocellular carcinoma cells.Oncotarget. 2017 May 5;8(37):60962-60974. doi: 10.18632/oncotarget.17631. eCollection 2017 Sep 22.
• [205] CTP synthase forms the cytoophidium in human hepatocellular carcinoma.Exp Cell Res. 2017 Dec 15;361(2):292-299. doi: 10.1016/j.yexcr.2017.10.030. Epub 2017 Oct 31.
• [206] Cullin-3/KCTD10 complex is essential for K27-polyubiquitination of EIF3D in human hepatocellular carcinoma HepG2 cells.Biochem Biophys Res Commun. 2019 Sep 3;516(4):1116-1122. doi: 10.1016/j.bbrc.2019.07.010. Epub 2019 Jul 5.
• [207] CXCL13 rather than IL-31 is a potential indicator in patients with hepatocellular carcinoma.Cytokine. 2017 Jan;89:91-97. doi: 10.1016/j.cyto.2016.08.016. Epub 2016 Sep 20.
• [208] Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma.J Cancer Res Clin Oncol. 2019 Mar;145(3):675-684. doi: 10.1007/s00432-018-2824-0. Epub 2018 Dec 18.
• [209] High nuclear NADPH oxidase 4 expression levels are correlated with cancer development and poor prognosis in hepatocellular carcinoma.Pathology. 2019 Oct;51(6):579-585. doi: 10.1016/j.pathol.2019.05.004. Epub 2019 Aug 20.
• [210] DEAD Box Protein 5 Inhibits Liver Tumorigenesis by Stimulating Autophagy via Interaction with p62/SQSTM1.Hepatology. 2019 Mar;69(3):1046-1063. doi: 10.1002/hep.30300. Epub 2019 Feb 8.
• [211] Diacylglycerol kinase -selective inhibitors induce apoptosis and reduce viability of melanoma and several other cancer cell lines.J Cell Biochem. 2019 Jun;120(6):10043-10056. doi: 10.1002/jcb.28288. Epub 2018 Dec 9.
• [212] Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells.Oncotarget. 2016 Jul 18;8(31):50542-50556. doi: 10.18632/oncotarget.10671. eCollection 2017 Aug 1.
• [213] Antitumor effects of circ-EPHB4 in hepatocellular carcinoma via inhibition of HIF-1.Mol Carcinog. 2019 Jun;58(6):875-886. doi: 10.1002/mc.22976. Epub 2019 Feb 18.
• [214] m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation.Am J Transl Res. 2019 Sep 15;11(9):6084-6092. eCollection 2019.
• [215] Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition.Acta Biochim Biophys Sin (Shanghai). 2018 Apr 1;50(4):370-380. doi: 10.1093/abbs/gmy009.
• [216] GABRQ expression is a potential prognostic marker for patients with clear cell renal cell carcinoma.Oncol Lett. 2019 Dec;18(6):5731-5738. doi: 10.3892/ol.2019.10960. Epub 2019 Oct 4.
• [217] Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells.J Exp Clin Cancer Res. 2019 Oct 22;38(1):423. doi: 10.1186/s13046-019-1402-x.
• [218] Expression and Significances of G-Protein-Coupled Receptor Kinase 3 in Hepatocellular Carcinoma.J Cancer. 2017 Jul 5;8(11):1972-1978. doi: 10.7150/jca.19201. eCollection 2017.
• [219] Sorafenib may enhance antitumour efficacy in hepatocellular carcinoma patients by modulating the proportions and functions of natural killer cells.Invest New Drugs. 2020 Oct;38(5):1247-1256. doi: 10.1007/s10637-019-00885-2. Epub 2019 Dec 13.
• [220] HAX-1 promotes the migration and invasion of hepatocellular carcinoma cells through the induction of epithelial-mesenchymal transition via the NF-B pathway.Exp Cell Res. 2019 Aug 1;381(1):66-76. doi: 10.1016/j.yexcr.2019.04.030. Epub 2019 Apr 30.
• [221] Orexin A affects HepG2 human hepatocellular carcinoma cells glucose metabolism via HIF-1-dependent and -independent mechanism.PLoS One. 2017 Sep 8;12(9):e0184213. doi: 10.1371/journal.pone.0184213. eCollection 2017.
• [222] Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.Cancers (Basel). 2019 Oct 18;11(10):1587. doi: 10.3390/cancers11101587.
• [223] HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma.Cancers (Basel). 2019 Nov 26;11(12):1876. doi: 10.3390/cancers11121876.
• [224] Long noncoding RNA miR503HG, a prognostic indicator, inhibits tumor metastasis by regulating the HNRNPA2B1/NF-B pathway in hepatocellular carcinoma.Theranostics. 2018 Apr 15;8(10):2814-2829. doi: 10.7150/thno.23012. eCollection 2018.
• [225] Investigation of ICOS, CD28 and CD80 polymorphisms with the risk of hepatocellular carcinoma: a case-control study in eastern Chinese population.Biosci Rep. 2019 Jul 5;39(7):BSR20181824. doi: 10.1042/BSR20181824. Print 2019 Jul 31.
• [226] Comparative analysis of hepatocellular carcinoma and cirrhosis gene expression profiles.Mol Med Rep. 2017 Jan;15(1):380-386. doi: 10.3892/mmr.2016.6021. Epub 2016 Dec 9.
• [227] Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment.J Exp Clin Cancer Res. 2019 Jul 11;38(1):303. doi: 10.1186/s13046-019-1271-3.
• [228] Interleukin-8 promotes integrin 3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma.J Exp Clin Cancer Res. 2019 Nov 4;38(1):449. doi: 10.1186/s13046-019-1455-x.
• [229] Modification of p27 with O-linked N-acetylglucosamine regulates cell proliferation in hepatocellular carcinoma.Mol Carcinog. 2017 Jan;56(1):258-271. doi: 10.1002/mc.22490. Epub 2016 May 13.
• [230] The Expression of ILT4 in Myeloid Dendritic Cells in Patients with Hepatocellular Carcinoma.Immunol Invest. 2019 Oct;48(7):704-718. doi: 10.1080/08820139.2019.1571507. Epub 2019 May 2.
• [231] EDG2 enhanced the progression of hepatocellular carcinoma by LPA/PI3K/AKT/ mTOR signaling.Oncotarget. 2017 Aug 2;8(39):66154-66168. doi: 10.18632/oncotarget.19825. eCollection 2017 Sep 12.
• [232] MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.Gastroenterology. 2017 Oct;153(4):1120-1132.e15. doi: 10.1053/j.gastro.2016.12.036. Epub 2017 Feb 27.
• [233] Long Intergenic Non-Protein Coding RNA 665 Regulates Viability, Apoptosis, and Autophagy via the MiR-186-5p/MAP4K3 Axis in Hepatocellular Carcinoma.Yonsei Med J. 2019 Sep;60(9):842-853. doi: 10.3349/ymj.2019.60.9.842.
• [234] MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression.BMC Cancer. 2018 Feb 20;18(1):200. doi: 10.1186/s12885-018-4056-8.
• [235] The oncoprotein HBXIP facilitates metastasis of hepatocellular carcinoma cells by activation of MMP15 expression.Cancer Manag Res. 2019 May 16;11:4529-4540. doi: 10.2147/CMAR.S198783. eCollection 2019.
• [236] EYA4 inhibits hepatocellular carcinoma by repressing MYCBP by dephosphorylating -catenin at Ser552.Cancer Sci. 2019 Oct;110(10):3110-3121. doi: 10.1111/cas.14159. Epub 2019 Aug 28.
• [237] Circular RNA MYLK promotes hepatocellular carcinoma progression by increasing Rab23 expression by sponging miR-362-3p.Cancer Cell Int. 2019 Aug 8;19:211. doi: 10.1186/s12935-019-0926-7. eCollection 2019.
• [238] Pathobiological and Radiological Approach For Hepatocellular Carcinoma Subclassification.Sci Rep. 2019 Oct 14;9(1):14749. doi: 10.1038/s41598-019-51303-9.
• [239] NK3 homeobox 1 (NKX3.1) up-regulates forkhead box O1 expression in hepatocellular carcinoma and thereby suppresses tumor proliferation and invasion.J Biol Chem. 2017 Nov 24;292(47):19146-19159. doi: 10.1074/jbc.M117.793760. Epub 2017 Sep 27.
• [240] NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/-catenin signalling pathway in clear cell renal cell carcinoma.Cancer Lett. 2019 Mar 1;444:9-19. doi: 10.1016/j.canlet.2018.11.024. Epub 2018 Dec 11.
• [241] Phase-contrast CT: Qualitative and Quantitative Evaluation of Capillarized Sinusoids and Trabecular Structure in Human Hepatocellular Carcinoma Tissues.Acad Radiol. 2017 Jan;24(1):67-75. doi: 10.1016/j.acra.2016.08.028. Epub 2016 Nov 3.
• [242] Dysregulation of metallothionein and circadian genes in human hepatocellular carcinoma.Chronobiol Int. 2017;34(2):192-202. doi: 10.1080/07420528.2016.1256300. Epub 2016 Dec 20.
• [243] Elevated expression of neuropilin-2 associated with unfavorable prognosis in hepatocellular carcinoma.Onco Targets Ther. 2017 Jul 31;10:3827-3833. doi: 10.2147/OTT.S139044. eCollection 2017.
• [244] CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.J Exp Clin Cancer Res. 2019 Nov 14;38(1):467. doi: 10.1186/s13046-019-1462-y.
• [245] Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure.PLoS One. 2017 Nov 27;12(11):e0188552. doi: 10.1371/journal.pone.0188552. eCollection 2017.
• [246] Mechanism of Inactivation of Ornithine Aminotransferase by (1S,3S)-3-Amino-4-(hexafluoropropan-2-ylidenyl)cyclopentane-1-carboxylic Acid.J Am Chem Soc. 2019 Jul 10;141(27):10711-10721. doi: 10.1021/jacs.9b03254. Epub 2019 Jun 28.
• [247] Down-regulation of the tumour suppressor -opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.BMC Cancer. 2017 Aug 18;17(1):553. doi: 10.1186/s12885-017-3541-9.
• [248] Inhibition of Orai1-mediated Ca(2+) entry enhances chemosensitivity of HepG2 hepatocarcinoma cells to 5-fluorouracil.J Cell Mol Med. 2017 May;21(5):904-915. doi: 10.1111/jcmm.13029. Epub 2016 Nov 23.
• [249] Carcinoma-specific expression of P2Y11 receptor and its contribution in ATP-induced purinergic signalling and cell migration in human hepatocellular carcinoma cells.Oncotarget. 2017 Jun 6;8(23):37278-37290. doi: 10.18632/oncotarget.16191.
• [250] Overexpressed pepsinogen C is associated with poor prognosis in human hepatocellular carcinoma: a tissue microarray study.Cancer Manag Res. 2019 Apr 10;11:2927-2934. doi: 10.2147/CMAR.S192241. eCollection 2019.
• [251] PIGU overexpression adds value to TNM staging in the prognostic stratification of patients with hepatocellular carcinoma.Hum Pathol. 2019 Jan;83:90-99. doi: 10.1016/j.humpath.2018.08.013. Epub 2018 Aug 30.
• [252] Oncogenic role of phospholipase C-1 in progression of hepatocellular carcinoma.Hepatol Res. 2019 May;49(5):559-569. doi: 10.1111/hepr.13309. Epub 2019 Feb 20.
• [253] Growth inhibitor of human hepatic carcinoma HepG2 cells by evodiamine is associated with downregulation of PRAME.Naunyn Schmiedebergs Arch Pharmacol. 2019 Dec;392(12):1551-1560. doi: 10.1007/s00210-019-01701-7. Epub 2019 Jul 29.
• [254] The Association of Peroxiredoxin 4 with the Initiation and Progression of Hepatocellular Carcinoma.Antioxid Redox Signal. 2019 Apr 1;30(10):1271-1284. doi: 10.1089/ars.2017.7426. Epub 2018 Jun 11.
• [255] An integrated PKD1-dependent signaling network amplifies IRE1 prosurvival signaling.J Biol Chem. 2019 Jul 19;294(29):11119-11130. doi: 10.1074/jbc.RA118.003311. Epub 2019 Jun 5.
• [256] PGE(2) synthesis and signaling in malignant transformation and progression of human hepatocellular carcinoma.Hum Pathol. 2017 May;63:120-127. doi: 10.1016/j.humpath.2017.02.018. Epub 2017 Mar 12.
• [257] Bioinformatics Analysis Identifies Protein Tyrosine Kinase 7 (PTK7) as a Potential Prognostic and Therapeutic Biomarker in Stages I to IV Hepatocellular Carcinoma.Med Sci Monit. 2019 Nov 15;25:8618-8627. doi: 10.12659/MSM.917142.
• [258] The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans.Hepatology. 2019 Nov;70(5):1600-1613. doi: 10.1002/hep.30697. Epub 2019 Jun 21.
• [259] Gadoxetic acid-enhanced MRI for the characterization of hepatocellular carcinoma: A systematic review and meta-analysis.J Magn Reson Imaging. 2017 Jan;45(1):281-290. doi: 10.1002/jmri.25345. Epub 2016 Jun 14.
• [260] The uptake exploration of 68Ga-labeled NGR in well-differentiated hepatocellular carcinoma xenografts: Indication for the new clinical translational of a tracer based on NGR.Oncol Rep. 2017 Nov;38(5):2859-2866. doi: 10.3892/or.2017.5933. Epub 2017 Aug 31.
• [261] Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma.Oncotarget. 2017 Apr 25;8(17):27953-27965. doi: 10.18632/oncotarget.15853.
• [262] Long-Read RNA Sequencing Identifies Alternative Splice Variants in Hepatocellular Carcinoma and Tumor-Specific Isoforms.Hepatology. 2019 Sep;70(3):1011-1025. doi: 10.1002/hep.30500. Epub 2019 Mar 22.
• [263] Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.J Cell Mol Med. 2019 Nov;23(11):7349-7359. doi: 10.1111/jcmm.14594. Epub 2019 Sep 10.
• [264] Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines.Korean J Radiol. 2019 Jun;20(6):863-879. doi: 10.3348/kjr.2018.0450.
• [265] Cotransfecting norepinephrine transporter and vesicular monoamine transporter 2 genes for increased retention of metaiodobenzylguanidine labeled with iodine 131 in malignant hepatocarcinoma cells.Front Med. 2017 Mar;11(1):120-128. doi: 10.1007/s11684-017-0501-3. Epub 2017 Mar 2.
• [266] Long non-coding RNA MEG3 regulates migration and invasion of lung cancer stem cells via miR-650/SLC34A2 axis.Biomed Pharmacother. 2019 Dec;120:109457. doi: 10.1016/j.biopha.2019.109457. Epub 2019 Oct 1.
• [267] Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis.Histopathology. 2017 Feb;70(3):492-498. doi: 10.1111/his.13034. Epub 2016 Nov 10.
• [268] MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5.Lab Invest. 2017 May;97(5):530-542. doi: 10.1038/labinvest.2017.12. Epub 2017 Feb 20.
• [269] Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/-Catenin Signaling.Mol Cancer Res. 2019 Feb;17(2):521-531. doi: 10.1158/1541-7786.MCR-18-0054. Epub 2018 Sep 26.
• [270] Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice.Nat Commun. 2019 Jan 15;10(1):221. doi: 10.1038/s41467-018-08096-8.
• [271] Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.Mol Cancer Ther. 2017 Jun;16(6):1155-1165. doi: 10.1158/1535-7163.MCT-16-0728. Epub 2017 Feb 28.
• [272] Early Therapeutic Vaccination Prediction of Hepatocellular Carcinoma via Imaging OX40-Mediated Tumor Infiltrating Lymphocytes.Mol Pharm. 2019 Oct 7;16(10):4252-4259. doi: 10.1021/acs.molpharmaceut.9b00590. Epub 2019 Sep 16.
• [273] Cell Culture System for Analysis of Genetic Heterogeneity WithinHepatocellular Carcinomas and Response to Pharmacologic Agents.Gastroenterology. 2017 Jan;152(1):232-242.e4. doi: 10.1053/j.gastro.2016.09.008. Epub 2016 Sep 14.
• [274] Anticancer effects of echinacoside in hepatocellular carcinoma mouse model and HepG2 cells.J Cell Physiol. 2019 Feb;234(2):1880-1888. doi: 10.1002/jcp.27063. Epub 2018 Aug 1.
• [275] TRIM59 promotes cell proliferation, migration and invasion in human hepatocellular carcinoma cells.Pharmazie. 2017 Nov 1;72(11):674-679. doi: 10.1691/ph.2017.7659.
• [276] Identification of a CIP4 PKA phosphorylation site involved in the regulation of cancer cell invasiveness and metastasis.Cancer Lett. 2019 Oct 1;461:65-77. doi: 10.1016/j.canlet.2019.07.006. Epub 2019 Jul 15.
• [277] Claudin-9 enhances the metastatic potential of hepatocytes via Tyk2/Stat3 signaling.Turk J Gastroenterol. 2019 Aug;30(8):722-731. doi: 10.5152/tjg.2019.18513.
• [278] Urotensin II receptor as a potential biomarker for the prognosis of hepatocellular carcinoma patients.Oncol Lett. 2017 Sep;14(3):2749-2756. doi: 10.3892/ol.2017.6545. Epub 2017 Jul 8.
• [279] mTOR and ERK regulate VKORC1 expression in both hepatoma cells and hepatocytes which influence blood coagulation.Clin Exp Med. 2019 Feb;19(1):121-132. doi: 10.1007/s10238-018-0528-z. Epub 2018 Oct 10.
• [280] HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein.Hepatology. 2020 May;71(5):1678-1695. doi: 10.1002/hep.30947. Epub 2020 Jan 26.
• [281] miR-33a expression sensitizes Lgr5+ HCC-CSCs to doxorubicin via ABCA1.Neoplasma. 2017;64(1):81-91. doi: 10.4149/neo_2017_110.
• [282] RMP/URI inhibits both intrinsic and extrinsic apoptosis through different signaling pathways.Int J Biol Sci. 2019 Oct 15;15(12):2692-2706. doi: 10.7150/ijbs.36829. eCollection 2019.
• [283] Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.J Hepatol. 2017 Jun;66(6):1182-1192. doi: 10.1016/j.jhep.2017.01.027. Epub 2017 Feb 9.
• [284] LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363.J Cell Mol Med. 2018 Jun;22(6):3238-3245. doi: 10.1111/jcmm.13605. Epub 2018 Mar 30.
• [285] Immunohistochemical Assessment of the Expression of Biliary Transportation Proteins MRP2 and MRP3 in Hepatocellular Carcinoma and in Cholangiocarcinoma.Pathol Oncol Res. 2019 Oct;25(4):1363-1371. doi: 10.1007/s12253-018-0386-8. Epub 2018 Feb 20.
• [286] TNF Induces Multidrug Resistance-Associated Protein 4 Expression through p38-E2F1-Nrf2 Signaling in Obstructive Cholestasis.Yonsei Med J. 2019 Nov;60(11):1045-1053. doi: 10.3349/ymj.2019.60.11.1045.
• [287] Cytotoxicity of isoflavones and biflavonoids from Ormocarpum kirkii towards multi-factorial drug resistant cancer.Phytomedicine. 2019 May;58:152853. doi: 10.1016/j.phymed.2019.152853. Epub 2019 Jan 30.
• [288] Metabolic profiling analysis upon acylcarnitines in tissues of hepatocellular carcinoma revealed the inhibited carnitine shuttle system caused by the downregulated carnitine palmitoyltransferase 2.Mol Carcinog. 2019 May;58(5):749-759. doi: 10.1002/mc.22967. Epub 2019 Jan 20.
• [289] Methionine adenosyltransferases in liver cancer.World J Gastroenterol. 2019 Aug 21;25(31):4300-4319. doi: 10.3748/wjg.v25.i31.4300.
• [290] Acetylcholinesterase is associated with a decrease in cell proliferation of hepatocellular carcinoma cells.Biochim Biophys Acta. 2015 Jul;1852(7):1380-7. doi: 10.1016/j.bbadis.2015.04.003. Epub 2015 Apr 11.
• [291] Plumbagin Restrains Hepatocellular Carcinoma Angiogenesis by Stromal Cell-Derived Factor (SDF-1)/CXCR4-CXCR7 Axis.Med Sci Monit. 2019 Aug 15;25:6110-6119. doi: 10.12659/MSM.915782.
• [292] Polymorphisms in genes of the de novo lipogenesis pathway and overall survival of hepatocellular carcinoma patients undergoing transarterial chemoembolization.Asian Pac J Cancer Prev. 2015;16(3):1051-6. doi: 10.7314/apjcp.2015.16.3.1051.
• [293] Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS.Mol Med Rep. 2010 Jul-Aug;3(4):589-96. doi: 10.3892/mmr_00000302.
• [294] ACR Ultrasound Liver Reporting and Data System: Multicenter Assessment of Clinical Performance at One Year.J Am Coll Radiol. 2019 Dec;16(12):1656-1662. doi: 10.1016/j.jacr.2019.05.020. Epub 2019 Jun 4.
• [295] RRAD suppresses the Warburg effect by downregulating ACTG1 in hepatocellular carcinoma.Onco Targets Ther. 2019 Feb 28;12:1691-1703. doi: 10.2147/OTT.S197844. eCollection 2019.
• [296] A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.Oncologist. 2019 Feb;24(2):161-e70. doi: 10.1634/theoncologist.2018-0654. Epub 2018 Oct 23.
• [297] Long noncoding LINC01551 promotes hepatocellular carcinoma cell proliferation, migration, and invasion by acting as a competing endogenous RNA of microRNA-122-5p to regulate ADAM10 expression.J Cell Biochem. 2019 Oct;120(10):16393-16407. doi: 10.1002/jcb.28549. Epub 2019 Jul 3.
• [298] High ADAM8 expression is associated with poor prognosis in patients with hepatocellular carcinoma.Pathol Oncol Res. 2013 Jan;19(1):79-88. doi: 10.1007/s12253-012-9560-6. Epub 2012 Sep 12.
• [299] ADAM9 mediates the interleukin-6-induced Epithelial-Mesenchymal transition and metastasis through ROS production in hepatoma cells.Cancer Lett. 2018 May 1;421:1-14. doi: 10.1016/j.canlet.2018.02.010. Epub 2018 Feb 10.
• [300] SP1 and USF differentially regulate ADAMTS1 gene expression under normoxic and hypoxic conditions in hepatoma cells.Gene. 2016 Jan 1;575(1):48-57. doi: 10.1016/j.gene.2015.08.035. Epub 2015 Aug 20.
• [301] VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.BMC Gastroenterol. 2019 Oct 21;19(1):167. doi: 10.1186/s12876-019-1082-1.
• [302] Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma.Cell. 2019 Oct 3;179(2):561-577.e22. doi: 10.1016/j.cell.2019.08.052.
• [303] Adiponectin accounts for gender differences in hepatocellular carcinoma incidence.J Exp Med. 2019 May 6;216(5):1108-1119. doi: 10.1084/jem.20181288. Epub 2019 Apr 3.
• [304] Apigenin sensitizes hepatocellular carcinoma cells to doxorubic through regulating miR-520b/ATG7 axis.Chem Biol Interact. 2018 Jan 25;280:45-50. doi: 10.1016/j.cbi.2017.11.020. Epub 2017 Dec 11.
• [305] Intermedin promotes hepatocellular carcinoma cell proliferation through the classical Wnt signaling pathway.Oncol Lett. 2018 Apr;15(4):5966-5970. doi: 10.3892/ol.2018.8033. Epub 2018 Feb 13.
• [306] Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.Hepatol Int. 2020 Jan;14(1):80-95. doi: 10.1007/s12072-019-10003-2. Epub 2019 Dec 4.
• [307] Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular carcinoma.J Enzyme Inhib Med Chem. 2018 Dec;33(1):858-866. doi: 10.1080/14756366.2018.1462801.
• [308] CD97 Promotes Tumor Aggressiveness Through the Traditional G Protein-Coupled Receptor-Mediated Signaling in Hepatocellular Carcinoma.Hepatology. 2018 Nov;68(5):1865-1878. doi: 10.1002/hep.30068. Epub 2018 Sep 22.
• [309] G protein-coupled receptor kinase 2 regulating 2-adrenergic receptor signaling in M2-polarized macrophages contributes to hepatocellular carcinoma progression.Onco Targets Ther. 2019 Jul 11;12:5499-5513. doi: 10.2147/OTT.S209291. eCollection 2019.
• [310] Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy.Cell Death Dis. 2018 Feb 14;9(2):225. doi: 10.1038/s41419-018-0329-z.
• [311] Novel angiotensin receptor blocker, azilsartan induces oxidative stress and NFkB-mediated apoptosis in hepatocellular carcinoma cell line HepG2.Biomed Pharmacother. 2018 Mar;99:939-946. doi: 10.1016/j.biopha.2018.01.117. Epub 2018 Feb 20.
• [312] Multiparametric FDG-PET/MRI of Hepatocellular Carcinoma: Initial Experience.Contrast Media Mol Imaging. 2018 Oct 3;2018:5638283. doi: 10.1155/2018/5638283. eCollection 2018.
• [313] A male-specific association between AGTR1 hypermethylation and coronary heart disease.Bosn J Basic Med Sci. 2020 Feb 5;20(1):31-36. doi: 10.17305/bjbms.2019.4321.
• [314] Epigenetically mediated inhibition of S-adenosylhomocysteine hydrolase and the associated dysregulation of 1-carbon metabolism in nonalcoholic steatohepatitis and hepatocellular carcinoma.FASEB J. 2018 Mar;32(3):1591-1601. doi: 10.1096/fj.201700866R. Epub 2018 Jan 3.
• [315] Ultrasensitivity dynamics of diverse aryl hydrocarbon receptor modulators in a hepatoma cell line.Arch Toxicol. 2019 Mar;93(3):635-647. doi: 10.1007/s00204-018-2380-z. Epub 2018 Dec 19.
• [316] The human hepatoma Hep3B cell line as an experimental model in the study of the long-term regulation of acute-phase proteins by cytokines.Biochem J. 1992 Oct 1;287 ( Pt 1)(Pt 1):255-9. doi: 10.1042/bj2870255.
• [317] Expression of Allograft Inflammatory Factor-1 (AIF-1) in Hepatocellular Carcinoma.Med Sci Monit. 2018 Sep 6;24:6218-6228. doi: 10.12659/MSM.908510.
• [318] Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.Gut. 2020 Feb;69(2):365-379. doi: 10.1136/gutjnl-2018-317257. Epub 2019 May 10.
• [319] Reduction of dihydrodiol dehydrogenase expression in resected hepatocellular carcinoma.Oncol Rep. 2003 Mar-Apr;10(2):271-6.
• [320] Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress.PLoS One. 2016 Sep 9;11(9):e0162634. doi: 10.1371/journal.pone.0162634. eCollection 2016.
• [321] CYP2E1 overexpression up-regulates both non-specific delta-aminolevulinate synthase and heme oxygenase-1 in the human hepatoma cell line HLE/2E1.Int J Mol Med. 2003 Jan;11(1):57-62.
• [322] Predicting Value of ALCAM as a Target Gene of microRNA-483-5p in Patients with Early Recurrence in Hepatocellular Carcinoma.Front Pharmacol. 2018 Jan 12;8:973. doi: 10.3389/fphar.2017.00973. eCollection 2017.
• [323] Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma.Anticancer Drugs. 2018 Jul;29(6):513-519. doi: 10.1097/CAD.0000000000000616.
• [324] Ischemia reperfusion injury promotes recurrence of hepatocellular carcinoma in fatty liver via ALOX12-12HETE-GPR31 signaling axis.J Exp Clin Cancer Res. 2019 Dec 12;38(1):489. doi: 10.1186/s13046-019-1480-9.
• [325] Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.Oncotarget. 2017 Feb 7;8(6):9466-9475. doi: 10.18632/oncotarget.14326.
• [326] Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.Mol Ther. 2015 Nov;23(11):1772-1782. doi: 10.1038/mt.2015.147. Epub 2015 Aug 17.
• [327] Retrodifferentiation of Human Tumor Hepatocytes to Stem Cells Leads to Metabolic Reprogramming and Chemoresistance.Cancer Res. 2019 Apr 15;79(8):1869-1883. doi: 10.1158/0008-5472.CAN-18-2110. Epub 2019 Mar 5.
• [328] In situ imaging of aminopeptidase N activity in hepatocellular carcinoma: a migration model for tumour using an activatable two-photon NIR fluorescent probe.Chem Sci. 2018 Nov 27;10(6):1619-1625. doi: 10.1039/c8sc04685a. eCollection 2019 Feb 14.
• [329] Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma.Int J Oncol. 2005 Apr;26(4):1053-61.
• [330] SWELL1 promotes cell growth and metastasis of hepatocellular carcinoma in vitro and in vivo.EBioMedicine. 2019 Oct;48:100-116. doi: 10.1016/j.ebiom.2019.09.007. Epub 2019 Oct 6.
• [331] APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.Theranostics. 2019 Jul 9;9(18):5246-5260. doi: 10.7150/thno.34713. eCollection 2019.
• [332] Clinical features of aflatoxin B1-exposed patients with liver cancer and the molecular mechanism of aflatoxin B1 on liver cancer cells.Environ Toxicol Pharmacol. 2019 Oct;71:103225. doi: 10.1016/j.etap.2019.103225. Epub 2019 Jul 25.
• [333] Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray.Oncol Rep. 2007 Oct;18(4):943-51.
• [334] A biphasic response pattern of lipid metabolomics in the stage progression of hepatitis B virus X tumorigenesis.Mol Carcinog. 2016 Jan;55(1):105-14. doi: 10.1002/mc.22266. Epub 2015 Jan 15.
• [335] Elevated apolipoprotein B predicts poor postsurgery prognosis in patients with hepatocellular carcinoma.Onco Targets Ther. 2019 Mar 12;12:1957-1964. doi: 10.2147/OTT.S192631. eCollection 2019.
• [336] APOBEC3G exerts tumor suppressive effects in human hepatocellular carcinoma.Anticancer Drugs. 2014 Apr;25(4):456-61. doi: 10.1097/CAD.0000000000000082.
• [337] Diagnostic and prognostic significance of mRNA expressions of apolipoprotein A and C family genes in hepatitis B virus-related hepatocellular carcinoma.J Cell Biochem. 2019 Oct;120(10):18246-18265. doi: 10.1002/jcb.29131. Epub 2019 Jun 18.
• [338] Aquaporin 3 maintains the stemness of CD133+ hepatocellular carcinoma cells by activating STAT3.Cell Death Dis. 2019 Jun 13;10(6):465. doi: 10.1038/s41419-019-1712-0.
• [339] Aquaporins in Digestive System.Adv Exp Med Biol. 2017;969:123-130. doi: 10.1007/978-94-024-1057-0_8.
• [340] The androgen receptor expression and association with patient's survival in different cancers.Genomics. 2020 Mar;112(2):1926-1940. doi: 10.1016/j.ygeno.2019.11.005. Epub 2019 Nov 20.
• [341] Elevated Expression of A-Raf and FA2H in Hepatocellular Carcinoma is Associated with Lipid Metabolism Dysregulation and Cancer Progression.Anticancer Agents Med Chem. 2019;19(2):236-247. doi: 10.2174/1871520618666181015142810.
• [342] Upregulation of amphiregulin by retinoic acid and Wnt signalling promotes liver cancer cell proliferation.J Cell Physiol. 2020 Feb;235(2):1689-1699. doi: 10.1002/jcp.29088. Epub 2019 Jul 12.
• [343] Correlation of PPM1A Downregulation with CYP3A4 Repression in the Tumor Liver Tissue of Hepatocellular Carcinoma Patients.Eur J Drug Metab Pharmacokinet. 2020 Apr;45(2):297-304. doi: 10.1007/s13318-019-00595-3.
• [344] Long non-coding RNA ANRIL enhances mitochondrial function of hepatocellular carcinoma by regulating the MiR-199a-5p/ARL2 axis.Environ Toxicol. 2020 Mar;35(3):313-321. doi: 10.1002/tox.22867. Epub 2019 Oct 31.
• [345] -Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling.Nat Commun. 2015 Jun 16;6:7369. doi: 10.1038/ncomms8369.
• [346] ASAP3 is a downstream target of HIF-1 and is critical for progression of lung adenocarcinoma.Onco Targets Ther. 2019 Jul 17;12:5793-5803. doi: 10.2147/OTT.S199603. eCollection 2019.
• [347] Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.Cancer Immunol Immunother. 2017 Apr;66(4):475-489. doi: 10.1007/s00262-016-1949-8. Epub 2016 Dec 29.
• [348] Dendritic cell-based vaccine targeting aspartate--hydroxylas represents a promising therapeutic strategy for HCC.Immunotherapy. 2019 Nov;11(16):1399-1407. doi: 10.2217/imt-2019-0081. Epub 2019 Oct 14.
• [349] Kinesin family member 15 promotes cancer stem cell phenotype and malignancy via reactive oxygen species imbalance in hepatocellular carcinoma.Cancer Lett. 2020 Jul 10;482:112-125. doi: 10.1016/j.canlet.2019.11.008. Epub 2019 Nov 13.
• [350] ATF3 inhibits the tumorigenesis and progression of hepatocellular carcinoma cells via upregulation of CYR61 expression.J Exp Clin Cancer Res. 2018 Oct 30;37(1):263. doi: 10.1186/s13046-018-0919-8.
• [351] Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway.Int J Biol Sci. 2019 Jul 21;15(9):1905-1920. doi: 10.7150/ijbs.32550. eCollection 2019.
• [352] Primary Cilia Blockage Promotes the Malignant Behaviors of Hepatocellular Carcinoma via Induction of Autophagy.Biomed Res Int. 2019 Oct 2;2019:5202750. doi: 10.1155/2019/5202750. eCollection 2019.
• [353] AICAR induces Nrf2 activation by an AMPK-independent mechanism in hepatocarcinoma cells.Biochem Pharmacol. 2014 Sep 15;91(2):168-80. doi: 10.1016/j.bcp.2014.07.010. Epub 2014 Jul 21.
• [354] Carbonic anhydrase 2 inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.Carcinogenesis. 2018 Apr 5;39(4):562-570. doi: 10.1093/carcin/bgx148.
• [355] Downregulation of hepatic multi-drug resistance protein 1 (MDR1) after copper exposure.Metallomics. 2017 Sep 20;9(9):1279-1287. doi: 10.1039/c7mt00189d.
• [356] Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18.J Biol Chem. 2012 Jul 27;287(31):26302-11. doi: 10.1074/jbc.M112.342113. Epub 2012 Jun 8.
• [357] The anticancer effects of cinobufagin on hepatocellular carcinoma Huh?cells are associated with activation of the p73 signaling pathway.Mol Med Rep. 2019 May;19(5):4119-4128. doi: 10.3892/mmr.2019.10108. Epub 2019 Mar 29.
• [358] Butein suppresses hepatocellular carcinoma growth via modulating Aurora B kinase activity.Int J Biol Sci. 2018 Sep 7;14(11):1521-1534. doi: 10.7150/ijbs.25334. eCollection 2018.
• [359] Higher Activity of Alcohol Dehydrogenase Is Correlated with Hepatic Fibrogenesis.J Pharmacol Exp Ther. 2018 Dec;367(3):473-482. doi: 10.1124/jpet.118.249425. Epub 2018 Sep 18.
• [360] Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics.Int J Mol Sci. 2018 Dec 18;19(12):4111. doi: 10.3390/ijms19124111.
• [361] Overexpression of the zinc-2-glycoprotein accelerates apoptosis and inhibits growth via the mTOR/PTEN signaling pathway in gastric carcinoma cells.Life Sci. 2020 Jan 1;240:117117. doi: 10.1016/j.lfs.2019.117117. Epub 2019 Nov 29.
• [362] Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma.J Hepatol. 2000 Apr;32(4):612-7. doi: 10.1016/s0168-8278(00)80223-8.
• [363] Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma.Biochim Biophys Acta. 2013 Dec;1833(12):2970-2979. doi: 10.1016/j.bbamcr.2013.08.001. Epub 2013 Aug 13.
• [364] Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation.Cancer Cell. 2019 Feb 11;35(2):191-203.e8. doi: 10.1016/j.ccell.2018.12.012. Epub 2019 Jan 31.
• [365] LncRNA CRNDE promotes hepatocellular carcinoma cell proliferation, invasion, and migration through regulating miR-203/ BCAT1 axis.J Cell Physiol. 2019 May;234(5):6548-6560. doi: 10.1002/jcp.27396. Epub 2018 Sep 19.
• [366] ACC1 is overexpressed in liver cancers and contributes to the proliferation of human hepatoma Hep G2 cells and the rat liver cell line BRL 3A.Mol Med Rep. 2019 May;19(5):3431-3440. doi: 10.3892/mmr.2019.9994. Epub 2019 Feb 27.
• [367] Copy Number Aberrations of Multiple Genes Identified as Prognostic Markers for Extrahepatic Metastasis-free Survival of Patients with Hepatocellular Carcinoma.Curr Med Sci. 2019 Oct;39(5):759-765. doi: 10.1007/s11596-019-2103-6. Epub 2019 Oct 14.
• [368] miRNA-125a-5p inhibits hepatocellular carcinoma cell proliferation and induces apoptosis by targeting TP53 regulated inhibitor of apoptosis 1 and Bcl-2-like-2 protein.Exp Ther Med. 2019 Aug;18(2):1196-1202. doi: 10.3892/etm.2019.7674. Epub 2019 Jun 14.
• [369] NMI promotes hepatocellular carcinoma progression via BDKRB2 and MAPK/ERK pathway.Oncotarget. 2017 Feb 14;8(7):12174-12185. doi: 10.18632/oncotarget.14556.
• [370] ASB3 knockdown promotes mitochondrial apoptosis via activating the interdependent cleavage of Beclin1 and caspase-8 in hepatocellular carcinoma.Sci China Life Sci. 2019 Dec;62(12):1692-1702. doi: 10.1007/s11427-018-9505-0. Epub 2019 Apr 15.
• [371] MicroRNA Biogenesis is Enhanced by Liposome-Encapsulated Pin1 Inhibitor in Hepatocellular Carcinoma.Theranostics. 2019 Jul 9;9(16):4704-4716. doi: 10.7150/thno.34588. eCollection 2019.
• [372] New insight into BIRC3: A novel prognostic indicator and a potential therapeutic target for liver cancer.J Cell Biochem. 2019 Apr;120(4):6035-6045. doi: 10.1002/jcb.27890. Epub 2018 Oct 28.
• [373] An autophagy-related gene expression signature for survival prediction in multiple cohorts of hepatocellular carcinoma patients.Oncotarget. 2018 Jan 9;9(25):17368-17395. doi: 10.18632/oncotarget.24089. eCollection 2018 Apr 3.
• [374] Bmi1 drives hepatocarcinogenesis by repressing the TGF2/SMAD signalling axis.Oncogene. 2020 Jan;39(5):1063-1079. doi: 10.1038/s41388-019-1043-8. Epub 2019 Oct 7.
• [375] LncRNA HOXA-AS3 Sponges miR-29c to Facilitate Cell Proliferation, Metastasis, and EMT Process and Activate the MEK/ERK Signaling Pathway in Hepatocellular Carcinoma.Hum Gene Ther Clin Dev. 2019 Sep;30(3):129-141. doi: 10.1089/humc.2018.266. Epub 2019 May 17.
• [376] BMP10 suppresses hepatocellular carcinoma progression via PTPRS-STAT3 axis.Oncogene. 2019 Nov;38(48):7281-7293. doi: 10.1038/s41388-019-0943-y. Epub 2019 Aug 15.
• [377] BMP2 secretion from hepatocellular carcinoma cell HepG2 enhances angiogenesis and tumor growth in endothelial cells via activation of the MAPK/p38 signaling pathway.Stem Cell Res Ther. 2019 Aug 6;10(1):237. doi: 10.1186/s13287-019-1301-2.
• [378] CBX8 exhibits oncogenic properties and serves as a prognostic factor in hepatocellular carcinoma.Cell Death Dis. 2019 Jan 18;10(2):52. doi: 10.1038/s41419-018-1288-0.
• [379] Decreased BMP-7 and p-Smad1/5/8 expression, and increased levels of gremlin in hepatocellular carcinoma.Oncol Lett. 2018 Aug;16(2):2113-2118. doi: 10.3892/ol.2018.8918. Epub 2018 Jun 6.
• [380] Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models.Acta Pharmacol Sin. 2009 May;30(5):617-27. doi: 10.1038/aps.2009.33. Epub 2009 Apr 13.
• [381] Prediction of sorafenib treatment-related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation.Eur Radiol. 2019 May;29(5):2272-2282. doi: 10.1007/s00330-018-5882-4. Epub 2018 Dec 13.
• [382] TGF beta gene transcription in normal and neoplastic liver growth.J Cell Biochem. 1989 Apr;39(4):477-87. doi: 10.1002/jcb.240390413.
• [383] Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma.Hepatology. 2019 Jun;69(6):2502-2517. doi: 10.1002/hep.30544. Epub 2019 Apr 16.
• [384] Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.Cancer Lett. 2016 Feb 1;371(1):107-16. doi: 10.1016/j.canlet.2015.11.027. Epub 2015 Nov 24.
• [385] CD317 Activates EGFR by Regulating Its Association with Lipid Rafts.Cancer Res. 2019 May 1;79(9):2220-2231. doi: 10.1158/0008-5472.CAN-18-2603. Epub 2019 Mar 19.
• [386] Abnormal expression and mechanism of miR-330-3p/BTG1 axis in hepatocellular carcinoma.Eur Rev Med Pharmacol Sci. 2019 Aug;23(16):6888-6898. doi: 10.26355/eurrev_201908_18728.
• [387] The prognostic value of LINC01296 in pan-cancers and the molecular regulatory mechanism in hepatocellular carcinoma: a comprehensive study based on data mining, bioinformatics, and in vitro validation.Onco Targets Ther. 2019 Jul 19;12:5861-5885. doi: 10.2147/OTT.S205853. eCollection 2019.
• [388] A silk fibroin based hepatocarcinoma model and the assessment of the drug response in hyaluronan-binding protein 1 overexpressed HepG2 cells.Biomaterials. 2013 Dec;34(37):9462-74. doi: 10.1016/j.biomaterials.2013.08.047. Epub 2013 Sep 7.
• [389] Straightforward and Highly Efficient Strategy for Hepatocellular Carcinoma Glycoprotein Biomarker Discovery Using a Nonglycopeptide-Based Mass Spectrometry Pipeline.Anal Chem. 2019 Oct 1;91(19):12435-12443. doi: 10.1021/acs.analchem.9b03074. Epub 2019 Sep 9.
• [390] C5a receptor enhances hepatocellular carcinoma cell invasiveness via activating ERK1/2-mediated epithelial-mesenchymal transition.Exp Mol Pathol. 2016 Feb;100(1):101-8. doi: 10.1016/j.yexmp.2015.10.001. Epub 2015 Oct 22.
• [391] SSTR5AS1 functions as a ceRNA to regulate CA2 by sponging miR?5b?p for the development and prognosis of HBVrelated hepatocellular carcinoma.Mol Med Rep. 2019 Dec;20(6):5021-5031. doi: 10.3892/mmr.2019.10736. Epub 2019 Oct 11.
• [392] The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma.Life Sci. 2003 Sep 12;73(17):2211-23. doi: 10.1016/s0024-3205(03)00597-6.
• [393] Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model.J Bioenerg Biomembr. 2019 Apr;51(2):121-129. doi: 10.1007/s10863-019-09788-6. Epub 2019 Feb 12.
• [394] Frequent methylation of HOXA9 gene in tumor tissues and plasma samples from human hepatocellular carcinomas.Clin Chem Lab Med. 2014 Aug;52(8):1235-45. doi: 10.1515/cclm-2013-0780.
• [395] Novel variants of voltage-operated calcium channel alpha 1-subunit transcripts in a rat liver-derived cell line: deletion in the IVS4 voltage sensing region.Cell Calcium. 1997 Jul;22(1):39-52. doi: 10.1016/s0143-4160(97)90088-9.
• [396] PBX3 is targeted by multiple miRNAs and is essential for liver tumour-initiating cells.Nat Commun. 2015 Sep 30;6:8271. doi: 10.1038/ncomms9271.
• [397] High-intensity focused ultrasound combined with transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma: A case report.Medicine (Baltimore). 2019 Aug;98(31):e16660. doi: 10.1097/MD.0000000000016660.
• [398] The camKK2/camKIV relay is an essential regulator of hepatic cancer.Hepatology. 2015 Aug;62(2):505-20. doi: 10.1002/hep.27832. Epub 2015 May 9.
• [399] Elevated expression of coactivator-associated arginine methyltransferase 1 is associated with early hepatocarcinogenesis.Oncol Rep. 2013 Oct;30(4):1669-74. doi: 10.3892/or.2013.2651. Epub 2013 Aug 2.
• [400] Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma.Cancer Biol Ther. 2018;19(11):1057-1064. doi: 10.1080/15384047.2018.1480280. Epub 2018 Oct 2.
• [401] Genetic variants in cell death pathway genes and HBV-related hepatocellular carcinoma among a Chinese Han population.Apoptosis. 2017 Aug;22(8):1035-1047. doi: 10.1007/s10495-017-1385-z.
• [402] DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression.J Biol Chem. 2012 Feb 17;287(8):5639-49. doi: 10.1074/jbc.M111.291229. Epub 2011 Nov 23.
• [403] Adoptive cell transfer therapy for hepatocellular carcinoma.Front Med. 2019 Feb;13(1):3-11. doi: 10.1007/s11684-019-0684-x. Epub 2019 Jan 18.
• [404] POH1 contributes to hyperactivation of TGF- signaling and facilitates hepatocellular carcinoma metastasis through deubiquitinating TGF- receptors and caveolin-1.EBioMedicine. 2019 Mar;41:320-332. doi: 10.1016/j.ebiom.2019.01.058. Epub 2019 Feb 7.
• [405] Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma.Int J Biochem Cell Biol. 2013 Nov;45(11):2501-11. doi: 10.1016/j.biocel.2013.08.005. Epub 2013 Aug 15.
• [406] A pharmacological probe identifies cystathionine -synthase as a new negative regulator for ferroptosis.Cell Death Dis. 2018 Sep 26;9(10):1005. doi: 10.1038/s41419-018-1063-2.
• [407] [ARTICLE WITHDRAWN] MicroRNA-18a Targets IRF2 and CBX7 to Promote Cell Proliferation in Hepatocellular Carcinoma.Oncol Res. 2018 Oct 17;26(9):1327-1334. doi: 10.3727/096504018X15165493852990. Epub 2018 Jan 31.
• [408] Long noncoding RNA Linc01296 promotes hepatocellular carcinoma development through regulation of the miR-26a/PTEN axis.Biol Chem. 2020 Feb 25;401(3):407-416. doi: 10.1515/hsz-2019-0231.
• [409] Targeting of cholecystokinin B/gastrin receptor in colonic, pancreatic and hepatocellular carcinoma cell lines.Int J Oncol. 2006 Dec;29(6):1429-35.
• [410] The Diagnostic Value of Chemokine/Chemokine Receptor Pairs in Hepatocellular Carcinoma and Colorectal Liver Metastasis.J Histochem Cytochem. 2019 May;67(5):299-308. doi: 10.1369/0022155418824274. Epub 2019 Jan 11.
• [411] Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression.Int J Cancer. 2006 Apr 15;118(8):1869-76. doi: 10.1002/ijc.21596.
• [412] Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.Hepatology. 2019 Jan;69(1):107-120. doi: 10.1002/hep.30036. Epub 2018 Jul 10.
• [413] CCN1/Cyr61 enhances the function of hepatic stellate cells in promoting the progression of hepatocellular carcinoma.Int J Mol Med. 2018 Mar;41(3):1518-1528. doi: 10.3892/ijmm.2017.3356. Epub 2017 Dec 29.
• [414] Curcumin Suppresses Hepatic Stellate Cell-Induced Hepatocarcinoma Angiogenesis and Invasion through Downregulating CTGF.Oxid Med Cell Longev. 2019 Jan 16;2019:8148510. doi: 10.1155/2019/8148510. eCollection 2019.
• [415] Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress.Nat Commun. 2018 Dec 7;9(1):5235. doi: 10.1038/s41467-018-07552-9.
• [416] Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma.Cancer Cell Int. 2019 Apr 11;19:90. doi: 10.1186/s12935-019-0817-y. eCollection 2019.
• [417] A miR-194/PTBP1/CCND3 axis regulates tumor growth in human hepatocellular carcinoma.J Pathol. 2019 Nov;249(3):395-408. doi: 10.1002/path.5325. Epub 2019 Aug 27.
• [418] CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma.Hepatology. 2019 Jan;69(1):143-159. doi: 10.1002/hep.30134. Epub 2018 Dec 31.
• [419] Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics.Oncotarget. 2017 Jun 28;8(37):62011-62028. doi: 10.18632/oncotarget.18782. eCollection 2017 Sep 22.
• [420] Mitochondrial fission-induced mtDNA stress promotes tumor-associated macrophage infiltration and HCC progression.Oncogene. 2019 Jun;38(25):5007-5020. doi: 10.1038/s41388-019-0772-z. Epub 2019 Mar 20.
• [421] Role of CD200/CD200R Signaling Pathway in Regulation of CD4+T Cell Subsets During Thermal Ablation of Hepatocellular Carcinoma.Med Sci Monit. 2019 Mar 6;25:1718-1728. doi: 10.12659/MSM.913094.
• [422] Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus.Biosci Rep. 2018 Nov 28;38(6):BSR20181423. doi: 10.1042/BSR20181423. Print 2018 Dec 21.
• [423] CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.J Cancer Res Clin Oncol. 2019 May;145(5):1179-1190. doi: 10.1007/s00432-019-02865-8. Epub 2019 Feb 18.
• [424] High expression of B7H2 or B7H3 is associated with poor prognosis in hepatocellular carcinoma.Mol Med Rep. 2019 May;19(5):4315-4325. doi: 10.3892/mmr.2019.10080. Epub 2019 Mar 22.
• [425] A functional insertion/deletion polymorphism in the proximal promoter of CD3G is associated with susceptibility for hepatocellular carcinoma in Chinese population.DNA Cell Biol. 2012 Sep;31(9):1480-5. doi: 10.1089/dna.2012.1706. Epub 2012 Jun 25.
• [426] CPAP promotes angiogenesis and metastasis by enhancing STAT3 activity.Cell Death Differ. 2020 Apr;27(4):1259-1273. doi: 10.1038/s41418-019-0413-7. Epub 2019 Sep 11.
• [427] HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-Mediated Anti-Tumorigenesis and Phagocytosis of Hepatocellular Carcinoma.Hepatology. 2019 Oct;70(4):1262-1279. doi: 10.1002/hep.30657. Epub 2019 May 21.
• [428] Hepatitis B virus X protein activates CD59 involving DNA binding and let-7i in protection of hepatoma and hepatic cells from complement attack.Carcinogenesis. 2011 Aug;32(8):1190-7. doi: 10.1093/carcin/bgr106. Epub 2011 Jun 10.
• [429] Independent modes of disease repair by AIM protein distinguished in AIM-felinized mice.Sci Rep. 2018 Sep 3;8(1):13157. doi: 10.1038/s41598-018-31580-6.
• [430] Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma.Int J Cancer. 2005 Jun 10;115(2):231-40. doi: 10.1002/ijc.20860.
• [431] Myrothecine A modulates the proliferation of HCC cells and the maturation of dendritic cells through downregulating miR-221.Int Immunopharmacol. 2019 Oct;75:105783. doi: 10.1016/j.intimp.2019.105783. Epub 2019 Jul 31.
• [432] Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs.Oncotarget. 2016 May 31;7(22):32493-503. doi: 10.18632/oncotarget.8679.
• [433] Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma.Hepatology. 2019 Jul;70(1):168-183. doi: 10.1002/hep.30347. Epub 2019 Mar 5.
• [434] Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma.Hepatology. 2007 Dec;46(6):1810-20. doi: 10.1002/hep.21893.
• [435] Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol. 2008 Mar;61(3):377-93. doi: 10.1007/s00280-007-0480-1. Epub 2007 May 23.
• [436] Generation and Validation of miR-100 Hepatocyte-Specific Knock-Out Mice.Front Oncol. 2019 Jun 26;9:535. doi: 10.3389/fonc.2019.00535. eCollection 2019.
• [437] SNHG16 as the miRNA let-7b-5p sponge facilitates the G2/M and epithelial-mesenchymal transition by regulating CDC25B and HMGA2 expression in hepatocellular carcinoma.J Cell Biochem. 2020 Mar;121(3):2543-2558. doi: 10.1002/jcb.29477. Epub 2019 Nov 7.
• [438] Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth.Liver Int. 2015 Apr;35(4):1403-15. doi: 10.1111/liv.12651. Epub 2014 Aug 25.
• [439] Neural cadherin overexpression is a predictive marker for early postoperative recurrence in hepatocellular carcinoma patients.J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 1):1112-8. doi: 10.1111/j.1440-1746.2007.05182.x. Epub 2007 Oct 17.
• [440] Integrated analysis of lncRNA-associated ceRNA network reveals potential biomarkers for the prognosis of hepatitis B virus-related hepatocellular carcinoma.Cancer Manag Res. 2019 Jan 17;11:877-897. doi: 10.2147/CMAR.S186561. eCollection 2019.
• [441] CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.Gut. 2020 Apr;69(4):727-736. doi: 10.1136/gutjnl-2019-318506. Epub 2019 Sep 13.
• [442] Insight into the molecular mechanism of LINC00152/miR-215/CDK13 axis in hepatocellular carcinoma progression.J Cell Biochem. 2019 Nov;120(11):18816-18825. doi: 10.1002/jcb.29197. Epub 2019 Jul 11.
• [443] Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells.Cancer Biol Ther. 2020;21(3):269-277. doi: 10.1080/15384047.2019.1685289. Epub 2019 Nov 21.
• [444] Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.Hepatology. 2019 Jan;69(1):376-393. doi: 10.1002/hep.30190. Epub 2018 Dec 22.
• [445] Circ-ZEB1.33 promotes the proliferation of human HCC by sponging miR-200a-3p and upregulating CDK6.Cancer Cell Int. 2018 Aug 13;18:116. doi: 10.1186/s12935-018-0602-3. eCollection 2018.
• [446] Identification of a 3,3-difluorinated tetrahydropyridinol compound as a novel antitumor agent for hepatocellular carcinoma acting via cell cycle arrest through disturbing CDK7-mediated phosphorylation of Cdc2.Invest New Drugs. 2020 Apr;38(2):287-298. doi: 10.1007/s10637-019-00792-6. Epub 2019 May 11.
• [447] Clinical significance of aberrant cyclin-dependent kinase-like 2 methylation in hepatocellular carcinoma.Gene. 2019 Jan 30;683:35-40. doi: 10.1016/j.gene.2018.10.009. Epub 2018 Oct 5.
• [448] LncRNA FOXD2-AS1 plays an oncogenic role in hepatocellular carcinoma through epigenetically silencing CDKN1B(p27) via EZH2.Exp Cell Res. 2019 Jul 15;380(2):198-204. doi: 10.1016/j.yexcr.2019.04.016. Epub 2019 Apr 17.
• [449] P57-mediated autophagy promotes the efficacy of EGFR inhibitors in hepatocellular carcinoma.Liver Int. 2019 Jan;39(1):147-157. doi: 10.1111/liv.13957. Epub 2018 Oct 8.
• [450] Apoptosis of hepatocarcinoma cells Hepg2 induced by Huaier extract through regulation of HBx and CEACAM1 gene expression..J Biol Regul Homeost Agents. 2018 Nov-Dec;32(6):1389-1398.
• [451] Serum Biomarkers AFP, CEA and CA19-9 Combined Detection for Early Diagnosis of Hepatocellular Carcinoma.Iran J Public Health. 2019 Feb;48(2):314-322.
• [452] C/EBP Regulates FOXC1 to Modulate Tumor Growth by Interacting with PPAR in Hepatocellular Carcinoma.Curr Cancer Drug Targets. 2020;20(1):59-66. doi: 10.2174/1568009619666190912161003.
• [453] Mechanisms involved in the activation of C/EBP by small activating RNA in hepatocellular carcinoma.Oncogene. 2019 May;38(18):3446-3457. doi: 10.1038/s41388-018-0665-6. Epub 2019 Jan 14.
• [454] Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma.Oncogene. 2016 Dec 8;35(49):6271-6280. doi: 10.1038/onc.2016.162. Epub 2016 May 2.
• [455] GSK923295 as a potential antihepatocellular carcinoma agent causing delay on liver regeneration after partial hepatectomy.Chin Med J (Engl). 2019 Feb 5;132(3):311-318. doi: 10.1097/CM9.0000000000000053.
• [456] Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma from other liver diseases in Korean patients.Int J Cancer. 2013 Jul 15;133(2):408-15. doi: 10.1002/ijc.28020. Epub 2013 Feb 13.
• [457] Biosynthesis and postsynthetic processing of human C3b/C4b inactivator (factor I) in three hepatoma cell lines.J Biol Chem. 1984 May 25;259(10):6492-7.
• [458] Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stressrelated autophagy in hepatocellular carcinoma.Oncol Rep. 2018 Oct;40(4):2206-2214. doi: 10.3892/or.2018.6606. Epub 2018 Jul 27.
• [459] Choline Kinase Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.Gastroenterology. 2017 Apr;152(5):1187-1202. doi: 10.1053/j.gastro.2016.12.033. Epub 2017 Jan 5.
• [460] Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.Cancer Res. 2011 Dec 1;71(23):7270-9. doi: 10.1158/0008-5472.CAN-11-1161. Epub 2011 Oct 11.
• [461] Induction of Apoptosis by Tithonia diversifolia in Human Hepatoma Cells.Pharmacogn Mag. 2017 Oct-Dec;13(52):702-706. doi: 10.4103/0973-1296.218113. Epub 2017 Nov 13.
• [462] Hepatitis B virus X protein induces IKK nuclear translocation via Akt-dependent phosphorylation to promote the motility of hepatocarcinoma cells.J Cell Physiol. 2012 Apr;227(4):1446-54. doi: 10.1002/jcp.22860.
• [463] Chloride channel 3 (CIC-3) predicts the tumor size in hepatocarcinoma.Acta Histochem. 2019 Apr;121(3):284-288. doi: 10.1016/j.acthis.2019.01.006. Epub 2019 Jan 22.
• [464] Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival.In Vivo. 2014 May-Jun;28(3):315-26.
• [465] Differential expression of candidate virus receptors in human T lymphocytes prone or resistant to infection with patient-derived hepatitis C virus.PLoS One. 2013 Apr 23;8(4):e62159. doi: 10.1371/journal.pone.0062159. Print 2013.
• [466] Clic1 plays a role in mouse hepatocarcinoma via modulating Annexin A7 and Gelsolin in vitro and in vivo.Biomed Pharmacother. 2015 Feb;69:416-9. doi: 10.1016/j.biopha.2014.11.019. Epub 2014 Nov 24.
• [467] Overexpression of CLN3 contributes to tumour progression and predicts poor prognosis in hepatocellular carcinoma.Surg Oncol. 2019 Mar;28:180-189. doi: 10.1016/j.suronc.2018.12.003. Epub 2018 Dec 20.
• [468] Regulation of Acetate Utilization by Monocarboxylate Transporter 1 (MCT1) in Hepatocellular Carcinoma (HCC).Oncol Res. 2018 Jan 19;26(1):71-81. doi: 10.3727/096504017X14902648894463. Epub 2017 Mar 23.
• [469] Endocannabinoid system and the expression of endogenous ceramides in human hepatocellular carcinoma.Oncol Lett. 2019 Aug;18(2):1530-1538. doi: 10.3892/ol.2019.10399. Epub 2019 May 27.
• [470] Suramin inhibits the stimulation of acute phase plasma protein genes by IL-6-type cytokines in rat hepatoma cells.J Immunol. 1993 Aug 1;151(3):1456-62.
• [471] Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females.Cancer Lett. 2004 Aug 30;212(2):195-201. doi: 10.1016/j.canlet.2004.04.032.
• [472] CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing -Catenin Ubiquitination.Dig Dis Sci. 2018 Jan;63(1):155-165. doi: 10.1007/s10620-017-4855-9. Epub 2017 Nov 30.
• [473] Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells.Thromb Haemost. 2011 Jun;105(6):999-1009. doi: 10.1160/TH10-06-0413. Epub 2011 Apr 20.
• [474] Integrated analysis of whole genome and transcriptome sequencing reveals diverse transcriptomic aberrations driven by somatic genomic changes in liver cancers.PLoS One. 2014 Dec 19;9(12):e114263. doi: 10.1371/journal.pone.0114263. eCollection 2014.
• [475] Genetic polymorphisms in complement receptor 1 gene and its association with HBV-related liver disease: A case-control study.Gene. 2019 Mar 10;688:107-118. doi: 10.1016/j.gene.2018.11.082. Epub 2018 Dec 5.
• [476] Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions.J Med Chem. 2019 Mar 14;62(5):2508-2520. doi: 10.1021/acs.jmedchem.8b01826. Epub 2019 Feb 22.
• [477] Epigenetic upregulation and functional role of the mitochondrial aspartate/glutamate carrier isoform 1 in hepatocellular carcinoma. Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):38-47.
• [478] Decreased CRHBP expression is predictive of poor prognosis in patients with hepatocellular carcinoma.Oncol Lett. 2018 Sep;16(3):3681-3689. doi: 10.3892/ol.2018.9073. Epub 2018 Jul 4.
• [479] An intronic polymorphism in the corticotropin-releasing hormone receptor 2 gene increases susceptibility to HBV-related hepatocellular carcinoma in Chinese population.Hum Genet. 2010 Jan;127(1):75-81. doi: 10.1007/s00439-009-0750-6. Epub 2009 Oct 8.
• [480] Functional polymorphisms of circadian negative feedback regulation genes are associated with clinical outcome in hepatocellular carcinoma patients receiving radical resection.Med Oncol. 2014 Dec;31(12):179. doi: 10.1007/s12032-014-0179-1. Epub 2014 Oct 26.
• [481] NAD(P)H: Quinone oxidoreductase 1 overexpression in hepatocellular carcinoma potentiates apoptosis evasion through regulating stabilization of X-linked inhibitor of apoptosis protein.Cancer Lett. 2019 Jun 1;451:156-167. doi: 10.1016/j.canlet.2019.02.053. Epub 2019 Mar 10.
• [482] The food contaminant acetamide is not an in vivo clastogen, aneugen, or mutagen in rodent hematopoietic tissue.Regul Toxicol Pharmacol. 2019 Nov;108:104451. doi: 10.1016/j.yrtph.2019.104451. Epub 2019 Aug 27.
• [483] Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.Gut. 2019 Sep;68(9):1653-1666. doi: 10.1136/gutjnl-2019-318419. Epub 2019 Mar 22.
• [484] Targeted sequencing of cancer-associated genes in hepatocellular carcinoma using next-generation sequencing.Oncol Lett. 2018 Jan;15(1):528-532. doi: 10.3892/ol.2017.7334. Epub 2017 Nov 2.
• [485] Integrin 9 Suppresses Hepatocellular Carcinoma Metastasis by Rho GTPase Signaling.J Immunol Res. 2018 May 24;2018:4602570. doi: 10.1155/2018/4602570. eCollection 2018.
• [486] Hypoxia disrupts the expression levels of circadian rhythm genes in hepatocellular carcinoma.Mol Med Rep. 2015 May;11(5):4002-8. doi: 10.3892/mmr.2015.3199. Epub 2015 Jan 14.
• [487] Oncogenic potential of CK2 and its regulatory role in EGF-induced HDAC2 expression in human liver cancer.FEBS J. 2014 Feb;281(3):851-61. doi: 10.1111/febs.12652.
• [488] Potential therapeutic value of dendritic cells loaded with NYESO? protein for the immunotherapy of advanced hepatocellular carcinoma.Int J Mol Med. 2013 Dec;32(6):1366-72. doi: 10.3892/ijmm.2013.1510. Epub 2013 Sep 27.
• [489] BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.Cancer Lett. 2017 Sep 10;403:165-174. doi: 10.1016/j.canlet.2017.06.017. Epub 2017 Jun 20.
• [490] Sp1 is involved in regulation of cystathionine -lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines.Cell Signal. 2012 Jun;24(6):1229-40. doi: 10.1016/j.cellsig.2012.02.003. Epub 2012 Feb 13.
• [491] Immunotherapy for hepatocellular carcinoma.Cancer Lett. 2020 Feb 1;470:8-17. doi: 10.1016/j.canlet.2019.12.002. Epub 2019 Dec 4.
• [492] SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1 and -2 in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets.Cancers (Basel). 2019 Dec 4;11(12):1933. doi: 10.3390/cancers11121933.
• [493] Tissue Levels of Stefin A and Stefin B in Hepatocellular Carcinoma.Anat Rec (Hoboken). 2016 Apr;299(4):428-38. doi: 10.1002/ar.23311. Epub 2016 Feb 8.
• [494] Cathepsin H regulated by the thyroid hormone receptors associate with tumor invasion in human hepatoma cells.Oncogene. 2011 Apr 28;30(17):2057-69. doi: 10.1038/onc.2010.585. Epub 2011 Jan 10.
• [495] Increased expression of cathepsin L: a novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients.PLoS One. 2014 Nov 10;9(11):e112136. doi: 10.1371/journal.pone.0112136. eCollection 2014.
• [496] Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma.Hepatology. 2014 Jul;60(1):179-91. doi: 10.1002/hep.27070. Epub 2014 May 29.
• [497] Cullin7: a new gene involved in liver carcinogenesis related to metabolic syndrome.Gut. 2013 Jun;62(6):911-9. doi: 10.1136/gutjnl-2012-302091. Epub 2012 Sep 1.
• [498] Lack of association between the functional CX3CR1 polymorphism V249I and hepatocellular carcinoma.Oncol Rep. 2005 May;13(5):957-63.
• [499] Receptor-Interacting Protein Kinase 3 Deficiency Recruits Myeloid-Derived Suppressor Cells to Hepatocellular Carcinoma Through the Chemokine (C-X-C Motif) Ligand 1-Chemokine (C-X-C Motif) Receptor 2 Axis.Hepatology. 2019 Nov;70(5):1564-1581. doi: 10.1002/hep.30676. Epub 2019 Jul 17.
• [500] Peri-tumor associated fibroblasts promote intrahepatic metastasis of hepatocellular carcinoma by recruiting cancer stem cells.Cancer Lett. 2017 Sep 28;404:19-28. doi: 10.1016/j.canlet.2017.07.006. Epub 2017 Jul 15.
• [501] CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4(+) T-Cell-Dependent Control of Senescence.Gastroenterology. 2019 May;156(6):1877-1889.e4. doi: 10.1053/j.gastro.2019.01.247. Epub 2019 Jan 30.
• [502] The 5'-flanking region of the human P-450(SCC) gene shows responsiveness to cAMP-dependent regulation in a transient gene-expression system of Y-1 adrenal tumor cells.Eur J Biochem. 1988 Feb 1;171(3):435-40. doi: 10.1111/j.1432-1033.1988.tb13808.x.
• [503] Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma.Oncotarget. 2017 Jun 13;8(24):38592-38601. doi: 10.18632/oncotarget.16951.
• [504] Hepatic CYP1A2 activity in liver tumors and the implications for preoperative volume-function analysis.Am J Physiol Gastrointest Liver Physiol. 2019 May 1;316(5):G608-G614. doi: 10.1152/ajpgi.00335.2018. Epub 2019 Mar 14.
• [505] Polymorphisms of the CYP1B1 gene and hepatocellular carcinoma risk in a Chinese population.Gene. 2015 Jun 10;564(1):14-20. doi: 10.1016/j.gene.2015.03.035. Epub 2015 Mar 18.
• [506] Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma.Nat Genet. 2013 Jan;45(1):72-5. doi: 10.1038/ng.2483. Epub 2012 Dec 16.
• [507] Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy.PLoS One. 2012;7(9):e45063. doi: 10.1371/journal.pone.0045063. Epub 2012 Sep 12.
• [508] Microarray analysis for the identification of specific proteins and functional modules involved in the process of hepatocellular carcinoma originating from cirrhotic liver.Mol Med Rep. 2018 Apr;17(4):5619-5626. doi: 10.3892/mmr.2018.8555. Epub 2018 Feb 2.
• [509] The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma.Cancer Med. 2018 Apr;7(4):966-980. doi: 10.1002/cam4.1299. Epub 2018 Feb 26.
• [510] Prediction and analysis of weighted genes in hepatocellular carcinoma using bioinformatics analysis.Mol Med Rep. 2019 Apr;19(4):2479-2488. doi: 10.3892/mmr.2019.9929. Epub 2019 Feb 4.
• [511] Stable expression of human cytochrome P450 2D6*10 in HepG2 cells.World J Gastroenterol. 2004 Jan 15;10(2):234-7. doi: 10.3748/wjg.v10.i2.234.
• [512] The inhibitory potential of Broussochalcone A for the human cytochrome P450 2J2 isoform and its anti-cancer effects via FOXO3 activation.Phytomedicine. 2018 Mar 15;42:199-206. doi: 10.1016/j.phymed.2018.03.032. Epub 2018 Mar 19.
• [513] CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma.Pharmacogenomics. 2019 Oct;20(15):1085-1092. doi: 10.2217/pgs-2019-0094.
• [514] Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.Oncol Rep. 2012 Oct;28(4):1193-9. doi: 10.3892/or.2012.1910. Epub 2012 Jul 13.
• [515] Cytohesin-2 as a novel prognostic marker for hepatocellular carcinoma.Oncol Rep. 2013 Jun;29(6):2211-8. doi: 10.3892/or.2013.2366. Epub 2013 Mar 26.
• [516] sZIP, an alternative splice variant of ZIP, antagonizes transcription repression and growth inhibition by ZIP.J Biol Chem. 2010 May 7;285(19):14301-7. doi: 10.1074/jbc.M110.107508. Epub 2010 Mar 16.
• [517] SETD3 is regulated by a couple of microRNAs and plays opposing roles in proliferation and metastasis of hepatocellular carcinoma.Clin Sci (Lond). 2019 Oct 30;133(20):2085-2105. doi: 10.1042/CS20190666.
• [518] Mallory-Denk bodies form when EZH2/H3K27me3 fails to methylate DNA in the nuclei of human and mice liver cells.Exp Mol Pathol. 2012 Jun;92(3):318-26. doi: 10.1016/j.yexmp.2012.02.003. Epub 2012 Mar 21.
• [519] Complement C1q stimulates the progression of hepatocellular tumor through the activation of discoidin domain receptor 1.Sci Rep. 2018 Mar 20;8(1):4908. doi: 10.1038/s41598-018-23240-6.
• [520] Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.PLoS One. 2018 Jul 26;13(7):e0200633. doi: 10.1371/journal.pone.0200633. eCollection 2018.
• [521] Ftx non coding RNA-derived miR-545 promotes cell proliferation by targeting RIG-I in hepatocellular carcinoma.Oncotarget. 2016 May 3;7(18):25350-65. doi: 10.18632/oncotarget.8129.
• [522] High expression of DEK is associated with poor prognosis in hepatocellular carcinoma.Histol Histopathol. 2019 Nov;34(11):1279-1288. doi: 10.14670/HH-18-125. Epub 2019 May 8.
• [523] DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis.Cancer Sci. 2019 Jan;110(1):157-165. doi: 10.1111/cas.13867. Epub 2018 Dec 13.
• [524] High-frequency Alu-mediated genomic recombination/deletion within the caspase-activated DNase gene in human hepatoma.Oncogene. 2005 Sep 29;24(43):6584-9. doi: 10.1038/sj.onc.1208803.
• [525] Quantitative free-breathing dynamic contrast-enhanced MRI in hepatocellular carcinoma using gadoxetic acid: correlations with Ki67 proliferation status, histological grades, and microvascular density.Abdom Radiol (NY). 2018 Jun;43(6):1393-1403. doi: 10.1007/s00261-017-1320-3.
• [526] The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma.Front Pharmacol. 2018 Nov 6;9:1298. doi: 10.3389/fphar.2018.01298. eCollection 2018.
• [527] Astrocyte Elevated Gene-1 (AEG-1) Contributes to Non-thyroidal Illness Syndrome (NTIS) Associated with Hepatocellular Carcinoma (HCC).J Biol Chem. 2015 Jun 19;290(25):15549-15558. doi: 10.1074/jbc.M115.649707. Epub 2015 May 5.
• [528] MicroRNA-197 Promotes Metastasis of Hepatocellular Carcinoma by Activating Wnt/-Catenin Signaling.Cell Physiol Biochem. 2018;51(1):470-486. doi: 10.1159/000495242. Epub 2018 Nov 19.
• [529] A Phase I/Ib trial of Ad-REIC in liver cancer: study protocol.Future Oncol. 2019 Nov;15(31):3547-3554. doi: 10.2217/fon-2019-0115. Epub 2019 Oct 30.
• [530] Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2.Oncogene. 2016 Feb 11;35(6):715-26. doi: 10.1038/onc.2015.122. Epub 2015 Apr 20.
• [531] Overexpression of protein O-fucosyltransferase 1 accelerates hepatocellular carcinoma progression via the Notch signaling pathway.Biochem Biophys Res Commun. 2016 Apr 29;473(2):503-10. doi: 10.1016/j.bbrc.2016.03.062. Epub 2016 Mar 18.
• [532] Expression of delta-like 3 is downregulated by aberrant DNA methylation and histone modification in hepatocellular carcinoma.Oncol Rep. 2018 May;39(5):2209-2216. doi: 10.3892/or.2018.6293. Epub 2018 Mar 5.
• [533] The expression profile of Jagged1 and Delta-like 4 in hepatocellular carcinoma.Asian Pac J Allergy Immunol. 2021 Mar;39(1):44-52. doi: 10.12932/AP-040818-0388.
• [534] Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings.Semin Diagn Pathol. 2017 Mar;34(2):146-152. doi: 10.1053/j.semdp.2016.12.010. Epub 2016 Dec 23.
• [535] Systematical analyses of variants in DNase I hypersensitive sites to identify hepatocellular carcinoma susceptibility loci in a Chinese population.J Gastroenterol Hepatol. 2017 Nov;32(11):1887-1894. doi: 10.1111/jgh.13790.
• [536] Grb2 dominantly associates with dynamin II in human hepatocellular carcinoma HepG2 cells.J Cell Biochem. 2001;84(1):150-5. doi: 10.1002/jcb.1275.
• [537] Contribution of Molecular Structure to Self-Assembling and Biological Properties of Bifunctional Lipid-Like 4-(N-Alkylpyridinium)-1,4-Dihydropyridines.Pharmaceutics. 2019 Mar 12;11(3):115. doi: 10.3390/pharmaceutics11030115.
• [538] Targeting DTL induces cell cycle arrest and senescence and suppresses cell growth and colony formation through TPX2 inhibition in human hepatocellular carcinoma cells.Onco Targets Ther. 2018 Mar 21;11:1601-1616. doi: 10.2147/OTT.S147453. eCollection 2018.
• [539] Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.J Hepatol. 2015 Jun;62(6):1278-86. doi: 10.1016/j.jhep.2014.12.033. Epub 2015 Jan 21.
• [540] MKP-4 suppresses hepatocarcinogenesis by targeting ERK1/2 pathway.Cancer Cell Int. 2019 Mar 18;19:61. doi: 10.1186/s12935-019-0776-3. eCollection 2019.
• [541] dUTP pyrophosphatase expression correlates with a poor prognosis in hepatocellular carcinoma.Liver Int. 2010 Mar;30(3):438-46. doi: 10.1111/j.1478-3231.2009.02177.x. Epub 2009 Nov 30.
• [542] miR-214/199a/199a* cluster levels predict poor survival in hepatocellular carcinoma through interference with cell-cycle regulators.Oncotarget. 2016 Jan 5;7(1):929-45. doi: 10.18632/oncotarget.6137.
• [543] Functional characterization of E2F3b in human HepG2 liver cancer cell line.J Cell Biochem. 2018 Apr;119(4):3429-3439. doi: 10.1002/jcb.26513. Epub 2017 Dec 26.
• [544] The clinical significance of endothelin receptor type B in hepatocellular carcinoma and its potential molecular mechanism.Exp Mol Pathol. 2019 Apr;107:141-157. doi: 10.1016/j.yexmp.2019.02.002. Epub 2019 Feb 12.
• [545] Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3.Int J Cancer. 2020 Mar 1;146(5):1383-1395. doi: 10.1002/ijc.32560. Epub 2019 Jul 22.
• [546] EGFL7 promotes hepatocellular carcinoma cell proliferation and inhibits cell apoptosis through increasing CKS2 expression by activating Wnt/-catenin signaling.J Cell Biochem. 2018 Dec;119(12):10327-10337. doi: 10.1002/jcb.27375. Epub 2018 Aug 20.
• [547] Gamma linolenic acid regulates PHD2 mediated hypoxia and mitochondrial apoptosis in DEN induced hepatocellular carcinoma.Drug Des Devel Ther. 2018 Dec 13;12:4241-4252. doi: 10.2147/DDDT.S178519. eCollection 2018.
• [548] CD24 isoform a promotes cell proliferation, migration and invasion and is downregulated by EGR1 in hepatocellular carcinoma.Onco Targets Ther. 2019 Feb 28;12:1705-1716. doi: 10.2147/OTT.S196506. eCollection 2019.
• [549] The role of autophagy in hepatocellular carcinoma: friend or foe.Oncotarget. 2017 Apr 18;8(34):57707-57722. doi: 10.18632/oncotarget.17202. eCollection 2017 Aug 22.
• [550] O-GlcNAc transferase activates stem-like cell potential in hepatocarcinoma through O-GlcNAcylation of eukaryotic initiation factor 4E.J Cell Mol Med. 2019 Apr;23(4):2384-2398. doi: 10.1111/jcmm.14043. Epub 2019 Jan 24.
• [551] A rapid and robust assay for the determination of the amino acid hypusine as a possible biomarker for a high-throughput screening of antimalarials and for the diagnosis and therapy of different diseases.Amino Acids. 2012 May;42(5):1651-9. doi: 10.1007/s00726-011-0859-5. Epub 2011 Mar 1.
• [552] Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis.Stem Cells. 2018 Feb;36(2):180-191. doi: 10.1002/stem.2734. Epub 2017 Nov 20.
• [553] Contact System Activation and Neutrophil Extracellular Trap Markers: Risk Factors for Portal Vein Thrombosis in Patients With Hepatocellular Carcinoma.Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029618825310. doi: 10.1177/1076029618825310.
• [554] WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.Mol Cancer. 2019 Aug 22;18(1):127. doi: 10.1186/s12943-019-1053-8.
• [555] Effect of NET-1 siRNA conjugated sub-micron bubble complex combined with low-frequency ultrasound exposure in gene transfection.Oncotarget. 2017 Dec 23;9(3):4150-4160. doi: 10.18632/oncotarget.23646. eCollection 2018 Jan 9.
• [556] ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.Lung Cancer. 2013 Jun;80(3):278-83. doi: 10.1016/j.lungcan.2013.01.019. Epub 2013 Feb 27.
• [557] Engagement with tNOX (ENOX2) to Inhibit SIRT1 and Activate p53-Dependent and -Independent Apoptotic Pathways by Novel 4,11-Diaminoanthra[2,3-b]furan-5,10-diones in Hepatocellular Carcinoma Cells.Cancers (Basel). 2019 Mar 24;11(3):420. doi: 10.3390/cancers11030420.
• [558] Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.J Hepatol. 2017 May;66(5):919-929. doi: 10.1016/j.jhep.2017.01.009. Epub 2017 Jan 23.
• [559] EphA1 activation promotes the homing of endothelial progenitor cells to hepatocellular carcinoma for tumor neovascularization through the SDF-1/CXCR4 signaling pathway.J Exp Clin Cancer Res. 2016 Apr 11;35:65. doi: 10.1186/s13046-016-0339-6.
• [560] Deregulation of miR-520d-3p promotes hepatocellular carcinoma development via lncRNA MIAT regulation and EPHA2 signaling activation.Biomed Pharmacother. 2019 Jan;109:1630-1639. doi: 10.1016/j.biopha.2018.11.014. Epub 2018 Nov 16.
• [561] Short Proline-Rich Lipopeptide Potentiates Minocycline and Rifampin against Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa.Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02374-17. doi: 10.1128/AAC.02374-17. Print 2018 Apr.
• [562] Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma.Tumour Biol. 2016 Aug;37(8):11429-41. doi: 10.1007/s13277-016-4892-6. Epub 2016 Mar 22.
• [563] Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type-A Receptor 5 Kinases in Hepatocellular Carcinoma.Hepatology. 2019 Feb;69(2):573-586. doi: 10.1002/hep.29792. Epub 2018 Mar 24.
• [564] A novel protein-tyrosine kinase, tec, is preferentially expressed in liver.Oncogene. 1990 Dec;5(12):1781-6.
• [565] KCNN4 promotes invasion and metastasis through the MAPK/ERK pathway in hepatocellular carcinoma.J Investig Med. 2020 Jan;68(1):68-74. doi: 10.1136/jim-2019-001073. Epub 2019 Aug 19.
• [566] Antineoplastic influence of nimesulide in chemically induced hepatocellular carcinoma by inhibition of DNA synthesis.Inflammopharmacology. 2019 Feb;27(1):89-98. doi: 10.1007/s10787-018-0481-1. Epub 2018 May 4.
• [567] Brucine Suppresses Vasculogenic Mimicry in Human Triple-Negative Breast Cancer Cell Line MDA-MB-231.Biomed Res Int. 2019 Jan 6;2019:6543230. doi: 10.1155/2019/6543230. eCollection 2019.
• [568] Erythropoietin promoted the proliferation of hepatocellular carcinoma through hypoxia induced translocation of its specific receptor.Cancer Cell Int. 2017 Dec 11;17:119. doi: 10.1186/s12935-017-0494-7. eCollection 2017.
• [569] ErbB4 acts as a suppressor in colitis and its associated carcinoma by negatively regulating cholesterol metabolism.Carcinogenesis. 2019 Jul 4;40(5):680-686. doi: 10.1093/carcin/bgy164.
• [570] Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4.Cancer Cell. 2012 Apr 17;21(4):504-16. doi: 10.1016/j.ccr.2012.02.007.
• [571] IRE1-XBP1 signaling pathway regulates IL-6 expression and promotes progression of hepatocellular carcinoma.Oncol Lett. 2018 Oct;16(4):4729-4736. doi: 10.3892/ol.2018.9176. Epub 2018 Jul 19.
• [572] Loss of the orphan nuclear receptor SHP is more pronounced in fibrolamellar carcinoma than in typical hepatocellular carcinoma.PLoS One. 2012;7(1):e30944. doi: 10.1371/journal.pone.0030944. Epub 2012 Jan 23.
• [573] Estrogen-related receptor is upregulated in liver cancer and its inhibition suppresses liver cancer cell proliferation via induction of p21 and p27.Exp Mol Med. 2016 Mar 4;48(3):e213. doi: 10.1038/emm.2015.115.
• [574] ETS1 is coexpressed with ZEB2 and mediates ZEB2-induced epithelial-mesenchymal transition in human tumors.Mol Carcinog. 2019 Jun;58(6):1068-1081. doi: 10.1002/mc.22994. Epub 2019 Mar 6.
• [575] Analysis of differentially co-expressed genes based on microarray data of hepatocellular carcinoma.Neoplasma. 2017;64(2):216-221. doi: 10.4149/neo_2017_207.
• [576] Cancer-Associated Fibroblasts Promote Angiogenesis of Hepatocellular Carcinoma by VEGF-Mediated EZH2/VASH1 Pathway.Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819879905. doi: 10.1177/1533033819879905.
• [577] Effects of arsenic trioxide on the expression of ezrin in hepatocellular carcinoma.Medicine (Baltimore). 2017 Sep;96(35):e7602. doi: 10.1097/MD.0000000000007602.
• [578] A new HIF-1/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice.Hepatology. 2016 May;63(5):1576-91. doi: 10.1002/hep.28468. Epub 2016 Mar 7.
• [579] Unique Biological Activity and Potential Role of Monomeric Laminin-2 as a Novel Biomarker for Hepatocellular Carcinoma: A Review.Int J Mol Sci. 2019 Jan 8;20(1):226. doi: 10.3390/ijms20010226.
• [580] Glypican-3 and Hep Par-1 are Useful Biomarkers in the Cytologic Assessment of Ascites.Appl Immunohistochem Mol Morphol. 2019 Jan;27(1):65-69. doi: 10.1097/PAI.0000000000000548.
• [581] Increased expression of protease-activated receptors 2 indicates poor prognosis in HBV related hepatocellular carcinoma.Infect Agent Cancer. 2019 Nov 21;14:39. doi: 10.1186/s13027-019-0256-3. eCollection 2019.
• [582] Proteinase-activated receptor 1- and 4-promoted migration of Hep3B hepatocellular carcinoma cells depends on ROS formation and RTK transactivation.J Cancer Res Clin Oncol. 2015 May;141(5):813-25. doi: 10.1007/s00432-014-1863-4. Epub 2014 Nov 6.
• [583] Targeting TF-AKT/ERK-EGFR Pathway Suppresses the Growth of Hepatocellular Carcinoma.Front Oncol. 2019 Mar 15;9:150. doi: 10.3389/fonc.2019.00150. eCollection 2019.
• [584] Thrombosis after liver transplantation for hepatocellular carcinoma.PLoS One. 2017 Oct 26;12(10):e0186699. doi: 10.1371/journal.pone.0186699. eCollection 2017.
• [585] HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.Cell Physiol Biochem. 2018;50(6):2124-2138. doi: 10.1159/000495056. Epub 2018 Nov 9.
• [586] Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma.Liver Int. 2018 Jun;38(6):1074-1083. doi: 10.1111/liv.13639. Epub 2017 Dec 22.
• [587] Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome.Oncogene. 2019 Apr;38(16):3033-3046. doi: 10.1038/s41388-018-0597-1. Epub 2018 Dec 21.
• [588] Fatty acid binding protein 5 promotes tumor angiogenesis and activates the IL6/STAT3/VEGFA pathway in hepatocellular carcinoma.Biomed Pharmacother. 2018 Oct;106:68-76. doi: 10.1016/j.biopha.2018.06.040. Epub 2018 Jun 26.
• [589] Transcriptome analysis of hepatitis B virus-associated small hepatocellular carcinoma by serial analysis of gene expression.Int J Oncol. 2009 Jul;35(1):129-37. doi: 10.3892/ijo_00000321.
• [590] FAM83D is associated with gender, AJCC stage, overall survival and disease-free survival in hepatocellular carcinoma.Biosci Rep. 2019 May 7;39(5):BSR20181640. doi: 10.1042/BSR20181640. Print 2019 May 31.
• [591] Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: A biopsy and resection matched study.Oncotarget. 2017 Oct 26;8(59):99359-99371. doi: 10.18632/oncotarget.22078. eCollection 2017 Nov 21.
• [592] Samsum Ant Venom Exerts Anticancer Activity Through Immunomodulation In Vitro and In Vivo.Cancer Biother Radiopharm. 2018 Mar;33(2):65-73. doi: 10.1089/cbr.2017.2400.
• [593] Significant association between FasL gene -844T/C polymorphism and risk to hepatocellular carcinoma in Egyptian patients.Immunol Lett. 2016 Apr;172:84-8. doi: 10.1016/j.imlet.2016.02.007. Epub 2016 Feb 15.
• [594] POU2F1 promotes growth and metastasis of hepatocellular carcinoma through the FAT1 signaling pathway.Am J Cancer Res. 2017 Aug 1;7(8):1665-1679. eCollection 2017.
• [595] MicroRNA?23 promotes hepatocellular carcinoma cell resistance to sorafenib by targeting FBW7.Oncol Rep. 2019 Feb;41(2):1231-1237. doi: 10.3892/or.2018.6908. Epub 2018 Dec 6.
• [596] Interactions of human mesangial cells with IgA and IgA-containing immune complexes.Kidney Int. 2002 Aug;62(2):465-75. doi: 10.1046/j.1523-1755.2002.00477.x.
• [597] Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab.Oncotarget. 2018 Jan 2;9(12):10436-10444. doi: 10.18632/oncotarget.23830. eCollection 2018 Feb 13.
• [598] KLHL21, a novel gene that contributes to the progression of hepatocellular carcinoma.BMC Cancer. 2016 Oct 21;16(1):815. doi: 10.1186/s12885-016-2851-7.
• [599] Inhibition of fibroblast growth factor receptor signaling impairs metastasis of hepatocellular carcinoma.Tumour Biol. 2014 Nov;35(11):11005-11. doi: 10.1007/s13277-014-2384-0. Epub 2014 Aug 5.
• [600] Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/-catenin-induced FGF18 expression in hepatocellular carcinoma.Oncogene. 2018 Mar;37(9):1220-1236. doi: 10.1038/s41388-017-0017-y. Epub 2017 Dec 15.
• [601] Effect of Fibroblast Growth Factor-2 and its Receptor Gene Polymorphisms on the Survival of Patients With Hepatitis B Virus-associated Hepatocellular Carcinoma.Anticancer Res. 2019 Apr;39(4):2217-2226. doi: 10.21873/anticanres.13337.
• [602] Clinicopathologic charcterization of sorafenib-induced endoplasmic reticulum stress in human liver cancer cells.J Physiol Pharmacol. 2018 Aug;69(4). doi: 10.26402/jpp.2018.4.08. Epub 2018 Nov 7.
• [603] FGF8 promotes cell proliferation and resistance to EGFR inhibitors via upregulation of EGFR in human hepatocellular carcinoma cells.Oncol Rep. 2017 Oct;38(4):2205-2210. doi: 10.3892/or.2017.5887. Epub 2017 Aug 7.
• [604] P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).Int J Pharm. 2020 Jan 5;573:118842. doi: 10.1016/j.ijpharm.2019.118842. Epub 2019 Nov 20.
• [605] FGG promotes migration and invasion in hepatocellular carcinoma cells through activating epithelial to mesenchymal transition. Cancer Manag Res. 2019 Feb 19;11:1653-1665.
• [606] Soluble fibrinogen-like protein 2 promotes the growth of hepatocellular carcinoma via attenuating dendritic cell-mediated cytotoxic T cell activity.J Exp Clin Cancer Res. 2019 Aug 13;38(1):351. doi: 10.1186/s13046-019-1326-5.
• [607] Genetic and Environmental Models of Circadian Disruption Link SRC-2 Function to Hepatic Pathology.J Biol Rhythms. 2016 Oct;31(5):443-60. doi: 10.1177/0748730416657921. Epub 2016 Jul 17.
• [608] Epigenetic analysis of FHL1 tumor suppressor gene in human liver cancer. Oncol Lett. 2017 Nov;14(5):6109-6116.
• [609] Proteomic mining in the dysplastic liver of WHV/c-myc mice--insights and indicators for early hepatocarcinogenesis.FEBS J. 2010 Oct;277(19):4039-53. doi: 10.1111/j.1742-4658.2010.07795.x. Epub 2010 Aug 27.
• [610] The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.EBioMedicine. 2016 Oct;12:55-67. doi: 10.1016/j.ebiom.2016.07.013. Epub 2016 Jul 14.
• [611] Thymidine phosphorylase promotes malignant progression in hepatocellular carcinoma through pentose Warburg effect.Cell Death Dis. 2019 Jan 17;10(2):43. doi: 10.1038/s41419-018-1282-6.
• [612] Co-expression of PDGF-B and VEGFR-3 strongly correlates with poor prognosis in hepatocellular carcinoma patients after hepatectomy.Clin Res Hepatol Gastroenterol. 2018 Apr;42(2):126-133. doi: 10.1016/j.clinre.2016.11.006. Epub 2017 Dec 19.
• [613] Impact of Interferon- Receptor-1 Promoter Polymorphisms on the Transcriptome of the Hepatitis B Virus-Associated Hepatocellular Carcinoma.Front Immunol. 2018 Apr 16;9:777. doi: 10.3389/fimmu.2018.00777. eCollection 2018.
• [614] Heterogeneous Uptake of 18F-FDG and 68Ga-PSMA-11 in Hepatocellular Carcinoma.Clin Nucl Med. 2019 Mar;44(3):e133-e135. doi: 10.1097/RLU.0000000000002452.
• [615] A novel role of the tumor suppressor GNMT in cellular defense against DNA damage.Int J Cancer. 2014 Feb 15;134(4):799-810. doi: 10.1002/ijc.28420. Epub 2013 Oct 5.
• [616] High expression of forkhead box protein C2 is associated with aggressive phenotypes and poor prognosis in clinical hepatocellular carcinoma.BMC Cancer. 2018 May 25;18(1):597. doi: 10.1186/s12885-018-4503-6.
• [617] ARHGAP9 suppresses the migration and invasion of hepatocellular carcinoma cells through up-regulating FOXJ2/E-cadherin.Cell Death Dis. 2018 Sep 11;9(9):916. doi: 10.1038/s41419-018-0976-0.
• [618] Opposing Roles of the Forkhead Box Factors FoxM1 and FoxA2 in Liver Cancer.Mol Cancer Res. 2019 May;17(5):1063-1074. doi: 10.1158/1541-7786.MCR-18-0968. Epub 2019 Feb 27.
• [619] miR-96 exerts carcinogenic effect by activating AKT/GSK-3/-catenin signaling pathway through targeting inhibition of FOXO1 in hepatocellular carcinoma.Cancer Cell Int. 2019 Feb 20;19:38. doi: 10.1186/s12935-019-0756-7. eCollection 2019.
• [620] FOXQ1/NDRG1 axis exacerbates hepatocellular carcinoma initiation via enhancing crosstalk between fibroblasts and tumor cells.Cancer Lett. 2018 Mar 28;417:21-34. doi: 10.1016/j.canlet.2017.12.021. Epub 2017 Dec 15.
• [621] FSCN? increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition.Int J Oncol. 2018 May;52(5):1455-1464. doi: 10.3892/ijo.2018.4327. Epub 2018 Mar 20.
• [622] LRG1 suppresses the migration and invasion of hepatocellular carcinoma cells.Med Oncol. 2015 May;32(5):146. doi: 10.1007/s12032-015-0598-7. Epub 2015 Mar 27.
• [623] Clinical and Therapeutic Implications of Follistatin in Solid Tumours.Cancer Genomics Proteomics. 2016 11-12;13(6):425-435. doi: 10.21873/cgp.20005.
• [624] Tumor necrosis factor- attenuates starvation-induced apoptosis through upregulation of ferritin heavy chain in hepatocellular carcinoma cells.BMC Cancer. 2013 Sep 25;13:438. doi: 10.1186/1471-2407-13-438.
• [625] cDNA and gene structure for a human subtilisin-like protease with cleavage specificity for paired basic amino acid residues.DNA Cell Biol. 1991 Jun;10(5):319-28. doi: 10.1089/dna.1991.10.319.
• [626] A FUS-LATS1/2 Axis Inhibits Hepatocellular Carcinoma Progression via Activating Hippo Pathway.Cell Physiol Biochem. 2018;50(2):437-451. doi: 10.1159/000494155. Epub 2018 Oct 11.
• [627] MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/-catenin signaling.Biomed Pharmacother. 2018 Nov;107:754-762. doi: 10.1016/j.biopha.2018.07.150. Epub 2018 Aug 21.
• [628] Activation of tumor-promoting pathways implicated in hepatocellular adenoma/carcinoma, a long-term complication of glycogen storage disease type Ia.Biochem Biophys Res Commun. 2020 Jan 29;522(1):1-7. doi: 10.1016/j.bbrc.2019.11.061. Epub 2019 Nov 15.
• [629] Gamma-aminobutyric acid promotes human hepatocellular carcinoma growth through overexpressed gamma-aminobutyric acid A receptor alpha 3 subunit.World J Gastroenterol. 2008 Dec 21;14(47):7175-82. doi: 10.3748/wjg.14.7175.
• [630] Long Non-coding RNA FENDRR Acts as a miR-423-5p Sponge to Suppress the Treg-Mediated Immune Escape of Hepatocellular Carcinoma Cells.Mol Ther Nucleic Acids. 2019 Sep 6;17:516-529. doi: 10.1016/j.omtn.2019.05.027. Epub 2019 Jun 12.
• [631] The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.Autophagy. 2019 Jul;15(7):1258-1279. doi: 10.1080/15548627.2019.1580105. Epub 2019 Feb 20.
• [632] A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.Hepatology. 2018 Jan;67(1):216-231. doi: 10.1002/hep.29478. Epub 2017 Nov 29.
• [633] Isolation of cDNA clones for human beta-glucocerebrosidase using the lambda gt11 expression system.Biochem Biophys Res Commun. 1984 Sep 17;123(2):574-80. doi: 10.1016/0006-291x(84)90268-7.
• [634] Brainstem GLP-1 signalling contributes to cancer anorexia-cachexia syndrome in the rat.Neuropharmacology. 2018 Mar 15;131:282-290. doi: 10.1016/j.neuropharm.2017.12.024. Epub 2017 Dec 13.
• [635] Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.Nat Commun. 2018 Jan 31;9(1):446. doi: 10.1038/s41467-017-02733-4.
• [636] -Glutamylcysteine synthetase (-GCS) as a target for overcoming chemo- and radio-resistance of human hepatocellular carcinoma cells. Life Sci. 2018 Apr 1;198:25-31. doi: 10.1016/j.lfs.2018.02.015. Epub 2018 Feb 14.
• [637] Circulating levels of growth differentiation factor 15 and sex hormones in male patients with HBV-associated hepatocellular carcinoma.Biomed Pharmacother. 2020 Jan;121:109574. doi: 10.1016/j.biopha.2019.109574. Epub 2019 Nov 19.
• [638] Human liver-derived CXCR6(+) NK cells are predominantly educated through NKG2A and show reduced cytokine production.J Leukoc Biol. 2019 Jun;105(6):1331-1340. doi: 10.1002/JLB.1MA1118-428R. Epub 2019 Feb 19.
• [639] Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines.Mol Oncol. 2008 Oct;2(3):241-9. doi: 10.1016/j.molonc.2008.06.004. Epub 2008 Jun 20.
• [640] Combined preoperative albumin-bilirubin (ALBI) and serum -glutamyl transpeptidase (GGT) predicts the outcome of hepatocellular carcinoma patients following hepatic resection.J Cancer. 2019 Aug 27;10(20):4836-4845. doi: 10.7150/jca.33877. eCollection 2019.
• [641] Growth hormone upregulates the pro-tumorigenic galectin 1 in mouse liver.Endocr Connect. 2019 Aug 1;8(8):1108-1117. doi: 10.1530/EC-19-0292.
• [642] Cx32 exerts anti-apoptotic and pro-tumor effects via the epidermal growth factor receptor pathway in hepatocellular carcinoma.J Exp Clin Cancer Res. 2019 Apr 4;38(1):145. doi: 10.1186/s13046-019-1142-y.
• [643] CpG site hypermethylation of E-cadherin and Connexin26 genes in hepatocellular carcinomas induced by a choline-deficient L-Amino Acid-defined diet in rats.Mol Carcinog. 2007 Apr;46(4):269-74. doi: 10.1002/mc.20268.
• [644] Invivo imaging of -galactosidase stimulated activity in hepatocellular carcinoma using ligand-targeted fluorescent probe.Biomaterials. 2017 Apr;122:83-90. doi: 10.1016/j.biomaterials.2017.01.009. Epub 2017 Jan 11.
• [645] A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA.Cancer Lett. 2019 May 28;450:98-109. doi: 10.1016/j.canlet.2019.02.033. Epub 2019 Feb 18.
• [646] Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter.Lab Invest. 2017 Jul;97(7):819-832. doi: 10.1038/labinvest.2017.34. Epub 2017 Apr 17.
• [647] Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma.Front Oncol. 2019 Aug 20;9:785. doi: 10.3389/fonc.2019.00785. eCollection 2019.
• [648] Enzymes of purine metabolism in cancer.Clin Biochem. 1983 Feb;16(1):57-63. doi: 10.1016/s0009-9120(83)94432-6.
• [649] GNAI3 inhibits tumor cell migration and invasion and is post-transcriptionally regulated by miR-222 in hepatocellular carcinoma.Cancer Lett. 2015 Jan 28;356(2 Pt B):978-84. doi: 10.1016/j.canlet.2014.11.013. Epub 2014 Nov 13.
• [650] DNMT1 mediated promoter methylation of GNAO1 in hepatoma carcinoma cells.Gene. 2018 Jul 30;665:67-73. doi: 10.1016/j.gene.2018.04.080. Epub 2018 Apr 27.
• [651] Expression of the messenger RNA for gonadotropin-releasing hormone and its receptor in human cancer cell lines.Life Sci. 1998;62(22):2015-23. doi: 10.1016/s0024-3205(98)00173-8.
• [652] Platelet GPIb is a mediator and potential interventional target for NASH and subsequent liver cancer.Nat Med. 2019 Apr;25(4):641-655. doi: 10.1038/s41591-019-0379-5. Epub 2019 Apr 1.
• [653] Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.Nat Rev Gastroenterol Hepatol. 2018 Feb;15(2):111-128. doi: 10.1038/nrgastro.2017.119. Epub 2017 Oct 11.
• [654] Transient infantile hypertriglyceridemia, fatty liver, and hepatic fibrosis caused by mutated GPD1, encoding glycerol-3-phosphate dehydrogenase 1. Am J Hum Genet. 2012 Jan 13;90(1):49-60. doi: 10.1016/j.ajhg.2011.11.028. Epub 2012 Jan 5.
• [655] Estrogen Activation of G-Protein-Coupled Estrogen Receptor 1 Regulates Phosphoinositide 3-Kinase and mTOR Signaling to Promote Liver Growth in Zebrafish and Proliferation of HumanHepatocytes.Gastroenterology. 2019 May;156(6):1788-1804.e13. doi: 10.1053/j.gastro.2019.01.010. Epub 2019 Jan 12.
• [656] Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells.J Hepatol. 2003 Nov;39(5):779-85. doi: 10.1016/s0168-8278(03)00361-1.
• [657] Down-regulation of G protein-coupled receptor 137 by RNA interference inhibits cell growth of two hepatoma cell lines.Cell Biol Int. 2015 Apr;39(4):418-26. doi: 10.1002/cbin.10412. Epub 2015 Jan 13.
• [658] GPR182 is a novel marker for sinusoidal endothelial differentiation with distinct GPCR signaling activity invitro.Biochem Biophys Res Commun. 2018 Feb 26;497(1):32-38. doi: 10.1016/j.bbrc.2018.01.185. Epub 2018 Feb 1.
• [659] microRNA-1914, which is regulated by lncRNA DUXAP10, inhibits cell proliferation by targeting the GPR39-mediated PI3K/AKT/mTOR pathway in HCC.J Cell Mol Med. 2019 Dec;23(12):8292-8304. doi: 10.1111/jcmm.14705. Epub 2019 Oct 1.
• [660] Quantitative reverse transcriptase polymerase chain reaction analysis for KiSS-1 and orphan G-protein-coupled receptor (hOT7T175) gene expression in hepatocellular carcinoma.J Cancer Res Clin Oncol. 2003 Sep;129(9):531-5. doi: 10.1007/s00432-003-0469-z. Epub 2003 Jul 25.
• [661] Association of Catalase and Glutathione Peroxidase 1 Polymorphisms with Chronic Hepatitis C Outcome.Ann Hum Genet. 2016 May;80(3):145-53. doi: 10.1111/ahg.12152. Epub 2016 Mar 18.
• [662] Integrated transcriptomic and proteomic analyses reveal -lipoic acid-regulated cell proliferation via Grb2-mediated signalling in hepatic cancer cells.J Cell Mol Med. 2018 Jun;22(6):2981-2992. doi: 10.1111/jcmm.13447. Epub 2018 Mar 25.
• [663] Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma.J Hepatol. 2008 Nov;49(5):746-57. doi: 10.1016/j.jhep.2008.06.019. Epub 2008 Jul 9.
• [664] Host genetic variants influencing the clinical course of hepatitis B virus infection.J Med Virol. 2016 Mar;88(3):371-9. doi: 10.1002/jmv.24350. Epub 2015 Aug 14.
• [665] Angiotensin II and tumor necrosis factor- stimulate the growth, migration and invasion of BEL-7402 cells via down-regulation of GRK2 expression.Dig Liver Dis. 2019 Feb;51(2):263-274. doi: 10.1016/j.dld.2018.06.007. Epub 2018 Jun 20.
• [666] Granulin A Synergizes with Cisplatin to Inhibit the Growth of Human Hepatocellular Carcinoma.Int J Mol Sci. 2018 Oct 7;19(10):3060. doi: 10.3390/ijms19103060.
• [667] Overexpression of protein kinase FA/GSK-3 alpha (a proline-directed protein kinase) correlates with human hepatoma dedifferentiation/progression.J Cell Biochem. 1996 May;61(2):238-45. doi: 10.1002/(SICI)1097-4644(19960501)61:2%3C238::AID-JCB7%3E3.0.CO;2-V.
• [668] Participation of liver stem cells in cholangiocarcinogenesis after aflatoxin B(1) exposure of glutathione S-transferase A3 knockout mice.Tumour Biol. 2018 May;40(5):1010428318777344. doi: 10.1177/1010428318777344.
• [669] Regulation of heparin-binding EGF-like growth factor expression by phorbol ester in a human hepatoma-derived cell line.Biochim Biophys Acta. 1996 Jan 10;1310(1):163-7. doi: 10.1016/0167-4889(95)00149-2.
• [670] Enhancement of radiation-induced DNA double-strand breaks and micronuclei in human colon carcinoma cells by N-methylformamide.Radiat Res. 1989 Jul;119(1):166-75.
• [671] HOXA10 knockdown inhibits proliferation, induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells through HDAC1.Cancer Manag Res. 2019 Jul 26;11:7065-7076. doi: 10.2147/CMAR.S199239. eCollection 2019.
• [672] Histone deacetylase 2 regulates the doxorubicin (Dox) resistance of hepatocarcinoma cells and transcription of ABCB1.Life Sci. 2019 Jan 1;216:200-206. doi: 10.1016/j.lfs.2018.11.043. Epub 2018 Nov 20.
• [673] HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition.Cancer Res. 2019 Jul 15;79(14):3676-3688. doi: 10.1158/0008-5472.CAN-18-3767. Epub 2019 May 16.
• [674] Highly expressed histone deacetylase 5 promotes the growth of hepatocellular carcinoma cells by inhibiting the TAp63-maspin pathway.Am J Cancer Res. 2018 Mar 1;8(3):462-475. eCollection 2018.
• [675] LncRNA ID2-AS1 suppresses tumor metastasis by activating the HDAC8/ID2 pathway in hepatocellular carcinoma.Cancer Lett. 2020 Jan 28;469:399-409. doi: 10.1016/j.canlet.2019.11.007. Epub 2019 Nov 13.
• [676] A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma.Hepatology. 2020 Jan;71(1):130-147. doi: 10.1002/hep.30795. Epub 2019 Aug 11.
• [677] Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma.Liver Int. 2012 Feb;32(2):331-8. doi: 10.1111/j.1478-3231.2011.02666.x. Epub 2011 Oct 30.
• [678] MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.Invest New Drugs. 2020 Feb;38(1):60-69. doi: 10.1007/s10637-019-00766-8. Epub 2019 Mar 30.
• [679] Dishevelled-3 phosphorylation is governed by HIPK2/PP1C/ITCH axis and the non-phosphorylated form promotes cancer stemness via LGR5 in hepatocellular carcinoma.Oncotarget. 2017 Jun 13;8(24):39430-39442. doi: 10.18632/oncotarget.17049.
• [680] Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection.J Virol. 2019 Feb 5;93(4):e01457-18. doi: 10.1128/JVI.01457-18. Print 2019 Feb 15.
• [681] Association between HLA-DQA1/DRB1 polymorphism and development of hepatocellular carcinoma during entecavir treatment.J Gastroenterol Hepatol. 2019 May;34(5):937-946. doi: 10.1111/jgh.14454. Epub 2018 Sep 26.
• [682] Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias.J Hepatol. 2015 Mar;62(3):734-8. doi: 10.1016/j.jhep.2014.11.029. Epub 2014 Nov 28.
• [683] KIFC1 is activated by TCF-4 and promotes hepatocellular carcinoma pathogenesis by regulating HMGA1 transcriptional activity.J Exp Clin Cancer Res. 2019 Jul 24;38(1):329. doi: 10.1186/s13046-019-1331-8.
• [684] Hepatitis B virus X protein promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma cell line HCCLM3 by targeting HMGA2.Oncol Lett. 2018 Nov;16(5):5709-5714. doi: 10.3892/ol.2018.9359. Epub 2018 Aug 23.
• [685] Silencing of long noncoding RNA HOXA11-AS inhibits the Wnt signaling pathway via the upregulation of HOXA11 and thereby inhibits the proliferation, invasion, and self-renewal of hepatocellular carcinoma stem cells.Exp Mol Med. 2019 Nov 22;51(11):1-20. doi: 10.1038/s12276-019-0328-x.
• [686] High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models.Lab Invest. 2018 Jan;98(1):95-105. doi: 10.1038/labinvest.2017.107. Epub 2017 Oct 16.
• [687] HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.APMIS. 2016 Mar;124(3):188-93. doi: 10.1111/apm.12483. Epub 2015 Nov 20.
• [688] Analysis of serum Haptoglobin using glycoproteomics and lectin immunoassay in liver diseases in Hepatitis B virus infection.Clin Chim Acta. 2019 Aug;495:309-317. doi: 10.1016/j.cca.2019.04.072. Epub 2019 Apr 20.
• [689] Melatonin maximizes the therapeutic potential of non-preconditioned MSCs in a DEN-induced rat model of HCC.Biomed Pharmacother. 2019 Jun;114:108732. doi: 10.1016/j.biopha.2019.108732. Epub 2019 Mar 27.
• [690] Ubiquitin specific peptidase 5 mediates Histidine-rich protein Hpn induced cell apoptosis in hepatocellular carcinoma through P14-P53 signaling.Proteomics. 2017 Jun;17(12). doi: 10.1002/pmic.201600350.
• [691] Knockdown of histidine-rich calcium-binding protein (HRC) suppresses liver fibrosis by inhibiting the activation of hepatic stellate cells.Biol Open. 2017 Jan 15;6(1):29-34. doi: 10.1242/bio.019828.
• [692] Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma.Oncogene. 2020 Feb;39(8):1724-1738. doi: 10.1038/s41388-019-1093-y. Epub 2019 Nov 18.
• [693] Upregulated histamine receptorH3 promotes tumor growth and metastasis in hepatocellular carcinoma.Oncol Rep. 2019 Jun;41(6):3347-3354. doi: 10.3892/or.2019.7119. Epub 2019 Apr 16.
• [694] Loss of 11HSD1 enhances glycolysis, facilitates intrahepatic metastasis, and indicates poor prognosis in hepatocellular carcinoma.Oncotarget. 2016 Jan 12;7(2):2038-53. doi: 10.18632/oncotarget.6661.
• [695] Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma.Nat Commun. 2013;4:2508. doi: 10.1038/ncomms3508.
• [696] Association of genetic polymorphisms in HSD17B1, HSD17B2 and SHBG genes with hepatocellular carcinoma risk.Pathol Oncol Res. 2014 Jul;20(3):661-6. doi: 10.1007/s12253-014-9746-1. Epub 2014 Feb 22.
• [697] A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.Hepatology. 2019 Jul;70(1):231-240. doi: 10.1002/hep.30623. Epub 2019 Apr 25.
• [698] NF-B increased expression of 17-hydroxysteroid dehydrogenase 4 promotes HepG2 proliferation via inactivating estradiol.Mol Cell Endocrinol. 2015 Feb 5;401:1-11. doi: 10.1016/j.mce.2014.11.016. Epub 2014 Nov 28.
• [699] HSF1 Regulates Mevalonate and Cholesterol Biosynthesis Pathways.Cancers (Basel). 2019 Sep 13;11(9):1363. doi: 10.3390/cancers11091363.
• [700] Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.Bioorg Chem. 2020 Jan;94:103433. doi: 10.1016/j.bioorg.2019.103433. Epub 2019 Nov 19.
• [701] Hsp90 promotes aggressive vasculogenic mimicry via epithelial-mesenchymal transition in hepatocellular carcinoma.Oncogene. 2019 Jan;38(2):228-243. doi: 10.1038/s41388-018-0428-4. Epub 2018 Aug 7.
• [702] Low levels of glycoprotein 96 indicate a worse prognosis in early-stage hepatocellular carcinoma patients after hepatectomy.Hum Pathol. 2019 Apr;86:193-202. doi: 10.1016/j.humpath.2018.11.025. Epub 2018 Dec 8.
• [703] miR-26b-5p helps in EpCAM+cancer stem cells maintenance via HSC71/HSPA8 and augments malignant features in HCC.Liver Int. 2019 Sep;39(9):1692-1703. doi: 10.1111/liv.14188. Epub 2019 Jul 25.
• [704] In silico analysis of the binding properties of solasonine to mortalin and p53, and in vitro pharmacological studies of its apoptotic and cytotoxic effects on human HepG2 and Hep3b hepatocellular carcinoma cells.Fundam Clin Pharmacol. 2019 Aug;33(4):385-396. doi: 10.1111/fcp.12447. Epub 2019 Jan 28.
• [705] The clinicopathological and prognostic value of HSP27 in hepatocellular carcinoma: a systematic review and meta-analysis.Onco Targets Ther. 2018 Mar 7;11:1293-1303. doi: 10.2147/OTT.S154227. eCollection 2018.
• [706] Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the suppression of the phosphoinositide 3-kinase (PI3K)/AKT pathway.Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1629-1639. doi: 10.1016/j.bbadis.2017.04.021. Epub 2017 Apr 26.
• [707] Effect of adipose-derived mesenchymal stem cells on hepatocellular carcinoma: In vitro inhibition of carcinogenesis.World J Gastroenterol. 2019 Feb 7;25(5):567-583. doi: 10.3748/wjg.v25.i5.567.
• [708] Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2 (HIF-2) and 30 kDa HIV Tat-Interacting Protein (TIP30).Med Sci Monit. 2018 Apr 14;24:2225-2234. doi: 10.12659/msm.906687.
• [709] 5-Hydroxytryptamine Receptor 1D Aggravates Hepatocellular Carcinoma Progression Through FoxO6 in AKT-Dependent and Independent Manners.Hepatology. 2019 May;69(5):2031-2047. doi: 10.1002/hep.30430. Epub 2019 Mar 10.
• [710] HtrA1 resensitizes multidrug-resistant hepatocellular carcinoma cells by targeting XIAP.Biomed Pharmacother. 2015 Mar;70:97-102. doi: 10.1016/j.biopha.2014.12.044. Epub 2015 Jan 12.
• [711] ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.J Exp Clin Cancer Res. 2017 Nov 23;36(1):166. doi: 10.1186/s13046-017-0637-7.
• [712] H(2)S suppresses indoleamine 2, 3-dioxygenase 1 and exhibits immunotherapeutic efficacy in murine hepatocellular carcinoma.J Exp Clin Cancer Res. 2019 Feb 18;38(1):88. doi: 10.1186/s13046-019-1083-5.
• [713] Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons.Gastroenterology. 2017 Aug;153(2):566-578.e5. doi: 10.1053/j.gastro.2017.04.021. Epub 2017 Apr 26.
• [714] Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma.Front Microbiol. 2019 Mar 15;10:475. doi: 10.3389/fmicb.2019.00475. eCollection 2019.
• [715] Macrophages-induced long noncoding RNA H19 up-regulation triggers and activates the miR-193b/MAPK1 axis and promotes cell aggressiveness in hepatocellular carcinoma.Cancer Lett. 2020 Jan 28;469:310-322. doi: 10.1016/j.canlet.2019.11.001. Epub 2019 Nov 6.
• [716] Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells.J Exp Clin Cancer Res. 2016 Mar 31;35:59. doi: 10.1186/s13046-016-0330-2.
• [717] IGFBP2 upregulates ZEB1 expression and promotes hepatocellular carcinoma progression through NF-B signaling pathway.Dig Liver Dis. 2020 May;52(5):573-581. doi: 10.1016/j.dld.2019.10.008. Epub 2019 Dec 7.
• [718] Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma.Hepatology. 2008 Feb;47(2):493-502. doi: 10.1002/hep.22027.
• [719] Circulating cell-free DNA of methylated insulin-like growth factor-binding protein 7 predicts a poor prognosis in hepatitis B virus-associated hepatocellular carcinoma after hepatectomy.Free Radic Res. 2018 Apr;52(4):455-464. doi: 10.1080/10715762.2018.1443448. Epub 2018 Mar 15.
• [720] Inhibition of microRNA-16 facilitates the paclitaxel resistance by targeting IKBKB via NF-B signaling pathway in hepatocellular carcinoma.Biochem Biophys Res Commun. 2018 Sep 5;503(2):1035-1041. doi: 10.1016/j.bbrc.2018.06.113. Epub 2018 Aug 2.
• [721] Role of IFN-ks, IFN-ks related genes and the DEPDC5 gene in Hepatitis B virus-related liver disease.J Viral Hepat. 2014 Jul;21(7):e29-38. doi: 10.1111/jvh.12235.
• [722] Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment.Mol Cancer Ther. 2019 Nov;18(11):2146-2157. doi: 10.1158/1535-7163.MCT-19-0004. Epub 2019 Aug 22.
• [723] IL12 Gene Polymorphism in Association with Hepatocellular Carcinoma in HCV-infected Egyptian Patients.Immunol Invest. 2017 Feb;46(2):123-133. doi: 10.1080/08820139.2016.1229789. Epub 2016 Nov 7.
• [724] Silencing of IL13RA2 promotes partial epithelial-mesenchymal transition in hepatocellular carcinoma via ERK signaling pathway activation.FEBS Open Bio. 2020 Feb;10(2):229-236. doi: 10.1002/2211-5463.12774. Epub 2020 Jan 10.
• [725] hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.J Cancer Res Clin Oncol. 2018 Jul;144(7):1279-1288. doi: 10.1007/s00432-018-2654-0. Epub 2018 May 8.
• [726] Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population.Infect Genet Evol. 2011 Dec;11(8):2083-8. doi: 10.1016/j.meegid.2011.09.025. Epub 2011 Oct 12.
• [727] IL-27, a cytokine, and IFN-1, a type III IFN, are coordinated to regulate virus replication through type I IFN.J Immunol. 2014 Jan 15;192(2):691-703. doi: 10.4049/jimmunol.1300252. Epub 2013 Dec 11.
• [728] Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miR-23a-3p and Up-regulate Programmed Death Ligand 1 Expression in Macrophages.Hepatology. 2019 Jul;70(1):241-258. doi: 10.1002/hep.30607. Epub 2019 Apr 25.
• [729] Anti-IL-20 monoclonal antibody suppresses hepatocellular carcinoma progression.Oncol Lett. 2018 Nov;16(5):6156-6162. doi: 10.3892/ol.2018.9402. Epub 2018 Sep 5.
• [730] T cells in hepatocellular carcinoma patients present cytotoxic activity but are reduced in potency due to IL-2 and IL-21 pathways.Int Immunopharmacol. 2019 May;70:167-173. doi: 10.1016/j.intimp.2019.02.019. Epub 2019 Feb 22.
• [731] NCR(-) group 3 innate lymphoid cells orchestrate IL-23/IL-17 axis to promote hepatocellular carcinoma development.EBioMedicine. 2019 Mar;41:333-344. doi: 10.1016/j.ebiom.2019.02.050. Epub 2019 Mar 1.
• [732] Correlations of IL-23R gene polymorphism with clinicopathological characteristics and prognosis of hepatocellular carcinoma patients after interventional therapy.Genomics. 2019 Jul;111(4):930-935. doi: 10.1016/j.ygeno.2018.05.023. Epub 2018 Jun 1.
• [733] Cationic Antheraea pernyi Silk Fibroin-Modified Adenovirus-Mediated ING4 and IL-24 Dual Gene Coexpression Vector Suppresses the Growth of Hepatoma Carcinoma Cells.Int J Nanomedicine. 2019 Dec 10;14:9745-9761. doi: 10.2147/IJN.S230693. eCollection 2019.
• [734] Interleukin-32: Frenemy in cancer?.BMB Rep. 2019 Mar;52(3):165-174. doi: 10.5483/BMBRep.2019.52.3.019.
• [735] Genetic variants in IL-33/ST2 pathway with the susceptibility to hepatocellular carcinoma in a Chinese population.Cytokine. 2019 Jun;118:124-129. doi: 10.1016/j.cyto.2018.03.036. Epub 2018 Apr 12.
• [736] High expression of IL-4R enhances proliferation and invasion of hepatocellular carcinoma cells.Int J Biol Markers. 2017 Oct 31;32(4):e384-e390. doi: 10.5301/ijbm.5000280.
• [737] A tumour-promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways.Clin Exp Pharmacol Physiol. 2017 Feb;44(2):213-221. doi: 10.1111/1440-1681.12689.
• [738] IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma.J Cancer Res Clin Oncol. 2014 Jun;140(6):883-93. doi: 10.1007/s00432-014-1639-x. Epub 2014 Mar 20.
• [739] Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells.Gastroenterology. 2004 Jun;126(7):1828-43. doi: 10.1053/j.gastro.2004.03.011.
• [740] Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma.World J Gastroenterol. 2015 Apr 7;21(13):3960-9. doi: 10.3748/wjg.v21.i13.3960.
• [741] EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.J Immunother Cancer. 2019 Nov 14;7(1):300. doi: 10.1186/s40425-019-0784-9.
• [742] Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1.Eur J Gastroenterol Hepatol. 2010 Apr;22(4):450-6. doi: 10.1097/MEG.0b013e3283329d00.
• [743] PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer.J Transl Med. 2019 Oct 16;17(1):343. doi: 10.1186/s12967-019-2091-0.
• [744] Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer.J Clin Invest. 2018 Mar 1;128(3):1010-1025. doi: 10.1172/JCI95802. Epub 2018 Feb 5.
• [745] Hepatitis C virus protein interaction network for HCV clearance and association of DAA to HCC occurrence via data mining approach: A systematic review and critical analysis.Rev Med Virol. 2019 Mar;29(2):e2033. doi: 10.1002/rmv.2033. Epub 2019 Jan 6.
• [746] ADAR1 p110 Enhances Adhesion of Tumor Cells to Extracellular Matrix in Hepatocellular Carcinoma via Up-Regulating ITGA2 Expression.Med Sci Monit. 2019 Feb 24;25:1469-1479. doi: 10.12659/MSM.911944.
• [747] SIN3B promotes integrin V subunit gene transcription and cell migration of hepatocellular carcinoma.J Mol Cell Biol. 2019 May 1;11(5):421-432. doi: 10.1093/jmcb/mjy050.
• [748] Integrin 6 targeted positron emission tomography imaging of hepatocellular carcinoma in mouse models.J Control Release. 2019 Sep 28;310:11-21. doi: 10.1016/j.jconrel.2019.08.003. Epub 2019 Aug 7.
• [749] MicroRNA?653 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting ITGB1.Oncol Rep. 2019 Mar;41(3):1669-1677. doi: 10.3892/or.2019.6971. Epub 2019 Jan 16.
• [750] Telomerase activated thymidine analogue pro-drug is a new molecule targeting hepatocellular carcinoma.J Hepatol. 2014 Nov;61(5):1064-72. doi: 10.1016/j.jhep.2014.05.027. Epub 2014 May 23.
• [751] A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma.J Hepatol. 2019 May;70(5):904-917. doi: 10.1016/j.jhep.2019.01.007. Epub 2019 Jan 14.
• [752] LncRNA 00152 promotes the development of hepatocellular carcinoma by activating JAK2/STAT3 pathway.Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1038-1046. doi: 10.26355/eurrev_201902_16991.
• [753] Relationships between cell cycle pathway gene polymorphisms and risk of hepatocellular carcinoma.World J Gastroenterol. 2016 Jun 28;22(24):5558-67. doi: 10.3748/wjg.v22.i24.5558.
• [754] Sulfatide epigenetically regulates miR-223 and promotes the migration of human hepatocellular carcinoma cells.J Hepatol. 2014 Apr;60(4):792-801. doi: 10.1016/j.jhep.2013.12.004. Epub 2013 Dec 11.
• [755] Treatment with MAPKAP2 (MK2) inhibitor and DNA methylation inhibitor, 5-aza dC, synergistically triggers apoptosis in hepatocellular carcinoma (HCC) via tristetraprolin (TTP).Cell Signal. 2016 Dec;28(12):1872-1880. doi: 10.1016/j.cellsig.2016.09.002. Epub 2016 Sep 13.
• [756] Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma.Int J Mol Sci. 2019 Mar 14;20(6):1292. doi: 10.3390/ijms20061292.
• [757] Astemizole-based anticancer therapy for hepatocellular carcinoma (HCC), and Eag1 channels as potential early-stage markers of HCC.Tumour Biol. 2015 Aug;36(8):6149-58. doi: 10.1007/s13277-015-3299-0. Epub 2015 Mar 18.
• [758] Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.EBioMedicine. 2019 Jan;39:239-254. doi: 10.1016/j.ebiom.2018.11.063. Epub 2018 Dec 13.
• [759] KCNK levels are prognostic and diagnostic markers for hepatocellular carcinoma.Aging (Albany NY). 2019 Oct 2;11(19):8169-8182. doi: 10.18632/aging.102311. Epub 2019 Oct 2.
• [760] Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.Biochem Biophys Res Commun. 2019 May 14;512(4):852-858. doi: 10.1016/j.bbrc.2019.03.154. Epub 2019 Mar 28.
• [761] The histone demethylase JMJD1A regulates adrenomedullin-mediated cell proliferation in hepatocellular carcinoma under hypoxia.Biochem Biophys Res Commun. 2013 May 17;434(4):722-7. doi: 10.1016/j.bbrc.2013.03.091. Epub 2013 Apr 10.
• [762] High Expression of Retinoblastoma-Binding Protein 2 (RBP2) in Patients with Hepatocellular Carcinoma and Its Prognostic Significance.Med Sci Monit. 2017 Jun 5;23:2736-2744. doi: 10.12659/msm.905262.
• [763] Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma.Oncotarget. 2018 Sep 28;9(76):34320-34335. doi: 10.18632/oncotarget.26144. eCollection 2018 Sep 28.
• [764] Lysine-specific demethylase 5C promotes hepatocellular carcinoma cell invasion through inhibition BMP7 expression.BMC Cancer. 2015 Oct 26;15:801. doi: 10.1186/s12885-015-1798-4.
• [765] Aberrant JMJD3 Expression Upregulates Slug to Promote Migration, Invasion, and Stem Cell-Like Behaviors in Hepatocellular Carcinoma.Cancer Res. 2016 Nov 15;76(22):6520-6532. doi: 10.1158/0008-5472.CAN-15-3029. Epub 2016 Sep 20.
• [766] SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC.Cell Death Differ. 2020 Mar;27(3):1086-1104. doi: 10.1038/s41418-019-0399-1. Epub 2019 Jul 31.
• [767] p62 functions as an oncogene in colorectal cancer through inhibiting apoptosis and promoting cell proliferation by interacting with the vitamin D receptor.Cell Prolif. 2019 May;52(3):e12585. doi: 10.1111/cpr.12585. Epub 2019 Feb 22.
• [768] Pseudopod-associated protein KIF20B promotes Gli1-induced epithelial-mesenchymal transition modulated by pseudopodial actin dynamic in human colorectal cancer.Mol Carcinog. 2018 Jul;57(7):911-925. doi: 10.1002/mc.22812. Epub 2018 Apr 10.
• [769] Expression of KiSS-1 gene and its role in invasion and metastasis of human hepatocellular carcinoma.Anat Rec (Hoboken). 2009 Aug;292(8):1128-34. doi: 10.1002/ar.20950.
• [770] FBXW10 promotes hepatocarcinogenesis in male patients and mice.Carcinogenesis. 2020 Jul 10;41(5):689-698. doi: 10.1093/carcin/bgz138.
• [771] TRAF7 enhances ubiquitin-degradation of KLF4 to promote hepatocellular carcinoma progression.Cancer Lett. 2020 Jan 28;469:380-389. doi: 10.1016/j.canlet.2019.11.012. Epub 2019 Nov 12.
• [772] Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma.Mol Cancer Ther. 2018 Jan;17(1):26-38. doi: 10.1158/1535-7163.MCT-17-0580. Epub 2017 Nov 15.
• [773] Monomethyltransferase SET8 facilitates hepatocellular carcinoma growth by enhancing aerobic glycolysis.Cell Death Dis. 2019 Apr 5;10(4):312. doi: 10.1038/s41419-019-1541-1.
• [774] Biomarker analysis of fucosylated kininogen through depletion of lectin reactive heterophilic antibodies in hepatocellular carcinoma.J Immunol Methods. 2018 Nov;462:59-64. doi: 10.1016/j.jim.2018.08.010. Epub 2018 Aug 23.
• [775] Genetic and phenotypic difference in CD8(+) T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma.J Med Genet. 2019 Jan;56(1):18-21. doi: 10.1136/jmedgenet-2018-105267. Epub 2018 Apr 17.
• [776] Clinicopathologic significance of LAIR-1 expression in hepatocellular carcinoma.Curr Probl Cancer. 2019 Feb;43(1):18-26. doi: 10.1016/j.currproblcancer.2018.04.005. Epub 2018 Apr 30.
• [777] Lamp2 inhibits epithelial-mesenchymal transition by suppressing Snail expression in HCC.Oncotarget. 2018 Jul 13;9(54):30240-30252. doi: 10.18632/oncotarget.25367. eCollection 2018 Jul 13.
• [778] PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas.Hepatology. 2003 Nov;38(5):1242-9. doi: 10.1053/jhep.2003.50457.
• [779] LAPTM4B facilitates tumor growth and induces autophagy in hepatocellular carcinoma.Cancer Manag Res. 2019 Mar 27;11:2485-2497. doi: 10.2147/CMAR.S201092. eCollection 2019.
• [780] Increased long noncoding RNA LASP1-AS is critical for hepatocellular carcinoma tumorigenesis via upregulating LASP1.J Cell Physiol. 2019 Aug;234(8):13493-13509. doi: 10.1002/jcp.28028. Epub 2019 Jan 24.
• [781] LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function.Nat Commun. 2019 Dec 17;10(1):5755. doi: 10.1038/s41467-019-13591-7.
• [782] The inducible effect of LBP on maturation of dendritic cells and the related immune signaling pathways in hepatocellular carcinoma (HCC).Curr Drug Deliv. 2012 Jul;9(4):414-20. doi: 10.2174/156720112801323107.
• [783] Analysis of schizophrenia and hepatocellular carcinoma genetic network with corresponding modularity and pathways: novel insights to the immune system.BMC Genomics. 2013;14 Suppl 5(Suppl 5):S10. doi: 10.1186/1471-2164-14-S5-S10. Epub 2013 Oct 16.
• [784] Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating -catenin/c-Myc signaling in human hepatocellular carcinoma.Cancer Lett. 2019 Feb 28;443:34-46. doi: 10.1016/j.canlet.2018.11.030. Epub 2018 Nov 29.
• [785] Garlic-derived compound S-allylmercaptocysteine inhibits hepatocarcinogenesis through targeting LRP6/Wnt pathway.Acta Pharm Sin B. 2018 Jul;8(4):575-586. doi: 10.1016/j.apsb.2017.10.003. Epub 2017 Nov 10.
• [786] Leptin induces muscle wasting in a zebrafish kras-driven hepatocellular carcinoma (HCC) model.Dis Model Mech. 2019 Feb 27;12(2):dmm038240. doi: 10.1242/dmm.038240.
• [787] Hepatic leptin receptor expression can partiallycompensate for IL-6R deficiency inDEN-induced hepatocellular carcinoma.Mol Metab. 2018 Nov;17:122-133. doi: 10.1016/j.molmet.2018.08.010. Epub 2018 Sep 5.
• [788] Detection and characterization of ciRS-7: a potential promoter of the development of cancer.Neoplasma. 2017;64(3):321-328. doi: 10.4149/neo_2017_301.
• [789] Expression of RNA-binding protein LIN28 in classic gastric hepatoid carcinomas, gastric fetal type gastrointestinal adenocarcinomas, and hepatocellular carcinomas: An immunohistochemical study with comparison to SALL4, alpha-fetoprotein, glypican-3, and Hep Par1.Pathol Res Pract. 2018 Oct;214(10):1707-1712. doi: 10.1016/j.prp.2018.07.037. Epub 2018 Aug 2.
• [790] Metabolic characteristics of a human hepatoma cell line stably transfected with hormone-sensitive lipase.Biochem J. 1999 Jul 15;341 ( Pt 2)(Pt 2):453-60.
• [791] Production and evaluation of chicken egg-yolk-derived antibodies against Campylobacter jejuni colonization-associated proteins.Foodborne Pathog Dis. 2013 Jul;10(7):624-31. doi: 10.1089/fpd.2012.1313. Epub 2013 Jun 6.
• [792] Lysyl oxidase assists tumorinitiating cells to enhance angiogenesis in hepatocellular carcinoma.Int J Oncol. 2019 Apr;54(4):1398-1408. doi: 10.3892/ijo.2019.4705. Epub 2019 Jan 31.
• [793] Increased Expression of the Matrix-Modifying Enzyme Lysyl Oxidase-Like 2 in Aggressive Hepatocellular Carcinoma with Poor Prognosis.Gut Liver. 2019 Jan 15;13(1):83-92. doi: 10.5009/gnl17569.
• [794] The Roles of Low-Density Lipoprotein Receptor-Related Proteins 5, 6, and 8 in Cancer: A Review.J Oncol. 2019 Mar 26;2019:4536302. doi: 10.1155/2019/4536302. eCollection 2019.
• [795] Hepatitis C Virus Downregulates Core Subunits of Oxidative Phosphorylation, Reminiscent of the Warburg Effect in Cancer Cells.Cells. 2019 Nov 8;8(11):1410. doi: 10.3390/cells8111410.
• [796] microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-Associated Protein 1 to Suppress Hepatocarcinogenesis.Gastroenterology. 2018 Dec;155(6):1951-1966.e26. doi: 10.1053/j.gastro.2018.08.032. Epub 2018 Aug 27.
• [797] RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation.Oncotarget. 2016 Mar 1;7(9):9832-43. doi: 10.18632/oncotarget.6954.
• [798] Genome-wide identification of differential methylation between primary and recurrent hepatocellular carcinomas.Mol Carcinog. 2016 Jul;55(7):1163-74. doi: 10.1002/mc.22359. Epub 2015 Jul 2.
• [799] Expression of MAGE genes and survival in patients with hepatocellular carcinoma.Int J Oncol. 1999 Dec;15(6):1227-32. doi: 10.3892/ijo.15.6.1227.
• [800] LINC01234/MicroRNA-31-5p/MAGEA3 Axis Mediates the Proliferation and Chemoresistance of Hepatocellular Carcinoma Cells.Mol Ther Nucleic Acids. 2020 Mar 6;19:168-178. doi: 10.1016/j.omtn.2019.10.035. Epub 2019 Nov 13.
• [801] MAGE-3 and MAGE-4 genes as possible markers for early detection of metastases in hepatitis C virus Egyptian patients complicated by hepatocellular carcinoma.Med Oncol. 2012 Jun;29(2):994-9. doi: 10.1007/s12032-011-9917-9. Epub 2011 Mar 31.
• [802] microRNA-448 inhibits stemness maintenance and self-renewal of hepatocellular carcinoma stem cells through the MAGEA6-mediated AMPK signaling pathway.J Cell Physiol. 2019 Dec;234(12):23461-23474. doi: 10.1002/jcp.28915. Epub 2019 Jun 24.
• [803] MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition.Onco Targets Ther. 2019 Sep 24;12:7843-7855. doi: 10.2147/OTT.S213164. eCollection 2019.
• [804] Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-B/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.Hepatology. 2020 Apr;71(4):1262-1278. doi: 10.1002/hep.30917. Epub 2020 Jan 26.
• [805] Characterization of the in vitro transcriptional activity of polymorphic alleles of the human monoamine oxidase-B gene.Neurosci Lett. 2005 Jul 22-29;383(1-2):171-5. doi: 10.1016/j.neulet.2005.04.004. Epub 2005 Apr 19.
• [806] Down-regulation of MAP2K1 by miR-539 inhibits hepatocarcinoma progression.Biochem Biophys Res Commun. 2018 Oct 12;504(4):784-791. doi: 10.1016/j.bbrc.2018.08.076. Epub 2018 Sep 11.
• [807] MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis invitro and invivo.Biochem Biophys Res Commun. 2020 Feb 26;523(1):147-152. doi: 10.1016/j.bbrc.2019.12.032. Epub 2019 Dec 11.
• [808] MEKK1 induces c-Jun complexes that act as negative regulators for cell survival and proliferation of HCC cells.Int J Oncol. 2002 Sep;21(3):553-9.
• [809] miR-125a-5p inhibits tumorigenesis in hepatocellular carcinoma.Aging (Albany NY). 2019 Sep 17;11(18):7639-7662. doi: 10.18632/aging.102276. Epub 2019 Sep 17.
• [810] High expression of PFTK1 in cancer cells predicts poor prognosis in colorectal cancer.Mol Med Rep. 2017 Jul;16(1):224-230. doi: 10.3892/mmr.2017.6560. Epub 2017 May 10.
• [811] Experimental Models to Define the Genetic Predisposition to Liver Cancer.Cancers (Basel). 2019 Sep 27;11(10):1450. doi: 10.3390/cancers11101450.
• [812] The MAP3K7-mTOR Axis Promotes the Proliferation and Malignancy of Hepatocellular Carcinoma Cells.Front Oncol. 2019 Jun 4;9:474. doi: 10.3389/fonc.2019.00474. eCollection 2019.
• [813] miR-589-5p inhibits MAP3K8 and suppresses CD90(+) cancer stem cells in hepatocellular carcinoma.J Exp Clin Cancer Res. 2016 Nov 11;35(1):176. doi: 10.1186/s13046-016-0452-6.
• [814] MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.Tumour Biol. 2016 Aug;37(8):11457-67. doi: 10.1007/s13277-016-5022-1. Epub 2016 Mar 24.
• [815] JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells.Hepatobiliary Pancreat Dis Int. 2010 Jun;9(3):287-95.
• [816] Circ_0001955 facilitates hepatocellular carcinoma (HCC) tumorigenesis by sponging miR-516a-5p to release TRAF6 and MAPK11.Cell Death Dis. 2019 Dec 10;10(12):945. doi: 10.1038/s41419-019-2176-y.
• [817] Gene expression profiles of hepatoma cell line HLE.World J Gastroenterol. 2003 Apr;9(4):683-7. doi: 10.3748/wjg.v9.i4.683.
• [818] The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma.Gut. 2015 Sep;64(9):1454-65. doi: 10.1136/gutjnl-2014-306761. Epub 2014 Sep 2.
• [819] Wnt/-catenin signaling regulates MAPK and Akt1 expression and growth of hepatocellular carcinoma cells.Neoplasma. 2011;58(3):239-44. doi: 10.4149/neo_2011_03_239.
• [820] Effect of propofol and sevoflurane anesthesia on postoperative cognitive function and levels of A-42 and Tau in patients undergoing hepatectomy.Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):849-856. doi: 10.26355/eurrev_201901_16900.
• [821] 8-bromo-5-hydroxy-7-methoxychrysin targeting for inhibition of the properties of liver cancer stem cells by modulation of Twist signaling.Int J Oncol. 2013 Nov;43(5):1719-29. doi: 10.3892/ijo.2013.2071. Epub 2013 Aug 21.
• [822] Survivin (BIRC5) cell cycle computational network in human no-tumor hepatitis/cirrhosis and hepatocellular carcinoma transformation.J Cell Biochem. 2011 May;112(5):1286-94. doi: 10.1002/jcb.23030.
• [823] MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes.Oncotarget. 2019 Apr 19;10(29):2835-2854. doi: 10.18632/oncotarget.26838. eCollection 2019 Apr 19.
• [824] Carboxyl-terminal truncated HBx contributes to invasion and metastasis via deregulating metastasis suppressors in hepatocellular carcinoma.Oncotarget. 2016 Aug 23;7(34):55110-55127. doi: 10.18632/oncotarget.10399.
• [825] Dysregulated cancer cell transdifferentiation into erythrocytes is an additional metabolic stress in hepatocellular carcinoma.Tumour Biol. 2018 Nov;40(11):1010428318811467. doi: 10.1177/1010428318811467.
• [826] The regulatory protein GADD34 inhibits TRAIL-induced apoptosis via TRAF6/ERK-dependent stabilization of myeloid cell leukemia 1 in liver cancer cells.J Biol Chem. 2019 Apr 12;294(15):5945-5955. doi: 10.1074/jbc.RA118.006029. Epub 2019 Feb 19.
• [827] Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex.Cell Death Dis. 2019 Jun 11;10(6):453. doi: 10.1038/s41419-019-1676-0.
• [828] Diagnostic accuracy of midkine for hepatocellular carcinoma: A meta-analysis.Mol Genet Genomic Med. 2020 Feb;8(2):e1071. doi: 10.1002/mgg3.1071. Epub 2019 Nov 27.
• [829] XPD suppresses cell proliferation and migration via miR-29a-3p-Mdm2/PDGF-B axis in HCC.Cell Biosci. 2019 Jan 5;9:6. doi: 10.1186/s13578-018-0269-4. eCollection 2019.
• [830] Melittin induces PTCH1 expression by down-regulating MeCP2 in human hepatocellular carcinoma SMMC-7721 cells.Toxicol Appl Pharmacol. 2015 Oct 1;288(1):74-83. doi: 10.1016/j.taap.2015.07.010. Epub 2015 Jul 17.
• [831] Correction to: MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis.Cancer Cell Int. 2018 Apr 10;18:55. doi: 10.1186/s12935-018-0556-5. eCollection 2018.
• [832] Host genetic variants influencing the clinical course of hepatitis C virus infection.J Med Virol. 2016 Feb;88(2):185-95. doi: 10.1002/jmv.24334. Epub 2015 Aug 4.
• [833] The cyanobacterial oligopeptides microginins induce DNA damage in the human hepatocellular carcinoma (HepG2) cell line.Chemosphere. 2020 Feb;240:124880. doi: 10.1016/j.chemosphere.2019.124880. Epub 2019 Sep 16.
• [834] Role of P14 and MGMT gene methylation in hepatocellular carcinomas: a meta-analysis.Asian Pac J Cancer Prev. 2014;15(16):6591-6. doi: 10.7314/apjcp.2014.15.16.6591.
• [835] Synthesis and preliminary biological evaluation for the anticancer activity of organochalcogen (S/se) tethered chrysin-based organometallic Ru(II)((6)-p-cymene) complexes.J Biomol Struct Dyn. 2019 Aug;37(13):3337-3353. doi: 10.1080/07391102.2018.1513867. Epub 2018 Nov 19.
• [836] Polymorphisms in the 3'-UTR of SCD5 gene are associated with hepatocellular carcinoma in Korean population.Mol Biol Rep. 2018 Dec;45(6):1705-1714. doi: 10.1007/s11033-018-4313-6. Epub 2018 Aug 30.
• [837] Elevated expression of cellular SYNE1, MMP10, and GTPase1 and their regulatory role in hepatocellular carcinoma progression.Protoplasma. 2020 Jan;257(1):157-167. doi: 10.1007/s00709-019-01423-w. Epub 2019 Aug 19.
• [838] Impact of matrix metalloproteinase-11 gene polymorphisms upon the development and progression of hepatocellular carcinoma.Int J Med Sci. 2018 Apr 3;15(6):653-658. doi: 10.7150/ijms.23733. eCollection 2018.
• [839] Dual functions of ARP101 in targeting membrane type-1 matrix metalloproteinase: Impact on U87 glioblastoma cell invasion and autophagy signaling.Chem Biol Drug Des. 2019 Mar;93(3):272-282. doi: 10.1111/cbdd.13410. Epub 2018 Oct 30.
• [840] MMP16 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma.Oncotarget. 2017 Aug 7;8(42):72197-72204. doi: 10.18632/oncotarget.20060. eCollection 2017 Sep 22.
• [841] CR6-interacting factor 1 inhibits invasiveness by suppressing TGF--mediated epithelial-mesenchymal transition in hepatocellular carcinoma.Oncotarget. 2017 Oct 19;8(55):94759-94768. doi: 10.18632/oncotarget.21925. eCollection 2017 Nov 7.
• [842] Identification of a human hepatocellular carcinoma-associated tumor suppressor gene by differential display polymerase chain reaction.Life Sci. 1995;57(11):1077-85. doi: 10.1016/0024-3205(95)02053-l.
• [843] MRC2 expression correlates with TGF1 and survival in hepatocellular carcinoma.Int J Mol Sci. 2014 Aug 26;15(9):15011-25. doi: 10.3390/ijms150915011.
• [844] Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells.FEBS Lett. 2015 Apr 2;589(8):897-903. doi: 10.1016/j.febslet.2015.02.026. Epub 2015 Mar 3.
• [845] Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.Cancer Lett. 2017 Jan 1;384:50-59. doi: 10.1016/j.canlet.2016.10.007. Epub 2016 Oct 6.
• [846] Sulfatase-1 knockdown promotes in vitro and in vivo aggressive behavior of murine hepatocarcinoma Hca-P cells through up-regulation of mesothelin.J Cell Commun Signal. 2018 Sep;12(3):603-613. doi: 10.1007/s12079-017-0411-9. Epub 2017 Dec 23.
• [847] Methionine Sulfoxide Reductase B1 Regulates Hepatocellular Carcinoma Cell Proliferation and Invasion via the Mitogen-Activated Protein Kinase Pathw... Oxid Med Cell Longev. 2018 May 10;2018:5287971.
• [848] The DNA methylation profile of liver tumors in C3H mice and identification of differentially methylated regions involved in the regulation of tumorigenic genes.BMC Cancer. 2018 Mar 22;18(1):317. doi: 10.1186/s12885-018-4221-0.
• [849] Astrocyte elevated gene 1 (AEG-1) promotes anoikis resistance and metastasis by inducing autophagy in hepatocellular carcinoma.J Cell Physiol. 2020 Jun;235(6):5084-5095. doi: 10.1002/jcp.29377. Epub 2019 Nov 6.
• [850] The phosphoinositide 3-kinase pathway and glycogen synthase kinase-3 positively regulate the activity of metal-responsive transcription factor-1 in response to zinc ions.Biochem Cell Biol. 2018 Apr 30:1-8. doi: 10.1139/bcb-2018-0073. Online ahead of print.
• [851] Prognostic Significance of 14-3-3, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.Anticancer Res. 2018 Dec;38(12):6855-6863. doi: 10.21873/anticanres.13060.
• [852] A splicing variant leads to complete loss of function of betaine-homocysteine methyltransferase (BHMT) gene in hepatocellular carcinoma.Int J Biochem Cell Biol. 2012 Feb;44(2):385-92. doi: 10.1016/j.biocel.2011.11.014. Epub 2011 Nov 26.
• [853] Identification of antisense transcripts of the microsomal triglyceride transfer protein genes in humans and mice.Biochem Biophys Res Commun. 2019 Sep 17;517(2):317-323. doi: 10.1016/j.bbrc.2019.07.069. Epub 2019 Jul 25.
• [854] Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma.Sci Rep. 2017 Mar 21;7(1):244. doi: 10.1038/s41598-017-00357-8.
• [855] An intronic single nucleotide polymorphism in the MUTYH gene is associated with increased risk for HCV-induced hepatocellular carcinoma.Free Radic Biol Med. 2018 Dec;129:88-96. doi: 10.1016/j.freeradbiomed.2018.09.010. Epub 2018 Sep 13.
• [856] Overexpression and correlation of HIF-2, VEGFA and EphA2 in residual hepatocellular carcinoma following high-intensity focused ultrasound treatment: Implications for tumor recurrence and progression.Exp Ther Med. 2017 Jun;13(6):3529-3534. doi: 10.3892/etm.2017.4428. Epub 2017 May 4.
• [857] A positive feedback loop involving the LINC00346/-catenin/MYC axis promotes hepatocellular carcinoma development.Cell Oncol (Dordr). 2020 Feb;43(1):137-153. doi: 10.1007/s13402-019-00478-4. Epub 2019 Nov 5.
• [858] Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid.Proc Natl Acad Sci U S A. 2018 May 8;115(19):4969-4974. doi: 10.1073/pnas.1802279115. Epub 2018 Apr 23.
• [859] MyD88-dependent signaling in non-parenchymal cells promotes liver carcinogenesis.Carcinogenesis. 2020 Apr 22;41(2):171-181. doi: 10.1093/carcin/bgy173.
• [860] FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells.Oncol Lett. 2018 Dec;16(6):7231-7238. doi: 10.3892/ol.2018.9541. Epub 2018 Oct 3.
• [861] Detection of tyrosinephosphorylated proteins in hepatocellular carcinoma tissues using a combination of GSTNck1SH2 pulldown and twodimensional electrophoresis.Mol Med Rep. 2013 Apr;7(4):1209-14. doi: 10.3892/mmr.2013.1324. Epub 2013 Feb 19.
• [862] Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Loss Activates Purine Metabolism and Promotes Hepatocellular Carcinoma Progression.Hepatology. 2019 Nov;70(5):1785-1803. doi: 10.1002/hep.30703. Epub 2019 Jun 21.
• [863] MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma.J Exp Clin Cancer Res. 2014 Sep 18;33(1):76. doi: 10.1186/s13046-014-0076-7.
• [864] GRIM-19 over-expression represses the proliferation and invasion of orthotopically implanted hepatocarcinoma tumors associated with downregulation of Stat3 signaling.Biosci Trends. 2019;13(4):342-350. doi: 10.5582/bst.2019.01185.
• [865] Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib.Oncol Rep. 2019 Jun;41(6):3257-3269. doi: 10.3892/or.2019.7098. Epub 2019 Apr 4.
• [866] NEDD9 may regulate hepatocellular carcinoma cell metastasis by promoting epithelial-mesenchymal-transition and stemness via repressing Smad7.Oncotarget. 2017 Jan 3;8(1):1714-1724. doi: 10.18632/oncotarget.13852.
• [867] NIMA-related kinase 2 overexpression is associated with poor survival in cancer patients: a systematic review and meta-analysis.Cancer Manag Res. 2019 Jan 3;11:455-465. doi: 10.2147/CMAR.S188347. eCollection 2019.
• [868] An inhibitory role of NEK6 in TGF/Smad signaling pathway.BMB Rep. 2015 Aug;48(8):473-8. doi: 10.5483/bmbrep.2015.48.8.225.
• [869] Anti-Cancer Effects of Citalopram on Hepatocellular Carcinoma Cells Occur via Cytochrome C Release and the Activation of NF-kB.Anticancer Agents Med Chem. 2017 Nov 24;17(11):1570-1577. doi: 10.2174/1871520617666170327155930.
• [870] Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features.PLoS One. 2013;8(2):e56130. doi: 10.1371/journal.pone.0056130. Epub 2013 Feb 14.
• [871] NLRC and NLRX gene family mRNA expression and prognostic value in hepatocellular carcinoma.Cancer Med. 2017 Nov;6(11):2660-2672. doi: 10.1002/cam4.1202. Epub 2017 Sep 29.
• [872] NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway.Int J Biochem Cell Biol. 2013 Jun;45(6):1099-108. doi: 10.1016/j.biocel.2013.02.017. Epub 2013 Mar 7.
• [873] Downregulation of NPM reverses multidrug resistance in human hepatoma cells via inhibition of P-glycoprotein expression.Mol Med Rep. 2017 Apr;15(4):2360-2368. doi: 10.3892/mmr.2017.6246. Epub 2017 Feb 24.
• [874] Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.Cell Commun Signal. 2019 Oct 16;17(1):127. doi: 10.1186/s12964-019-0430-7.
• [875] Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization.Oncol Lett. 2017 Sep;14(3):3028-3034. doi: 10.3892/ol.2017.6489. Epub 2017 Jun 28.
• [876] Waltonitone inhibits proliferation of hepatoma cells and tumorigenesis via FXR-miR-22-CCNA2 signaling pathway.Oncotarget. 2016 Nov 15;7(46):75165-75175. doi: 10.18632/oncotarget.12614.
• [877] MicroRNA-766 promotes cancer progression by targeting NR3C2 in hepatocellular carcinoma.FASEB J. 2019 Jan;33(1):1456-1467. doi: 10.1096/fj.201801151R. Epub 2018 Aug 21.
• [878] Nur77 suppresses hepatocellular carcinoma via switching glucose metabolism toward gluconeogenesis through attenuating phosphoenolpyruvate carboxykinase sumoylation.Nat Commun. 2017 Feb 27;8:14420. doi: 10.1038/ncomms14420.
• [879] Activated Notch signaling augments cell growth in hepatocellular carcinoma via up-regulating the nuclear receptor NR4A2.Oncotarget. 2017 Apr 4;8(14):23289-23302. doi: 10.18632/oncotarget.15576.
• [880] NOR1 expression and its relationship with prognosis in patients with hepatocellular carcinoma.J BUON. 2017 Sep-Oct;22(5):1186-1190.
• [881] Regulation of liver receptor homologue-1 by DDB2 E3 ligase activity is critical for hepatic glucose metabolism.Sci Rep. 2019 Mar 28;9(1):5304. doi: 10.1038/s41598-019-41411-x.
• [882] Neuropilin 1 (NRP1) is a novel tumor marker in hepatocellular carcinoma.Clin Chim Acta. 2018 Oct;485:158-165. doi: 10.1016/j.cca.2018.06.046. Epub 2018 Jun 30.
• [883] CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110 and predicts poor prognosis.J Hematol Oncol. 2019 Apr 11;12(1):37. doi: 10.1186/s13045-019-0724-7.
• [884] Hepatocellular carcinoma-associated depletion of the netrin-1 receptor Uncoordinated Phenotype-5A (UNC5A) skews the hepatic unfolded protein response towards prosurvival outcomes.Biochem Biophys Res Commun. 2018 Jan 22;495(4):2425-2431. doi: 10.1016/j.bbrc.2017.12.129. Epub 2017 Dec 24.
• [885] DNA methylation-dependent regulation of TrkA, TrkB, and TrkC genes in human hepatocellular carcinoma.Biochem Biophys Res Commun. 2011 Mar 4;406(1):89-95. doi: 10.1016/j.bbrc.2011.01.116. Epub 2011 Feb 3.
• [886] Neurotensin/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of Tumor-Associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells.Oncoimmunology. 2018 Mar 13;7(7):e1440166. doi: 10.1080/2162402X.2018.1440166. eCollection 2018.
• [887] ARK5 promotes invasion and migration in hepatocellular carcinoma cells by regulating epithelial-mesenchymal transition.Oncol Lett. 2018 Feb;15(2):1511-1516. doi: 10.3892/ol.2017.7453. Epub 2017 Nov 21.
• [888] Anti-hepatocellular carcinoma properties of the anti-alcoholism drug disulfiram discovered to enzymatically inhibit the AMPK-related kinase SNARK in vitro.Oncotarget. 2016 Nov 15;7(46):74987-74999. doi: 10.18632/oncotarget.11820.
• [889] NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection.Int J Cancer. 2019 Aug 1;145(3):662-670. doi: 10.1002/ijc.32134. Epub 2019 Feb 4.
• [890] ODC1 promotes proliferation and mobility via the AKT/GSK3/-catenin pathway and modulation of acidotic microenvironment in human hepatocellular carcinoma.Onco Targets Ther. 2019 May 27;12:4081-4092. doi: 10.2147/OTT.S198341. eCollection 2019.
• [891] Integrated Proteomic and Transcriptomic Analysis Reveals Long Noncoding RNA HOX Transcript Antisense Intergenic RNA (HOTAIR) Promotes Hepatocellular Carcinoma Cell Proliferation by Regulating Opioid Growth Factor Receptor (OGFr).Mol Cell Proteomics. 2018 Jan;17(1):146-159. doi: 10.1074/mcp.RA117.000277. Epub 2017 Oct 27.
• [892] Combined radionuclide-chemotherapy and in vivo imaging of hepatocellular carcinoma cells after transfection of a triple-gene construct, NIS, HSV1-sr39tk, and EGFP.Cancer Lett. 2010 Apr 1;290(1):129-38. doi: 10.1016/j.canlet.2009.09.004. Epub 2009 Oct 9.
• [893] Chromosomal abnormalities in liver cell dysplasia detected by comparative genomic hybridisation.Mol Pathol. 2001 Aug;54(4):270-4. doi: 10.1136/mp.54.4.270.
• [894] The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.Br J Anaesth. 2019 Jun;122(6):e157-e167. doi: 10.1016/j.bja.2018.09.030. Epub 2018 Dec 12.
• [895] CXCR7 correlates with the differentiation of hepatocellular carcinoma and suppresses HNF4 expression through the ERK pathway.Oncol Rep. 2014 Dec;32(6):2387-96. doi: 10.3892/or.2014.3501. Epub 2014 Sep 19.
• [896] Genomewide association study for C-reactive protein in Indians replicates known associations of common variants.J Genet. 2019 Mar;98:20.
• [897] Ornithine transcarbamylase downregulation is associated with poor prognosis in hepatocellular carcinoma.Oncol Lett. 2019 Jun;17(6):5030-5038. doi: 10.3892/ol.2019.10174. Epub 2019 Mar 21.
• [898] Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma.Genes Chromosomes Cancer. 2009 Dec;48(12):1057-68. doi: 10.1002/gcc.20708.
• [899] P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients.Oncotarget. 2015 Dec 1;6(38):41162-79. doi: 10.18632/oncotarget.6240.
• [900] Role of purinergic receptors in hepatobiliary carcinoma in Pakistani population: an approach towards proinflammatory role of P2X4 and P2X7 receptors.Purinergic Signal. 2019 Sep;15(3):367-374. doi: 10.1007/s11302-019-09675-0. Epub 2019 Aug 10.
• [901] Upregulation of P2Y2 nucleotide receptor in human hepatocellular carcinoma cells.J Int Med Res. 2016 Dec;44(6):1234-1247. doi: 10.1177/0300060516662135. Epub 2016 Nov 2.
• [902] circRNA of AR-suppressed PABPC1 91 bp enhances the cytotoxicity of natural killer cells against hepatocellular carcinoma via upregulating UL16 binding protein 1.Oncol Lett. 2019 Jan;17(1):388-397. doi: 10.3892/ol.2018.9606. Epub 2018 Oct 22.
• [903] Decreased PADI4 mRNA association with global hypomethylation in hepatocellular carcinoma during HBV exposure.Cell Biochem Biophys. 2013 Mar;65(2):187-95. doi: 10.1007/s12013-012-9417-3.
• [904] PAK1 promotes proliferation, migration and invasion of hepatocellular carcinoma by facilitating EMT via directly up-regulating Snail.Genomics. 2020 Jan;112(1):694-702. doi: 10.1016/j.ygeno.2019.05.002. Epub 2019 May 7.
• [905] Expression and prognostic significance of p21-activated kinase 6 in hepatocellular carcinoma.J Surg Res. 2014 Jun 1;189(1):81-8. doi: 10.1016/j.jss.2014.01.049. Epub 2014 Jan 29.
• [906] p21-activated kinase 4 as a switch between caspase-8 apoptosis and NF-B survival signals in response to TNF- in hepatocarcinoma cells.Biochem Biophys Res Commun. 2018 Sep 18;503(4):3003-3010. doi: 10.1016/j.bbrc.2018.08.085. Epub 2018 Aug 24.
• [907] Evaluation of dendrimer type bio-reducible polymer as a siRNA delivery carrier for cancer therapy.J Control Release. 2015 Jul 10;209:179-85. doi: 10.1016/j.jconrel.2015.04.039. Epub 2015 Apr 30.
• [908] Autophagy suppresses radiation damage by activating PARP-1 and attenuating reactive oxygen species in hepatoma cells.Int J Radiat Biol. 2019 Aug;95(8):1051-1057. doi: 10.1080/09553002.2019.1605461. Epub 2019 Apr 24.
• [909] Aberrant methylation of tumour suppressor genes WT1, GATA5 and PAX5 in hepatocellular carcinoma.Clin Chem Lab Med. 2016 Dec 1;54(12):1971-1980. doi: 10.1515/cclm-2015-1198.
• [910] PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway.Cancer Lett. 2019 Jun 28;452:90-102. doi: 10.1016/j.canlet.2019.03.028. Epub 2019 Mar 23.
• [911] Cholangiolocellular Carcinoma With "Ductal Plate Malformation" Pattern May Be Characterized by ARID1A Genetic Alterations.Am J Surg Pathol. 2019 Mar;43(3):352-360. doi: 10.1097/PAS.0000000000001201.
• [912] Could PCSK9 be a new therapeutic target of Eugenol? In vitro and in silico evaluation of hypothesis.Med Hypotheses. 2020 Mar;136:109513. doi: 10.1016/j.mehy.2019.109513. Epub 2019 Nov 27.
• [913] TPP-related mitochondrial targeting copper (II) complex induces p53-dependent apoptosis in hepatoma cells through ROS-mediated activation of Drp1.Cell Commun Signal. 2019 Nov 19;17(1):149. doi: 10.1186/s12964-019-0468-6.
• [914] Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis.Front Oncol. 2019 Feb 13;9:47. doi: 10.3389/fonc.2019.00047. eCollection 2019.
• [915] Genome-wide analysis of copy number variation identifies candidate gene loci associated with the progression of non-alcoholic fatty liver disease.PLoS One. 2014 Apr 17;9(4):e95604. doi: 10.1371/journal.pone.0095604. eCollection 2014.
• [916] Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.Cancer Med. 2013 Feb;2(1):40-9. doi: 10.1002/cam4.56. Epub 2013 Feb 3.
• [917] PDE4a predicts poor prognosis and promotes metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.J Cancer. 2018 Jun 14;9(13):2389-2396. doi: 10.7150/jca.24079. eCollection 2018.
• [918] Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.J Hepatol. 2019 Mar;70(3):449-457. doi: 10.1016/j.jhep.2018.10.040. Epub 2018 Nov 9.
• [919] Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma.Oncotarget. 2014 Nov 15;5(21):10307-17. doi: 10.18632/oncotarget.2537.
• [920] Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System for the treatment of hepatocellular carcinoma.PLoS One. 2017 Sep 1;12(9):e0183861. doi: 10.1371/journal.pone.0183861. eCollection 2017.
• [921] Inhibition of microRNA-214 ameliorates hepatic fibrosis and tumor incidence in platelet-derived growth factor C transgenic mice.Cancer Sci. 2015 Sep;106(9):1143-52. doi: 10.1111/cas.12730. Epub 2015 Sep 1.
• [922] Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway.Oncotarget. 2013 Nov;4(11):1999-2009. doi: 10.18632/oncotarget.1471.
• [923] Lenvatinib as a therapy for unresectable hepatocellular carcinoma.Expert Rev Anticancer Ther. 2018 Nov;18(11):1069-1076. doi: 10.1080/14737140.2018.1524297. Epub 2018 Sep 21.
• [924] Quantitative screening of serum protein biomarkers by reverse phase protein arrays.Oncotarget. 2018 Aug 24;9(66):32624-32641. doi: 10.18632/oncotarget.25976. eCollection 2018 Aug 24.
• [925] Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma.Br J Cancer. 2020 Jan;122(1):111-120. doi: 10.1038/s41416-019-0639-7. Epub 2019 Dec 10.
• [926] Heterogeneity in predisposition of hepatic cells to be induced into pancreatic endocrine cells by PDX-1.World J Gastroenterol. 2005 Apr 21;11(15):2277-82. doi: 10.3748/wjg.v11.i15.2277.
• [927] Tumor-promoting/progressing role of additional chromosome instability in hepatic carcinogenesis in Sgo1 (Shugoshin 1) haploinsufficient mice.Carcinogenesis. 2015 Apr;36(4):429-40. doi: 10.1093/carcin/bgv011. Epub 2015 Mar 4.
• [928] Potential Therapeutic Applications of MDA-9/Syntenin-NF-B-RKIP Loop in Human Liver Carcinoma.Curr Mol Med. 2018;18(9):630-639. doi: 10.2174/1566524019666190104105043.
• [929] Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies.Arch Biochem Biophys. 2019 Jan;661:97-106. doi: 10.1016/j.abb.2018.11.008. Epub 2018 Nov 13.
• [930] Expression of phosphatidylethanolamine N-methyltransferase in human hepatocellular carcinomas.Oncology. 2003;65(2):152-8. doi: 10.1159/000072341.
• [931] PFKFB3/HIF-1 feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.Biochem Biophys Res Commun. 2019 Jun 4;513(3):642-650. doi: 10.1016/j.bbrc.2019.03.109. Epub 2019 Apr 10.
• [932] CAF-induced placental growth factor facilitates neoangiogenesis in hepatocellular carcinoma.Acta Biochim Biophys Sin (Shanghai). 2020 Jan 2;52(1):18-25. doi: 10.1093/abbs/gmz134.
• [933] PHF8 Plays an Oncogene Function in Hepatocellular Carcinoma Formation.Oncol Res. 2019 May 7;27(5):613-621. doi: 10.3727/096504018X15410353669149. Epub 2019 Feb 14.
• [934] NRF2 SUMOylation promotes de novo serine synthesis and maintains HCC tumorigenesis.Cancer Lett. 2019 Dec 1;466:39-48. doi: 10.1016/j.canlet.2019.09.010. Epub 2019 Sep 20.
• [935] Overexpression of phosphatidylinositol 4-kinase type III is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma.BMC Cancer. 2014 Jan 6;14:7. doi: 10.1186/1471-2407-14-7.
• [936] MicroRNA-26b-5p enhances T cell responses by targeting PIM-2 in hepatocellular carcinoma.Cell Signal. 2019 Jul;59:182-190. doi: 10.1016/j.cellsig.2018.11.011. Epub 2018 Dec 27.
• [937] Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells.Oncotarget. 2017 Aug 10;8(42):72652-72665. doi: 10.18632/oncotarget.20194. eCollection 2017 Sep 22.
• [938] Discovery of 4,6-bis(benzyloxy)-3-phenylbenzofuran as a novel Pin1 inhibitor to suppress hepatocellular carcinoma via upregulating microRNA biogenesis.Bioorg Med Chem. 2019 Jun 1;27(11):2235-2244. doi: 10.1016/j.bmc.2019.04.028. Epub 2019 Apr 19.
• [939] Overexpression of PKMYT1 indicates the poor prognosis and enhances proliferation and tumorigenesis in non-small cell lung cancer via activation of Notch signal pathway.Eur Rev Med Pharmacol Sci. 2019 May;23(10):4210-4219. doi: 10.26355/eurrev_201905_17925.
• [940] Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA.Lipids Health Dis. 2017 Jan 11;16(1):5. doi: 10.1186/s12944-016-0400-7.
• [941] Cytosolic phospholipase A2 modulates cell-matrix adhesion via the FAK/paxillin pathway in hepatocellular carcinoma.Cancer Biol Med. 2019 May;16(2):377-390. doi: 10.20892/j.issn.2095-3941.2018.0386.
• [942] [Corrigendum] Oncogenic function of Plac1 on the proliferation and metastasis in hepatocellular carcinoma cells.Oncol Rep. 2019 Mar;41(3):2068. doi: 10.3892/or.2019.6955. Epub 2019 Jan 4.
• [943] MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.J Cell Physiol. 2007 Aug;212(2):526-36. doi: 10.1002/jcp.21049.
• [944] Diagnostic and prognostic value of mRNA expression of phospholipase C family genes in hepatitis B virusassociated hepatocellular carcinoma.Oncol Rep. 2019 May;41(5):2855-2875. doi: 10.3892/or.2019.7066. Epub 2019 Mar 14.
• [945] Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection.BMC Cancer. 2019 Dec 2;19(1):1169. doi: 10.1186/s12885-019-6397-3.
• [946] Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.Anticancer Agents Med Chem. 2019;19(6):740-749. doi: 10.2174/1871520619666190301145637.
• [947] Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma.Hepatology. 2010 Mar;51(3):857-68. doi: 10.1002/hep.23467.
• [948] PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection.Liver Int. 2012 Jan;32(1):110-8. doi: 10.1111/j.1478-3231.2011.02619.x. Epub 2011 Aug 11.
• [949] Flavonoid Composition and Antitumor Activity of Bee Bread Collected in Northeast Portugal.Molecules. 2017 Feb 7;22(2):248. doi: 10.3390/molecules22020248.
• [950] Promyelocytic leukemia protein deficiency leads to spontaneous formation of liver tumors in hepatitis C virus transgenic mice.Cancer Med. 2019 Jul;8(8):3793-3802. doi: 10.1002/cam4.2162. Epub 2019 May 29.
• [951] Mismatch repair genes (hMLH1, hPMS1, hPMS2, GTBP/hMSH6, hMSH2) in the pathogenesis of hepatocellular carcinoma.World J Gastroenterol. 2005 May 28;11(20):3020-6. doi: 10.3748/wjg.v11.i20.3020.
• [952] An ultrasonic nanobubble-mediated PNP/fludarabine suicide gene system: A new approach for the treatment of hepatocellular carcinoma.PLoS One. 2018 May 2;13(5):e0196686. doi: 10.1371/journal.pone.0196686. eCollection 2018.
• [953] Genetic variants and Expression of Cytochrome p450 Oxidoreductase Predict Postoperative Survival in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma.J Cancer. 2019 Feb 23;10(6):1453-1465. doi: 10.7150/jca.28919. eCollection 2019.
• [954] Periostin involved in the activated hepatic stellate cells-induced progression of residual hepatocellular carcinoma after sublethal heat treatment: its role and potential for therapeutic inhibition.J Transl Med. 2018 Nov 6;16(1):302. doi: 10.1186/s12967-018-1676-3.
• [955] SIRT4 silencing in tumor-associated macrophages promotes HCC development via PPAR signalling-mediated alternative activation of macrophages.J Exp Clin Cancer Res. 2019 Nov 19;38(1):469. doi: 10.1186/s13046-019-1456-9.
• [956] Molecular cloning of human amidophosphoribosyltransferase.Biochem Biophys Res Commun. 1993 Jan 15;190(1):192-200. doi: 10.1006/bbrc.1993.1030.
• [957] High expression level of peptidylprolyl isomerase A is correlated with poor prognosis of liver hepatocellular carcinoma.Oncol Lett. 2019 Nov;18(5):4691-4702. doi: 10.3892/ol.2019.10846. Epub 2019 Sep 10.
• [958] Release of overexpressed CypB activates ERK signaling through CD147 binding for hepatoma cell resistance to oxidative stress.Apoptosis. 2012 Aug;17(8):784-96. doi: 10.1007/s10495-012-0730-5.
• [959] Expression of P450 and nuclear receptors in normal and end-stage Chinese livers.World J Gastroenterol. 2014 Jul 14;20(26):8681-90. doi: 10.3748/wjg.v20.i26.8681.
• [960] A suppressive role of ionizing radiation-responsive miR-29c in the development of liver carcinoma via targeting WIP1.Oncotarget. 2015 Apr 30;6(12):9937-50. doi: 10.18632/oncotarget.3157.
• [961] Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6R signaling.Cell Rep. 2013 Aug 29;4(4):669-80. doi: 10.1016/j.celrep.2013.07.023. Epub 2013 Aug 15.
• [962] Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma.Cancer Biol Ther. 2016;17(2):151-62. doi: 10.1080/15384047.2015.1121345. Epub 2015 Nov 30.
• [963] Knockdown of protein phosphatase 5 (PPP5C) suppresses the growth of leukemic cell line U937.Cell Mol Biol (Noisy-le-grand). 2016 Sep 30;62(11):27-31.
• [964] Mitochondrial Respiratory Dysfunction Induces Claudin-1 Expression via Reactive Oxygen Species-mediated Heat Shock Factor 1 Activation, Leading to Hepatoma Cell Invasiveness.J Biol Chem. 2015 Aug 28;290(35):21421-31. doi: 10.1074/jbc.M115.654913. Epub 2015 Jul 8.
• [965] Interplay Between Mitochondrial Peroxiredoxins and ROS in Cancer Development and Progression.Int J Mol Sci. 2019 Sep 7;20(18):4407. doi: 10.3390/ijms20184407.
• [966] Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC.Cell Death Dis. 2019 Sep 23;10(10):703. doi: 10.1038/s41419-019-1885-6.
• [967] Dietary fat/cholesterol-sensitive PKC-RB signaling: Potential role in NASH/HCC axis.Oncotarget. 2017 May 15;8(43):73757-73765. doi: 10.18632/oncotarget.17890. eCollection 2017 Sep 26.
• [968] Downregulation of microRNA-143 promotes cell proliferation by regulating PKC in hepatocellular carcinoma cells.Mol Med Rep. 2017 Oct;16(4):4348-4354. doi: 10.3892/mmr.2017.7092. Epub 2017 Jul 27.
• [969] Increased expression of growth hormone and prolactin receptors in hepatocellular carcinomas.Endocrine. 2000 Jun;12(3):265-71. doi: 10.1385/ENDO:12:3:265.
• [970] PRMT1 Promoted HCC Growth and Metastasis In Vitro and In Vivo via Activating the STAT3 Signalling Pathway.Cell Physiol Biochem. 2018;47(4):1643-1654. doi: 10.1159/000490983. Epub 2018 Jun 23.
• [971] Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT--catenin signaling pathway.Carcinogenesis. 2020 Apr 22;41(2):130-138. doi: 10.1093/carcin/bgz065.
• [972] CD133 and epithelial cell adhesion molecule expressions in the cholangiocarcinoma component are prognostic factors for combined hepatocellular cholangiocarcinoma.Hepatol Res. 2020 Feb;50(2):258-267. doi: 10.1111/hepr.13443. Epub 2019 Dec 18.
• [973] PRSS8 is Downregulated and Suppresses Tumour Growth and Metastases in Hepatocellular Carcinoma.Cell Physiol Biochem. 2016;40(3-4):757-769. doi: 10.1159/000453136. Epub 2016 Dec 5.
• [974] Modulation of the gamma-secretase activity as a therapy against human hepatocellular carcinoma.J Cancer Res Ther. 2018 Jun;14(Supplement):S473-S479. doi: 10.4103/0973-1482.174542.
• [975] Transcriptional synergism on the pS2 gene promoter between a p160 coactivator and estrogen receptor-alpha depends on the coactivator subtype, the type of estrogen response element, and the promoter context.Mol Endocrinol. 2002 Nov;16(11):2571-81. doi: 10.1210/me.2002-0051.
• [976] Three Gene Signature for Predicting the Development of Hepatocellular Carcinoma in Chronically Infected Hepatitis C Virus Patients.J Interferon Cytokine Res. 2016 Dec;36(12):698-705. doi: 10.1089/jir.2016.0042. Epub 2016 Oct 11.
• [977] Lin28b is involved in curcumin-reversed paclitaxel chemoresistance and associated with poor prognosis in hepatocellular carcinoma.J Cancer. 2019 Oct 15;10(24):6074-6087. doi: 10.7150/jca.33421. eCollection 2019.
• [978] Association of over-expressed TFDP1 with progression of hepatocellular carcinomas. J Hum Genet. 2003;48(12):609-613.
• [979] Cryptotanshinone (Dsh-003) from Salvia miltiorrhiza Bunge inhibits prostaglandin E2-induced survival and invasion effects in HA22T hepatocellular carcinoma cells. Environ Toxicol. 2018 Dec;33(12):1254-1260. doi: 10.1002/tox.22633. Epub 2018 Sep 12.
• [980] 15d-PGJ?decreases PGE?synthesis in HBx-positive liver cells by interfering EGR1 binding to mPGES-1 promoter.Biochem Pharmacol. 2014 Oct 1;91(3):337-47. doi: 10.1016/j.bcp.2014.07.032. Epub 2014 Aug 6.
• [981] Decreased expression of PTH1R is a poor prognosis in hepatocellular carcinoma.Cancer Biomark. 2018 Feb 14;21(3):723-730. doi: 10.3233/CBM-170823.
• [982] Integrin alpha 7 correlates with poor clinical outcomes, and it regulates cell proliferation, apoptosis and stemness via PTK2-PI3K-Akt signaling pathway in hepatocellular carcinoma.Cell Signal. 2020 Feb;66:109465. doi: 10.1016/j.cellsig.2019.109465. Epub 2019 Nov 5.
• [983] Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma.J Cell Mol Med. 2017 Nov;21(11):3023-3043. doi: 10.1111/jcmm.13213. Epub 2017 May 30.
• [984] Exploring the cause of the inhibitor 4AX attaching to binding site disrupting protein tyrosine phosphatase 4A1 trimerization by molecular dynamic simulation.J Biomol Struct Dyn. 2019 Nov;37(18):4840-4851. doi: 10.1080/07391102.2019.1567392. Epub 2019 Jan 31.
• [985] Up-Regulation of Phosphatase in Regenerating Liver-3 (PRL-3) Contributes to Malignant Progression of Hepatocellular Carcinoma by Activating Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN)/Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway.Med Sci Monit. 2018 Nov 12;24:8105-8114. doi: 10.12659/MSM.913307.
• [986] Expression of cytoskeletal-associated protein tyrosine phosphatase PTPH1 mRNA in human hepatocellular carcinoma.J Gastroenterol. 1994 Dec;29(6):727-32. doi: 10.1007/BF02349278.
• [987] NASH and HCC Are Driven by Different Signaling Pathways with a Common Regulator.Cell Metab. 2019 Jan 8;29(1):3-4. doi: 10.1016/j.cmet.2018.12.012.
• [988] Different but synergistic effects of bone marrow-derived VEGFR2(+) and VEGFR2(-)CD45(+) cells during hepatocellular carcinoma progression.Oncol Lett. 2017 Jan;13(1):63-68. doi: 10.3892/ol.2016.5411. Epub 2016 Nov 22.
• [989] The overexpression of Rabl3 is associated with pathogenesis and clinicopathologic variables in hepatocellular carcinoma.Tumour Biol. 2017 Apr;39(4):1010428317696230. doi: 10.1177/1010428317696230.
• [990] Prognostic value and prospective molecular mechanism of miR-100-5p in hepatocellular carcinoma: A comprehensive study based on 1,258 samples.Oncol Lett. 2019 Dec;18(6):6126-6142. doi: 10.3892/ol.2019.10962. Epub 2019 Oct 4.
• [991] RACK1 Promotes Self-Renewal and Chemoresistance of Cancer Stem Cells in Human Hepatocellular Carcinoma through Stabilizing Nanog.Theranostics. 2019 Jan 24;9(3):811-828. doi: 10.7150/thno.29271. eCollection 2019.
• [992] miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.Liver Int. 2020 Jan;40(1):240-251. doi: 10.1111/liv.14276. Epub 2019 Oct 31.
• [993] Positive feedback loop of IL-1/Akt/RAR/Akt signaling mediates oncogenic property of RAR in gastric carcinoma.Oncotarget. 2017 Jan 24;8(4):6718-6729. doi: 10.18632/oncotarget.14267.
• [994] Retinoic Acid Receptor- Is Downregulated in Hepatocellular Carcinoma and Cirrhosis and Its Expression Inhibits Myosin-Driven Activation and Durotaxis in Hepatic Stellate Cells.Hepatology. 2019 Feb;69(2):785-802. doi: 10.1002/hep.30193. Epub 2018 Dec 17.
• [995] Oncogenic retinoic acid receptor knockdown reverses multi-drug resistance of human colorectal cancer via Wnt/-catenin pathway.Cell Cycle. 2017 Apr 3;16(7):685-692. doi: 10.1080/15384101.2017.1295180. Epub 2017 Mar 8.
• [996] Down-regulation of RASA1 Is Associated with Poor Prognosis in Human Hepatocellular Carcinoma.Anticancer Res. 2017 Feb;37(2):781-785. doi: 10.21873/anticanres.11377.
• [997] Down-regulation of retinol binding protein 5 is associated with aggressive tumor features in hepatocellular carcinoma.J Cancer Res Clin Oncol. 2007 Dec;133(12):929-36. doi: 10.1007/s00432-007-0230-0. Epub 2007 May 12.
• [998] Rce1 suppresses invasion and metastasis of hepatocellular carcinoma via epithelial-mesenchymal transition induced by the TGF-1/H-Ras signaling pathway.J Cell Physiol. 2020 Mar;235(3):2506-2520. doi: 10.1002/jcp.29155. Epub 2019 Sep 11.
• [999] RASSF1A, RECK genotypes and haplotypes in Egyptian population with Hepatocellular carcinoma.Immunol Lett. 2016 May;173:36-41. doi: 10.1016/j.imlet.2016.02.013. Epub 2016 Feb 26.
• [1000] Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation.Diabetologia. 2006 Dec;49(12):3094-9. doi: 10.1007/s00125-006-0437-7. Epub 2006 Sep 27.
• [1001] The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.Hepatol Int. 2019 Mar;13(2):199-204. doi: 10.1007/s12072-019-09929-4. Epub 2019 Jan 22.
• [1002] Mechanism of miR-107-targeting of regulator of G-protein signaling 4 in hepatocellular carcinoma.Oncol Lett. 2019 Nov;18(5):5145-5154. doi: 10.3892/ol.2019.10857. Epub 2019 Sep 12.
• [1003] DLC2/StarD13 plays a role of a tumor suppressor in astrocytoma.Oncol Rep. 2012 Aug;28(2):511-8. doi: 10.3892/or.2012.1819. Epub 2012 May 17.
• [1004] Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.Cancer Res. 2005 Oct 1;65(19):8861-8. doi: 10.1158/0008-5472.CAN-05-1318.
• [1005] Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB.Mol Cancer Res. 2010 May;8(5):691-700. doi: 10.1158/1541-7786.MCR-09-0465. Epub 2010 May 11.
• [1006] Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis.Oncogene. 2015 Jan 15;34(3):364-72. doi: 10.1038/onc.2013.551. Epub 2014 Jan 13.
• [1007] The ribonuclease L-dependent antiviral roles of human 2',5'-oligoadenylate synthetase family members against hepatitis C virus.FEBS Lett. 2013 Jan 16;587(2):156-64. doi: 10.1016/j.febslet.2012.11.010. Epub 2012 Nov 26.
• [1008] Reversing effect of ring finger protein 43 inhibition on malignant phenotypes of human hepatocellular carcinoma.Mol Cancer Ther. 2013 Jan;12(1):94-103. doi: 10.1158/1535-7163.MCT-12-0672. Epub 2012 Nov 6.
• [1009] RNF6 facilitates metastasis and radioresistance in hepatocellular carcinoma through ubiquitination of FoxA1. Exp Cell Res. 2019 Jan 1;374(1):152-161.
• [1010] MiR-490-5p Inhibits Hepatocellular Carcinoma Cell Proliferation, Migration and Invasion by Directly Regulating ROBO1.Pathol Oncol Res. 2019 Jan;25(1):1-9. doi: 10.1007/s12253-017-0305-4. Epub 2017 Sep 19.
• [1011] Quantification of SLIT-ROBO transcripts in hepatocellular carcinoma reveals two groups of genes with coordinate expression.BMC Cancer. 2008 Dec 29;8:392. doi: 10.1186/1471-2407-8-392.
• [1012] Overlapping and unique roles played by ROCK1 and 2 in the modulation of coding and long noncoding RNA expression.BMC Genomics. 2019 May 22;20(1):409. doi: 10.1186/s12864-019-5715-0.
• [1013] RhoC/ROCK2 promotes vasculogenic mimicry formation primarily through ERK/MMPs in hepatocellular carcinoma.Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1113-1125. doi: 10.1016/j.bbadis.2018.12.007. Epub 2019 Feb 16.
• [1014] Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis.World J Gastroenterol. 2012 Mar 28;18(12):1328-38. doi: 10.3748/wjg.v18.i12.1328.
• [1015] Regulation of the human hydroxysteroid sulfotransferase (SULT2A1) by ROR and ROR and its potential relevance to human liver diseases.Mol Endocrinol. 2013 Jan;27(1):106-15. doi: 10.1210/me.2012-1145. Epub 2012 Dec 4.
• [1016] Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling.Redox Biol. 2020 Jan;28:101315. doi: 10.1016/j.redox.2019.101315. Epub 2019 Sep 3.
• [1017] Transmembrane 4L Six Family Member 5 Senses Arginine for mTORC1 Signaling.Cell Metab. 2019 Jun 4;29(6):1306-1319.e7. doi: 10.1016/j.cmet.2019.03.005. Epub 2019 Apr 4.
• [1018] Rsf-1 overexpression serves as a prognostic marker in human hepatocellular carcinoma.Tumour Biol. 2014 Aug;35(8):7595-601. doi: 10.1007/s13277-014-2008-8. Epub 2014 May 6.
• [1019] High Expression of MicroRNA-196a is Associated with Progression of Hepatocellular Carcinoma in Younger Patients.Cancers (Basel). 2019 Oct 13;11(10):1549. doi: 10.3390/cancers11101549.
• [1020] Methylation of tumour suppressor genes RUNX3, RASSF1A and E-Cadherin in HCV-related liver cirrhosis and hepatocellular carcinoma.Br J Biomed Sci. 2020 Jan;77(1):35-40. doi: 10.1080/09674845.2019.1694123. Epub 2019 Dec 2.
• [1021] Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats.BMC Cancer. 2018 Nov 26;18(1):1164. doi: 10.1186/s12885-018-5099-6.
• [1022] Role of S100A3 in human hepatocellular carcinoma and the anticancer effect of sodium cantharidinate. Exp Ther Med. 2017 Jun;13(6):2812-2818.
• [1023] Lack of galectin-1 exacerbates chronic hepatitis, liver fibrosis, and carcinogenesis in murine hepatocellular carcinoma model.FASEB J. 2019 Jul;33(7):7995-8007. doi: 10.1096/fj.201900017R. Epub 2019 Mar 21.
• [1024] Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma.J Mol Med (Berl). 2014 Mar;92(3):291-303. doi: 10.1007/s00109-013-1104-3. Epub 2013 Nov 27.
• [1025] Elevated Serum S100A9 Indicated Poor Prognosis in Hepatocellular Carcinoma after Curative Resection.J Cancer. 2019 Jan 1;10(2):408-415. doi: 10.7150/jca.28409. eCollection 2019.
• [1026] Endoplasmic reticulum resident oxidase ERO1-Lalpha promotes hepatocellular carcinoma metastasis and angiogenesis through the S1PR1/STAT3/VEGF-A pathway.Cell Death Dis. 2018 Oct 30;9(11):1105. doi: 10.1038/s41419-018-1134-4.
• [1027] Serum Amyloid A-Positive Hepatocellular Neoplasm: A New Type of Tumor Arising in Patients with Advanced Alcoholic Disease.Dig Dis. 2015 Sep;33(5):648-54. doi: 10.1159/000438474. Epub 2015 Sep 23.
• [1028] Ganodermanontriol inhibits expression of special AT rich sequence binding protein 1 gene in human hepatocellular carcinoma.J Cancer Res Ther. 2018 Dec;14(Supplement):S964-S968. doi: 10.4103/0973-1482.203597.
• [1029] Cholesterol attenuated the progression of DEN-induced hepatocellular carcinoma via inhibiting SCAP mediated fatty acid de novo synthesis.Biochem Biophys Res Commun. 2019 Feb 19;509(4):855-861. doi: 10.1016/j.bbrc.2018.12.181. Epub 2019 Jan 11.
• [1030] Personalized siRNA-Nanoparticle Systemic Therapy using Metastatic Lymph Node Specimens Obtained with EBUS-TBNA in Lung Cancer.Mol Cancer Res. 2018 Jan;16(1):47-57. doi: 10.1158/1541-7786.MCR-16-0341. Epub 2017 Oct 9.
• [1031] Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target.BMC Cancer. 2019 Aug 1;19(1):760. doi: 10.1186/s12885-019-5963-z.
• [1032] Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma.J Hepatol. 2006 Dec;45(6):825-35. doi: 10.1016/j.jhep.2006.06.016. Epub 2006 Jul 28.
• [1033] Syndecan-1 in Liver Diseases.Pathol Oncol Res. 2020 Apr;26(2):813-819. doi: 10.1007/s12253-019-00617-0. Epub 2019 Mar 2.
• [1034] Cytotoxic and partial hepatoprotective activity of sodium ascorbate against hepatocellular carcinoma through inhibition of sulfatase-2 in vivo and in vitro.Biomed Pharmacother. 2018 Jul;103:362-372. doi: 10.1016/j.biopha.2018.04.060. Epub 2018 Apr 24.
• [1035] Polymorphisms in Genes of Tricarboxylic Acid Cycle Key Enzymes Are Associated with Early Recurrence of Hepatocellular Carcinoma.PLoS One. 2015 Apr 20;10(4):e0124471. doi: 10.1371/journal.pone.0124471. eCollection 2015.
• [1036] MicroRNA-192-5p Promote the Proliferation and Metastasis of Hepatocellular Carcinoma Cell by Targeting SEMA3A.Appl Immunohistochem Mol Morphol. 2017 Apr;25(4):251-260. doi: 10.1097/PAI.0000000000000296.
• [1037] The Balance between Mono- and NEDD8-Chains Controlled by NEDP1 upon DNA Damage Is a Regulatory Module of the HSP70 ATPase Activity.Cell Rep. 2019 Oct 1;29(1):212-224.e8. doi: 10.1016/j.celrep.2019.08.070.
• [1038] Activation of peroxisome proliferator-activated receptor- (PPAR) inhibits hepatoma cell growth via downregulation of SEPT2 expression.Cancer Lett. 2015 Apr 1;359(1):127-35. doi: 10.1016/j.canlet.2015.01.004. Epub 2015 Jan 12.
• [1039] NorUDCA promotes degradation of 1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway.PLoS One. 2018 Aug 1;13(8):e0200897. doi: 10.1371/journal.pone.0200897. eCollection 2018.
• [1040] Comparative analysis of ginsenosides in human glucocorticoid receptor binding, transactivation, and transrepression.Eur J Pharmacol. 2017 Nov 15;815:501-511. doi: 10.1016/j.ejphar.2017.10.019. Epub 2017 Oct 12.
• [1041] Serpin peptidase inhibitor (SERPINB5) haplotypes are associated with susceptibility to hepatocellular carcinoma.Sci Rep. 2016 May 25;6:26605. doi: 10.1038/srep26605.
• [1042] Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activity.PLoS One. 2017 Apr 13;12(4):e0175359. doi: 10.1371/journal.pone.0175359. eCollection 2017.
• [1043] The contrary intracellular and extracellular functions of PEDF in HCC development.Cell Death Dis. 2019 Oct 3;10(10):742. doi: 10.1038/s41419-019-1976-4.
• [1044] Characterisation of a new C1 inhibitor mutant in a patient with hepatocellular carcinoma.Mol Immunol. 2006 Jul;43(14):2161-8. doi: 10.1016/j.molimm.2006.01.006. Epub 2006 Mar 10.
• [1045] HIF-1-derived cell-penetrating peptides inhibit ERK-dependent activation of HIF-1 and trigger apoptosis of cancer cells under hypoxia.Cell Mol Life Sci. 2019 Feb;76(4):809-825. doi: 10.1007/s00018-018-2985-7. Epub 2018 Dec 10.
• [1046] SET7/9 promotes hepatocellular carcinoma progression through regulation of E2F1.Oncol Rep. 2018 Oct;40(4):1863-1874. doi: 10.3892/or.2018.6621. Epub 2018 Aug 2.
• [1047] Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.Hepatology. 2020 Jan;71(1):164-182. doi: 10.1002/hep.30811. Epub 2019 Aug 12.
• [1048] AFP computational secreted network construction and analysis between human hepatocellular carcinoma (HCC) and no-tumor hepatitis/cirrhotic liver tissues.Tumour Biol. 2010 Oct;31(5):417-25. doi: 10.1007/s13277-010-0050-8. Epub 2010 Jun 8.
• [1049] Plasmin-Binding Tripeptide-Decorated Liposomes Loading Pyrazolo[3,4-d]pyrimidines for Targeting Hepatocellular Carcinoma.ACS Med Chem Lett. 2018 May 7;9(7):646-651. doi: 10.1021/acsmedchemlett.8b00062. eCollection 2018 Jul 12.
• [1050] Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma.Lab Invest. 2018 Jun;98(6):734-744. doi: 10.1038/s41374-018-0027-6. Epub 2018 Feb 21.
• [1051] Knockdown of the Sonic Hedgehog (SHH) Gene Inhibits Proliferation of Hep3B and SMMC-7721 Hepatocellular Carcinoma Cells via the PI3K/Akt/PCK1 Signaling Pathway.Med Sci Monit. 2019 Aug 13;25:6023-6033. doi: 10.12659/MSM.914768.
• [1052] Role of salt inducible kinase 1 in high glucose-induced lipid accumulation in HepG2 cells and metformin intervention.Life Sci. 2017 Mar 15;173:107-115. doi: 10.1016/j.lfs.2017.02.001. Epub 2017 Feb 6.
• [1053] Sirtuin2 enhances the tumoricidal function of liver natural killer cells in a mouse hepatocellular carcinoma model.Cancer Immunol Immunother. 2019 Jun;68(6):961-971. doi: 10.1007/s00262-019-02337-5. Epub 2019 Apr 6.
• [1054] SIRT5 Promotes Hepatocellular Carcinoma Progression by Regulating Mitochondrial Apoptosis.J Cancer. 2019 Jun 10;10(16):3871-3882. doi: 10.7150/jca.31266. eCollection 2019.
• [1055] Sirtuin6 (SIRT6) Promotes the EMT of Hepatocellular Carcinoma by Stimulating Autophagic Degradation of E-Cadherin.Mol Cancer Res. 2019 Nov;17(11):2267-2280. doi: 10.1158/1541-7786.MCR-19-0321. Epub 2019 Sep 24.
• [1056] Schistosoma japonicum MiRNA-7-5p Inhibits the Growth and Migration of Hepatoma Cells via Cross-Species Regulation of S-Phase Kinase-Associated Protein 2.Front Oncol. 2019 Mar 22;9:175. doi: 10.3389/fonc.2019.00175. eCollection 2019.
• [1057] NTCP S267F variant associates with decreased susceptibility to HBV and HDV infection and decelerated progression of related liver diseases.Int J Infect Dis. 2019 Mar;80:147-152. doi: 10.1016/j.ijid.2019.01.038. Epub 2019 Jan 24.
• [1058] Low DMT1 Expression Associates With IncreasedOxidative Phosphorylation and EarlyRecurrence in Hepatocellular Carcinoma.J Surg Res. 2019 Feb;234:343-352. doi: 10.1016/j.jss.2018.11.008.
• [1059] Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells.J Biol Chem. 2017 Aug 18;292(33):13890-13901. doi: 10.1074/jbc.M117.783860. Epub 2017 Jun 27.
• [1060] Specific expression of proton-coupled oligopeptide transporter 1 in primary hepatocarcinoma-a novel strategy for tumor-targeted therapy.Oncol Lett. 2017 Oct;14(4):4158-4166. doi: 10.3892/ol.2017.6724. Epub 2017 Aug 4.
• [1061] SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma. Oncotarget. 2015 Jun 30;6(18):16449-60.
• [1062] Targeted inhibition of MCT4 disrupts intracellular pH homeostasis and confers self-regulated apoptosis on hepatocellular carcinoma.Exp Cell Res. 2019 Nov 1;384(1):111591. doi: 10.1016/j.yexcr.2019.111591. Epub 2019 Aug 31.
• [1063] Alpha-fetoprotein to transaminase ratio is related to higher diagnostic efficacy for hepatocellular carcinoma.Medicine (Baltimore). 2019 Apr;98(17):e15414. doi: 10.1097/MD.0000000000015414.
• [1064] Hypoxia-inducible factors enhance glutamate signaling in cancer cells.Oncotarget. 2014 Oct 15;5(19):8853-68. doi: 10.18632/oncotarget.2593.
• [1065] Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1.Clin Pharmacol Ther. 2020 Jan;107(1):227-237. doi: 10.1002/cpt.1588. Epub 2019 Sep 3.
• [1066] Aberrant CpG island hypermethylation and down-regulation of Oct-6 mRNA expression in human hepatocellular carcinoma.Dig Dis Sci. 2011 Oct;56(10):3072-7. doi: 10.1007/s10620-011-1686-y. Epub 2011 Mar 30.
• [1067] Oct3/4 is potentially useful for the suppression of the proliferation and motility of hepatocellular carcinoma cells.Oncol Lett. 2018 Oct;16(4):5243-5248. doi: 10.3892/ol.2018.9292. Epub 2018 Aug 10.
• [1068] Comparison of survival outcomes of alcohol-related hepatocellular carcinoma with or without liver cirrhosis; a ten-year experience.Medicine (Baltimore). 2019 Nov;98(47):e18020. doi: 10.1097/MD.0000000000018020.
• [1069] TO901317 inhibits the development of hepatocellular carcinoma by LXR/Glut1 decreasing glycometabolism.Am J Physiol Gastrointest Liver Physiol. 2019 May 1;316(5):G598-G607. doi: 10.1152/ajpgi.00061.2018. Epub 2019 Feb 28.
• [1070] Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2.Cancer Res. 2014 Sep 1;74(17):4752-61. doi: 10.1158/0008-5472.CAN-13-3531. Epub 2014 Jun 23.
• [1071] Overexpression of Uric Acid Transporter SLC2A9 Inhibits Proliferation of Hepatocellular Carcinoma Cells.Oncol Res. 2019 May 7;27(5):533-540. doi: 10.3727/096504018X15199489058224. Epub 2018 Mar 9.
• [1072] Glucocorticoids regulate the expression of angiotensin AT1 receptors, in the human hepatoma cell line, PLC-PRF-5.Eur J Pharmacol. 1995 Feb 15;288(3):365-71. doi: 10.1016/0922-4106(95)90050-0.
• [1073] Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.Hepatology. 2016 Jan;63(1):159-72. doi: 10.1002/hep.28223. Epub 2015 Nov 26.
• [1074] Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues.Int J Oncol. 2007 Jul;31(1):81-7.
• [1075] miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma.Oncotarget. 2016 Jan 19;7(3):2672-83. doi: 10.18632/oncotarget.6603.
• [1076] Dominant Suppression of 1 Integrin by Ectopic CD98-ICD Inhibits Hepatocellular Carcinoma Progression.Int J Mol Sci. 2016 Nov 10;17(11):1882. doi: 10.3390/ijms17111882.
• [1077] FLIP(L) is critical for aerobic glycolysis in hepatocellular carcinoma.J Exp Clin Cancer Res. 2016 May 13;35:79. doi: 10.1186/s13046-016-0358-3.
• [1078] The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.Int J Mol Sci. 2019 Oct 22;20(20):5237. doi: 10.3390/ijms20205237.
• [1079] Insurance status impacts treatment for hepatocellular carcinoma.Ann Hepatol. 2019 May-Jun;18(3):461-465. doi: 10.1016/j.aohep.2018.10.001. Epub 2019 Apr 12.
• [1080] Inhibition of NET-1 suppresses proliferation and promotes apoptosis of hepatocellular carcinoma cells by activating the PI3K/AKT signaling pathway.Exp Ther Med. 2019 Mar;17(3):2334-2340. doi: 10.3892/etm.2019.7211. Epub 2019 Jan 29.
• [1081] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [1082] Anti-tumor effects of mAb against L-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes.Cancer Sci. 2019 Feb;110(2):674-685. doi: 10.1111/cas.13908. Epub 2019 Jan 4.
• [1083] Suppression of Na+/H + exchanger 1 by RNA interference or amiloride inhibits human hepatoma cell line SMMC-7721 cell invasion.Med Oncol. 2011 Mar;28(1):385-90. doi: 10.1007/s12032-010-9447-x. Epub 2010 Feb 12.
• [1084] microRNA-206 modulates the hepatic expression of the organic anion-transporting polypeptide 1B1.Liver Int. 2019 Dec;39(12):2350-2359. doi: 10.1111/liv.14212. Epub 2019 Sep 3.
• [1085] Gadoxetic acid-enhanced magnetic resonance imaging reflects co-activation of -catenin and hepatocyte nuclear factor 4 in hepatocellular carcinoma.Hepatol Res. 2018 Feb;48(2):205-216. doi: 10.1111/hepr.12911. Epub 2017 Jun 13.
• [1086] Methylation analysis of p16, SLIT2, SCARA5, and Runx3 genes in hepatocellular carcinoma.Medicine (Baltimore). 2017 Oct;96(41):e8279. doi: 10.1097/MD.0000000000008279.
• [1087] The prognostic correlation between CD105 expression level in tumor tissue and peripheral blood and sunitinib administration in advanced hepatocellular carcinoma.Cancer Biol Ther. 2018;19(11):1006-1014. doi: 10.1080/15384047.2018.1470731. Epub 2018 Sep 5.
• [1088] TINAGL1 promotes hepatocellular carcinogenesis through the activation of TGF- signaling-medicated VEGF expression.Cancer Manag Res. 2019 Jan 15;11:767-775. doi: 10.2147/CMAR.S190390. eCollection 2019.
• [1089] Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7.Gastroenterology. 2017 Jan;152(1):257-270.e7. doi: 10.1053/j.gastro.2016.09.033. Epub 2016 Sep 30.
• [1090] Shikonin suppresses progression and epithelial-mesenchymal transition in hepatocellular carcinoma (HCC) cells by modulating miR-106b/SMAD7/TGF- signaling pathway.Cell Biol Int. 2020 Feb;44(2):467-476. doi: 10.1002/cbin.11247. Epub 2019 Nov 4.
• [1091] lncRNA MALAT1 binds chromatin remodeling subunit BRG1 to epigenetically promote inflammation-related hepatocellular carcinoma progression.Oncoimmunology. 2018 Oct 16;8(1):e1518628. doi: 10.1080/2162402X.2018.1518628. eCollection 2019.
• [1092] Paracrine effects of CCN3 from non-cancerous hepatic cells increase signaling and progression of hepatocellular carcinoma.BMC Cancer. 2019 Apr 27;19(1):395. doi: 10.1186/s12885-019-5603-7.
• [1093] Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.Oncogene. 2019 Jun;38(25):4948-4961. doi: 10.1038/s41388-019-0766-x. Epub 2019 Mar 6.
• [1094] Long non-coding RNA AK058003, as a precursor of miR-15a, interacts with HuR to inhibit the expression of -synuclein in hepatocellular carcinoma cells.Oncotarget. 2017 Feb 7;8(6):9451-9465. doi: 10.18632/oncotarget.14276.
• [1095] Human acyl-CoA:cholesterol acyltransferase 2 gene expression in intestinal Caco-2 cells and in hepatocellular carcinoma.Biochem J. 2006 Mar 15;394(Pt 3):617-26. doi: 10.1042/BJ20051417.
• [1096] Expression and prognostic value of HER-2/neu, STAT3 and SOCS3 in hepatocellular carcinoma.Clin Res Hepatol Gastroenterol. 2019 Jun;43(3):282-291. doi: 10.1016/j.clinre.2018.09.011. Epub 2018 Oct 29.
• [1097] Atorvastatin induces mitochondrial dysfunction and cell apoptosis in HepG2 cells via inhibition of the Nrf2 pathway. J Appl Toxicol. 2019 Oct;39(10):1394-1404. doi: 10.1002/jat.3825. Epub 2019 Aug 18.
• [1098] MicroRNA-548b inhibits proliferation and invasion of hepatocellular carcinoma cells by directly targeting specificity protein 1.Exp Ther Med. 2019 Sep;18(3):2332-2340. doi: 10.3892/etm.2019.7812. Epub 2019 Jul 25.
• [1099] Secreted protein acidic and rich in cysteine gene variants: Impact on susceptibility and survival of hepatocellular carcinoma patients.J Gastroenterol Hepatol. 2019 Aug;34(8):1424-1431. doi: 10.1111/jgh.14541. Epub 2018 Dec 9.
• [1100] Prostate-derived ETS factor improves prognosis and represses proliferation and invasion in hepatocellular carcinoma.Oncotarget. 2017 Jan 31;8(32):52488-52500. doi: 10.18632/oncotarget.14924. eCollection 2017 Aug 8.
• [1101] A novel oncolytic adenovirus inhibits hepatocellular carcinoma growth.J Zhejiang Univ Sci B. 2019 Dec.;20(12):1003-1013. doi: 10.1631/jzus.B1900089.
• [1102] The role of sphingosine kinase 2 in alcoholic liver disease.Dig Liver Dis. 2019 Aug;51(8):1154-1163. doi: 10.1016/j.dld.2019.03.020. Epub 2019 Apr 16.
• [1103] Differential expression of sprouty genes in hepatocellular carcinoma.J Surg Oncol. 2012 Mar;105(3):273-6. doi: 10.1002/jso.22095. Epub 2011 Sep 19.
• [1104] Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target.Sci Transl Med. 2018 Apr 18;10(437):eaap9840. doi: 10.1126/scitranslmed.aap9840.
• [1105] Channeling of newly synthesized fatty acids to cholesterol esterification limits triglyceride synthesis in SND1-overexpressing hepatoma cells.Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Feb;1864(2):137-146. doi: 10.1016/j.bbalip.2018.11.004. Epub 2018 Nov 16.
• [1106] Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients.Med Oncol. 2013 Dec;30(4):707. doi: 10.1007/s12032-013-0707-4. Epub 2013 Aug 31.
• [1107] MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.Mol Cancer. 2017 Jun 12;16(1):103. doi: 10.1186/s12943-017-0675-y.
• [1108] Screening key miRNAs for human hepatocellular carcinoma based on miRNA-mRNA functional synergistic network.Neoplasma. 2017;64(6):816-823. doi: 10.4149/neo_2017_602.
• [1109] SSRP1 Contributes to the Malignancy of Hepatocellular Carcinoma and Is Negatively Regulated by miR-497.Mol Ther. 2016 May;24(5):903-14. doi: 10.1038/mt.2016.9. Epub 2016 Jan 12.
• [1110] 68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma.Clin Nucl Med. 2019 Mar;44(3):238-239. doi: 10.1097/RLU.0000000000002426.
• [1111] Genomics of hepatitis B virus-related hepatocellular carcinoma and adjacent noncancerous tissues with cDNA microarray.Chin Med J (Engl). 2011 Jul 5;124(13):2057-64.
• [1112] Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilin-2 expression in peri-tumourous liver correlates with increased survival.Liver Int. 2013 Oct;33(9):1428-40. doi: 10.1111/liv.12262. Epub 2013 Jul 21.
• [1113] Silencing of lncRNA SNHG20 delays the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma via regulating liver Kupffer cells polarization.IUBMB Life. 2019 Dec;71(12):1952-1961. doi: 10.1002/iub.2137. Epub 2019 Aug 13.
• [1114] Effects of STC1 overexpression on tumorigenicity and metabolism of hepatocellular carcinoma.Oncotarget. 2017 Dec 21;9(6):6852-6861. doi: 10.18632/oncotarget.23566. eCollection 2018 Jan 23.
• [1115] Clinical significance of high expression of stanniocalcin-2 in hepatocellular carcinoma.Biosci Rep. 2019 Apr 26;39(4):BSR20182057. doi: 10.1042/BSR20182057. Print 2019 Apr 30.
• [1116] STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma.J Clin Invest. 2015 Nov 2;125(11):4239-54. doi: 10.1172/JCI81203. Epub 2015 Oct 12.
• [1117] STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway.Cancer Sci. 2020 Feb;111(2):406-417. doi: 10.1111/cas.14262. Epub 2019 Dec 23.
• [1118] Silence of Stomatin-Like Protein 2 Represses Migration and Invasion Ability of Human Liver Cancer Cells via Inhibiting the Nuclear Factor Kappa B (NF-B) Pathway.Med Sci Monit. 2018 Oct 25;24:7625-7632. doi: 10.12659/MSM.909156.
• [1119] Sorafenib with ASC-J9() synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.Int J Cancer. 2017 Feb 1;140(3):705-717. doi: 10.1002/ijc.30446. Epub 2016 Nov 9.
• [1120] STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.Sci Rep. 2016 Sep 15;6:33205. doi: 10.1038/srep33205.
• [1121] Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.Int J Cancer. 2015 Jan 15;136(2):289-98. doi: 10.1002/ijc.28985. Epub 2014 May 30.
• [1122] Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis.Hepatology. 2018 Sep;68(3):1125-1139. doi: 10.1002/hep.29881. Epub 2018 May 21.
• [1123] Simple and rapid radiosynthesis of N-(18)F-labeled glutamic acid as a hepatocellular carcinoma PET tracer.Nucl Med Biol. 2017 Jun;49:38-43. doi: 10.1016/j.nucmedbio.2017.02.003. Epub 2017 Mar 2.
• [1124] TAGLN2, a novel regulator involved in Hepatitis B virus transcription and replication.Biochem Biophys Res Commun. 2016 Sep 2;477(4):1051-1058. doi: 10.1016/j.bbrc.2016.07.034. Epub 2016 Jul 9.
• [1125] Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma.J Gastroenterol Hepatol. 2002 Aug;17(8):897-907. doi: 10.1046/j.1440-1746.2002.02837.x.
• [1126] The hepatitis B viral X protein activates NF-kappaB signaling pathway through the up-regulation of TBK1.FEBS Lett. 2010 Feb 5;584(3):525-30. doi: 10.1016/j.febslet.2009.11.091. Epub 2009 Dec 3.
• [1127] Downregulation of miR-610 promotes proliferation and tumorigenicity and activates Wnt/-catenin signaling in human hepatocellular carcinoma.Mol Cancer. 2014 Dec 10;13:261. doi: 10.1186/1476-4598-13-261.
• [1128] Transducin (Beta)-Like 1 X-Linked Receptor 1 Correlates with Clinical Prognosis and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.Dig Dis Sci. 2016 Feb;61(2):489-500. doi: 10.1007/s10620-015-3879-2. Epub 2015 Sep 19.
• [1129] Diffusion-weighted magnetic resonance imaging using a preclinical 1T PET/MRI in healthy and tumor-bearing rats.EJNMMI Res. 2019 Feb 22;9(1):21. doi: 10.1186/s13550-019-0489-6.
• [1130] Prognostic Analysis of Hepatocellular Carcinoma With Hepatitis C Virus Infection Using Epithelial-Mesenchymal Transition Gene Profiles.J Surg Res. 2020 Jan;245:302-308. doi: 10.1016/j.jss.2019.07.077. Epub 2019 Aug 14.
• [1131] Long Noncoding RNA MALAT1 Regulates Cancer Glucose Metabolism by Enhancing mTOR-Mediated Translation of TCF7L2.Cancer Res. 2019 May 15;79(10):2480-2493. doi: 10.1158/0008-5472.CAN-18-1432. Epub 2019 Mar 26.
• [1132] PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis.Gut. 2014 Oct;63(10):1635-47. doi: 10.1136/gutjnl-2013-305302. Epub 2013 Dec 18.
• [1133] Telomeric 3' overhangs in chronic HBV-related hepatitis and hepatocellular carcinoma.Int J Cancer. 2008 Jul 15;123(2):264-272. doi: 10.1002/ijc.23376.
• [1134] Nucleolar TRF2 attenuated nucleolus stress-induced HCC cell-cycle arrest by altering rRNA synthesis.Cell Death Dis. 2018 May 1;9(5):518. doi: 10.1038/s41419-018-0572-3.
• [1135] Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.World J Gastroenterol. 2015 Nov 14;21(42):12022-41. doi: 10.3748/wjg.v21.i42.12022.
• [1136] Long non-coding RNA CCAL promotes hepatocellular carcinoma progression by regulating AP-2 and Wnt/-catenin pathway.Int J Biol Macromol. 2018 Apr 1;109:424-434. doi: 10.1016/j.ijbiomac.2017.12.110. Epub 2017 Dec 22.
• [1137] Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli.Thromb Haemost. 1994 Mar;71(3):339-46.
• [1138] Phosphorylated Heat Shock Protein 20 (HSPB6) Regulates Transforming Growth Factor--Induced Migration and Invasion of Hepatocellular Carcinoma Cells.PLoS One. 2016 Apr 5;11(4):e0151907. doi: 10.1371/journal.pone.0151907. eCollection 2016.
• [1139] Role of TGF3-Smads-Sp1 axis in DcR3-mediated immune escape of hepatocellular carcinoma.Oncogenesis. 2019 Aug 13;8(8):43. doi: 10.1038/s41389-019-0152-0.
• [1140] Overexpression of RNF38 facilitates TGF- signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma.J Exp Clin Cancer Res. 2019 Mar 5;38(1):113. doi: 10.1186/s13046-019-1113-3.
• [1141] MicroRNA-302d downregulates TGFBR2 expression and promotes hepatocellular carcinoma growth and invasion.Exp Ther Med. 2017 Feb;13(2):681-687. doi: 10.3892/etm.2016.3970. Epub 2016 Dec 13.
• [1142] Arachidonic acid suppresses hepatic cell growth through ROS-mediated activation of transglutaminase.FEBS Open Bio. 2018 Sep 11;8(10):1703-1710. doi: 10.1002/2211-5463.12511. eCollection 2018 Oct.
• [1143] Sympathetic nervous system promotes hepatocarcinogenesis by modulating inflammation through activation of alpha1-adrenergic receptors of Kupffer cells.Brain Behav Immun. 2017 Jan;59:118-134. doi: 10.1016/j.bbi.2016.08.016. Epub 2016 Aug 29.
• [1144] A new data analysis method based on feature linear combination.J Biomed Inform. 2019 Jun;94:103173. doi: 10.1016/j.jbi.2019.103173. Epub 2019 Apr 6.
• [1145] Thrombopoietin production in human hepatic cell cultures (HepG2) is resistant to IFN-alpha, IFN-beta, and IFN-gamma treatment.J Interferon Cytokine Res. 2002 Dec;22(12):1185-9. doi: 10.1089/10799900260475704.
• [1146] Thyroid hormone promotes cell invasion through activation of furin expression in human hepatoma cell lines.Endocrinology. 2008 Aug;149(8):3817-31. doi: 10.1210/en.2007-0989. Epub 2008 May 8.
• [1147] Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway.Anticancer Res. 2002 Jan-Feb;22(1A):379-86.
• [1148] Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner.J Exp Clin Cancer Res. 2019 Apr 11;38(1):154. doi: 10.1186/s13046-019-1131-1.
• [1149] Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells.Cancer Lett. 2007 Aug 8;253(1):108-14. doi: 10.1016/j.canlet.2007.01.010. Epub 2007 Feb 23.
• [1150] Long noncoding RNA LINC00488 functions as a ceRNA to regulate hepatocellular carcinoma cell growth and angiogenesis through miR-330-5.Dig Liver Dis. 2019 Jul;51(7):1050-1059. doi: 10.1016/j.dld.2019.03.012. Epub 2019 Apr 17.
• [1151] Over-expression of MiR-122 promotes apoptosis of hepatocellular carcinoma via targeting TLR4.Ann Hepatol. 2019 Nov-Dec;18(6):869-878. doi: 10.1016/j.aohep.2019.07.005. Epub 2019 Aug 24.
• [1152] Polymorphism of TLR5 rs5744174 is associated with disease progression in Chinese patients with chronic HBV infection.APMIS. 2017 Aug;125(8):708-716. doi: 10.1111/apm.12707. Epub 2017 May 25.
• [1153] PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.Int J Cancer. 2019 Feb 1;144(3):533-544. doi: 10.1002/ijc.31910. Epub 2018 Nov 9.
• [1154] Bax inhibitor-1 down-regulation in the progression of chronic liver diseases.BMC Gastroenterol. 2010 Apr 1;10:35. doi: 10.1186/1471-230X-10-35.
• [1155] Emerging role of zinc finger protein A20 as a suppressor of hepatocellular carcinoma.J Cell Physiol. 2019 Dec;234(12):21479-21484. doi: 10.1002/jcp.28877. Epub 2019 May 27.
• [1156] Knockdown of the differentially expressed gene TNFRSF12A inhibits hepatocellular carcinoma cell proliferation and migration invitro.Mol Med Rep. 2017 Mar;15(3):1172-1178. doi: 10.3892/mmr.2017.6154. Epub 2017 Jan 26.
• [1157] The role of death receptor 3 in the biological behavior of hepatocellular carcinoma cells.Mol Med Rep. 2015 Feb;11(2):797-804. doi: 10.3892/mmr.2014.2858. Epub 2014 Nov 4.
• [1158] 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8(+) T Cells in Hepatocellular Carcinoma.Hepatology. 2020 Mar;71(3):955-971. doi: 10.1002/hep.30881. Epub 2019 Oct 18.
• [1159] RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-B-mediated epithelial-mesenchymal transition.PLoS One. 2014 Sep 30;9(9):e108507. doi: 10.1371/journal.pone.0108507. eCollection 2014.
• [1160] Synergisic effect of APRIL knockdown and Jiedu Xiaozheng Yin, a Chinese medicinal recipe, on the inhibition of hepatocellular carcinoma cell proliferation.Oncol Rep. 2017 Feb;37(2):754-760. doi: 10.3892/or.2016.5339. Epub 2016 Dec 28.
• [1161] Caspase-3 gene transfected with LIGHT gene: can it be used for therapy of human hepatocellular carcinoma?.Clin Chem Lab Med. 2008;46(4):470-4. doi: 10.1515/CCLM.2008.094.
• [1162] Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma.Int J Cancer. 2012 Mar 15;130(6):1319-28. doi: 10.1002/ijc.26136. Epub 2011 Jul 21.
• [1163] Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.Oncotarget. 2015 Dec 1;6(38):40622-41. doi: 10.18632/oncotarget.5872.
• [1164] Tankyrase Promotes Aerobic Glycolysis and Proliferation of Ovarian Cancer through Activation of Wnt/-Catenin Signaling.Biomed Res Int. 2019 Feb 20;2019:2686340. doi: 10.1155/2019/2686340. eCollection 2019.
• [1165] The transcription factor RFX5 is a transcriptional activator of the TPP1 gene in hepatocellular carcinoma.Oncol Rep. 2017 Jan;37(1):289-296. doi: 10.3892/or.2016.5240. Epub 2016 Nov 9.
• [1166] Overexpression of CDCA5, KIF4A, TPX2, and FOXM1 Coregulated Cell Cycle and Promoted Hepatocellular Carcinoma Development.J Comput Biol. 2020 Jun;27(6):965-974. doi: 10.1089/cmb.2019.0254. Epub 2019 Oct 9.
• [1167] Tumor Necrosis Factor Receptor-Associated Factor 6 Promotes Hepatocarcinogenesis by Interacting With Histone Deacetylase 3 to Enhance c-Myc Gene Expression and Protein Stability.Hepatology. 2020 Jan;71(1):148-163. doi: 10.1002/hep.30801. Epub 2019 Aug 7.
• [1168] TRIM24 promotes hepatocellular carcinoma progression via AMPK signaling.Exp Cell Res. 2018 Jun 15;367(2):274-281. doi: 10.1016/j.yexcr.2018.04.006. Epub 2018 Apr 6.
• [1169] Establishment of monoclonal HCC cell lines with organ site-specific tropisms.BMC Cancer. 2015 Oct 12;15:678. doi: 10.1186/s12885-015-1692-0.
• [1170] Post-transcriptional regulation of cancer/testis antigen MAGEC2 expression by TRIM28 in tumor cells.BMC Cancer. 2018 Oct 11;18(1):971. doi: 10.1186/s12885-018-4844-1.
• [1171] Simultaneous measurement of cytosolic and mitochondrial calcium levels: observations in TRPC1-silenced hepatocellular carcinoma cells.J Pharmacol Toxicol Methods. 2015 Mar-Apr;72:29-34. doi: 10.1016/j.vascn.2014.12.004. Epub 2014 Dec 20.
• [1172] Inhibition of TRPM7 blocks MRTF/SRF-dependent transcriptional and tumorigenic activity.Oncogene. 2020 Mar;39(11):2328-2344. doi: 10.1038/s41388-019-1140-8. Epub 2019 Dec 16.
• [1173] Targeting TRPV1 on cellular plasticity regulated by Ovol 2 and Zeb 1 in hepatocellular carcinoma.Biomed Pharmacother. 2019 Oct;118:109270. doi: 10.1016/j.biopha.2019.109270. Epub 2019 Aug 8.
• [1174] Transient receptor potential vanilloid-type 2 targeting on stemness in liver cancer.Biomed Pharmacother. 2018 Sep;105:697-706. doi: 10.1016/j.biopha.2018.06.029. Epub 2018 Jun 12.
• [1175] A LIN28B Tumor-Specific Transcript in Cancer.Cell Rep. 2018 Feb 20;22(8):2016-2025. doi: 10.1016/j.celrep.2018.02.002.
• [1176] The concomitant loss of APC and HNF4 in adult hepatocytes does not contribute to hepatocarcinogenesis driven by -catenin activation.Liver Int. 2019 Apr;39(4):727-739. doi: 10.1111/liv.14068. Epub 2019 Feb 24.
• [1177] A combination of -fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma.Ann Hepatol. 2020 Mar-Apr;19(2):179-185. doi: 10.1016/j.aohep.2019.09.002. Epub 2019 Oct 1.
• [1178] TXNDC12 promotes EMT and metastasis of hepatocellular carcinoma cells via activation of -catenin.Cell Death Differ. 2020 Apr;27(4):1355-1368. doi: 10.1038/s41418-019-0421-7. Epub 2019 Sep 30.
• [1179] High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.PLoS One. 2019 Jul 10;14(7):e0219469. doi: 10.1371/journal.pone.0219469. eCollection 2019.
• [1180] Functional Genomics Identifies Hepatitis-Induced STAT3-TYRO3-STAT3 Signaling as a Potential Therapeutic Target of Hepatoma.Clin Cancer Res. 2020 Mar 1;26(5):1185-1197. doi: 10.1158/1078-0432.CCR-18-3531. Epub 2019 Dec 12.
• [1181] Identification of hepatocellular carcinoma-related genes with a machine learning and network analysis.J Comput Biol. 2015 Jan;22(1):63-71. doi: 10.1089/cmb.2014.0122.
• [1182] UBE2T promotes proliferation via G2/M checkpoint in hepatocellular carcinoma.Cancer Manag Res. 2019 Sep 13;11:8359-8370. doi: 10.2147/CMAR.S202631. eCollection 2019.
• [1183] Upregulation of Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Mediates the Reversal Effect of Verapamil on Chemo-Resistance to Adriamycin of Hepatocellular Carcinoma.Med Sci Monit. 2018 Apr 8;24:2072-2082. doi: 10.12659/msm.908925.
• [1184] Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence.J Dig Dis. 2018 Mar;19(3):155-169. doi: 10.1111/1751-2980.12580.
• [1185] Stabilization of E2-EPF UCP protein is implicated in hepatitis B virus-associated hepatocellular carcinoma progression.Cell Mol Life Sci. 2019 Jul;76(13):2647-2662. doi: 10.1007/s00018-019-03066-9. Epub 2019 Mar 22.
• [1186] Metabolomic and transcriptomic profiling of hepatocellular carcinomas in Hras12V transgenic mice.Cancer Med. 2017 Oct;6(10):2370-2384. doi: 10.1002/cam4.1177. Epub 2017 Sep 21.
• [1187] Development of a Label-Free LC-MS/MS-Based Glucosylceramide Synthase Assay and Its Application to Inhibitors Screening for Ceramide-Related Diseases.Biomol Ther (Seoul). 2019 Mar 1;27(2):193-200. doi: 10.4062/biomolther.2018.122.
• [1188] UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population.Liver Int. 2017 Sep;37(9):1345-1353. doi: 10.1111/liv.13411. Epub 2017 Apr 6.
• [1189] USP14 activation promotes tumor progression in hepatocellular carcinoma.Oncol Rep. 2015 Dec;34(6):2917-24. doi: 10.3892/or.2015.4296. Epub 2015 Sep 21.
• [1190] USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma.Theranostics. 2019 Jan 1;9(2):573-587. doi: 10.7150/thno.27654. eCollection 2019.
• [1191] Increase in the nuclear localization of PTEN by the Toxoplasma GRA16 protein and subsequent induction of p53-dependent apoptosis and anticancer effect.J Cell Mol Med. 2019 May;23(5):3234-3245. doi: 10.1111/jcmm.14207. Epub 2019 Mar 4.
• [1192] Drp1-mediated mitochondrial fission promotes cell proliferation through crosstalk of p53 and NF-B pathways in hepatocellular carcinoma.Oncotarget. 2016 Oct 4;7(40):65001-65011. doi: 10.18632/oncotarget.11339.
• [1193] The effects of urotensin II on migration and invasion are mediated by NADPH oxidase-derived reactive oxygen species through the c-Jun N-terminal kinase pathway in human hepatoma cells.Peptides. 2017 Feb;88:106-114. doi: 10.1016/j.peptides.2016.12.005. Epub 2016 Dec 14.
• [1194] Downregulation of VANGL1 inhibits cellular invasion rather than cell motility in hepatocellular carcinoma cells without stimulation.Genet Test Mol Biomarkers. 2015 Jun;19(6):283-7. doi: 10.1089/gtmb.2015.0014. Epub 2015 Apr 15.
• [1195] CD151 supports VCAM-1-mediated lymphocyte adhesion to liver endothelium and is upregulated in chronic liver disease and hepatocellular carcinoma.Am J Physiol Gastrointest Liver Physiol. 2017 Aug 1;313(2):G138-G149. doi: 10.1152/ajpgi.00411.2016. Epub 2017 May 4.
• [1196] Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma.Sci Transl Med. 2017 Aug 23;9(404):eaam7996. doi: 10.1126/scitranslmed.aam7996.
• [1197] Targeting the mitochondrial VDAC in hepatocellular carcinoma using a polyclonal antibody-conjugated to a nitrosyl ruthenium complex.J Biol Inorg Chem. 2018 Aug;23(6):903-916. doi: 10.1007/s00775-018-1589-x. Epub 2018 Jul 3.
• [1198] miR-3928v is induced by HBx via NF-B/EGR1 and contributes to hepatocellular carcinoma malignancy by down-regulating VDAC3.J Exp Clin Cancer Res. 2018 Jan 29;37(1):14. doi: 10.1186/s13046-018-0681-y.
• [1199] Apa1 (rs7975232) SNP in the vitamin D receptor is linked to hepatocellular carcinoma in hepatitis C virus cirrhosis.Br J Biomed Sci. 2020 Apr;77(2):53-57. doi: 10.1080/09674845.2019.1680166. Epub 2019 Nov 25.
• [1200] Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters.J Surg Oncol. 2008 Sep 1;98(3):190-6. doi: 10.1002/jso.21095.
• [1201] Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway.Biochem Biophys Res Commun. 2017 Apr 1;485(2):432-439. doi: 10.1016/j.bbrc.2017.02.060. Epub 2017 Feb 13.
• [1202] Andrographolide decreased VEGFD expression in hepatoma cancer cells by inducing ubiquitin/proteasome-mediated cFos protein degradation.Biochim Biophys Acta. 2015 Apr;1850(4):750-8. doi: 10.1016/j.bbagen.2015.01.005. Epub 2015 Jan 14.
• [1203] Adipose-derived exosomes deliver miR-23a/b to regulate tumor growth in hepatocellular cancer by targeting the VHL/HIF axis.J Physiol Biochem. 2019 Aug;75(3):391-401. doi: 10.1007/s13105-019-00692-6. Epub 2019 Jul 18.
• [1204] Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis.HPB (Oxford). 2019 Aug;21(8):935-944. doi: 10.1016/j.hpb.2019.02.003. Epub 2019 Mar 11.
• [1205] Vasoactive intestinal peptide increases apoptosis of hepatocellular carcinoma by inhibiting the cAMP/Bcl-xL pathway.Cancer Sci. 2019 Jan;110(1):235-244. doi: 10.1111/cas.13861. Epub 2018 Dec 4.
• [1206] Downregulation of B7-H4 suppresses tumor progression of hepatocellular carcinoma.Sci Rep. 2019 Oct 16;9(1):14854. doi: 10.1038/s41598-019-51253-2.
• [1207] von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma.Gut Liver. 2020 Mar 15;14(2):218-224. doi: 10.5009/gnl17115.
• [1208] Increased expression of Wiskott-Aldrich syndrome protein family verprolin-homologous protein 2 correlated with poor prognosis of hepatocellular carcinoma.Clin Cancer Res. 2006 Oct 1;12(19):5673-9. doi: 10.1158/1078-0432.CCR-06-0022.
• [1209] Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition.Cancer Res. 2020 Feb 1;80(3):510-523. doi: 10.1158/0008-5472.CAN-18-3374. Epub 2019 Sep 24.
• [1210] Up-regulation of Wnt5a inhibits proliferation and migration of hepatocellular carcinoma cells.J Cancer Res Ther. 2019;15(4):904-908. doi: 10.4103/jcrt.JCRT_886_18.
• [1211] Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer.Carcinogenesis. 2017 Jan;38(1):2-11. doi: 10.1093/carcin/bgw118. Epub 2016 Nov 12.
• [1212] Loss of Xanthine Oxidoreductase Potentiates Propagation of Hepatocellular Carcinoma Stem Cells.Hepatology. 2020 Jun;71(6):2033-2049. doi: 10.1002/hep.30978. Epub 2020 Feb 13.
• [1213] The association of six polymorphisms of five genes involved in three steps of nucleotide excision repair pathways with hepatocellular cancer risk.Oncotarget. 2016 Apr 12;7(15):20357-67. doi: 10.18632/oncotarget.7952.
• [1214] Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein.Oncotarget. 2016 Apr 26;7(17):24339-47. doi: 10.18632/oncotarget.8248.
• [1215] Overexpression of miR-623 suppresses progression of hepatocellular carcinoma via regulating the PI3K/Akt signaling pathway by targeting XRCC5.J Cell Biochem. 2020 Jan;121(1):213-223. doi: 10.1002/jcb.29117. Epub 2019 Jun 12.
• [1216] Downregulation of CENPK suppresses hepatocellular carcinoma malignant progression through regulating YAP1.Onco Targets Ther. 2019 Jan 29;12:869-882. doi: 10.2147/OTT.S190061. eCollection 2019.
• [1217] Up-regulation of microRNA-210 inhibits proliferation of hepatocellular carcinoma cells by targeting YES1.World J Gastroenterol. 2015 Dec 14;21(46):13030-41. doi: 10.3748/wjg.v21.i46.13030.
• [1218] Integrated bioinformatics analysis reveals role of the LINC01093/miR-96-5p/ZFAND5/NF-B signaling axis in hepatocellular carcinoma.Exp Ther Med. 2019 Nov;18(5):3853-3860. doi: 10.3892/etm.2019.8046. Epub 2019 Sep 25.
• [1219] MicroRNA-197-3p acts as a prognostic marker and inhibits cell invasion in hepatocellular carcinoma. Oncol Lett. 2019 Feb;17(2):2317-2327.
• [1220] The coordination between ZNF217 and LSD1 contributes to hepatocellular carcinoma progress and is negatively regulated by miR-101.Exp Cell Res. 2019 Jun 1;379(1):1-10. doi: 10.1016/j.yexcr.2019.03.017. Epub 2019 Mar 18.
• [1221] Decreased Expression of ZWINT is Associated With Poor Prognosis in Patients With HCC After Surgery. Technol Cancer Res Treat. 2018 Jan 1;17:1533033818794190.
• [1222] Single-nucleotide polymorphisms in the coding region of a disintegrin and metalloproteinase with thrombospondin motifs 4 and hepatocellular carcinoma: A retrospective case-control study.Cancer Med. 2019 Dec;8(18):7869-7880. doi: 10.1002/cam4.2646. Epub 2019 Oct 30.
• [1223] MSH2 Dysregulation Is Triggered by Proinflammatory Cytokine Stimulation and Is Associated with Liver Cancer Development.Cancer Res. 2016 Aug 1;76(15):4383-93. doi: 10.1158/0008-5472.CAN-15-2926. Epub 2016 Jun 3.
• [1224] Lipid metabolism enzyme 5-LOX and its metabolite LTB4 are capable of activating transcription factor NF-B in hepatoma cells.Biochem Biophys Res Commun. 2012 Feb 24;418(4):647-51. doi: 10.1016/j.bbrc.2012.01.068. Epub 2012 Jan 24.
• [1225] Overexpression of -methylacyl-CoA racemase is associated with CTNNB1 mutations in hepatocellular carcinomas.Histopathology. 2011 Apr;58(5):712-9. doi: 10.1111/j.1365-2559.2011.03798.x. Epub 2011 Apr 4.
• [1226] Hypersplenism is correlated with increased risk of hepatocellular carcinoma in patients with post-hepatitis cirrhosis.Tumour Biol. 2016 Jul;37(7):8889-900. doi: 10.1007/s13277-015-4764-5. Epub 2016 Jan 11.
• [1227] Hypermethylation leads to bone morphogenetic protein 6 downregulation in hepatocellular carcinoma.PLoS One. 2014 Jan 30;9(1):e87994. doi: 10.1371/journal.pone.0087994. eCollection 2014.
• [1228] Bioinformatic analysis of the membrane cofactor protein CD46 and microRNA expression in hepatocellular carcinoma.Oncol Rep. 2014 Feb;31(2):557-64. doi: 10.3892/or.2013.2877. Epub 2013 Nov 28.
• [1229] YC-1 Antagonizes Wnt/-Catenin Signaling Through the EBP1 p42 Isoform in Hepatocellular Carcinoma.Cancers (Basel). 2019 May 13;11(5):661. doi: 10.3390/cancers11050661.
• [1230] CD8+CXCR5+T cells infiltrating hepatocellular carcinomas are activated and predictive of a better prognosis.Aging (Albany NY). 2019 Oct 30;11(20):8879-8891. doi: 10.18632/aging.102308. Epub 2019 Oct 30.
• [1231] [(18)F] Clofarabine for PET Imaging of Hepatocellular Carcinoma.Cancers (Basel). 2019 Nov 7;11(11):1748. doi: 10.3390/cancers11111748.
• [1232] DEPTOR induces a partial epithelial-to-mesenchymal transition and metastasis via autocrine TGF1 signaling and is associated with poor prognosis in hepatocellular carcinoma.J Exp Clin Cancer Res. 2019 Jun 22;38(1):273. doi: 10.1186/s13046-019-1220-1.
• [1233] Dgat2 reduces hepatocellular carcinoma malignancy via downregulation of cell cycle-related gene expression.Biomed Pharmacother. 2019 Jul;115:108950. doi: 10.1016/j.biopha.2019.108950. Epub 2019 May 8.
• [1234] Intracellular signaling and hepatocellular carcinoma.Semin Cancer Biol. 2011 Feb;21(1):28-34. doi: 10.1016/j.semcancer.2010.09.001. Epub 2010 Sep 17.
• [1235] FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway.Cell Death Dis. 2013 Nov 14;4(11):e923. doi: 10.1038/cddis.2013.450.
• [1236] Distribution of Glutathione S-Transferase Omega Gene Polymorphism with Different Stages of HBV Infection Including Hepatocellular Carcinoma in the Egyptian Population.Asian Pac J Cancer Prev. 2016;17(4):2145-50. doi: 10.7314/apjcp.2016.17.4.2145.
• [1237] HLA-G genetic variants and hepatocellular carcinoma: a meta-analysis.Genet Mol Res. 2016 Aug 26;15(3). doi: 10.4238/gmr.15038263.
• [1238] Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-/5-fluorouracil and their clinical significance.PLoS One. 2013;8(2):e56197. doi: 10.1371/journal.pone.0056197. Epub 2013 Feb 15.
• [1239] Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.Br J Cancer. 2009 May 19;100(10):1647-58. doi: 10.1038/sj.bjc.6605064. Epub 2009 Apr 28.
• [1240] Expression of the type 3 InsP(3) receptor is a final common event in the development of hepatocellular carcinoma.Gut. 2019 Sep;68(9):1676-1687. doi: 10.1136/gutjnl-2018-317811. Epub 2019 Jul 17.
• [1241] miR-450b-5p loss mediated KIF26B activation promoted hepatocellular carcinoma progression by activating PI3K/AKT pathway.Cancer Cell Int. 2019 Jul 31;19:205. doi: 10.1186/s12935-019-0923-x. eCollection 2019.
• [1242] Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.Cancer Res. 2014 Jun 15;74(12):3306-16. doi: 10.1158/0008-5472.CAN-14-0208. Epub 2014 Apr 11.
• [1243] Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients.J Transl Med. 2019 Jun 18;17(1):203. doi: 10.1186/s12967-019-1946-8.
• [1244] Hepatitis B virus X protein enhances the development of liver fibrosis and the expression of genes associated with epithelial-mesenchymal transitions and tumor progenitor cells.Carcinogenesis. 2020 May 14;41(3):358-367. doi: 10.1093/carcin/bgz109.
• [1245] Decrease of MLK4 prevents hepatocellular carcinoma (HCC) through reducing metastasis and inducing apoptosis regulated by ROS/MAPKs signaling.Biomed Pharmacother. 2019 Aug;116:108749. doi: 10.1016/j.biopha.2019.108749. Epub 2019 May 6.
• [1246] Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma.Sci Rep. 2019 Oct 31;9(1):15788. doi: 10.1038/s41598-019-52356-6.
• [1247] Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA).Am J Pathol. 2011 Mar;178(3):1145-52. doi: 10.1016/j.ajpath.2010.11.059. Epub 2011 Jan 28.
• [1248] Elevated Preoperative Serum CA125 Predicts Larger Tumor Diameter in Patients with Hepatocellular Carcinoma and Low AFP Levels.Biomed Res Int. 2019 Sep 29;2019:6959637. doi: 10.1155/2019/6959637. eCollection 2019.
• [1249] The involvement of cell surface nucleolin in the initiation of CCR6 signaling in human hepatocellular carcinoma.Med Oncol. 2015 Mar;32(3):75. doi: 10.1007/s12032-015-0530-1. Epub 2015 Feb 20.
• [1250] MicroRNA-214 suppresses cell proliferation and migration and cell metabolism by targeting PDK2 and PHF6 in hepatocellular carcinoma.Cell Biol Int. 2020 Jan;44(1):117-126. doi: 10.1002/cbin.11207. Epub 2019 Aug 19.
• [1251] Platelet-activating factor in cirrhotic liver and hepatocellular carcinoma.World J Gastroenterol. 2006 May 7;12(17):2773-8. doi: 10.3748/wjg.v12.i17.2773.
• [1252] Role and mechanism of circ-PRKCI in hepatocellular carcinoma.World J Gastroenterol. 2019 Apr 28;25(16):1964-1974. doi: 10.3748/wjg.v25.i16.1964.
• [1253] Prostaglandin E2 stimulates 1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-B pathway.Sci Rep. 2014 Oct 7;4:6538. doi: 10.1038/srep06538.
• [1254] Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance.Tumour Biol. 2016 Jul;37(7):9691-8. doi: 10.1007/s13277-016-4843-2. Epub 2016 Jan 23.
• [1255] Combined serum and tissue proteomic study applied to a c-Myc transgenic mouse model of hepatocellular carcinoma identified novel disease regulated proteins suitable for diagnosis and therapeutic intervention strategies.J Proteome Res. 2011 Jul 1;10(7):3012-30. doi: 10.1021/pr101207t. Epub 2011 Jun 6.
• [1256] Chronic liver inflammation and hepatocellular carcinogenesis are independent of S100A9.Int J Cancer. 2015 May 15;136(10):2458-63. doi: 10.1002/ijc.29282. Epub 2014 Nov 13.
• [1257] CCRDB: a cancer circRNAs-related database and its application in hepatocellular carcinoma-related circRNAs.Database (Oxford). 2019 Jan 1;2019:baz063. doi: 10.1093/database/baz063.
• [1258] Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers.Clin Chim Acta. 2011 Jan 14;412(1-2):152-8. doi: 10.1016/j.cca.2010.09.028. Epub 2010 Sep 29.
• [1259] Association of PINX1 but not TEP1 Polymorphisms with Progression to Hepatocellular Carcinoma in Thai Patients with Chronic Hepatitis B Virus Infection.Asian Pac J Cancer Prev. 2016;17(4):2019-25. doi: 10.7314/apjcp.2016.17.4.2019.
• [1260] Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM(+) AFP(+) hepatocellular carcinoma.Oncogene. 2015 Sep 24;34(39):5095-104. doi: 10.1038/onc.2014.438. Epub 2015 Jan 19.
• [1261] The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading.Redox Biol. 2018 Apr;14:164-177. doi: 10.1016/j.redox.2017.08.022. Epub 2017 Sep 14.
• [1262] Effects of PKM2 on global metabolic changes and prognosis in hepatocellular carcinoma: from gene expression to drug discovery.BMC Cancer. 2018 Nov 21;18(1):1150. doi: 10.1186/s12885-018-5023-0.
• [1263] The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma.Cancers (Basel). 2018 Mar 20;10(3):82. doi: 10.3390/cancers10030082.
• [1264] The anti-inflammatory NHE-06 restores antitumor immunity by targeting NF-B/IL-6/STAT3 signaling in hepatocellular carcinoma.Biomed Pharmacother. 2018 Jun;102:420-427. doi: 10.1016/j.biopha.2018.03.099. Epub 2018 Mar 22.
• [1265] SLC6A19 is a novel putative gene, induced by dioxins via AhR in human hepatoma HepG2 cells.Environ Pollut. 2018 Jun;237:508-514. doi: 10.1016/j.envpol.2018.02.079. Epub 2018 Mar 15.
• [1266] Copper/MYC/CTR1 interplay: a dangerous relationship in hepatocellular carcinoma.Oncotarget. 2018 Jan 20;9(10):9325-9343. doi: 10.18632/oncotarget.24282. eCollection 2018 Feb 6.
• [1267] Comparative analysis of ATP-binding cassette (ABC) transporter gene expression levels in peripheral blood leukocytes and in liver with hepatocellular carcinoma.Cancer Sci. 2004 Jun;95(6):530-6. doi: 10.1111/j.1349-7006.2004.tb03244.x.
• [1268] Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma.Hepatobiliary Pancreat Dis Int. 2018 Dec;17(6):524-530. doi: 10.1016/j.hbpd.2018.10.003. Epub 2018 Oct 29.
• [1269] ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma.Curr Med Chem. 2019;26(7):1224-1250. doi: 10.2174/0929867325666180105103637.
• [1270] Increased Risk of Death in First Year After Liver Transplantation Among Patients With Nonalcoholic Steatohepatitis vs Liver Disease of Other Etiologies.Clin Gastroenterol Hepatol. 2019 Dec;17(13):2759-2768.e5. doi: 10.1016/j.cgh.2019.04.033. Epub 2019 Apr 17.
• [1271] ABCD2 is a direct target of -catenin and TCF-4: implications for X-linked adrenoleukodystrophy therapy.PLoS One. 2013;8(2):e56242. doi: 10.1371/journal.pone.0056242. Epub 2013 Feb 21.
• [1272] The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study.Liver Int. 2019 Aug;39(8):1478-1489. doi: 10.1111/liv.14154. Epub 2019 Jun 26.
• [1273] NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification.Cancer Epidemiol. 2012 Oct;36(5):e294-9. doi: 10.1016/j.canep.2012.05.012. Epub 2012 Jun 23.
• [1274] Characteristics of L-carnitine transport in cultured human hepatoma HLF cells.J Pharm Pharmacol. 1999 Aug;51(8):935-40. doi: 10.1211/0022357991773195.
• [1275] Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study.J Gastroenterol. 2014 Mar;49(3):502-10. doi: 10.1007/s00535-013-0791-4. Epub 2013 Mar 30.
• [1276] SLC25A13 gene mutations in Taiwanese patients with non-viral hepatocellular carcinoma.Mol Genet Metab. 2011 Jul;103(3):293-6. doi: 10.1016/j.ymgme.2011.03.013. Epub 2011 Mar 15.
• [1277] Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas.Genes Chromosomes Cancer. 1996 Mar;15(3):187-90. doi: 10.1002/(SICI)1098-2264(199603)15:3<187::AID-GCC8>3.0.CO;2-Z.
• [1278] Point mutations of ornithine decarboxylase gene are an infrequent event in colorectal cancer but a missense mutation was found in a replication error positive patient with hMSH2 germline mutation.Jpn J Clin Oncol. 1998 Jun;28(6):383-7. doi: 10.1093/jjco/28.6.383.
• [1279] Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling.Mol Ther. 2015 Apr;23(4):746-56. doi: 10.1038/mt.2015.13. Epub 2015 Jan 26.
• [1280] Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.Oncol Rep. 2017 Apr;37(4):2071-2078. doi: 10.3892/or.2017.5498. Epub 2017 Mar 10.
• [1281] Hepatitis E virus infection as a promoting factor for hepatocellular carcinoma in Cameroon: Preliminary Observations.Int J Infect Dis. 2017 Nov;64:4-8. doi: 10.1016/j.ijid.2017.08.010. Epub 2017 Aug 25.
• [1282] Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma.J Gastroenterol. 2007 Sep;42(9):761-8. doi: 10.1007/s00535-007-2085-1. Epub 2007 Sep 25.
• [1283] Hepatobiliary transporter expression in human hepatocellular carcinoma.Liver Int. 2005 Apr;25(2):367-79. doi: 10.1111/j.1478-3231.2005.01033.x.
• [1284] Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma.Hepatology. 2010 Nov;52(5):1690-701. doi: 10.1002/hep.23847.
• [1285] Expressions of Carbohydrate Response Element Binding Protein and Glucose Transporters in Liver Cancer and Clinical Significance.Pathol Oncol Res. 2020 Apr;26(2):1331-1340. doi: 10.1007/s12253-019-00708-y. Epub 2019 Aug 12.
• [1286] Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res. 2007 Mar 15;67(6):2736-46.
• [1287] MAGE-1 and related MAGE gene expression may be associated with hepatocellular carcinoma.J Cancer Res Clin Oncol. 1999 Dec;125(12):685-9. doi: 10.1007/s004320050334.
• [1288] A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation.Glycobiology. 2007 Dec;17(12):1311-20. doi: 10.1093/glycob/cwm094. Epub 2007 Sep 20.
• [1289] Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets.Mol Genet Genomics. 2016 Jun;291(3):1035-51. doi: 10.1007/s00438-015-1163-y. Epub 2015 Dec 28.
• [1290] Zip4 (Slc39a4) expression is activated in hepatocellular carcinomas and functions to repress apoptosis, enhance cell cycle and increase migration.PLoS One. 2010 Oct 4;5(10):e13158. doi: 10.1371/journal.pone.0013158.
• [1291] Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.J Pathol. 2019 Jun;248(2):164-178. doi: 10.1002/path.5243. Epub 2019 Mar 8.
• [1292] Reduction of anion exchanger 2 expression induces apoptosis of human hepatocellular carcinoma cells.Mol Cell Biochem. 2009 Jul;327(1-2):135-44. doi: 10.1007/s11010-009-0051-3. Epub 2009 Feb 18.
• [1293] Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma.Mol Ther Nucleic Acids. 2017 Dec 15;9:274-283. doi: 10.1016/j.omtn.2017.10.002. Epub 2017 Oct 7.
• [1294] Downregulation of SLC5A8 inhibits hepatocellular carcinoma progression through regulation of Wnt/-catenin signaling.Tumour Biol. 2016 Oct;37(10):13445-13453. doi: 10.1007/s13277-016-5170-3. Epub 2016 Jul 27.
• [1295] Long non-coding RNA AGAP2-AS1, functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma.J Exp Clin Cancer Res. 2019 May 14;38(1):194. doi: 10.1186/s13046-019-1188-x.
• [1296] Investigation of the clinical significance and prospective molecular mechanisms of cystatin genes in patients with hepatitis B virusrelated hepatocellular carcinoma.Oncol Rep. 2019 Jul;42(1):189-201. doi: 10.3892/or.2019.7154. Epub 2019 May 9.
• [1297] Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.Mol Oncol. 2019 May;13(5):1311-1331. doi: 10.1002/1878-0261.12488. Epub 2019 Apr 15.
• [1298] Dietary Tomato Powder Inhibits High-Fat Diet-Promoted Hepatocellular Carcinoma with Alteration of Gut Microbiota in Mice Lacking Carotenoid Cleavage Enzymes.Cancer Prev Res (Phila). 2018 Dec;11(12):797-810. doi: 10.1158/1940-6207.CAPR-18-0188. Epub 2018 Nov 16.
• [1299] Cytochrome P450 family members are associated with fast-growing hepatocellular carcinoma and patient survival: An integrated analysis of gene expression profiles.Saudi J Gastroenterol. 2019 May-Jun;25(3):167-175. doi: 10.4103/sjg.SJG_290_18.
• [1300] Profiling cytochrome P450 family 4 gene expression in human hepatocellular carcinoma.Mol Med Rep. 2018 Dec;18(6):4865-4876. doi: 10.3892/mmr.2018.9526. Epub 2018 Oct 1.
• [1301] Glycine decarboxylase induces autophagy and is downregulated by miRNA-30d-5p in hepatocellular carcinoma.Cell Death Dis. 2019 Feb 25;10(3):192. doi: 10.1038/s41419-019-1446-z.
• [1302] GSTZ1-1 downregulates Wnt/-catenin signalling in hepatocellular carcinoma cells.FEBS Open Bio. 2020 Jan;10(1):6-17. doi: 10.1002/2211-5463.12769. Epub 2019 Dec 10.
• [1303] DM1 Loaded Ultrasmall Gold Nanoparticles Display Significant Efficacy and Improved Tolerability in Murine Models of Hepatocellular Carcinoma.Bioconjug Chem. 2019 Mar 20;30(3):703-713. doi: 10.1021/acs.bioconjchem.8b00873. Epub 2019 Jan 11.
• [1304] Phosphoglucomutase 1 inhibits hepatocellular carcinoma progression by regulating glucose trafficking.PLoS Biol. 2018 Oct 18;16(10):e2006483. doi: 10.1371/journal.pbio.2006483. eCollection 2018 Oct.
• [1305] Spermine oxidase is upregulated and promotes tumor growth in hepatocellular carcinoma.Hepatol Res. 2018 Nov;48(12):967-977. doi: 10.1111/hepr.13206. Epub 2018 Jul 27.
• [1306] Low apolipoprotein A-I levels in Friedreich's ataxia and in frataxin-deficient cells: Implications for therapy.PLoS One. 2018 Feb 15;13(2):e0192779. doi: 10.1371/journal.pone.0192779. eCollection 2018.
• [1307] Expression of genes that control core fucosylation in hepatocellular carcinoma: Systematic review.World J Gastroenterol. 2019 Jun 21;25(23):2947-2960. doi: 10.3748/wjg.v25.i23.2947.
• [1308] Aspirin targets P4HA2 through inhibiting NF-B and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma.EBioMedicine. 2019 Jul;45:168-180. doi: 10.1016/j.ebiom.2019.06.048. Epub 2019 Jul 2.
• [1309] Dopamine-induced SULT1A3/4 promotes EMT and cancer stemness in hepatocellular carcinoma.Tumour Biol. 2017 Oct;39(10):1010428317719272. doi: 10.1177/1010428317719272.
• [1310] Downregulation of circDYNC1H1 exhibits inhibitor effect on cell proliferation and migration in hepatocellular carcinoma through miR-140-5p.J Cell Physiol. 2019 Aug;234(10):17775-17785. doi: 10.1002/jcp.28403. Epub 2019 Mar 12.
• [1311] Transcriptional profiling on chromosome 19p indicated frequent downregulation of ACP5 expression in hepatocellular carcinoma.Int J Cancer. 2005 May 10;114(6):902-8. doi: 10.1002/ijc.20684.
• [1312] Evaluation of the ACS NSQIP Surgical Risk Calculator in Elderly Patients Undergoing Hepatectomy for Hepatocellular Carcinoma.J Gastrointest Surg. 2020 Mar;24(3):551-559. doi: 10.1007/s11605-019-04174-4. Epub 2019 Apr 1.
• [1313] Hepatocarcinogenesis driven by GSNOR deficiency is prevented by iNOS inhibition.Cancer Res. 2013 May 1;73(9):2897-904. doi: 10.1158/0008-5472.CAN-12-3980. Epub 2013 Feb 25.
• [1314] Identification of Circulating Biomarker Candidates for Hepatocellular Carcinoma (HCC): An Integrated Prioritization Approach.PLoS One. 2015 Sep 28;10(9):e0138913. doi: 10.1371/journal.pone.0138913. eCollection 2015.
• [1315] A multiple mediator analysis approach to quantify the effects of the ADH1B and ALDH2 genes on hepatocellular carcinoma risk.Genet Epidemiol. 2018 Jun;42(4):394-404. doi: 10.1002/gepi.22120. Epub 2018 Mar 30.
• [1316] Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.J Gastroenterol. 2019 Jun;54(6):549-557. doi: 10.1007/s00535-019-01551-3. Epub 2019 Feb 1.
• [1317] The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene.Gene. 2010 Jul 1;459(1-2):11-23. doi: 10.1016/j.gene.2010.03.006. Epub 2010 Mar 23.
• [1318] Disparate phenotypic expression of ALAS2 R452H (nt 1407 G --> A) in two brothers, one with severe sideroblastic anemia and iron overload, hepatic cirrhosis, and hepatocellular carcinoma.Blood Cells Mol Dis. 2006 May-Jun;36(3):342-6. doi: 10.1016/j.bcmd.2006.01.010. Epub 2006 Mar 15.
• [1319] Identification of metabolism-associated pathways and genes involved in male and female liver cancer patients.J Theor Biol. 2019 Nov 7;480:218-228. doi: 10.1016/j.jtbi.2019.08.011. Epub 2019 Aug 13.
• [1320] The murine hepatic sequelae of long-term ethanol consumption are sex-specific and exacerbated by Aldh1b1 loss.Exp Mol Pathol. 2018 Aug;105(1):63-70. doi: 10.1016/j.yexmp.2018.05.008. Epub 2018 Jun 1.
• [1321] Polymorphism in asparagine synthetase is associated with overall survival of hepatocellular carcinoma patients.BMC Gastroenterol. 2017 Jun 19;17(1):79. doi: 10.1186/s12876-017-0635-4.
• [1322] Two specific inhibitors of the phosphatidylinositol 3-kinase LY294002 and wortmannin up-regulate beta1,4-galactosyltransferase I and thus sensitize SMMC-7721 human hepatocarcinoma cells to cycloheximide-induced apoptosis.Mol Cell Biochem. 2007 Oct;304(1-2):361-7. doi: 10.1007/s11010-007-9519-1. Epub 2007 Jun 8.
• [1323] Identification of the bleomycin hydrolase gene as a methylated tumor suppressor gene in hepatocellular carcinoma using a novel triple-combination array method.Cancer Lett. 2011 Dec 22;312(2):150-7. doi: 10.1016/j.canlet.2011.07.028. Epub 2011 Aug 22.
• [1324] Genetic variants underlying vitamin D metabolism and VDR-TGF-1-SMAD3 interaction may impact on HCV progression: a study based on dbGaP data from the HALT-C study.J Hum Genet. 2017 Nov;62(11):969-977. doi: 10.1038/jhg.2017.75. Epub 2017 Jul 13.
• [1325] Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma.Int J Oncol. 2005 Sep;27(3):661-7.
• [1326] Cytochrome P450 4A11 expression in tumor cells: A favorable prognostic factor for hepatocellular carcinoma patients.J Gastroenterol Hepatol. 2019 Jan;34(1):224-233. doi: 10.1111/jgh.14406. Epub 2018 Aug 29.
• [1327] Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma.Cancer Gene Ther. 2000 Jul;7(7):1008-14. doi: 10.1038/sj.cgt.7700190.
• [1328] Interactions between CYP1A1 polymorphisms and cigarette smoking are associated with the risk of hepatocellular carcinoma: evidence from epidemiological studies.Mol Biol Rep. 2012 Jun;39(6):6641-6. doi: 10.1007/s11033-012-1469-3.
• [1329] Interactions Between Regulatory Variants in CYP7A1 (Cholesterol 7-Hydroxylase) Promoter and Enhancer Regions Regulate CYP7A1 Expression.Circ Genom Precis Med. 2018 Oct;11(10):e002082. doi: 10.1161/CIRCGEN.118.002082.
• [1330] Decreased expression of the human carbonyl reductase 2 gene HCR2 in hepatocellular carcinoma.Cell Mol Biol Lett. 2006;11(2):230-41. doi: 10.2478/s11658-006-0022-6.
• [1331] A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1.Angiogenesis. 2017 Nov;20(4):557-565. doi: 10.1007/s10456-017-9567-4. Epub 2017 Jul 24.
• [1332] DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival.J Biol Chem. 2011 Sep 2;286(35):30706-30713. doi: 10.1074/jbc.M111.229831. Epub 2011 Jul 7.
• [1333] alpha-1,3-Fucosyltransferase-VII stimulates the growth of hepatocarcinoma cells via the cyclin-dependent kinase inhibitor p27Kip1.Cell Mol Life Sci. 2005 Jan;62(2):171-8. doi: 10.1007/s00018-004-4349-8.
• [1334] High GCLC level in tumor tissues is associated with poor prognosis of hepatocellular carcinoma after curative resection.J Cancer. 2019 Jun 2;10(15):3333-3343. doi: 10.7150/jca.29769. eCollection 2019.
• [1335] Characterization and regulatory effect of gamma-glutamyltransferase messenger RNA untranslated regions in human leukemia.Leukemia. 1995 Aug;9(8):1332-7.
• [1336] Glutathione S-transferase O2 gene rs157077 polymorphism predicts response to transarterial chemoembolization in hepatocellular carcinoma.Tumour Biol. 2015 Aug;36(8):6463-9. doi: 10.1007/s13277-015-3336-z. Epub 2015 Apr 3.
• [1337] Hint1 Up-Regulates IB by Targeting the -TrCP Subunit of SCF E3 Ligase in Human Hepatocellular Carcinoma Cells.Dig Dis Sci. 2016 Mar;61(3):785-94. doi: 10.1007/s10620-015-3927-y. Epub 2015 Oct 31.
• [1338] 15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPAR-mediated activation of p21WAF1/Cip1.Oncogene. 2014 Feb 27;33(9):1101-12. doi: 10.1038/onc.2013.69. Epub 2013 Apr 1.
• [1339] Suitable reference genes for real-time PCR in human HBV-related hepatocellular carcinoma with different clinical prognoses.BMC Cancer. 2009 Feb 6;9:49. doi: 10.1186/1471-2407-9-49.
• [1340] Circular RNA MAT2B Promotes Glycolysis and Malignancy of Hepatocellular Carcinoma Through the miR-338-3p/PKM2 Axis Under Hypoxic Stress.Hepatology. 2019 Oct;70(4):1298-1316. doi: 10.1002/hep.30671. Epub 2019 May 28.
• [1341] Malic enzyme 1 is a potential marker of combined hepatocellular cholangiocarcinoma, subtype with stem-cell features, intermediate-cell type.Hepatol Res. 2019 Sep;49(9):1066-1075. doi: 10.1111/hepr.13365. Epub 2019 Jun 18.
• [1342] Identification of MSRA gene on chromosome 8p as a candidate metastasis suppressor for human hepatitis B virus-positive hepatocellular carcinoma.BMC Cancer. 2007 Sep 4;7:172. doi: 10.1186/1471-2407-7-172.
• [1343] Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) gene polymorphisms as risk factors for hepatocellular carcinoma in a Korean population.Anticancer Res. 2008 Sep-Oct;28(5A):2807-11.
• [1344] Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk.Gut. 2000 Nov;47(5):703-9. doi: 10.1136/gut.47.5.703.
• [1345] N-Acetyltransferase 10 Enhances Doxorubicin Resistance in Human Hepatocellular Carcinoma Cell Lines by Promoting the Epithelial-to-Mesenchymal Transition.Oxid Med Cell Longev. 2019 Jul 1;2019:7561879. doi: 10.1155/2019/7561879. eCollection 2019.
• [1346] Elevated N-methyltransferase expression induced by hepatic stellate cells contributes to the metastasis of hepatocellular carcinoma via regulation of the CD44v3 isoform.Mol Oncol. 2019 Sep;13(9):1993-2009. doi: 10.1002/1878-0261.12544. Epub 2019 Jul 11.
• [1347] Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study.Eur J Hum Genet. 2009 Oct;17(10):1250-9. doi: 10.1038/ejhg.2009.48. Epub 2009 Apr 1.
• [1348] DJ-1 knockdown inhibits growth and xenograftinduced tumor generation of human hepatocellular carcinoma cells.Oncol Rep. 2015 Jan;33(1):201-6. doi: 10.3892/or.2014.3594. Epub 2014 Nov 7.
• [1349] PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27(Kip1) axis.J Exp Clin Cancer Res. 2019 Feb 4;38(1):50. doi: 10.1186/s13046-019-1029-y.
• [1350] PERIOD1 is an anti-apoptotic factor in human pancreatic and hepatic cancer cells.J Biochem. 2009 Dec;146(6):833-8. doi: 10.1093/jb/mvp126. Epub 2009 Aug 12.
• [1351] Proliferation-linked increase in phosphoribosylformylglycinamidine synthetase activity (EC 6.3.5.3).Cancer Res. 1984 Jun;44(6):2430-4.
• [1352] Differential sensitivity of hepatocellular carcinoma cells to suppression of hepatocystin transcription under hypoxic conditions.J Bioenerg Biomembr. 2016 Dec;48(6):581-590. doi: 10.1007/s10863-016-9677-5. Epub 2016 Sep 17.
• [1353] Ptgr1 expression is regulated by NRF2 in rat hepatocarcinogenesis and promotes cell proliferation and resistance to oxidative stress.Free Radic Biol Med. 2017 Jan;102:87-99. doi: 10.1016/j.freeradbiomed.2016.11.027. Epub 2016 Nov 18.
• [1354] Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy.Cancer Manag Res. 2018 Jul 25;10:2231-2239. doi: 10.2147/CMAR.S167417. eCollection 2018.
• [1355] [Differential display of messenger RNA and identification of selenocysteine lyase gene in hepatocellular carcinoma cells transiently expressing hepatitis C virus core protein].Biomedica. 2006 Jun;26(2):194-205.
• [1356] Association of genetic polymorphisms in STAT1 gene with increased risk of hepatocellular carcinoma.Oncology. 2010;78(5-6):382-8. doi: 10.1159/000320521. Epub 2010 Aug 27.
• [1357] Overexpression of a novel imprinted gene, PEG10, in human hepatocellular carcinoma and in regenerating mouse livers.J Biomed Sci. 2003;10(6 Pt 1):625-35. doi: 10.1159/000073528.
• [1358] Down-regulation of dehydroepiandrosterone sulfotransferase gene in human hepatocellular carcinoma.Mol Cell Endocrinol. 2005 Feb 28;231(1-2):87-94. doi: 10.1016/j.mce.2004.10.002. Epub 2004 Dec 8.
• [1359] TGM3 promotes epithelial-mesenchymal transition and hepatocellular carcinogenesis and predicts poor prognosis for patients after curative resection.Dig Liver Dis. 2020 Jun;52(6):668-676. doi: 10.1016/j.dld.2019.10.010. Epub 2019 Dec 9.
• [1360] Expression analysis of THOP1 in background liver, a prognostic predictive factor in hepatocellular carcinoma, extracted by multiarray analysis.Ann Surg Oncol. 2014 Jun;21 Suppl 3:S443-50. doi: 10.1245/s10434-014-3581-1. Epub 2014 Mar 7.
• [1361] Analysis of hepatitis B virus transcripts in infected human livers.Hepatology. 1989 Feb;9(2):180-5. doi: 10.1002/hep.1840090203.
• [1362] UCK2 upregulation might serve as an indicator of unfavorable prognosis of hepatocellular carcinoma.IUBMB Life. 2019 Jan;71(1):105-112. doi: 10.1002/iub.1941. Epub 2018 Oct 10.
• [1363] Identification of a four-gene metabolic signature predicting overall survival for hepatocellular carcinoma.J Cell Physiol. 2020 Feb;235(2):1624-1636. doi: 10.1002/jcp.29081. Epub 2019 Jul 16.
• [1364] Transcriptome-Wide Analysis Reveals the Landscape of Aberrant Alternative Splicing Events in Liver Cancer.Hepatology. 2019 Jan;69(1):359-375. doi: 10.1002/hep.30158. Epub 2018 Dec 18.
• [1365] Variations of chromosome 2 gene expressions among patients with lung cancer or non-cancer.Cell Biol Toxicol. 2016 Oct;32(5):419-35. doi: 10.1007/s10565-016-9343-z. Epub 2016 Jun 15.
• [1366] Epigenetic regulation of UDP-Glucuronosyltransferase by microRNA-200a/-183: implications for responses to sorafenib treatment in patients with hepatocellular carcinoma.Cancer Lett. 2019 Jul 10;454:14-25. doi: 10.1016/j.canlet.2019.03.030. Epub 2019 Mar 22.
• [1367] Ages of hepatocellular carcinoma occurrence and life expectancy are associated with a UGT2B28 genomic variation.BMC Cancer. 2019 Dec 5;19(1):1190. doi: 10.1186/s12885-019-6409-3.
• [1368] Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells.J Pharmacol Exp Ther. 2017 Jun;361(3):386-397. doi: 10.1124/jpet.116.239707. Epub 2017 Apr 7.
• [1369] Drug-Metabolizing Activity, Protein and Gene Expression of UDP-Glucuronosyltransferases Are Significantly Altered in Hepatocellular Carcinoma Patients.PLoS One. 2015 May 26;10(5):e0127524. doi: 10.1371/journal.pone.0127524. eCollection 2015.
• [1370] Carboxypeptidase A4 promotes proliferation and stem cell characteristics of hepatocellular carcinoma.Int J Exp Pathol. 2019 Apr;100(2):133-138. doi: 10.1111/iep.12315. Epub 2019 May 6.
• [1371] Expression of SLCO1B3 is associated with intratumoral cholestasis and CTNNB1 mutations in hepatocellular carcinoma.Cancer Sci. 2011 Sep;102(9):1742-7. doi: 10.1111/j.1349-7006.2011.01990.x. Epub 2011 Jul 3.
• [1372] Alkaline ceramidase 3 promotes growth of hepatocellular carcinoma cells via regulating S1P/S1PR2/PI3K/AKT signaling.Pathol Res Pract. 2018 Sep;214(9):1381-1387. doi: 10.1016/j.prp.2018.07.029. Epub 2018 Jul 27.
• [1373] ARP3 promotes tumor metastasis and predicts a poor prognosis in hepatocellular carcinoma.Pathol Res Pract. 2018 Sep;214(9):1356-1361. doi: 10.1016/j.prp.2018.05.028. Epub 2018 Jun 7.
• [1374] ELTD1 Function in Hepatocellular Carcinoma is Carcinoma-Associated Fibroblast-Dependent.J Cancer. 2018 Jun 14;9(14):2415-2427. doi: 10.7150/jca.24406. eCollection 2018.
• [1375] AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma.Cancer Lett. 2018 Feb 1;414:71-80. doi: 10.1016/j.canlet.2017.11.003. Epub 2017 Nov 8.
• [1376] LncRNA OR3A4 participates in the angiogenesis of hepatocellular carcinoma through modulating AGGF1/akt/mTOR pathway.Eur J Pharmacol. 2019 Apr 15;849:106-114. doi: 10.1016/j.ejphar.2019.01.049. Epub 2019 Jan 30.
• [1377] Tudor-staphylococcal nuclease regulates the expression and biological function of alkylglycerone phosphate synthase via nuclear factor-B and microRNA-127 in human glioma U87MG cells.Oncol Lett. 2018 Jun;15(6):9553-9558. doi: 10.3892/ol.2018.8484. Epub 2018 Apr 13.
• [1378] Higher expression of A-kinase anchoring-protein 1 predicts poor prognosis in human hepatocellular carcinoma.Oncol Lett. 2018 Jul;16(1):131-136. doi: 10.3892/ol.2018.8685. Epub 2018 May 10.
• [1379] Long noncoding RNA GAS5 inhibits metastasis by targeting miR-182/ANGPTL1 in hepatocellular carcinoma.Am J Cancer Res. 2019 Jan 1;9(1):108-121. eCollection 2019.
• [1380] Hepatocellular Carcinoma-Associated Protein TD26 Interacts and Enhances Sterol Regulatory Element-Binding Protein 1 Activity to Promote Tumor Cell Proliferation and Growth.Hepatology. 2018 Nov;68(5):1833-1850. doi: 10.1002/hep.30030. Epub 2018 Sep 19.
• [1381] Bufalin inhibits cell proliferation and migration of hepatocellular carcinoma cells via APOBEC3F induced intestinal immune network for IgA production signaling pathway.Biochem Biophys Res Commun. 2018 Sep 10;503(3):2124-2131. doi: 10.1016/j.bbrc.2018.07.169. Epub 2018 Aug 6.
• [1382] LncRNA CDKN2BAS predicts poor prognosis in patients with hepatocellular carcinoma and promotes metastasis via the miR-153-5p/ARHGAP18 signaling axis.Aging (Albany NY). 2018 Nov 29;10(11):3371-3381. doi: 10.18632/aging.101645.
• [1383] Expression of Rho Guanine Nucleotide Exchange Factor 39 (ARHGEF39) and Its Prognostic Significance in Hepatocellular Carcinoma.Med Sci Monit. 2019 Oct 18;25:7826-7835. doi: 10.12659/MSM.918270.
• [1384] Identification of TAF1, SAT1, and ARHGEF9 as DNA methylation biomarkers for hepatocellular carcinoma.J Cell Physiol. 2020 Jan;235(1):611-618. doi: 10.1002/jcp.28999. Epub 2019 Jul 8.
• [1385] Overexpression of ARID4B predicts poor survival in patients with hepatocellular carcinoma.Hum Pathol. 2018 Mar;73:114-121. doi: 10.1016/j.humpath.2017.12.012. Epub 2017 Dec 27.
• [1386] The ASH1-miR-375-YWHAZ Signaling Axis Regulates Tumor Properties in Hepatocellular Carcinoma.Mol Ther Nucleic Acids. 2018 Jun 1;11:538-553. doi: 10.1016/j.omtn.2018.04.007. Epub 2018 Apr 25.
• [1387] Increased B3GALNT2 in hepatocellular carcinoma promotes macrophage recruitment via reducing acetoacetate secretion and elevating MIF activity.J Hematol Oncol. 2018 Apr 4;11(1):50. doi: 10.1186/s13045-018-0595-3.
• [1388] The BRUCE-ATR Signaling Axis Is Required for Accurate DNA Replication and Suppression of Liver Cancer Development.Hepatology. 2019 Jun;69(6):2608-2622. doi: 10.1002/hep.30529. Epub 2019 Mar 13.
• [1389] Identification of IFITM3 and MGAT1 as novel interaction partners of BRI3 by yeast two-hybrid screening.Turk J Biol. 2018 Dec 10;42(6):463-470. doi: 10.3906/biy-1805-47. eCollection 2018.
• [1390] Myc target gene, long intergenic noncoding RNA, Linc00176 in hepatocellular carcinoma regulates cell cycle and cell survival by titrating tumor suppressor microRNAs.Oncogene. 2018 Jan 4;37(1):75-85. doi: 10.1038/onc.2017.312. Epub 2017 Sep 4.
• [1391] lncRNA CADM1-AS1 inhibits cell-cycle progression and invasion via PTEN/AKT/GSK-3 axis in hepatocellular carcinoma.Cancer Manag Res. 2019 Apr 30;11:3813-3828. doi: 10.2147/CMAR.S197673. eCollection 2019.
• [1392] Dynamic network biomarker indicates pulmonary metastasis at the tipping point of hepatocellular carcinoma.Nat Commun. 2018 Feb 14;9(1):678. doi: 10.1038/s41467-018-03024-2.
• [1393] Targeting CAND1 promotes caspase-8/RIP1-dependent apoptosis in liver cancer cells.Am J Transl Res. 2018 May 15;10(5):1357-1372. eCollection 2018.
• [1394] Hypoxia induces actin cytoskeleton remodeling by regulating the binding of CAPZA1 to F-actin via PIP2 to drive EMT in hepatocellular carcinoma.Cancer Lett. 2019 Apr 28;448:117-127. doi: 10.1016/j.canlet.2019.01.042. Epub 2019 Feb 8.
• [1395] Liver cancer: WISP3 suppresses hepatocellular carcinoma progression by negative regulation of -catenin/TCF/LEF signalling.Cell Prolif. 2019 May;52(3):e12583. doi: 10.1111/cpr.12583. Epub 2019 Feb 22.
• [1396] Cyclin Y Modulates the Proliferation, Invasion, and Metastasis of Hepatocellular Carcinoma Cells.Med Sci Monit. 2018 Mar 20;24:1642-1653. doi: 10.12659/msm.906075.
• [1397] The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.Cell Death Dis. 2018 Feb 14;9(2):232. doi: 10.1038/s41419-018-0267-9.
• [1398] Prognostic genes of hepatocellular carcinoma based on gene coexpression network analysis.J Cell Biochem. 2019 Jul;120(7):11616-11623. doi: 10.1002/jcb.28441. Epub 2019 Feb 18.
• [1399] LINC00707 contributes to hepatocellular carcinoma progression via sponging miR-206 to increase CDK14.J Cell Physiol. 2019 Jul;234(7):10615-10624. doi: 10.1002/jcp.27737. Epub 2018 Nov 29.
• [1400] Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma.Carcinogenesis. 2019 Mar 12;40(1):155-163. doi: 10.1093/carcin/bgy130.
• [1401] KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.Cancer Lett. 2019 Jul 10;454:78-89. doi: 10.1016/j.canlet.2019.03.049. Epub 2019 Apr 11.
• [1402] Bioinformatics analysis of the interactions among lncRNA, miRNA and mRNA expression, genetic mutations and epigenetic modifications in hepatocellular carcinoma.Mol Med Rep. 2019 Feb;19(2):1356-1364. doi: 10.3892/mmr.2018.9728. Epub 2018 Dec 5.
• [1403] CFHR3 is a potential novel biomarker for hepatocellular carcinoma.J Cell Biochem. 2020 Apr;121(4):2970-2980. doi: 10.1002/jcb.29551. Epub 2019 Nov 10.
• [1404] Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma.Hepatology. 2018 Oct;68(4):1412-1428. doi: 10.1002/hep.30091.
• [1405] CHL1 expression differentiates Hrthle cell carcinoma from benign Hrthle cell nodules.J Surg Oncol. 2018 Nov;118(6):1042-1049. doi: 10.1002/jso.25214. Epub 2018 Oct 12.
• [1406] Hepatitis B Virus Precore Protein p22 Inhibits Alpha Interferon Signaling by Blocking STAT Nuclear Translocation.J Virol. 2019 Jun 14;93(13):e00196-19. doi: 10.1128/JVI.00196-19. Print 2019 Jul 1.
• [1407] LncRNA n335586/miR-924/CKMT1A axis contributes to cell migration and invasion in hepatocellular carcinoma cells.Cancer Lett. 2018 Aug 10;429:89-99. doi: 10.1016/j.canlet.2018.05.010. Epub 2018 May 16.
• [1408] CLCA4 inhibits cell proliferation and invasion of hepatocellular carcinoma by suppressing epithelial-mesenchymal transition via PI3K/AKT signaling.Aging (Albany NY). 2018 Oct 11;10(10):2570-2584. doi: 10.18632/aging.101571.
• [1409] Increased expression of claudin-17 promotes a malignant phenotype in hepatocyte via Tyk2/Stat3 signaling and is associated with poor prognosis in patients with hepatocellular carcinoma.Diagn Pathol. 2018 Sep 15;13(1):72. doi: 10.1186/s13000-018-0749-1.
• [1410] Canopy Homolog 2 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma with Tumor Hemorrhage.Cell Physiol Biochem. 2018;50(6):2017-2028. doi: 10.1159/000495048. Epub 2018 Nov 9.
• [1411] CPEB1 mediates hepatocellular carcinoma cancer stemness and chemoresistance.Cell Death Dis. 2018 Sep 20;9(10):957. doi: 10.1038/s41419-018-0974-2.
• [1412] Silencing the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib.Cancer Manag Res. 2018 Aug 29;10:3057-3067. doi: 10.2147/CMAR.S167781. eCollection 2018.
• [1413] Identification of special key genes for alcohol-related hepatocellular carcinoma through bioinformatic analysis.PeerJ. 2019 Feb 6;7:e6375. doi: 10.7717/peerj.6375. eCollection 2019.
• [1414] Quercetin suppresses the chymotrypsin-like activity of proteasome via inhibition of MEK1/ERK1/2 signaling pathway in hepatocellular carcinoma HepG2 cells.Can J Physiol Pharmacol. 2018 May;96(5):521-526. doi: 10.1139/cjpp-2017-0655. Epub 2018 Feb 2.
• [1415] miR-106b targets DAB2 to promote hepatocellular carcinoma cell proliferation and metastasis.Oncol Lett. 2018 Sep;16(3):3063-3069. doi: 10.3892/ol.2018.8970. Epub 2018 Jun 15.
• [1416] A Comprehensive Analysis of Argonaute-CLIP Data Identifies Novel, Conserved and Species-Specific Targets of miR-21 in Human Liver and Hepatocellular Carcinoma.Int J Mol Sci. 2018 Mar 14;19(3):851. doi: 10.3390/ijms19030851.
• [1417] DDX39 promotes hepatocellular carcinoma growth and metastasis through activating Wnt/-catenin pathway.Cell Death Dis. 2018 Jun 4;9(6):675. doi: 10.1038/s41419-018-0591-0.
• [1418] The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population.Pathol Res Pract. 2018 May;214(5):625-630. doi: 10.1016/j.prp.2018.04.005. Epub 2018 Apr 17.
• [1419] Diacylglycerol kinase predicts prognosis and functions as a tumor suppressor by negatively regulating glucose transporter 1 in hepatocellular carcinoma.Exp Cell Res. 2018 Dec 15;373(1-2):211-220. doi: 10.1016/j.yexcr.2018.11.001. Epub 2018 Nov 3.
• [1420] DIAPH3 promoted the growth, migration and metastasis of hepatocellular carcinoma cells by activating beta-catenin/TCF signaling.Mol Cell Biochem. 2018 Jan;438(1-2):183-190. doi: 10.1007/s11010-017-3125-7. Epub 2017 Aug 9.
• [1421] Investigating Pathogenic and Hepatocarcinogenic Mechanisms from Normal Liver to HCC by Constructing Genetic and Epigenetic Networks via Big Genetic and Epigenetic Data Mining and Genome-Wide NGS Data Identification.Dis Markers. 2018 Sep 23;2018:8635329. doi: 10.1155/2018/8635329. eCollection 2018.
• [1422] In vitro study of anti-ER positive breast cancer effect and mechanism of 1,2,3,4-6-pentyl-O-galloyl-beta-d-glucose (PGG).Biomed Pharmacother. 2019 Mar;111:813-820. doi: 10.1016/j.biopha.2018.12.062. Epub 2019 Jan 4.
• [1423] Identification of survival-related predictors in hepatocellular carcinoma through integrated genomic, transcriptomic, and proteomic analyses.Biomed Pharmacother. 2019 Jun;114:108856. doi: 10.1016/j.biopha.2019.108856. Epub 2019 Apr 10.
• [1424] The endoplasmic reticulum co-chaperone ERdj3/DNAJB11 promotes hepatocellular carcinoma progression through suppressing AATZ degradation.Future Oncol. 2018 Dec;14(29):3001-3013. doi: 10.2217/fon-2018-0401. Epub 2018 Jul 11.
• [1425] DPY30 functions in glucose homeostasis via integrating activated histone epigenetic modifications.Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):286-290. doi: 10.1016/j.bbrc.2018.11.023. Epub 2018 Nov 15.
• [1426] Effect of Upregulated DNA Replication and Sister Chromatid Cohesion 1 Expression on Proliferation and Prognosis in Hepatocellular Carcinoma.Chin Med J (Engl). 2018 Dec 5;131(23):2827-2835. doi: 10.4103/0366-6999.246076.
• [1427] Desmoglein-2 overexpression predicts poor prognosis in hepatocellular carcinoma patients.Eur Rev Med Pharmacol Sci. 2018 Sep;22(17):5481-5489. doi: 10.26355/eurrev_201809_15808.
• [1428] Elevated DSN1 expression is associated with poor survival in patients with hepatocellular carcinoma.Hum Pathol. 2018 Nov;81:113-120. doi: 10.1016/j.humpath.2018.06.032. Epub 2018 Jul 3.
• [1429] Tripartite motif-containing protein 7 regulates hepatocellular carcinoma cell proliferation via the DUSP6/p38 pathway.Biochem Biophys Res Commun. 2019 Apr 16;511(4):889-895. doi: 10.1016/j.bbrc.2019.02.001. Epub 2019 Mar 5.
• [1430] Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis.Oncogene. 2019 Jun;38(24):4804-4819. doi: 10.1038/s41388-019-0759-9. Epub 2019 Feb 25.
• [1431] Development Of A Three-Gene Prognostic Signature For Hepatitis B Virus Associated Hepatocellular Carcinoma Based On Integrated Transcriptomic Analysis.J Cancer. 2018 Apr 30;9(11):1989-2002. doi: 10.7150/jca.23762. eCollection 2018.
• [1432] ELF3 promotes epithelial-mesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma.Cell Death Dis. 2018 Mar 9;9(3):387. doi: 10.1038/s41419-018-0399-y.
• [1433] Overexpression of EPS8L3 promotes cell proliferation by inhibiting the transactivity of FOXO1 in HCC.Neoplasma. 2018 Sep 19;65(5):701-707. doi: 10.4149/neo_2018_170725N503. Epub 2018 Jun 17.
• [1434] ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma.Clin Cancer Res. 2019 Oct 1;25(19):5859-5865. doi: 10.1158/1078-0432.CCR-19-0859. Epub 2019 Jul 29.
• [1435] EXO1 overexpression is associated with poor prognosis of hepatocellular carcinoma patients.Cell Cycle. 2018;17(19-20):2386-2397. doi: 10.1080/15384101.2018.1534511. Epub 2018 Oct 20.
• [1436] LINC00511 as a ceRNA promotes cell malignant behaviors and correlates with prognosis of hepatocellular carcinoma patients by modulating miR-195/EYA1 axis.Biomed Pharmacother. 2020 Jan;121:109642. doi: 10.1016/j.biopha.2019.109642. Epub 2019 Nov 12.
• [1437] Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues.Lab Invest. 2005 Feb;85(2):205-13. doi: 10.1038/labinvest.3700220.
• [1438] Disruption of FBXL5-mediated cellular iron homeostasis promotes liver carcinogenesis.J Exp Med. 2019 Apr 1;216(4):950-965. doi: 10.1084/jem.20180900. Epub 2019 Mar 15.
• [1439] Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma.Nat Commun. 2018 Mar 1;9(1):894. doi: 10.1038/s41467-018-03276-y.
• [1440] Elevated serum activity of MBL and ficolin-2 as biomarkers for progression to hepatocellular carcinoma in chronic HCV infection.Virology. 2019 Apr;530:99-106. doi: 10.1016/j.virol.2019.02.002. Epub 2019 Feb 12.
• [1441] Fli? promotes metastasis by regulating MMP2 signaling in hepatocellular carcinoma.Mol Med Rep. 2018 Jan;17(1):1986-1992. doi: 10.3892/mmr.2017.8047. Epub 2017 Nov 14.
• [1442] MicroRNA?63b targets GAB2 to restrict cell proliferation and invasion in hepatocellular carcinoma.Mol Med Rep. 2019 Apr;19(4):2913-2920. doi: 10.3892/mmr.2019.9934. Epub 2019 Feb 5.
• [1443] The long noncoding RNA GAS8-AS1 suppresses hepatocarcinogenesis by epigenetically activating the tumor suppressor GAS8.J Biol Chem. 2018 Nov 2;293(44):17154-17165. doi: 10.1074/jbc.RA118.003055. Epub 2018 Sep 18.
• [1444] Deregulated GATA6 modulates stem cell-like properties and metabolic phenotype in hepatocellular carcinoma.Int J Cancer. 2019 Oct 1;145(7):1860-1873. doi: 10.1002/ijc.32248. Epub 2019 Mar 28.
• [1445] Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3.Hepatology. 2018 Jun;67(6):2302-2319. doi: 10.1002/hep.29750. Epub 2018 Mar 23.
• [1446] GGA2 interacts with EGFR cytoplasmic domain to stabilize the receptor expression and promote cell growth.Sci Rep. 2018 Jan 22;8(1):1368. doi: 10.1038/s41598-018-19542-4.
• [1447] Aberrantly DNA Methylated-Differentially Expressed Genes and Pathways in Hepatocellular Carcinoma.J Cancer. 2019 Jan 1;10(2):355-366. doi: 10.7150/jca.27832. eCollection 2019.
• [1448] MicroRNA-370 Regulates Cellepithelial-Mesenchymal Transition, Migration, Invasion, and Prognosis of Hepatocellular Carcinoma by Targeting GUCD1.Yonsei Med J. 2019 Mar;60(3):267-276. doi: 10.3349/ymj.2019.60.3.267.
• [1449] Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study.Hepatology. 2018 Feb;67(2):651-661. doi: 10.1002/hep.29531. Epub 2018 Jan 1.
• [1450] HOXC6 predicts invasion and poor survival in hepatocellular carcinoma by driving epithelial-mesenchymal transition.Aging (Albany NY). 2018 Jan 15;10(1):115-130. doi: 10.18632/aging.101363.
• [1451] Hepatitis C virus core impacts expression of miR122 and miR204 involved in carcinogenic progression via regulation of TGFBRAP1 and HOTTIP expression.Onco Targets Ther. 2018 Mar 2;11:1173-1182. doi: 10.2147/OTT.S149254. eCollection 2018.
• [1452] Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma.BMC Cancer. 2018 Aug 13;18(1):815. doi: 10.1186/s12885-018-4719-5.
• [1453] Quantified postsurgical small cell size CTCs and EpCAM(+) circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse.Cancer Lett. 2018 Jan 1;412:99-107. doi: 10.1016/j.canlet.2017.10.004. Epub 2017 Oct 13.
• [1454] Targeting HSP60 by subcutaneous injections of jetPEI/HSP60-shRNA destabilizes cytoplasmic survivin and inhibits hepatocellular carcinoma growth.Mol Carcinog. 2018 Sep;57(9):1087-1101. doi: 10.1002/mc.22827. Epub 2018 May 2.
• [1455] 4 is highly expressed in carcinogen-transformed human cells and primary human cancers.Oncogene. 2011 Jun 30;30(26):2943-53. doi: 10.1038/onc.2011.20. Epub 2011 Feb 21.
• [1456] The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma.Nat Commun. 2018 Apr 20;9(1):1572. doi: 10.1038/s41467-018-04006-0.
• [1457] High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma.Hepatol Res. 2019 Sep;49(9):1046-1053. doi: 10.1111/hepr.13350. Epub 2019 May 29.
• [1458] Ambient PM(2.5) air pollutionexposure and hepatocellular carcinoma incidence in the United States.Cancer Causes Control. 2018 Jun;29(6):563-572. doi: 10.1007/s10552-018-1036-x. Epub 2018 Apr 25.
• [1459] Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocarcinogenesis via modulating TGF-/TR and Imp7/8.Exp Ther Med. 2018 Aug;16(2):1052-1060. doi: 10.3892/etm.2018.6292. Epub 2018 Jun 12.
• [1460] Long-Noncoding RNA Colorectal Neoplasia Differentially Expressed Gene as a Potential Target to Upregulate the Expression of IRX5 by miR-136-5P to Promote Oncogenic Properties in Hepatocellular Carcinoma.Cell Physiol Biochem. 2018;50(6):2229-2248. doi: 10.1159/000495084. Epub 2018 Nov 13.
• [1461] Integrin-5, a miR-185-targeted gene, promotes hepatocellular carcinoma tumorigenesis by regulating -catenin stability.J Exp Clin Cancer Res. 2018 Jan 31;37(1):17. doi: 10.1186/s13046-018-0691-9.
• [1462] A novel HIF1AN substrate KANK3 plays a tumor-suppressive role in hepatocellular carcinoma.Cell Biol Int. 2018 Mar;42(3):303-312. doi: 10.1002/cbin.10895. Epub 2017 Nov 15.
• [1463] Ubiquitin-Specific Protease 22/Silent Information Regulator 1 Axis Plays a Pivotal Role in the Prognosis and 5-Fluorouracil Resistance in Hepatocellular Carcinoma.Dig Dis Sci. 2020 Apr;65(4):1064-1073. doi: 10.1007/s10620-019-05844-8. Epub 2019 Oct 5.
• [1464] MicroRNA-10b regulates epithelial-mesenchymal transition by modulating KLF4/KLF11/Smads in hepatocellular carcinoma.Cancer Cell Int. 2018 Jan 17;18:10. doi: 10.1186/s12935-018-0508-0. eCollection 2018.
• [1465] LncRNA DGCR5 represses the development of hepatocellular carcinoma by targeting the miR-346/KLF14 axis.J Cell Physiol. 2018 Jan;234(1):572-580. doi: 10.1002/jcp.26779. Epub 2018 Sep 14.
• [1466] Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.Biomacromolecules. 2018 Jun 11;19(6):2330-2339. doi: 10.1021/acs.biomac.8b00358. Epub 2018 May 29.
• [1467] Co-delivery of LETM1 and CTMP synergistically inhibits tumor growth in H-ras12V liver cancer model mice.Cancer Gene Ther. 2013 Mar;20(3):186-94. doi: 10.1038/cgt.2013.6. Epub 2013 Feb 8.
• [1468] A nonsense mutant of the hepatitis B virus large S protein antagonizes multiple tumor suppressor pathways through c-Jun activation domain-binding protein1.PLoS One. 2019 Mar 14;14(3):e0208665. doi: 10.1371/journal.pone.0208665. eCollection 2019.
• [1469] High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma.Curr Res Transl Med. 2018 Mar;66(1):27-32. doi: 10.1016/j.retram.2017.11.002. Epub 2017 Dec 21.
• [1470] microRNA-501-3p suppresses metastasis and progression of hepatocellular carcinoma through targeting LIN7A.Cell Death Dis. 2018 May 1;9(5):535. doi: 10.1038/s41419-018-0577-y.
• [1471] LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling.J Exp Clin Cancer Res. 2018 Sep 15;37(1):228. doi: 10.1186/s13046-018-0903-3.
• [1472] Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma.J Immunother Cancer. 2018 Nov 20;6(1):125. doi: 10.1186/s40425-018-0431-x.
• [1473] Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis.Mol Cancer. 2019 Jan 31;18(1):18. doi: 10.1186/s12943-019-0948-8.
• [1474] Identification of recurrent fusion genes across multiple cancer types.Sci Rep. 2019 Jan 31;9(1):1074. doi: 10.1038/s41598-019-38550-6.
• [1475] LRP16 prevents hepatocellular carcinoma progression through regulation of Wnt/-catenin signaling.J Mol Med (Berl). 2018 Jun;96(6):547-558. doi: 10.1007/s00109-018-1639-4. Epub 2018 May 11.
• [1476] Involvement of MAFB and MAFF in Retinoid-Mediated Suppression of Hepatocellular Carcinoma Invasion.Int J Mol Sci. 2018 May 13;19(5):1450. doi: 10.3390/ijms19051450.
• [1477] Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.Gastroenterology. 2018 Aug;155(2):557-571.e14. doi: 10.1053/j.gastro.2018.04.032. Epub 2018 May 5.
• [1478] Downregulation of MAGE family member H1 enhances hepatocellular carcinoma progression and serves as a biomarker for patient prognosis.Future Oncol. 2018 May;14(12):1177-1186. doi: 10.2217/fon-2017-0672. Epub 2018 Jan 10.
• [1479] Distinct Diagnostic and Prognostic Values of Minichromosome Maintenance Gene Expression in Patients with Hepatocellular Carcinoma.J Cancer. 2018 Jun 12;9(13):2357-2373. doi: 10.7150/jca.25221. eCollection 2018.
• [1480] Potential use of TIA-1, MFF, microRNA-200a-3p, and microRNA-27 as a novel marker for hepatocellular carcinoma.Biochem Biophys Res Commun. 2018 Mar 18;497(4):1117-1122. doi: 10.1016/j.bbrc.2018.02.189. Epub 2018 Feb 26.
• [1481] MFN1-dependent alteration of mitochondrial dynamics drives hepatocellular carcinoma metastasis by glucose metabolic reprogramming.Br J Cancer. 2020 Jan;122(2):209-220. doi: 10.1038/s41416-019-0658-4. Epub 2019 Dec 10.
• [1482] Epigenetic restriction of Hippo signaling by MORC2 underlies stemness of hepatocellular carcinoma cells.Cell Death Differ. 2018 Dec;25(12):2086-2100. doi: 10.1038/s41418-018-0095-6. Epub 2018 Mar 19.
• [1483] Function of mitochondrial pyruvate carriers in hepatocellular carcinoma patients.Oncol Lett. 2018 Jun;15(6):9110-9116. doi: 10.3892/ol.2018.8466. Epub 2018 Apr 11.
• [1484] Knockout of Mpv17-Like Protein (M-LPH) Gene in Human Hepatoma Cells Results in Impairment of mtDNA Integrity through Reduction of TFAM, OGG1, and LIG3 at the Protein Levels.Oxid Med Cell Longev. 2018 Sep 17;2018:6956414. doi: 10.1155/2018/6956414. eCollection 2018.
• [1485] MTP18 overexpression contributes to tumor growth and metastasis and associates with poor survival in hepatocellular carcinoma.Cell Death Dis. 2018 Sep 20;9(10):956. doi: 10.1038/s41419-018-0987-x.
• [1486] Indospicine cytotoxicity and transport in human cell lines.Food Chem. 2018 Nov 30;267:119-123. doi: 10.1016/j.foodchem.2017.08.029. Epub 2017 Aug 8.
• [1487] Overexpression of MUC13, a Poor Prognostic Predictor, Promotes Cell Growth by Activating Wnt Signaling in Hepatocellular Carcinoma.Am J Pathol. 2018 Feb;188(2):378-391. doi: 10.1016/j.ajpath.2017.10.016. Epub 2017 Nov 22.
• [1488] MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development.J Exp Clin Cancer Res. 2018 Feb 13;37(1):28. doi: 10.1186/s13046-018-0693-7.
• [1489] MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.Diagn Pathol. 2018 Nov 3;13(1):85. doi: 10.1186/s13000-018-0763-3.
• [1490] Single-stranded DNA binding protein 2 expression is associated with patient survival in hepatocellular carcinoma.BMC Cancer. 2018 Dec 12;18(1):1244. doi: 10.1186/s12885-018-5158-z.
• [1491] Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver disease.Liver Int. 2018 Aug;38(8):1475-1486. doi: 10.1111/liv.13696. Epub 2018 Feb 10.
• [1492] NASP antagonize chromatin accessibility through maintaining histone H3K9me1 in hepatocellular carcinoma.Biochim Biophys Acta Mol Basis Dis. 2018 Oct;1864(10):3438-3448. doi: 10.1016/j.bbadis.2018.07.033. Epub 2018 Aug 1.
• [1493] Hepatocellular Carcinoma Outcome Is Predicted by Expression of Neuronal Calcium Sensor 1.Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1091-1100. doi: 10.1158/1055-9965.EPI-18-0167. Epub 2018 May 22.
• [1494] Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts.Oncol Lett. 2018 Apr;15(4):4676-4682. doi: 10.3892/ol.2018.7890. Epub 2018 Jan 29.
• [1495] Downregulation of Nedd4L predicts poor prognosis, promotes tumor growth and inhibits MAPK/ERK signal pathway in hepatocellular carcinoma.Biochem Biophys Res Commun. 2018 Jan 1;495(1):1136-1143. doi: 10.1016/j.bbrc.2017.11.139. Epub 2017 Nov 22.
• [1496] Polymorphisms of base-excision repair genes and the hepatocarcinogenesis.Gene. 2018 Oct 30;675:62-68. doi: 10.1016/j.gene.2018.06.056. Epub 2018 Jun 20.
• [1497] lncRNA involvement in hepatocellular carcinoma metastasis and prognosis.EXCLI J. 2018 Sep 4;17:900-913. doi: 10.17179/excli2018-1541. eCollection 2018.
• [1498] Hypermethylation of NF-B-Activating Protein-Like (NKAPL) Promoter in Hepatocellular Carcinoma Suppresses Its Expression and Predicts a Poor Prognosis.Dig Dis Sci. 2018 Mar;63(3):676-686. doi: 10.1007/s10620-018-4929-3. Epub 2018 Jan 20.
• [1499] Low expression of NKD2 is associated with enhanced cell proliferation and poor prognosis in human hepatocellular carcinoma.Hum Pathol. 2018 Feb;72:80-90. doi: 10.1016/j.humpath.2017.09.016. Epub 2017 Nov 8.
• [1500] Oncogenic Activation of Nrf2, Though as a Master Antioxidant Transcription Factor, Liberated by Specific Knockout of the Full-Length Nrf1 that Acts as a Dominant Tumor Repressor.Cancers (Basel). 2018 Dec 17;10(12):520. doi: 10.3390/cancers10120520.
• [1501] Transcriptome Analysis Revealed a Highly Connected Gene Module Associated With Cirrhosis to Hepatocellular Carcinoma Development.Front Genet. 2019 Apr 2;10:305. doi: 10.3389/fgene.2019.00305. eCollection 2019.
• [1502] Overexpression of Opa interacting protein5 increases the progression of liver cancer via BMPR2/JUN/CHEK1/RAC1 dysregulation.Oncol Rep. 2019 Apr;41(4):2075-2088. doi: 10.3892/or.2019.7006. Epub 2019 Feb 11.
• [1503] Expression of OTUB1 in hepatocellular carcinoma and its effects on HCC cell migration and invasion.Acta Biochim Biophys Sin (Shanghai). 2017 Aug 1;49(8):680-688. doi: 10.1093/abbs/gmx056.
• [1504] Hepatic loss of Lissencephaly 1 (Lis1) induces fatty liver and accelerates liver tumorigenesis in mice.J Biol Chem. 2018 Apr 6;293(14):5160-5171. doi: 10.1074/jbc.RA117.001474. Epub 2018 Feb 23.
• [1505] PARP12 (ARTD12) suppresses hepatocellular carcinoma metastasis through interacting with FHL2 and regulating its stability.Cell Death Dis. 2018 Aug 28;9(9):856. doi: 10.1038/s41419-018-0906-1.
• [1506] Methylation of PCDH19 predicts poor prognosis of hepatocellular carcinoma.Asia Pac J Clin Oncol. 2018 Oct;14(5):e352-e358. doi: 10.1111/ajco.12982. Epub 2018 May 11.
• [1507] Downregulation of protein disulfideisomerase A3 expression inhibits cell proliferation and induces apoptosis through STAT3 signaling in hepatocellular carcinoma.Int J Oncol. 2019 Apr;54(4):1409-1421. doi: 10.3892/ijo.2019.4710. Epub 2019 Feb 4.
• [1508] High PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patients.Cell Death Dis. 2018 Sep 24;9(10):991. doi: 10.1038/s41419-018-1017-8.
• [1509] Myofibrillogenesis regulator 1 (MR-1): a potential therapeutic target for cancer and PNKD.J Drug Target. 2018 Sep;26(8):643-648. doi: 10.1080/1061186X.2017.1401077. Epub 2017 Nov 15.
• [1510] PNMA1, regulated by miR-33a-5p, promotes proliferation and EMT in hepatocellular carcinoma by activating the Wnt/-catenin pathway.Biomed Pharmacother. 2018 Dec;108:492-499. doi: 10.1016/j.biopha.2018.09.059. Epub 2018 Sep 19.
• [1511] Linc-POU3F3 is overexpressed in hepatocellular carcinoma and regulates cell proliferation, migration and invasion.Biomed Pharmacother. 2018 Sep;105:683-689. doi: 10.1016/j.biopha.2018.06.006. Epub 2018 Jun 12.
• [1512] Cyclophilin J PPIase Inhibitors Derived from 2,3-Quinoxaline-6 Amine Exhibit Antitumor Activity.Front Pharmacol. 2018 Feb 21;9:126. doi: 10.3389/fphar.2018.00126. eCollection 2018.
• [1513] Protein phosphatase inhibitor-1 mRNA expression correlates with neoplastic transformation of epithelial liver cells and progression of hepatocellular carcinomas.Int J Oncol. 2004 Apr;24(4):869-77.
• [1514] PRAF2 expression indicates unfavorable clinical outcome in hepatocellular carcinoma.Cancer Manag Res. 2018 Jul 25;10:2241-2248. doi: 10.2147/CMAR.S166789. eCollection 2018.
• [1515] PRDM8 exhibits antitumor activities toward hepatocellular carcinoma by targeting NAP1L1.Hepatology. 2018 Sep;68(3):994-1009. doi: 10.1002/hep.29890. Epub 2018 May 21.
• [1516] PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3/Snail signaling.Cancer Sci. 2018 May;109(5):1414-1427. doi: 10.1111/cas.13598.
• [1517] NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression.Oncogene. 2018 Aug;37(35):4887-4900. doi: 10.1038/s41388-018-0280-6. Epub 2018 May 21.
• [1518] Clinical Implication and the Hereditary Factors of NM23 in Hepatocellular Carcinoma Based on Bioinformatics Analysis and Genome-Wide Association Study.J Oncol. 2018 Dec 18;2018:6594169. doi: 10.1155/2018/6594169. eCollection 2018.
• [1519] Hepatocellular Carcinoma and Nuclear Paraspeckles: Induction in Chemoresistance and Prediction for Poor Survival.Cell Physiol Biochem. 2019;52(4):787-801. doi: 10.33594/000000055.
• [1520] PTBP3 splicing factor promotes hepatocellular carcinoma by destroying the splicing balance of NEAT1 and pre-miR-612.Oncogene. 2018 Dec;37(50):6399-6413. doi: 10.1038/s41388-018-0416-8. Epub 2018 Aug 1.
• [1521] Prognostic Value of Phosphotyrosine Phosphatases in Hepatocellular Carcinoma.Cell Physiol Biochem. 2018;46(6):2335-2346. doi: 10.1159/000489625. Epub 2018 May 4.
• [1522] Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.J Hepatol. 2020 Apr;72(4):725-735. doi: 10.1016/j.jhep.2019.10.026. Epub 2019 Nov 11.
• [1523] Expression and regulation of glycogen phosphorylase in preneoplastic and neoplastic hepatic lesions in rats.Virchows Arch B Cell Pathol Incl Mol Pathol. 1987;53(1):44-51. doi: 10.1007/BF02890223.
• [1524] Role of exosomal competing endogenous RNA in patients with hepatocellular carcinoma.J Cell Biochem. 2018 Nov;119(10):8600-8610. doi: 10.1002/jcb.27109. Epub 2018 Jul 17.
• [1525] O-GlcNAcylation on Rab3A attenuates its effects on mitochondrial oxidative phosphorylation and metastasis in hepatocellular carcinoma.Cell Death Dis. 2018 Sep 20;9(10):970. doi: 10.1038/s41419-018-0961-7.
• [1526] Inhibition of RAD54B suppresses proliferation and promotes apoptosis in hepatoma cells.Oncol Rep. 2018 Sep;40(3):1233-1242. doi: 10.3892/or.2018.6522. Epub 2018 Jun 25.
• [1527] Overexpression of RALY promotes migration and predicts poor prognosis in hepatocellular carcinoma.Cancer Manag Res. 2018 Nov 9;10:5559-5572. doi: 10.2147/CMAR.S182996. eCollection 2018.
• [1528] RAMP3 is a prognostic indicator of liver cancer and might reduce the adverse effect of TP53 mutation on survival.Future Oncol. 2018 Oct;14(25):2615-2625. doi: 10.2217/fon-2018-0296. Epub 2018 Jun 8.
• [1529] Rap1b enhances the invasion and migration of hepatocellular carcinoma cells by up-regulating Twist 1.Exp Cell Res. 2018 Jun 1;367(1):56-64. doi: 10.1016/j.yexcr.2018.03.019. Epub 2018 Mar 17.
• [1530] Methylation patterns of RASA3 associated with clinicopathological factors in hepatocellular carcinoma.J Cancer. 2018 May 25;9(12):2116-2122. doi: 10.7150/jca.24567. eCollection 2018.
• [1531] RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma.Cell Mol Biol (Noisy-le-grand). 2018 Apr 30;64(5):73-79.
• [1532] Retinoblastoma Binding Protein 5 Correlates with the Progression in Hepatocellular Carcinoma.Biomed Res Int. 2018 Nov 7;2018:1073432. doi: 10.1155/2018/1073432. eCollection 2018.
• [1533] Upregulation of RECQL4 expression predicts poor prognosis in hepatocellular carcinoma.Oncol Lett. 2018 Apr;15(4):4248-4254. doi: 10.3892/ol.2018.7860. Epub 2018 Jan 25.
• [1534] The clinical significance and biological function of lncRNA RGMB-AS1 in hepatocellular carcinoma.Biomed Pharmacother. 2018 Feb;98:577-584. doi: 10.1016/j.biopha.2017.12.067. Epub 2017 Dec 27.
• [1535] Diagnostic Value of Serum SMP30 and Anti-SMP30 Antibody in Hepatocellular Carcinoma.Lab Med. 2018 Jul 5;49(3):203-210. doi: 10.1093/labmed/lmy004.
• [1536] MicroRNA-199 suppresses cell proliferation, migration and invasion by downregulating RGS17 in hepatocellular carcinoma.Gene. 2018 Jun 15;659:22-28. doi: 10.1016/j.gene.2018.03.053. Epub 2018 Mar 17.
• [1537] miR-1260b promotes cell migration and invasion of hepatocellular carcinoma by targeting the regulator of G-protein signaling 22.Biotechnol Lett. 2018 Jan;40(1):57-62. doi: 10.1007/s10529-017-2455-6. Epub 2017 Oct 16.
• [1538] Oncogene RPA1 promotes proliferation of hepatocellular carcinoma via CDK4/Cyclin-D pathway.Biochem Biophys Res Commun. 2018 Apr 6;498(3):424-430. doi: 10.1016/j.bbrc.2018.02.167. Epub 2018 Mar 15.
• [1539] Programmed Death Receptor 1 (PD1) Knockout and Human Telomerase Reverse Transcriptase (hTERT) Transduction Can Enhance Persistence and Antitumor Efficacy of Cytokine-Induced Killer Cells Against Hepatocellular Carcinoma.Med Sci Monit. 2018 Jul 3;24:4573-4582. doi: 10.12659/MSM.910903.
• [1540] Hepatitis B Virus-Upregulated LNC-HUR1 Promotes Cell Proliferation and Tumorigenesis by Blocking p53 Activity.Hepatology. 2018 Dec;68(6):2130-2144. doi: 10.1002/hep.30098. Epub 2018 Sep 19.
• [1541] Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling.Nat Commun. 2018 Oct 26;9(1):4490. doi: 10.1038/s41467-018-06931-6.
• [1542] Scinderin is a novel transcriptional target of BRMS1 involved in regulation of hepatocellular carcinoma cell apoptosis.Am J Cancer Res. 2018 Jun 1;8(6):1008-1018. eCollection 2018.
• [1543] MiR-205 suppresses tumor growth, invasion, and epithelial-mesenchymal transition by targeting SEMA4C in hepatocellular carcinoma.FASEB J. 2018 May 25:fj201800113R. doi: 10.1096/fj.201800113R. Online ahead of print.
• [1544] Speckle-type POZ protein suppresses hepatocellular carcinoma cell migration and invasion via ubiquitin-dependent proteolysis of SUMO1/sentrin specific peptidase 7.Biochem Biophys Res Commun. 2018 Jul 7;502(1):30-42. doi: 10.1016/j.bbrc.2018.05.115. Epub 2018 May 24.
• [1545] Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma.EBioMedicine. 2018 Apr;30:138-147. doi: 10.1016/j.ebiom.2018.03.029. Epub 2018 Mar 28.
• [1546] Prognostic importance of bile duct invasion in surgical resection with curative intent for hepatocellular carcinoma using PSM analysis.Oncol Lett. 2018 Sep;16(3):3593-3602. doi: 10.3892/ol.2018.9108. Epub 2018 Jul 10.
• [1547] Demethylation-Induced Overexpression of Shc3 Drives c-Raf-Independent Activation of MEK/ERK in HCC.Cancer Res. 2018 May 1;78(9):2219-2232. doi: 10.1158/0008-5472.CAN-17-2432. Epub 2018 Jan 12.
• [1548] SHMT1 inhibits the metastasis of HCC by repressing NOX1-mediated ROS production.J Exp Clin Cancer Res. 2019 Feb 12;38(1):70. doi: 10.1186/s13046-019-1067-5.
• [1549] Key signaling pathways, genes and transcription factors associated with hepatocellular carcinoma.Mol Med Rep. 2018 Jun;17(6):8153-8160. doi: 10.3892/mmr.2018.8871. Epub 2018 Apr 12.
• [1550] Overexpression of miR-664 is associated with poor overall survival and accelerates cell proliferation, migration and invasion in hepatocellular carcinoma.Onco Targets Ther. 2019 Mar 28;12:2373-2381. doi: 10.2147/OTT.S188658. eCollection 2019.
• [1551] A novel long noncoding RNA lncWDR26 suppresses the growth and metastasis of hepatocellular carcinoma cells through interaction with SIX3.Am J Cancer Res. 2018 Apr 1;8(4):688-698. eCollection 2018.
• [1552] Suppression of Slit3 induces tumor proliferation and chemoresistance in hepatocellular carcinoma through activation of GSK3/-catenin pathway.BMC Cancer. 2018 Jun 1;18(1):621. doi: 10.1186/s12885-018-4326-5.
• [1553] Induction of tolerogenic dendritic cells by activated TGF-/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells.BMC Cancer. 2019 May 14;19(1):439. doi: 10.1186/s12885-019-5670-9.
• [1554] Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma.Clin Chim Acta. 2019 May;492:37-44. doi: 10.1016/j.cca.2019.02.001. Epub 2019 Feb 2.
• [1555] Phosphorylation of SMC1A promotes hepatocellular carcinoma cell proliferation and migration.Int J Biol Sci. 2018 Jun 8;14(9):1081-1089. doi: 10.7150/ijbs.24692. eCollection 2018.
• [1556] Silencing non-SMC chromosome-associated polypeptide G inhibits proliferation and induces apoptosis in hepatocellular carcinoma cells.Can J Physiol Pharmacol. 2018 Dec;96(12):1246-1254. doi: 10.1139/cjpp-2018-0195. Epub 2018 Aug 8.
• [1557] MicroRNA-196a/-196b regulate the progression of hepatocellular carcinoma through modulating the JAK/STAT pathway via targeting SOCS2.Cell Death Dis. 2019 Apr 15;10(5):333. doi: 10.1038/s41419-019-1530-4.
• [1558] miR-96 targets SOX6 and promotes proliferation, migration, and invasion of hepatocellular carcinoma. Biochem Cell Biol. 2018 Jun;96(3):365-371.
• [1559] Spartan deficiency causes accumulation of Topoisomerase 1 cleavage complexes and tumorigenesis.Nucleic Acids Res. 2017 May 5;45(8):4564-4576. doi: 10.1093/nar/gkx107.
• [1560] Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide Arrays.Gut Liver. 2018 May 15;12(3):306-315. doi: 10.5009/gnl17277.
• [1561] Hepatitis B virus promotes proliferation and metastasis in male Chinese hepatocellular carcinoma patients through the LEF-1/miR-371a-5p/SRCIN1/pleiotrophin/Slug pathway.Exp Cell Res. 2018 Sep 1;370(1):174-188. doi: 10.1016/j.yexcr.2018.06.020. Epub 2018 Jun 19.
• [1562] Overexpression of signal sequence receptor predicts poor survival in patients with hepatocellular carcinoma.Hum Pathol. 2018 Nov;81:47-54. doi: 10.1016/j.humpath.2018.06.014. Epub 2018 Jun 23.
• [1563] STK17B promotes carcinogenesis and metastasis via AKT/GSK-3/Snail signaling in hepatocellular carcinoma.Cell Death Dis. 2018 Feb 14;9(2):236. doi: 10.1038/s41419-018-0262-1.
• [1564] The Oncogenic Potential of SUV39H2: A Comprehensive and Perspective View.J Cancer. 2019 Jan 1;10(3):721-729. doi: 10.7150/jca.28254. eCollection 2019.
• [1565] High expression of TACC2 in hepatocellular carcinoma is associated with poor prognosis.Cancer Biomark. 2018;22(4):611-619. doi: 10.3233/CBM-170091.
• [1566] Identification of potential transcription factors, long noncoding RNAs, and microRNAs associated with hepatocellular carcinoma.J Cancer Res Ther. 2018 Sep;14(Supplement):S622-S627. doi: 10.4103/0973-1482.204846.
• [1567] Abnormal expression of YEATS4 associates with poor prognosis and promotes cell proliferation of hepatic carcinoma cell by regulation the TCEA1/DDX3 axis.Am J Cancer Res. 2018 Oct 1;8(10):2076-2087. eCollection 2018.
• [1568] Expression tendency and prognostic value of TCF21 in hepatocellular carcinoma.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1466-1470. doi: 10.1080/21691401.2019.1601102.
• [1569] Thrombospondin-4 expression as a prognostic marker in hepatocellular carcinoma.Gene. 2019 May 15;696:219-224. doi: 10.1016/j.gene.2019.02.049. Epub 2019 Feb 22.
• [1570] Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.Cancer Biomark. 2018;23(1):33-43. doi: 10.3233/CBM-181277.
• [1571] TMEM100 expression suppresses metastasis and enhances sensitivity to chemotherapy in gastric cancer.Biol Chem. 2020 Feb 25;401(2):285-296. doi: 10.1515/hsz-2019-0161.
• [1572] TMEM165, a Golgi transmembrane protein, is a novel marker for hepatocellular carcinoma and its depletion impairs invasion activity.Oncol Rep. 2018 Sep;40(3):1297-1306. doi: 10.3892/or.2018.6565. Epub 2018 Jul 12.
• [1573] Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma.Clin Epigenetics. 2018 Nov 6;10(1):137. doi: 10.1186/s13148-018-0570-4.
• [1574] Gelsolin-like Actin-capping Protein (CapG) Overexpression in the Cytoplasm of Human Hepatocellular Carcinoma, Associated with Cellular Invasion, Migration and Tumor Prognosis.Anticancer Res. 2018 Jul;38(7):3943-3950. doi: 10.21873/anticanres.12680.
• [1575] Thymosin 10 is overexpressed and associated with unfavorable prognosis in hepatocellular carcinoma.Biosci Rep. 2019 Mar 15;39(3):BSR20182355. doi: 10.1042/BSR20182355. Print 2019 Mar 29.
• [1576] Binding of thiazolidinediones to the endoplasmic reticulum protein nutrient-deprivation autophagy factor-1.Bioorg Med Chem Lett. 2019 Apr 1;29(7):901-904. doi: 10.1016/j.bmcl.2019.01.041. Epub 2019 Feb 1.
• [1577] MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29.Life Sci. 2019 May 1;224:1-11. doi: 10.1016/j.lfs.2019.03.028. Epub 2019 Mar 12.
• [1578] TRIM50 suppressed hepatocarcinoma progression through directly targeting SNAIL for ubiquitous degradation.Cell Death Dis. 2018 May 22;9(6):608. doi: 10.1038/s41419-018-0644-4.
• [1579] TRIM66 confers tumorigenicity of hepatocellular carcinoma cells by regulating GSK-3-dependent Wnt/-catenin signaling.Eur J Pharmacol. 2019 May 5;850:109-117. doi: 10.1016/j.ejphar.2019.01.054. Epub 2019 Jan 30.
• [1580] Multiple novel hepatocellular carcinoma signature genes are commonly controlled by the master pluripotency factor OCT4.Cell Oncol (Dordr). 2020 Apr;43(2):279-295. doi: 10.1007/s13402-019-00487-3. Epub 2019 Dec 17.
• [1581] Screening of biomarkers for liver adenoma in low-dose-rate -ray-irradiated mice.Int J Radiat Biol. 2018 Apr;94(4):315-326. doi: 10.1080/09553002.2018.1439193. Epub 2018 Mar 2.
• [1582] Fructose-Bisphosphate Aldolase A Regulates Hypoxic Adaptation in Hepatocellular Carcinoma and Involved with Tumor Malignancy.Dig Dis Sci. 2019 Nov;64(11):3215-3227. doi: 10.1007/s10620-019-05642-2. Epub 2019 Apr 30.
• [1583] Association of AlkB homolog 3 expression with tumor recurrence and unfavorable prognosis in hepatocellular carcinoma.J Gastroenterol Hepatol. 2018 Feb 7. doi: 10.1111/jgh.14117. Online ahead of print.
• [1584] LicA induces autophagy through ULK1/Atg13 and ROS pathway in human hepatocellular carcinoma cells.Int J Mol Med. 2018 May;41(5):2601-2608. doi: 10.3892/ijmm.2018.3499. Epub 2018 Feb 16.
• [1585] MicroRNA-1468 promotes tumor progression by activating PPAR--mediated AKT signaling in human hepatocellular carcinoma.J Exp Clin Cancer Res. 2018 Mar 6;37(1):49. doi: 10.1186/s13046-018-0717-3.
• [1586] miR-1226-3p Promotes Sorafenib Sensitivity of Hepatocellular Carcinoma via Downregulation of DUSP4 Expression.J Cancer. 2019 Jun 2;10(12):2745-2753. doi: 10.7150/jca.31804. eCollection 2019.
• [1587] LncRNA FAL1 promotes cell proliferation and migration by acting as a CeRNA of miR-1236 in hepatocellular carcinoma cells.Life Sci. 2018 Mar 15;197:122-129. doi: 10.1016/j.lfs.2018.02.006. Epub 2018 Feb 6.
• [1588] Integration of metabolomics and expression of enolase-phosphatase 1 links to hepatocellular carcinoma progression.Theranostics. 2019 May 26;9(12):3639-3652. doi: 10.7150/thno.31693. eCollection 2019.
• [1589] Prognostic significance of sodium-potassium ATPase regulator, FXYD3, in human hepatocellular carcinoma.Oncol Lett. 2018 Mar;15(3):3024-3030. doi: 10.3892/ol.2017.7688. Epub 2017 Dec 21.
• [1590] CircRNA circ_0067934 promotes tumor growth and metastasis in hepatocellular carcinoma through regulation of miR-1324/FZD5/Wnt/-catenin axis.Biochem Biophys Res Commun. 2018 Mar 4;497(2):626-632. doi: 10.1016/j.bbrc.2018.02.119. Epub 2018 Feb 16.
• [1591] Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma.Oncotarget. 2018 Jan 22;9(11):10054-10068. doi: 10.18632/oncotarget.24300. eCollection 2018 Feb 9.
• [1592] GTSF1 gene may serve as a novel potential diagnostic biomarker for liver cancer.Oncol Lett. 2018 Mar;15(3):3133-3140. doi: 10.3892/ol.2017.7695. Epub 2017 Dec 27.
• [1593] LncRNA MCM3AP-AS1 Regulates Epidermal Growth Factor Receptor and Autophagy to Promote Hepatocellular Carcinoma Metastasis by Interacting with miR-455.DNA Cell Biol. 2019 Aug;38(8):857-864. doi: 10.1089/dna.2019.4770. Epub 2019 Jun 25.
• [1594] No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5cm.J Hepatol. 2018 Jun;68(6):1172-1180. doi: 10.1016/j.jhep.2018.01.014. Epub 2018 Feb 2.
• [1595] PARP10 suppresses tumor metastasis through regulation of Aurora A activity.Oncogene. 2018 May;37(22):2921-2935. doi: 10.1038/s41388-018-0168-5. Epub 2018 Mar 8.
• [1596] Research Progress on PARP14 as a Drug Target.Front Pharmacol. 2019 Mar 5;10:172. doi: 10.3389/fphar.2019.00172. eCollection 2019.
• [1597] POU5F1B promotes hepatocellular carcinoma proliferation by activating AKT.Biomed Pharmacother. 2018 Apr;100:374-380. doi: 10.1016/j.biopha.2018.02.023. Epub 2018 Feb 16.
• [1598] The RNA-binding protein RBM3 promotes cell proliferation in hepatocellular carcinoma by regulating circular RNA SCD-circRNA 2 production.EBioMedicine. 2019 Jul;45:155-167. doi: 10.1016/j.ebiom.2019.06.030. Epub 2019 Jun 22.
• [1599] Long noncoding RNA RUSC1-AS-N indicates poor prognosis and increases cell viability in hepatocellular carcinoma.Eur Rev Med Pharmacol Sci. 2018 Jan;22(2):388-396. doi: 10.26355/eurrev_201801_14185.
• [1600] Comprehensive characterization of cancer genes in hepatocellular carcinoma genomes.Oncol Lett. 2018 Feb;15(2):1503-1510. doi: 10.3892/ol.2017.7521. Epub 2017 Dec 5.
• [1601] High Levels of TRIM14 Are Associated with Poor Prognosis in Hepatocellular Carcinoma.Oncol Res Treat. 2018;41(3):129-134. doi: 10.1159/000485625. Epub 2018 Feb 27.
• [1602] Oncogenic function and prognostic significance of Abelson interactor 1 in hepatocellular carcinoma.Int J Oncol. 2017 May;50(5):1889-1898. doi: 10.3892/ijo.2017.3920. Epub 2017 Mar 20.
• [1603] An integrated genomic and proteomic approach to identify signatures of endosulfan exposure in hepatocellular carcinoma cells. Pestic Biochem Physiol. 2015 Nov;125:8-16.
• [1604] ACOT12-Dependent Alteration of Acetyl-CoA Drives Hepatocellular Carcinoma Metastasis by Epigenetic Induction of Epithelial-Mesenchymal Transition.Cell Metab. 2019 Apr 2;29(4):886-900.e5. doi: 10.1016/j.cmet.2018.12.019. Epub 2019 Jan 22.
• [1605] Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.Cell Physiol Biochem. 2017;41(6):2289-2306. doi: 10.1159/000475648. Epub 2017 Apr 26.
• [1606] Overexpression of a disintegrin and metalloproteinase 21 is associated with motility, metastasis, and poor prognosis in hepatocellular carcinoma.Sci Rep. 2017 Nov 14;7(1):15485. doi: 10.1038/s41598-017-15800-z.
• [1607] The competing endogenous circular RNA ADAMTS14 suppressed hepatocellular carcinoma progression through regulating microRNA-572/regulator of calcineurin 1.J Cell Physiol. 2019 Mar;234(3):2460-2470. doi: 10.1002/jcp.26764. Epub 2018 Oct 14.
• [1608] Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.Gastroenterology. 2017 Jul;153(1):249-262.e2. doi: 10.1053/j.gastro.2017.03.024. Epub 2017 Mar 29.
• [1609] Prognostic relevance of miR-137 and its liver microenvironment regulatory target gene AFM in hepatocellular carcinoma.J Cell Physiol. 2019 Jul;234(7):11888-11899. doi: 10.1002/jcp.27855. Epub 2018 Dec 6.
• [1610] Overexpression of apoptosis-inducing factor mitochondrion-associated 1 (AIFM1) induces apoptosis by promoting the transcription of caspase3 and DRAM in hepatoma cells.Biochem Biophys Res Commun. 2018 Apr 6;498(3):453-457. doi: 10.1016/j.bbrc.2018.02.203. Epub 2018 Mar 1.
• [1611] ZNF479 downregulates metallothionein-1 expression by regulating ASH2L and DNMT1 in hepatocellular carcinoma.Cell Death Dis. 2019 May 28;10(6):408. doi: 10.1038/s41419-019-1651-9.
• [1612] Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells.Oncol Rep. 2017 Feb;37(2):969-978. doi: 10.3892/or.2016.5334. Epub 2016 Dec 23.
• [1613] Histone deacetylase inhibitors promote ATP2A3 gene expression in hepatocellular carcinoma cells: p300 as a transcriptional regulator.Int J Biochem Cell Biol. 2019 Aug;113:8-16. doi: 10.1016/j.biocel.2019.05.014. Epub 2019 May 27.
• [1614] Silencing of ATP4B of ATPase H(+)/K(+) Transporting Beta Subunit by Intragenic Epigenetic Alteration in Human Gastric Cancer Cells.Oncol Res. 2017 Mar 13;25(3):317-329. doi: 10.3727/096504016X14734735156265.
• [1615] LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.Eur Radiol. 2019 Jan;29(1):401-410. doi: 10.1007/s00330-018-5559-z. Epub 2018 Jun 19.
• [1616] High expression FUT1 and B3GALT5 is an independent predictor of postoperative recurrence and survival in hepatocellular carcinoma.Sci Rep. 2017 Sep 7;7(1):10750. doi: 10.1038/s41598-017-11136-w.
• [1617] Six genes as potential diagnosis and prognosis biomarkers for hepatocellular carcinoma through data mining.J Cell Physiol. 2019 Jun;234(6):9787-9792. doi: 10.1002/jcp.27664. Epub 2018 Dec 17.
• [1618] MiR-HCC2 Up-regulates BAMBI and ELMO1 Expression to Facilitate the Proliferation and EMT of Hepatocellular Carcinoma Cells.J Cancer. 2019 Jun 9;10(15):3407-3419. doi: 10.7150/jca.30858. eCollection 2019.
• [1619] Loss of Barx1 promotes hepatocellular carcinoma metastasis through up-regulating MGAT5 and MMP9 expression and indicates poor prognosis.Oncotarget. 2017 May 30;8(42):71867-71880. doi: 10.18632/oncotarget.18288. eCollection 2017 Sep 22.
• [1620] Stress Hormone Cortisol Enhances Bcl2 Like-12 Expression to Inhibit p53 in Hepatocellular Carcinoma Cells.Dig Dis Sci. 2017 Dec;62(12):3495-3500. doi: 10.1007/s10620-017-4798-1. Epub 2017 Oct 17.
• [1621] Bclaf1 promotes angiogenesis by regulating HIF-1 transcription in hepatocellular carcinoma.Oncogene. 2019 Mar;38(11):1845-1859. doi: 10.1038/s41388-018-0552-1. Epub 2018 Oct 26.
• [1622] Overexpression of DBC1, correlated with poor prognosis, is a potential therapeutic target for hepatocellular carcinoma.Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):511-517. doi: 10.1016/j.bbrc.2017.10.134. Epub 2017 Oct 26.
• [1623] MicroRNA-519c-3p promotes tumor growth and metastasis of hepatocellular carcinoma by targeting BTG3.Biomed Pharmacother. 2019 Oct;118:109267. doi: 10.1016/j.biopha.2019.109267. Epub 2019 Aug 3.
• [1624] Inhibition of CTRP6 prevented survival and migration in hepatocellular carcinoma through inactivating the AKT signaling pathway.J Cell Biochem. 2019 Oct;120(10):17059-17066. doi: 10.1002/jcb.28967. Epub 2019 May 20.
• [1625] Deep sequencing and comprehensive expression analysis identifies several molecules potentially related to human poorly differentiated hepatocellular carcinoma.FEBS Open Bio. 2017 Sep 25;7(11):1696-1706. doi: 10.1002/2211-5463.12310. eCollection 2017 Nov.
• [1626] CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma.J Exp Clin Cancer Res. 2018 Mar 5;37(1):46. doi: 10.1186/s13046-018-0699-1.
• [1627] Upregulation of caprin1 expression is associated with poor prognosis in hepatocellular carcinoma.Pathol Res Pract. 2017 Dec;213(12):1563-1567. doi: 10.1016/j.prp.2017.07.014. Epub 2017 Jul 15.
• [1628] Integrated analysis of competing endogenous RNA network revealing potential prognostic biomarkers of hepatocellular carcinoma.J Cancer. 2019 Jun 2;10(14):3267-3283. doi: 10.7150/jca.29986. eCollection 2019.
• [1629] CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma.Oncotarget. 2017 Mar 21;8(12):18872-18884. doi: 10.18632/oncotarget.14770.
• [1630] Cell Cycle and Apoptosis Regulator 1, CCAR1, Regulates Enhancer-Dependent Nuclear Receptor CAR Transactivation.Mol Pharmacol. 2019 Jan;95(1):120-126. doi: 10.1124/mol.118.114272. Epub 2018 Nov 5.
• [1631] CCDC178 promotes hepatocellular carcinoma metastasis through modulation of anoikis.Oncogene. 2017 Jul 13;36(28):4047-4059. doi: 10.1038/onc.2017.10. Epub 2017 Mar 20.
• [1632] Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate.Pathology. 2019 Oct;51(6):586-592. doi: 10.1016/j.pathol.2019.06.001. Epub 2019 Aug 21.
• [1633] CTGF secreted by mesenchymal-like hepatocellular carcinoma cells plays a role in the polarization of macrophages in hepatocellular carcinoma progression.Biomed Pharmacother. 2017 Nov;95:111-119. doi: 10.1016/j.biopha.2017.08.004. Epub 2017 Sep 12.
• [1634] CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis.Oncotarget. 2017 Jan 17;8(3):5135-5148. doi: 10.18632/oncotarget.14095.
• [1635] Inhibition of CUG-binding protein 1 and activation of caspases are critically involved in piperazine derivative BK10007S induced apoptosis in hepatocellular carcinoma cells.PLoS One. 2017 Oct 16;12(10):e0186490. doi: 10.1371/journal.pone.0186490. eCollection 2017.
• [1636] Tumor repressor gene chondroadherin oppose migration and proliferation in hepatocellular carcinoma and predicts a good survival.Oncotarget. 2017 Aug 2;8(36):60270-60279. doi: 10.18632/oncotarget.19811. eCollection 2017 Sep 1.
• [1637] CHCHD2 promotes hepatocellular carcinoma and indicates poor prognosis of hepatocellular carcinoma patients.J Cancer. 2019 Nov 1;10(27):6822-6828. doi: 10.7150/jca.31158. eCollection 2019.
• [1638] Expression of CHODL in hepatocellular carcinoma affects invasion and migration of liver cancer cells.Oncol Lett. 2017 Feb;13(2):715-721. doi: 10.3892/ol.2016.5466. Epub 2016 Dec 6.
• [1639] Synthesis of Dual Target CPT-Ala-Nor Conjugates and Their Biological Activity Evaluation.Anticancer Agents Med Chem. 2019;19(4):502-508. doi: 10.2174/1871520619666190121121933.
• [1640] CKLF1 Enhances Inflammation-Mediated Carcinogenesis and Prevents Doxorubicin-Induced Apoptosis via IL6/STAT3 Signaling in HCC.Clin Cancer Res. 2019 Jul 1;25(13):4141-4154. doi: 10.1158/1078-0432.CCR-18-3510. Epub 2019 Mar 27.
• [1641] Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation.Hepatology. 2019 Mar;69(3):1180-1192. doi: 10.1002/hep.30244. Epub 2019 Feb 5.
• [1642] CKLF-Like MARVEL Transmembrane Domain-Containing Member 3 (CMTM3) Inhibits the Proliferation and Tumorigenisis in Hepatocellular Carcinoma Cells.Oncol Res. 2017 Jan 26;25(2):285-293. doi: 10.3727/096504016X14732523471442. Epub 2016 Sep 13.
• [1643] Clinical significance of CMTM4 expression in hepatocellular carcinoma.Onco Targets Ther. 2017 Nov 14;10:5439-5443. doi: 10.2147/OTT.S149786. eCollection 2017.
• [1644] Expression and Clinical Significance of CMTM6 in Hepatocellular Carcinoma.DNA Cell Biol. 2019 Feb;38(2):193-197. doi: 10.1089/dna.2018.4513. Epub 2018 Dec 18.
• [1645] LncRNA NEAT1 Promotes Proliferation, Migration And Invasion Via Regulating miR-296-5p/CNN2 Axis In Hepatocellular Carcinoma Cells.Onco Targets Ther. 2019 Nov 18;12:9887-9897. doi: 10.2147/OTT.S228917. eCollection 2019.
• [1646] RMP promotes epithelial-mesenchymal transition through NF-B/CSN2/Snail pathway in hepatocellular carcinoma.Oncotarget. 2017 Jun 20;8(25):40373-40388. doi: 10.18632/oncotarget.16177.
• [1647] Zinc Salts Block Hepatitis E Virus Replication by Inhibiting the Activity of Viral RNA-Dependent RNA Polymerase.J Virol. 2017 Oct 13;91(21):e00754-17. doi: 10.1128/JVI.00754-17. Print 2017 Nov 1.
• [1648] Cytoglobin ameliorates the stemness of hepatocellular carcinoma via coupling oxidative-nitrosative stress signals.Mol Carcinog. 2019 Mar;58(3):334-343. doi: 10.1002/mc.22931. Epub 2018 Dec 4.
• [1649] Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway.J Exp Clin Cancer Res. 2017 Oct 19;36(1):148. doi: 10.1186/s13046-017-0618-x.
• [1650] Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.Hepatology. 2019 Mar;69(3):1032-1045. doi: 10.1002/hep.30303. Epub 2019 Feb 10.
• [1651] -TrCP-mediated ubiquitination and degradation of Dlg5 regulates hepatocellular carcinoma cell proliferation.Cancer Cell Int. 2019 Nov 15;19:298. doi: 10.1186/s12935-019-1029-1. eCollection 2019.
• [1652] An indel polymorphism within pre-miR3131 confers risk for hepatocellular carcinoma.Carcinogenesis. 2017 Feb 1;38(2):168-176. doi: 10.1093/carcin/bgw206.
• [1653] NADPH Oxidase 1 in Liver Macrophages Promotes Inflammation and Tumor Development in Mice.Gastroenterology. 2019 Mar;156(4):1156-1172.e6. doi: 10.1053/j.gastro.2018.11.019. Epub 2018 Nov 13.
• [1654] Cks1 regulates human hepatocellular carcinoma cell progression through osteopontin expression.Biochem Biophys Res Commun. 2019 Jan 1;508(1):275-281. doi: 10.1016/j.bbrc.2018.11.070. Epub 2018 Nov 26.
• [1655] Amphiphilic poly-N-vinylpyrrolidone nanoparticles as carriers for non-steroidal, anti-inflammatory drugs: In vitro cytotoxicity and in vivo acute toxicity study.Nanomedicine. 2017 Apr;13(3):1021-1030. doi: 10.1016/j.nano.2016.11.006. Epub 2016 Nov 22.
• [1656] Downregulation of esophageal cancer-related gene 4 promotes proliferation and migration of hepatocellular carcinoma.Oncol Lett. 2017 Sep;14(3):3689-3696. doi: 10.3892/ol.2017.6616. Epub 2017 Jul 20.
• [1657] Alterations in Eukaryotic Elongation Factor complex proteins (EEF1s) in cancer and their implications in epigenetic regulation.Life Sci. 2019 Dec 1;238:116977. doi: 10.1016/j.lfs.2019.116977. Epub 2019 Oct 19.
• [1658] Euphorbia factor L2 inhibits TGF--induced cell growth and migration of hepatocellular carcinoma through AKT/STAT3.Phytomedicine. 2019 Sep;62:152931. doi: 10.1016/j.phymed.2019.152931. Epub 2019 Apr 17.
• [1659] miR-503 inhibits proliferation making human hepatocellular carcinoma cells susceptible to 5fluorouracil by targeting EIF4E.Oncol Rep. 2017 Jan;37(1):563-570. doi: 10.3892/or.2016.5220. Epub 2016 Nov 7.
• [1660] CircRNA-100338 Is Associated With mTOR Signaling Pathway and Poor Prognosis in Hepatocellular Carcinoma.Front Oncol. 2019 May 14;9:392. doi: 10.3389/fonc.2019.00392. eCollection 2019.
• [1661] Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma.EBioMedicine. 2019 Aug;46:105-118. doi: 10.1016/j.ebiom.2019.07.002. Epub 2019 Jul 16.
• [1662] Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma.Nat Commun. 2017 Sep 11;8(1):517. doi: 10.1038/s41467-017-00530-7.
• [1663] LINC00052 upregulates EPB41L3 to inhibit migration and invasion of hepatocellular carcinoma by binding miR-452-5p.Oncotarget. 2017 Jun 29;8(38):63724-63737. doi: 10.18632/oncotarget.18892. eCollection 2017 Sep 8.
• [1664] A Noninvasive Prediction Nomogram for Lymph Node Metastasis of Hepatocellular Carcinoma Based on Serum Long Noncoding RNAs.Biomed Res Int. 2019 Jul 1;2019:1710670. doi: 10.1155/2019/1710670. eCollection 2019.
• [1665] LncRNA KTN1-AS1 promotes tumor growth of hepatocellular carcinoma by targeting miR-23c/ERBB2IP axis.Biomed Pharmacother. 2019 Jan;109:1140-1147. doi: 10.1016/j.biopha.2018.10.105. Epub 2018 Nov 6.
• [1666] Novel pyrimidine-2,4-dione-1,2,3-triazole and furo[2,3-d]pyrimidine-2-one-1,2,3-triazole hybrids as potential anti-cancer agents: Synthesis, computational and X-ray analysis and biological evaluation.Eur J Med Chem. 2017 Jan 5;125:1247-1267. doi: 10.1016/j.ejmech.2016.11.028. Epub 2016 Nov 14.
• [1667] HBx-K130M/V131I Promotes Liver Cancer in Transgenic Mice via AKT/FOXO1 Signaling Pathway and Arachidonic Acid Metabolism.Mol Cancer Res. 2019 Jul;17(7):1582-1593. doi: 10.1158/1541-7786.MCR-18-1127. Epub 2019 Apr 11.
• [1668] Lycorine Promotes Autophagy and Apoptosis via TCRP1/Akt/mTOR Axis Inactivation in Human Hepatocellular Carcinoma.Mol Cancer Ther. 2017 Dec;16(12):2711-2723. doi: 10.1158/1535-7163.MCT-17-0498. Epub 2017 Sep 28.
• [1669] Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.BMC Cancer. 2019 Aug 8;19(1):789. doi: 10.1186/s12885-019-6002-9.
• [1670] miR-219 regulates liver cancer stem cell expansion via E-cadherin pathway.Cell Cycle. 2019 Dec;18(24):3550-3561. doi: 10.1080/15384101.2019.1691762. Epub 2019 Nov 14.
• [1671] Expression and purification of an FGF9 fusion protein in E. coli, and the effects of the FGF9 subfamily on human hepatocellular carcinoma cell proliferation and migration.Appl Microbiol Biotechnol. 2017 Nov;101(21):7823-7835. doi: 10.1007/s00253-017-8468-1. Epub 2017 Sep 18.
• [1672] MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1.Phytomedicine. 2019 Apr;57:18-29. doi: 10.1016/j.phymed.2018.10.027. Epub 2018 Oct 22.
• [1673] Circular RNAs negatively regulate cancer stem cells by physically binding FMRP against CCAR1 complex in hepatocellular carcinoma.Theranostics. 2019 May 26;9(12):3526-3540. doi: 10.7150/thno.32796. eCollection 2019.
• [1674] Effect of cancer/testis antigen NY-SAR-35 on the proliferation, migration and invasion of cancer cells.Oncol Lett. 2017 Feb;13(2):784-790. doi: 10.3892/ol.2016.5498. Epub 2016 Dec 14.
• [1675] Increased FNDC5/Irisin expression in human hepatocellular carcinoma.Peptides. 2017 Feb;88:62-66. doi: 10.1016/j.peptides.2016.12.014. Epub 2016 Dec 21.
• [1676] Forkhead box (FOX) G1 promotes hepatocellular carcinoma epithelial-Mesenchymal transition by activating Wnt signal through forming T-cell factor-4/Beta-catenin/FOXG1 complex.J Exp Clin Cancer Res. 2019 Nov 27;38(1):475. doi: 10.1186/s13046-019-1433-3.
• [1677] Upregulation of FoxP4 in HCC promotes migration and invasion through regulation of EMT.Oncol Lett. 2019 Apr;17(4):3944-3951. doi: 10.3892/ol.2019.10049. Epub 2019 Feb 19.
• [1678] Frizzled 2-induced epithelial-mesenchymal transition correlates with vasculogenic mimicry, stemness, and Hippo signaling in hepatocellular carcinoma.Cancer Sci. 2019 Apr;110(4):1169-1182. doi: 10.1111/cas.13949. Epub 2019 Mar 6.
• [1679] Loss of N-Acetylgalactosaminyltransferase-4 Orchestrates Oncogenic MicroRNA-9 in Hepatocellular Carcinoma.J Biol Chem. 2017 Feb 24;292(8):3186-3200. doi: 10.1074/jbc.M116.751685. Epub 2017 Jan 6.
• [1680] GATA5 inhibits hepatocellular carcinoma cells malignant behaviours by blocking expression of reprogramming genes.J Cell Mol Med. 2019 Apr;23(4):2536-2548. doi: 10.1111/jcmm.14144. Epub 2019 Jan 22.
• [1681] Mutations acquired by hepatocellular carcinoma recurrence give rise to an aggressive phenotype.Oncotarget. 2017 Apr 4;8(14):22903-22916. doi: 10.18632/oncotarget.14248.
• [1682] Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma.BMC Cancer. 2017 Sep 1;17(1):610. doi: 10.1186/s12885-017-3629-2.
• [1683] Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection.Clin Gastroenterol Hepatol. 2019 Dec;17(13):2808-2810.e2. doi: 10.1016/j.cgh.2019.01.002. Epub 2019 Jan 11.
• [1684] LncRNA HANR Promotes Tumorigenesis and Increase of Chemoresistance in Hepatocellular Carcinoma.Cell Physiol Biochem. 2017;43(5):1926-1938. doi: 10.1159/000484116. Epub 2017 Oct 20.
• [1685] Knockdown of GTPBP4 inhibits cell growth and survival in human hepatocellular carcinoma and its prognostic significance.Oncotarget. 2017 Oct 5;8(55):93984-93997. doi: 10.18632/oncotarget.21500. eCollection 2017 Nov 7.
• [1686] Histone Acetyltransferase 1 Promotes Cell Proliferation and Induces Cisplatin Resistance in Hepatocellular Carcinoma.Oncol Res. 2017 Jul 5;25(6):939-946. doi: 10.3727/096504016X14809827856524. Epub 2016 Dec 8.
• [1687] CSR1 suppresses tumor growth and metastasis of human hepatocellular carcinoma via inhibition of HPIP.Eur Rev Med Pharmacol Sci. 2017 Oct;21(17):3813-3820.
• [1688] The HRP3 PWWP domain recognizes the minor groove of double-stranded DNA and recruits HRP3 to chromatin.Nucleic Acids Res. 2019 Jun 4;47(10):5436-5448. doi: 10.1093/nar/gkz294.
• [1689] A novel function for HEG1 in promoting metastasis in hepatocellular carcinoma.Clin Sci (Lond). 2019 Oct 15;133(19):2019-2022. doi: 10.1042/CS20190704.
• [1690] HELLS Regulates Chromatin Remodeling and Epigenetic Silencing of Multiple Tumor Suppressor Genes in Human Hepatocellular Carcinoma.Hepatology. 2019 May;69(5):2013-2030. doi: 10.1002/hep.30414. Epub 2019 Mar 27.
• [1691] HERC4 Is Overexpressed in Hepatocellular Carcinoma and Contributes to the Proliferation and Migration of Hepatocellular Carcinoma Cells.DNA Cell Biol. 2017 Jun;36(6):490-500. doi: 10.1089/dna.2016.3626. Epub 2017 Apr 21.
• [1692] Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway.Cell Death Dis. 2019 Dec 9;10(12):934. doi: 10.1038/s41419-019-2155-3.
• [1693] HEY2 acting as a co-repressor with smad3 and smad4 interferes with the response of TGF-beta in hepatocellular carcinoma.Am J Transl Res. 2019 Jul 15;11(7):4367-4381. eCollection 2019.
• [1694] Hypoxia-inducible gene 2 promotes the immune escape of hepatocellular carcinoma from nature killer cells through the interleukin-10-STAT3 signaling pathway.J Exp Clin Cancer Res. 2019 May 29;38(1):229. doi: 10.1186/s13046-019-1233-9.
• [1695] Mycoplasma infection promotes tumor progression via interaction of the mycoplasmal protein p37 and epithelial cell adhesion molecule in hepatocellular carcinoma.Cancer Lett. 2019 Jul 10;454:44-52. doi: 10.1016/j.canlet.2019.04.007. Epub 2019 Apr 10.
• [1696] Systematic analysis and prediction model construction of alternative splicing events in hepatocellular carcinoma: a study on the basis of large-scale spliceseq data from The Cancer Genome Atlas.PeerJ. 2019 Dec 9;7:e8245. doi: 10.7717/peerj.8245. eCollection 2019.
• [1697] Glycolysis gene expression profilings screen for prognostic risk signature of hepatocellular carcinoma.Aging (Albany NY). 2019 Dec 2;11(23):10861-10882. doi: 10.18632/aging.102489. Epub 2019 Dec 2.
• [1698] Characterization of the GNMT-HectH9-PREX2 tripartite relationship in the pathogenesis of hepatocellular carcinoma.Int J Cancer. 2017 May 15;140(10):2284-2297. doi: 10.1002/ijc.30652.
• [1699] ICMT contributes to hepatocellular carcinoma growth, survival, migration and chemoresistance via multiple oncogenic pathways.Biochem Biophys Res Commun. 2019 Oct 20;518(3):584-589. doi: 10.1016/j.bbrc.2019.08.094. Epub 2019 Aug 24.
• [1700] Id4 promotes cell proliferation in hepatocellular carcinoma.Chin J Cancer. 2017 Feb 1;36(1):19. doi: 10.1186/s40880-017-0186-7.
• [1701] Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7.Tumour Biol. 2016 Apr;37(4):5225-30. doi: 10.1007/s13277-015-4358-2. Epub 2015 Nov 10.
• [1702] Hepatic IFIT3 predicts interferon- therapeutic response in patients of hepatocellular carcinoma.Hepatology. 2017 Jul;66(1):152-166. doi: 10.1002/hep.29156. Epub 2017 May 26.
• [1703] Non-coding RNAs: the cancer genome dark matter that matters!.Clin Chem Lab Med. 2017 May 1;55(5):705-714. doi: 10.1515/cclm-2016-0740.
• [1704] Cytotoxic, genotoxic, and oxidative stress-inducing effect of an l-amino acid oxidase isolated from Bothrops jararacussu venom in a co-culture model of HepG2 and HUVEC cells.Int J Biol Macromol. 2019 Apr 15;127:425-432. doi: 10.1016/j.ijbiomac.2019.01.059. Epub 2019 Jan 15.
• [1705] Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination.J Hepatol. 2017 Jul;67(1):186-191. doi: 10.1016/j.jhep.2017.03.009. Epub 2017 Mar 18.
• [1706] ING3 is required for ATM signaling and DNA repair in response to DNA double strand breaks.Cell Death Differ. 2019 Nov;26(11):2344-2357. doi: 10.1038/s41418-019-0305-x. Epub 2019 Feb 25.
• [1707] Long-term Administration of Nuclear Bile Acid Receptor FXR Agonist Prevents Spontaneous Hepatocarcinogenesis in Abcb4(-/-) Mice.Sci Rep. 2017 Sep 11;7(1):11203. doi: 10.1038/s41598-017-11549-7.
• [1708] KDM4B-mediated epigenetic silencing of miRNA-615-5p augments RAB24 to facilitate malignancy of hepatoma cells.Oncotarget. 2017 Mar 14;8(11):17712-17725. doi: 10.18632/oncotarget.10832.
• [1709] MicroRNA-591 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Lowering Drug Resistance through Inhibition of Far-Upstream Element-Binding Protein 2-Mediated Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Axis.Pharmacology. 2019;104(3-4):173-186. doi: 10.1159/000501162. Epub 2019 Jul 5.
• [1710] KIF3B Promotes the Proliferation of Pancreatic Cancer.Cancer Biother Radiopharm. 2019 Aug;34(6):355-361. doi: 10.1089/cbr.2018.2716. Epub 2019 Jun 3.
• [1711] Kinesin superfamily protein expression and its association with progression and prognosis in hepatocellular carcinoma.J Cancer Res Ther. 2017;13(4):651-659. doi: 10.4103/jcrt.JCRT_491_17.
• [1712] Pyridine nucleotide-disulphide oxidoreductase domain 2 (PYROXD2): Role in mitochondrial function.Mitochondrion. 2019 Jul;47:114-124. doi: 10.1016/j.mito.2019.05.007. Epub 2019 Jun 3.
• [1713] LDB2 inhibits proliferation and migration in liver cancer cells by abrogating HEY1 expression.Oncotarget. 2017 Oct 10;8(55):94440-94449. doi: 10.18632/oncotarget.21772. eCollection 2017 Nov 7.
• [1714] Expression of LDL receptor-related proteins (LRPs) in common solid malignancies correlates with patient survival.PLoS One. 2017 Oct 31;12(10):e0186649. doi: 10.1371/journal.pone.0186649. eCollection 2017.
• [1715] Suppressor of hepatocellular carcinoma RASSF1A activates autophagy initiation and maturation.Cell Death Differ. 2019 Aug;26(8):1379-1395. doi: 10.1038/s41418-018-0211-7. Epub 2018 Oct 12.
• [1716] Hepatitis C Virus Screening and Care: Complexity of Implementation in Primary Care Practices Serving Disadvantaged Populations.Ann Intern Med. 2019 Dec 17;171(12):865-874. doi: 10.7326/M18-3573. Epub 2019 Dec 3.
• [1717] MARVELD1 interacting with catalase regulates reactive oxygen species metabolism and mediates the sensitivity to chemotherapeutic drugs in epithelial tumors of the reproductive system.Mol Carcinog. 2019 Aug;58(8):1410-1426. doi: 10.1002/mc.23024. Epub 2019 May 7.
• [1718] Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model.Oncotarget. 2017 Dec 14;8(70):115582-115595. doi: 10.18632/oncotarget.23312. eCollection 2017 Dec 29.
• [1719] Minichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF-B pathway.J Exp Clin Cancer Res. 2019 Jun 17;38(1):263. doi: 10.1186/s13046-019-1241-9.
• [1720] miR-186 modulates hepatocellular carcinoma cell proliferation and mobility via targeting MCRS1-mediated Wnt/-catenin signaling.J Cell Physiol. 2019 Dec;234(12):23135-23145. doi: 10.1002/jcp.28878. Epub 2019 May 29.
• [1721] Prognostic significance of MEOX2 in gliomas.Mod Pathol. 2019 Jun;32(6):774-786. doi: 10.1038/s41379-018-0192-6. Epub 2019 Jan 18.
• [1722] METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6) -methyladenosine-dependent primary MicroRNA processing.Hepatology. 2017 Feb;65(2):529-543. doi: 10.1002/hep.28885. Epub 2016 Dec 24.
• [1723] The association between aquaporin-1 expression, microvessel density and the clinicopathological features of hepatocellular carcinoma.Oncol Lett. 2017 Dec;14(6):7077-7084. doi: 10.3892/ol.2017.7106. Epub 2017 Sep 29.
• [1724] Immature colon carcinoma transcript-1 promotes cell growth of hepatocellular carcinoma via facilitating cell cycle progression and apoptosis resistance.Oncol Rep. 2017 Dec;38(6):3489-3496. doi: 10.3892/or.2017.6046. Epub 2017 Oct 19.
• [1725] Metastasis-associated protein 2 regulates human hepatocellular carcinoma metastasis progression through modulating p38MAPK/MMP2 pathways.J Cancer. 2019 Oct 22;10(26):6716-6725. doi: 10.7150/jca.35626. eCollection 2019.
• [1726] Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma.J Clin Invest. 2017 May 1;127(5):1856-1872. doi: 10.1172/JCI90253. Epub 2017 Apr 10.
• [1727] The novel MKL target gene myoferlin modulates expansion and senescence of hepatocellular carcinoma.Oncogene. 2017 Jun 15;36(24):3464-3476. doi: 10.1038/onc.2016.496. Epub 2017 Jan 23.
• [1728] NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma.Cancer Cell Int. 2019 Sep 5;19:228. doi: 10.1186/s12935-019-0949-0. eCollection 2019.
• [1729] Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma.J Gastroenterol. 2019 May;54(5):427-436. doi: 10.1007/s00535-018-01533-x. Epub 2018 Nov 30.
• [1730] NCKAP1 improves patient outcome and inhibits cell growth by enhancing Rb1/p53 activation in hepatocellular carcinoma.Cell Death Dis. 2019 May 8;10(5):369. doi: 10.1038/s41419-019-1603-4.
• [1731] Knockdown of COBRA1 decreases the proliferation and migration of hepatocellular carcinoma cells.Oncol Rep. 2017 Mar;37(3):1896-1906. doi: 10.3892/or.2017.5390. Epub 2017 Jan 19.
• [1732] Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.Clin Transl Oncol. 2017 Mar;19(3):364-372. doi: 10.1007/s12094-016-1537-6. Epub 2016 Aug 19.
• [1733] Association of Inflammasome Components in Background Liver with Poor Prognosis After Curatively-resected Hepatocellular Carcinoma.Anticancer Res. 2017 Jan;37(1):293-300. doi: 10.21873/anticanres.11320.
• [1734] Splicing Regulator p54(nrb) /Non-POU Domain-Containing Octamer-Binding Protein Enhances Carcinogenesis Through Oncogenic Isoform Switch of MYC Box-Dependent Interacting Protein 1 in Hepatocellular Carcinoma.Hepatology. 2020 Aug;72(2):548-568. doi: 10.1002/hep.31062. Epub 2020 Mar 25.
• [1735] Nardilysin promotes hepatocellular carcinoma through activation of signal transducer and activator of transcription 3.Cancer Sci. 2017 May;108(5):910-917. doi: 10.1111/cas.13204. Epub 2017 Apr 24.
• [1736] Genome-wide DNA methylation analysis during non-alcoholic steatohepatitis-related multistage hepatocarcinogenesis: comparison with hepatitis virus-related carcinogenesis.Carcinogenesis. 2017 Mar 1;38(3):261-270. doi: 10.1093/carcin/bgx005.
• [1737] Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.Cell Death Dis. 2017 Oct 26;8(10):e3138. doi: 10.1038/cddis.2017.512.
• [1738] OCIAD2 suppressed tumor growth and invasion via AKT pathway in Hepatocelluar carcinoma.Carcinogenesis. 2017 Sep 1;38(9):910-919. doi: 10.1093/carcin/bgx073.
• [1739] Discovery of NKCC1 as a potential therapeutic target to inhibit hepatocellular carcinoma cell growth and metastasis.Oncotarget. 2017 Aug 12;8(39):66328-66342. doi: 10.18632/oncotarget.20240. eCollection 2017 Sep 12.
• [1740] Microvascular Flow Imaging of Residual or Recurrent Hepatocellular Carcinoma after Transarterial Chemoembolization: Comparison with Color/Power Doppler Imaging.Korean J Radiol. 2019 Jul;20(7):1114-1123. doi: 10.3348/kjr.2018.0932.
• [1741] PTIP promotes recurrence and metastasis of hepatocellular carcinoma by regulating epithelial-mesenchymal transition.Oncotarget. 2017 Mar 22;8(35):58184-58198. doi: 10.18632/oncotarget.16436. eCollection 2017 Aug 29.
• [1742] Novel compound cedrelone inhibits hepatocellular carcinoma progression via PBLD and Ras/Rap1.Exp Ther Med. 2019 Dec;18(6):4209-4220. doi: 10.3892/etm.2019.8080. Epub 2019 Oct 7.
• [1743] Sporadic PCDH18 somatic mutations in EpCAM-positive hepatocellular carcinoma.Cancer Cell Int. 2017 Oct 23;17:94. doi: 10.1186/s12935-017-0467-x. eCollection 2017.
• [1744] Overexpression of Pyruvate Dehydrogenase E1 Subunit Inhibits Warburg Effect and Induces Cell Apoptosis Through Mitochondria-Mediated Pathway in Hepatocellular Carcinoma.Oncol Res. 2019 Mar 29;27(4):407-414. doi: 10.3727/096504018X15180451872087. Epub 2018 Feb 14.
• [1745] Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma.Oncotarget. 2017 Oct 4;8(54):92589-92603. doi: 10.18632/oncotarget.21506. eCollection 2017 Nov 3.
• [1746] Profilin 1, negatively regulated by microRNA-19a-3p, serves as a tumor suppressor in human hepatocellular carcinoma.Pathol Res Pract. 2019 Mar;215(3):499-505. doi: 10.1016/j.prp.2018.12.012. Epub 2018 Dec 12.
• [1747] Co-expression of Piwil2/Piwil4 in nucleus indicates poor prognosis of hepatocellular carcinoma.Oncotarget. 2017 Jan 17;8(3):4607-4617. doi: 10.18632/oncotarget.13491.
• [1748] SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.J Exp Clin Cancer Res. 2019 Jun 13;38(1):252. doi: 10.1186/s13046-019-1246-4.
• [1749] NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF- receptor blocker galunisertib in HCC.Cell Death Dis. 2017 Feb 23;8(2):e2634. doi: 10.1038/cddis.2017.44.
• [1750] An alternative POLDIP3 transcript promotes hepatocellular carcinoma progression.Biomed Pharmacother. 2017 May;89:276-283. doi: 10.1016/j.biopha.2017.01.139. Epub 2017 Feb 24.
• [1751] miR-874-3p is down-regulated in hepatocellular carcinoma and negatively regulates PIN1 expression.Oncotarget. 2017 Feb 14;8(7):11343-11355. doi: 10.18632/oncotarget.14526.
• [1752] Myosin phosphatase and RhoA-activated kinase modulate arginine methylation by the regulation of protein arginine methyltransferase 5 in hepatocellular carcinoma cells.Sci Rep. 2017 Jan 11;7:40590. doi: 10.1038/srep40590.
• [1753] Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma.Radiology. 2017 Jun;283(3):702-710. doi: 10.1148/radiol.2017160728. Epub 2017 Mar 2.
• [1754] PRDM1 levels are associated with clinical diseases in chronic HBV infection and survival of patients with HBV-related hepatocellular carcinoma.Int Immunopharmacol. 2019 Aug;73:156-162. doi: 10.1016/j.intimp.2019.05.012. Epub 2019 May 14.
• [1755] CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation.Hepatology. 2020 Apr;71(4):1279-1296. doi: 10.1002/hep.30923. Epub 2020 Jan 24.
• [1756] Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma.J Mol Med (Berl). 2017 Nov;95(11):1237-1249. doi: 10.1007/s00109-017-1578-5. Epub 2017 Aug 26.
• [1757] Post-surgical resection prognostic value of combined OPN, MMP7, and PSG9 plasma biomarkers in hepatocellular carcinoma.Front Med. 2019 Apr;13(2):250-258. doi: 10.1007/s11684-018-0632-1. Epub 2018 May 16.
• [1758] Inhibition of PSMD4 blocks the tumorigenesis of hepatocellular carcinoma.Gene. 2019 Jun 20;702:66-74. doi: 10.1016/j.gene.2019.03.063. Epub 2019 Mar 28.
• [1759] MEG2 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting AKT pathway.Gene. 2019 Mar 1;687:1-8. doi: 10.1016/j.gene.2018.11.003. Epub 2018 Nov 3.
• [1760] Overexpression of RAB34 correlates with poor prognosis and tumor progression in hepatocellular carcinoma.Oncol Rep. 2017 Nov;38(5):2967-2974. doi: 10.3892/or.2017.5957. Epub 2017 Sep 18.
• [1761] Evaluating the role of RAD52 and its interactors as novel potential molecular targets for hepatocellular carcinoma.Cancer Cell Int. 2019 Nov 6;19:279. doi: 10.1186/s12935-019-0996-6. eCollection 2019.
• [1762] Identification of downstream target genes regulated by CX43 in hepatocellular carcinoma.Neoplasma. 2019 Jun 29;66(6):870-878. doi: 10.4149/neo_2018_181225N995. Print 2019 Nov.
• [1763] Knockdown of Rap2B Inhibits the Proliferation and Invasion in Hepatocellular Carcinoma Cells.Oncol Res. 2017 Jan 2;25(1):19-27. doi: 10.3727/096504016X14685034103914.
• [1764] Upregulation of RASAL2 promotes proliferation and metastasis, and is targeted by miR-203 in hepatocellular carcinoma.Mol Med Rep. 2017 May;15(5):2720-2726. doi: 10.3892/mmr.2017.6320. Epub 2017 Mar 14.
• [1765] Overexpression of RAS-Association Domain Family 6 (RASSF6) Inhibits Proliferation and Tumorigenesis in Hepatocellular Carcinoma Cells.Oncol Res. 2017 Jul 5;25(6):1001-1008. doi: 10.3727/096504016X14796039599926. Epub 2016 Nov 24.
• [1766] Decrease of RBM4 indicates poor prognosis in patients with hepatocellular carcinoma after hepatectomy.Onco Targets Ther. 2017 Jan 11;10:339-345. doi: 10.2147/OTT.S125250. eCollection 2017.
• [1767] Expression and gene regulation network of RBM8A in hepatocellular carcinoma based on data mining.Aging (Albany NY). 2019 Jan 22;11(2):423-447. doi: 10.18632/aging.101749.
• [1768] TGF-1 promotes cell migration in hepatocellular carcinoma by suppressing reelin expression.Gene. 2019 Mar 10;688:19-25. doi: 10.1016/j.gene.2018.11.033. Epub 2018 Nov 14.
• [1769] NRSF/REST levels are decreased in cholangiocellular carcinoma but not hepatocellular carcinoma compared with normal liver tissues: A tissue microarray study.Oncol Lett. 2018 May;15(5):6592-6598. doi: 10.3892/ol.2018.8169. Epub 2018 Mar 5.
• [1770] CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, and RFC4 May Be Potential Therapeutic Targets for Hepatocellular Carcinoma Using Integrated Bioinformatic Analysis.Biomed Res Int. 2019 Oct 13;2019:1245072. doi: 10.1155/2019/1245072. eCollection 2019.
• [1771] Regulatory factor X5 promotes hepatocellular carcinoma progression by transactivating tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta and suppressing apoptosis.Chin Med J (Engl). 2019 Jul 5;132(13):1572-1581. doi: 10.1097/CM9.0000000000000296.
• [1772] Ring1 promotes the transformation of hepatic progenitor cells into cancer stem cells through the Wnt/-catenin signaling pathway.J Cell Biochem. 2020 Aug;121(8-9):3941-3951. doi: 10.1002/jcb.29496. Epub 2019 Nov 7.
• [1773] HIF-1-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.Cancer Lett. 2019 Sep 28;460:96-107. doi: 10.1016/j.canlet.2019.06.016. Epub 2019 Jun 24.
• [1774] RLIM suppresses hepatocellular carcinogenesis by up-regulating p15 and p21.Oncotarget. 2017 Sep 15;8(47):83075-83087. doi: 10.18632/oncotarget.20904. eCollection 2017 Oct 10.
• [1775] MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation.Biochem Biophys Res Commun. 2017 Jan 29;483(1):630-637. doi: 10.1016/j.bbrc.2016.12.091. Epub 2016 Dec 18.
• [1776] Down-regulation of salt-inducible kinase 1 (SIK1) is mediated by RNF2 in hepatocarcinogenesis.Oncotarget. 2017 Jan 10;8(2):3144-3155. doi: 10.18632/oncotarget.13673.
• [1777] CACYBP Enhances Cytoplasmic Retention of P27(Kip1) to Promote Hepatocellular Carcinoma Progression in the Absence of RNF41 Mediated Degradation.Theranostics. 2019 Oct 22;9(26):8392-8408. doi: 10.7150/thno.36838. eCollection 2019.
• [1778] MicroRNA-146a-5p enhances radiosensitivity in hepatocellular carcinoma through replication protein A3-induced activation of the DNA repair pathway.Am J Physiol Cell Physiol. 2019 Mar 1;316(3):C299-C311. doi: 10.1152/ajpcell.00189.2018. Epub 2018 Nov 21.
• [1779] Ribose-5-phosphate isomerase A overexpression promotes liver cancer development in transgenic zebrafish via activation of ERK and -catenin pathways.Carcinogenesis. 2019 May 14;40(3):461-473. doi: 10.1093/carcin/bgy155.
• [1780] Knockdown of RRS1 by lentiviral-mediated RNAi promotes apoptosis and suppresses proliferation of human hepatocellular carcinoma cells.Oncol Rep. 2017 Oct;38(4):2166-2172. doi: 10.3892/or.2017.5906. Epub 2017 Aug 14.
• [1781] MicroRNA-152 inhibits tumor cell growth by directly targeting RTKN in hepatocellular carcinoma.Oncol Rep. 2017 Feb;37(2):1227-1234. doi: 10.3892/or.2016.5290. Epub 2016 Dec 5.
• [1782] The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma.Digestion. 2019;100(1):15-26. doi: 10.1159/000493136. Epub 2018 Oct 3.
• [1783] MiR-425-5p promotes invasion and metastasis of hepatocellular carcinoma cells through SCAI-mediated dysregulation of multiple signaling pathways.Oncotarget. 2017 May 9;8(19):31745-31757. doi: 10.18632/oncotarget.15958.
• [1784] Oncogenic Role of SND1 in Development and Progression of Hepatocellular Carcinoma.Cancer Res. 2017 Jun 15;77(12):3306-3316. doi: 10.1158/0008-5472.CAN-17-0298. Epub 2017 Apr 20.
• [1785] Sec62 promotes early recurrence of hepatocellular carcinoma through activating integrin/CAV1 signalling.Oncogenesis. 2019 Dec 10;8(12):74. doi: 10.1038/s41389-019-0183-6.
• [1786] MiR-218 suppresses the metastasis and EMT of HCC cells via targeting SERBP1.Acta Biochim Biophys Sin (Shanghai). 2017 May 1;49(5):383-391. doi: 10.1093/abbs/gmx017.
• [1787] Bif-1 promotes tumor cell migration and metastasis via Cdc42 expression and activity.Clin Exp Metastasis. 2017 Jan;34(1):11-23. doi: 10.1007/s10585-016-9825-7. Epub 2016 Oct 11.
• [1788] Discs large homolog 5 decreases formation and function of invadopodia in human hepatocellular carcinoma via Girdin and Tks5.Int J Cancer. 2017 Jul 15;141(2):364-376. doi: 10.1002/ijc.30730. Epub 2017 May 9.
• [1789] p66Shc promotes HCC progression in the tumor microenvironment via STAT3 signaling.Exp Cell Res. 2019 Oct 15;383(2):111550. doi: 10.1016/j.yexcr.2019.111550. Epub 2019 Aug 6.
• [1790] Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma.J Proteomics. 2017 Mar 22;157:40-51. doi: 10.1016/j.jprot.2017.02.005. Epub 2017 Feb 10.
• [1791] Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine-Monophosphate-Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice.Hepatology. 2019 Apr;69(4):1614-1631. doi: 10.1002/hep.30421. Epub 2019 Mar 12.
• [1792] Six2 is negatively correlated with prognosis and facilitates epithelial-mesenchymal transition via TGF-/Smad signal pathway in hepatocellular carcinoma.Hepatobiliary Pancreat Dis Int. 2019 Dec;18(6):525-531. doi: 10.1016/j.hbpd.2019.09.005. Epub 2019 Sep 14.
• [1793] MALAT1 functions as a competing endogenous RNA to regulate SMAD5 expression by acting as a sponge for miR-142-3p in hepatocellular carcinoma.Cell Biosci. 2019 May 10;9:39. doi: 10.1186/s13578-019-0299-6. eCollection 2019.
• [1794] MicroRNA-802 induces hepatitis B virus replication and replication through regulating SMARCE1 expression in hepatocellular carcinoma.Cell Death Dis. 2019 Oct 14;10(10):783. doi: 10.1038/s41419-019-1999-x.
• [1795] Hepatitis B virus replicating in hepatocellular carcinoma encodes HBx variants with preserved ability to antagonize restriction by Smc5/6.Antiviral Res. 2019 Dec;172:104618. doi: 10.1016/j.antiviral.2019.104618. Epub 2019 Oct 7.
• [1796] Ubiquitination of UVRAG by SMURF1 promotes autophagosome maturation and inhibits hepatocellular carcinoma growth.Autophagy. 2019 Jul;15(7):1130-1149. doi: 10.1080/15548627.2019.1570063. Epub 2019 Jan 27.
• [1797] SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.Cell Death Dis. 2019 Aug 13;10(8):612. doi: 10.1038/s41419-019-1856-y.
• [1798] Cyclin-like proteins tip regenerative balance in the liver to favour cancer formation.Carcinogenesis. 2020 Jul 10;41(6):850-862. doi: 10.1093/carcin/bgz164.
• [1799] Promoter Hypomethylation Is Responsible for Upregulated Expression of HAI-1 in Hepatocellular Carcinoma.Dis Markers. 2019 Aug 28;2019:9175215. doi: 10.1155/2019/9175215. eCollection 2019.
• [1800] Sorcin Predicts Poor Prognosis and Promotes Metastasis by Facilitating Epithelial-mesenchymal Transition in Hepatocellular Carcinoma.Sci Rep. 2017 Aug 30;7(1):10049. doi: 10.1038/s41598-017-10365-3.
• [1801] Scutellaria barbata polysaccharides inhibit tumor growth and affect the serum proteomic profiling of hepatoma H22bearing mice.Mol Med Rep. 2019 Mar;19(3):2254-2262. doi: 10.3892/mmr.2019.9862. Epub 2019 Jan 15.
• [1802] Long noncoding RNA SchLAH suppresses metastasis of hepatocellular carcinoma through interacting with fused in sarcoma.Cancer Sci. 2017 Apr;108(4):653-662. doi: 10.1111/cas.13200. Epub 2017 Apr 17.
• [1803] Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease.J Med Virol. 2017 Jun;89(6):1062-1068. doi: 10.1002/jmv.24720. Epub 2016 Dec 9.
• [1804] Up-Regulation of hsa_circ_0000517 Predicts Adverse Prognosis of Hepatocellular Carcinoma.Front Oncol. 2019 Oct 22;9:1105. doi: 10.3389/fonc.2019.01105. eCollection 2019.
• [1805] Synaptotagmin-7 is overexpressed in hepatocellular carcinoma and regulates hepatocellular carcinoma cell proliferation via Chk1-p53 signaling.Onco Targets Ther. 2017 Aug 29;10:4283-4293. doi: 10.2147/OTT.S143619. eCollection 2017.
• [1806] Clinical significance of SLP-2 in hepatocellular carcinoma tissues and its regulation in cancer cell proliferation, migration, and EMT.Onco Targets Ther. 2017 Sep 20;10:4665-4673. doi: 10.2147/OTT.S144638. eCollection 2017.
• [1807] Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population.Carcinogenesis. 2017 Oct 1;38(10):1021-1028. doi: 10.1093/carcin/bgx078.
• [1808] Tcf7l1 Acts as a Suppressor for the Self-Renewal of Liver Cancer Stem Cells and Is Regulated by IGF/MEK/ERK Signaling Independent of -Catenin.Stem Cells. 2019 Nov;37(11):1389-1400. doi: 10.1002/stem.3063. Epub 2019 Aug 26.
• [1809] Tex10 promotes stemness and EMT phenotypes in esophageal squamous cell carcinoma via the Wnt/catenin pathway.Oncol Rep. 2019 Dec;42(6):2600-2610. doi: 10.3892/or.2019.7376. Epub 2019 Oct 16.
• [1810] The positive correlation of TIPRL with LC3 and CD133 contributes to cancer aggressiveness: potential biomarkers for early liver cancer.Sci Rep. 2019 Nov 14;9(1):16802. doi: 10.1038/s41598-019-53191-5.
• [1811] Prognostic Role of TMED3 in Clear Cell Renal Cell Carcinoma: A Retrospective Multi-Cohort Analysis.Front Genet. 2019 Apr 17;10:355. doi: 10.3389/fgene.2019.00355. eCollection 2019.
• [1812] TNFAIP8 interacts with LATS1 and promotes aggressiveness through regulation of Hippo pathway in hepatocellular carcinoma.Oncotarget. 2017 Feb 28;8(9):15689-15703. doi: 10.18632/oncotarget.14938.
• [1813] The Oncogenic Role of Tribbles 1 in Hepatocellular Carcinoma Is Mediated by a Feedback Loop Involving microRNA-23a and p53.Front Physiol. 2017 Nov 10;8:789. doi: 10.3389/fphys.2017.00789. eCollection 2017.
• [1814] The mRNA repressor TRIM71 cooperates with Nonsense-Mediated Decay factors to destabilize the mRNA of CDKN1A/p21.Nucleic Acids Res. 2019 Dec 16;47(22):11861-11879. doi: 10.1093/nar/gkz1057.
• [1815] TRIP6 promotes cell proliferation in hepatocellular carcinoma via suppression of FOXO3a.Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):594-601. doi: 10.1016/j.bbrc.2017.10.117. Epub 2017 Oct 28.
• [1816] The Y-linked proto-oncogene TSPY contributes to poor prognosis of the male hepatocellular carcinoma patients by promoting the pro-oncogenic and suppressing the anti-oncogenic gene expression.Cell Biosci. 2019 Mar 4;9:22. doi: 10.1186/s13578-019-0287-x. eCollection 2019.
• [1817] Identifying tumor promoting genomic alterations in tumor-associated fibroblasts via retrovirus-insertional mutagenesis.Oncotarget. 2017 Oct 16;8(57):97231-97245. doi: 10.18632/oncotarget.21881. eCollection 2017 Nov 14.
• [1818] Hepatitis B virus X antigen promotes transforming growth factor-beta1 (TGF-beta1) activity by up-regulation of TGF-beta1 and down-regulation of alpha2-macroglobulin.J Gen Virol. 2004 Feb;85(Pt 2):275-282. doi: 10.1099/vir.0.19650-0.
• [1819] Upregulation of miR-362-3p Modulates Proliferation and Anchorage-Independent Growth by Directly Targeting Tob2 in Hepatocellular Carcinoma.J Cell Biochem. 2015 Aug;116(8):1563-73. doi: 10.1002/jcb.25110.
• [1820] A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.Hepatology. 2019 Apr;69(4):1520-1534. doi: 10.1002/hep.30346. Epub 2019 Mar 4.
• [1821] Circ-TCF4.85 silencing inhibits cancer progression through microRNA-486-5p-targeted inhibition of ABCF2 in hepatocellular carcinoma.Mol Oncol. 2020 Feb;14(2):447-461. doi: 10.1002/1878-0261.12603. Epub 2020 Jan 10.
• [1822] Identification of hepatocellular carcinoma-associated hub genes and pathways by integrated microarray analysis.Tumori. 2015 Mar-Apr;101(2):206-14. doi: 10.5301/tj.5000241. Epub 2015 Mar 13.
• [1823] A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma.Funct Integr Genomics. 2011 Sep;11(3):419-29. doi: 10.1007/s10142-011-0230-7. Epub 2011 May 12.
• [1824] Associated measurement of fucosylated levels of AFP, DCP, and GPC3 for early diagnosis in hepatocellular carcinoma.Int J Biol Markers. 2019 Mar;34(1):20-26. doi: 10.1177/1724600818812472. Epub 2019 Mar 10.
• [1825] CC chemokine receptor-like 1 functions as a tumour suppressor by impairing CCR7-related chemotaxis in hepatocellular carcinoma.J Pathol. 2015 Mar;235(4):546-58. doi: 10.1002/path.4450. Epub 2014 Dec 18.
• [1826] Purification and molecular cloning of rat 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase.Biochem J. 2002 Feb 1;361(Pt 3):567-75. doi: 10.1042/0264-6021:3610567.
• [1827] Effect of hypoxia on the binding and subcellular distribution of iron regulatory proteins.Mol Cell Biochem. 2007 Jul;301(1-2):21-32. doi: 10.1007/s11010-006-9393-2. Epub 2007 Jan 3.
• [1828] Fatty acid metabolic enzyme acyl-CoA thioesterase8 promotes the development of hepatocellular carcinoma.Oncol Rep. 2014 Jun;31(6):2797-803. doi: 10.3892/or.2014.3155. Epub 2014 Apr 24.
• [1829] SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer.EMBO Rep. 2018 May;19(5):e45124. doi: 10.15252/embr.201745124. Epub 2018 Feb 28.
• [1830] Comprehensive gene expression analysis of 5'-end of mRNA identified novel intronic transcripts associated with hepatocellular carcinoma.Genomics. 2010 Apr;95(4):217-23. doi: 10.1016/j.ygeno.2010.01.004. Epub 2010 Jan 21.
• [1831] Hypermethylation of ACP1, BMP4, and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance.Dig Dis Sci. 2016 Jan;61(1):149-57. doi: 10.1007/s10620-015-3878-3. Epub 2015 Sep 19.
• [1832] Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro.Int J Clin Exp Pathol. 2015 Jul 1;8(7):7786-97. eCollection 2015.
• [1833] Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.Anticancer Res. 2017 Jun;37(6):3183-3187. doi: 10.21873/anticanres.11678.
• [1834] Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway.Cancer Res. 2015 Mar 1;75(5):846-57. doi: 10.1158/0008-5472.CAN-14-1192. Epub 2015 Jan 15.
• [1835] Long chain acyl-CoA synthetase 3-mediated phosphatidylcholine synthesis is required for assembly of very low density lipoproteins in human hepatoma Huh7 cells.J Biol Chem. 2008 Jan 11;283(2):849-54. doi: 10.1074/jbc.M706160200. Epub 2007 Nov 14.
• [1836] Overexpression of Acyl-CoA Ligase 4 (ACSL4) in Patients with Hepatocellular Carcinoma and its Prognosis.Med Sci Monit. 2017 Sep 9;23:4343-4350. doi: 10.12659/msm.906639.
• [1837] Downregulation of ACSM3 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma.Am J Cancer Res. 2017 Mar 1;7(3):543-553. eCollection 2017.
• [1838] Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization.Cell Rep. 2015 Dec 1;13(9):2014-26. doi: 10.1016/j.celrep.2015.10.045. Epub 2015 Nov 19.
• [1839] Identification of ACTG2 functions as a promoter gene in hepatocellular carcinoma cells migration and tumor metastasis.Biochem Biophys Res Commun. 2017 Sep 16;491(2):537-544. doi: 10.1016/j.bbrc.2017.04.007. Epub 2017 Apr 4.
• [1840] ACTL6A expression promotes invasion, metastasis and epithelial mesenchymal transition of colon cancer.BMC Cancer. 2018 Oct 22;18(1):1020. doi: 10.1186/s12885-018-4931-3.
• [1841] Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.J Exp Clin Cancer Res. 2019 Sep 18;38(1):409. doi: 10.1186/s13046-019-1401-y.
• [1842] Repression by ARP-1 sensitizes apolipoprotein AI gene responsiveness to RXR alpha and retinoic acid.Mol Cell Biol. 1992 Aug;12(8):3380-9. doi: 10.1128/mcb.12.8.3380-3389.1992.
• [1843] Down-regulation of beta-centractin might be involved in dendritic cells dysfunction and subsequent hepatocellular carcinoma immune escape: a proteomic study.J Cancer Res Clin Oncol. 2008 Feb;134(2):179-86. doi: 10.1007/s00432-007-0267-0. Epub 2007 Jul 7.
• [1844] Aminoacylase 3 Is a New Potential Marker and Therapeutic Target in Hepatocellular Carcinoma.J Cancer. 2018 Jan 1;9(1):1-12. doi: 10.7150/jca.21747. eCollection 2018.
• [1845] Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor.J Natl Cancer Inst. 2012 Jun 20;104(12):906-22. doi: 10.1093/jnci/djs232. Epub 2012 May 25.
• [1846] A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma.Gut. 2014 May;63(5):832-43. doi: 10.1136/gutjnl-2012-304037. Epub 2013 Jun 13.
• [1847] Circular RNA circ-ADD3 inhibits hepatocellular carcinoma metastasis through facilitating EZH2 degradation via CDK1-mediated ubiquitination.Am J Cancer Res. 2019 Aug 1;9(8):1695-1707. eCollection 2019.
• [1848] Transcriptome sequencing identified hub genes for hepatocellular carcinoma by weighted-gene co-expression analysis.Oncotarget. 2016 Jun 21;7(25):38487-38499. doi: 10.18632/oncotarget.9555.
• [1849] Clinicopathological and prognostic significance of aberrant G protein-couple receptor 110 (GPR110) expression in gastric cancer.Pathol Res Pract. 2019 Mar;215(3):539-545. doi: 10.1016/j.prp.2018.12.004. Epub 2018 Dec 6.
• [1850] The methionine salvage pathway-involving ADI1 inhibits hepatoma growth by epigenetically altering genes expression via elevating S-adenosylmethionine.Cell Death Dis. 2019 Mar 11;10(3):240. doi: 10.1038/s41419-019-1486-4.
• [1851] MiR-221 mediates the epithelial-mesenchymal transition of hepatocellular carcinoma by targeting AdipoR1.Int J Biol Macromol. 2017 Oct;103:1054-1061. doi: 10.1016/j.ijbiomac.2017.05.108. Epub 2017 May 21.
• [1852] XB130 Knockdown Inhibits the Proliferation, Invasiveness, and Metastasis of Hepatocellular Carcinoma Cells and Sensitizes them to TRAIL-Induced Apoptosis.Chin Med J (Engl). 2018 Oct 5;131(19):2320-2331. doi: 10.4103/0366-6999.241800.
• [1853] AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.Gastroenterology. 2019 Jun;156(8):2149-2157. doi: 10.1053/j.gastro.2019.02.046. Epub 2019 Mar 13.
• [1854] ASAP3 is a focal adhesion-associated Arf GAP that functions in cell migration and invasion.J Biol Chem. 2008 May 30;283(22):14915-26. doi: 10.1074/jbc.M709717200. Epub 2008 Apr 8.
• [1855] AGO1 may influence the prognosis of hepatocellular carcinoma through TGF- pathway.Cell Death Dis. 2018 Feb 27;9(3):324. doi: 10.1038/s41419-018-0338-y.
• [1856] Differential expression of anterior gradient protein 3 in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.Exp Mol Pathol. 2014 Jun;96(3):375-81. doi: 10.1016/j.yexmp.2014.04.002. Epub 2014 Apr 18.
• [1857] Long interspersed nuclear element ORF-1 protein promotes proliferation and resistance to chemotherapy in hepatocellular carcinoma.World J Gastroenterol. 2013 Feb 21;19(7):1068-78. doi: 10.3748/wjg.v19.i7.1068.
• [1858] AIM2 deficiency reduces the development of hepatocellular carcinoma in mice.Int J Cancer. 2018 Dec 1;143(11):2997-3007. doi: 10.1002/ijc.31827. Epub 2018 Oct 9.
• [1859] Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden.J Intern Med. 2011 May;269(5):538-45. doi: 10.1111/j.1365-2796.2010.02335.x. Epub 2010 Dec 28.
• [1860] MiR-552 promotes the proliferation, migration and EMT of hepatocellular carcinoma cells by inhibiting AJAP1 expression.J Cell Mol Med. 2019 Feb;23(2):1541-1552. doi: 10.1111/jcmm.14062. Epub 2018 Dec 30.
• [1861] A-kinase anchoring protein 12 is downregulated in human hepatocellular carcinoma and its deficiency in mice aggravates thioacetamide-induced liver injury.Oncol Lett. 2018 Nov;16(5):5907-5915. doi: 10.3892/ol.2018.9396. Epub 2018 Sep 4.
• [1862] Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma.Oncol Rep. 2012 Nov;28(5):1792-8. doi: 10.3892/or.2012.2002. Epub 2012 Aug 30.
• [1863] AKIP1 promotes early recurrence of hepatocellular carcinoma through activating the Wnt/-catenin/CBP signaling pathway.Oncogene. 2019 Jul;38(27):5516-5529. doi: 10.1038/s41388-019-0807-5. Epub 2019 Apr 1.
• [1864] MicroRNA-137 represses FBI-1 to inhibit proliferation and in vitro invasion and migration of hepatocellular carcinoma cells.Tumour Biol. 2016 Oct;37(10):13995-14008. doi: 10.1007/s13277-016-5230-8. Epub 2016 Aug 4.
• [1865] Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.Dig Dis Sci. 2018 Apr;63(4):934-944. doi: 10.1007/s10620-018-4943-5. Epub 2018 Jan 30.
• [1866] Knockdown of Myosin VI Inhibits Proliferation of Hepatocellular Carcinoma Cells In Vitro.Chem Biol Drug Des. 2015 Oct;86(4):723-30. doi: 10.1111/cbdd.12544. Epub 2015 Mar 17.
• [1867] The basal body gene, RPGRIP1L, is a candidate tumour suppressor gene in human hepatocellular carcinoma.Eur J Cancer. 2009 Jul;45(11):2041-9. doi: 10.1016/j.ejca.2009.04.012. Epub 2009 May 4.
• [1868] ALDH1L1 variant rs2276724 and mRNA expression predict post-operative clinical outcomes and are associated with TP53 expression in HBV-related hepatocellular carcinoma.Oncol Rep. 2017 Sep;38(3):1451-1463. doi: 10.3892/or.2017.5822. Epub 2017 Jul 14.
• [1869] Molecular cloning and expression of rat aldolase C messenger RNA during development and hepatocarcinogenesis.Eur J Biochem. 1987 Mar 16;163(3):513-8. doi: 10.1111/j.1432-1033.1987.tb10898.x.
• [1870] Mutational analysis of WTX gene in Wnt/ beta-catenin pathway in gastric, colorectal, and hepatocellular carcinomas.Dig Dis Sci. 2009 May;54(5):1011-4. doi: 10.1007/s10620-008-0458-9. Epub 2008 Aug 22.
• [1871] Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma.Dig Dis Sci. 2007 Mar;52(3):770-5. doi: 10.1007/s10620-006-9479-4.
• [1872] Expression patterns of AMP-deaminase isozymes in human hepatocellular carcinoma (HCC).Mol Cell Biochem. 2008 Nov;318(1-2):1-5. doi: 10.1007/s11010-008-9773-x. Epub 2008 May 21.
• [1873] A restriction endonuclease assay for expression of human alpha-amylase isozymes.Clin Chim Acta. 2002 Aug;322(1-2):113-6. doi: 10.1016/s0009-8981(02)00161-4.
• [1874] Mutation analysis of p31comet gene, a negative regulator of Mad2, in human hepatocellular carcinoma.Exp Mol Med. 2007 Aug 31;39(4):508-13. doi: 10.1038/emm.2007.56.
• [1875] Diagnostic value of angiopoietin-like protein 2 for CHB-related hepatocellular carcinoma.Cancer Manag Res. 2019 Jul 29;11:7159-7169. doi: 10.2147/CMAR.S217170. eCollection 2019.
• [1876] ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.J Exp Clin Cancer Res. 2019 Jan 15;38(1):18. doi: 10.1186/s13046-018-1011-0.
• [1877] Identification of significant gene and pathways involved in HBV-related hepatocellular carcinoma by bioinformatics analysis.PeerJ. 2019 Jul 30;7:e7408. doi: 10.7717/peerj.7408. eCollection 2019.
• [1878] Translational implication of Kallmann syndrome-1 gene expression in hepatocellular carcinoma.Int J Oncol. 2015;46(6):2546-54. doi: 10.3892/ijo.2015.2965. Epub 2015 Apr 16.
• [1879] Involvement of hepatopoietin Cn in the development of human hepatocellular carcinoma.Clin Exp Metastasis. 2010 Dec;27(8):571-80. doi: 10.1007/s10585-010-9346-8. Epub 2010 Aug 4.
• [1880] Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma.Ann Surg Oncol. 2018 Jun;25(6):1686-1694. doi: 10.1245/s10434-018-6402-0. Epub 2018 Apr 6.
• [1881] The transcription factor Ikaros inhibits cell proliferation by downregulating ANXA4 expression in hepatocellular carcinoma.Am J Cancer Res. 2017 Jun 1;7(6):1285-1297. eCollection 2017.
• [1882] Annexin A6 protein is downregulated in human hepatocellular carcinoma.Mol Cell Biochem. 2016 Jul;418(1-2):81-90. doi: 10.1007/s11010-016-2735-9. Epub 2016 Jun 23.
• [1883] AnnexinA7 down-regulation might suppress the proliferation and metastasis of human hepatocellular carcinoma cells via MAPK/ ERK pathway.Cancer Biomark. 2018;23(4):527-537. doi: 10.3233/CBM-181651.
• [1884] MEG3 promotes liver cancer by activating PI3K/AKT pathway through regulating AP1G1.Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1459-1467. doi: 10.26355/eurrev_201902_17103.
• [1885] AP-2 inhibits hepatocellular carcinoma invasion and metastasis through Slug and Snail to suppress epithelial-mesenchymal transition.Theranostics. 2018 Jun 12;8(13):3707-3721. doi: 10.7150/thno.25166. eCollection 2018.
• [1886] The AP2M1 gene expression is a promising biomarker for predicting survival of patients with hepatocellular carcinoma.J Cell Biochem. 2019 Mar;120(3):4140-4146. doi: 10.1002/jcb.27699. Epub 2018 Sep 27.
• [1887] Apoptotic protease activating factor-1 negatively regulates Wnt signaling in hepatocellular carcinoma.Kaohsiung J Med Sci. 2019 Aug;35(8):459-466. doi: 10.1002/kjm2.12089. Epub 2019 May 15.
• [1888] Pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-kappaB pathway.Pathol Oncol Res. 2010 Jun;16(2):229-37. doi: 10.1007/s12253-009-9215-4. Epub 2009 Oct 12.
• [1889] The role of apolipoprotein A5 in non-alcoholic fatty liver disease.Gut. 2011 Jul;60(7):985-91. doi: 10.1136/gut.2010.222224. Epub 2011 Feb 21.
• [1890] Absence of APOBEC-1 mediated mRNA editing in human carcinomas.Oncogene. 1999 Nov 4;18(46):6357-66. doi: 10.1038/sj.onc.1203039.
• [1891] Excessive activity of apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis.Int J Cancer. 2012 Mar 15;130(6):1294-301. doi: 10.1002/ijc.26114. Epub 2011 May 30.
• [1892] Apolipoprotein C-II mRNA levels in primate liver. Induction by estrogen in the human hepatocarcinoma cell line, HepG2.J Biol Chem. 1985 Feb 10;260(3):1676-81.
• [1893] Clinicopathologic and prognostic values of apolipoprotein D alterations in hepatocellular carcinoma.Int J Cancer. 2005 Aug 10;116(1):105-9. doi: 10.1002/ijc.20986.
• [1894] Microarray analysis provides new insights into the function of apolipoprotein O in HepG2 cell line.Lipids Health Dis. 2013 Dec 17;12:186. doi: 10.1186/1476-511X-12-186.
• [1895] MicroRNA-325-3p inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma by down-regulation of aquaporin 5.Cell Mol Biol Lett. 2019 Feb 12;24:13. doi: 10.1186/s11658-019-0137-1. eCollection 2019.
• [1896] Proteome Differences between Hepatitis B Virus Genotype-B- and Genotype-C-Induced Hepatocellular Carcinoma Revealed by iTRAQ-Based Quantitative Proteomics.J Proteome Res. 2016 Feb 5;15(2):487-98. doi: 10.1021/acs.jproteome.5b00838. Epub 2016 Jan 14.
• [1897] Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma.J Biol Chem. 2003 Mar 21;278(12):10824-30. doi: 10.1074/jbc.M208310200. Epub 2003 Jan 16.
• [1898] Blockade of ARHGAP11A reverses malignant progress via inactivating Rac1B in hepatocellular carcinoma.Cell Commun Signal. 2018 Dec 13;16(1):99. doi: 10.1186/s12964-018-0312-4.
• [1899] Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues.J Exp Clin Cancer Res. 2009 Aug 28;28(1):122. doi: 10.1186/1756-9966-28-122.
• [1900] A novel amplification target, ARHGAP5, promotes cell spreading and migration by negatively regulating RhoA in Huh-7 hepatocellular carcinoma cells.Cancer Lett. 2009 Mar 8;275(1):27-34. doi: 10.1016/j.canlet.2008.09.036. Epub 2008 Nov 8.
• [1901] Prognostic value of Rho GDP dissociation inhibitors in patients with hepatocellular carcinoma following liver transplantation.Oncol Lett. 2017 Aug;14(2):1395-1402. doi: 10.3892/ol.2017.6333. Epub 2017 Jun 7.
• [1902] ARHGEF10L contributes to liver tumorigenesis through RhoA-ROCK1 signaling and the epithelial-mesenchymal transition.Exp Cell Res. 2019 Jan 1;374(1):46-68. doi: 10.1016/j.yexcr.2018.11.007. Epub 2018 Nov 13.
• [1903] GEF-H1 over-expression in hepatocellular carcinoma promotes cell motility via activation of RhoA signalling.J Pathol. 2012 Dec;228(4):575-85. doi: 10.1002/path.4084. Epub 2012 Sep 28.
• [1904] A system for detecting high impact-low frequency mutations in primary tumors and metastases.Oncogene. 2018 Jan 11;37(2):185-196. doi: 10.1038/onc.2017.322. Epub 2017 Sep 11.
• [1905] Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth.Mol Cancer Ther. 2019 Mar;18(3):602-612. doi: 10.1158/1535-7163.MCT-18-0824. Epub 2019 Jan 15.
• [1906] A specific splicing variant of SVH, a novel human armadillo repeat protein, is up-regulated in hepatocellular carcinomas.Cancer Res. 2003 Jul 1;63(13):3775-82.
• [1907] Silencing of hypoxia-inducible factor-1 induces anti-tumor effects in hepatoma cell lines under tumor hypoxia.PLoS One. 2014 Jul 28;9(7):e103304. doi: 10.1371/journal.pone.0103304. eCollection 2014.
• [1908] Downregulation of ARNT2 promotes tumor growth and predicts poor prognosis in human hepatocellular carcinoma.J Gastroenterol Hepatol. 2015 Jun;30(6):1085-93. doi: 10.1111/jgh.12905.
• [1909] Increased ARPP-19 expression is associated with hepatocellular carcinoma.Int J Mol Sci. 2014 Dec 24;16(1):178-92. doi: 10.3390/ijms16010178.
• [1910] The effects of MIBG on the invasive properties of HepG2 hepatocellular carcinoma cells.Int J Mol Med. 2014 Sep;34(3):842-8. doi: 10.3892/ijmm.2014.1819. Epub 2014 Jun 24.
• [1911] Tumor-Induced Generation of Splenic Erythroblast-like Ter-Cells Promotes Tumor Progression.Cell. 2018 Apr 19;173(3):634-648.e12. doi: 10.1016/j.cell.2018.02.061. Epub 2018 Mar 29.
• [1912] eIF5B increases ASAP1 expression to promote HCC proliferation and invasion.Oncotarget. 2016 Sep 20;7(38):62327-62339. doi: 10.18632/oncotarget.11469.
• [1913] H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1.Hum Pathol. 2010 Feb;41(2):181-9. doi: 10.1016/j.humpath.2009.08.007. Epub 2009 Nov 6.
• [1914] ASF1a inhibition induces p53-dependent growth arrest and senescence of cancer cells.Cell Death Dis. 2019 Jan 28;10(2):76. doi: 10.1038/s41419-019-1357-z.
• [1915] Meta-analysis of association studies of CYP1A1 genetic polymorphisms with digestive tract cancer susceptibility in Chinese.Asian Pac J Cancer Prev. 2014;15(11):4689-95. doi: 10.7314/apjcp.2014.15.11.4689.
• [1916] Hepatitis B Virus X Protein Upregulates hELG1/ ATAD5 Expression through E2F1 in Hepatocellular Carcinoma.Int J Biol Sci. 2016 Jan 1;12(1):30-41. doi: 10.7150/ijbs.12310. eCollection 2016.
• [1917] LncRNA GHET1 activated by H3K27 acetylation promotes cell tumorigenesis through regulating ATF1 in hepatocellular carcinoma.Biomed Pharmacother. 2017 Oct;94:326-331. doi: 10.1016/j.biopha.2017.07.046. Epub 2017 Jul 31.
• [1918] Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.Mol Med Rep. 2018 Jun;17(6):8053-8060. doi: 10.3892/mmr.2018.8921. Epub 2018 Apr 23.
• [1919] Hepatitis B virus-regulated growth of liver cancer cells occurs through the microRNA-340-5p-activating transcription factor 7-heat shock protein A member 1B axis.Cancer Sci. 2019 May;110(5):1633-1643. doi: 10.1111/cas.14004. Epub 2019 Apr 11.
• [1920] RNA Binding Protein HuR Promotes Autophagosome Formation by Regulating Expression of Autophagy-Related Proteins 5, 12, and 16 in Human Hepatocellular Carcinoma Cells.Mol Cell Biol. 2019 Mar 1;39(6):e00508-18. doi: 10.1128/MCB.00508-18. Print 2019 Mar 15.
• [1921] The ATG16L1 gene variant rs2241880 (p.T300A) is associated with susceptibility to HCC in patients with cirrhosis.Liver Int. 2019 Dec;39(12):2360-2367. doi: 10.1111/liv.14239. Epub 2019 Sep 11.
• [1922] LncRNA NEAT1 promotes autophagy via regulating miR-204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma.J Cell Physiol. 2020 Apr;235(4):3402-3413. doi: 10.1002/jcp.29230. Epub 2019 Sep 23.
• [1923] AKT-mediated phosphorylation of ATG4B impairs mitochondrial activity and enhances the Warburg effect in hepatocellular carcinoma cells.Autophagy. 2018;14(4):685-701. doi: 10.1080/15548627.2017.1407887. Epub 2018 Jan 29.
• [1924] Autophagy-Related 5 Gene rs510432 Polymorphism Is Associated with Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection.Immunol Invest. 2019 May;48(4):378-391. doi: 10.1080/08820139.2019.1567532. Epub 2019 Mar 25.
• [1925] MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2.Cell Death Dis. 2017 Mar 30;8(3):e2706. doi: 10.1038/cddis.2017.123.
• [1926] HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma.Cancer Sci. 2017 Jul;108(7):1328-1337. doi: 10.1111/cas.13277. Epub 2017 Jun 14.
• [1927] Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.Gastroenterology. 2015 Oct;149(4):1068-81.e5. doi: 10.1053/j.gastro.2015.06.010. Epub 2015 Jun 20.
• [1928] Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma.Hepatology. 2015 Oct;62(4):1122-31. doi: 10.1002/hep.27923. Epub 2015 Jul 3.
• [1929] Expression and functional role of vacuolar H(+)-ATPase in human hepatocellular carcinoma.Carcinogenesis. 2012 Dec;33(12):2432-40. doi: 10.1093/carcin/bgs277. Epub 2012 Sep 7.
• [1930] ATXN7 Gene Variants and Expression Predict Post-Operative Clinical Outcomes in Hepatitis B Virus-Related Hepatocellular Carcinoma.Cell Physiol Biochem. 2016;39(6):2427-2438. doi: 10.1159/000452511. Epub 2016 Nov 11.
• [1931] Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/-catenin pathway.Cell Death Differ. 2018 Aug;25(8):1426-1441. doi: 10.1038/s41418-018-0059-x. Epub 2018 Feb 14.
• [1932] Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma.Nat Med. 2013 Feb;19(2):209-16. doi: 10.1038/nm.3043. Epub 2013 Jan 6.
• [1933] Comparison of pulsed and oscillating gradient diffusion-weighted MRI for characterizing hepatocellular nodules in liver cirrhosis: ex vivo study in a rat model.J Magn Reson Imaging. 2020 Apr;51(4):1065-1074. doi: 10.1002/jmri.26919. Epub 2019 Sep 11.
• [1934] B3GNT2, a polylactosamine synthase, regulates glycosylation of EGFR in H7721 human hepatocellular carcinoma cells.Asian Pac J Cancer Prev. 2014;15(24):10875-8. doi: 10.7314/apjcp.2014.15.24.10875.
• [1935] Overexpression of beta 1,4N-acetylgalactosaminyl- transferase mRNA as a molecular marker for various types of cancers.Oncology. 2002;62(2):149-56. doi: 10.1159/000048261.
• [1936] Identification of beta-1,4-galactosyltransferase I as a target gene of HBx-induced cell cycle progression of hepatoma cell.J Hepatol. 2008 Dec;49(6):1029-37. doi: 10.1016/j.jhep.2008.09.003. Epub 2008 Sep 26.
• [1937] BRE over-expression promotes growth of hepatocellular carcinoma.Biochem Biophys Res Commun. 2010 Jan 15;391(3):1522-5. doi: 10.1016/j.bbrc.2009.12.111. Epub 2009 Dec 24.
• [1938] Zolmitriptan attenuates hepatocellular carcinoma via activation of caspase mediated apoptosis.Chem Biol Interact. 2019 Aug 1;308:120-129. doi: 10.1016/j.cbi.2019.05.033. Epub 2019 May 23.
• [1939] BAI1-Associated Protein 2-Like 1 (BAIAP2L1) Is a Potential Biomarker in Ovarian Cancer.PLoS One. 2015 Jul 29;10(7):e0133081. doi: 10.1371/journal.pone.0133081. eCollection 2015.
• [1940] Up-regulation of BRCA1-associated RING Domain 1 Promotes Hepatocellular Carcinoma Progression by Targeting Akt Signaling.Sci Rep. 2017 Aug 9;7(1):7649. doi: 10.1038/s41598-017-07962-7.
• [1941] The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma.Int J Oncol. 2010 Jan;36(1):205-12.
• [1942] Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma.Int J Cancer. 2011 Feb 15;128(4):771-7. doi: 10.1002/ijc.25407.
• [1943] Soluble Lutheran/basal cell adhesion molecule is detectable in plasma of hepatocellular carcinoma patients and modulates cellular interaction with laminin-511 in vitro.Exp Cell Res. 2014 Oct 15;328(1):197-206. doi: 10.1016/j.yexcr.2014.07.012. Epub 2014 Jul 19.
• [1944] Systems biology analysis of hepatitis C virus infection reveals the role of copy number increases in regions of chromosome 1q in hepatocellular carcinoma metabolism.Mol Biosyst. 2016 Apr 26;12(5):1496-506. doi: 10.1039/c5mb00827a.
• [1945] Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus.Biochem Biophys Res Commun. 2001 Mar 30;282(2):529-35. doi: 10.1006/bbrc.2001.4573.
• [1946] Enhanced antitumor activity by combining an adenovirus harboring ING4 with cisplatin for hepatocarcinoma cells.Cancer Gene Ther. 2011 Mar;18(3):176-88. doi: 10.1038/cgt.2010.67. Epub 2010 Nov 5.
• [1947] MicroRNA-18a promotes hepatocellular carcinoma proliferation, migration, and invasion by targeting Bcl2L10.Onco Targets Ther. 2018 Nov 9;11:7919-7934. doi: 10.2147/OTT.S180971. eCollection 2018.
• [1948] Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.Cell Oncol (Dordr). 2019 Jun;42(3):369-380. doi: 10.1007/s13402-019-00432-4. Epub 2019 Feb 20.
• [1949] Macrophage membrane interleukin 1 regulates the expression of acute phase proteins in human hepatoma Hep 3B cells.J Immunol. 1987 Sep 15;139(6):1896-901.
• [1950] MicroRNA-627-5p inhibits the proliferation of hepatocellular carcinoma cells by targeting BCL3 transcription coactivator.Clin Exp Pharmacol Physiol. 2020 Mar;47(3):485-494. doi: 10.1111/1440-1681.13218. Epub 2019 Dec 21.
• [1951] Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.Oncotarget. 2015 May 10;6(13):11547-60. doi: 10.18632/oncotarget.3413.
• [1952] MicroRNA-3194-3p inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by decreasing Wnt/-catenin signaling through targeting BCL9.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3885-3895. doi: 10.1080/21691401.2019.1670190.
• [1953] Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma.Hepatol Int. 2020 May;14(3):373-384. doi: 10.1007/s12072-019-09977-w. Epub 2019 Aug 22.
• [1954] Clarifying the impact of polycomb complex component disruption in human cancers.Mol Cancer Res. 2014 Apr;12(4):479-84. doi: 10.1158/1541-7786.MCR-13-0596. Epub 2014 Feb 10.
• [1955] MicroRNA-876-5p inhibits epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by targeting BCL6 corepressor like 1.Biomed Pharmacother. 2018 Jul;103:645-652. doi: 10.1016/j.biopha.2018.04.037. Epub 2018 Apr 24.
• [1956] An X-chromosomal association study identifies a susceptibility locus at Xq22.1 for hepatitis B virus-related hepatocellular carcinoma.Clin Res Hepatol Gastroenterol. 2013 Dec;37(6):586-95. doi: 10.1016/j.clinre.2013.09.002. Epub 2013 Oct 25.
• [1957] Molecular functions of brain expressed X-linked 2 (BEX2) in malignancies.Exp Cell Res. 2019 Mar 15;376(2):221-226. doi: 10.1016/j.yexcr.2019.02.014. Epub 2019 Feb 16.
• [1958] Utilization of spectrins I and III in diagnosis of hepatocellular carcinoma.Ann Diagn Pathol. 2019 Apr;39:86-91. doi: 10.1016/j.anndiagpath.2019.02.009. Epub 2019 Feb 15.
• [1959] Aberrant expression of cell cycle and material metabolism related genes contributes to hepatocellular carcinoma occurrence.Pathol Res Pract. 2017 Apr;213(4):316-321. doi: 10.1016/j.prp.2017.01.019. Epub 2017 Jan 25.
• [1960] A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.Cancer Chemother Pharmacol. 2018 May;81(5):957-963. doi: 10.1007/s00280-018-3553-4. Epub 2018 Mar 8.
• [1961] RNA over-editing of BLCAP contributes to hepatocarcinogenesis identified by whole-genome and transcriptome sequencing.Cancer Lett. 2015 Feb 28;357(2):510-9. doi: 10.1016/j.canlet.2014.12.006. Epub 2014 Dec 8.
• [1962] LncRNA HAND2-AS1 promotes liver cancer stem cell self-renewal via BMP signaling.EMBO J. 2019 Sep 2;38(17):e101110. doi: 10.15252/embj.2018101110. Epub 2019 Jul 23.
• [1963] Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma.Cell Metab. 2019 Jan 8;29(1):174-182.e5. doi: 10.1016/j.cmet.2018.08.020. Epub 2018 Sep 20.
• [1964] Decreased Expression of BNC1 and BNC2 Is Associated with Genetic or Epigenetic Regulation in Hepatocellular Carcinoma.Int J Mol Sci. 2016 Jan 25;17(2):153. doi: 10.3390/ijms17020153.
• [1965] Insufficient radiofrequency ablation-induced autophagy contributes to the rapid progression of residual hepatocellular carcinoma through the HIF-1/BNIP3 signaling pathway.BMB Rep. 2019 Apr;52(4):277-282. doi: 10.5483/BMBRep.2019.52.4.263.
• [1966] cDNA expression array analysis of gene expression in human hepatocarcinoma Hep3B cells induced by BNIPL-1.Acta Biochim Biophys Sin (Shanghai). 2005 Sep;37(9):618-24. doi: 10.1111/j.1745-7270.2005.00086.x.
• [1967] BolA family member 2 enhances cell proliferation and predicts a poor prognosis in hepatocellular carcinoma with tumor hemorrhage.J Cancer. 2019 Jul 10;10(18):4293-4304. doi: 10.7150/jca.31829. eCollection 2019.
• [1968] Gene expression profiling with microarray and SAGE identifies PLUNC as a marker for hepatoid adenocarcinoma of the stomach.Mod Pathol. 2008 Apr;21(4):464-75. doi: 10.1038/modpathol.3801050. Epub 2008 Jan 18.
• [1969] BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.Redox Biol. 2019 Jan;20:427-441. doi: 10.1016/j.redox.2018.10.018. Epub 2018 Oct 25.
• [1970] The RNA polymerase III repressor MAF1 is regulated by ubiquitin-dependent proteasome degradation and modulates cancer drug resistance and apoptosis. J Biol Chem. 2019 Dec 13;294(50):19255-19268. doi: 10.1074/jbc.RA119.008849. Epub 2019 Oct 23.
• [1971] Silencing of the HCCR2 gene induces apoptosis and suppresses the aggressive phenotype of hepatocellular carcinoma cells in culture.J Gastrointest Surg. 2011 Oct;15(10):1807-13. doi: 10.1007/s11605-011-1633-4. Epub 2011 Jul 28.
• [1972] miR-346 Promotes HCC Progression by Suppressing Breast Cancer Metastasis Suppressor 1 Expression.Oncol Res. 2018 Aug 23;26(7):1073-1081. doi: 10.3727/096504017X15145088802439. Epub 2018 Jan 2.
• [1973] MicroRNA-423 enhances the invasiveness of hepatocellular carcinoma via regulation of BRMS1.Am J Transl Res. 2017 Dec 15;9(12):5576-5584. eCollection 2017.
• [1974] Preliminary investigation of the role of BTB domain-containing 3 gene in the proliferation and metastasis of hepatocellular carcinoma.Oncol Lett. 2017 Aug;14(2):2505-2510. doi: 10.3892/ol.2017.6369. Epub 2017 Jun 9.
• [1975] FUP1, a gene associated with hepatocellular carcinoma, stimulates NIH3T3 cell proliferation and tumor formation in nude mice.Biochem Biophys Res Commun. 2001 Sep 7;286(5):1033-8. doi: 10.1006/bbrc.2001.5478.
• [1976] Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis.Hum Pathol. 2006 Oct;37(10):1324-32. doi: 10.1016/j.humpath.2006.04.022. Epub 2006 Jul 27.
• [1977] MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway.J Exp Clin Cancer Res. 2019 Jan 8;38(1):7. doi: 10.1186/s13046-018-1020-z.
• [1978] CD166 positively regulates MCAM via inhibition to ubiquitin E3 ligases Smurf1 and TrCP through PI3K/AKT and c-Raf/MEK/ERK signaling in Bel-7402 hepatocellular carcinoma cells.Cell Signal. 2015 Sep;27(9):1694-702. doi: 10.1016/j.cellsig.2015.05.006. Epub 2015 May 22.
• [1979] Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer.Int J Cancer. 2001 Jul 20;95(4):223-7. doi: 10.1002/1097-0215(20010720)95:4<223::aid-ijc1038>3.0.co;2-l.
• [1980] MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA.PLoS One. 2014 Jul 3;9(7):e101330. doi: 10.1371/journal.pone.0101330. eCollection 2014.
• [1981] Role of the novel gene BZW2 in the development of hepatocellular carcinoma.J Cell Physiol. 2019 Sep;234(9):16592-16600. doi: 10.1002/jcp.28331. Epub 2019 Feb 25.
• [1982] C1GALT1 promotes invasive phenotypes of hepatocellular carcinoma cells by modulating integrin 1 glycosylation and activity.PLoS One. 2014 Aug 4;9(8):e94995. doi: 10.1371/journal.pone.0094995. eCollection 2014.
• [1983] C1GALT1C1/COSMC is a novel prognostic biomarker for hepatocellular carcinoma.Clin Res Hepatol Gastroenterol. 2020 Jun;44(3):310-320. doi: 10.1016/j.clinre.2019.07.017. Epub 2019 Aug 27.
• [1984] Up-regulation of NICE-3 as a novel EDC gene could contribute to human hepatocellular carcinoma.Asian Pac J Cancer Prev. 2012;13(9):4363-8. doi: 10.7314/apjcp.2012.13.9.4363.
• [1985] Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2.Cell Signal. 2014 May;26(5):1125-34. doi: 10.1016/j.cellsig.2014.02.002. Epub 2014 Feb 8.
• [1986] Gene Variations of Sixth Complement Component Affecting Tacrolimus Metabolism in Patients with Liver Transplantation for Hepatocellular Carcinoma.Chin Med J (Engl). 2017 Jul 20;130(14):1670-1676. doi: 10.4103/0366-6999.209886.
• [1987] Calcium-binding protein 39 promotes hepatocellular carcinoma growth and metastasis by activating extracellular signal-regulated kinase signaling pathway.Hepatology. 2017 Nov;66(5):1529-1545. doi: 10.1002/hep.29312. Epub 2017 Sep 29.
• [1988] Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.Aliment Pharmacol Ther. 2019 May;49(10):1260-1273. doi: 10.1111/apt.15253. Epub 2019 Apr 15.
• [1989] Upregulated calcium-binding tyrosine phosphorylation-regulated protein-a/b regulates cell proliferation and apoptosis and predicts poor prognosis in hepatocellular carcinoma.J Cell Biochem. 2020 Apr;121(4):2938-2949. doi: 10.1002/jcb.29538. Epub 2019 Nov 6.
• [1990] Phosphorylation of Caldesmon by PFTAIRE1 kinase promotes actin binding and formation of stress fibers.Mol Cell Biochem. 2011 Apr;350(1-2):201-6. doi: 10.1007/s11010-010-0699-8. Epub 2010 Dec 24.
• [1991] Long Noncoding RNA lncCAMTA1 Promotes Proliferation and Cancer Stem Cell-Like Properties of Liver Cancer by Inhibiting CAMTA1.Int J Mol Sci. 2016 Sep 23;17(10):1617. doi: 10.3390/ijms17101617.
• [1992] Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer.Oncogene. 2002 Jul 25;21(32):5006-15. doi: 10.1038/sj.onc.1205625.
• [1993] Role of exosomes in hepatocellular carcinoma cell mobility alteration.Oncol Lett. 2017 Dec;14(6):8122-8131. doi: 10.3892/ol.2017.7257. Epub 2017 Oct 23.
• [1994] Calpain-3 gene expression is decreased during experimental cancer cachexia.Biochim Biophys Acta. 2000 Jun 1;1475(1):5-9. doi: 10.1016/s0304-4165(00)00050-7.
• [1995] Prognostic significance of Capn4 overexpression in intrahepatic cholangiocarcinoma.PLoS One. 2013;8(1):e54619. doi: 10.1371/journal.pone.0054619. Epub 2013 Jan 22.
• [1996] CARMA3/NF-B signaling contributes to tumorigenesis of hepatocellular carcinoma and is inhibited by sodium aescinate.World J Gastroenterol. 2019 Sep 28;25(36):5483-5493. doi: 10.3748/wjg.v25.i36.5483.
• [1997] Expression Quantitative Trait Loci for CARD8 Contributes to Risk of Two Infection-Related Cancers--Hepatocellular Carcinoma and Cervical Cancer.PLoS One. 2015 Jul 6;10(7):e0132352. doi: 10.1371/journal.pone.0132352. eCollection 2015.
• [1998] Mutational analysis of caspase-14 gene in common carcinomas.Pathology. 2007 Jun;39(3):330-3. doi: 10.1080/00313020701329815.
• [1999] Ibulocydine sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis via calpain-mediated Bax cleavage.Int J Biochem Cell Biol. 2017 Feb;83:47-55. doi: 10.1016/j.biocel.2016.12.001. Epub 2016 Dec 5.
• [2000] Prognostic and Diagnostic Significance of SDPR-Cavin-2 in Hepatocellular Carcinoma.Cell Physiol Biochem. 2016;39(3):950-60. doi: 10.1159/000447803. Epub 2016 Aug 12.
• [2001] Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-B activity in hepatocellular carcinoma.Cell Death Dis. 2019 Sep 26;10(10):719. doi: 10.1038/s41419-019-1881-x.
• [2002] Transcriptional expressions of Chromobox 1/2/3/6/8 as independent indicators for survivals in hepatocellular carcinoma patients.Aging (Albany NY). 2018 Nov 27;10(11):3450-3473. doi: 10.18632/aging.101658.
• [2003] A Coiled-Coil Domain Containing 50 Splice Variant Is Modulated by Serine/Arginine-Rich Splicing Factor 3 and Promotes Hepatocellular Carcinoma in Mice by the Ras Signaling Pathway.Hepatology. 2019 Jan;69(1):179-195. doi: 10.1002/hep.30147. Epub 2018 Dec 22.
• [2004] Genome-Wide Association Study of MKI67 Expression and its Clinical Implications in HBV-Related Hepatocellular Carcinoma in Southern China.Cell Physiol Biochem. 2017;42(4):1342-1357. doi: 10.1159/000478963. Epub 2017 Jul 13.
• [2005] Silencing the Girdin gene enhances radio-sensitivity of hepatocellular carcinoma via suppression of glycolytic metabolism.J Exp Clin Cancer Res. 2017 Aug 15;36(1):110. doi: 10.1186/s13046-017-0580-7.
• [2006] CCL14 serves as a novel prognostic factor and tumor suppressor of HCC by modulating cell cycle and promoting apoptosis.Cell Death Dis. 2019 Oct 22;10(11):796. doi: 10.1038/s41419-019-1966-6.
• [2007] The alpha1-6-fucosyltransferase gene and its biological significance.Biochim Biophys Acta. 1999 Dec 6;1473(1):9-20. doi: 10.1016/s0304-4165(99)00166-x.
• [2008] The effect of chemokine CC motif ligand 19 on the proliferation and migration of hepatocellular carcinoma.Tumour Biol. 2014 Dec;35(12):12575-81. doi: 10.1007/s13277-014-2578-5. Epub 2014 Sep 16.
• [2009] Hepatocellular carcinoma cells cause different responses in expressions of cancer-promoting genes in different cancer-associated fibroblasts.Kaohsiung J Med Sci. 2013 Jun;29(6):312-8. doi: 10.1016/j.kjms.2012.08.012. Epub 2012 Oct 13.
• [2010] Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer.Oncotarget. 2016 Nov 15;7(46):75763-75773. doi: 10.18632/oncotarget.12409.
• [2011] TGF- as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives.Semin Liver Dis. 2019 Feb;39(1):53-69. doi: 10.1055/s-0038-1676121. Epub 2018 Dec 26.
• [2012] Repeated hepatocyte injury promotes hepatic tumorigenesis in hepatitis C virus transgenic mice.Cancer Sci. 2003 Aug;94(8):679-85. doi: 10.1111/j.1349-7006.2003.tb01502.x.
• [2013] Impacts of WNT1-inducible signaling pathway protein 1 polymorphism on hepatocellular carcinoma development.PLoS One. 2018 Jun 11;13(6):e0198967. doi: 10.1371/journal.pone.0198967. eCollection 2018.
• [2014] MicroRNA-1271 functions as a potential tumor suppressor in hepatitis B virus-associated hepatocellular carcinoma through the AMPK signaling pathway by binding to CCNA1.J Cell Physiol. 2019 Apr;234(4):3555-3569. doi: 10.1002/jcp.26955. Epub 2018 Nov 22.
• [2015] Cyclin B2 Overexpression in Human Hepatocellular Carcinoma is Associatedwith Poor Prognosis.Arch Med Res. 2019 Jan;50(1):10-17. doi: 10.1016/j.arcmed.2019.03.003. Epub 2019 Apr 4.
• [2016] LINE-1 hypomethylation in human hepatocellular carcinomas correlates with shorter overall survival and CIMP phenotype.PLoS One. 2019 May 6;14(5):e0216374. doi: 10.1371/journal.pone.0216374. eCollection 2019.
• [2017] Human homologue of maid is a useful marker protein in hepatocarcinogenesis.Gastroenterology. 2005 May;128(5):1369-80. doi: 10.1053/j.gastro.2005.03.014.
• [2018] LncRNA HOTAIR epigenetically suppresses miR-122 expression in hepatocellular carcinoma via DNA methylation.EBioMedicine. 2018 Oct;36:159-170. doi: 10.1016/j.ebiom.2018.08.055. Epub 2018 Sep 5.
• [2019] CCNJ detected by triple combination array analysis as a tumor-related gene of hepatocellular carcinoma.Int J Oncol. 2015 May;46(5):1963-70. doi: 10.3892/ijo.2015.2892. Epub 2015 Feb 11.
• [2020] Cyclin L2, a novel RNA polymerase II-associated cyclin, is involved in pre-mRNA splicing and induces apoptosis of human hepatocellular carcinoma cells.J Biol Chem. 2004 Mar 19;279(12):11639-48. doi: 10.1074/jbc.M312895200. Epub 2003 Dec 17.
• [2021] Clinical and prognostic value of chaperonin containing T-complex 1 subunit 3 in hepatocellular carcinoma: A Study based on microarray and RNA-sequencing with 4272 cases.Pathol Res Pract. 2019 Jan;215(1):177-194. doi: 10.1016/j.prp.2018.11.006. Epub 2018 Nov 10.
• [2022] Overexpressing CCT6A Contributes To Cancer Cell Growth By Affecting The G1-To-S Phase Transition And Predicts A Negative Prognosis In Hepatocellular Carcinoma.Onco Targets Ther. 2019 Nov 29;12:10427-10439. doi: 10.2147/OTT.S229231. eCollection 2019.
• [2023] Glucose-regulated protein 94 mediates metastasis by CCT8 and the JNK pathway in hepatocellular carcinoma.Tumour Biol. 2016 Jun;37(6):8219-27. doi: 10.1007/s13277-015-4669-3. Epub 2015 Dec 30.
• [2024] CD109 Mediates Cell Survival in Hepatocellular Carcinoma Cells.Dig Dis Sci. 2016 Aug;61(8):2303-2314. doi: 10.1007/s10620-016-4149-7. Epub 2016 Apr 13.
• [2025] LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma.J Cell Physiol. 2019 Mar;234(3):2788-2794. doi: 10.1002/jcp.27095. Epub 2018 Aug 21.
• [2026] Elevated Hepatic CD1d Levels Coincide with Invariant NKT Cell Defects in Chronic Hepatitis B Virus Infection.J Immunol. 2018 May 15;200(10):3530-3538. doi: 10.4049/jimmunol.1701801. Epub 2018 Apr 11.
• [2027] Association of genetic polymorphisms in CD8+ T cell inhibitory genes and susceptibility to and progression of chronic HBV infection.Infect Genet Evol. 2015 Dec;36:467-474. doi: 10.1016/j.meegid.2015.08.018. Epub 2015 Aug 18.
• [2028] CD81(+) Exosomes Play a Pivotal Role in the Establishment of Hepatitis C Persistent Infection and Contribute Toward the Progression of Hepatocellular Carcinoma.Viral Immunol. 2019 Dec;32(10):453-462. doi: 10.1089/vim.2019.0077. Epub 2019 Nov 22.
• [2029] Interaction of transforming growth factor--Smads/microRNA-362-3p/CD82 mediated by M2 macrophages promotes the process of epithelial-mesenchymal transition in hepatocellular carcinoma cells.Cancer Sci. 2019 Aug;110(8):2507-2519. doi: 10.1111/cas.14101. Epub 2019 Jul 9.
• [2030] TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.Hepatology. 2002 Jun;35(6):1476-84. doi: 10.1053/jhep.2002.33683.
• [2031] Association of APC, GSTP1 and SOCS1 promoter methylation with the risk of hepatocellular carcinoma: a meta-analysis.Eur J Cancer Prev. 2015 Nov;24(6):470-83. doi: 10.1097/CEJ.0000000000000121.
• [2032] Enhanced expression of mRNAs of antisecretory factor-1, gp96, DAD1 and CDC34 in human hepatocellular carcinomas.Biochim Biophys Acta. 2001 Apr 30;1536(1):1-12. doi: 10.1016/s0925-4439(01)00026-6.
• [2033] HBx-induced MiR-1269b in NF-B dependent manner upregulates cell division cycle 40 homolog (CDC40) to promote proliferation and migration in hepatoma cells.J Transl Med. 2016 Jun 27;14(1):189. doi: 10.1186/s12967-016-0949-y.
• [2034] LncRNA-H19 activates CDC42/PAK1 pathway to promote cell proliferation, migration and invasion by targeting miR-15b in hepatocellular carcinoma.Genomics. 2019 Dec;111(6):1862-1872. doi: 10.1016/j.ygeno.2018.12.009. Epub 2018 Dec 10.
• [2035] Prp19 Arrests Cell Cycle via Cdc5L in Hepatocellular Carcinoma Cells.Int J Mol Sci. 2017 Apr 7;18(4):778. doi: 10.3390/ijms18040778.
• [2036] Potential clinical value and putative biological function of miR-122-5p in hepatocellular carcinoma: A comprehensive study using microarray and RNA sequencing data.Oncol Lett. 2018 Dec;16(6):6918-6929. doi: 10.3892/ol.2018.9523. Epub 2018 Sep 28.
• [2037] Silymarin-mediated regulation of the cell cycle and DNA damage response exerts antitumor activity in human hepatocellular carcinoma.Oncol Lett. 2018 Jan;15(1):885-892. doi: 10.3892/ol.2017.7425. Epub 2017 Nov 15.
• [2038] CDCA7L promotes hepatocellular carcinoma progression by regulating the cell cycle.Int J Oncol. 2013 Dec;43(6):2082-90. doi: 10.3892/ijo.2013.2142. Epub 2013 Oct 17.
• [2039] Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma.Oncol Lett. 2018 Jan;15(1):559-567. doi: 10.3892/ol.2017.7320. Epub 2017 Nov 1.
• [2040] Long non-coding RNA linc-cdh4-2 inhibits the migration and invasion of HCC cells by targeting R-cadherin pathway.Biochem Biophys Res Commun. 2016 Nov 18;480(3):348-354. doi: 10.1016/j.bbrc.2016.10.048. Epub 2016 Oct 17.
• [2041] Cadherin Related Family Member 2 Acts As A Tumor Suppressor By Inactivating AKT In Human Hepatocellular Carcinoma.J Cancer. 2019 Jan 29;10(4):864-873. doi: 10.7150/jca.27663. eCollection 2019.
• [2042] CDHR5 inhibits proliferation of hepatocellular carcinoma and predicts clinical prognosis.Ir J Med Sci. 2020 May;189(2):439-447. doi: 10.1007/s11845-019-02092-7. Epub 2019 Sep 3.
• [2043] Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas.Cell Oncol (Dordr). 2013 Jul;36(4):323-31. doi: 10.1007/s13402-013-0137-5. Epub 2013 Jun 6.
• [2044] Effect of p58GTA on beta-1,4-galactosyltransferase 1 activity and cell-cycle in human hepatocarcinoma cells.Mol Cell Biochem. 2001 May;221(1-2):161-8. doi: 10.1023/a:1010932211745.
• [2045] Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib.Onco Targets Ther. 2019 Jun 28;12:5025-5036. doi: 10.2147/OTT.S196607. eCollection 2019.
• [2046] Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.Tohoku J Exp Med. 2014 Mar;232(3):187-94. doi: 10.1620/tjem.232.187.
• [2047] Nucleotide change of codon 182 in the surface gene of hepatitis B virus genotype C leading to truncated surface protein is associated with progression of liver diseases.J Hepatol. 2012 Jan;56(1):63-9. doi: 10.1016/j.jhep.2011.06.028. Epub 2011 Aug 7.
• [2048] Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy.Surg Oncol. 2016 Sep;25(3):171-7. doi: 10.1016/j.suronc.2016.05.026. Epub 2016 May 24.
• [2049] Aberrant CDX2 expression in hepatocellular carcinomas: an important diagnostic pitfall.Hum Pathol. 2017 Jun;64:13-18. doi: 10.1016/j.humpath.2016.12.029. Epub 2017 Jan 13.
• [2050] CELSR3 mRNA expression is increased in hepatocellular carcinoma and indicates poor prognosis.PeerJ. 2019 Oct 7;7:e7816. doi: 10.7717/peerj.7816. eCollection 2019.
• [2051] Lymphoid-specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression.Cancer Sci. 2019 Jul;110(7):2133-2144. doi: 10.1111/cas.14037. Epub 2019 May 25.
• [2052] Overexpression of CENP-H as a novel prognostic biomarker for human hepatocellular carcinoma progression and patient survival.Oncol Rep. 2013 Nov;30(5):2238-44. doi: 10.3892/or.2013.2675. Epub 2013 Aug 20.
• [2053] Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms.J Exp Clin Cancer Res. 2019 Nov 8;38(1):458. doi: 10.1186/s13046-019-1444-0.
• [2054] Overexpression of caltractin gene in tumor-infiltrating lymphocytes.Int J Oncol. 1998 Dec;13(6):1135-40. doi: 10.3892/ijo.13.6.1135.
• [2055] Transcriptional regulation of human transcription factor IIB in SMMC-7721 human hepatocellular carcinoma cells by all-trans-retinoic acid and phorbol 12-myristate 13-acetate.J Cancer Res Clin Oncol. 1998;124(9):493-6. doi: 10.1007/s004320050204.
• [2056] WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferation.Neoplasia. 2005 Apr;7(4):348-55. doi: 10.1593/neo.04544.
• [2057] Downregulated expression of CFHL1 is associated with unfavorable prognosis in postoperative patients with hepatocellular carcinoma.Exp Ther Med. 2019 May;17(5):4073-4079. doi: 10.3892/etm.2019.7455. Epub 2019 Mar 29.
• [2058] CHAF1B knockdown blocks migration in a hepatocellular carcinoma model.Oncol Rep. 2018 Jul;40(1):405-413. doi: 10.3892/or.2018.6437. Epub 2018 May 16.
• [2059] CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-B axis in human non-small-cell lung cancer.Cell Death Dis. 2019 Feb 4;10(2):99. doi: 10.1038/s41419-019-1371-1.
• [2060] Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.J Hepatol. 2015 Nov;63(5):1164-72. doi: 10.1016/j.jhep.2015.06.009. Epub 2015 Jun 18.
• [2061] A rare CHD5 haplotype and its interactions with environmental factors predicting hepatocellular carcinoma risk.BMC Cancer. 2018 Jun 15;18(1):658. doi: 10.1186/s12885-018-4551-y.
• [2062] Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake.J Hepatol. 2011 Apr;54(4):705-15. doi: 10.1016/j.jhep.2010.07.027. Epub 2010 Sep 25.
• [2063] CHST11/13 Regulate the Metastasis and Chemosensitivity of Human Hepatocellular Carcinoma Cells Via Mitogen-Activated Protein Kinase Pathway.Dig Dis Sci. 2016 Jul;61(7):1972-85. doi: 10.1007/s10620-016-4114-5. Epub 2016 Mar 18.
• [2064] CHSY1 promotes aggressive phenotypes of hepatocellular carcinoma cells via activation of the hedgehog signaling pathway.Cancer Lett. 2017 Sep 10;403:280-288. doi: 10.1016/j.canlet.2017.06.023. Epub 2017 Jun 23.
• [2065] Combination therapy of hTERTR and FAM96A for hepatocellular carcinoma through enhancing apoptosis sensitivity.Exp Ther Med. 2018 Jan;15(1):641-648. doi: 10.3892/etm.2017.5505. Epub 2017 Nov 13.
• [2066] The study on expression of CIAPIN1 interfering hepatocellular carcinoma cell proliferation and its mechanisms.Eur Rev Med Pharmacol Sci. 2017 Jul;21(13):3054-3060.
• [2067] Silencing of KIF14 interferes with cell cycle progression and cytokinesis by blocking the p27(Kip1) ubiquitination pathway in hepatocellular carcinoma.Exp Mol Med. 2014 May 23;46(5):e97. doi: 10.1038/emm.2014.23.
• [2068] The degradation of cell cycle regulators by SKP2/CKS1 ubiquitin ligase is genetically controlled in rodent liver cancer and contributes to determine the susceptibility to the disease.Int J Cancer. 2010 Mar 1;126(5):1275-81. doi: 10.1002/ijc.24650.
• [2069] Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.Stem Cells. 2015 Feb;33(2):354-66. doi: 10.1002/stem.1850.
• [2070] Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma.Biochem Biophys Res Commun. 2018 Jan 8;495(2):1807-1814. doi: 10.1016/j.bbrc.2017.11.124. Epub 2017 Nov 21.
• [2071] Cold-inducible RNA-binding protein promotes the development of liver cancer.Cancer Sci. 2015 Apr;106(4):352-8. doi: 10.1111/cas.12611. Epub 2015 Mar 3.
• [2072] Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma.Hepatology. 2012 Sep;56(3):994-1003. doi: 10.1002/hep.25706. Epub 2012 Aug 2.
• [2073] RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma.Cancer Biomark. 2019;24(2):241-247. doi: 10.3233/CBM-181638.
• [2074] CIZ1 interacts with YAP and activates its transcriptional activity in hepatocellular carcinoma cells.Tumour Biol. 2016 Aug;37(8):11073-9. doi: 10.1007/s13277-016-4866-8. Epub 2016 Feb 23.
• [2075] Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma.Onco Targets Ther. 2018 Dec 31;12:359-364. doi: 10.2147/OTT.S189425. eCollection 2019.
• [2076] Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.Dis Markers. 2019 Oct 22;2019:8964015. doi: 10.1155/2019/8964015. eCollection 2019.
• [2077] Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma.PLoS Pathog. 2018 Mar 14;14(3):e1006916. doi: 10.1371/journal.ppat.1006916. eCollection 2018 Mar.
• [2078] CLDN10 is Associated with Papillary Thyroid Cancer Progression.J Cancer. 2018 Nov 25;9(24):4712-4717. doi: 10.7150/jca.28636. eCollection 2018.
• [2079] miR-99b promotes metastasis of hepatocellular carcinoma through inhibition of claudin11 expression and may serve as a prognostic marker.Oncol Rep. 2015 Sep;34(3):1415-23. doi: 10.3892/or.2015.4104. Epub 2015 Jul 2.
• [2080] CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.Carcinogenesis. 2016 Jun;37(6):557-566. doi: 10.1093/carcin/bgw036. Epub 2016 Mar 31.
• [2081] Plasma claudin-3 is associated with tumor necrosis factor-alpha-induced intestinal endotoxemia in liver disease.Clin Res Hepatol Gastroenterol. 2019 Aug;43(4):410-416. doi: 10.1016/j.clinre.2018.11.014. Epub 2019 Apr 30.
• [2082] CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage.Transl Oncol. 2018 Apr;11(2):552-558. doi: 10.1016/j.tranon.2018.02.010. Epub 2018 Mar 8.
• [2083] External Radiation versus Internal Radiation for Patients with Advanced Unresectable HCC -A SEER Based Study.J Cancer. 2019 Jan 29;10(5):1171-1180. doi: 10.7150/jca.28983. eCollection 2019.
• [2084] Evaluating hepatocellular carcinoma cell lines for tumour samples using within-sample relative expression orderings of genes.Liver Int. 2017 Nov;37(11):1688-1696. doi: 10.1111/liv.13467. Epub 2017 Jun 6.
• [2085] Critical cholangiocarcinogenesis control by cryptochrome clock genes.Int J Cancer. 2017 Jun 1;140(11):2473-2483. doi: 10.1002/ijc.30663. Epub 2017 Mar 16.
• [2086] Polymorphisms of TERT and CLPTM1L and the risk of hepatocellular carcinoma in Chinese males.Asian Pac J Cancer Prev. 2014;15(19):8197-201. doi: 10.7314/apjcp.2014.15.19.8197.
• [2087] Cellular retinaldehyde-binding protein-like (CRALBPL), a novel human Sec14p-like gene that is upregulated in human hepatocellular carcinomas, may be used as a marker for human hepatocellular carcinomas.DNA Cell Biol. 2008 Mar;27(3):159-63. doi: 10.1089/dna.2007.0634.
• [2088] Up-regulation of miR-10b-3p promotes the progression of hepatocellular carcinoma cells via targeting CMTM5.J Cell Mol Med. 2018 Jul;22(7):3434-3441. doi: 10.1111/jcmm.13620. Epub 2018 Apr 24.
• [2089] Identification of carboxypeptidase of glutamate like-B as a candidate suppressor in cell growth and metastasis in human hepatocellular carcinoma.Clin Cancer Res. 2006 Nov 15;12(22):6617-25. doi: 10.1158/1078-0432.CCR-06-1307.
• [2090] Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.Gastroenterology. 2008 Jun;134(7):1890-9; quiz 2155. doi: 10.1053/j.gastro.2008.02.064. Epub 2008 Mar 4.
• [2091] TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.Int J Clin Exp Pathol. 2015 Mar 1;8(3):2690-9. eCollection 2015.
• [2092] Genetic association between functional haplotype of collagen type III alpha 1 and chronic hepatitis B and cirrhosis in Koreans.Tissue Antigens. 2008 Dec;72(6):539-48. doi: 10.1111/j.1399-0039.2008.01144.x. Epub 2008 Oct 18.
• [2093] Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis.Int J Oncol. 2008 Jul;33(1):33-40.
• [2094] All-trans retinoic acid protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating collagen 8A2.FEBS J. 2013 Mar;280(5):1308-19. doi: 10.1111/febs.12122. Epub 2013 Feb 6.
• [2095] COMMD7 Regulates NF-B Signaling Pathway in Hepatocellular Carcinoma Stem-like Cells.Mol Ther Oncolytics. 2018 Dec 14;12:112-123. doi: 10.1016/j.omto.2018.12.006. eCollection 2019 Mar 29.
• [2096] Long non-coding RNA MNX1-AS1 promotes hepatocellular carcinoma proliferation and invasion through targeting miR-218-5p/COMMD8 axis.Biochem Biophys Res Commun. 2019 Jun 4;513(3):669-674. doi: 10.1016/j.bbrc.2019.04.012. Epub 2019 Apr 11.
• [2097] Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma.Cancer Res. 2010 Nov 1;70(21):8264-9. doi: 10.1158/0008-5472.CAN-10-0749. Epub 2010 Oct 19.
• [2098] Knockdown of COPS3 inhibits the progress of prostate cancer through reducing phosphorylated p38 MAPK expression and impairs the epithelial-mesenchymal transition process.Prostate. 2019 Dec;79(16):1823-1831. doi: 10.1002/pros.23907. Epub 2019 Sep 11.
• [2099] Overexpression of CSN6 promotes the epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma.Clin Res Hepatol Gastroenterol. 2020 Jun;44(3):340-348. doi: 10.1016/j.clinre.2019.07.012. Epub 2019 Aug 14.
• [2100] Coronin 3 negatively regulates G6PC3 in HepG2 cells, as identified by labelfree massspectrometry.Mol Med Rep. 2017 Sep;16(3):3407-3414. doi: 10.3892/mmr.2017.7002. Epub 2017 Jul 15.
• [2101] POD-1/TCF21 Reduces SHP Expression, Affecting LRH-1 Regulation and Cell Cycle Balance in Adrenocortical and Hepatocarcinoma Tumor Cells.Biomed Res Int. 2015;2015:841784. doi: 10.1155/2015/841784. Epub 2015 Sep 2.
• [2102] Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors.J Hepatol. 2004 May;40(5):792-8. doi: 10.1016/j.jhep.2004.01.016.
• [2103] Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma.Hepatol Res. 2018 Oct;48(11):872-881. doi: 10.1111/hepr.13187. Epub 2018 Jun 3.
• [2104] HBx co-localizes with COXIII in HL-7702 cells to upregulate mitochondrial function and ROS generation.Oncol Rep. 2015 May;33(5):2461-7. doi: 10.3892/or.2015.3852. Epub 2015 Mar 13.
• [2105] Use of cyclooxygenase inhibitor and the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nested case-control study using a nationwide population-based data.J Viral Hepat. 2020 Jan;27(1):68-73. doi: 10.1111/jvh.13201. Epub 2019 Oct 2.
• [2106] Relevance of non-ceruloplasmin copper to oxidative stress in patients with hepatocellular carcinoma.Biol Trace Elem Res. 2009 Sep;130(3):229-40. doi: 10.1007/s12011-009-8338-5. Epub 2009 Feb 20.
• [2107] SiRNA-targeted carboxypeptidase D inhibits hepatocellular carcinoma growth.Cell Biol Int. 2013 Sep;37(9):929-39. doi: 10.1002/cbin.10113. Epub 2013 Apr 30.
• [2108] Effects of Lidocaine-Mediated CPEB3 Upregulation in Human Hepatocellular Carcinoma Cell Proliferation In Vitro.Biomed Res Int. 2018 Apr 17;2018:8403157. doi: 10.1155/2018/8403157. eCollection 2018.
• [2109] Biphasic and Stage-Associated Expression of CPEB4 in Hepatocellular Carcinoma.PLoS One. 2016 May 9;11(5):e0155025. doi: 10.1371/journal.pone.0155025. eCollection 2016.
• [2110] CPSF7 regulates liver cancer growth and metastasis by facilitating WWP2-FL and targeting the WWP2/PTEN/AKT signaling pathway.Biochim Biophys Acta Mol Cell Res. 2020 Feb;1867(2):118624. doi: 10.1016/j.bbamcr.2019.118624. Epub 2019 Dec 12.
• [2111] Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma.Clin Cancer Res. 2009 Feb 1;15(3):812-20. doi: 10.1158/1078-0432.CCR-08-0266.
• [2112] HN1L-mediated transcriptional axis AP-2/METTL13/TCF3-ZEB1 drives tumor growth and metastasis in hepatocellular carcinoma.Cell Death Differ. 2019 Nov;26(11):2268-2283. doi: 10.1038/s41418-019-0301-1. Epub 2019 Feb 18.
• [2113] Upregulation of Leucine Zipper Protein mRNA in Hepatocellular Carcinoma Associated With Poor Prognosis.Technol Cancer Res Treat. 2016 Jun;15(3):517-22. doi: 10.1177/1533034615587432. Epub 2015 Jun 1.
• [2114] Epigenetically regulated miR-449a enhances hepatitis B virus replication by targeting cAMP-responsive element binding protein 5 and modulating hepatocytes phenotype.Sci Rep. 2016 May 3;6:25389. doi: 10.1038/srep25389.
• [2115] Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1.Mol Cell Biochem. 2001 Jan;216(1-2):21-9. doi: 10.1023/a:1011022822077.
• [2116] Clinical and prognostic significance of urinary trypsin inhibitor in patients with hepatocellular carcinoma after hepatectomy.Ann Surg Oncol. 2009 Oct;16(10):2805-17. doi: 10.1245/s10434-009-0622-2. Epub 2009 Jul 28.
• [2117] miR-429 suppresses tumor migration and invasion by targeting CRKL in hepatocellular carcinoma via inhibiting Raf/MEK/ERK pathway and epithelial-mesenchymal transition.Sci Rep. 2018 Feb 5;8(1):2375. doi: 10.1038/s41598-018-20258-8.
• [2118] Small regulatory polypeptide of amino acid response negatively relates to poor prognosis and controls hepatocellular carcinoma progression via regulating microRNA-5581-3p/human cardiolipin synthase 1.J Cell Physiol. 2019 Aug;234(10):17589-17599. doi: 10.1002/jcp.28383. Epub 2019 Mar 1.
• [2119] The centrosomal protein Tax1 binding protein 2 is a novel tumor suppressor in hepatocellular carcinoma regulated by cyclin-dependent kinase 2.Hepatology. 2012 Nov;56(5):1770-81. doi: 10.1002/hep.25851. Epub 2012 Sep 17.
• [2120] Caspase polymorphisms and prognosis of hepatocellular carcinoma.PLoS One. 2017 Apr 28;12(4):e0176802. doi: 10.1371/journal.pone.0176802. eCollection 2017.
• [2121] Transcriptome profiling identifies a recurrent CRYL1-IFT88 chimeric transcript in hepatocellular carcinoma.Oncotarget. 2017 Jun 20;8(25):40693-40704. doi: 10.18632/oncotarget.17244.
• [2122] Inhibition of Csn3 expression induces growth arrest and apoptosis of hepatocellular carcinoma cells.Cancer Chemother Pharmacol. 2012 May;69(5):1173-80. doi: 10.1007/s00280-011-1810-x. Epub 2012 Jan 12.
• [2123] C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation.PLoS One. 2019 May 29;14(5):e0216677. doi: 10.1371/journal.pone.0216677. eCollection 2019.
• [2124] Hypomethylation-mediated activation of cancer/testis antigen KK-LC-1 facilitates hepatocellular carcinoma progression through activating the Notch1/Hes1 signalling.Cell Prolif. 2019 May;52(3):e12581. doi: 10.1111/cpr.12581. Epub 2019 Mar 20.
• [2125] Genomewide investigation of the clinical implications and molecular mechanism of long noncoding RNA LINC00668 and proteincoding genes in hepatocellular carcinoma.Int J Oncol. 2019 Oct;55(4):860-878. doi: 10.3892/ijo.2019.4858. Epub 2019 Aug 14.
• [2126] Evaluation of Circulatory RNA-Based Biomarker Panel in Hepatocellular Carcinoma.Mol Diagn Ther. 2016 Jun;20(3):265-77. doi: 10.1007/s40291-016-0200-9.
• [2127] HBV Upregulates CtBP2 Expression via the X Gene.Biomed Res Int. 2018 Jul 31;2018:6960573. doi: 10.1155/2018/6960573. eCollection 2018.
• [2128] The effect of CTCF binding sites destruction by CRISPR/Cas9 on transcription of metallothionein gene family in liver hepatocellular carcinoma.Biochem Biophys Res Commun. 2019 Mar 19;510(4):530-538. doi: 10.1016/j.bbrc.2019.01.107. Epub 2019 Feb 7.
• [2129] Circulatory miR-98-5p levels are deregulated during diabetes and it inhibits proliferation and promotes apoptosis by targeting PPP1R15B in keratinocytes.RNA Biol. 2020 Feb;17(2):188-201. doi: 10.1080/15476286.2019.1673117. Epub 2019 Oct 15.
• [2130] CTNNA3 is a tumor suppressor in hepatocellular carcinomas and is inhibited by miR-425.Oncotarget. 2016 Feb 16;7(7):8078-89. doi: 10.18632/oncotarget.6978.
• [2131] MiR-424-5p reversed epithelial-mesenchymal transition of anchorage-independent HCC cells by directly targeting ICAT and suppressed HCC progression.Sci Rep. 2014 Sep 1;4:6248. doi: 10.1038/srep06248.
• [2132] Exosome-transmitted p120-catenin suppresses hepatocellular carcinoma progression via STAT3 pathways.Mol Carcinog. 2019 Aug;58(8):1389-1399. doi: 10.1002/mc.23022. Epub 2019 Apr 17.
• [2133] Hypoxia induced -Catenin to enhance mice hepatocellular carcinoma progression via Wnt signaling.Exp Cell Res. 2019 Jan 1;374(1):94-103. doi: 10.1016/j.yexcr.2018.11.011. Epub 2018 Nov 17.
• [2134] The HBx-CTTN interaction promotes cell proliferation and migration of hepatocellular carcinoma via CREB1.Cell Death Dis. 2019 May 28;10(6):405. doi: 10.1038/s41419-019-1650-x.
• [2135] Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response.Oncogene. 2011 Oct 6;30(40):4175-84. doi: 10.1038/onc.2011.126. Epub 2011 Apr 18.
• [2136] Twist1 Regulates Vimentin through Cul2 Circular RNA to Promote EMT in Hepatocellular Carcinoma.Cancer Res. 2018 Aug 1;78(15):4150-4162. doi: 10.1158/0008-5472.CAN-17-3009. Epub 2018 May 29.
• [2137] CUL4A facilitates hepatocarcinogenesis by promoting cell cycle progression and epithelial-mesenchymal transition.Sci Rep. 2015 Nov 23;5:17006. doi: 10.1038/srep17006.
• [2138] CUL4B activates Wnt/-catenin signalling in hepatocellular carcinoma by repressing Wnt antagonists.J Pathol. 2015 Apr;235(5):784-95. doi: 10.1002/path.4492. Epub 2015 Jan 23.
• [2139] Downregulation of MicroRNA-145 Caused by Hepatitis B Virus X Protein Promotes Expression of CUL5 and Contributes to Pathogenesis of Hepatitis B Virus-Associated Hepatocellular Carcinoma.Cell Physiol Biochem. 2015;37(4):1547-59. doi: 10.1159/000438522. Epub 2015 Oct 30.
• [2140] Suppressed Expression of CXCL14 in Hepatocellular Carcinoma Tissues and Its Reduction in the Advanced Stage of Chronic HBV Infection.Cancer Manag Res. 2019 Dec 12;11:10435-10443. doi: 10.2147/CMAR.S220528. eCollection 2019.
• [2141] CXCL17 promotes cell metastasis and inhibits autophagy via the LKB1-AMPK pathway in hepatocellular carcinoma.Gene. 2019 Mar 30;690:129-136. doi: 10.1016/j.gene.2018.12.043. Epub 2018 Dec 28.
• [2142] HIF-1 plays a role in the chemotactic migration of hepatocarcinoma cells through the modulation of CXCL6 expression.Cell Physiol Biochem. 2014;34(5):1536-46. doi: 10.1159/000366357. Epub 2014 Oct 10.
• [2143] The expression of tumor suppressor gene Cyld is upregulated by histone deacetylace inhibitors in human hepatocellular carcinoma cell lines.Cell Biochem Funct. 2016 Oct;34(7):465-468. doi: 10.1002/cbf.3212. Epub 2016 Aug 29.
• [2144] Cytochrome P450 2W1 (CYP2W1) - ready for use as the biomarker and drug target for cancer?.Xenobiotica. 2017 Oct;47(10):923-932. doi: 10.1080/00498254.2016.1244370. Epub 2016 Oct 24.
• [2145] Mitochondrial miR-181a-5p promotes glucose metabolism reprogramming in liver cancer by regulating the electron transport chain.Carcinogenesis. 2020 Jul 14;41(7):972-983. doi: 10.1093/carcin/bgz174.
• [2146] Cytohesin-3 is upregulated in hepatocellular carcinoma and contributes to tumor growth and vascular invasion.Int J Clin Exp Pathol. 2014 Apr 15;7(5):2123-32. eCollection 2014.
• [2147] SIX1 and DACH1 influence the proliferation and apoptosis of hepatocellular carcinoma through regulating p53.Cancer Biol Ther. 2018 May 4;19(5):381-390. doi: 10.1080/15384047.2018.1423920. Epub 2018 Feb 12.
• [2148] MiR-324-3p promotes tumor growth through targeting DACT1 and activation of Wnt/-catenin pathway in hepatocellular carcinoma.Oncotarget. 2017 Aug 7;8(39):65687-65698. doi: 10.18632/oncotarget.20058. eCollection 2017 Sep 12.
• [2149] Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling.PLoS One. 2014 Nov 6;9(11):e112336. doi: 10.1371/journal.pone.0112336. eCollection 2014.
• [2150] Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver.Int J Cancer. 2008 Jun 15;122(12):2800-4. doi: 10.1002/ijc.23433.
• [2151] Association of single nucleotide polymorphisms in VDR and DBP genes with HBV-related hepatocellular carcinoma risk in a Chinese population.PLoS One. 2014 Dec 26;9(12):e116026. doi: 10.1371/journal.pone.0116026. eCollection 2014.
• [2152] Dbx2 exhibits a tumor-promoting function in hepatocellular carcinoma cell lines via regulating Shh-Gli1 signaling.World J Gastroenterol. 2019 Feb 28;25(8):923-940. doi: 10.3748/wjg.v25.i8.923.
• [2153] The overexpression and prognostic role of DCAF13 in hepatocellular carcinoma.Tumour Biol. 2017 Jun;39(6):1010428317705753. doi: 10.1177/1010428317705753.
• [2154] The Role of Dermcidin in the Diagnosis and Staging of Hepatocellular Carcinoma.Genet Test Mol Biomarkers. 2018 Apr;22(4):218-223. doi: 10.1089/gtmb.2017.0230. Epub 2018 Mar 16.
• [2155] Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells.Int J Med Sci. 2019 Oct 21;16(12):1541-1548. doi: 10.7150/ijms.37427. eCollection 2019.
• [2156] Hepatitis B virus X protein affects S phase progression leading to chromosome segregation defects by binding to damaged DNA binding protein 1.Hepatology. 2008 Nov;48(5):1467-76. doi: 10.1002/hep.22542.
• [2157] DDIAS suppresses TRAIL-mediated apoptosis by inhibiting DISC formation and destabilizing caspase-8 in cancer cells.Oncogene. 2018 Mar;37(9):1251-1262. doi: 10.1038/s41388-017-0025-y. Epub 2017 Dec 15.
• [2158] Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in Hepatocellular carcinoma cells. BMC Gastroenterol. 2016 Feb 25;16:25. doi: 10.1186/s12876-016-0442-3.
• [2159] High expression of DDX20 enhances the proliferation and metastatic potential of prostate cancer cells through the NF-B pathway.Int J Mol Med. 2016 Jun;37(6):1551-7. doi: 10.3892/ijmm.2016.2575. Epub 2016 Apr 25.
• [2160] Structures and bioactivities of seven flavonoids from Osmanthus fragrans 'Jinqiu' essential oil extraction residues.Nat Prod Res. 2018 Mar;32(5):588-591. doi: 10.1080/14786419.2017.1318387. Epub 2017 Apr 21.
• [2161] DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control.Oncogene. 2006 Mar 30;25(14):1991-2003. doi: 10.1038/sj.onc.1209239.
• [2162] Oncogene RNA helicase DDX6 promotes the process of c-Myc expression in gastric cancer cells.Mol Carcinog. 2018 May;57(5):579-589. doi: 10.1002/mc.22781. Epub 2018 Jan 30.
• [2163] 6PGD inhibition sensitizes hepatocellular carcinoma to chemotherapy via AMPK activation and metabolic reprogramming.Biomed Pharmacother. 2019 Mar;111:1353-1358. doi: 10.1016/j.biopha.2019.01.028. Epub 2019 Jan 17.
• [2164] Expression of c-myc promoter binding protein (MBP-1), a novel eukaryotic repressor gene, in cirrhosis and human hepatocellular carcinoma.Dig Dis Sci. 2001 Mar;46(3):563-6. doi: 10.1023/a:1005651216212.
• [2165] XTP8 promotes hepatocellular carcinoma growth by forming a positive feedback loop with FOXM1 oncogene.Biochem Biophys Res Commun. 2019 Jul 30;515(3):455-461. doi: 10.1016/j.bbrc.2019.05.164. Epub 2019 Jun 1.
• [2166] A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-1 dependent mechanisms.Sci Rep. 2019 Feb 5;9(1):1439. doi: 10.1038/s41598-018-35736-2.
• [2167] Cloning and characterization of F-LANa, upregulated in human liver cancer.Biochem Biophys Res Commun. 2001 Aug 17;286(2):394-400. doi: 10.1006/bbrc.2001.5390.
• [2168] PPPDE1 promotes hepatocellular carcinoma development by negatively regulate p53 and apoptosis.Apoptosis. 2019 Feb;24(1-2):135-144. doi: 10.1007/s10495-018-1491-6.
• [2169] Clinical significance of aberrant DEUP1 promoter methylation in hepatocellular carcinoma.Oncol Lett. 2019 Aug;18(2):1356-1364. doi: 10.3892/ol.2019.10421. Epub 2019 May 30.
• [2170] Hepatomas are exquisitely sensitive to pharmacologic ascorbate (P-AscH(-)).Theranostics. 2019 Oct 18;9(26):8109-8126. doi: 10.7150/thno.35378. eCollection 2019.
• [2171] Overexpression and clinical relevance of the RNA helicase DHX15 in hepatocellular carcinoma.Hum Pathol. 2019 Feb;84:213-220. doi: 10.1016/j.humpath.2018.10.006. Epub 2018 Oct 17.
• [2172] DHX33 expression is increased in hepatocellular carcinoma and indicates poor prognosis.Biochem Biophys Res Commun. 2016 May 13;473(4):1163-1169. doi: 10.1016/j.bbrc.2016.04.033. Epub 2016 Apr 9.
• [2173] Downregulated expression of DIXDC1 in hepatocellular carcinoma and its correlation with prognosis.Tumour Biol. 2016 Oct;37(10):13607-13616. doi: 10.1007/s13277-016-5213-9. Epub 2016 Jul 28.
• [2174] Oxidatively Modified Protein-Disulfide Isomerase-Associated 3 Promotes Dyskerin Pseudouridine Synthase 1-Mediated Malignancy and Survival of Hepatocellular Carcinoma Cells.Hepatology. 2018 Nov;68(5):1851-1864. doi: 10.1002/hep.30039. Epub 2018 Jul 23.
• [2175] Glucose induced activation of canonical Wnt signaling pathway in hepatocellular carcinoma is regulated by DKK4.Sci Rep. 2016 Jun 8;6:27558. doi: 10.1038/srep27558.
• [2176] Deleted in Liver Cancer 2 (DLC2) protein expression in hepatocellular carcinoma.Eur J Histochem. 2019 Feb 18;63(1):2981. doi: 10.4081/ejh.2019.2981.
• [2177] Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.Hepatol Int. 2017 Jan;11(1):45-53. doi: 10.1007/s12072-016-9743-4. Epub 2016 Jun 7.
• [2178] Actinidia chinensis Planch root extract attenuates proliferation and metastasis of hepatocellular carcinoma by inhibiting epithelial-mesenchymal transition.J Ethnopharmacol. 2019 Mar 1;231:474-485. doi: 10.1016/j.jep.2018.11.014. Epub 2018 Nov 8.
• [2179] Regulation of the oncogenic function of distal-less 4 by microRNA-122 in hepatocellular carcinoma.Mol Med Rep. 2015 Jul;12(1):1375-80. doi: 10.3892/mmr.2015.3554. Epub 2015 Mar 27.
• [2180] Expression of deleted in malignant brain tumours 1 (DMBT1) relates to the proliferation and malignant transformation of hepatic progenitor cells in hepatitis B virus-related liver diseases.Histopathology. 2012 Jan;60(2):249-60. doi: 10.1111/j.1365-2559.2011.04082.x.
• [2181] The association between methylation patterns of DNAH17 and clinicopathological factors in hepatocellular carcinoma.Cancer Med. 2019 Jan;8(1):337-350. doi: 10.1002/cam4.1930. Epub 2018 Dec 21.
• [2182] Hepatitis B virus protein up-regulated HLJ1 expression via the transcription factor YY1 in human hepatocarcinoma cells.Virus Res. 2011 Apr;157(1):76-81. doi: 10.1016/j.virusres.2011.02.009. Epub 2011 Feb 21.
• [2183] Increased expression of specific thioredoxin family proteins; a pilot immunohistochemical study on human hepatocellular carcinoma.Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):17-24. doi: 10.1177/039463200702000103.
• [2184] Protein kinase R is increased and is functional in hepatitis C virus-related hepatocellular carcinoma.Am J Gastroenterol. 2003 Nov;98(11):2528-34. doi: 10.1111/j.1572-0241.2003.08663.x.
• [2185] Gankyrin gene deletion followed by proteomic analysis: insight into the roles of Gankyrin in tumorigenesis and metastasis.BMC Med Genomics. 2012 Aug 22;5:36. doi: 10.1186/1755-8794-5-36.
• [2186] RNA-binding protein Dnd1 inhibits epithelial-mesenchymal transition and cancer stem cell-related traits on hepatocellular carcinoma cells.Biotechnol Lett. 2017 Sep;39(9):1359-1367. doi: 10.1007/s10529-017-2375-5. Epub 2017 Jun 7.
• [2187] Bromodomain and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver Regeneration.Am J Pathol. 2018 Jun;188(6):1389-1405. doi: 10.1016/j.ajpath.2018.02.006. Epub 2018 Mar 12.
• [2188] Dynamin 3 suppresses growth and induces apoptosis of hepatocellular carcinoma cells by activating inducible nitric oxide synthase production.Oncol Lett. 2017 Jun;13(6):4776-4784. doi: 10.3892/ol.2017.6057. Epub 2017 Apr 20.
• [2189] Different molecular pathways determining extrahepatic and intrahepatic recurrences of hepatocellular carcinoma.Oncol Rep. 2006 Nov;16(5):1137-42.
• [2190] Novel PNLIPRP3 and DOCK8 gene expression and prognostic implications of DNA loss on chromosome 10q25.3 in hepatocellular carcinoma.Asian Pac J Cancer Prev. 2009 Jul-Sep;10(3):501-6.
• [2191] RASSF1A and DOK1 Promoter Methylation Levels in Hepatocellular Carcinoma, Cirrhotic and Non-Cirrhotic Liver, and Correlation with Liver Cancer in Brazilian Patients.PLoS One. 2016 Apr 14;11(4):e0153796. doi: 10.1371/journal.pone.0153796. eCollection 2016.
• [2192] Dysregulation of the miR-325-3p/DPAGT1 axis supports HBV-positive HCC chemoresistance.Biochem Biophys Res Commun. 2019 Nov 5;519(2):358-365. doi: 10.1016/j.bbrc.2019.08.116. Epub 2019 Sep 10.
• [2193] DNA methylation-mediated silencing of matricellular protein dermatopontin promotes hepatocellular carcinoma metastasis by 31 integrin-Rho GTPase signaling.Oncotarget. 2014 Aug 30;5(16):6701-15. doi: 10.18632/oncotarget.2239.
• [2194] Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor.J Gastroenterol. 2015 May;50(5):590-600. doi: 10.1007/s00535-014-0993-4. Epub 2014 Aug 31.
• [2195] Phosphorylated AKT inhibits the apoptosis induced by DRAM-mediated mitophagy in hepatocellular carcinoma by preventing the translocation of DRAM to mitochondria.Cell Death Dis. 2014 Feb 20;5(2):e1078. doi: 10.1038/cddis.2014.51.
• [2196] Efficacy of early treatment on 52 patients with preneoplastic hepatitis B virus-associated hepatocellular carcinoma by compound Phyllanthus Urinaria L.Chin J Integr Med. 2014 Apr;20(4):263-71. doi: 10.1007/s11655-013-1320-7. Epub 2013 Mar 25.
• [2197] DSE regulates the malignant characters of hepatocellular carcinoma cells by modulating CCL5/CCR1 axis.Am J Cancer Res. 2019 Feb 1;9(2):347-362. eCollection 2019.
• [2198] RNA interference against cancer/testis genes identifies dual specificity phosphatase 21 as a potential therapeutic target in human hepatocellular carcinoma.Hepatology. 2014 Feb;59(2):518-30. doi: 10.1002/hep.26665. Epub 2013 Dec 18.
• [2199] DUSP28 contributes to human hepatocellular carcinoma via regulation of the p38 MAPK signaling.Int J Oncol. 2014 Dec;45(6):2596-604. doi: 10.3892/ijo.2014.2653. Epub 2014 Sep 16.
• [2200] Identification of two novel human dynein light chain genes, DNLC2A and DNLC2B, and their expression changes in hepatocellular carcinoma tissues from 68 Chinese patients.Gene. 2001 Dec 27;281(1-2):103-13. doi: 10.1016/s0378-1119(01)00787-9.
• [2201] The transcription factor FOXN3 inhibits cell proliferation by downregulating E2F5 expression in hepatocellular carcinoma cells.Oncotarget. 2016 Jul 12;7(28):43534-43545. doi: 10.18632/oncotarget.9780.
• [2202] Promising diagnostic and prognostic value of E2Fs in human hepatocellular carcinoma.Cancer Manag Res. 2019 Feb 19;11:1725-1740. doi: 10.2147/CMAR.S182001. eCollection 2019.
• [2203] MicroRNA-302a/d inhibits the self-renewal capability and cell cycle entry of liver cancer stem cells by targeting the E2F7/AKT axis.J Exp Clin Cancer Res. 2018 Oct 16;37(1):252. doi: 10.1186/s13046-018-0927-8.
• [2204] Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
• [2205] Gene and protein expression of RCAS1 in hepatocellular carcinoma.Anticancer Res. 2003 Nov-Dec;23(6D):4967-71.
• [2206] MiR-490-5p inhibits the stemness of hepatocellular carcinoma cells by targeting ECT2.J Cell Biochem. 2019 Jan;120(1):967-976. doi: 10.1002/jcb.27459. Epub 2018 Sep 11.
• [2207] EDIL3 is a novel regulator of epithelial-mesenchymal transition controlling early recurrence of hepatocellular carcinoma.J Hepatol. 2015 Oct;63(4):863-73. doi: 10.1016/j.jhep.2015.05.005. Epub 2015 May 14.
• [2208] Opposing roles of C/EBP and eEF1A1 in Sp1-regulated miR-122 transcription.RNA Biol. 2020 Feb;17(2):202-210. doi: 10.1080/15476286.2019.1673656. Epub 2019 Oct 7.
• [2209] Etiology-dependent molecular mechanisms in human hepatocarcinogenesis.Hepatology. 2008 Feb;47(2):511-20. doi: 10.1002/hep.22033.
• [2210] Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC.Oncotarget. 2017 Feb 14;8(7):11950-11962. doi: 10.18632/oncotarget.14447.
• [2211] Replication the association of 2q32.2-q32.3 and 14q32.11 with hepatocellular carcinoma.Gene. 2015 Apr 25;561(1):63-7. doi: 10.1016/j.gene.2015.02.006. Epub 2015 Feb 7.
• [2212] EFEMP1 inhibits migration of hepatocellular carcinoma by regulating MMP2 and MMP9 via ERK1/2 activity.Oncol Rep. 2016 Jun;35(6):3489-95. doi: 10.3892/or.2016.4733. Epub 2016 Apr 5.
• [2213] Role of C-X-C chemokine ligand 12/C-X-C chemokine receptor 4 in the progression of hepatocellular carcinoma.Oncol Lett. 2017 Aug;14(2):1905-1910. doi: 10.3892/ol.2017.6396. Epub 2017 Jun 16.
• [2214] Trans-dominant inhibition of transcription activator LFB1.Nucleic Acids Res. 1992 Oct 25;20(20):5321-8. doi: 10.1093/nar/20.20.5321.
• [2215] Expression of ephrin-B1 in hepatocellular carcinoma: possible involvement in neovascularization.J Hepatol. 2003 Dec;39(6):991-6. doi: 10.1016/s0168-8278(03)00498-7.
• [2216] Tumor-endothelial cell interaction in an experimental model of human hepatocellular carcinoma.Exp Cell Res. 2018 Nov 1;372(1):16-24. doi: 10.1016/j.yexcr.2018.09.001. Epub 2018 Sep 8.
• [2217] Early growth response 3 inhibits growth of hepatocellular carcinoma cells via upregulation of Fas ligand.Int J Oncol. 2017 Mar;50(3):805-814. doi: 10.3892/ijo.2017.3855. Epub 2017 Jan 18.
• [2218] Decreased expression of the peroxisomal bifunctional enzyme and carbonyl reductase in human hepatocellular carcinomas.J Cancer Res Clin Oncol. 1999;125(2):83-8. doi: 10.1007/s004320050246.
• [2219] The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis.Oncogene. 1999 Mar 4;18(9):1677-87. doi: 10.1038/sj.onc.1202470.
• [2220] eIF3a mediates HIF1-dependent glycolytic metabolism in hepatocellular carcinoma cells through translational regulation.Am J Cancer Res. 2019 May 5;9(5):1079-1090. eCollection 2019.
• [2221] New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors.Eur J Cancer. 2017 Sep;83:56-70. doi: 10.1016/j.ejca.2017.06.003. Epub 2017 Jul 14.
• [2222] EIF3C-enhanced exosome secretion promotes angiogenesis and tumorigenesis of human hepatocellular carcinoma.Oncotarget. 2018 Jan 11;9(17):13193-13205. doi: 10.18632/oncotarget.24149. eCollection 2018 Mar 2.
• [2223] Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma.Oncotarget. 2015 Feb 20;6(5):2903-16. doi: 10.18632/oncotarget.3093.
• [2224] Generation of a tumor- and tissue-specific episomal non-viral vector system.BMC Biotechnol. 2013 Jun 4;13:49. doi: 10.1186/1472-6750-13-49.
• [2225] Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray.Mol Cells. 2002 Dec 31;14(3):382-7.
• [2226] Identification of potential hub genes related to the progression and prognosis of hepatocellular carcinoma through integrated bioinformatics analysis.Oncol Rep. 2020 Jan;43(1):133-146. doi: 10.3892/or.2019.7400. Epub 2019 Nov 6.
• [2227] Loss of cooperative function of transforming growth factor-beta signaling proteins, smad3 with embryonic liver fodrin, a beta-spectrin, in primary biliary cirrhosis.Liver Int. 2004 Dec;24(6):637-45. doi: 10.1111/j.1478-3231.2004.0958.x.
• [2228] MZF-1/Elk-1/PKC is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.J Cancer. 2017 Sep 2;8(15):3028-3036. doi: 10.7150/jca.20467. eCollection 2017.
• [2229] Molecular prognostic profile of Egyptian HCC cases infected with hepatitis C virus.Asian Pac J Cancer Prev. 2012;13(11):5433-8. doi: 10.7314/apjcp.2012.13.11.5433.
• [2230] Biosynthesis of very long-chain polyunsaturated fatty acids in hepatocytes expressing ELOVL4.Adv Exp Med Biol. 2014;801:631-6. doi: 10.1007/978-1-4614-3209-8_79.
• [2231] Decreased expression levels of ELOVL6 indicate poor prognosis in hepatocellular carcinoma.Oncol Lett. 2019 Dec;18(6):6214-6220. doi: 10.3892/ol.2019.10974. Epub 2019 Oct 9.
• [2232] Marked sequence diversity in the putative envelope proteins of hepatitis C viruses.Virus Res. 1992 Feb;22(2):107-23. doi: 10.1016/0168-1702(92)90038-b.
• [2233] Comprehensive study of tumour single nucleotide polymorphism array data reveals significant driver aberrations and disrupted signalling pathways in human hepatocellular cancer.IET Syst Biol. 2014 Apr;8(2):24-32. doi: 10.1049/iet-syb.2013.0027.
• [2234] Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.World J Gastroenterol. 2012 Jul 21;18(27):3527-36. doi: 10.3748/wjg.v18.i27.3527.
• [2235] Targetting an LncRNA P5848-ENO1 axis inhibits tumor growth in hepatocellular carcinoma.Biosci Rep. 2019 Nov 29;39(11):BSR20180896. doi: 10.1042/BSR20180896.
• [2236] Update on a tumor-associated NADH oxidase in gastric cancer cell growth. World J Gastroenterol. 2016 Mar 14;22(10):2900-5.
• [2237] Integrated analyses of DNA methylation and hydroxymethylation reveal tumor suppressive roles of ECM1, ATF5, and EOMES in human hepatocellular carcinoma.Genome Biol. 2014 Dec 3;15(12):533. doi: 10.1186/s13059-014-0533-9.
• [2238] A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma.Eur J Cancer. 2014 Mar;50(5):928-36. doi: 10.1016/j.ejca.2013.11.026. Epub 2013 Dec 11.
• [2239] Integrative Functional Genomics Implicates EPB41 Dysregulation in Hepatocellular Carcinoma Risk.Am J Hum Genet. 2016 Aug 4;99(2):275-86. doi: 10.1016/j.ajhg.2016.05.029. Epub 2016 Jul 21.
• [2240] EPS15R, TASP1, and PRPF3 are novel disease candidate genes targeted by HNF4alpha splice variants in hepatocellular carcinomas.Gastroenterology. 2008 Apr;134(4):1191-202. doi: 10.1053/j.gastro.2008.01.027. Epub 2008 Jan 17.
• [2241] The role of ERCC1 and AFP gene polymorphism in hepatocellular carcinoma.Medicine (Baltimore). 2019 Apr;98(14):e15090. doi: 10.1097/MD.0000000000015090.
• [2242] RecQL1 DNA repair helicase: A potential tumor marker and therapeutic target against hepatocellular carcinoma.Int J Mol Med. 2010 Apr;25(4):537-45. doi: 10.3892/ijmm_00000375.
• [2243] The effect of adenovirus-conjugated NDRG2 on p53-mediated apoptosis of hepatocarcinoma cells through attenuation of nucleotide excision repair capacity.Biomaterials. 2014 Jan;35(3):993-1003. doi: 10.1016/j.biomaterials.2013.09.096.
• [2244] Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma.Sci Rep. 2015 Apr 9;5:9357. doi: 10.1038/srep09357.
• [2245] High glucose regulates ERp29 in hepatocellular carcinoma by LncRNA MEG3-miRNA 483-3p pathway.Life Sci. 2019 Sep 1;232:116602. doi: 10.1016/j.lfs.2019.116602. Epub 2019 Jun 26.
• [2246] MicroRNA-374a Promotes Hepatocellular Carcinoma Cell Proliferation by Targeting Mitogen-Inducible Gene 6 (MIG-6).Oncol Res. 2018 May 7;26(4):557-563. doi: 10.3727/096504017X15000784459799. Epub 2017 Jul 21.
• [2247] Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein. Am J Hum Genet. 2004 Feb;74(2):239-52. doi: 10.1086/381653. Epub 2004 Jan 19.
• [2248] AGXT2L1 is down-regulated in heptocellular carcinoma and associated with abnormal lipogenesis.J Clin Pathol. 2016 Mar;69(3):215-20. doi: 10.1136/jclinpath-2015-203042. Epub 2015 Aug 20.
• [2249] Myc/Max dependent intronic long antisense noncoding RNA, EVA1A-AS, suppresses the expression of Myc/Max dependent anti-proliferating gene EVA1A in a U2 dependent manner.Sci Rep. 2019 Nov 21;9(1):17319. doi: 10.1038/s41598-019-53944-2.
• [2250] EVI5 is a novel independent prognostic predictor in hepatocellular carcinoma after radical hepatectomy.Oncol Rep. 2017 Oct;38(4):2251-2258. doi: 10.3892/or.2017.5862. Epub 2017 Aug 1.
• [2251] Exo70 is transcriptionally up-regulated by hepatic nuclear factor 4 and contributes to cell cycle control in hepatoma cells.Oncotarget. 2016 Feb 23;7(8):9150-62. doi: 10.18632/oncotarget.7133.
• [2252] Viral integration drives multifocal HCC during the occult HBV infection.J Exp Clin Cancer Res. 2019 Jun 14;38(1):261. doi: 10.1186/s13046-019-1273-1.
• [2253] EYA4 serves as a prognostic biomarker in hepatocellular carcinoma and suppresses tumour angiogenesis and metastasis.J Cell Mol Med. 2019 Jun;23(6):4208-4216. doi: 10.1111/jcmm.14309. Epub 2019 Apr 7.
• [2254] Association of p38MAPK-p53-Fas aggregation in S-allyl cysteine mediated regulation of hepatocarcinoma.Environ Toxicol. 2019 Aug;34(8):928-940. doi: 10.1002/tox.22764. Epub 2019 May 8.
• [2255] LncRNA DCST1-AS1 functions as a competing endogenous RNA to regulate FAIM2 expression by sponging miR-1254 in hepatocellular carcinoma.Clin Sci (Lond). 2019 Jan 30;133(2):367-379. doi: 10.1042/CS20180814. Print 2019 Jan 31.
• [2256] A non-secretory form of FAM3B promotes invasion and metastasis of human colon cancer cells by upregulating Slug expression.Cancer Lett. 2013 Jan 28;328(2):278-84. doi: 10.1016/j.canlet.2012.09.026. Epub 2012 Oct 8.
• [2257] ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression.Oncogene. 2009 Feb 5;28(5):638-50. doi: 10.1038/onc.2008.418. Epub 2008 Nov 17.
• [2258] Expression of a novel gene FAM43B repressing cell proliferation is regulated by DNA methylation in hepatocellular carcinoma cell lines.Mol Cell Biochem. 2011 Aug;354(1-2):11-20. doi: 10.1007/s11010-011-0800-y. Epub 2011 Apr 2.
• [2259] FAM83H is involved in the progression of hepatocellular carcinoma and is regulated by MYC.Sci Rep. 2017 Jun 12;7(1):3274. doi: 10.1038/s41598-017-03639-3.
• [2260] FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.Oncol Rep. 2013 Sep;30(3):1275-84. doi: 10.3892/or.2013.2592. Epub 2013 Jul 5.
• [2261] Anticancer potential of ZnO nanoparticle-ferulic acid conjugate on Huh-7 and HepG2 cells and diethyl nitrosamine induced hepatocellular cancer on Wistar albino rat.Nanomedicine. 2018 Feb;14(2):415-428. doi: 10.1016/j.nano.2017.11.003. Epub 2017 Nov 21.
• [2262] Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents.Mol Cancer. 2010 May 28;9:127. doi: 10.1186/1476-4598-9-127.
• [2263] Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma.Hepatology. 2014 Oct;60(4):1241-50. doi: 10.1002/hep.27218. Epub 2014 Jul 31.
• [2264] Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy.Eur J Gastroenterol Hepatol. 2020 Mar;32(3):433-439. doi: 10.1097/MEG.0000000000001520.
• [2265] circFBLIM1 act as a ceRNA to promote hepatocellular cancer progression by sponging miR-346.J Exp Clin Cancer Res. 2018 Jul 27;37(1):172. doi: 10.1186/s13046-018-0838-8.
• [2266] Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma.PLoS One. 2017 Mar 23;12(3):e0174265. doi: 10.1371/journal.pone.0174265. eCollection 2017.
• [2267] Effect of fibulin-5 on adhesion, migration and invasion of hepatocellular carcinoma cells via an integrin-dependent mechanism.World J Gastroenterol. 2015 Oct 21;21(39):11127-40. doi: 10.3748/wjg.v21.i39.11127.
• [2268] Radiological features and outcomes ofcombined hepatocellular-cholangiocarcinoma inpatients undergoingsurgical resection.J Formos Med Assoc. 2020 Jan;119(1 Pt 1):125-133. doi: 10.1016/j.jfma.2019.02.012. Epub 2019 Mar 12.
• [2269] Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma.Hepatology. 2019 Feb;69(2):587-603. doi: 10.1002/hep.30168. Epub 2019 Jan 4.
• [2270] FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/-catenin pathway.Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8265-8273. doi: 10.26355/eurrev_201910_19137.
• [2271] FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.J Exp Clin Cancer Res. 2019 Feb 26;38(1):101. doi: 10.1186/s13046-019-1058-6.
• [2272] FBXO31 is down-regulated and may function as a tumor suppressor in hepatocellular carcinoma.Oncol Rep. 2010 Sep;24(3):715-20. doi: 10.3892/or_00000912.
• [2273] Screening therapeutic targets of ribavirin in hepatocellular carcinoma.Oncol Lett. 2018 Jun;15(6):9625-9632. doi: 10.3892/ol.2018.8552. Epub 2018 Apr 20.
• [2274] c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival.Anticancer Res. 2013 Aug;33(8):3241-5.
• [2275] Discovery and validation of DNA hypomethylation biomarkers for liver cancer using HRM-specific probes.PLoS One. 2013 Aug 7;8(8):e68439. doi: 10.1371/journal.pone.0068439. eCollection 2013.
• [2276] Genome-wide association study of chronic hepatitis B virus infection reveals a novel candidate risk allele on 11q22.3.J Med Genet. 2013 Nov;50(11):725-32. doi: 10.1136/jmedgenet-2013-101724. Epub 2013 Sep 24.
• [2277] Identification of Flap endonuclease 1 as a potential core gene in hepatocellular carcinoma by integrated bioinformatics analysis.PeerJ. 2019 Sep 6;7:e7619. doi: 10.7717/peerj.7619. eCollection 2019.
• [2278] Expression of Kindlin-1 in human hepatocellular carcinoma and its prognostic significance.Tumour Biol. 2015 Jun;36(6):4235-41. doi: 10.1007/s13277-015-3060-8. Epub 2015 Jan 16.
• [2279] Prognostic value of Kindlin-2 expression in patients with solid tumors: a meta-analysis.Cancer Cell Int. 2018 Oct 22;18:166. doi: 10.1186/s12935-018-0651-7. eCollection 2018.
• [2280] Hepatitis B virus X protein related lncRNA WEE2-AS1 promotes hepatocellular carcinoma proliferation and invasion.Biochem Biophys Res Commun. 2019 Jan 1;508(1):79-86. doi: 10.1016/j.bbrc.2018.11.091. Epub 2018 Nov 22.
• [2281] The liver of woodchucks chronically infected with the woodchuck hepatitis virus contains foci of virus core antigen-negative hepatocytes with both altered and normal morphology.Virology. 2007 Mar 15;359(2):283-94. doi: 10.1016/j.virol.2006.09.034. Epub 2006 Oct 31.
• [2282] An adiponectin receptor, T-cadherin, was selectively expressed in intratumoral capillary endothelial cells in hepatocellular carcinoma: possible cross talk between T-cadherin and FGF-2 pathways.Virchows Arch. 2006 Mar;448(3):311-8. doi: 10.1007/s00428-005-0098-9. Epub 2005 Nov 5.
• [2283] Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis.Hepatology. 2011 Mar;53(3):854-64. doi: 10.1002/hep.24099. Epub 2011 Feb 11.
• [2284] Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015 May;47(5):505-511. doi: 10.1038/ng.3252. Epub 2015 Mar 30.
• [2285] Exosomal miR-9-3p suppresses HBGF-5 expression and is a functional biomarker in hepatocellular carcinoma.Minerva Med. 2018 Feb;109(1):15-23. doi: 10.23736/S0026-4806.17.05167-9. Epub 2017 Jul 27.
• [2286] MicroRNA-210 promotes cancer angiogenesis by targeting fibroblast growth factor receptor-like1 in hepatocellular carcinoma.Oncol Rep. 2016 Nov;36(5):2553-2562. doi: 10.3892/or.2016.5129. Epub 2016 Sep 23.
• [2287] Identification of FKBP11 as a biomarker for hepatocellular carcinoma.Anticancer Res. 2013 Jun;33(6):2763-9.
• [2288] Ectopic overexpression of filamin C scaffolds MEK1/2 and ERK1/2 to promote the progression of human hepatocellular carcinoma.Cancer Lett. 2017 Mar 1;388:167-176. doi: 10.1016/j.canlet.2016.11.037. Epub 2016 Dec 3.
• [2289] Flot2 promotes tumor growth and metastasis through modulating cell cycle and inducing epithelial-mesenchymal transition of hepatocellular carcinoma.Am J Cancer Res. 2017 May 1;7(5):1068-1083. eCollection 2017.
• [2290] An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.Radiat Res. 2014 Aug;182(2):201-10. doi: 10.1667/RR13617.1. Epub 2014 Jul 3.
• [2291] Effect of protocatechuic acid-layered double hydroxide nanoparticles on diethylnitrosamine/phenobarbital-induced hepatocellular carcinoma in mice.PLoS One. 2019 May 29;14(5):e0217009. doi: 10.1371/journal.pone.0217009. eCollection 2019.
• [2292] Down-regulation of formin-like 2 predicts poor prognosis in hepatocellular carcinoma.Hum Pathol. 2011 Nov;42(11):1603-12. doi: 10.1016/j.humpath.2010.08.025. Epub 2011 Apr 14.
• [2293] Genome-Wide Association Study Identifies a Genetic Prediction Model for Postoperative Survival in Patients with Hepatocellular Carcinoma.Med Sci Monit. 2019 Apr 4;25:2452-2478. doi: 10.12659/MSM.915511.
• [2294] A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.Mol Cancer. 2019 Feb 19;18(1):28. doi: 10.1186/s12943-019-0957-7.
• [2295] Conversion of hepatoma cells to hepatocyte-like cells by defined hepatocyte nuclear factors.Cell Res. 2019 Feb;29(2):124-135. doi: 10.1038/s41422-018-0111-x. Epub 2018 Dec 18.
• [2296] miR?25?p promotes cell proliferation, migration and invasion by directly targeting FOXD3 in hepatocellular carcinoma cells.Mol Med Rep. 2019 Aug;20(2):1883-1892. doi: 10.3892/mmr.2019.10427. Epub 2019 Jun 26.
• [2297] Double-negative feedback loop between microRNA-422a and forkhead box (FOX)G1/Q1/E1 regulates hepatocellular carcinoma tumor growth and metastasis.Hepatology. 2015 Feb;61(2):561-73. doi: 10.1002/hep.27491.
• [2298] FOXF2 deficiency promotes hepatocellular carcinoma metastasis by inducing mesenchymal-epithelial transition.Cancer Biomark. 2017 Jul 4;19(4):447-454. doi: 10.3233/CBM-170139.
• [2299] Expression of FOXJ1 in hepatocellular carcinoma: correlation with patients' prognosis and tumor cell proliferation.Mol Carcinog. 2013 Aug;52(8):647-59. doi: 10.1002/mc.21904. Epub 2012 Apr 4.
• [2300] High FOXK1 expression correlates with poor outcomes in hepatocellular carcinoma and regulates stemness of hepatocellular carcinoma cells.Life Sci. 2019 Jul 1;228:128-134. doi: 10.1016/j.lfs.2019.04.068. Epub 2019 May 1.
• [2301] FOXK2, regulted by miR-1271-5p, promotes cell growth and indicates unfavorable prognosis in hepatocellular carcinoma.Int J Biochem Cell Biol. 2017 Jul;88:155-161. doi: 10.1016/j.biocel.2017.05.019. Epub 2017 May 12.
• [2302] Genome-wide association analysis identifies a GLUL haplotype for familial hepatitis B virus-related hepatocellular carcinoma.Cancer. 2017 Oct 15;123(20):3966-3976. doi: 10.1002/cncr.30851. Epub 2017 Jun 29.
• [2303] FOXN3 is downregulated in osteosarcoma and transcriptionally regulates SIRT6, and suppresses migration and invasion in osteosarcoma.Oncol Rep. 2019 Feb;41(2):1404-1414. doi: 10.3892/or.2018.6878. Epub 2018 Nov 21.
• [2304] Oncogenic Akt-FOXO3 loop favors tumor-promoting modes and enhances oxidative damage-associated hepatocellular carcinogenesis.BMC Cancer. 2019 Sep 5;19(1):887. doi: 10.1186/s12885-019-6110-6.
• [2305] NCAPG Promotes The Proliferation Of Hepatocellular Carcinoma Through PI3K/AKT Signaling.Onco Targets Ther. 2019 Oct 16;12:8537-8552. doi: 10.2147/OTT.S217916. eCollection 2019.
• [2306] Knockdown of FRAT1 inhibits hypoxia-induced epithelial-to-mesenchymal transition via suppression of the Wnt/-catenin pathway in hepatocellular carcinoma cells.Oncol Rep. 2016 Nov;36(5):2999-3004. doi: 10.3892/or.2016.5130. Epub 2016 Sep 23.
• [2307] In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma.Bioinformatics. 2013 Feb 15;29(4):420-7. doi: 10.1093/bioinformatics/bts715. Epub 2012 Dec 24.
• [2308] C-terminal truncated HBx protein activates caveolin-1/LRP6/-catenin/FRMD5 axis in promoting hepatocarcinogenesis.Cancer Lett. 2019 Mar 1;444:60-69. doi: 10.1016/j.canlet.2018.12.003. Epub 2018 Dec 21.
• [2309] Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.Epigenetics. 2018;13(3):214-227. doi: 10.1080/15592294.2016.1229730. Epub 2018 Apr 18.
• [2310] miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9.Onco Targets Ther. 2019 Mar 22;12:2149-2157. doi: 10.2147/OTT.S197326. eCollection 2019.
• [2311] FSTL1 contributes to tumor progression via attenuating apoptosis in a AKT/GSK-3 - dependent manner in hepatocellular carcinoma.Cancer Biomark. 2017 Jul 19;20(1):75-85. doi: 10.3233/CBM-170132.
• [2312] Follistatin-like protein 5 inhibits hepatocellular carcinoma progression by inducing caspase-dependent apoptosis and regulating Bcl-2 family proteins.J Cell Mol Med. 2018 Dec;22(12):6190-6201. doi: 10.1111/jcmm.13906. Epub 2018 Sep 25.
• [2313] Formiminotransferase Cyclodeaminase Suppresses Hepatocellular Carcinoma by Modulating Cell Apoptosis, DNA Damage, and Phosphatidylinositol 3-Kinases (PI3K)/Akt Signaling Pathway.Med Sci Monit. 2019 Jun 16;25:4474-4484. doi: 10.12659/MSM.916202.
• [2314] Far upstream element-binding protein 1 facilitates hepatocellular carcinoma invasion and metastasis.Carcinogenesis. 2020 Jul 14;41(7):950-960. doi: 10.1093/carcin/bgz171.
• [2315] Nuclear expression of the ubiquitin ligase seven in absentia homolog (SIAH)-1 induces proliferation and migration of liver cancer cells.J Hepatol. 2011 Nov;55(5):1049-57. doi: 10.1016/j.jhep.2011.02.019. Epub 2011 Feb 26.
• [2316] FUN14 Domain-Containing 1-Mediated Mitophagy Suppresses Hepatocarcinogenesis by Inhibition of Inflammasome Activation in Mice.Hepatology. 2019 Feb;69(2):604-621. doi: 10.1002/hep.30191. Epub 2019 Jan 7.
• [2317] MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood). 2013 Sep;238(9):1024-32.
• [2318] Downregulation of microRNA-15b by hepatitis B virus X enhances hepatocellular carcinoma proliferation via fucosyltransferase 2-induced Globo H expression.Int J Cancer. 2014 Apr 1;134(7):1638-47. doi: 10.1002/ijc.28501. Epub 2013 Oct 15.
• [2319] -1,3-Fucosyltransferase-VII siRNA inhibits the expression of SLex and hepatocarcinoma cell proliferation.Int J Mol Med. 2018 Nov;42(5):2700-2708. doi: 10.3892/ijmm.2018.3850. Epub 2018 Aug 31.
• [2320] Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells.PLoS One. 2016 Dec 15;11(12):e0168355. doi: 10.1371/journal.pone.0168355. eCollection 2016.
• [2321] Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells.J Hepatol. 2011 Jan;54(1):122-31. doi: 10.1016/j.jhep.2010.06.026. Epub 2010 Aug 26.
• [2322] Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma.Br J Cancer. 2008 Jul 8;99(1):143-50. doi: 10.1038/sj.bjc.6604422. Epub 2008 Jun 24.
• [2323] LncRNA ASB16-AS1 Promotes Growth And Invasion Of Hepatocellular Carcinoma Through Regulating miR-1827/FZD4 Axis And Activating Wnt/-Catenin Pathway.Cancer Manag Res. 2019 Nov 7;11:9371-9378. doi: 10.2147/CMAR.S220434. eCollection 2019.
• [2324] ERRATUM.Oncol Res. 2019 Feb 5;27(2):281-282. doi: 10.3727/096504019X15476499940873.
• [2325] Low expression of GABARAPL1 is associated with a poor outcome for patients with hepatocellular carcinoma.Oncol Rep. 2014 May;31(5):2043-8. doi: 10.3892/or.2014.3096. Epub 2014 Mar 19.
• [2326] Decreased hepatocyte membrane potential differences and GABAA-beta3 expression in human hepatocellular carcinoma.Hepatology. 2007 Mar;45(3):735-45. doi: 10.1002/hep.21562.
• [2327] Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis.Tumour Biol. 2016 May;37(5):5951-61. doi: 10.1007/s13277-015-4362-6. Epub 2015 Nov 23.
• [2328] Different gene expression of MDM2, GAGE-1, -2 and FHIT in hepatocellular carcinoma and focal nodular hyperplasia.Br J Cancer. 1999 Apr;80(1-2):73-8. doi: 10.1038/sj.bjc.6690324.
• [2329] Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling.Oncotarget. 2015 Mar 20;6(8):5650-65. doi: 10.18632/oncotarget.3117.
• [2330] Decreased expression of hepatocyte nuclear factor 4 (Hnf4)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity.J Biol Chem. 2015 Jan 9;290(2):1170-85. doi: 10.1074/jbc.M114.601203. Epub 2014 Nov 24.
• [2331] A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy.Pharmacogenomics J. 2020 Feb;20(1):57-68. doi: 10.1038/s41397-019-0106-0. Epub 2019 Oct 14.
• [2332] Growth arrest-specific gene 2 suppresses hepatocarcinogenesis by intervention of cell cycle and p53-dependent apoptosis.World J Gastroenterol. 2019 Aug 28;25(32):4715-4726. doi: 10.3748/wjg.v25.i32.4715.
• [2333] Decreased expression of GATA2 promoted proliferation, migration and invasion of HepG2 in vitro and correlated with poor prognosis of hepatocellular carcinoma.PLoS One. 2014 Jan 30;9(1):e87505. doi: 10.1371/journal.pone.0087505. eCollection 2014.
• [2334] Gel-based proteomics of liver cancer progression in rat.Biochim Biophys Acta. 2011 Oct;1814(10):1367-76. doi: 10.1016/j.bbapap.2011.05.018. Epub 2011 Jun 6.
• [2335] PIN1 genetic polymorphisms and the susceptibility of HBV-related hepatocellular carcinoma in a Guangxi population.Tumour Biol. 2016 May;37(5):6599-606. doi: 10.1007/s13277-015-4539-z. Epub 2015 Dec 7.
• [2336] The transcriptional profiling of glycogenes associated with hepatocellular carcinoma metastasis.PLoS One. 2014 Sep 18;9(9):e107941. doi: 10.1371/journal.pone.0107941. eCollection 2014.
• [2337] Role of miR-16-5p in the proliferation and metastasis of hepatocellular carcinoma.Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):137-145. doi: 10.26355/eurrev_201901_16757.
• [2338] GDF11 exhibits tumor suppressive properties in hepatocellular carcinoma cells by restricting clonal expansion and invasion.Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1540-1554. doi: 10.1016/j.bbadis.2019.03.003. Epub 2019 Mar 16.
• [2339] SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation.BMC Cancer. 2011 Jun 6;11:223. doi: 10.1186/1471-2407-11-223.
• [2340] Single nucleotide polymorphisms of microRNA processing machinery genes and outcome of hepatocellular carcinoma.PLoS One. 2014 Mar 27;9(3):e92791. doi: 10.1371/journal.pone.0092791. eCollection 2014.
• [2341] Augmenter of liver regeneration: A key protein in liver regeneration and pathophysiology.Hepatol Res. 2018 Jul;48(8):587-596. doi: 10.1111/hepr.13077. Epub 2018 May 14.
• [2342] High expression of GFAT1 predicts unfavorable prognosis in patients with hepatocellular carcinoma.Oncotarget. 2017 Mar 21;8(12):19205-19217. doi: 10.18632/oncotarget.15164.
• [2343] Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C.Hepatology. 2005 Oct;42(4):846-53. doi: 10.1002/hep.20860.
• [2344] The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches.Cancers (Basel). 2017 May 26;9(6):58. doi: 10.3390/cancers9060058.
• [2345] GGPPS1 predicts the biological character of hepatocellular carcinoma in patients with cirrhosis.BMC Cancer. 2014 Apr 9;14:248. doi: 10.1186/1471-2407-14-248.
• [2346] Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study.Hepatol Int. 2019 May;13(3):293-301. doi: 10.1007/s12072-019-09939-2. Epub 2019 Feb 28.
• [2347] Dysregulation of GTPase IMAP family members in hepatocellular cancer.Mol Med Rep. 2016 Nov;14(5):4119-4123. doi: 10.3892/mmr.2016.5764. Epub 2016 Sep 22.
• [2348] Gastrokine 1 protein is a potential theragnostic target for gastric cancer.Gastric Cancer. 2018 Nov;21(6):956-967. doi: 10.1007/s10120-018-0828-8. Epub 2018 Apr 27.
• [2349] Identification and characterization of CRG-L2, a new marker for liver tumor development.Oncogene. 2003 Mar 20;22(11):1730-6. doi: 10.1038/sj.onc.1206309.
• [2350] Upregulation of Twist is involved in Gli1 induced migration and invasion of hepatocarcinoma cells.Biol Chem. 2018 Jul 26;399(8):911-919. doi: 10.1515/hsz-2018-0131.
• [2351] Hypoxia promotes epithelial--mesenchymal transition of hepatocellular carcinoma cells via inducing GLIPR-2 expression.PLoS One. 2013 Oct 29;8(10):e77497. doi: 10.1371/journal.pone.0077497. eCollection 2013.
• [2352] The promoter analysis of the human C17orf25 gene, a novel chromosome 17p13.3 gene.Cell Res. 2002 Dec;12(5-6):339-52. doi: 10.1038/sj.cr.7290136.
• [2353] Expression of thioredoxins and glutaredoxins in human hepatocellular carcinoma: correlation to cell proliferation, tumor size and metabolic syndrome.Int J Immunopathol Pharmacol. 2014 Apr-Jun;27(2):169-83. doi: 10.1177/039463201402700204.
• [2354] Purification and characterization of l-glutaminase enzyme from camel liver: Enzymatic anticancer property.Int J Biol Macromol. 2020 May 1;150:1213-1222. doi: 10.1016/j.ijbiomac.2019.10.131. Epub 2019 Nov 16.
• [2355] Designation of enzyme activity of glycine-N-acyltransferase family genes and depression of glycine-N-acyltransferase in human hepatocellular carcinoma.Biochem Biophys Res Commun. 2012 Apr 20;420(4):901-6. doi: 10.1016/j.bbrc.2012.03.099. Epub 2012 Mar 27.
• [2356] Structure of Patt1 human proapoptotic histone acetyltransferase.J Mol Model. 2013 Dec;19(12):5533-8. doi: 10.1007/s00894-013-2043-1. Epub 2013 Nov 19.
• [2357] High expression of GNA13 is associated with poor prognosis in hepatocellular carcinoma.Sci Rep. 2016 Nov 24;6:35948. doi: 10.1038/srep35948.
• [2358] MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma.Hepatology. 2010 Mar;51(3):846-56. doi: 10.1002/hep.23443.
• [2359] Nucleostemin promotes hepatocellular carcinoma by regulating the function of STAT3.Exp Cell Res. 2020 Feb 1;387(1):111748. doi: 10.1016/j.yexcr.2019.111748. Epub 2019 Nov 27.
• [2360] Delta-like 3 is silenced by HBx via histone acetylation in HBV-associated HCCs.Sci Rep. 2018 Mar 19;8(1):4842. doi: 10.1038/s41598-018-23318-1.
• [2361] PEGylated doxorubicin nanoparticles mediated by HN-1 peptide for targeted treatment of oral squamous cell carcinoma.Int J Pharm. 2017 Jun 15;525(1):21-31. doi: 10.1016/j.ijpharm.2017.04.027. Epub 2017 Apr 12.
• [2362] SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma.Carcinogenesis. 2012 Aug;33(8):1581-8. doi: 10.1093/carcin/bgs162. Epub 2012 May 7.
• [2363] Altered epidermal fatty acid-binding protein expression in hepatocellular carcinoma predicts unfavorable outcomes.Cancer Manag Res. 2018 Nov 23;10:6275-6284. doi: 10.2147/CMAR.S181555. eCollection 2018.
• [2364] Increased expression of glycosyl-phosphatidylinositol anchor attachment protein 1 (GPAA1) is associated with gene amplification in hepatocellular carcinoma.Int J Cancer. 2006 Sep 15;119(6):1330-7. doi: 10.1002/ijc.22005.
• [2365] High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.Cancer Med. 2018 Nov;7(11):5525-5533. doi: 10.1002/cam4.1833. Epub 2018 Oct 24.
• [2366] miR-709 up-regulated in hepatocellular carcinoma, promotes proliferation and invasion by targeting GPC5.Cell Prolif. 2015 Jun;48(3):330-7. doi: 10.1111/cpr.12181. Epub 2015 Mar 27.
• [2367] Extracellular processing of proapolipoprotein A-II in Hep G2 cell cultures is mediated by a 54-kDa protease immunologically related to cathepsin B.J Biol Chem. 1985 Nov 25;260(27):14824-31.
• [2368] A low level of GPR37 is associated with human hepatocellular carcinoma progression and poor patient survival.Pathol Res Pract. 2014 Dec;210(12):885-92. doi: 10.1016/j.prp.2014.07.011. Epub 2014 Aug 9.
• [2369] Aberrant TIG1 methylation associated with its decreased expression and clinicopathological significance in hepatocellular carcinoma.Tumour Biol. 2014 Feb;35(2):967-71. doi: 10.1007/s13277-013-1129-9. Epub 2013 Sep 5.
• [2370] High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway.Tumour Biol. 2017 Mar;39(3):1010428317695971. doi: 10.1177/1010428317695971.
• [2371] GPX2 overexpression indicates poor prognosis in patients with hepatocellular carcinoma.Tumour Biol. 2017 Jun;39(6):1010428317700410. doi: 10.1177/1010428317700410.
• [2372] Methylation of promoter and expression silencing of GPX3 gene in hepatocellular carcinoma tissue.Clin Res Hepatol Gastroenterol. 2015 Apr;39(2):198-204. doi: 10.1016/j.clinre.2014.09.003. Epub 2014 Oct 13.
• [2373] GRAM domain-containing protein 1A (GRAMD1A) promotes the expansion of hepatocellular carcinoma stem cell and hepatocellular carcinoma growth through STAT5.Sci Rep. 2016 Sep 2;6:31963. doi: 10.1038/srep31963.
• [2374] Role of growth factor receptor bound protein 7 in hepatocellular carcinoma.Mol Cancer Res. 2007 Jul;5(7):667-73. doi: 10.1158/1541-7786.MCR-06-0282.
• [2375] Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation.Oncol Rep. 2010 Aug;24(2):441-8. doi: 10.3892/or_00000877.
• [2376] Changes in S-adenosylmethionine synthetase in human liver cancer: molecular characterization and significance.Hepatology. 1996 Nov;24(5):1090-7. doi: 10.1002/hep.510240519.
• [2377] The expression and regulation of DFNA5 in human hepatocellular carcinoma DFNA5 in hepatocellular carcinoma.Mol Biol Rep. 2013 Dec;40(12):6525-31. doi: 10.1007/s11033-013-2581-8. Epub 2013 Oct 24.
• [2378] Autophagy and apoptosis in hepatocellular carcinoma induced by EF25-(GSH)2: a novel curcumin analog.PLoS One. 2014 Sep 30;9(9):e107876. doi: 10.1371/journal.pone.0107876. eCollection 2014.
• [2379] General transcription factor IIb overexpression and a potential link to proliferation in human hepatocellular carcinoma.Pathol Oncol Res. 2013 Apr;19(2):195-203. doi: 10.1007/s12253-012-9569-x. Epub 2012 Oct 5.
• [2380] A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma.J Exp Med. 1999 Apr 5;189(7):1101-10. doi: 10.1084/jem.189.7.1101.
• [2381] The receptor for beta(2)GP I on membrane of hepatocellular carcinoma cell line SMMC-7721 is annexin II.World J Gastroenterol. 2007 Jun 28;13(24):3364-8. doi: 10.3748/wjg.v13.i24.3364.
• [2382] Evidence for increased somatic cell mutations in patients with hepatocellular carcinoma.Carcinogenesis. 1997 Feb;18(2):445-9. doi: 10.1093/carcin/18.2.445.
• [2383] Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?.Asian Pac J Cancer Prev. 2013;14(12):7345-9. doi: 10.7314/apjcp.2013.14.12.7345.
• [2384] A GYS2/p53 Negative Feedback Loop Restricts Tumor Growth in HBV-Related Hepatocellular Carcinoma.Cancer Res. 2019 Feb 1;79(3):534-545. doi: 10.1158/0008-5472.CAN-18-2357. Epub 2018 Dec 24.
• [2385] The expression of the histone H1 (0) gene in the human hepatoma cell line HepG2 is independent of the state of cell proliferation.Differentiation. 1990 Jun;43(3):212-9. doi: 10.1111/j.1432-0436.1990.tb00448.x.
• [2386] Anti-malarial atovaquone exhibits anti-tumor effects by inducing DNA damage in hepatocellular carcinoma.Am J Cancer Res. 2018 Sep 1;8(9):1697-1711. eCollection 2018.
• [2387] H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma.Int J Oncol. 2018 Apr;52(4):1235-1245. doi: 10.3892/ijo.2018.4292. Epub 2018 Feb 28.
• [2388] Long noncoding RNA DLGAP1-AS1 promotes cell proliferation in hepatocellular carcinoma via sequestering miR-486-5p.J Cell Biochem. 2020 Feb;121(2):1953-1962. doi: 10.1002/jcb.29430. Epub 2019 Oct 21.
• [2389] LncRNA NEAT1 Promotes Deterioration of Hepatocellular Carcinoma Based on In Vitro Experiments, Data Mining, and RT-qPCR Analysis.Cell Physiol Biochem. 2018;48(2):540-555. doi: 10.1159/000491811. Epub 2018 Jul 18.
• [2390] De novo HAPLN1 expression hallmarks Wnt-induced stem cell and fibrogenic networks leading to aggressive human hepatocellular carcinomas.Oncotarget. 2016 Jun 28;7(26):39026-39043. doi: 10.18632/oncotarget.9346.
• [2391] Hyaluronan histochemistry-a potential new tool to assess the progress of liver disease from simple steatosis to hepatocellular carcinoma.Glycobiology. 2019 Apr 1;29(4):298-306. doi: 10.1093/glycob/cwz002.
• [2392] High Expression of Human AugminComplex Submit 3 Indicates Poor Prognosis and Associates with Tumor Progression in Hepatocellular Carcinoma.J Cancer. 2019 Feb 23;10(6):1434-1443. doi: 10.7150/jca.28317. eCollection 2019.
• [2393] Tim-3 Hampers Tumor Surveillance of Liver-Resident and Conventional NK Cells by Disrupting PI3K Signaling.Cancer Res. 2020 Mar 1;80(5):1130-1142. doi: 10.1158/0008-5472.CAN-19-2332. Epub 2019 Dec 17.
• [2394] The role of c-Jun phosphorylation in EpRE activation of phase II genes.Free Radic Biol Med. 2009 Oct 15;47(8):1172-9. doi: 10.1016/j.freeradbiomed.2009.07.036. Epub 2009 Aug 7.
• [2395] Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma.Sci Rep. 2017 Sep 19;7(1):11912. doi: 10.1038/s41598-017-10363-5.
• [2396] HDGF-related protein-2 (HRP-2) acts as an oncogene to promote cell growth in hepatocellular carcinoma.Biochem Biophys Res Commun. 2015 Mar 20;458(4):849-55. doi: 10.1016/j.bbrc.2015.02.042. Epub 2015 Feb 14.
• [2397] The Human Homolog of Drosophila Headcase Acts as a Tumor Suppressor through Its Blocking Effect on the Cell Cycle in Hepatocellular Carcinoma.PLoS One. 2015 Sep 10;10(9):e0137579. doi: 10.1371/journal.pone.0137579. eCollection 2015.
• [2398] lncRNA DRHC inhibits proliferation and invasion in hepatocellular carcinoma via c-Myb-regulated MEK/ERK signaling.Mol Carcinog. 2019 Mar;58(3):366-375. doi: 10.1002/mc.22934. Epub 2018 Nov 25.
• [2399] Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells.Carcinogenesis. 2008 Dec;29(12):2298-305. doi: 10.1093/carcin/bgn226. Epub 2008 Oct 8.
• [2400] HZ-6d targeted HERC5 to regulate p53 ISGylation in human hepatocellular carcinoma.Toxicol Appl Pharmacol. 2017 Nov 1;334:180-191. doi: 10.1016/j.taap.2017.09.011. Epub 2017 Sep 15.
• [2401] HES5 promotes cell proliferation and invasion through activation of STAT3 and predicts poor survival in hepatocellular carcinoma.Exp Mol Pathol. 2015 Dec;99(3):474-84. doi: 10.1016/j.yexmp.2015.09.002. Epub 2015 Sep 3.
• [2402] LncSHRG promotes hepatocellular carcinoma progression by activating HES6.Oncotarget. 2017 Aug 3;8(41):70630-70641. doi: 10.18632/oncotarget.19906. eCollection 2017 Sep 19.
• [2403] Phase angle as a severity indicator for liver diseases.Nutrition. 2020 Feb;70:110607. doi: 10.1016/j.nut.2019.110607. Epub 2019 Oct 11.
• [2404] A novel long noncoding RNA HHIP-AS1 suppresses hepatocellular carcinoma progression through stabilizing HHIP mRNA.Biochem Biophys Res Commun. 2019 Dec 3;520(2):333-340. doi: 10.1016/j.bbrc.2019.09.137. Epub 2019 Oct 8.
• [2405] Tumour necrosis factor- suppresses the hypoxic response by NF-B-dependent induction of inhibitory PAS domain protein in PC12 cells.J Biochem. 2011 Sep;150(3):311-8. doi: 10.1093/jb/mvr061. Epub 2011 May 10.
• [2406] Clinical significance of down-regulated HINT2 in hepatocellular carcinoma.Medicine (Baltimore). 2019 Nov;98(48):e17815. doi: 10.1097/MD.0000000000017815.
• [2407] Hedgehog signaling in human hepatocellular carcinoma.Cancer Biol Ther. 2006 Jan;5(1):111-7. doi: 10.4161/cbt.5.1.2379. Epub 2006 Jan 5.
• [2408] HJURP Promotes Epithelial-to-Mesenchymal Transition via Upregulating SPHK1 in Hepatocellular Carcinoma.Int J Biol Sci. 2019 May 7;15(6):1139-1147. doi: 10.7150/ijbs.30904. eCollection 2019.
• [2409] Association of cytotoxic T-lymphocyte antigen-4 + 49A/G gene polymorphism with hepatocellular carcinoma risk in Chinese.J Cancer Res Ther. 2018 Dec;14(Supplement):S1117-S1120. doi: 10.4103/0973-1482.203604.
• [2410] Diagnostic and prognostic biomarkers of Human Leukocyte Antigen complex for hepatitis B virus-related hepatocellular carcinoma.J Cancer. 2019 Aug 28;10(21):5173-5190. doi: 10.7150/jca.29655. eCollection 2019.
• [2411] TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients.BMC Cancer. 2012 Mar 8;12:85. doi: 10.1186/1471-2407-12-85.
• [2412] Human Leukocyte Antigen F Locus Adjacent Transcript 10 Overexpression Disturbs WISP1 Protein and mRNA Expression to Promote Hepatocellular Carcinoma Progression.Hepatology. 2018 Dec;68(6):2268-2284. doi: 10.1002/hep.30105. Epub 2018 Nov 8.
• [2413] Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.Oncol Rep. 2018 Feb;39(2):843-850. doi: 10.3892/or.2017.6153. Epub 2017 Dec 13.
• [2414] Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma.J Gastroenterol. 2013 Jan;48(1):132-43. doi: 10.1007/s00535-012-0621-0. Epub 2012 Jul 6.
• [2415] H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.Tumour Biol. 2016 May;37(5):6419-28. doi: 10.1007/s13277-015-4490-z. Epub 2015 Dec 2.
• [2416] Abnormal expression of HMGB-3 is significantly associated with malignant transformation of hepatocytes.World J Gastroenterol. 2018 Aug 28;24(32):3650-3662. doi: 10.3748/wjg.v24.i32.3650.
• [2417] Identification of novel biomarkers for hepatocellular carcinoma using transcriptome analysis.J Cell Physiol. 2019 Apr;234(4):4851-4863. doi: 10.1002/jcp.27283. Epub 2018 Sep 11.
• [2418] Hepatitis B Virus X Protein Induces RHAMM-Dependent Motility in Hepatocellular Carcinoma Cells via PI3K-Akt-Oct-1 Signaling.Mol Cancer Res. 2020 Mar;18(3):375-389. doi: 10.1158/1541-7786.MCR-19-0463. Epub 2019 Dec 2.
• [2419] Acetylation drives hepatocyte nuclear factor 1 stability by blocking proteasome-mediated degradation.J Cell Biochem. 2019 Jun;120(6):9337-9344. doi: 10.1002/jcb.28209. Epub 2018 Dec 7.
• [2420] Long noncoding RNA NEAT1 promotes cell proliferation and invasion by regulating hnRNP A2 expression in hepatocellular carcinoma cells.Onco Targets Ther. 2017 Feb 20;10:1003-1016. doi: 10.2147/OTT.S116319. eCollection 2017.
• [2421] Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma.Clin Chem Lab Med. 2018 Feb 23;56(3):479-484. doi: 10.1515/cclm-2017-0327.
• [2422] Long Noncoding RNA p53-Stabilizing and Activating RNA Promotes p53 Signaling by Inhibiting Heterogeneous Nuclear Ribonucleoprotein K deSUMOylation and Suppresses Hepatocellular Carcinoma.Hepatology. 2020 Jan;71(1):112-129. doi: 10.1002/hep.30793. Epub 2019 Aug 12.
• [2423] Hook1 inhibits malignancy and epithelial-mesenchymal transition in hepatocellular carcinoma.Tumour Biol. 2017 Jul;39(7):1010428317711098. doi: 10.1177/1010428317711098.
• [2424] MicroRNA?77 inhibits the migration and invasion of hepatocellular carcinoma cells by targeting homeobox A1.Oncol Rep. 2018 Jun;39(6):2987-2995. doi: 10.3892/or.2018.6388. Epub 2018 Apr 23.
• [2425] HoxA10 Facilitates SHP-1-Catalyzed Dephosphorylation of p38 MAPK/STAT3 To Repress Hepatitis B Virus Replication by a Feedback Regulatory Mechanism.J Virol. 2019 Mar 21;93(7):e01607-18. doi: 10.1128/JVI.01607-18. Print 2019 Apr 1.
• [2426] The let-7c/HoxB7 axis regulates the cell proliferation, migration and apoptosis in hepatocellular carcinoma.Anticancer Drugs. 2020 Jan;31(1):6-18. doi: 10.1097/CAD.0000000000000843.
• [2427] GRP78 activates the Wnt/HOXB9 pathway to promote invasion and metastasis of hepatocellular carcinoma by chaperoning LRP6.Exp Cell Res. 2019 Oct 1;383(1):111493. doi: 10.1016/j.yexcr.2019.07.006. Epub 2019 Jul 13.
• [2428] Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.Dig Dis Sci. 2015 Nov;60(11):3351-63. doi: 10.1007/s10620-015-3774-x. Epub 2015 Jun 30.
• [2429] Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma.Clin Epigenetics. 2017 Oct 23;9:116. doi: 10.1186/s13148-017-0412-9. eCollection 2017.
• [2430] The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.Cancer Immunol Immunother. 2019 Mar;68(3):353-363. doi: 10.1007/s00262-018-2271-4. Epub 2018 Dec 1.
• [2431] HOXD3 targeted by miR-203a suppresses cell metastasis and angiogenesis through VEGFR in human hepatocellular carcinoma cells.Sci Rep. 2018 Feb 5;8(1):2431. doi: 10.1038/s41598-018-20859-3.
• [2432] MiR-5692a promotes proliferation and inhibits apoptosis by targeting HOXD8 in hepatocellular carcinoma.J BUON. 2019 Jan-Feb;24(1):178-186.
• [2433] Ruthenium Complexes Induce HepG2 Human Hepatocellular Carcinoma Cell Apoptosis and Inhibit Cell Migration and Invasion through Regulation of the Nrf2 Pathway.Int J Mol Sci. 2016 May 19;17(5):775. doi: 10.3390/ijms17050775.
• [2434] Heme-hemopexin-mediated induction of metallothionein gene expression.J Biol Chem. 1992 Aug 15;267(23):16379-84.
• [2435] Histidine-rich glycoprotein function in hepatocellular carcinoma depends on its N-glycosylation status, and it regulates cell proliferation by inhibiting Erk1/2 phosphorylation.Oncotarget. 2015 Oct 6;6(30):30222-31. doi: 10.18632/oncotarget.4997.
• [2436] HSF2 regulates aerobic glycolysis by suppression of FBP1 in hepatocellular carcinoma.Am J Cancer Res. 2019 Aug 1;9(8):1607-1621. eCollection 2019.
• [2437] Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma.Int J Med Sci. 2015 Feb 15;12(3):256-63. doi: 10.7150/ijms.10735. eCollection 2015.
• [2438] Meta-analysis of gene expression profiles indicates genes in spliceosome pathway are up-regulated in hepatocellular carcinoma (HCC).Med Oncol. 2015 Apr;32(4):96. doi: 10.1007/s12032-014-0425-6. Epub 2015 Mar 3.
• [2439] Genetic variants of heat shock protein A1L2437 and A1B1267 as possible risk factors for hepatocellular carcinoma in India.J Viral Hepat. 2013 Apr;20(4):e141-7. doi: 10.1111/jvh.12021. Epub 2012 Nov 20.
• [2440] Expression of HSPA2 in human hepatocellular carcinoma and its clinical significance.Tumour Biol. 2014 Nov;35(11):11283-7. doi: 10.1007/s13277-014-2430-y. Epub 2014 Aug 13.
• [2441] The Molecular Chaperone Heat Shock Protein 70 Controls Liver Cancer Initiation and Progression by Regulating Adaptive DNA Damage and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling Pathways.Mol Cell Biol. 2019 Apr 16;39(9):e00391-18. doi: 10.1128/MCB.00391-18. Print 2019 May 1.
• [2442] VEGF Overexpression Predicts Poor Survival in Hepatocellular Carcinoma.Open Med (Wars). 2017 Dec 9;12:430-439. doi: 10.1515/med-2017-0061. eCollection 2017.
• [2443] Apg-2 has a chaperone-like activity similar to Hsp110 and is overexpressed in hepatocellular carcinomas.FEBS Lett. 2004 Feb 27;560(1-3):19-24. doi: 10.1016/S0014-5793(04)00034-1.
• [2444] Transforming genes in human hepatomas detected by a tumorigenicity assay.Jpn J Cancer Res. 1987 Oct;78(10):1036-40.
• [2445] The expression of HtrA2 and its diagnostic value in patients with hepatocellular carcinoma.Medicine (Baltimore). 2018 Apr;97(14):e0128. doi: 10.1097/MD.0000000000010128.
• [2446] HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma.Mol Carcinog. 2019 Jan;58(1):76-87. doi: 10.1002/mc.22908. Epub 2018 Sep 19.
• [2447] Upregulated expression of miR-106a by DNA hypomethylation plays an oncogenic role in hepatocellular carcinoma.Tumour Biol. 2015 Apr;36(4):3093-100. doi: 10.1007/s13277-014-2945-2. Epub 2014 Dec 16.
• [2448] NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.Cell Death Dis. 2016 Jun 23;7(6):e2269. doi: 10.1038/cddis.2016.175.
• [2449] IFI16 restoration in hepatocellular carcinoma induces tumour inhibition via activation of p53 signals and inflammasome.Cell Prolif. 2017 Dec;50(6):e12392. doi: 10.1111/cpr.12392. Epub 2017 Oct 8.
• [2450] Interferon-induced transmembrane protein-3 rs12252-CC is associated with low differentiation and progression of hepatocellular carcinoma.Medicine (Baltimore). 2019 Jan;98(2):e13996. doi: 10.1097/MD.0000000000013996.
• [2451] RHPN1-AS1 Drives the Progression of Hepatocellular Carcinoma via Regulating miR-596/IGF2BP2 Axis.Curr Pharm Des. 2020;25(43):4630-4640. doi: 10.2174/1381612825666191105104549.
• [2452] Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas.Cancer Sci. 2005 Aug;96(8):498-506. doi: 10.1111/j.1349-7006.2005.00073.x.
• [2453] Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells.Biochimie. 2015 May;112:85-95. doi: 10.1016/j.biochi.2015.02.015. Epub 2015 Mar 3.
• [2454] Tumor-suppressing effect of miR-4458 on human hepatocellular carcinoma.Cell Physiol Biochem. 2015;35(5):1797-807. doi: 10.1159/000373991. Epub 2015 Mar 26.
• [2455] Non-CSCs nourish CSCs through interleukin-17E-mediated activation of NF-B and JAK/STAT3 signaling in human hepatocellular carcinoma.Cancer Lett. 2016 Jun 1;375(2):390-399. doi: 10.1016/j.canlet.2016.03.012. Epub 2016 Mar 18.
• [2456] Expression of IL-26 predicts prognosis of patients with hepatocellular carcinoma after surgical resection.Hepatobiliary Pancreat Dis Int. 2019 Jun;18(3):242-248. doi: 10.1016/j.hbpd.2019.03.006. Epub 2019 Mar 27.
• [2457] The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by -PD-L1 or -IL6 antibodies.J Leukoc Biol. 2018 Nov;104(5):969-985. doi: 10.1002/JLB.MA1217-495R. Epub 2018 Jul 24.
• [2458] High expression of IL-9R promotes the progression of human hepatocellular carcinoma and indicates a poor clinical outcome.Oncol Rep. 2015 Aug;34(2):795-802. doi: 10.3892/or.2015.4060. Epub 2015 Jun 15.
• [2459] LncRNA LINC00470 promotes proliferation through association with NF45/NF90 complex in hepatocellular carcinoma.Hum Cell. 2020 Jan;33(1):131-139. doi: 10.1007/s13577-019-00288-8. Epub 2019 Oct 14.
• [2460] IGF2 mRNA Binding Protein 2 Transgenic Mice Are More Prone to Develop a Ductular Reaction and to Progress Toward Cirrhosis.Front Med (Lausanne). 2019 Sep 4;6:179. doi: 10.3389/fmed.2019.00179. eCollection 2019.
• [2461] Analysis of loss of heterozygosity on chromosome 4q in hepatocellular carcinoma using high-throughput SNP array.Oncol Rep. 2010 Feb;23(2):445-55.
• [2462] ING4 suppresses hepatocellular carcinoma via a NF-B/miR-155/FOXO3a signaling axis.Int J Biol Sci. 2019 Jan 1;15(2):369-385. doi: 10.7150/ijbs.28422. eCollection 2019.
• [2463] Expression pattern and level of ING5 protein in normal and cancer tissues.Oncol Lett. 2019 Jan;17(1):63-68. doi: 10.3892/ol.2018.9581. Epub 2018 Oct 16.
• [2464] Inhibin/activin expression in human and rodent liver: subunits and B as new players in human hepatocellular carcinoma?.Br J Cancer. 2011 Apr 12;104(8):1303-12. doi: 10.1038/bjc.2011.53. Epub 2011 Mar 15.
• [2465] INPP4B inhibits cell proliferation, invasion and chemoresistance in human hepatocellular carcinoma.Onco Targets Ther. 2019 May 7;12:3491-3507. doi: 10.2147/OTT.S196832. eCollection 2019.
• [2466] High SKIP expression is correlated with poor prognosis and cell proliferation of hepatocellular carcinoma.Med Oncol. 2013;30(3):537. doi: 10.1007/s12032-013-0537-4. Epub 2013 May 22.
• [2467] Downregulation of SHIP2 by Hepatitis B Virus X Promotes the Metastasis and Chemoresistance of Hepatocellular Carcinoma through SKP2.Cancers (Basel). 2019 Jul 27;11(8):1065. doi: 10.3390/cancers11081065.
• [2468] Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma.Cancer Res. 1994 Jun 15;54(12):3107-10.
• [2469] CREB3L4, INTS3, and SNAPAP are targets for the 1q21 amplicon frequently detected in hepatocellular carcinoma.Cancer Genet Cytogenet. 2008 Jan 1;180(1):30-6. doi: 10.1016/j.cancergencyto.2007.09.013.
• [2470] Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker.BMC Cancer. 2017 Sep 12;17(1):644. doi: 10.1186/s12885-017-3628-3.
• [2471] INTS8 accelerates the epithelial-to-mesenchymal transition in hepatocellular carcinoma by upregulating the TGF- signaling pathway.Cancer Manag Res. 2019 Feb 26;11:1869-1879. doi: 10.2147/CMAR.S184392. eCollection 2019.
• [2472] IQGAP1 gene silencing induces apoptosis and decreases the invasive capacity of human hepatocellular carcinoma cells.Tumour Biol. 2016 Oct;37(10):13927-13939. doi: 10.1007/s13277-016-5283-8. Epub 2016 Aug 3.
• [2473] Differential expression of IQGAP1/2 in Hepatocellular carcinoma and its relationship with clinical outcomes.Asian Pac J Cancer Prev. 2014;15(12):4951-6. doi: 10.7314/apjcp.2014.15.12.4951.
• [2474] E2F1 transactivates IQGAP3 and promotes proliferation of hepatocellular carcinoma cells through IQGAP3-mediated PKC-alpha activation.Am J Cancer Res. 2019 Feb 1;9(2):285-299. eCollection 2019.
• [2475] GEP100/Arf6 is required for epidermal growth factor-induced ERK/Rac1 signaling and cell migration in human hepatoma HepG2 cells.PLoS One. 2012;7(6):e38777. doi: 10.1371/journal.pone.0038777. Epub 2012 Jun 11.
• [2476] The Reciprocal Interaction Between LncRNA CCAT1 and miR-375-3p Contribute to the Downregulation of IRF5 Gene Expression by Solasonine in HepG2 Human Hepatocellular Carcinoma Cells.Front Oncol. 2019 Oct 18;9:1081. doi: 10.3389/fonc.2019.01081. eCollection 2019.
• [2477] In vitro studies of water-stable cationic carbosilane dendrimers as delivery vehicles for gene therapy against HIV and hepatocarcinoma.Curr Med Chem. 2012;19(29):5052-61. doi: 10.2174/0929867311209025052.
• [2478] Downregulation of miR-377 contributes to IRX3 deregulation in hepatocellular carcinoma.Oncol Rep. 2016 Jul;36(1):247-52. doi: 10.3892/or.2016.4815. Epub 2016 May 18.
• [2479] Aryl hydrocarbon receptor promotes hepatocellular carcinoma tumorigenesis by targeting intestine-specific homeobox expression.Mol Carcinog. 2017 Oct;56(10):2167-2177. doi: 10.1002/mc.22658. Epub 2017 Jul 28.
• [2480] FAS promoter polymorphisms correlate with activity grade in hepatitis C patients.Eur J Gastroenterol Hepatol. 2005 Oct;17(10):1081-8. doi: 10.1097/00042737-200510000-00012.
• [2481] Changes in adhesive and migratory characteristics of hepatocellular carcinoma (HCC) cells induced by expression of alpha3beta1 integrin.Biochim Biophys Acta. 2008 Mar;1780(3):564-70. doi: 10.1016/j.bbagen.2007.09.007. Epub 2007 Sep 25.
• [2482] Integrin 4 promotes cell invasion and epithelial-mesenchymal transition through the modulation of Slug expression in hepatocellular carcinoma.Sci Rep. 2017 Jan 13;7:40464. doi: 10.1038/srep40464.
• [2483] Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.BMC Cancer. 2019 Jun 25;19(1):621. doi: 10.1186/s12885-019-5825-8.
• [2484] High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.Gastroenterology. 2019 Dec;157(6):1518-1529.e3. doi: 10.1053/j.gastro.2019.08.028. Epub 2019 Aug 27.
• [2485] The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus.J Gastroenterol. 2016 Apr;51(4):370-9. doi: 10.1007/s00535-015-1116-6. Epub 2015 Sep 3.
• [2486] miR-501 acts as an independent prognostic factor that promotes the epithelial-mesenchymal transition through targeting JDP2 in hepatocellular carcinoma.Hum Cell. 2019 Jul;32(3):343-351. doi: 10.1007/s13577-019-00243-7. Epub 2019 Mar 15.
• [2487] JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4.Int J Cancer. 2019 May 15;144(10):2489-2500. doi: 10.1002/ijc.31816. Epub 2018 Oct 31.
• [2488] Increased expression of hematological and neurological expressed 1 (HN1) is associated with a poor prognosis of hepatocellular carcinoma and its knockdown inhibits cell growth and migration partly by down-regulation of c-Met.Kaohsiung J Med Sci. 2020 Mar;36(3):196-205. doi: 10.1002/kjm2.12156. Epub 2019 Nov 20.
• [2489] HBsAg inhibits the translocation of JTB into mitochondria in HepG2 cells and potentially plays a role in HCC progression.PLoS One. 2012;7(5):e36914. doi: 10.1371/journal.pone.0036914. Epub 2012 May 15.
• [2490] Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes.Hepatology. 2020 Jan;71(1):275-290. doi: 10.1002/hep.30807. Epub 2019 Aug 11.
• [2491] miR-639 Expression Is Silenced by DNMT3A-Mediated Hypermethylation and Functions as a Tumor Suppressor in Liver Cancer Cells.Mol Ther. 2020 Feb 5;28(2):587-598. doi: 10.1016/j.ymthe.2019.11.021. Epub 2019 Nov 28.
• [2492] Genetic and expression analysis of the KCNRG gene in hepatocellular carcinomas.Exp Mol Med. 2006 Jun 30;38(3):247-55. doi: 10.1038/emm.2006.30.
• [2493] KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling.Oncotarget. 2017 Jun 6;8(23):37717-37729. doi: 10.18632/oncotarget.17145.
• [2494] Plasma membrane gp96 enhances invasion and metastatic potential of liver cancer via regulation of uPAR.Mol Oncol. 2015 Aug;9(7):1312-23. doi: 10.1016/j.molonc.2015.03.004. Epub 2015 Mar 24.
• [2495] Histone demethylase KDM3B regulates the transcriptional network of cell-cycle genes in hepatocarcinoma HepG2 cells.Biochem Biophys Res Commun. 2019 Jan 8;508(2):576-582. doi: 10.1016/j.bbrc.2018.11.179. Epub 2018 Dec 1.
• [2496] Aberrant KIF20A expression might independently predict poor overall survival and recurrence-free survival of hepatocellular carcinoma.IUBMB Life. 2018 Apr;70(4):328-335. doi: 10.1002/iub.1726. Epub 2018 Mar 2.
• [2497] Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.Mol Cancer Ther. 2009 Nov;8(11):3001-8. doi: 10.1158/1535-7163.MCT-09-0556. Epub 2009 Nov 3.
• [2498] KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.Oncogene. 2019 Jan;38(3):406-420. doi: 10.1038/s41388-018-0440-8. Epub 2018 Aug 16.
• [2499] Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.PLoS One. 2015 Feb 20;10(2):e0117420. doi: 10.1371/journal.pone.0117420. eCollection 2015.
• [2500] KIR and HLA loci are associated with hepatocellular carcinoma development in patients with hepatitis B virus infection: a case-control study.PLoS One. 2011;6(10):e25682. doi: 10.1371/journal.pone.0025682. Epub 2011 Oct 5.
• [2501] Klotho: a tumor suppressor and modulator of the Wnt/-catenin pathway in human hepatocellular carcinoma.Lab Invest. 2016 Feb;96(2):197-205. doi: 10.1038/labinvest.2015.86. Epub 2015 Aug 3.
• [2502] Transactivation of the TIEG1 confers growth inhibition of transforming growth factor--susceptible hepatocellular carcinoma cells.World J Gastroenterol. 2012 May 7;18(17):2035-42. doi: 10.3748/wjg.v18.i17.2035.
• [2503] Krppel-like factors in hepatocellular carcinoma.Tumour Biol. 2015 Feb;36(2):533-41. doi: 10.1007/s13277-015-3127-6. Epub 2015 Feb 6.
• [2504] Krppel-like factor 2 inhibits hepatocarcinogenesis through negative regulation of the Hedgehog pathway.Cancer Sci. 2019 Apr;110(4):1220-1231. doi: 10.1111/cas.13961. Epub 2019 Mar 4.
• [2505] Krppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury.Sci Rep. 2017 Aug 14;7(1):8119. doi: 10.1038/s41598-017-08680-w.
• [2506] Krppel-like factor 8 regulates VEGFA expression and angiogenesis in hepatocellular carcinoma.Sci Rep. 2018 Nov 27;8(1):17415. doi: 10.1038/s41598-018-35786-6.
• [2507] HRAS, EGFR, MET, and RON Genes Are Recurrently Activated by Provirus Insertion in Liver Tumors Induced by the Retrovirus Myeloblastosis-Associated Virus 2.J Virol. 2017 Sep 27;91(20):e00467-17. doi: 10.1128/JVI.00467-17. Print 2017 Oct 15.
• [2508] Genome-wide analysis of DNA methylation identifies novel cancer-related genes in hepatocellular carcinoma.Tumour Biol. 2012 Oct;33(5):1307-17. doi: 10.1007/s13277-012-0378-3. Epub 2012 Mar 29.
• [2509] NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.Cell Mol Immunol. 2015 May;12(3):292-302. doi: 10.1038/cmi.2014.91. Epub 2014 Oct 13.
• [2510] Resolvin D1 attenuates liver ischaemia/reperfusion injury through modulating thioredoxin 2-mediated mitochondrial quality control.Br J Pharmacol. 2018 Jun;175(12):2441-2453. doi: 10.1111/bph.14212. Epub 2018 May 2.
• [2511] Identification of HBV-MLL4 Integration and Its Molecular Basis in Chinese Hepatocellular Carcinoma.PLoS One. 2015 Apr 22;10(4):e0123175. doi: 10.1371/journal.pone.0123175. eCollection 2015.
• [2512] Upregulated KPNA2 promotes hepatocellular carcinoma progression and indicates prognostic significance across human cancer types.Acta Biochim Biophys Sin (Shanghai). 2019 Mar 1;51(3):285-292. doi: 10.1093/abbs/gmz003.
• [2513] KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition.J Cancer. 2019 Jun 24;10(17):3914-3925. doi: 10.7150/jca.31448. eCollection 2019.
• [2514] Screening and identification of the tumor-associated antigen CK10, a novel potential liver cancer marker.FEBS Open Bio. 2017 Mar 21;7(5):627-635. doi: 10.1002/2211-5463.12122. eCollection 2017 May.
• [2515] High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype.Transl Oncol. 2019 Feb;12(2):256-268. doi: 10.1016/j.tranon.2018.10.010. Epub 2018 Nov 12.
• [2516] Reversion of tumor hepatocytes to normal hepatocytes during liver tumor regression in an oncogene-expressing transgenic zebrafish model.Dis Model Mech. 2019 Oct 17;12(10):dmm039578. doi: 10.1242/dmm.039578.
• [2517] Mucin-producing hepatocellular carcinoma without morphological features of biliary differentiation: A case report.Medicine (Baltimore). 2018 Sep;97(36):e12159. doi: 10.1097/MD.0000000000012159.
• [2518] Multiple variants and a differential splicing pattern of kinectin in human hepatocellular carcinoma.Biochem Cell Biol. 2004 Apr;82(2):321-7. doi: 10.1139/o04-003.
• [2519] Diverse modes of genomic alteration in hepatocellular carcinoma.Genome Biol. 2014 Aug 26;15(8):436. doi: 10.1186/s13059-014-0436-9.
• [2520] LAMA4, highly expressed in human hepatocellular carcinoma from Chinese patients, is a novel marker of tumor invasion and metastasis.J Cancer Res Clin Oncol. 2008 Jun;134(6):705-14. doi: 10.1007/s00432-007-0342-6. Epub 2007 Dec 14.
• [2521] Laminin alpha 5 mediates ectopic adhesion of hepatocellular carcinoma through integrins and/or Lutheran/basal cell adhesion molecule.Exp Cell Res. 2008 Aug 15;314(14):2579-90. doi: 10.1016/j.yexcr.2008.05.021. Epub 2008 Jun 7.
• [2522] The PDGFR-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma.Oncogene. 2017 Nov 23;36(47):6605-6616. doi: 10.1038/onc.2017.260. Epub 2017 Aug 7.
• [2523] Lamc1 promotes the Warburg effect in hepatocellular carcinoma cells by regulating PKM2 expression through AKT pathway.Cancer Biol Ther. 2019;20(5):711-719. doi: 10.1080/15384047.2018.1564558. Epub 2019 Feb 12.
• [2524] Corosolic Acid Induces Non-Apoptotic Cell Death through Generation of Lipid Reactive Oxygen Species Production in Human Renal Carcinoma Caki Cells.Int J Mol Sci. 2018 Apr 27;19(5):1309. doi: 10.3390/ijms19051309.
• [2525] miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma.Cell Death Dis. 2019 Jan 18;10(2):48. doi: 10.1038/s41419-018-1281-7.
• [2526] Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.Curr Cancer Drug Targets. 2015;15(3):196-204. doi: 10.2174/1568009615666150212112753.
• [2527] Cytotoxic effect of a replication-incompetent adenoviral vector with cytosine deaminase gene driven by L-plastin promoter in hepatocellular carcinoma cells.Arch Pharm Res. 2007 Jun;30(6):770-7. doi: 10.1007/BF02977641.
• [2528] Decreased lactate dehydrogenase B expression enhances claudin 1-mediated hepatoma cell invasiveness via mitochondrial defects.Exp Cell Res. 2011 May 1;317(8):1108-18. doi: 10.1016/j.yexcr.2011.02.011. Epub 2011 Feb 26.
• [2529] Lymphoid enhancer-binding factor-1 promotes stemness and poor differentiation of hepatocellular carcinoma by directly activating the NOTCH pathway.Oncogene. 2019 May;38(21):4061-4074. doi: 10.1038/s41388-019-0704-y. Epub 2019 Jan 29.
• [2530] Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.PLoS One. 2016 Aug 5;11(8):e0160822. doi: 10.1371/journal.pone.0160822. eCollection 2016.
• [2531] Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis.J Infect Dis. 2020 Feb 3;221(4):589-597. doi: 10.1093/infdis/jiz496.
• [2532] Galectin-4 serves as a prognostic biomarker for the early recurrence / metastasis of hepatocellular carcinoma.Cancer Sci. 2014 Nov;105(11):1510-7. doi: 10.1111/cas.12536. Epub 2014 Oct 27.
• [2533] Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.Cancer Immunol Immunother. 2019 Dec;68(12):2055-2066. doi: 10.1007/s00262-019-02427-4. Epub 2019 Nov 13.
• [2534] Clinical value of LHPP-associated microRNAs combined with protein induced by vitamin K deficiency or antagonist-II in the diagnosis of alpha-fetoprotein-negative hepatocellular carcinoma.J Clin Lab Anal. 2020 Feb;34(2):e23071. doi: 10.1002/jcla.23071. Epub 2019 Nov 6.
• [2535] Characterisation of the DNA repair enzyme for O(6)-methylguanine in cirrhosis.J Hepatol. 1996 Aug;25(2):158-65. doi: 10.1016/s0168-8278(96)80068-7.
• [2536] Aberrant splicing of Hugl-1 is associated with hepatocellular carcinoma progression.Clin Cancer Res. 2009 May 15;15(10):3287-96. doi: 10.1158/1078-0432.CCR-08-2078. Epub 2009 May 15.
• [2537] Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma.Oncogene. 2012 May 24;31(21):2640-52. doi: 10.1038/onc.2011.440. Epub 2011 Sep 26.
• [2538] Analysis of Lamin B1, Vimentin and Anti-Ku86 as Prospective Biomarkers of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Infection.Cell Physiol Biochem. 2019;52(3):595-605. doi: 10.33594/000000042.
• [2539] miR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2.Oncol Res. 2020 Feb 7;28(1):41-49. doi: 10.3727/096504019X15615433287579. Epub 2019 Sep 26.
• [2540] Silencing of lemur tyrosine kinase 2 restricts the proliferation and invasion of hepatocellular carcinoma through modulation of GSK-3/Wnt/-catenin signaling.Biochem Biophys Res Commun. 2019 Oct 1;517(4):722-728. doi: 10.1016/j.bbrc.2019.07.122. Epub 2019 Aug 5.
• [2541] PDZRN4 acts as a suppressor of cell proliferation in human liver cancer cell lines.Cell Biochem Funct. 2015 Oct;33(7):443-9. doi: 10.1002/cbf.3130. Epub 2015 Oct 20.
• [2542] Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression.J Hepatol. 2013 Aug;59(2):292-9. doi: 10.1016/j.jhep.2013.02.030. Epub 2013 Apr 6.
• [2543] Regulation of -catenin transcription activity by leupaxin in hepatocellular carcinoma.Tumour Biol. 2016 Feb;37(2):2313-20. doi: 10.1007/s13277-015-4060-4. Epub 2015 Sep 11.
• [2544] Long non-coding RNA LINC00461/miR-149-5p/LRIG2 axis regulates hepatocellular carcinoma progression.Biochem Biophys Res Commun. 2019 Apr 30;512(2):176-181. doi: 10.1016/j.bbrc.2019.03.049. Epub 2019 Mar 14.
• [2545] Immunohistochemical detection of ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma.Am J Gastroenterol. 1987 Jun;82(6):512-8.
• [2546] Leucine-rich protein 130 contributes to apoptosis resistance of human hepatocarcinoma cells.Int J Oncol. 2011 Jan;38(1):169-78.
• [2547] Knockdown of GCF2/LRRFIP1 by RNAi causes cell growth inhibition and increased apoptosis in human hepatoma HepG2 cells.Asian Pac J Cancer Prev. 2014;15(6):2753-8. doi: 10.7314/apjcp.2014.15.6.2753.
• [2548] Leucine-rich repeat and sterile alpha motif containing 1 promotes the oncogenic growth of human hepatocellular carcinoma cells.Cancer Cell Int. 2019 Oct 3;19:255. doi: 10.1186/s12935-019-0976-x. eCollection 2019.
• [2549] Lymphocyte-Specific Protein-1 Controls Sorafenib Sensitivity and Hepatocellular Proliferation through Extracellular Signal-Regulated Kinase1/2 Activation.Am J Pathol. 2018 Sep;188(9):2074-2086. doi: 10.1016/j.ajpath.2018.06.005. Epub 2018 Jul 3.
• [2550] Expression and clinical significance of latent-transforming growth factor beta-binding protein 2 in primary hepatocellular carcinoma.Medicine (Baltimore). 2019 Sep;98(39):e17216. doi: 10.1097/MD.0000000000017216.
• [2551] HBx-related long non-coding RNA MALAT1 promotes cell metastasis via up-regulating LTBP3 in hepatocellular carcinoma.Am J Cancer Res. 2017 Apr 1;7(4):845-856. eCollection 2017.
• [2552] Latexin exhibits tumor suppressor potential in hepatocellular carcinoma.Oncol Rep. 2014 Mar;31(3):1364-72. doi: 10.3892/or.2014.2966. Epub 2014 Jan 8.
• [2553] Identification and characterization of genes associated with human hepatocellular carcinogenesis.Cancer Res. 1999 Oct 1;59(19):4990-6.
• [2554] The E3 ligase for metastasis associated 1 protein, TRIM25, is targeted by microRNA-873 in hepatocellular carcinoma.Exp Cell Res. 2018 Jul 1;368(1):37-41. doi: 10.1016/j.yexcr.2018.04.010. Epub 2018 Apr 12.
• [2555] The tumor-suppressor gene LZTS1 suppresses hepatocellular carcinoma proliferation by impairing PI3K/Akt pathway.Biomed Pharmacother. 2015 Dec;76:141-6. doi: 10.1016/j.biopha.2015.10.006. Epub 2015 Nov 18.
• [2556] MiR-302 a/b/c suppresses tumor angiogenesis in hepatocellular carcinoma by targeting MACC1.Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):7863-7873. doi: 10.26355/eurrev_201909_18996.
• [2557] Induction of cancer cell stemness by depletion of macrohistone H2A1 in hepatocellular carcinoma.Hepatology. 2018 Feb;67(2):636-650. doi: 10.1002/hep.29519. Epub 2018 Jan 2.
• [2558] Transcription Factor MafB Promotes Hepatocellular Carcinoma Cell Proliferation through Up-Regulation of Cyclin D1.Cell Physiol Biochem. 2016;39(2):700-8. doi: 10.1159/000445661. Epub 2016 Jul 25.
• [2559] Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients.J Surg Oncol. 2013 Dec;108(8):557-62. doi: 10.1002/jso.23440. Epub 2013 Sep 20.
• [2560] Downregulation of MAGI1 associates with poor prognosis of hepatocellular carcinoma.J Invest Surg. 2012 Apr;25(2):93-9. doi: 10.3109/08941939.2011.606875. Epub 2011 Sep 26.
• [2561] MAGI2 enhances the sensitivity of BEL-7404 human hepatocellular carcinoma cells to staurosporine-induced apoptosis by increasing PTEN stability.Int J Mol Med. 2013 Aug;32(2):439-47. doi: 10.3892/ijmm.2013.1411. Epub 2013 Jun 7.
• [2562] Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells.Int J Nanomedicine. 2013;8:3271-83. doi: 10.2147/IJN.S47597. Epub 2013 Aug 26.
• [2563] Dynamics of MAL2 during glycosylphosphatidylinositol-anchored protein transcytotic transport to the apical surface of hepatoma HepG2 cells.Traffic. 2006 Jan;7(1):61-73. doi: 10.1111/j.1600-0854.2005.00361.x.
• [2564] Hepatitis B virus upregulates host expression of -1,2-mannosidases via the PPAR pathway.World J Gastroenterol. 2016 Nov 21;22(43):9534-9543. doi: 10.3748/wjg.v22.i43.9534.
• [2565] ERManI is a target of miR-125b and promotes transformation phenotypes in hepatocellular carcinoma (HCC).PLoS One. 2013 Aug 5;8(8):e72829. doi: 10.1371/journal.pone.0072829. Print 2013.
• [2566] Autophagy-related gene 7 (ATG7) and reactive oxygen species/extracellular signal-regulated kinase regulate tetrandrine-induced autophagy in human hepatocellular carcinoma.J Biol Chem. 2012 Oct 12;287(42):35576-35588. doi: 10.1074/jbc.M112.370585. Epub 2012 Aug 27.
• [2567] Combination of ULK1 and LC3B improve prognosis assessment of hepatocellular carcinoma.Biomed Pharmacother. 2018 Jan;97:195-202. doi: 10.1016/j.biopha.2017.10.025. Epub 2017 Nov 6.
• [2568] MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3.BMC Cancer. 2013 Oct 10;13:469. doi: 10.1186/1471-2407-13-469.
• [2569] The MAP3K13-TRIM25-FBXW7 axis affects c-Myc protein stability and tumor development.Cell Death Differ. 2020 Feb;27(2):420-433. doi: 10.1038/s41418-019-0363-0. Epub 2019 Jun 11.
• [2570] The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma.PLoS One. 2011;6(11):e27362. doi: 10.1371/journal.pone.0027362. Epub 2011 Nov 9.
• [2571] Identifying the optimal gene and gene set in hepatocellular carcinoma based on differential expression and differential co-expression algorithm.Oncol Rep. 2017 Feb;37(2):1066-1074. doi: 10.3892/or.2016.5333. Epub 2016 Dec 23.
• [2572] Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma.Hepatology. 2008 Dec;48(6):1851-63. doi: 10.1002/hep.22552.
• [2573] MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K-AKT--catenin pathways.J Cell Mol Med. 2019 May;23(5):3386-3401. doi: 10.1111/jcmm.14235. Epub 2019 Feb 22.
• [2574] Mitochondria ubiquitin ligase, MARCH5 resolves hepatitis B virus X protein aggregates in the liver pathogenesis.Cell Death Dis. 2019 Dec 9;10(12):938. doi: 10.1038/s41419-019-2175-z.
• [2575] MicroRNA Gene Polymorphisms in Evaluating Therapeutic Efficacy After Transcatheter Arterial Chemoembolization for Primary Hepatocellular Carcinoma.Genet Test Mol Biomarkers. 2016 Oct;20(10):579-586. doi: 10.1089/gtmb.2016.0073. Epub 2016 Aug 15.
• [2576] Inflammatory cytokine-induced expression of MASTL is involved in hepatocarcinogenesis by regulating cell cycle progression.Oncol Lett. 2019 Mar;17(3):3163-3172. doi: 10.3892/ol.2019.9983. Epub 2019 Jan 29.
• [2577] Expression of matrilin-2 in liver cirrhosis and hepatocellular carcinoma.Pathol Oncol Res. 2008 Mar;14(1):15-22. doi: 10.1007/s12253-008-9005-4. Epub 2008 Apr 2.
• [2578] Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.Cancer Res. 2003 Nov 15;63(22):7936-41.
• [2579] A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.J Hepatol. 2019 Jul;71(1):78-90. doi: 10.1016/j.jhep.2019.03.007. Epub 2019 Mar 15.
• [2580] Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis.Hepatology. 2001 Mar;33(3):561-8. doi: 10.1053/jhep.2001.22507.
• [2581] Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression.J Cell Sci. 1991 Mar;98 ( Pt 3):317-22. doi: 10.1242/jcs.98.3.317.
• [2582] The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1.Nat Cell Biol. 2017 Jul;19(7):820-832. doi: 10.1038/ncb3538. Epub 2017 May 29.
• [2583] Absence of APC gene mutation in the mutation cluster region in hepatocellular carcinoma.Cancer Lett. 1998 Dec 11;134(1):23-8. doi: 10.1016/s0304-3835(98)00238-9.
• [2584] Evaluation of the diagnostic and therapeutic roles of non-coding RNA and cell proliferation related gene association in hepatocellular carcinoma.Gene. 2019 Jul 20;706:97-105. doi: 10.1016/j.gene.2019.04.054. Epub 2019 Apr 26.
• [2585] Minichromosome maintenance helicase paralog MCM9 is dispensible for DNA replication but functions in germ-line stem cells and tumor suppression.Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17702-7. doi: 10.1073/pnas.1113524108. Epub 2011 Oct 10.
• [2586] Multicarotenoids at Physiological Levels Inhibit Metastasis in Human Hepatocarcinoma SK-Hep-1 Cells.Nutr Cancer. 2015;67(4):676-86. doi: 10.1080/01635581.2015.1019633. Epub 2015 Apr 14.
• [2587] MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma.J Exp Clin Cancer Res. 2019 Mar 25;38(1):136. doi: 10.1186/s13046-019-1135-x.
• [2588] EVI1 promotes cell proliferation in HBx-induced hepatocarcinogenesis as a critical transcription factor regulating lncRNAs.Oncotarget. 2016 Apr 19;7(16):21887-99. doi: 10.18632/oncotarget.7993.
• [2589] Increased mediator complex subunit 15 expression is associated with poor prognosis in hepatocellular carcinoma.Oncol Lett. 2018 Apr;15(4):4303-4313. doi: 10.3892/ol.2018.7820. Epub 2018 Jan 18.
• [2590] The role of Med19 in the proliferation and tumorigenesis of human hepatocellular carcinoma cells.Acta Pharmacol Sin. 2011 Mar;32(3):354-60. doi: 10.1038/aps.2010.223.
• [2591] Mediator subunit 23 overexpression as a novel target for suppressing proliferation and tumorigenesis in hepatocellular carcinoma.J Gastroenterol Hepatol. 2015 Jun;30(6):1094-103. doi: 10.1111/jgh.12923.
• [2592] Houttuynia cordata Thunb Promotes Activation of HIF-1A-FOXO3 and MEF2A Pathways to Induce Apoptosis in Human HepG2 Hepatocellular Carcinoma Cells.Integr Cancer Ther. 2017 Sep;16(3):360-372. doi: 10.1177/1534735416670987. Epub 2016 Oct 3.
• [2593] Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/-catenin signaling.Oncogene. 2015 Jul 30;34(31):4089-97. doi: 10.1038/onc.2014.337. Epub 2014 Oct 20.
• [2594] Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.Gastroenterology. 2020 Feb;158(3):664-678.e24. doi: 10.1053/j.gastro.2019.10.025. Epub 2019 Oct 31.
• [2595] miRNA expression profiling regulates necroptotic cell death in hepatocellular carcinoma.Int J Oncol. 2018 Aug;53(2):771-780. doi: 10.3892/ijo.2018.4410. Epub 2018 May 17.
• [2596] Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4.Am J Cancer Res. 2018 Jun 1;8(6):1040-1049. eCollection 2018.
• [2597] MEIS2C and MEIS2D promote tumor progression via Wnt/-catenin and hippo/YAP signaling in hepatocellular carcinoma.J Exp Clin Cancer Res. 2019 Oct 17;38(1):417. doi: 10.1186/s13046-019-1417-3.
• [2598] Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma.Int J Oncol. 2013 Feb;42(2):411-8. doi: 10.3892/ijo.2012.1724. Epub 2012 Nov 30.
• [2599] METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN.J Mol Med (Berl). 2019 Nov;97(11):1535-1545. doi: 10.1007/s00109-019-01830-9. Epub 2019 Aug 28.
• [2600] The prognostic value of major facilitator superfamily domain-containing protein 2A in patients with hepatocellular carcinoma.Aging (Albany NY). 2019 Oct 4;11(19):8474-8483. doi: 10.18632/aging.102333. Epub 2019 Oct 4.
• [2601] Opposing changes in N-acetylglucosaminyltransferase-V and -III during the cell cycle and all-trans retinoic acid treatment of hepatocarcinoma cell line.Biochim Biophys Acta. 2000 Feb 28;1495(3):297-307. doi: 10.1016/s0167-4889(99)00157-3.
• [2602] The X protein of hepatitis B virus activates hepatoma cell proliferation through repressing melanoma inhibitory activity 2 gene.Biochem Biophys Res Commun. 2011 Dec 16;416(3-4):379-84. doi: 10.1016/j.bbrc.2011.11.046. Epub 2011 Nov 19.
• [2603] Reduced expression of TANGO in colon and hepatocellular carcinomas.Oncol Rep. 2007 Oct;18(4):885-91.
• [2604] MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability.Oncogene. 2015 Jan 8;34(2):237-45. doi: 10.1038/onc.2013.536. Epub 2013 Dec 16.
• [2605] Finding a novel interacting protein of the hepatic carcinoma related gene MIP: NF-B essential modulator (NEMO).Oncol Rep. 2011 Jan;25(1):231-5.
• [2606] Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma.PLoS One. 2008 Jul 23;3(7):e2779. doi: 10.1371/journal.pone.0002779.
• [2607] Upregulated MMP28 in Hepatocellular Carcinoma Promotes Metastasis via Notch3 Signaling and Predicts Unfavorable Prognosis.Int J Biol Sci. 2019 Feb 19;15(4):812-825. doi: 10.7150/ijbs.31335. eCollection 2019.
• [2608] CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGF-induced HSC-T6 cells activation.Int J Nanomedicine. 2019 Apr 26;14:2927-2944. doi: 10.2147/IJN.S171280. eCollection 2019.
• [2609] Effect of ethanol on p36 protein kinase substrate and insulin receptor substrate 1 expression and tyrosyl phosphorylation in human hepatocellular carcinoma cells.Alcohol Clin Exp Res. 1995 Apr;19(2):441-6. doi: 10.1111/j.1530-0277.1995.tb01528.x.
• [2610] MNT inhibits the migration of human hepatocellular carcinoma SMMC7721 cells.Biochem Biophys Res Commun. 2012 Feb 3;418(1):93-7. doi: 10.1016/j.bbrc.2011.12.140. Epub 2012 Jan 5.
• [2611] The homeobox gene HLXB9 is upregulated in a morphological subset of poorly differentiated hepatocellular carcinoma.Virchows Arch. 2011 Jun;458(6):697-708. doi: 10.1007/s00428-011-1070-5. Epub 2011 Apr 12.
• [2612] Identification and characterization of a novel human hepatocellular carcinoma-associated gene.Br J Cancer. 2001 Oct 19;85(8):1162-7. doi: 10.1054/bjoc.2001.2059.
• [2613] Circular RNA 101368/miR-200a axis modulates the migration of hepatocellular carcinoma through HMGB1/RAGE signaling.Cell Cycle. 2018;17(19-20):2349-2359. doi: 10.1080/15384101.2018.1526599. Epub 2018 Oct 22.
• [2614] Hypomethylation of c-myc and epidermal growth factor receptor genes in human hepatocellular carcinoma and fetal liver.Jpn J Cancer Res. 1985 Dec;76(12):1136-40.
• [2615] PIG11 over-expression predicts good prognosis and induces HepG2 cell apoptosis via reactive oxygen species-dependent mitochondrial pathway.Biomed Pharmacother. 2018 Dec;108:435-442. doi: 10.1016/j.biopha.2018.09.062. Epub 2018 Sep 18.
• [2616] siRNA suppression of hTERT using activatable cell-penetrating peptides in hepatoma cells.Biosci Rep. 2015 Mar 18;35(2):e00181. doi: 10.1042/BSR20140145.
• [2617] MPZL1 is highly expressed in advanced gallbladder carcinoma and promotes the aggressive behavior of human gallbladder carcinoma GBCSD cells.Mol Med Rep. 2019 Sep;20(3):2725-2733. doi: 10.3892/mmr.2019.10506. Epub 2019 Jul 18.
• [2618] Relationship between the rs2596542 polymorphism in the MICA gene promoter and HBV/HCV infection-induced hepatocellular carcinoma: a meta-analysis.BMC Med Genet. 2019 Aug 16;20(1):142. doi: 10.1186/s12881-019-0871-2.
• [2619] Genes associated with recurrence of hepatocellular carcinoma: integrated analysis by gene expression and methylation profiling.J Korean Med Sci. 2011 Nov;26(11):1428-38. doi: 10.3346/jkms.2011.26.11.1428. Epub 2011 Oct 27.
• [2620] Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.J Exp Clin Cancer Res. 2016 Feb 25;35:37. doi: 10.1186/s13046-016-0311-5.
• [2621] Hcc-2, a novel mammalian ER thioredoxin that is differentially expressed in hepatocellular carcinoma.FEBS Lett. 2006 Apr 17;580(9):2216-26. doi: 10.1016/j.febslet.2006.03.029. Epub 2006 Mar 20.
• [2622] Expression Levels of the Uridine-Cytidine Kinase Like-1 Protein As a Novel Prognostic Factor for Hepatitis C Virus-Associated Hepatocellular Carcinomas.Acta Naturae. 2017 Jul-Sep;9(3):108-114.
• [2623] High MRPS23 expression contributes to hepatocellular carcinoma proliferation and indicates poor survival outcomes.Tumour Biol. 2017 Jul;39(7):1010428317709127. doi: 10.1177/1010428317709127.
• [2624] Sirtuin-1/Mitochondrial Ribosomal Protein S5 Axis Enhances the Metabolic Flexibility of Liver Cancer Stem Cells.Hepatology. 2019 Oct;70(4):1197-1213. doi: 10.1002/hep.30622. Epub 2019 Jun 26.
• [2625] The Therapeutic Potential of Adipose Tissue-Derived Mesenchymal Stem Cells to Enhance Radiotherapy Effects on Hepatocellular Carcinoma.Front Cell Dev Biol. 2019 Nov 12;7:267. doi: 10.3389/fcell.2019.00267. eCollection 2019.
• [2626] USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway.Mol Oncol. 2017 Jun;11(6):682-695. doi: 10.1002/1878-0261.12067. Epub 2017 May 11.
• [2627] Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.Int J Nanomedicine. 2017 Jun 12;12:4361-4370. doi: 10.2147/IJN.S135626. eCollection 2017.
• [2628] Berberine induced modulation of PHLPP2-Akt-MST1 kinase signaling is coupled with mitochondrial impairment and hepatoma cell death.Toxicol Appl Pharmacol. 2018 May 15;347:92-103. doi: 10.1016/j.taap.2018.03.033. Epub 2018 Apr 4.
• [2629] MT1G serves as a tumor suppressor in hepatocellular carcinoma by interacting with p53.Oncogenesis. 2019 Nov 15;8(12):67. doi: 10.1038/s41389-019-0176-5.
• [2630] Regulator of G-protein signaling 5 enhances portal vein invasion in hepatocellular carcinoma.Oncol Lett. 2018 Feb;15(2):1763-1770. doi: 10.3892/ol.2017.7474. Epub 2017 Nov 23.
• [2631] Catalpol inhibits cell proliferation, invasion and migration through regulating miR-22-3p/MTA3 signalling in hepatocellular carcinoma.Exp Mol Pathol. 2019 Aug;109:51-60. doi: 10.1016/j.yexmp.2019.104265. Epub 2019 May 27.
• [2632] MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma.Oncotarget. 2018 Apr 20;9(30):21429-21443. doi: 10.18632/oncotarget.25117. eCollection 2018 Apr 20.
• [2633] Overexpression of MTHFD1 in hepatocellular carcinoma predicts poorer survival and recurrence.Future Oncol. 2019 May;15(15):1771-1780. doi: 10.2217/fon-2018-0606. Epub 2019 Apr 18.
• [2634] Methylenetetrahydrofolate dehydrogenase 2 overexpression is associated with tumor aggressiveness and poor prognosis in hepatocellular carcinoma.Dig Liver Dis. 2016 Aug;48(8):953-60. doi: 10.1016/j.dld.2016.04.015. Epub 2016 May 16.
• [2635] Missing-in-metastasis B (MIM-B) combined with caveolin-1 promotes metastasis of hepatocellular carcinoma.Oncotarget. 2017 Sep 8;8(56):95450-95465. doi: 10.18632/oncotarget.20735. eCollection 2017 Nov 10.
• [2636] Dryocrassin ABBA Induces Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells Through a Caspase-Dependent Mitochondrial Pathway.Asian Pac J Cancer Prev. 2016;17(4):1823-8. doi: 10.7314/apjcp.2016.17.4.1823.
• [2637] Mutation analysis of the 8p22 candidate tumor suppressor gene ATIP/MTUS1 in hepatocellular carcinoma.Mol Cell Endocrinol. 2006 Jun 27;252(1-2):207-15. doi: 10.1016/j.mce.2006.03.014. Epub 2006 May 2.
• [2638] Synthesis and biological evaluation of novel mono- and bivalent ASGP-R-targeted drug-conjugates.Bioorg Med Chem Lett. 2018 Feb 1;28(3):382-387. doi: 10.1016/j.bmcl.2017.12.032. Epub 2017 Dec 14.
• [2639] Mus81 knockdown sensitizes colon cancer cells to chemotherapeutic drugs by activating CHK1 pathway.Clin Res Hepatol Gastroenterol. 2017 Oct;41(5):592-601. doi: 10.1016/j.clinre.2017.01.011. Epub 2017 Mar 11.
• [2640] Major Vault Protein Promotes Hepatocellular Carcinoma Through Targeting Interferon Regulatory Factor 2 and Decreasing p53 Activity.Hepatology. 2020 Aug;72(2):518-534. doi: 10.1002/hep.31045. Epub 2020 Mar 23.
• [2641] A positive feedback loop between ROS and Mxi1-0 promotes hypoxia-induced VEGF expression in human hepatocellular carcinoma cells.Cell Signal. 2017 Feb;31:79-86. doi: 10.1016/j.cellsig.2017.01.007. Epub 2017 Jan 6.
• [2642] Identification and Characterization of a Novel Protein ASP-3 Purified from Arca subcrenata and Its Antitumor Mechanism.Mar Drugs. 2019 Sep 9;17(9):528. doi: 10.3390/md17090528.
• [2643] A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma.J Proteome Res. 2008 Oct;7(10):4289-98. doi: 10.1021/pr800197z. Epub 2008 Aug 21.
• [2644] YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells.Oncogene. 2019 Jul;38(27):5541-5550. doi: 10.1038/s41388-019-0801-y. Epub 2019 Apr 1.
• [2645] An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region.Hepatology. 2001 Jun;33(6):1415-24. doi: 10.1053/jhep.2001.24751.
• [2646] miR-632 Functions as Oncogene in Hepatocellular Carcinoma via Targeting MYCT1.Hum Gene Ther Clin Dev. 2019 Jun;30(2):67-73. doi: 10.1089/humc.2019.040. Epub 2019 May 8.
• [2647] Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells.J Biol Chem. 1998 Feb 27;273(9):5146-54. doi: 10.1074/jbc.273.9.5146.
• [2648] Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor suppressor in hepatocellular carcinoma.Clin Cancer Res. 2012 Jul 1;18(13):3541-51. doi: 10.1158/1078-0432.CCR-11-1007. Epub 2012 May 9.
• [2649] Deficiency in Embryonic Stem Cell Marker Reduced Expression 1 Activates Mitogen-Activated Protein Kinase Kinase 6-Dependent p38 Mitogen-Activated Protein Kinase Signaling to Drive Hepatocarcinogenesis.Hepatology. 2020 Jul;72(1):183-197. doi: 10.1002/hep.31020. Epub 2020 Apr 8.
• [2650] MRNA expression of genes altered by 5-azacytidine treatment in cancer cell lines is associated with clinicopathological parameters of human cancers.J Cancer Res Clin Oncol. 2001 Dec;127(12):697-706. doi: 10.1007/s004320100284.
• [2651] ARD1/NAA10 in hepatocellular carcinoma: pathways and clinical implications.Exp Mol Med. 2018 Jul 27;50(7):1-12. doi: 10.1038/s12276-018-0106-1.
• [2652] LOH analysis of genes around D4S2964 identifies ARD1B as a prognostic predictor of hepatocellular carcinoma.World J Gastroenterol. 2010 Apr 28;16(16):2046-54. doi: 10.3748/wjg.v16.i16.2046.
• [2653] Patt1, a novel protein acetyltransferase that is highly expressed in liver and downregulated in hepatocellular carcinoma, enhances apoptosis of hepatoma cells.Int J Biochem Cell Biol. 2009 Dec;41(12):2528-37. doi: 10.1016/j.biocel.2009.08.009. Epub 2009 Aug 18.
• [2654] hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas.Oncogene. 2011 May 12;30(19):2219-29. doi: 10.1038/onc.2010.596. Epub 2011 Jan 17.
• [2655] Decreased levels of nitric oxide production and nitric oxide synthase-2 expression are associated with the development and metastasis of hepatocellular carcinoma.Mol Med Rep. 2012 Dec;6(6):1261-6. doi: 10.3892/mmr.2012.1096. Epub 2012 Sep 24.
• [2656] Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.PLoS One. 2013 Dec 13;8(12):e82426. doi: 10.1371/journal.pone.0082426. eCollection 2013.
• [2657] Non-SMC condensin I complex subunit H enhances proliferation, migration, and invasion of hepatocellular carcinoma.Mol Carcinog. 2019 Dec;58(12):2266-2275. doi: 10.1002/mc.23114. Epub 2019 Sep 15.
• [2658] Imbalanced expression pattern of steroid receptor coactivator-1 and -3 in liver cancer compared with normal liver: An immunohistochemical study with tissue microarray.Oncol Lett. 2018 Nov;16(5):6339-6348. doi: 10.3892/ol.2018.9443. Epub 2018 Sep 17.
• [2659] Knockout of NCOA5 impairs proliferation and migration of hepatocellular carcinoma cells by suppressing epithelial-to-mesenchymal transition.Biochem Biophys Res Commun. 2018 Jun 2;500(2):177-183. doi: 10.1016/j.bbrc.2018.04.017. Epub 2018 Apr 14.
• [2660] Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs.Oncogene. 2006 Jun 15;25(25):3576-88. doi: 10.1038/sj.onc.1209389. Epub 2006 Jan 23.
• [2661] LncRNA MIR22HG inhibits growth, migration and invasion through regulating the miR-10a-5p/NCOR2 axis in hepatocellular carcinoma cells.Cancer Sci. 2019 Mar;110(3):973-984. doi: 10.1111/cas.13950. Epub 2019 Feb 23.
• [2662] Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma.Hepatology. 2019 Mar;69(3):1165-1179. doi: 10.1002/hep.30235. Epub 2019 Feb 14.
• [2663] Identification of potential driver genes in human liver carcinoma by genomewide screening.Cancer Res. 2009 May 1;69(9):4059-66. doi: 10.1158/0008-5472.CAN-09-0164. Epub 2009 Apr 14.
• [2664] Aspartate -hydroxylase disrupts mitochondrial DNA stability and function in hepatocellular carcinoma.Oncogenesis. 2017 Jul 17;6(7):e362. doi: 10.1038/oncsis.2017.64.
• [2665] Increased level of the mitochondrial ND5 transcript in chemically induced rat hepatomas.Exp Cell Res. 1989 Sep;184(1):158-66. doi: 10.1016/0014-4827(89)90374-1.
• [2666] Nm23/NDP kinases in hepatocellular carcinoma.J Bioenerg Biomembr. 2006 Aug;38(3-4):169-75. doi: 10.1007/s10863-006-9031-4.
• [2667] Long noncoding RNA CCAT2 promotes hepatocellular carcinoma proliferation and metastasis through up-regulation of NDRG1.Exp Cell Res. 2019 Jun 1;379(1):19-29. doi: 10.1016/j.yexcr.2019.03.029. Epub 2019 Mar 25.
• [2668] Combined Aberrant Expression of NDRG2 and LDHA Predicts Hepatocellular Carcinoma Prognosis and Mediates the Anti-tumor Effect of Gemcitabine.Int J Biol Sci. 2019 Jul 3;15(9):1771-1786. doi: 10.7150/ijbs.35094. eCollection 2019.
• [2669] NDRG3 overexpression is associated with a poor prognosis in patients with hepatocellular carcinoma.Biosci Rep. 2018 Dec 7;38(6):BSR20180907. doi: 10.1042/BSR20180907. Print 2018 Dec 21.
• [2670] NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma.Clin Cancer Res. 2016 Jun 15;22(12):3105-17. doi: 10.1158/1078-0432.CCR-15-1987. Epub 2016 Jan 27.
• [2671] Ficolin-2 levels and FCN2 haplotypes influence hepatitis B infection outcome in Vietnamese patients.PLoS One. 2011;6(11):e28113. doi: 10.1371/journal.pone.0028113. Epub 2011 Nov 22.
• [2672] Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma.Gastroenterology. 2013 Dec;145(6):1424-35.e1-25. doi: 10.1053/j.gastro.2013.08.055. Epub 2013 Sep 5.
• [2673] Mechanisms underlying aflatoxin-associated mutagenesis - Implications in carcinogenesis.DNA Repair (Amst). 2019 May;77:76-86. doi: 10.1016/j.dnarep.2019.03.004. Epub 2019 Mar 7.
• [2674] NELFE-Dependent MYC Signature Identifies a Unique Cancer Subtype in Hepatocellular Carcinoma.Sci Rep. 2019 Mar 4;9(1):3369. doi: 10.1038/s41598-019-39727-9.
• [2675] Neuraminidase 1 (NEU1) promotes proliferation and migration as a diagnostic and prognostic biomarker of hepatocellular carcinoma.Oncotarget. 2016 Oct 4;7(40):64957-64966. doi: 10.18632/oncotarget.11778.
• [2676] Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis.Gut. 2019 Feb;68(2):347-358. doi: 10.1136/gutjnl-2017-315348. Epub 2018 Feb 2.
• [2677] NFATc1 is a tumor suppressor in hepatocellular carcinoma and induces tumor cell apoptosis by activating the FasL-mediated extrinsic signaling pathway.Cancer Med. 2018 Sep;7(9):4701-4717. doi: 10.1002/cam4.1716. Epub 2018 Aug 7.
• [2678] MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.Cancer Lett. 2019 Sep 10;459:156-167. doi: 10.1016/j.canlet.2019.114429. Epub 2019 Jun 7.
• [2679] Short hairpin RNA-mediated knockdown of nuclear factor erythroid 2-like 3 exhibits tumor-suppressing effects in hepatocellular carcinoma cells.World J Gastroenterol. 2019 Mar 14;25(10):1210-1223. doi: 10.3748/wjg.v25.i10.1210.
• [2680] Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk.Mol Pharmacol. 2013 May;83(5):1109-19. doi: 10.1124/mol.112.083634. Epub 2013 Mar 11.
• [2681] XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.BMC Cancer. 2017 May 19;17(1):344. doi: 10.1186/s12885-017-3345-y.
• [2682] Elevated levels of serum nidogen-2 in esophageal squamous cell carcinoma.Cancer Biomark. 2018 Feb 14;21(3):583-590. doi: 10.3233/CBM-170484.
• [2683] Long non-coding RNA HNF1A-AS1 promotes hepatocellular carcinoma cell proliferation by repressing NKD1 and P21 expression.Biomed Pharmacother. 2017 May;89:926-932. doi: 10.1016/j.biopha.2017.01.031. Epub 2017 Mar 8.
• [2684] Abnormal expression of NRF-2 in hepatocellular carcinoma identified with a newly prepared monoclonal antibody against human NRF-2 protein.Mol Biol Rep. 2011 Jun;38(5):3083-8. doi: 10.1007/s11033-010-9976-6. Epub 2010 Feb 3.
• [2685] Prognostic significance of Nemo-like kinase expression in patients with hepatocellular carcinoma.Tumour Biol. 2015 Nov;36(11):8447-53. doi: 10.1007/s13277-015-3609-6. Epub 2015 May 29.
• [2686] The correlation of NLRC3 expression with the progression and prognosis of hepatocellular carcinoma.Hum Pathol. 2018 Dec;82:273-281. doi: 10.1016/j.humpath.2018.07.031. Epub 2018 Aug 4.
• [2687] NLRP12 suppresses hepatocellular carcinoma via downregulation of cJun N-terminal kinase activation in the hepatocyte.Elife. 2019 Apr 16;8:e40396. doi: 10.7554/eLife.40396.
• [2688] The protein histidine phosphatase LHPP is a tumour suppressor.Nature. 2018 Mar 29;555(7698):678-682. doi: 10.1038/nature26140. Epub 2018 Mar 21.
• [2689] Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.Cancer Res. 2007 Jan 1;67(1):309-17. doi: 10.1158/0008-5472.CAN-06-1945.
• [2690] Downregulation of NIN/RPN12 binding protein inhibit the growth of human hepatocellular carcinoma cells.Mol Biol Rep. 2012 Jan;39(1):501-7. doi: 10.1007/s11033-011-0764-8. Epub 2011 May 15.
• [2691] Numerical aberrations of chromosomes 16, 17, and 18 in hepatocellular carcinoma: a FISH and FCM analysis of 20 cases.Dig Dis Sci. 1998 Jan;43(1):1-7. doi: 10.1023/a:1018838731634.
• [2692] Enhanced NOLC1 promotes cell senescence and represses hepatocellular carcinoma cell proliferation by disturbing the organization of nucleolus.Aging Cell. 2017 Aug;16(4):726-737. doi: 10.1111/acel.12602. Epub 2017 May 10.
• [2693] Clinical significance of PICT1 in patients of hepatocellular carcinoma with wild-type TP53.Ann Surg Oncol. 2013 Dec;20 Suppl 3:S537-44. doi: 10.1245/s10434-013-2958-x. Epub 2013 Mar 27.
• [2694] Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF.Cancer Sci. 2008 Jun;99(6):1139-46. doi: 10.1111/j.1349-7006.2008.00814.x. Epub 2008 Apr 21.
• [2695] RNA binding protein Nova1 promotes tumor growth in vivo and its potential mechanism as an oncogene may due to its interaction with GABA(A) Receptor-2.J Biomed Sci. 2016 Oct 12;23(1):71. doi: 10.1186/s12929-016-0288-6.
• [2696] The anti-metastatic effect of 8-MOP on hepatocellular carcinoma is potentiated by the down-regulation of bHLH transcription factor DEC1.Pharmacol Res. 2016 Mar;105:121-33. doi: 10.1016/j.phrs.2016.01.025. Epub 2016 Jan 22.
• [2697] Circadian clock gene NPAS2 promotes reprogramming of glucose metabolism in hepatocellular carcinoma cells.Cancer Lett. 2020 Jan 28;469:498-509. doi: 10.1016/j.canlet.2019.11.024. Epub 2019 Nov 22.
• [2698] The tumor suppressor NPRL2 in hepatocellular carcinoma plays an important role in progression and can be served as an independent prognostic factor.J Surg Oncol. 2009 Oct 1;100(5):358-63. doi: 10.1002/jso.21241.
• [2699] Telmisartan attenuates N-nitrosodiethylamine-induced hepatocellular carcinoma in mice by modulating the NF-B-TAK1-ERK1/2 axis in the context of PPAR agonistic activity.Naunyn Schmiedebergs Arch Pharmacol. 2019 Dec;392(12):1591-1604. doi: 10.1007/s00210-019-01706-2. Epub 2019 Jul 31.
• [2700] Long noncoding RNA NR2F1-AS1 enhances the malignant properties of osteosarcoma by increasing forkhead box A1 expression via sponging of microRNA-483-3p.Aging (Albany NY). 2019 Dec 4;11(23):11609-11623. doi: 10.18632/aging.102563. Epub 2019 Dec 4.
• [2701] NRBP2 Overexpression Increases the Chemosensitivity of Hepatocellular Carcinoma Cells via Akt Signaling.Cancer Res. 2016 Dec 1;76(23):7059-7071. doi: 10.1158/0008-5472.CAN-16-0937. Epub 2016 Sep 7.
• [2702] Synergistic effect of receptor-interacting protein 140 and simvastatin on the inhibition of proliferation and survival of hepatocellular carcinoma cells.Oncol Lett. 2018 Apr;15(4):4344-4350. doi: 10.3892/ol.2018.7831. Epub 2018 Jan 19.
• [2703] NRSN2 promotes osteosarcoma cell proliferation and growth through PI3K/Akt/MTOR and Wnt/-catenin signaling.Am J Cancer Res. 2017 Mar 1;7(3):565-573. eCollection 2017.
• [2704] Identification of NUCKS1 as a putative oncogene and immunodiagnostic marker of hepatocellular carcinoma.Gene. 2016 Jun 10;584(1):47-53. doi: 10.1016/j.gene.2016.03.006. Epub 2016 Mar 9.
• [2705] Karonudib is a promising anticancer therapy in hepatocellular carcinoma.Ther Adv Med Oncol. 2019 Aug 23;11:1758835919866960. doi: 10.1177/1758835919866960. eCollection 2019.
• [2706] NUDT21 regulates circRNA cyclization and ceRNA crosstalk in hepatocellular carcinoma.Oncogene. 2020 Jan;39(4):891-904. doi: 10.1038/s41388-019-1030-0. Epub 2019 Sep 30.
• [2707] Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19-FGF4-KLB Pathway Inhibition.Cancer Discov. 2019 Dec;9(12):1646-1649. doi: 10.1158/2159-8290.CD-19-1156.
• [2708] Nucleoporin 88 expression in hepatitis B and C virus-related liver diseases.World J Gastroenterol. 2006 Sep 28;12(36):5870-4. doi: 10.3748/wjg.v12.i36.5870.
• [2709] Induction of nuclear protein-1 by thyroid hormone enhances platelet-derived growth factor A mediated angiogenesis in liver cancer.Theranostics. 2019 Apr 13;9(8):2361-2379. doi: 10.7150/thno.29628. eCollection 2019.
• [2710] Nogo-B receptor promotes epithelial-mesenchymal transition in non-small cell lung cancer cells through the Ras/ERK/Snail1 pathway.Cancer Lett. 2018 Apr 1;418:135-146. doi: 10.1016/j.canlet.2018.01.030. Epub 2018 Jan 11.
• [2711] Identification of genes involved in the regulation of TERT in hepatocellular carcinoma.Cancer Sci. 2019 Feb;110(2):550-560. doi: 10.1111/cas.13884. Epub 2019 Jan 4.
• [2712] AF119895 regulates NXF3 expression to promote migration and invasion of hepatocellular carcinoma through an interaction with miR-6508-3p.Exp Cell Res. 2018 Feb 1;363(1):129-139. doi: 10.1016/j.yexcr.2017.12.016. Epub 2017 Dec 20.
• [2713] Donor onecarbon metabolism gene single nucleotide polymorphisms predict the susceptibility of cancer recurrence after liver transplantation.Gene. 2019 Mar 20;689:97-101. doi: 10.1016/j.gene.2018.11.035. Epub 2018 Dec 7.
• [2714] O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation.Med Oncol. 2012 Jun;29(2):985-93. doi: 10.1007/s12032-011-9912-1. Epub 2011 Apr 3.
• [2715] Mining featured biomarkers associated with vascular invasion in HCC by bioinformatics analysis with TCGA RNA sequencing data.Biomed Pharmacother. 2019 Oct;118:109274. doi: 10.1016/j.biopha.2019.109274. Epub 2019 Aug 28.
• [2716] Krppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6.Clin Cancer Res. 2016 Jan 15;22(2):502-12. doi: 10.1158/1078-0432.CCR-15-0528. Epub 2015 Sep 2.
• [2717] Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma.Oncotarget. 2016 Dec 6;7(49):81255-81267. doi: 10.18632/oncotarget.13221.
• [2718] Inhibition of the Wnt/-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.Cancer Lett. 2016 Oct 10;381(1):58-66. doi: 10.1016/j.canlet.2016.07.013. Epub 2016 Jul 16.
• [2719] Inhibition of hepatocarcinoma and tumor metastasis to liver by gene therapy with recombinant CBD-HepII polypeptide of fibronectin.Int J Cancer. 2007 Jul 1;121(1):184-92. doi: 10.1002/ijc.22644.
• [2720] Opsin3 sensitizes hepatocellular carcinoma cells to 5-fluorouracil treatment by regulating the apoptotic pathway.Cancer Lett. 2012 Jul 1;320(1):96-103. doi: 10.1016/j.canlet.2012.01.035. Epub 2012 Feb 4.
• [2721] RNA stability regulates differential expression of the metastasis protein, osteopontin, in hepatocellular cancer.Surgery. 2008 Jun;143(6):803-12. doi: 10.1016/j.surg.2008.02.005. Epub 2008 Apr 18.
• [2722] Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up.Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):169-179. doi: 10.1016/j.ijrobp.2018.09.004. Epub 2018 Sep 10.
• [2723] Urine -fetoprotein and orosomucoid 1 as biomarkers of hepatitis B virus-associated hepatocellular carcinoma.Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G305-G312. doi: 10.1152/ajpgi.00267.2019. Epub 2019 Nov 18.
• [2724] Allele-specific imbalance of oxidative stress-induced growth inhibitor 1 associates with progression of hepatocellular carcinoma.Gastroenterology. 2014 Apr;146(4):1084-96. doi: 10.1053/j.gastro.2013.12.041. Epub 2014 Jan 11.
• [2725] Snail1-dependent transcriptional repression of Cezanne2 in hepatocellular carcinoma.Oncogene. 2014 May 29;33(22):2836-45. doi: 10.1038/onc.2013.243. Epub 2013 Jun 24.
• [2726] Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma.Cell Death Dis. 2017 Sep 7;8(9):e3043. doi: 10.1038/cddis.2017.428.
• [2727] OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway.J Korean Med Sci. 2016 Aug;31(8):1215-23. doi: 10.3346/jkms.2016.31.8.1215. Epub 2016 Jun 3.
• [2728] Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas.Mod Pathol. 2006 Mar;19(3):460-9. doi: 10.1038/modpathol.3800549.
• [2729] Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress.Cell Res. 2016 Oct;26(10):1112-1130. doi: 10.1038/cr.2016.109. Epub 2016 Sep 20.
• [2730] miR-192-5p Silencing by Genetic Aberrations Is a Key Event in Hepatocellular Carcinomas with Cancer Stem Cell Features.Cancer Res. 2019 Mar 1;79(5):941-953. doi: 10.1158/0008-5472.CAN-18-1675. Epub 2018 Dec 7.
• [2731] Novel Pd(II)-salen complexes showing high in vitro anti-proliferative effects against human hepatoma cancer by modulating specific regulatory genes.Dalton Trans. 2012 Sep 21;41(35):10854-64. doi: 10.1039/c2dt31143g. Epub 2012 Aug 3.
• [2732] MicroRNA-526a targets p21-activated kinase 7 to inhibit tumorigenesis in hepatocellular carcinoma.Mol Med Rep. 2017 Jul;16(1):837-844. doi: 10.3892/mmr.2017.6658. Epub 2017 May 31.
• [2733] Panx1 promotes invasion-metastasis cascade in hepatocellular carcinoma.J Cancer. 2019 Sep 7;10(23):5681-5688. doi: 10.7150/jca.32986. eCollection 2019.
• [2734] Identification of PAQR3 as a new candidate tumor suppressor in hepatocellular carcinoma.Oncol Rep. 2014 Dec;32(6):2687-95. doi: 10.3892/or.2014.3532. Epub 2014 Oct 6.
• [2735] Effects of acute-liver-failure-plasma exposure on hepatic functionality of HepaRG-AMC-bioartificial liver.Liver Int. 2013 Apr;33(4):516-24. doi: 10.1111/liv.12090. Epub 2013 Feb 7.
• [2736] Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.Dig Dis Sci. 2019 Oct;64(10):2878-2892. doi: 10.1007/s10620-019-05608-4. Epub 2019 Apr 4.
• [2737] HBx regulates transcription factor PAX8 stabilization to promote the progression of hepatocellular carcinoma.Oncogene. 2019 Oct;38(40):6696-6710. doi: 10.1038/s41388-019-0907-2. Epub 2019 Aug 7.
• [2738] Association between the overexpression of PBOV1 and the prognosis of patients with hepatocellular carcinoma.Oncol Lett. 2018 Sep;16(3):3401-3407. doi: 10.3892/ol.2018.9013. Epub 2018 Jun 25.
• [2739] Rev-erb activation down-regulates hepatic Pck1 enzyme to lower plasma glucose in mice.Pharmacol Res. 2019 Mar;141:310-318. doi: 10.1016/j.phrs.2019.01.010. Epub 2019 Jan 11.
• [2740] Proteomic and functional analyses reveal the potential involvement of endoplasmic reticulum stress and -CP1 in the anticancer activities of oridonin in HepG2 cells.Integr Cancer Ther. 2011 Jun;10(2):160-7. doi: 10.1177/1534735410383171. Epub 2010 Oct 6.
• [2741] Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma.Oncol Rep. 2016 Dec;36(6):3456-3464. doi: 10.3892/or.2016.5167. Epub 2016 Oct 13.
• [2742] Loss of protocadherin-17 (PCDH-17) promotes metastasis and invasion through hyperactivation of EGFR/MEK/ERK signaling pathway in hepatocellular carcinoma.Tumour Biol. 2016 Feb;37(2):2527-35. doi: 10.1007/s13277-015-3970-5. Epub 2015 Sep 19.
• [2743] Decreased expression of protocadherin 20 is associated with poor prognosis in hepatocellular carcinoma.Oncotarget. 2017 Jan 10;8(2):3018-3028. doi: 10.18632/oncotarget.13822.
• [2744] KIAA0101 is a novel transcriptional target of FoxM1 and is involved in the regulation of hepatocellular carcinoma microvascular invasion by regulating epithelial-mesenchymal transition.J Cancer. 2019 Jun 9;10(15):3501-3516. doi: 10.7150/jca.29490. eCollection 2019.
• [2745] Centrosome aberration accompanied with p53 mutation can induce genetic instability in hepatocellular carcinoma.Mod Pathol. 2004 Jun;17(6):722-7. doi: 10.1038/modpathol.3800115.
• [2746] The miR-93 promotes proliferation by directly targeting PDCD4 in hepatocellular carcinoma.Neoplasma. 2017;64(5):770-777. doi: 10.4149/neo_2017_516.
• [2747] Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma.Theranostics. 2019 May 9;9(10):2967-2983. doi: 10.7150/thno.30562. eCollection 2019.
• [2748] A functional insertion/deletion polymorphism in the promoter of PDCD6IP is associated with the susceptibility of hepatocellular carcinoma in a Chinese population.DNA Cell Biol. 2013 Aug;32(8):451-7. doi: 10.1089/dna.2013.2061. Epub 2013 Jun 18.
• [2749] The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression.Cancers (Basel). 2019 Mar 21;11(3):398. doi: 10.3390/cancers11030398.
• [2750] The phosphorylation of SEPT2 on Ser218 by casein kinase 2 is important to hepatoma carcinoma cell proliferation.Mol Cell Biochem. 2009 May;325(1-2):61-7. doi: 10.1007/s11010-008-0020-2. Epub 2009 Jan 23.
• [2751] PDLIM1 Inhibits Tumor Metastasis Through Activating Hippo Signaling in Hepatocellular Carcinoma.Hepatology. 2020 May;71(5):1643-1659. doi: 10.1002/hep.30930. Epub 2020 Jan 21.
• [2752] Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.J Clin Invest. 2010 Dec;120(12):4493-506. doi: 10.1172/JCI42674. Epub 2010 Nov 8.
• [2753] MicroRNA-326 inhibits cell proliferation and invasion, activating apoptosis in hepatocellular carcinoma by directly targeting LIM and SH3 protein 1.Oncol Rep. 2017 Sep;38(3):1569-1578. doi: 10.3892/or.2017.5810. Epub 2017 Jul 12.
• [2754] Evaluation of Podoplanin Expression in Hepatocellular Carcinoma Using RNAscope and Immunohistochemistry - A Preliminary Report.Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):383-387. doi: 10.21873/cgp.20048.
• [2755] PDSS2 Deficiency Induces Hepatocarcinogenesis by Decreasing Mitochondrial Respiration and Reprogramming Glucose Metabolism.Cancer Res. 2018 Aug 15;78(16):4471-4481. doi: 10.1158/0008-5472.CAN-17-2172. Epub 2018 Jul 2.
• [2756] Lnc-PDZD7 contributes to stemness properties and chemosensitivity in hepatocellular carcinoma through EZH2-mediated ATOH8 transcriptional repression.J Exp Clin Cancer Res. 2019 Feb 20;38(1):92. doi: 10.1186/s13046-019-1106-2.
• [2757] TSG101 promotes the proliferation, migration and invasion of hepatocellular carcinoma cells by regulating the PEG10.J Cell Mol Med. 2019 Jan;23(1):70-82. doi: 10.1111/jcmm.13878. Epub 2018 Nov 18.
• [2758] Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers.Mol Carcinog. 2017 Feb;56(2):425-435. doi: 10.1002/mc.22505. Epub 2016 Jun 10.
• [2759] PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway.Life Sci. 2019 Feb 15;219:182-189. doi: 10.1016/j.lfs.2018.12.054. Epub 2019 Jan 8.
• [2760] Protein-mimicking nanoparticles for the reproduction of transient protein-receptor interactions.Colloids Surf B Biointerfaces. 2017 Dec 1;160:682-687. doi: 10.1016/j.colsurfb.2017.10.023. Epub 2017 Oct 7.
• [2761] Multiple genes identified as targets for 20q13.12-13.33 gain contributing to unfavorable clinical outcomes in patients with hepatocellular carcinoma.Hepatol Int. 2015 Jul;9(3):438-46. doi: 10.1007/s12072-015-9642-0. Epub 2015 Jun 12.
• [2762] Phosphorylation of PPAR at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4.Oncotarget. 2016 Nov 22;7(47):76984-76994. doi: 10.18632/oncotarget.12764.
• [2763] (125)I suppressed the Warburg effect viaregulating miR-338/PFKL axis in hepatocellular carcinoma.Biomed Pharmacother. 2019 Nov;119:109402. doi: 10.1016/j.biopha.2019.109402. Epub 2019 Sep 9.
• [2764] Metformin attenuates hepatoma cell proliferation by decreasing glycolytic flux through the HIF-1/PFKFB3/PFK1 pathway.Life Sci. 2019 Dec 15;239:116966. doi: 10.1016/j.lfs.2019.116966. Epub 2019 Oct 15.
• [2765] Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma.Mol Cancer. 2010 Apr 19;9:81. doi: 10.1186/1476-4598-9-81.
• [2766] Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma.World J Gastroenterol. 2006 Feb 14;12(6):868-73. doi: 10.3748/wjg.v12.i6.868.
• [2767] Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.Am J Physiol Gastrointest Liver Physiol. 2020 Jan 1;318(1):G174-G188. doi: 10.1152/ajpgi.00041.2019. Epub 2019 Oct 21.
• [2768] Knockdown of PHF5A Inhibits Migration and Invasion of HCC Cells via Downregulating NF-B Signaling.Biomed Res Int. 2019 Jan 15;2019:1621854. doi: 10.1155/2019/1621854. eCollection 2019.
• [2769] miR-190 promotes HCC proliferation and metastasis by targeting PHLPP1.Exp Cell Res. 2018 Oct 1;371(1):185-195. doi: 10.1016/j.yexcr.2018.08.008. Epub 2018 Aug 6.
• [2770] Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma.EBioMedicine. 2019 Feb;40:422-431. doi: 10.1016/j.ebiom.2018.12.063. Epub 2019 Jan 9.
• [2771] Tetraspanin CD81-regulated cell motility plays a critical role in intrahepatic metastasis of hepatocellular carcinoma.Gastroenterology. 2008 Jul;135(1):244-256.e1. doi: 10.1053/j.gastro.2008.03.024. Epub 2008 Mar 21.
• [2772] IL-17 promotes hepatocellular carcinoma through inhibiting apoptosis induced by IFN-.Biochem Biophys Res Commun. 2020 Feb 5;522(2):525-531. doi: 10.1016/j.bbrc.2019.11.134. Epub 2019 Nov 26.
• [2773] A single nucleotide polymorphism in the human PIGK gene associates with low PIGK expression in colorectal cancer patients.Int J Oncol. 2012 Oct;41(4):1405-10. doi: 10.3892/ijo.2012.1567. Epub 2012 Jul 23.
• [2774] Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma.Hepatology. 2017 Jun;65(6):1948-1962. doi: 10.1002/hep.29036. Epub 2017 Apr 28.
• [2775] High miR-139-3p expression predicts a better prognosis for hepatocellular carcinoma: a pooled analysis.J Int Med Res. 2019 Jan;47(1):383-390. doi: 10.1177/0300060518802727. Epub 2018 Nov 5.
• [2776] PIK3C2A mRNA functions as a miR-124 sponge to facilitate CD151 expression and enhance malignancy of hepatocellular carcinoma cells.Oncotarget. 2016 Jul 12;7(28):43376-43389. doi: 10.18632/oncotarget.9716.
• [2777] A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication.Biochem Biophys Res Commun. 2013 Oct 11;440(1):150-6. doi: 10.1016/j.bbrc.2013.09.048. Epub 2013 Sep 18.
• [2778] MiR-126-3p suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting LRP6 and PIK3R2.J Transl Med. 2014 Sep 22;12:259. doi: 10.1186/s12967-014-0259-1.
• [2779] MicroRNA?01 serves as a potential tumor suppressor in hepatocellular carcinoma by directly targeting PIK3R3.Mol Med Rep. 2019 Mar;19(3):2431-2439. doi: 10.3892/mmr.2019.9857. Epub 2019 Jan 15.
• [2780] Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.Oncotarget. 2017 Dec 11;9(3):3605-3618. doi: 10.18632/oncotarget.23188. eCollection 2018 Jan 9.
• [2781] Hiwi overexpression does not affect proliferation, migration or apoptosis of liver cancer cells in vitro or in vivo.Oncol Lett. 2018 Jun;15(6):9711-9718. doi: 10.3892/ol.2018.8585. Epub 2018 Apr 26.
• [2782] Protein kinase D2 contributes to TNF--induced epithelial mesenchymal transition and invasion via the PI3K/GSK-3/-catenin pathway in hepatocellular carcinoma.Oncotarget. 2016 Feb 2;7(5):5327-41. doi: 10.18632/oncotarget.6633.
• [2783] The human RNA surveillance factor UPF1 regulates tumorigenesis by targeting Smad7 in hepatocellular carcinoma.J Exp Clin Cancer Res. 2016 Jan 13;35:8. doi: 10.1186/s13046-016-0286-2.
• [2784] Elevated Expression of Cytosolic Phospholipase A2 Delta Is Associated with Lipid Metabolism Dysregulation during Hepatocellular Carcinoma Progression.Cell J. 2020 Apr;22(1):17-22. doi: 10.22074/cellj.2020.6527. Epub 2019 Sep 8.
• [2785] Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.Acta Biomater. 2019 Dec;100:352-364. doi: 10.1016/j.actbio.2019.09.034. Epub 2019 Sep 26.
• [2786] PLCE1 polymorphisms and expression combined with serum AFP level predicts survival of HBV-related hepatocellular carcinoma patients after hepatectomy.Oncotarget. 2017 Apr 25;8(17):29202-29219. doi: 10.18632/oncotarget.16346.
• [2787] Plectin deficiency in liver cancer cells promotes cell migration and sensitivity to sorafenib treatment.Cell Adh Migr. 2018 Jan 2;12(1):19-27. doi: 10.1080/19336918.2017.1288789. Epub 2017 Feb 17.
• [2788] Hepatitis B virus X induces inflammation and cancer in mice liver through dysregulation of cytoskeletal remodeling and lipid metabolism.Oncotarget. 2016 Oct 25;7(43):70559-70574. doi: 10.18632/oncotarget.12372.
• [2789] Perilipin 5 and Lipocalin 2 Expression in Hepatocellular Carcinoma.Cancers (Basel). 2019 Mar 19;11(3):385. doi: 10.3390/cancers11030385.
• [2790] Expressions of cysteine-rich61, connective tissue growth factor and Nov genes in hepatocellular carcinoma and their clinical significance.World J Gastroenterol. 2004 Dec 1;10(23):3414-8. doi: 10.3748/wjg.v10.i23.3414.
• [2791] Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review.Eur J Gastroenterol Hepatol. 2013 Jul;25(7):830-41. doi: 10.1097/MEG.0b013e32835eb8d4.
• [2792] Identification of novel human high-density lipoprotein receptor Up-regulators using a cell-based high-throughput screening assay.J Biomol Screen. 2007 Mar;12(2):211-9. doi: 10.1177/1087057106297568. Epub 2007 Jan 26.
• [2793] Genome-Wide RNAi Screen Identifies PMPCB as a Therapeutic Vulnerability in EpCAM(+) Hepatocellular Carcinoma.Cancer Res. 2019 May 1;79(9):2379-2391. doi: 10.1158/0008-5472.CAN-18-3015. Epub 2019 Mar 12.
• [2794] Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs.PLoS One. 2014 Jan 6;9(1):e84453. doi: 10.1371/journal.pone.0084453. eCollection 2014.
• [2795] Pinin associates with prognosis of hepatocellular carcinoma through promoting cell proliferation and suppressing glucose deprivation-induced apoptosis.Oncotarget. 2016 Jun 28;7(26):39694-39704. doi: 10.18632/oncotarget.9233.
• [2796] PNPLA3, CGI-58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice.Hepatology. 2019 Jun;69(6):2427-2441. doi: 10.1002/hep.30583. Epub 2019 Apr 9.
• [2797] Caveolin-1 promotes invasion and metastasis by upregulating Pofut1 expression in mouse hepatocellular carcinoma.Cell Death Dis. 2019 Jun 17;10(7):477. doi: 10.1038/s41419-019-1703-1.
• [2798] Synergistic effect of berberine and HMQ1611 impairs cell proliferation and migration by regulating Wnt signaling pathway in hepatocellular carcinoma.Phytother Res. 2019 Mar;33(3):745-755. doi: 10.1002/ptr.6267. Epub 2018 Dec 18.
• [2799] Polymorphisms in POLG were associated with the prognosis and mtDNA content in hepatocellular carcinoma patients.Bull Cancer. 2017 Jun;104(6):500-507. doi: 10.1016/j.bulcan.2017.02.005. Epub 2017 Apr 28.
• [2800] Cloning, expression and characterization of human tissue-specific DNA polymerase lambda2.Sci China C Life Sci. 2007 Aug;50(4):457-65. doi: 10.1007/s11427-007-0059-4.
• [2801] Rpb3 promotes hepatocellular carcinoma through its N-terminus.Oncotarget. 2014 Oct 15;5(19):9256-68. doi: 10.18632/oncotarget.2389.
• [2802] Overexpression of interleukin-32 promotes invasion by modulating VEGF in hepatocellular carcinoma.Oncol Rep. 2018 Mar;39(3):1155-1162. doi: 10.3892/or.2017.6162. Epub 2017 Dec 19.
• [2803] Expression Profiling of lncRNAs, miRNAs, and mRNAs and Their Differential Expression in Leiomyoma Using Next-Generation RNA Sequencing.Reprod Sci. 2018 Feb;25(2):246-255. doi: 10.1177/1933719117711265. Epub 2017 Jun 7.
• [2804] CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells.Eur J Cancer. 2012 Jan;48(1):138-48. doi: 10.1016/j.ejca.2011.06.044. Epub 2011 Jul 19.
• [2805] Pancreatic progenitor cell differentiation and proliferation factor predicts poor prognosis in heptaocellular carcinoma.Medicine (Baltimore). 2019 Mar;98(9):e14552. doi: 10.1097/MD.0000000000014552.
• [2806] The down-regulation of the CYP2C19 gene is associated with aggressive tumor potential and the poorer recurrence-free survival of hepatocellular carcinoma.Oncotarget. 2018 Apr 24;9(31):22058-22068. doi: 10.18632/oncotarget.25178. eCollection 2018 Apr 24.
• [2807] CircSLC3A2 functions as an oncogenic factor in hepatocellular carcinoma by sponging miR-490-3p and regulating PPM1F expression.Mol Cancer. 2018 Nov 23;17(1):165. doi: 10.1186/s12943-018-0909-7.
• [2808] Transcribed pseudogene PPM1K generates endogenous siRNA to suppress oncogenic cell growth in hepatocellular carcinoma.Nucleic Acids Res. 2013 Apr 1;41(6):3734-47. doi: 10.1093/nar/gkt047. Epub 2013 Feb 1.
• [2809] Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma.Hepatology. 2010 Jan;51(1):142-53. doi: 10.1002/hep.23247.
• [2810] Down-regulation of iASPP in human hepatocellular carcinoma cells inhibits cell proliferation and tumor growth.Neoplasma. 2011;58(3):205-10. doi: 10.4149/neo_2011_03_205.
• [2811] Loss of protein targeting to glycogen sensitizes human hepatocellular carcinoma cells towards glucose deprivation mediated oxidative stress and cell death.Biosci Rep. 2015 May 1;35(3):e00207. doi: 10.1042/BSR20150090.
• [2812] Mitochondrial prohibitins and septin 9 are implicated in the onset of rat hepatocarcinogenesis.Toxicol Sci. 2011 Jan;119(1):61-72. doi: 10.1093/toxsci/kfq307. Epub 2010 Oct 8.
• [2813] Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma.Br J Cancer. 2013 May 14;108(9):1830-7. doi: 10.1038/bjc.2013.165. Epub 2013 Apr 16.
• [2814] Role of a novel functional variant in the PPP2R1A promoter on the regulation of PP2A-Aalpha and the risk of hepatocellular carcinoma.PLoS One. 2013;8(3):e59574. doi: 10.1371/journal.pone.0059574. Epub 2013 Mar 29.
• [2815] Alterations of tumour suppressor gene PPP2R1B in hepatocellular carcinoma.Cancer Lett. 2007 Aug 8;253(1):138-43. doi: 10.1016/j.canlet.2007.01.016. Epub 2007 Feb 26.
• [2816] Protein phosphatase 2A-B55 enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.J Exp Clin Cancer Res. 2016 Apr 14;35:67. doi: 10.1186/s13046-016-0341-z.
• [2817] Protein phosphatase 2 regulatory subunit B''Alpha silencing inhibits tumor cell proliferation in liver cancer.Cancer Med. 2019 Dec;8(18):7741-7753. doi: 10.1002/cam4.2620. Epub 2019 Oct 24.
• [2818] MicroRNA-373, a new regulator of protein phosphatase 6, functions as an oncogene in hepatocellular carcinoma.FEBS J. 2011 Jun;278(12):2044-54. doi: 10.1111/j.1742-4658.2011.08120.x. Epub 2011 May 17.
• [2819] Proline-rich acidic protein 1 (PRAP1) is a novel interacting partner of MAD1 and has a suppressive role in mitotic checkpoint signalling in hepatocellular carcinoma.J Pathol. 2014 May;233(1):51-60. doi: 10.1002/path.4319. Epub 2014 Jan 27.
• [2820] Hepatitis C virus core protein modulates pRb2/p130 expression in human hepatocellular carcinoma cell lines through promoter methylation.J Exp Clin Cancer Res. 2015 Nov 14;34:140. doi: 10.1186/s13046-015-0255-1.
• [2821] MicroRNA-194 inhibits cell invasion and migration in hepatocellular carcinoma through PRC1-mediated inhibition of Wnt/-catenin signaling pathway.Dig Liver Dis. 2019 Sep;51(9):1314-1322. doi: 10.1016/j.dld.2019.02.012. Epub 2019 Mar 1.
• [2822] The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/-catenin signaling and is frequently silenced in multiple tumors.PLoS One. 2011;6(11):e27346. doi: 10.1371/journal.pone.0027346. Epub 2011 Nov 8.
• [2823] Peroxiredoxin2 downregulation enhances hepatocellular carcinoma proliferation and migration, and is associated with unfavorable prognosis in patients.Oncol Rep. 2019 Mar;41(3):1539-1548. doi: 10.3892/or.2019.6977. Epub 2019 Jan 22.
• [2824] LncRNA MYCNOS facilitates proliferation and invasion in hepatocellular carcinoma by regulating miR-340.Hum Cell. 2020 Jan;33(1):148-158. doi: 10.1007/s13577-019-00303-y. Epub 2019 Nov 27.
• [2825] Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5(+) liver cancer initiating cells by suppressing negative regulators of -catenin signaling.Oncogene. 2015 Jun 11;34(24):3188-98. doi: 10.1038/onc.2015.129. Epub 2015 Apr 20.
• [2826] In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.Carcinogenesis. 2008 Jul;29(7):1428-34. doi: 10.1093/carcin/bgm266. Epub 2007 Nov 28.
• [2827] Metabolism-induced tumor activator 1 (MITA1), an Energy Stress-Inducible Long Noncoding RNA, Promotes Hepatocellular Carcinoma Metastasis.Hepatology. 2019 Jul;70(1):215-230. doi: 10.1002/hep.30602. Epub 2019 Apr 26.
• [2828] Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma.PLoS One. 2013 Sep 10;8(9):e74870. doi: 10.1371/journal.pone.0074870. eCollection 2013.
• [2829] Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma.J Exp Clin Cancer Res. 2006 Sep;25(3):403-9.
• [2830] Suppression of PROX1-mediated TERT expression in hepatitis B viral hepatocellular carcinoma.Int J Cancer. 2018 Dec 15;143(12):3155-3168. doi: 10.1002/ijc.31731. Epub 2018 Sep 27.
• [2831] Genome-Wide Screening and Functional Analysis Identifies Tumor Suppressor Long Noncoding RNAs Epigenetically Silenced in Hepatocellular Carcinoma.Cancer Res. 2019 Apr 1;79(7):1305-1317. doi: 10.1158/0008-5472.CAN-18-1659. Epub 2019 Feb 4.
• [2832] miR-371-5p down-regulates pre mRNA processing factor 4 homolog B (PRPF4B) and facilitates the G1/S transition in human hepatocellular carcinoma cells.Cancer Lett. 2013 Jul 28;335(2):351-60. doi: 10.1016/j.canlet.2013.02.045. Epub 2013 Mar 4.
• [2833] Mutational analysis of proapoptotic ARTS P-loop domain in common human cancers.Pathol Res Pract. 2006;202(2):67-70. doi: 10.1016/j.prp.2005.11.001. Epub 2005 Dec 22.
• [2834] Proline-rich protein 11 silencing inhibits hepatocellular carcinoma growth and epithelial-mesenchymal transition through -catenin signaling.Gene. 2019 Jan 10;681:7-14. doi: 10.1016/j.gene.2018.09.036. Epub 2018 Sep 21.
• [2835] Pre-metastatic niche triggers SDF-1/CXCR4 axis and promotes organ colonisation by hepatocellular circulating tumour cells via downregulation of Prrx1.J Exp Clin Cancer Res. 2019 Nov 21;38(1):473. doi: 10.1186/s13046-019-1475-6.
• [2836] Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras/Forkhead box M1 signaling pathway.Oncogene. 2016 Jul 7;35(27):3503-13. doi: 10.1038/onc.2015.411. Epub 2015 Oct 26.
• [2837] Thyroid hormone enhanced human hepatoma cell motility involves brain-specific serine protease 4 activation via ERK signaling.Mol Cancer. 2014 Jul 1;13:162. doi: 10.1186/1476-4598-13-162.
• [2838] Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus.Science. 1988 Aug 26;241(4869):1098-101. doi: 10.1126/science.2842863.
• [2839] Transfected human liver cytochrome P-450 hydroxylates vitamin D analogs at different side-chain positions.Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8668-72. doi: 10.1073/pnas.90.18.8668.
• [2840] Significance and expression of atypical protein kinase C-iota in human hepatocellular carcinoma.J Surg Res. 2009 Jun 1;154(1):143-9. doi: 10.1016/j.jss.2008.05.036. Epub 2008 Jun 30.
• [2841] Knockdown of PSMC3IP suppresses the proliferation and xenografted tumorigenesis of hepatocellular carcinoma cell.J Cell Biochem. 2019 Apr;120(4):5449-5458. doi: 10.1002/jcb.27824. Epub 2018 Oct 25.
• [2842] Deubiquitinase PSMD14 enhances hepatocellular carcinoma growth and metastasis by stabilizing GRB2.Cancer Lett. 2020 Jan 28;469:22-34. doi: 10.1016/j.canlet.2019.10.025. Epub 2019 Oct 18.
• [2843] Hepatitis B virus X protein activates proteasomal activator 28 gamma expression via upregulation of p53 levels to stimulate virus replication.J Gen Virol. 2018 May;99(5):655-666. doi: 10.1099/jgv.0.001054. Epub 2018 Apr 3.
• [2844] Expression of liver cancer associated gene HCCA3.World J Gastroenterol. 2001 Dec;7(6):821-5. doi: 10.3748/wjg.v7.i6.821.
• [2845] LncRNA PAPAS promotes hepatocellular carcinoma by interacting with miR-188-5p.J Cell Biochem. 2019 Aug;120(8):13494-13500. doi: 10.1002/jcb.28623. Epub 2019 Mar 28.
• [2846] Inhibition of JNK and prothymosin-alpha sensitizes hepatocellular carcinoma cells to cisplatin.Biochem Pharmacol. 2016 Dec 15;122:80-89. doi: 10.1016/j.bcp.2016.10.003. Epub 2016 Oct 14.
• [2847] Prostate tumor overexpressed 1 is a novel prognostic marker for hepatocellular carcinoma progression and overall patient survival.Medicine (Baltimore). 2015 Jan;94(4):e423. doi: 10.1097/MD.0000000000000423.
• [2848] Suppression of hepatitis B viral gene expression by protein-tyrosine phosphatase PTPN3.J Biomed Sci. 2007 Nov;14(6):731-44. doi: 10.1007/s11373-007-9187-x. Epub 2007 Jun 24.
• [2849] PTPRD is homozygously deleted and epigenetically downregulated in human hepatocellular carcinomas.OMICS. 2015 Apr;19(4):220-9. doi: 10.1089/omi.2015.0010.
• [2850] Downregulation of stomach cancer-associated protein tyrosine phosphatase-1 (SAP-1) in advanced human hepatocellular carcinoma.Oncogene. 2003 Jul 24;22(30):4656-63. doi: 10.1038/sj.onc.1206588.
• [2851] Epigenome-wide association study in hepatocellular carcinoma: Identification of stochastic epigenetic mutations through an innovative statistical approach.Oncotarget. 2017 Jun 27;8(26):41890-41902. doi: 10.18632/oncotarget.17462.
• [2852] Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3.Hepatology. 2013 Feb;57(2):678-88. doi: 10.1002/hep.25980. Epub 2012 Oct 30.
• [2853] Mutational analysis of PTPRT phosphatase domains in common human cancers.APMIS. 2007 Jan;115(1):47-51. doi: 10.1111/j.1600-0463.2007.apm_554.x.
• [2854] Identification of mutations causing 6-pyruvoyl-tetrahydropterin synthase deficiency in four Italian families.Hum Mutat. 1997;10(1):25-35. doi: 10.1002/(SICI)1098-1004(1997)10:1<25::AID-HUMU4>3.0.CO;2-L.
• [2855] PTTG1 is involved in TNF--related hepatocellular carcinoma via the induction of c-myc.Cancer Med. 2019 Sep;8(12):5702-5715. doi: 10.1002/cam4.2473. Epub 2019 Aug 6.
• [2856] Pentraxin 3 overexpression accelerated tumor metastasis and indicated poor prognosis in hepatocellular carcinoma via driving epithelial-mesenchymal transition.J Cancer. 2018 Jun 23;9(15):2650-2658. doi: 10.7150/jca.25188. eCollection 2018.
• [2857] Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma.Mol Med Rep. 2019 Oct;20(4):3773-3781. doi: 10.3892/mmr.2019.10641. Epub 2019 Sep 2.
• [2858] Pygopus-2 promotes invasion and metastasis of hepatic carcinoma cell by decreasing E-cadherin expression.Oncotarget. 2015 May 10;6(13):11074-86. doi: 10.18632/oncotarget.3570.
• [2859] Association of T-cell immunoglobulin and mucin domain-containing molecule 3 (Tim-3) polymorphisms with susceptibility and disease progression of HBV infection.PLoS One. 2014 May 27;9(5):e98280. doi: 10.1371/journal.pone.0098280. eCollection 2014.
• [2860] RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma.Oncotarget. 2017 Apr 18;8(16):26434-26447. doi: 10.18632/oncotarget.15507.
• [2861] Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1 to promote the metastasis of hepatocellular carcinoma.Oncogene. 2015 Dec 3;34(49):6007-17. doi: 10.1038/onc.2015.49. Epub 2015 Mar 9.
• [2862] Rab17 inhibits the tumourigenic properties of hepatocellular carcinomas via the Erk pathway.Tumour Biol. 2015 Aug;36(8):5815-24. doi: 10.1007/s13277-015-3251-3. Epub 2015 Feb 24.
• [2863] RAB18 promotes proliferation and metastasis in hepatocellular carcinoma.Am J Transl Res. 2019 Feb 15;11(2):1009-1019. eCollection 2019.
• [2864] Expression analysis and implication of Rab1A in gastrointestinal relevant tumor.Sci Rep. 2019 Sep 16;9(1):13384. doi: 10.1038/s41598-019-49786-7.
• [2865] lncRNA OSER1-AS1 acts as a ceRNA to promote tumorigenesis in hepatocellular carcinoma by regulating miR-372-3p/Rab23 axis.Biochem Biophys Res Commun. 2020 Jan 1;521(1):196-203. doi: 10.1016/j.bbrc.2019.10.105. Epub 2019 Oct 18.
• [2866] Overexpression of Rab25 promotes hepatocellular carcinoma cell proliferation and invasion.Tumour Biol. 2016 Jun;37(6):7713-8. doi: 10.1007/s13277-015-4606-5. Epub 2015 Dec 21.
• [2867] HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway.Cell Death Dis. 2018 May 1;9(5):513. doi: 10.1038/s41419-018-0534-9.
• [2868] Downregulation of serum RAB27B confers improved prognosis and is associated with hepatocellular carcinoma progression through PI3K-AKT-P21 signaling.Oncotarget. 2017 May 19;8(37):61118-61132. doi: 10.18632/oncotarget.18010. eCollection 2017 Sep 22.
• [2869] Rab31 promoted hepatocellular carcinoma (HCC) progression via inhibition of cell apoptosis induced by PI3K/AKT/Bcl-2/BAX pathway.Tumour Biol. 2015 Nov;36(11):8661-70. doi: 10.1007/s13277-015-3626-5. Epub 2015 Jun 6.
• [2870] Long non-coding RNA HOTAIR promotes exosome secretion by regulating RAB35 and SNAP23 in hepatocellular carcinoma.Mol Cancer. 2019 Apr 3;18(1):78. doi: 10.1186/s12943-019-0990-6.
• [2871] Hepatitis C virus Core protein overcomes all-trans retinoic acid-induced cell growth arrest by inhibiting retinoic acid receptor-2 expression via DNA methylation.Cancer Lett. 2013 Jul 28;335(2):372-9. doi: 10.1016/j.canlet.2013.02.057. Epub 2013 Mar 6.
• [2872] Overexpression of Rab5a promotes hepatocellular carcinoma cell proliferation and invasion via FAK signaling pathway.Tumour Biol. 2016 Mar;37(3):3341-7. doi: 10.1007/s13277-015-4124-5. Epub 2015 Oct 6.
• [2873] The Pivotal Role of Long Noncoding RNA RAB5IF in the Proliferation of Hepatocellular Carcinoma Via LGR5 Mediated -Catenin and c-Myc Signaling.Biomolecules. 2019 Nov 8;9(11):718. doi: 10.3390/biom9110718.
• [2874] New 2-Oxoindolin Phosphonates as Novel Agents to Treat Cancer: A Green Synthesis and Molecular Modeling.Molecules. 2018 Aug 8;23(8):1981. doi: 10.3390/molecules23081981.
• [2875] Mice lacking RAP1 show early onset and higher rates of DEN-induced hepatocellular carcinomas in female mice.PLoS One. 2018 Oct 11;13(10):e0204909. doi: 10.1371/journal.pone.0204909. eCollection 2018.
• [2876] Association between an insertion/deletion polymorphism within 3'UTR of SGSM3 and risk of hepatocellular carcinoma.Tumour Biol. 2014 Jan;35(1):295-301. doi: 10.1007/s13277-013-1039-x. Epub 2013 Aug 6.
• [2877] High throughput circRNA sequencing analysis reveals novel insights into the mechanism of nitidine chloride against hepatocellular carcinoma.Cell Death Dis. 2019 Sep 10;10(9):658. doi: 10.1038/s41419-019-1890-9.
• [2878] Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma.J Hepatol. 2005 Aug;43(2):288-93. doi: 10.1016/j.jhep.2005.02.020. Epub 2005 Apr 25.
• [2879] Genes encoding Pir51, Beclin 1, RbAp48 and aldolase b are up or down-regulated in human primary hepatocellular carcinoma.World J Gastroenterol. 2004 Feb 15;10(4):509-13. doi: 10.3748/wjg.v10.i4.509.
• [2880] Association between polymorphisms in MicroRNA target sites of RAD51D genes and risk of hepatocellular carcinoma.Cancer Med. 2019 May;8(5):2545-2552. doi: 10.1002/cam4.2068. Epub 2019 Mar 18.
• [2881] Depletion of three combined THOC5 mRNA export protein target genes synergistically induces human hepatocellular carcinoma cell death.Oncogene. 2016 Jul 21;35(29):3872-9. doi: 10.1038/onc.2015.433. Epub 2015 Nov 9.
• [2882] Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of -catenin.J Hepatol. 2011 Mar;54(3):506-12. doi: 10.1016/j.jhep.2010.07.020. Epub 2010 Oct 29.
• [2883] Serum Chemerin Does Not Differentiate Colorectal Liver Metastases from Hepatocellular Carcinoma.Int J Mol Sci. 2019 Aug 12;20(16):3919. doi: 10.3390/ijms20163919.
• [2884] Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1.Oncol Rep. 2017 Jan;37(1):273-280. doi: 10.3892/or.2016.5248. Epub 2016 Nov 15.
• [2885] UCN-01 induces S and G2/M cell cycle arrest through the p53/p21(waf1) or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines.BMC Cancer. 2013 Mar 28;13:167. doi: 10.1186/1471-2407-13-167.
• [2886] Hepatoma cells from mice deficient in glycine N-methyltransferase have increased RAS signaling and activation of liver kinase B1.Gastroenterology. 2012 Sep;143(3):787-798.e13. doi: 10.1053/j.gastro.2012.05.050. Epub 2012 Jun 8.
• [2887] Study on the relationship between the RASSF10 gene and the biological behavior of hepatocellular carcinoma cells.Eur Rev Med Pharmacol Sci. 2017 Aug;21(16):3576-3580.
• [2888] RBFOX3 Regulates the Chemosensitivity of Cancer Cells to 5-Fluorouracil via the PI3K/AKT, EMT and Cytochrome-C/Caspase Pathways.Cell Physiol Biochem. 2018;46(4):1365-1380. doi: 10.1159/000489153. Epub 2018 Apr 18.
• [2889] Genetic variants of cell cycle pathway genes predict disease-free survival of hepatocellular carcinoma.Cancer Med. 2017 Jul;6(7):1512-1522. doi: 10.1002/cam4.1067. Epub 2017 Jun 22.
• [2890] Glucose regulates heat shock factor 1 transcription activity via mTOR pathway in HCC cell lines.Cell Biol Int. 2015 Nov;39(11):1217-24. doi: 10.1002/cbin.10493. Epub 2015 Jul 6.
• [2891] RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.J Exp Clin Cancer Res. 2018 Sep 3;37(1):212. doi: 10.1186/s13046-018-0852-x.
• [2892] A novel microRNA identified in hepatocellular carcinomas is responsive to LEF1 and facilitates proliferation and epithelial-mesenchymal transition via targeting of NFIX.Oncogenesis. 2018 Feb 23;7(2):22. doi: 10.1038/s41389-017-0010-x.
• [2893] High expression of RBM8A predicts poor patient prognosis and promotes tumor progression in hepatocellular carcinoma.Oncol Rep. 2017 Apr;37(4):2167-2176. doi: 10.3892/or.2017.5457. Epub 2017 Feb 15.
• [2894] Cellular retinol-binding protein-1 in hepatocellular carcinoma correlates with beta-catenin, Ki-67 index, and patient survival.Hepatology. 2003 Aug;38(2):470-80. doi: 10.1053/jhep.2003.50321.
• [2895] Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway.Oncogene. 2017 Nov 30;36(48):6747-6748. doi: 10.1038/onc.2017.366.
• [2896] Forced expression of RDH10 gene retards growth of HepG2 cells.Cancer Biol Ther. 2007 Feb;6(2):238-44. doi: 10.4161/cbt.6.2.3625. Epub 2007 Feb 25.
• [2897] Interaction between hepatitis C virus core protein and translin protein--a possible molecular mechanism for hepatocellular carcinoma and lymphoma caused by hepatitis C virus.World J Gastroenterol. 2003 Feb;9(2):300-3. doi: 10.3748/wjg.v9.i2.300.
• [2898] Clinical significance and function of RDH16 as a tumor-suppressing gene in hepatocellular carcinoma.Hepatol Res. 2020 Jan;50(1):110-120. doi: 10.1111/hepr.13432. Epub 2019 Dec 8.
• [2899] Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways.Mol Oncol. 2020 Feb;14(2):373-386. doi: 10.1002/1878-0261.12593. Epub 2019 Dec 19.
• [2900] Decreased radixin function for ATP-binding cassette transporters in liver in adjuvant-induced arthritis rats.J Pharm Sci. 2014 Dec;103(12):4058-4065. doi: 10.1002/jps.24210. Epub 2014 Oct 20.
• [2901] Hepatitis B virus X protein (HBx) enhances centrosomal P4.1-associated protein (CPAP) expression to promote hepatocarcinogenesis.J Biomed Sci. 2019 Jun 6;26(1):44. doi: 10.1186/s12929-019-0534-9.
• [2902] Expression of the RERG gene is gender-dependent in hepatocellular carcinoma and regulated by histone deacetyltransferases.J Korean Med Sci. 2006 Oct;21(5):891-6. doi: 10.3346/jkms.2006.21.5.891.
• [2903] FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.Mol Oncol. 2019 Apr;13(4):792-810. doi: 10.1002/1878-0261.12429. Epub 2019 Jan 24.
• [2904] shRNA-mediated silencing of the RFC3 gene suppresses hepatocellular carcinoma cell proliferation.Int J Mol Med. 2015 Nov;36(5):1393-9. doi: 10.3892/ijmm.2015.2350. Epub 2015 Sep 21.
• [2905] Downregulation of RFX1 predicts poor prognosis of patients with small hepatocellular carcinoma.Eur J Surg Oncol. 2018 Jul;44(7):1087-1093. doi: 10.1016/j.ejso.2018.04.017. Epub 2018 Apr 27.
• [2906] LincRNA-p21 knockdown enhances radiosensitivity of hypoxic tumor cells by reducing autophagy through HIF-1/Akt/mTOR/P70S6K pathway.Exp Cell Res. 2017 Sep 15;358(2):188-198. doi: 10.1016/j.yexcr.2017.06.016. Epub 2017 Jul 8.
• [2907] Programmed death-ligand 1 expression is an unfavorable prognostic factor of hepatocellular carcinoma after archiving sustained virologic response for hepatitis C virus infection.Oncol Lett. 2019 Aug;18(2):1458-1466. doi: 10.3892/ol.2019.10448. Epub 2019 Jun 7.
• [2908] Lentivirus-mediated silencing of rhomboid domain containing 1 suppresses tumor growth and induces apoptosis in hepatoma HepG2 cells.Asian Pac J Cancer Prev. 2013;14(1):5-9. doi: 10.7314/apjcp.2013.14.1.5.
• [2909] Reduced expression of epidermal growth factor receptor-related protein in hepatocellular carcinoma: implications for cancer growth.Digestion. 2004;69(4):219-24. doi: 10.1159/000079151. Epub 2004 Jun 16.
• [2910] RhoC is essential for angiogenesis induced by hepatocellular carcinoma cells via regulation of endothelial cell organization.Cancer Sci. 2008 Oct;99(10):2012-8. doi: 10.1111/j.1349-7006.2008.00902.x.
• [2911] Low RIN1 expression in HCC is associated with tumor invasion and unfavorable prognosis.Am J Clin Pathol. 2013 Jul;140(1):73-81. doi: 10.1309/AJCPEGWYDD86WWJK.
• [2912] Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity.Cell Death Dis. 2017 May 4;8(5):e2766. doi: 10.1038/cddis.2017.165.
• [2913] RBP-J-interacting and tubulin-associated protein induces apoptosis and cell cycle arrest in human hepatocellular carcinoma by activating the p53-Fbxw7 pathway.Biochem Biophys Res Commun. 2014 Nov 7;454(1):71-7. doi: 10.1016/j.bbrc.2014.10.023. Epub 2014 Oct 14.
• [2914] Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.J Cancer Res Clin Oncol. 2018 Aug;144(8):1487-1501. doi: 10.1007/s00432-018-2672-y. Epub 2018 Jun 1.
• [2915] The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.Cell Death Dis. 2018 May 1;9(5):486. doi: 10.1038/s41419-018-0517-x.
• [2916] Screening and verification of proteins that interact with HSPC238.Oncol Rep. 2015 Dec;34(6):3097-103. doi: 10.3892/or.2015.4289. Epub 2015 Sep 18.
• [2917] An essential role of RNF187 in Notch1 mediated metastasis of hepatocellular carcinoma.J Exp Clin Cancer Res. 2019 Sep 2;38(1):384. doi: 10.1186/s13046-019-1382-x.
• [2918] Two variants of the human hepatocellular carcinoma-associated HCAP1 gene and their effect on the growth of the human liver cancer cell line Hep3B.Genes Chromosomes Cancer. 2004 Jan;39(1):48-58. doi: 10.1002/gcc.10293.
• [2919] First Synthesis for Bis-Spirothiazolidine Derivatives as a Novel Heterocyclic Framework and Their Biological Activity.Mini Rev Med Chem. 2020;20(2):152-160. doi: 10.2174/1389557519666190920114852.
• [2920] Metabolism of ethanol and carcinogens by glutathione transferases.Proc Natl Acad Sci U S A. 1989 Jun;86(12):4470-3. doi: 10.1073/pnas.86.12.4470.
• [2921] Enhanced expression of S8, L12, L23a, L27 and L30 ribosomal protein mRNAs in human hepatocellular carcinoma.Anticancer Res. 2001 Jul-Aug;21(4A):2429-33.
• [2922] Drug resistance effects of ribosomal protein L24 overexpression in hepatocellular carcinoma HepG2 cells.Asian Pac J Cancer Prev. 2014;15(22):9853-7. doi: 10.7314/apjcp.2014.15.22.9853.
• [2923] Identification of the antigens predominantly reacted with serum from patients with hepatocellular carcinoma.Cancer. 2003 May 15;97(10):2474-9. doi: 10.1002/cncr.11374.
• [2924] RPL36 as a prognostic marker in hepatocellular carcinoma.Pathol Int. 2011 Nov;61(11):638-44. doi: 10.1111/j.1440-1827.2011.02716.x. Epub 2011 Sep 23.
• [2925] Differentially expressed genes associated with hepatitis B virus HBx and MHBs protein function in hepatocellular carcinoma.Methods Mol Biol. 2006;317:141-55. doi: 10.1385/1-59259-968-0:141.
• [2926] RPL39L is an example of a recently evolved ribosomal protein paralog that shows highly specific tissue expression patterns and is upregulated in ESCs and HCC tumors.RNA Biol. 2014;11(1):33-41. doi: 10.4161/rna.27427. Epub 2013 Dec 20.
• [2927] LncRNA SNHG7 accelerates the proliferation, migration and invasion of hepatocellular carcinoma cells via regulating miR-122-5p and RPL4.Biomed Pharmacother. 2019 Oct;118:109386. doi: 10.1016/j.biopha.2019.109386. Epub 2019 Aug 30.
• [2928] Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene.Oncogene. 2003 Jun 19;22(25):3911-6. doi: 10.1038/sj.onc.1206492.
• [2929] Expression and significance of tumor-related genes in HCC.World J Gastroenterol. 2005 Jul 7;11(25):3850-4. doi: 10.3748/wjg.v11.i25.3850.
• [2930] RPN2 promotes metastasis of hepatocellular carcinoma cell and inhibits autophagy via STAT3 and NF-B pathways.Aging (Albany NY). 2019 Sep 3;11(17):6674-6690. doi: 10.18632/aging.102167. Epub 2019 Sep 3.
• [2931] MicroRNA-300 inhibits the growth of hepatocellular carcinoma cells by downregulating CREPT/Wnt/-catenin signaling.Oncol Lett. 2019 Oct;18(4):3743-3753. doi: 10.3892/ol.2019.10712. Epub 2019 Aug 5.
• [2932] Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags.Int J Oncol. 2006 Aug;29(2):315-27.
• [2933] Ribosomal proteins: insight into molecular roles and functions in hepatocellular carcinoma.Oncogene. 2018 Jan 18;37(3):277-285. doi: 10.1038/onc.2017.343. Epub 2017 Sep 25.
• [2934] Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans.Cancer Res. 2003 Aug 1;63(15):4594-601.
• [2935] RNA-binding protein RPS3 contributes to hepatocarcinogenesis by post-transcriptionally up-regulating SIRT1.Nucleic Acids Res. 2019 Feb 28;47(4):2011-2028. doi: 10.1093/nar/gky1209.
• [2936] RPS3a over-expressed in HBV-associated hepatocellular carcinoma enhances the HBx-induced NF-B signaling via its novel chaperoning function.PLoS One. 2011;6(8):e22258. doi: 10.1371/journal.pone.0022258. Epub 2011 Aug 16.
• [2937] Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma.World J Gastroenterol. 2008 Oct 21;14(39):6072-7. doi: 10.3748/wjg.14.6072.
• [2938] Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling.Mol Cell Proteomics. 2014 Jun;13(6):1429-38. doi: 10.1074/mcp.M113.033845. Epub 2014 Mar 18.
• [2939] Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas.PLoS One. 2012;7(8):e43223. doi: 10.1371/journal.pone.0043223. Epub 2012 Aug 13.
• [2940] Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms.Hepatology. 2006 Aug;44(2):446-57. doi: 10.1002/hep.21272.
• [2941] CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression.Oncotarget. 2015 Mar 10;6(7):4733-44. doi: 10.18632/oncotarget.2900.
• [2942] MicroRNA-493 suppresses hepatocellular carcinoma tumorigenesis through down-regulation of anthrax toxin receptor 1 (ANTXR1) and R-Spondin 2 (RSPO2).Biomed Pharmacother. 2017 Sep;93:334-343. doi: 10.1016/j.biopha.2017.06.047. Epub 2017 Jun 24.
• [2943] Elimination of Ras Suppressor-1 from hepatocellular carcinoma cells hinders their in vitro metastatic properties.Anticancer Res. 2015 Mar;35(3):1509-12.
• [2944] Knockdown of Rhotekin2 expression suppresses proliferation and invasion and induces apoptosis in hepatocellular carcinoma cells.Mol Med Rep. 2016 Jun;13(6):4865-71. doi: 10.3892/mmr.2016.5113. Epub 2016 Apr 13.
• [2945] The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma.Cancer Genet Cytogenet. 2007 Aug;177(1):6-15. doi: 10.1016/j.cancergencyto.2007.04.007.
• [2946] C14orf166 Is a Biomarker for Predicting Hepatocellular Carcinoma Recurrence.J Invest Surg. 2020 Dec;33(10):914-923. doi: 10.1080/08941939.2019.1586015. Epub 2019 Mar 24.
• [2947] Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression.Int J Cancer. 2020 Jun 15;146(12):3410-3422. doi: 10.1002/ijc.32787. Epub 2019 Nov 28.
• [2948] Multilevel regulation of RUVBL2 expression predicts poor prognosis in hepatocellular carcinoma.Cancer Cell Int. 2019 Sep 27;19:249. doi: 10.1186/s12935-019-0974-z. eCollection 2019.
• [2949] MicroRNA-769-5p contributes to the proliferation, migration and invasion of hepatocellular carcinoma cells by attenuating RYBP.Biomed Pharmacother. 2019 Oct;118:109343. doi: 10.1016/j.biopha.2019.109343. Epub 2019 Aug 13.
• [2950] S100A14 promotes the growth and metastasis of hepatocellular carcinoma.Asian Pac J Cancer Prev. 2013;14(6):3831-6. doi: 10.7314/apjcp.2013.14.6.3831.
• [2951] Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma.World J Gastroenterol. 2012 Jun 7;18(21):2719-26. doi: 10.3748/wjg.v18.i21.2719.
• [2952] SAMD9L inactivation promotes cell proliferation via facilitating G1-S transition in hepatitis B virus-associated hepatocellular carcinoma.Int J Biol Sci. 2014 Jul 17;10(8):807-16. doi: 10.7150/ijbs.9143. eCollection 2014.
• [2953] Cyclin E2-CDK2 mediates SAMHD1 phosphorylation to abrogate its restriction of HBV replication in hepatoma cells.FEBS Lett. 2018 Jun;592(11):1893-1904. doi: 10.1002/1873-3468.13105. Epub 2018 Jun 6.
• [2954] Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers.PLoS One. 2018 Jan 31;13(1):e0185490. doi: 10.1371/journal.pone.0185490. eCollection 2018.
• [2955] Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1453-60. doi: 10.1245/s10434-015-4524-1. Epub 2015 Mar 25.
• [2956] S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients.J Virol. 2004 Jun;78(12):6134-42. doi: 10.1128/JVI.78.12.6134-6142.2004.
• [2957] Promoter methylation assay of SASH1 gene in hepatocellular carcinoma.J BUON. 2014 Oct-Dec;19(4):1041-7.
• [2958] Global DNA methylation in a population with aflatoxin B1 exposure.Epigenetics. 2013 Sep;8(9):962-9. doi: 10.4161/epi.25696. Epub 2013 Jul 18.
• [2959] Higher expression of SATB2 in hepatocellular carcinoma of African Americans determines more aggressive phenotypes than those of Caucasian Americans.J Cell Mol Med. 2019 Dec;23(12):7999-8009. doi: 10.1111/jcmm.14652. Epub 2019 Oct 11.
• [2960] Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):E10417-E10426. doi: 10.1073/pnas.1808968115. Epub 2018 Oct 16.
• [2961] Overexpression of SCAMP3 is an indicator of poor prognosis in hepatocellular carcinoma.Oncotarget. 2017 Nov 27;8(65):109247-109257. doi: 10.18632/oncotarget.22665. eCollection 2017 Dec 12.
• [2962] Overexpression of N-terminal kinase like gene promotes tumorigenicity of hepatocellular carcinoma by regulating cell cycle progression and cell motility.Oncotarget. 2015 Jan 30;6(3):1618-30. doi: 10.18632/oncotarget.2730.
• [2963] Significance of DNA polymerase delta catalytic subunit p125 induced by mutant p53 in the invasive potential of human hepatocellular carcinoma.Oncology. 2010;79(3-4):229-37. doi: 10.1159/000322374. Epub 2011 Mar 3.
• [2964] Bcl-2 gene silencing in pediatric epithelial liver tumors.J Surg Res. 2008 Jan;144(1):43-8. doi: 10.1016/j.jss.2007.03.054. Epub 2007 Jun 14.
• [2965] A study on the structural features of SELK, an over-expressed protein in hepatocellular carcinoma, by molecular dynamics simulations in a lipid-water system.Mol Biosyst. 2016 Oct 20;12(10):3209-22. doi: 10.1039/c6mb00469e. Epub 2016 Aug 15.
• [2966] Structure-function relationship and evolutionary history of the human selenoprotein M (SelM) found over-expressed in hepatocellular carcinoma.Biochim Biophys Acta. 2014 Feb;1844(2):447-56. doi: 10.1016/j.bbapap.2013.12.001. Epub 2013 Dec 9.
• [2967] Selenium and selenoprotein P in nonalcoholic fatty liver disease.Hormones (Athens). 2020 Mar;19(1):61-72. doi: 10.1007/s42000-019-00127-3. Epub 2019 Sep 6.
• [2968] Secretion of the glucose-regulated selenoprotein SEPS1 from hepatoma cells.Biochem Biophys Res Commun. 2007 May 11;356(3):636-41. doi: 10.1016/j.bbrc.2007.03.018. Epub 2007 Mar 12.
• [2969] Doxorubicin-induced epithelial-mesenchymal transition through SEMA 4A in hepatocellular carcinoma.Biochem Biophys Res Commun. 2016 Oct 28;479(4):610-614. doi: 10.1016/j.bbrc.2016.09.167. Epub 2016 Sep 30.
• [2970] Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma.Oncogene. 2008 Sep 18;27(42):5578-89. doi: 10.1038/onc.2008.168. Epub 2008 May 26.
• [2971] Neuroimmune Semaphorin 4A in Cancer Angiogenesis and Inflammation: A Promoter or a Suppressor?.Int J Mol Sci. 2018 Dec 30;20(1):124. doi: 10.3390/ijms20010124.
• [2972] Ziziphus spina-christi leaves methanolic extract alleviates diethylnitrosamine-induced hepatocellular carcinoma in rats.Biochem Cell Biol. 2019 Aug;97(4):437-445. doi: 10.1139/bcb-2018-0318. Epub 2019 Jan 3.
• [2973] SUMO-specific protease 2 (SENP2) functions as a tumor suppressor in osteosarcoma via SOX9 degradation.Exp Ther Med. 2018 Dec;16(6):5359-5365. doi: 10.3892/etm.2018.6838. Epub 2018 Oct 9.
• [2974] Saikosaponin-d Inhibits the Hepatoma Cells and Enhances Chemosensitivity Through SENP5-Dependent Inhibition of Gli1 SUMOylation Under Hypoxia.Front Pharmacol. 2019 Sep 20;10:1039. doi: 10.3389/fphar.2019.01039. eCollection 2019.
• [2975] Inhibition of SENP6-induced radiosensitization of human hepatocellular carcinoma cells by blocking radiation-induced NF-B activation.Cancer Biother Radiopharm. 2013 Apr;28(3):196-200. doi: 10.1089/cbr.2012.1288. Epub 2013 Mar 5.
• [2976] Coupling function of cyclin-dependent kinase 2 and Septin2 in the promotion of hepatocellular carcinoma.Cancer Sci. 2019 Feb;110(2):540-549. doi: 10.1111/cas.13882. Epub 2018 Dec 26.
• [2977] MicroRNA-127 post-transcriptionally downregulates Sept7 and suppresses cell growth in hepatocellular carcinoma cells.Cell Physiol Biochem. 2014;33(5):1537-46. doi: 10.1159/000358717. Epub 2014 May 14.
• [2978] siRNA-mediated knockdown of hTDE2 retards cell cycle progression through transcriptional activation of p21.Oncol Rep. 2014 Mar;31(3):1314-22. doi: 10.3892/or.2014.2980. Epub 2014 Jan 14.
• [2979] SERPINA3 is a key modulator of HNRNP-K transcriptional activity against oxidative stress in HCC.Redox Biol. 2019 Jun;24:101217. doi: 10.1016/j.redox.2019.101217. Epub 2019 May 12.
• [2980] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [2981] SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin 1 signaling pathway in hepatocellular carcinoma.Mol Oncol. 2014 Mar;8(2):366-77. doi: 10.1016/j.molonc.2013.12.003. Epub 2013 Dec 18.
• [2982] Decreased expression of SERPINB1 correlates with tumor invasion and poor prognosis in hepatocellular carcinoma.J Mol Histol. 2014 Feb;45(1):59-68. doi: 10.1007/s10735-013-9529-0. Epub 2013 Oct 9.
• [2983] Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms.Hepatol Int. 2019 Mar;13(2):180-189. doi: 10.1007/s12072-018-9920-8. Epub 2019 Jan 1.
• [2984] New genetic markers for diagnosis of hepatitis C related hepatocellular carcinoma in Egyptian patients.J Gastrointestin Liver Dis. 2013 Dec;22(4):419-25.
• [2985] TRIP-Br2 promotes oncogenesis in nude mice and is frequently overexpressed in multiple human tumors.J Transl Med. 2009 Jan 20;7:8. doi: 10.1186/1479-5876-7-8.
• [2986] Circular RNA hsa_circ_0000673 promotes hepatocellular carcinoma malignance by decreasing miR-767-3p targeting SET.Biochem Biophys Res Commun. 2018 Jun 2;500(2):211-216. doi: 10.1016/j.bbrc.2018.04.041. Epub 2018 Apr 13.
• [2987] MicroRNA-621 Acts as a Tumor Radiosensitizer by Directly Targeting SETDB1 in Hepatocellular Carcinoma.Mol Ther. 2019 Feb 6;27(2):355-364. doi: 10.1016/j.ymthe.2018.11.005. Epub 2018 Nov 13.
• [2988] An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma.Oncogene. 2005 May 26;24(23):3737-47. doi: 10.1038/sj.onc.1208479.
• [2989] SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma.BMB Rep. 2018 Feb;51(2):57-58. doi: 10.5483/bmbrep.2018.51.2.021.
• [2990] miR-629-5p promotes growth and metastasis of hepatocellular carcinoma by activating -catenin.Exp Cell Res. 2019 Jul 15;380(2):124-130. doi: 10.1016/j.yexcr.2019.03.042. Epub 2019 Apr 4.
• [2991] Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.World J Gastroenterol. 2015 May 28;21(20):6317-28. doi: 10.3748/wjg.v21.i20.6317.
• [2992] SGK2 promotes hepatocellular carcinoma progression and mediates GSK-3/-catenin signaling in HCC cells.Tumour Biol. 2017 Jun;39(6):1010428317700408. doi: 10.1177/1010428317700408.
• [2993] Functional role of SGK3 in PI3K/Pten driven liver tumor development.BMC Cancer. 2019 Apr 11;19(1):343. doi: 10.1186/s12885-019-5551-2.
• [2994] The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/-catenin signalling pathway.Gut. 2016 Sep;65(9):1522-34. doi: 10.1136/gutjnl-2015-310625. Epub 2016 Mar 3.
• [2995] Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma.Hepatology. 2016 Sep;64(3):828-42. doi: 10.1002/hep.28684. Epub 2016 Jul 15.
• [2996] Hepatitis B virus X protein-induced SH2 domain-containing 5 (SH2D5) expression promotes hepatoma cell growth via an SH2D5-transketolase interaction.J Biol Chem. 2019 Mar 29;294(13):4815-4827. doi: 10.1074/jbc.RA118.005739. Epub 2019 Jan 18.
• [2997] SH3-domain binding protein 1 in the tumor microenvironment promotes hepatocellular carcinoma metastasis through WAVE2 pathway.Oncotarget. 2016 Apr 5;7(14):18356-70. doi: 10.18632/oncotarget.7786.
• [2998] Quantitative dynamic contrast-enhanced ultrasound may help predict the outcome of hepatocellular carcinoma after microwave ablation.Int J Hyperthermia. 2019 Jan 1;35(1):105-111. doi: 10.1080/02656736.2018.1483533. Epub 2018 Oct 9.
• [2999] Sex hormone-binding globulin suppresses NAFLD-triggered hepatocarcinogenesis after menopause.Carcinogenesis. 2019 Aug 22;40(8):1031-1041. doi: 10.1093/carcin/bgz107.
• [3000] Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells.Med Sci Monit. 2019 Aug 5;25:5823-5832. doi: 10.12659/MSM.915754.
• [3001] Elevated SHOX2 expression is associated with tumor recurrence of hepatocellular carcinoma.Ann Surg Oncol. 2013 Dec;20 Suppl 3:S644-9. doi: 10.1245/s10434-013-3132-1. Epub 2013 Jul 13.
• [3002] Nuclear accumulation of seven in absentia homologue-2 supports motility and proliferation of liver cancer cells.Int J Cancer. 2012 Nov 1;131(9):2016-26. doi: 10.1002/ijc.27473. Epub 2012 Mar 27.
• [3003] Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity.Gene. 1998 Feb 27;208(2):331-6. doi: 10.1016/s0378-1119(98)00030-4.
• [3004] Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells.Eur J Pharmacol. 2019 Oct 15;861:172599. doi: 10.1016/j.ejphar.2019.172599. Epub 2019 Aug 9.
• [3005] LINC00339 promotes growth and invasiveness of hepatocellular carcinoma by the miR-1182/SKA1 pathway.Onco Targets Ther. 2019 Jun 6;12:4481-4488. doi: 10.2147/OTT.S207397. eCollection 2019.
• [3006] SKA3 Promotes tumor growth by regulating CDK2/P53 phosphorylation in hepatocellular carcinoma.Cell Death Dis. 2019 Dec 5;10(12):929. doi: 10.1038/s41419-019-2163-3.
• [3007] Hsa_circ_101280 promotes hepatocellular carcinoma by regulating miR-375/JAK2.Immunol Cell Biol. 2019 Feb;97(2):218-228. doi: 10.1111/imcb.12213. Epub 2018 Nov 26.
• [3008] Loss of parental-specific methylation at the IGF2 locus in human hepatocellular carcinoma.J Pathol. 2003 Nov;201(3):473-9. doi: 10.1002/path.1477.
• [3009] Identification of tumor-associated antigens in human hepatocellular carcinoma by autoantibodies.Oncol Rep. 2008 Oct;20(4):979-85.
• [3010] Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.Biomed Pharmacother. 2019 Jun;114:108864. doi: 10.1016/j.biopha.2019.108864. Epub 2019 Apr 10.
• [3011] Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression.Oncogene. 2016 Sep 8;35(36):4719-29. doi: 10.1038/onc.2015.517. Epub 2016 Jan 25.
• [3012] Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma.Contrast Media Mol Imaging. 2017 Jun 21;2017:9265098. doi: 10.1155/2017/9265098. eCollection 2017.
• [3013] HIF-1-miR-219-SMC4 Regulatory Pathway Promoting Proliferation and Migration of HCC under Hypoxic Condition.Biomed Res Int. 2019 Nov 7;2019:8983704. doi: 10.1155/2019/8983704. eCollection 2019.
• [3014] LncRNA MAGI2-AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR-374b-5p/SMG1 signaling pathway.J Cell Physiol. 2019 Aug;234(10):18825-18836. doi: 10.1002/jcp.28521. Epub 2019 Mar 28.
• [3015] Overexpression of SMOC2 Attenuates the Tumorigenicity of Hepatocellular Carcinoma Cells and Is Associated With a Positive Postoperative Prognosis in Human Hepatocellular Carcinoma.J Cancer. 2017 Oct 17;8(18):3812-3827. doi: 10.7150/jca.20775. eCollection 2017.
• [3016] Increased liver tumor formation in neutral sphingomyelinase-2-deficient mice.J Lipid Res. 2018 May;59(5):795-804. doi: 10.1194/jlr.M080879. Epub 2018 Mar 22.
• [3017] Biological and clinical implications of retinoic acid-responsive genes in human hepatocellular carcinoma cells.J Hepatol. 2013 Nov;59(5):1037-44. doi: 10.1016/j.jhep.2013.06.024. Epub 2013 Jul 2.
• [3018] Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression.Cancer Res. 2020 Feb 1;80(3):561-575. doi: 10.1158/0008-5472.CAN-19-1117. Epub 2019 Nov 4.
• [3019] SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma.RNA Biol. 2018;15(10):1364-1375. doi: 10.1080/15476286.2018.1534525. Epub 2018 Oct 25.
• [3020] Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway.Oncogene. 2020 Mar;39(10):2140-2155. doi: 10.1038/s41388-019-1131-9. Epub 2019 Dec 9.
• [3021] Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma.Nature. 2019 Mar;567(7747):257-261. doi: 10.1038/s41586-019-0987-8. Epub 2019 Feb 27.
• [3022] MiR-183 modulates multi-drug resistance in hepatocellular cancer (HCC) cells via miR-183-IDH2/SOCS6-HIF-1 feedback loop.Eur Rev Med Pharmacol Sci. 2016 May;20(10):2020-7.
• [3023] Nuclear EGFR impairs ASPP2-p53 complex-induced apoptosis by inducing SOS1 expression in hepatocellular carcinoma.Oncotarget. 2015 Jun 30;6(18):16507-16. doi: 10.18632/oncotarget.3757.
• [3024] Methylation of SOX1 and VIM promoters in serum as potential biomarkers for hepatocellular carcinoma.Neoplasma. 2017;64(5):745-753. doi: 10.4149/neo_2017_513.
• [3025] SOX11 regulates apoptosis and cell cycle in hepatocellular carcinoma via Wnt/-catenin signaling pathway.Biotechnol Appl Biochem. 2019 Mar;66(2):240-246. doi: 10.1002/bab.1718. Epub 2018 Dec 17.
• [3026] MicroRNA?44 inhibits migration and invasion of hepatocellular carcinoma cells by targeting SOX12.Oncol Rep. 2018 Dec;40(6):3585-3592. doi: 10.3892/or.2018.6774. Epub 2018 Oct 8.
• [3027] Sox17 inhibits hepatocellular carcinoma progression by downregulation of KIF14 expression.Tumour Biol. 2014 Nov;35(11):11199-207. doi: 10.1007/s13277-014-2398-7. Epub 2014 Aug 10.
• [3028] Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.Hepatology. 2020 May;71(5):1712-1731. doi: 10.1002/hep.30951. Epub 2020 Feb 10.
• [3029] MicroRNA-645 represses hepatocellular carcinoma progression by inhibiting SOX30-mediated p53 transcriptional activation.Int J Biol Macromol. 2019 Jan;121:214-222. doi: 10.1016/j.ijbiomac.2018.10.032. Epub 2018 Oct 9.
• [3030] The Long Noncoding RNA LINC00908 Facilitates Hepatocellular Carcinoma Progression Via Interaction With Sox-4.Cancer Manag Res. 2019 Sep 30;11:8789-8797. doi: 10.2147/CMAR.S216774. eCollection 2019.
• [3031] miR-935 Promotes Liver Cancer Cell Proliferation and Migration by Targeting SOX7.Oncol Res. 2017 Mar 13;25(3):427-435. doi: 10.3727/096504016X14747300207374. Epub 2016 Sep 30.
• [3032] Oncogenicity of the transcription factor SOX8 in hepatocellular carcinoma.Med Oncol. 2014 Apr;31(4):918. doi: 10.1007/s12032-014-0918-3. Epub 2014 Mar 19.
• [3033] The miR-491-3p/Sp3/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma.Cancer Lett. 2017 Nov 1;408:102-111. doi: 10.1016/j.canlet.2017.08.027. Epub 2017 Aug 24.
• [3034] SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying -catenin degradation.J Exp Clin Cancer Res. 2018 Sep 18;37(1):229. doi: 10.1186/s13046-018-0891-3.
• [3035] Sperm-associated antigen 9 is upregulated in hepatocellular carcinoma tissue and enhances QGY cell proliferation and invasion in vitro.Oncol Lett. 2018 Jan;15(1):415-422. doi: 10.3892/ol.2017.7270. Epub 2017 Oct 26.
• [3036] SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma.J Pathol. 2006 Dec;210(4):459-68. doi: 10.1002/path.2068.
• [3037] SPC24 is critical for anaplastic thyroid cancer progression.Oncotarget. 2017 Mar 28;8(13):21884-21891. doi: 10.18632/oncotarget.15670.
• [3038] SPIN1 triggers abnormal lipid metabolism and enhances tumor growth in liver cancer.Cancer Lett. 2020 Feb 1;470:54-63. doi: 10.1016/j.canlet.2019.11.032. Epub 2019 Nov 29.
• [3039] Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo.Pharmacol Res. 2019 May;143:73-85. doi: 10.1016/j.phrs.2019.03.009. Epub 2019 Mar 9.
• [3040] Suppression of hepatocarcinoma model in vitro and in vivo by ECRG2 delivery using adenoviral vector.Cancer Gene Ther. 2012 Dec;19(12):875-9. doi: 10.1038/cgt.2012.77. Epub 2012 Oct 19.
• [3041] Aberrant methylation of promoter region of SPINT2/HAI-2 gene: an epigenetic mechanism in hepatitis C virus-induced hepatocarcinogenesis.Genet Test Mol Biomarkers. 2015 Jul;19(7):399-404. doi: 10.1089/gtmb.2015.0025. Epub 2015 Jun 1.
• [3042] Upregulation of Spondin-2 protein expression correlates with poor prognosis in hepatocellular carcinoma.J Int Med Res. 2019 Feb;47(2):569-579. doi: 10.1177/0300060518803232. Epub 2018 Oct 14.
• [3043] Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors.Oncogene. 2006 Oct 5;25(45):6056-66. doi: 10.1038/sj.onc.1209635. Epub 2006 May 1.
• [3044] Regulation of human hepatocellular carcinoma cells by Spred2 and correlative studies on its mechanism.Biochem Biophys Res Commun. 2011 Jul 15;410(4):803-8. doi: 10.1016/j.bbrc.2011.06.068. Epub 2011 Jun 15.
• [3045] miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling.Oncogenesis. 2018 Nov 21;7(11):90. doi: 10.1038/s41389-018-0097-8.
• [3046] Potential diagnostic value of lncRNA SPRY4-IT1 in hepatocellular carcinoma.Oncol Rep. 2016 Aug;36(2):1085-92. doi: 10.3892/or.2016.4859. Epub 2016 Jun 7.
• [3047] Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death.Cell Oncol (Dordr). 2019 Feb;42(1):55-66. doi: 10.1007/s13402-018-0407-3. Epub 2018 Sep 20.
• [3048] Transcription factor SPZ1 promotes TWIST-mediated epithelial-mesenchymal transition and oncogenesis in human liver cancer.Oncogene. 2017 Aug;36(31):4405-4414. doi: 10.1038/onc.2017.69. Epub 2017 Apr 3.
• [3049] Fully validated SRM-MS-based method for absolute quantification of PIVKA-II in human serum: Clinical applications for patients with HCC.J Pharm Biomed Anal. 2018 Jul 15;156:142-146. doi: 10.1016/j.jpba.2018.04.025. Epub 2018 Apr 21.
• [3050] Subcellular localization of APMCF1 and its biological significance of expression pattern in normal and malignant human tissues.J Exp Clin Cancer Res. 2009 Aug 9;28(1):111. doi: 10.1186/1756-9966-28-111.
• [3051] SRPX2, an independent prognostic marker, promotes cell migration and invasion in hepatocellular carcinoma.Biomed Pharmacother. 2017 Sep;93:398-405. doi: 10.1016/j.biopha.2017.06.075. Epub 2017 Jun 24.
• [3052] Expression and prognostic value of Ars2 in hepatocellular carcinoma.Int J Clin Oncol. 2014 Oct;19(5):880-8. doi: 10.1007/s10147-013-0642-6. Epub 2013 Nov 23.
• [3053] Long Noncoding RNA MALAT1 Promotes Hepatocellular Carcinoma Development by SRSF1 Upregulation and mTOR Activation.Cancer Res. 2017 Mar 1;77(5):1155-1167. doi: 10.1158/0008-5472.CAN-16-1508. Epub 2016 Dec 19.
• [3054] Serine/arginine rich splicing factor 2 expression and clinic pathological features indicating a prognostic factor in human hepatocellular carcinoma patients.Cancer Biomark. 2018 Feb 14;21(3):681-687. doi: 10.3233/CBM-170770.
• [3055] lncRNA MEG3 inhibits the growth of hepatocellular carcinoma cells by sponging miR-9-5p to upregulate SOX11.Braz J Med Biol Res. 2019;52(10):e8631. doi: 10.1590/1414-431X20198631. Epub 2019 Sep 16.
• [3056] Expression of cancer-testis antigen (CTA) in tumor tissues and peripheral blood of Chinese patients with hepatocellular carcinoma.Life Sci. 2006 Jul 17;79(8):744-8. doi: 10.1016/j.lfs.2006.02.024. Epub 2006 Feb 28.
• [3057] Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma.Cell. 2013 Mar 28;153(1):101-11. doi: 10.1016/j.cell.2013.02.032.
• [3058] Differences in CD75s- and iso-CD75s-ganglioside content and altered mRNA expression of sialyltransferases ST6GAL1 and ST3GAL6 in human hepatocellular carcinomas and nontumoral liver tissues.Glycobiology. 2011 May;21(5):584-94. doi: 10.1093/glycob/cwq200. Epub 2010 Dec 7.
• [3059] Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice.Am J Transl Res. 2019 May 15;11(5):2668-2682. eCollection 2019.
• [3060] Sialyltransferase ST3GAL6 mediates the effect of microRNA-26a on cell growth, migration, and invasion in hepatocellular carcinoma through the protein kinase B/mammalian target of rapamycin pathway.Cancer Sci. 2017 Feb;108(2):267-276. doi: 10.1111/cas.13128.
• [3061] 2,6-Sialylation promotes immune escape in hepatocarcinoma cells by regulating T cell functions and CD147/MMP signaling.J Physiol Biochem. 2019 Jun;75(2):199-207. doi: 10.1007/s13105-019-00674-8. Epub 2019 Apr 10.
• [3062] Mutations in the ST7/RAY1/HELG locus rarely occur in primary colorectal, gastric, and hepatocellular carcinomas.Br J Cancer. 2003 Jun 16;88(12):1909-13. doi: 10.1038/sj.bjc.6600942.
• [3063] Long noncoding RNA MIR31HG inhibits hepatocellular carcinoma proliferation and metastasis by sponging microRNA-575 to modulate ST7L expression.J Exp Clin Cancer Res. 2018 Sep 3;37(1):214. doi: 10.1186/s13046-018-0853-9.
• [3064] A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.Nat Genet. 2013 Feb;45(2):164-71. doi: 10.1038/ng.2521. Epub 2013 Jan 6.
• [3065] STAT gene family mRNA expression and prognostic value in hepatocellular carcinoma.Onco Targets Ther. 2019 Sep 3;12:7175-7191. doi: 10.2147/OTT.S202122. eCollection 2019.
• [3066] Polymorphism of T-cell receptor gamma short tandem repeats as a susceptibility risk factor of hepatocellular carcinoma.Anticancer Res. 2006 Sep-Oct;26(5B):3787-91.
• [3067] Copper transporters are responsible for copper isotopic fractionation in eukaryotic cells.Sci Rep. 2017 Mar 17;7:44533. doi: 10.1038/srep44533.
• [3068] Suppression of stromal interaction molecule 1 inhibits SMMC7721 hepatocellular carcinoma cell proliferation by inducing cell cycle arrest.Biotechnol Appl Biochem. 2015 Jan-Feb;62(1):107-11. doi: 10.1002/bab.1245. Epub 2014 Dec 15.
• [3069] The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma.Oncogene. 2020 Feb;39(8):1652-1664. doi: 10.1038/s41388-019-1108-8. Epub 2019 Nov 18.
• [3070] Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation.Oncogene. 2018 Jun;37(26):3514-3527. doi: 10.1038/s41388-018-0169-4. Epub 2018 Mar 21.
• [3071] MST4 promotes hepatocellular carcinoma epithelial-mesenchymal transition and metastasis via activation of the p-ERK pathway.Int J Oncol. 2014 Aug;45(2):629-40. doi: 10.3892/ijo.2014.2455. Epub 2014 May 22.
• [3072] Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma.Gut. 2018 Sep;67(9):1692-1703. doi: 10.1136/gutjnl-2017-314061. Epub 2017 Sep 2.
• [3073] The subcellular localization of syntaxin 17 varies among different cell types and is altered in some malignant cells.J Histochem Cytochem. 2005 Nov;53(11):1371-82. doi: 10.1369/jhc.4A6508.2005. Epub 2005 Jun 13.
• [3074] SUCO as a Promising Diagnostic Biomarker of Hepatocellular Carcinoma: Integrated Analysis and Experimental Validation.Med Sci Monit. 2019 Aug 22;25:6292-6303. doi: 10.12659/MSM.915262.
• [3075] Small ubiquitin-related modifier 2/3 interacts with p65 and stabilizes it in the cytoplasm in HBV-associated hepatocellular carcinoma.BMC Cancer. 2015 Oct 12;15:675. doi: 10.1186/s12885-015-1665-3.
• [3076] A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus.J Biol Chem. 2004 Jun 25;279(26):27233-8. doi: 10.1074/jbc.M402273200. Epub 2004 Apr 29.
• [3077] The Down-Regulation of SUZ12 Accelerates the Migration and Invasion of Liver Cancer Cells via Activating ERK1/2 Pathway.J Cancer. 2019 Feb 23;10(6):1375-1384. doi: 10.7150/jca.29932. eCollection 2019.
• [3078] Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma.Oncogene. 2013 Mar 28;32(13):1724-34. doi: 10.1038/onc.2012.177. Epub 2012 May 21.
• [3079] Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma.Mol Cell Biochem. 2015 Dec;410(1-2):1-9. doi: 10.1007/s11010-015-2533-9. Epub 2015 Aug 11.
• [3080] EGFR and SYNE2 are associated with p21 expression and SYNE2 variants predict post-operative clinical outcomes in HBV-related hepatocellular carcinoma.Sci Rep. 2016 Aug 9;6:31237. doi: 10.1038/srep31237.
• [3081] SYNJ2BP inhibits tumor growth and metastasis by activating DLL4 pathway in hepatocellular carcinoma.J Exp Clin Cancer Res. 2016 Jul 20;35(1):115. doi: 10.1186/s13046-016-0385-0.
• [3082] Synemin down-regulation in human hepatocellular carcinoma does not destabilize cytoskeletons in vivo.Biochem Biophys Res Commun. 2011 Jan 7;404(1):488-93. doi: 10.1016/j.bbrc.2010.12.008. Epub 2010 Dec 6.
• [3083] SYPL1 overexpression predicts poor prognosis of hepatocellular carcinoma and associates with epithelial-mesenchymal transition.Oncol Rep. 2017 Sep;38(3):1533-1542. doi: 10.3892/or.2017.5843. Epub 2017 Jul 21.
• [3084] TAB3 defect induces augmented cardioprotection loss from ischemic injury.Cell Biol Int. 2017 Jul;41(7):787-797. doi: 10.1002/cbin.10781. Epub 2017 May 11.
• [3085] A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.Gastroenterology. 2013 Jul;145(1):176-187. doi: 10.1053/j.gastro.2013.03.051. Epub 2013 Apr 6.
• [3086] Association of TAP1 and TAP2 polymorphisms with the outcome of persistent HBV infection in a northeast Han Chinese population.Scand J Gastroenterol. 2012 Nov;47(11):1368-74. doi: 10.3109/00365521.2012.725090. Epub 2012 Sep 19.
• [3087] Expression of protein TARBP1 in human hepatocellular carcinoma and its prognostic significance.Int J Clin Exp Pathol. 2015 Aug 1;8(8):9089-96. eCollection 2015.
• [3088] TRB3 reverses chemotherapy resistance and mediates crosstalk between endoplasmic reticulum stress and AKT signaling pathways in MHCC97H human hepatocellular carcinoma cells.Oncol Lett. 2018 Jan;15(1):1343-1349. doi: 10.3892/ol.2017.7361. Epub 2017 Nov 8.
• [3089] Three-dimensional liver-derived extracellular matrix hydrogel promotes liver organoids function.J Cell Biochem. 2018 Jun;119(6):4320-4333. doi: 10.1002/jcb.26622. Epub 2018 Mar 1.
• [3090] LncRNA TATDN1 induces the progression of hepatocellular carcinoma via targeting miRNA-6089.Eur Rev Med Pharmacol Sci. 2019 Aug;23(15):6459-6466. doi: 10.26355/eurrev_201908_18529.
• [3091] T-box Transcription Factor Tbx3 Contributes to Human Hepatocellular Carcinoma Cell Migration and Invasion by Repressing E-Cadherin Expression.Oncol Res. 2018 Jul 5;26(6):959-966. doi: 10.3727/096504017X15145624664031. Epub 2018 Jan 2.
• [3092] TCF12 promotes the tumorigenesis and metastasis of hepatocellular carcinoma via upregulation of CXCR4 expression.Theranostics. 2019 Aug 12;9(20):5810-5827. doi: 10.7150/thno.34973. eCollection 2019.
• [3093] TCF19 Promotes Cell Proliferation through Binding to the Histone H3K4me3 Mark.Biochemistry. 2020 Feb 4;59(4):389-399. doi: 10.1021/acs.biochem.9b00771. Epub 2019 Dec 2.
• [3094] Association of Methylation Signatures at Hepatocellular Carcinoma Pathway Genes with Adiposity and Insulin Resistance Phenotypes.Nutr Cancer. 2019;71(5):840-851. doi: 10.1080/01635581.2018.1531136. Epub 2018 Nov 20.
• [3095] Association between hepatocellular carcinoma and tumor necrosis factor alpha polymorphisms in South Korea.World J Gastroenterol. 2015 Dec 14;21(46):13064-72. doi: 10.3748/wjg.v21.i46.13064.
• [3096] 1810011o10 Rik Inhibits the Antitumor Effect of Intratumoral CD8(+) T Cells through Suppression of Notch2 Pathway in a Murine Hepatocellular Carcinoma Model.Front Immunol. 2017 Mar 22;8:320. doi: 10.3389/fimmu.2017.00320. eCollection 2017.
• [3097] Overexpression of Transcobalamin 1 is an Independent Negative Prognosticator in Rectal Cancers Receiving Concurrent Chemoradiotherapy.J Cancer. 2017 May 12;8(8):1330-1337. doi: 10.7150/jca.18274. eCollection 2017.
• [3098] The commonly used antimicrobial additive triclosan is a liver tumor promoter.Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17200-5. doi: 10.1073/pnas.1419119111. Epub 2014 Nov 17.
• [3099] TCP10L acts as a tumor suppressor by inhibiting cell proliferation in hepatocellular carcinoma.Biochem Biophys Res Commun. 2014 Mar 28;446(1):61-7. doi: 10.1016/j.bbrc.2014.02.049. Epub 2014 Feb 21.
• [3100] Aldolase B inhibits metastasis through Ten-Eleven Translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma.Mol Cancer. 2015 Sep 17;14:170. doi: 10.1186/s12943-015-0437-7.
• [3101] FAM46C is critical for the anti-proliferation and pro-apoptotic effects of norcantharidin in hepatocellular carcinoma cells.Sci Rep. 2017 Mar 24;7(1):396. doi: 10.1038/s41598-017-00313-6.
• [3102] Role of ten-eleven translocation proteins and 5-hydroxymethylcytosine in hepatocellular carcinoma.Cell Prolif. 2019 Jul;52(4):e12626. doi: 10.1111/cpr.12626. Epub 2019 Apr 29.
• [3103] Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1.PLoS One. 2013 May 9;8(5):e62828. doi: 10.1371/journal.pone.0062828. Print 2013.
• [3104] PSPC1-interchanged interactions with PTK6 and -catenin synergize oncogenic subcellular translocations and tumor progression.Nat Commun. 2019 Dec 16;10(1):5716. doi: 10.1038/s41467-019-13665-6.
• [3105] Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies.Clin Cancer Res. 2011 Dec 15;17(24):7625-33. doi: 10.1158/1078-0432.CCR-10-3099. Epub 2011 Nov 3.
• [3106] Mitochondrial DNA depletion, mitochondrial mutations and high TFAM expression in hepatocellular carcinoma.Oncotarget. 2017 Sep 16;8(48):84373-84383. doi: 10.18632/oncotarget.21033. eCollection 2017 Oct 13.
• [3107] Transcription factor AP-4 promotes tumorigenic capability and activates the Wnt/-catenin pathway in hepatocellular carcinoma.Theranostics. 2018 Jun 7;8(13):3571-3583. doi: 10.7150/thno.25194. eCollection 2018.
• [3108] Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.J Vasc Interv Radiol. 2019 Mar;30(3):314-319. doi: 10.1016/j.jvir.2018.10.016.
• [3109] TFDP3 Regulates Epithelial-Mesenchymal Transition in Breast Cancer.PLoS One. 2017 Jan 23;12(1):e0170573. doi: 10.1371/journal.pone.0170573. eCollection 2017.
• [3110] The predictive powers of plasma trefoil factor 3 or its related micro RNAs for patients with hepatocellular carcinoma.BMC Cancer. 2018 Nov 13;18(1):1110. doi: 10.1186/s12885-018-5017-y.
• [3111] Hydrogen peroxide inducible clone-5 sustains NADPH oxidase-dependent reactive oxygen species-c-jun N-terminal kinase signaling in hepatocellular carcinoma.Oncogenesis. 2019 Aug 6;8(8):40. doi: 10.1038/s41389-019-0149-8.
• [3112] Downregulation of Epidermal Growth Factor Receptor in hepatocellular carcinoma facilitates Transforming Growth Factor--induced epithelial to amoeboid transition.Cancer Lett. 2019 Nov 1;464:15-24. doi: 10.1016/j.canlet.2019.08.011. Epub 2019 Aug 26.
• [3113] THAP11, a novel binding protein of PCBP1, negatively regulates CD44 alternative splicing and cell invasion in a human hepatoma cell line.FEBS Lett. 2012 May 21;586(10):1431-8. doi: 10.1016/j.febslet.2012.04.016. Epub 2012 Apr 21.
• [3114] CircRNA has_circ_0078710 acts as the sponge of microRNA-31 involved in hepatocellular carcinoma progression.Gene. 2019 Jan 30;683:253-261. doi: 10.1016/j.gene.2018.10.043. Epub 2018 Oct 17.
• [3115] Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas.Cancer Lett. 2002 Dec 1;186(1):59-65. doi: 10.1016/s0304-3835(02)00244-6.
• [3116] Sp1-mediated ectopic expression of T-cell lymphoma invasion and metastasis 2 in hepatocellular carcinoma.Cancer Med. 2016 Mar;5(3):465-77. doi: 10.1002/cam4.611. Epub 2016 Jan 14.
• [3117] Potent effects of dioscin against hepatocellular carcinoma through regulating TP53-induced glycolysis and apoptosis regulator (TIGAR)-mediated apoptosis, autophagy, and DNA damage.Br J Pharmacol. 2019 Apr;176(7):919-937. doi: 10.1111/bph.14594. Epub 2019 Mar 18.
• [3118] Potentiation of -lactam antibiotics and -lactam/-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates.J Antimicrob Chemother. 2019 Sep 1;74(9):2640-2648. doi: 10.1093/jac/dkz228.
• [3119] In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2.J Pathol. 2012 Jul;227(3):275-85. doi: 10.1002/path.3995. Epub 2012 Apr 18.
• [3120] Timp3 deficiency affects the progression of DEN-related hepatocellular carcinoma during diet-induced obesity in mice.Acta Diabetol. 2019 Dec;56(12):1265-1274. doi: 10.1007/s00592-019-01382-x. Epub 2019 Jul 10.
• [3121] TIMP-3 -1296 T>C and TIMP-4 -55 T>C gene polymorphisms play a role in the susceptibility of hepatocellular carcinoma among women.Tumour Biol. 2014 Sep;35(9):8999-9007. doi: 10.1007/s13277-014-2170-z. Epub 2014 Jun 7.
• [3122] Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis.Am J Pathol. 2005 Jan;166(1):73-80. doi: 10.1016/S0002-9440(10)62233-X.
• [3123] Increased systemic zonula occludens 1 associated with inflammation and independent biomarker in patients with hepatocellular carcinoma.BMC Cancer. 2018 May 18;18(1):572. doi: 10.1186/s12885-018-4484-5.
• [3124] From mosquito to man: identification of a novel protein kinase, HsHPK, which is highly expressed in human hepatoma tissues.J Biomed Sci. 1998;5(2):135-40. doi: 10.1007/BF02258367.
• [3125] Both Talin-1 and Talin-2 correlate with malignancy potential of the human hepatocellular carcinoma MHCC-97 L cell.BMC Cancer. 2016 Jan 28;16:45. doi: 10.1186/s12885-016-2076-9.
• [3126] miR-508-5p acts as an anti-oncogene by targeting MESDC1 in hepatocellular carcinoma.Neoplasma. 2017;64(1):40-47. doi: 10.4149/neo_2017_105.
• [3127] microRNA-520f inhibits hepatocellular carcinoma cell proliferation and invasion by targeting TM4SF1.Gene. 2018 May 30;657:30-38. doi: 10.1016/j.gene.2018.03.003. Epub 2018 Mar 2.
• [3128] Adenovirus-mediated delivery of siRNA targeting TM4SF4 attenuated liver cancer cell growth in vitro and in vivo.Acta Biochim Biophys Sin (Shanghai). 2013 Mar;45(3):213-9. doi: 10.1093/abbs/gms115. Epub 2013 Jan 7.
• [3129] The Expression of TMEM74 in Liver Cancer and Lung Cancer Correlating With Survival Outcomes.Appl Immunohistochem Mol Morphol. 2019 Sep;27(8):618-625. doi: 10.1097/PAI.0000000000000659.
• [3130] Effects of TMEM9 gene on cell progression in hepatocellular carcinoma by RNA interference.Oncol Rep. 2016 Jul;36(1):299-305. doi: 10.3892/or.2016.4821. Epub 2016 May 19.
• [3131] Identification of transmembrane protein 98 as a novel chemoresistance-conferring gene in hepatocellular carcinoma.Mol Cancer Ther. 2014 May;13(5):1285-97. doi: 10.1158/1535-7163.MCT-13-0806. Epub 2014 Mar 7.
• [3132] TMPRSS4 promotes cancer stem cell traits by regulating CLDN1 in hepatocellular carcinoma.Biochem Biophys Res Commun. 2017 Aug 26;490(3):906-912. doi: 10.1016/j.bbrc.2017.06.139. Epub 2017 Jun 23.
• [3133] Transmembrane and Ubiquitin-Like Domain Containing 1 Protein (TMUB1) Negatively Regulates Hepatocellular Carcinoma Proliferation via Regulating Signal Transducer and Activator of Transcription 1 (STAT1).Med Sci Monit. 2019 Dec 12;25:9471-9482. doi: 10.12659/MSM.920319.
• [3134] TIPE1 induces apoptosis by negatively regulating Rac1 activation in hepatocellular carcinoma cells.Oncogene. 2015 May 14;34(20):2566-74. doi: 10.1038/onc.2014.208. Epub 2014 Jul 21.
• [3135] Tumor necrosis factor--induced protein 8-like 2 mRNA in peripheral blood mononuclear cells is associated with the disease progression of chronic hepatitis B virus infection.Virol J. 2019 Oct 28;16(1):120. doi: 10.1186/s12985-019-1224-7.
• [3136] Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma.World J Gastroenterol. 2003 Nov;9(11):2433-40. doi: 10.3748/wjg.v9.i11.2433.
• [3137] Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8(+) T Cells in HCC.Mol Ther. 2019 Nov 6;27(11):1906-1918. doi: 10.1016/j.ymthe.2019.07.019. Epub 2019 Aug 5.
• [3138] MiR-1180 promoted the proliferation of hepatocellular carcinoma cells by repressing TNIP2 expression.Biomed Pharmacother. 2016 Apr;79:315-20. doi: 10.1016/j.biopha.2016.02.025. Epub 2016 Mar 15.
• [3139] Targeted inhibition of mitochondrial Hsp90 induces mitochondrial elongation in Hep3B hepatocellular carcinoma cells undergoing apoptosis by increasing the ROS level.Int J Oncol. 2015 Nov;47(5):1783-92. doi: 10.3892/ijo.2015.3150. Epub 2015 Sep 7.
• [3140] Overexpression of heat shock protein HSP90AA1 and translocase of the outer mitochondrial membrane TOM34 in HCV-induced hepatocellular carcinoma: A pilot study.Clin Biochem. 2019 Jan;63:10-17. doi: 10.1016/j.clinbiochem.2018.12.001. Epub 2018 Dec 3.
• [3141] Overexpression of TONSL might be an independent unfavorable prognostic indicator in hepatocellular carcinoma.Pathol Res Pract. 2019 May;215(5):939-945. doi: 10.1016/j.prp.2019.01.044. Epub 2019 Jan 30.
• [3142] Orosomucoid 2 inhibits tumor metastasis and is upregulated by CCAAT/enhancer binding protein in hepatocellular carcinomas.Oncotarget. 2015 Jun 30;6(18):16106-19. doi: 10.18632/oncotarget.3867.
• [3143] Altered binding site selection of p53 transcription cassettes by hepatitis B virus X protein.Mol Cell Biol. 2013 Feb;33(3):485-97. doi: 10.1128/MCB.01189-12. Epub 2012 Nov 12.
• [3144] LncRNA GAS5-mediated miR-1323 promotes tumor progression by targeting TP53INP1 in hepatocellular carcinoma.Onco Targets Ther. 2019 May 21;12:4013-4023. doi: 10.2147/OTT.S209439. eCollection 2019.
• [3145] Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma.Oncotarget. 2016 Feb 2;7(5):6323-34. doi: 10.18632/oncotarget.6319.
• [3146] Identification and characterization of tropomyosin 3 associated with granulin-epithelin precursor in human hepatocellular carcinoma.PLoS One. 2012;7(7):e40324. doi: 10.1371/journal.pone.0040324. Epub 2012 Jul 6.
• [3147] Anticancer activity of an antisense oligonucleotide targeting TRADD combined with proteasome inhibitors in chemoresistant hepatocellular carcinoma cells.J Chemother. 2013 Oct;25(5):292-7. doi: 10.1179/1973947813Y.0000000087.
• [3148] The tumor suppressive miR-302c-3p inhibits migration and invasion of hepatocellular carcinoma cells by targeting TRAF4.J Cancer. 2018 Jun 23;9(15):2693-2701. doi: 10.7150/jca.25569. eCollection 2018.
• [3149] The inhibitor of Ca(2+)-dependent K+ channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB.Invest New Drugs. 2013 Apr;31(2):452-7. doi: 10.1007/s10637-012-9879-6. Epub 2012 Oct 2.
• [3150] Tripartite motif 16 inhibits hepatocellular carcinoma cell migration and invasion.Int J Oncol. 2016 Apr;48(4):1639-49. doi: 10.3892/ijo.2016.3398. Epub 2016 Feb 17.
• [3151] TRIM11 Upregulation Contributes to Proliferation, Invasion, and EMT of Hepatocellular Carcinoma Cells.Oncol Res. 2017 May 24;25(5):691-699. doi: 10.3727/096504016X14774897404770. Epub 2016 Dec 15.
• [3152] Downregulation of TRIM21 contributes to hepatocellular carcinoma carcinogenesis and indicates poor prognosis of cancers.Tumour Biol. 2015 Nov;36(11):8761-72. doi: 10.1007/s13277-015-3572-2. Epub 2015 Jun 9.
• [3153] TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis.Biochem Biophys Res Commun. 2015 Jul 31;463(3):458-65. doi: 10.1016/j.bbrc.2015.05.117. Epub 2015 Jun 1.
• [3154] Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.Chin J Cancer. 2017 Sep 26;36(1):77. doi: 10.1186/s40880-017-0240-5.
• [3155] TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex.Oncogene. 2018 Jan 25;37(4):478-488. doi: 10.1038/onc.2017.349. Epub 2017 Oct 2.
• [3156] miR-4417 Targets Tripartite Motif-Containing 35 (TRIM35) and Regulates Pyruvate Kinase Muscle 2 (PKM2) Phosphorylation to Promote Proliferation and Suppress Apoptosis in Hepatocellular Carcinoma Cells.Med Sci Monit. 2017 Apr 10;23:1741-1750. doi: 10.12659/msm.900296.
• [3157] High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma.Tumour Biol. 2016 Nov;37(11):14615-14628. doi: 10.1007/s13277-016-5316-3. Epub 2016 Sep 12.
• [3158] TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A.J Exp Clin Cancer Res. 2018 Jun 13;37(1):116. doi: 10.1186/s13046-018-0780-9.
• [3159] Overexpression of Tripartite Motif Conaining 55 (TRIM55) Inhibits Migration and Invasion of Hepatocellular Carcinoma (HCC) Cells via Epithelial-Mesenchymal Transition and Matrix Metalloproteinase-2 (MMP2).Med Sci Monit. 2019 Jan 27;25:771-777. doi: 10.12659/MSM.910984.
• [3160] Growth suppression of the hepatocellular carcinoma cell line Hepa1-6 by an activatable interferon regulatory factor-1 in mice.Cancer Res. 2001 Mar 15;61(6):2609-17.
• [3161] TRIM65 triggers -catenin signaling via ubiquitylation of Axin1 to promote hepatocellular carcinoma.J Cell Sci. 2017 Sep 15;130(18):3108-3115. doi: 10.1242/jcs.206623. Epub 2017 Jul 28.
• [3162] Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma.Tumour Biol. 2015 Sep;36(9):6901-8. doi: 10.1007/s13277-015-3377-3. Epub 2015 Apr 8.
• [3163] KIAA1114, a full-length protein encoded by the trophinin gene, is a novel surface marker for isolating tumor-initiating cells of multiple hepatocellular carcinoma subtypes.Oncotarget. 2014 Mar 15;5(5):1226-40. doi: 10.18632/oncotarget.1677.
• [3164] The Upregulation of Trophinin-Associated Protein (TROAP) Predicts a Poor Prognosis in Hepatocellular Carcinoma.J Cancer. 2019 Jan 29;10(4):957-967. doi: 10.7150/jca.26666. eCollection 2019.
• [3165] TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication.Gut. 2017 Aug;66(8):1496-1506. doi: 10.1136/gutjnl-2016-312734. Epub 2016 Dec 14.
• [3166] Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity.Microbiol Immunol. 2004;48(4):339-45. doi: 10.1111/j.1348-0421.2004.tb03515.x.
• [3167] BRCA1-mediated inflammation and growth activated & inhibited transition mechanisms between no-tumor hepatitis/cirrhotic tissues and HCC.J Cell Biochem. 2014 Apr;115(4):641-50. doi: 10.1002/jcb.24699.
• [3168] Association of CAA and TATC Insertion/Deletion Genetic Polymorphisms in RTN4 3'-UTR with Hepatocellular Carcinoma Risk.Pathol Oncol Res. 2018 Jan;24(1):31-34. doi: 10.1007/s12253-017-0204-8. Epub 2017 Jan 31.
• [3169] Tspan15 Is a New Stemness-Related Marker in Hepatocellular Carcinoma.Proteomics. 2019 Nov;19(21-22):e1900025. doi: 10.1002/pmic.201900025. Epub 2019 Sep 2.
• [3170] Tetraspanin 8 mediates AEG-1-induced invasion and metastasis in hepatocellular carcinoma cells.FEBS Lett. 2016 Aug;590(16):2700-8. doi: 10.1002/1873-3468.12268. Epub 2016 Jul 21.
• [3171] The X-linked tumor suppressor TSPX interacts and promotes degradation of the hepatitis B viral protein HBx via the proteasome pathway.PLoS One. 2011;6(7):e22979. doi: 10.1371/journal.pone.0022979. Epub 2011 Jul 29.
• [3172] TTF1NP induces protective autophagy during apoptosis by inhibiting the Akt/mTOR pathway and activating JNK in human liver cancer cells.Oncol Rep. 2018 Mar;39(3):1423-1431. doi: 10.3892/or.2018.6196. Epub 2018 Jan 5.
• [3173] WITHDRAWN: Prognostic biomarker AASS suppresses proliferation, migration and predicts a good survival of hepatocellular carcinoma in vivo and in vitro.Life Sci. 2019 May 31:S0024-3205(19)30436-9. doi: 10.1016/j.lfs.2019.05.080. Online ahead of print.
• [3174] The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma.Cancer Lett. 2019 Aug 10;457:98-109. doi: 10.1016/j.canlet.2019.05.010. Epub 2019 May 14.
• [3175] ACADS acts as a potential methylation biomarker associated with the proliferation and metastasis of hepatocellular carcinomas.Aging (Albany NY). 2019 Oct 25;11(20):8825-8844. doi: 10.18632/aging.102292. Epub 2019 Oct 25.
• [3176] Long non-coding RNA SNHG1 functions as a competitive endogenous RNA to regulate PDCD4 expression by sponging miR-195-5p in hepatocellular carcinoma.Gene. 2019 Sep 25;714:143994. doi: 10.1016/j.gene.2019.143994. Epub 2019 Jul 19.
• [3177] Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.Cancer Lett. 2015 Sep 28;366(1):112-22. doi: 10.1016/j.canlet.2015.06.014. Epub 2015 Jun 25.
• [3178] Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells.J Gastroenterol Hepatol. 2014 May;29(5):1092-101. doi: 10.1111/jgh.12484.
• [3179] Associations between the single nucleotide polymorphisms of APOBEC3A, APOBEC3B and APOBEC3H, and chronic hepatitis B progression and hepatocellular carcinoma in a Chinese population.Mol Med Rep. 2019 Sep;20(3):2177-2188. doi: 10.3892/mmr.2019.10455. Epub 2019 Jul 2.
• [3180] RICH2, a potential tumor suppressor in hepatocellular carcinoma.Front Biosci (Landmark Ed). 2019 Jun 1;24(8):1363-1376. doi: 10.2741/4784.
• [3181] Nucleophosmin (NPM1/B23) interacts with activating transcription factor 5 (ATF5) protein and promotes proteasome- and caspase-dependent ATF5 degradation in hepatocellular carcinoma cells.J Biol Chem. 2012 Jun 1;287(23):19599-609. doi: 10.1074/jbc.M112.363622. Epub 2012 Apr 23.
• [3182] Functional variants of autophagy-related genes are associated with the development of hepatocellular carcinoma.Life Sci. 2019 Oct 15;235:116675. doi: 10.1016/j.lfs.2019.116675. Epub 2019 Jul 21.
• [3183] BDH2 is downregulated in hepatocellular carcinoma and acts as a tumor suppressor regulating cell apoptosis and autophagy.J Cancer. 2019 Jun 9;10(16):3735-3745. doi: 10.7150/jca.32022. eCollection 2019.
• [3184] CBX3/HP1 promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma.Aging (Albany NY). 2019 Aug 2;11(15):5483-5497. doi: 10.18632/aging.102132. Epub 2019 Aug 2.
• [3185] Prognostic significance of Cbx4 expression and its beneficial effect for transarterial chemoembolization in hepatocellular carcinoma.Cell Death Dis. 2015 Mar 12;6(3):e1689. doi: 10.1038/cddis.2015.57.
• [3186] CDK5RAP3 is a novel repressor of p14ARF in hepatocellular carcinoma cells.PLoS One. 2012;7(7):e42210. doi: 10.1371/journal.pone.0042210. Epub 2012 Jul 31.
• [3187] Carboxypeptidase A6 Promotes the Proliferation and Migration of Hepatocellular Carcinoma by Up-regulating AKT Signaling Pathway.Curr Med Sci. 2019 Oct;39(5):727-733. doi: 10.1007/s11596-019-2098-z. Epub 2019 Oct 14.
• [3188] Upregulation of cystatin SN promotes hepatocellular carcinoma progression and predicts a poor prognosis.J Cell Physiol. 2019 Dec;234(12):22623-22634. doi: 10.1002/jcp.28828. Epub 2019 May 20.
• [3189] DDX17 promotes hepatocellular carcinoma progression via inhibiting Klf4 transcriptional activity.Cell Death Dis. 2019 Oct 25;10(11):814. doi: 10.1038/s41419-019-2044-9.
• [3190] DIS3L2 Promotes Progression of Hepatocellular Carcinoma via hnRNP U-Mediated Alternative Splicing.Cancer Res. 2019 Oct 1;79(19):4923-4936. doi: 10.1158/0008-5472.CAN-19-0376. Epub 2019 Jul 22.
• [3191] Enoyl-coenzyme A hydratase short chain 1 silencing attenuates the proliferation of hepatocellular carcinoma by inhibiting epidermal growth factor signaling in vitro and in vivo.Mol Med Rep. 2015 Jul;12(1):1421-8. doi: 10.3892/mmr.2015.3453. Epub 2015 Mar 9.
• [3192] Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma.J Vasc Interv Radiol. 2019 Jul;30(7):1098-1105. doi: 10.1016/j.jvir.2019.02.023. Epub 2019 May 14.
• [3193] Expression and significance of ETFDH in hepatocellular carcinoma.Pathol Res Pract. 2019 Dec;215(12):152702. doi: 10.1016/j.prp.2019.152702. Epub 2019 Oct 23.
• [3194] Long noncoding RNA FAM83A-AS1 facilitates hepatocellular carcinoma progression by binding with NOP58 to enhance the mRNA stability of FAM83A.Biosci Rep. 2019 Nov 29;39(11):BSR20192550. doi: 10.1042/BSR20192550.
• [3195] The role of hepassocin in the development of non-alcoholic fatty liver disease.J Hepatol. 2013 Nov;59(5):1065-72. doi: 10.1016/j.jhep.2013.06.004. Epub 2013 Jun 18.
• [3196] MTA2 promotes HCC progression through repressing FRMD6, a key upstream component of hippo signaling pathway.Biochem Biophys Res Commun. 2019 Jul 12;515(1):112-118. doi: 10.1016/j.bbrc.2019.05.025. Epub 2019 May 22.
• [3197] Nucleoporin Nup155 is part of the p53 network in liver cancer.Nat Commun. 2019 May 14;10(1):2147. doi: 10.1038/s41467-019-10133-z.
• [3198] LncRNA GABPB1-AS1 and GABPB1 regulate oxidative stress during erastin-induced ferroptosis in HepG2 hepatocellular carcinoma cells.Sci Rep. 2019 Nov 7;9(1):16185. doi: 10.1038/s41598-019-52837-8.
• [3199] Prognostic Value of Gamma-Glutamyl Transpeptidase to Lymphocyte Count Ratio in Patients With Single Tumor Size ?5 cm Hepatocellular Carcinoma After Radical Resection.Front Oncol. 2019 May 21;9:347. doi: 10.3389/fonc.2019.00347. eCollection 2019.
• [3200] MicroRNA-21 promotes cell proliferation in human hepatocellular carcinoma partly by targeting HEPN1.Tumour Biol. 2015 Jul;36(7):5467-72. doi: 10.1007/s13277-015-3213-9. Epub 2015 Feb 17.
• [3201] Prognostic significance of Hes-1, a downstream target of notch signaling in hepatocellular carcinoma.Asian Pac J Cancer Prev. 2015;16(9):3811-6. doi: 10.7314/apjcp.2015.16.9.3811.
• [3202] Quantitative methylation analysis of multiple genes using methylation-sensitive restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma.Exp Mol Pathol. 2011 Aug;91(1):455-60. doi: 10.1016/j.yexmp.2011.05.001. Epub 2011 May 11.
• [3203] Non-classical MHC- genes in chronic hepatitis B and hepatocellular carcinoma.Immunogenetics. 2012 Mar;64(3):251-8. doi: 10.1007/s00251-011-0580-2. Epub 2011 Oct 21.
• [3204] Comprehensive Characterization of the Human Endogenous Retrovirus HERV-K(HML-6) Group: Overview of Structure, Phylogeny, and Contribution to the Human Genome.J Virol. 2019 Jul 30;93(16):e00110-19. doi: 10.1128/JVI.00110-19. Print 2019 Aug 15.
• [3205] hsa_circ_0091570 acts as a ceRNA to suppress hepatocellular cancer progression by sponging hsa-miR-1307.Cancer Lett. 2019 Sep 28;460:128-138. doi: 10.1016/j.canlet.2019.06.007. Epub 2019 Jun 14.
• [3206] miR-584-5p regulates hepatocellular carcinoma cell migration and invasion through targeting KCNE2.Mol Genet Genomic Med. 2019 Jun;7(6):e702. doi: 10.1002/mgg3.702. Epub 2019 May 1.
• [3207] PET imaging of hepatocellular carcinoma with anti-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in comparison with L-[S-methyl-(11)C]methionine.EJNMMI Res. 2019 May 22;9(1):47. doi: 10.1186/s13550-019-0519-4.
• [3208] LHX3 is an advanced-stage prognostic biomarker and metastatic oncogene in hepatocellular carcinoma.Cancer Biomark. 2019;26(1):31-39. doi: 10.3233/CBM-182257.
• [3209] Exosomal miR-451a Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Targeting LPIN1.Cell Physiol Biochem. 2019;53(1):19-35. doi: 10.33594/000000118.
• [3210] Tumor suppressive functions of LZTFL1 in hepatocellular carcinoma.Onco Targets Ther. 2019 Jul 10;12:5537-5544. doi: 10.2147/OTT.S196925. eCollection 2019.
• [3211] Detection of fusion transcripts in the serum samples of patients with hepatocellular carcinoma.Oncotarget. 2019 May 21;10(36):3352-3360. eCollection 2019 May 21.
• [3212] Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology.Mol Cancer Ther. 2019 Sep;18(9):1506-1519. doi: 10.1158/1535-7163.MCT-18-0571. Epub 2019 Jun 18.
• [3213] Discovery of Coumarin as Microtubule Affinity-Regulating Kinase 4 Inhibitor That Sensitize Hepatocellular Carcinoma to Paclitaxel.Front Chem. 2019 May 24;7:366. doi: 10.3389/fchem.2019.00366. eCollection 2019.
• [3214] Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets.Cancer Manag Res. 2019 May 1;11:3921-3931. doi: 10.2147/CMAR.S191565. eCollection 2019.
• [3215] AlkB Homologue 1 Demethylates N(3)-Methylcytidine in mRNA of Mammals.ACS Chem Biol. 2019 Jul 19;14(7):1418-1425. doi: 10.1021/acschembio.8b01001. Epub 2019 Jun 24.
• [3216] Antiviral therapy may decrease HBx, affecting cccDNA and MSL2 in hepatocarcinogenesis.Oncol Lett. 2019 Nov;18(5):4984-4991. doi: 10.3892/ol.2019.10833. Epub 2019 Sep 10.
• [3217] Targeting Mybbp1a suppresses HCC progression via inhibiting IGF1/AKT pathway by CpG islands hypo-methylation dependent promotion of IGFBP5.EBioMedicine. 2019 Jun;44:225-236. doi: 10.1016/j.ebiom.2019.05.029. Epub 2019 May 17.
• [3218] NCAPG2 overexpression promotes hepatocellular carcinoma proliferation and metastasis through activating the STAT3 and NF-B/miR-188-3p pathways.EBioMedicine. 2019 Jun;44:237-249. doi: 10.1016/j.ebiom.2019.05.053. Epub 2019 Jun 5.
• [3219] The miR-873/NDFIP1 axis promotes hepatocellular carcinoma growth and metastasis through the AKT/mTOR-mediated Warburg effect.Am J Cancer Res. 2019 May 1;9(5):927-944. eCollection 2019.
• [3220] Tumor-suppressive miR-3650 inhibits tumor metastasis by directly targeting NFASC in hepatocellular carcinoma.Aging (Albany NY). 2019 Jun 4;11(11):3432-3444. doi: 10.18632/aging.101981.
• [3221] Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery.Mol Imaging Biol. 2020 Jun;22(3):476-485. doi: 10.1007/s11307-019-01389-4.
• [3222] As a downstream target of the AKT pathway, NPTX1 inhibits proliferation and promotes apoptosis in hepatocellular carcinoma.Biosci Rep. 2019 Jun 4;39(6):BSR20181662. doi: 10.1042/BSR20181662. Print 2019 Jun 28.
• [3223] Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression.Mol Cancer. 2019 Jul 19;18(1):119. doi: 10.1186/s12943-019-1046-7.
• [3224] A comprehensive genome-wide profiling comparison between HBV and HCV infected hepatocellular carcinoma.BMC Med Genomics. 2019 Oct 28;12(1):147. doi: 10.1186/s12920-019-0580-x.
• [3225] Serum and tissue proteomic signatures of patients with hepatocellular carcinoma using 2D gel electrophoresis.Mol Med Rep. 2019 Aug;20(2):1025-1038. doi: 10.3892/mmr.2019.10311. Epub 2019 May 29.
• [3226] MiR-221 Promotes Hepatocellular Carcinoma Cells Migration via Targeting PHF2.Biomed Res Int. 2019 May 12;2019:4371405. doi: 10.1155/2019/4371405. eCollection 2019.
• [3227] Integrated mRNA-Seq and miRNA-Seq analysis of PLC2-overexpressing hepatocarcinoma cells and identification of the associated miRNA-mRNA network.J Cell Biochem. 2019 Dec;120(12):19878-19890. doi: 10.1002/jcb.29294. Epub 2019 Jul 16.
• [3228] Genomic aberrations in the HTPAP promoter affect tumor metastasis and clinical prognosis of hepatocellular carcinoma.PLoS One. 2014 Mar 6;9(3):e90528. doi: 10.1371/journal.pone.0090528. eCollection 2014.
• [3229] PSMD1 and PSMD2 regulate HepG2 cell proliferation and apoptosis via modulating cellular lipid droplet metabolism.BMC Mol Biol. 2019 Nov 8;20(1):24. doi: 10.1186/s12867-019-0141-z.
• [3230] Hydrogen peroxide inducible clone-5 mediates reactive oxygen species signaling for hepatocellular carcinoma progression.Oncotarget. 2015 Oct 20;6(32):32526-44. doi: 10.18632/oncotarget.5322.
• [3231] CHML promotes liver cancer metastasis by facilitating Rab14 recycle.Nat Commun. 2019 Jun 7;10(1):2510. doi: 10.1038/s41467-019-10364-0.
• [3232] Long noncoding RNA SNHG7 represses the expression of RBM5 to strengthen metastasis of hepatocellular carcinoma.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5699-5704. doi: 10.26355/eurrev_201907_18307.
• [3233] The diagnostic and prognostic role of RhoA in hepatocellular carcinoma.Aging (Albany NY). 2019 Jul 22;11(14):5158-5172. doi: 10.18632/aging.102110.
• [3234] Sesn3 deficiency promotes carcinogen-induced hepatocellular carcinoma via regulation of the hedgehog pathway.Biochim Biophys Acta Mol Basis Dis. 2019 Oct 1;1865(10):2685-2693. doi: 10.1016/j.bbadis.2019.07.011. Epub 2019 Jul 24.
• [3235] Circular RNA hsa_circ_0001649 inhibits hepatocellular carcinoma progression via multiple miRNAs sponge.Aging (Albany NY). 2019 May 28;11(10):3362-3375. doi: 10.18632/aging.101988.
• [3236] The RNA-binding protein SORBS2 suppresses hepatocellular carcinoma tumourigenesis and metastasis by stabilizing RORA mRNA.Liver Int. 2019 Nov;39(11):2190-2203. doi: 10.1111/liv.14202. Epub 2019 Sep 25.
• [3237] Aberrant methylation status of SPG20 promoter in hepatocellular carcinoma: A potential tumor metastasis biomarker.Cancer Genet. 2019 Apr;233-234:48-55. doi: 10.1016/j.cancergen.2019.04.003. Epub 2019 Apr 12.
• [3238] HNF4-Deficient Fatty Liver Provides a Permissive Environment for Sex-Independent Hepatocellular Carcinoma.Cancer Res. 2019 Nov 15;79(22):5860-5873. doi: 10.1158/0008-5472.CAN-19-1277. Epub 2019 Oct 1.
• [3239] Transcriptional Up-Regulation of APE1/Ref-1 in Hepatic Tumor: Role in Hepatocytes Resistance to Oxidative Stress and Apoptosis.PLoS One. 2015 Dec 1;10(12):e0143289. doi: 10.1371/journal.pone.0143289. eCollection 2015.
• [3240] TLX3 repressed SNAI1-induced epithelial-mesenchymal transition by directly constraining STAT3 phosphorylation and functionally sensitized 5-FU chemotherapy in hepatocellular carcinoma.Int J Biol Sci. 2019 Jun 5;15(8):1696-1711. doi: 10.7150/ijbs.33844. eCollection 2019.
• [3241] Tropomodulin 3 modulates EGFR-PI3K-AKT signaling to drive hepatocellular carcinoma metastasis.Mol Carcinog. 2019 Oct;58(10):1897-1907. doi: 10.1002/mc.23083. Epub 2019 Jul 16.
• [3242] TOX promotes the exhaustion of antitumor CD8(+) T cells by preventing PD1 degradation in hepatocellular carcinoma.J Hepatol. 2019 Oct;71(4):731-741. doi: 10.1016/j.jhep.2019.05.015. Epub 2019 Jun 5.
• [3243] Dysregulation of miR484-TUSC5 axis takes part in the progression of hepatocellular carcinoma.J Biochem. 2019 Sep 1;166(3):271-279. doi: 10.1093/jb/mvz034.
• [3244] Circular RNA circTRIM33-12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression.Mol Cancer. 2019 Jun 1;18(1):105. doi: 10.1186/s12943-019-1031-1.
• [3245] Clinical Significance of TRMT6 in Hepatocellular Carcinoma: A Bioinformatics-Based Study.Med Sci Monit. 2019 May 25;25:3894-3901. doi: 10.12659/MSM.913556.